0001628280-24-04728510-Q RadNet, Inc. 20241112202411121706041706051706050 0001628280-24-047285 10-Q 68 20240930 20241112 20241112 RadNet, Inc. 0000790526 8071 133326724 DE 1231 10-Q 34 001-33307 241449726 1510 COTNER AVE LOS ANGELES CA 90025 3104787808 1510 COTNER AVE LOS ANGELES CA 90025 PRIMEDEX HEALTH SYSTEMS INC 19930518 CCC FRANCHISING CORP 19920703 10-Q 1 rdnt-20240930.htm 10-Q rdnt-20240930000007905 26false12/31Q32024http://fasb.org/us-gaap/2024#InterestExpenseDebthttp://fasb.org/us-gaap/2024#InterestExpenseDebtxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesrdnt:centerxbrli:purerdnt:incentivePlanrdnt:agreementrdnt:securityrdnt:jointVenturerdnt:locationrdnt:tranche001-012024-09-300000790526 2024-11-080000790526 2024-09-300000790526 2023-12-310000790526srt:AffiliatedEntityMember2024-09-300000790526srt:AffiliatedEntityMember2023-12-310000790526us-gaap:HealthCarePatientServiceMember2024-07-012024-09-300000790526us-gaap:HealthCarePatientServiceMember2023-07-012023-09-300000790526us-gaap:HealthCarePatientServiceMember2024-01-012024-09-300000790526us-gaap:HealthCarePatientServiceMember2023-01-012023-09-300000790526rdnt:CapitationArrangementsMember2024-07-012024-09-300000790526rdnt:CapitationArrangementsMember2023-07-012023-09-300000790526rdnt:CapitationArrangementsMember2024-01-012024-09-300000790526rdnt:CapitationArrangementsMember2023-01-012023-09-300000790526 2024-07-012024-09-300000790526 2023-07-012023-09-300000790526 2023-01-012023-09-300000790526us-gaap:CommonStockMember2024-06-300000790526us-gaap:AdditionalPaidInCapitalMember2024-06-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000790526us-gaap:RetainedEarningsMember2024-06-300000790526us-gaap:ParentMember2024-06-300000790526us-gaap:NoncontrollingInterestMember2024-06-300000790526 2024-06-300000790526us-gaap:CommonStockMember2024-07-012024-09-300000790526us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000790526us-gaap:ParentMember2024-07-012024-09-300000790526us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000790526us-gaap:RetainedEarningsMember2024-07-012024-09-300000790526us-gaap:CommonStockMember2024-09-300000790526us-gaap:AdditionalPaidInCapitalMember2024-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000790526us-gaap:RetainedEarningsMember2024-09-300000790526us-gaap:ParentMember2024-09-300000790526us-gaap:NoncontrollingInterestMember2024-09-300000790526us-gaap:CommonStockMember2023-06-300000790526us-gaap:AdditionalPaidInCapitalMember2023-06-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000790526us-gaap:RetainedEarningsMember2023-06-300000790526us-gaap:ParentMember2023-06-300000790526us-gaap:NoncontrollingInterestMember2023-06-300000790526 2023-07-012023-09-300000790526us-gaap:CommonStockMember2023-07-012023-09-300000790526us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000790526us-gaap:ParentMember2023-07-012023-09-300000790526rdnt:DeepHealthInc.Memberus-gaap:CommonStockMember2023-07-012023-09-300000790526us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000790526us-gaap:RetainedEarningsMember2023-07-012023-09-300000790526us-gaap:CommonStockMember2023-09-300000790526us-gaap:AdditionalPaidInCapitalMember2023-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000790526us-gaap:RetainedEarningsMember2023-09-300000790526us-gaap:ParentMember2023-09-300000790526us-gaap:NoncontrollingInterestMember2023-09-300000790526 2023-09-310000790526us-gaap:CommonStockMember2023-12-310000790526us-gaap:AdditionalPaidInCapitalMember2023-12-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000790526us-gaap:RetainedEarningsMember2023-12-310000790526us-gaap:ParentMember2023-12-310000790526us-gaap:NoncontrollingInterestMember2023-12-310000790526us-gaap:CommonStockMember2024-01-012024-09-300000790526us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000790526us-gaap:ParentMember2024-01-012024-09-300000790526rdnt:DeepHealthInc.Memberus-gaap:CommonStockMember2024-01-012024-09-300000790526us-gaap:NoncontrollingInterestMember2024-01-012024-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000790526us-gaap:RetainedEarningsMember2024-01-012024-09-300000790526us-gaap:CommonStockMember2022-12-310000790526us-gaap:AdditionalPaidInCapitalMember2022-12-310000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000790526us-gaap:RetainedEarningsMember2022-12-310000790526us-gaap:ParentMember2022-12-310000790526us-gaap:NoncontrollingInterestMember2022-12-310000790526 2022-12-310000790526us-gaap:CommonStockMember2023-01-012023-09-300000790526us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000790526rdnt:DeepHealthInc.Memberus-gaap:CommonStockMember2023-01-012023-09-300000790526us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000790526us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000790526us-gaap:RetainedEarningsMember2023-01-012023-09-300000790526us-gaap:CommercialPaperMember2024-04-010000790526rdnt:TriValleyImagingGroupLLCMemberrdnt:TriValleyImagingGroupLLCMemberrdnt:FixedAssetsMember2024-03-290000790526rdnt:TriValleyImagingGroupLLCMemberrdnt:TriValleyImagingGroupLLCMember2024-03-290000790526rdnt:HeartLungImagingLimitedMemberrdnt:StockHoldbackMember2024-03-272024-03-270000790526rdnt:HeartLungImagingLimitedMemberrdnt:StockHoldbackMember2024-03-270000790526us-gaap:CommercialPaperMember2024-01-150000790526us-gaap:CommonStockMemberrdnt:PublicOfferingMember2024-03-012024-03-310000790526us-gaap:CommonStockMemberrdnt:SoldPursuantToExerciseMemberrdnt:PublicOfferingMember2024-03-012024-03-310000790526us-gaap:CommonStockMemberrdnt:PublicOfferingMember2024-03-310000790526us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-09-300000790526us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310000790526rdnt:CommercialInsurance1Member2024-07-012024-09-300000790526rdnt:CommercialInsurance1Member2023-07-012023-09-300000790526rdnt:CommercialInsurance1Member2024-01-012024-09-300000790526rdnt:CommercialInsurance1Member2023-01-012023-09-300000790526rdnt:Medicare1Member2024-07-012024-09-300000790526rdnt:Medicare1Member2023-07-012023-09-300000790526rdnt:Medicare1Member2024-01-012024-09-300000790526rdnt:Medicare1Member2023-01-012023-09-300000790526rdnt:Medicaid1Member2024-07-012024-09-300000790526rdnt:Medicaid1Member2023-07-012023-09-300000790526rdnt:Medicaid1Member2024-01-012024-09-300000790526rdnt:Medicaid1Member2023-01-012023-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2024-07-012024-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2023-07-012023-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2024-01-012024-09-300000790526rdnt:WorkersCompensationPersonalInjury1Member2023-01-012023-09-300000790526rdnt:HealthCarePatientServiceOtherMember2024-07-012024-09-300000790526rdnt:HealthCarePatientServiceOtherMember2023-07-012023-09-300000790526rdnt:HealthCarePatientServiceOtherMember2024-01-012024-09-300000790526rdnt:HealthCarePatientServiceOtherMember2023-01-012023-09-300000790526rdnt:HealthCareManagementServiceMember2024-07-012024-09-300000790526rdnt:HealthCareManagementServiceMember2023-07-012023-09-300000790526rdnt:HealthCareManagementServiceMember2024-01-012024-09-300000790526rdnt:HealthCareManagementServiceMember2023-01-012023-09-300000790526rdnt:HeartAndLungMember2024-07-012024-09-300000790526rdnt:HeartAndLungMember2023-07-012023-09-300000790526rdnt:HeartAndLungMember2024-01-012024-09-300000790526rdnt:HeartAndLungMember2023-01-012023-09-300000790526us-gaap:HealthCareOtherMember2024-07-012024-09-300000790526us-gaap:HealthCareOtherMember2023-07-012023-09-300000790526us-gaap:HealthCareOtherMember2024-01-012024-09-300000790526us-gaap:HealthCareOtherMember2023-01-012023-09-300000790526rdnt:ImagingCenterSegmentRevenueMember2024-07-012024-09-300000790526rdnt:ImagingCenterSegmentRevenueMember2023-07-012023-09-300000790526rdnt:ImagingCenterSegmentRevenueMember2024-01-012024-09-300000790526rdnt:ImagingCenterSegmentRevenueMember2023-01-012023-09-300000790526rdnt:DigitalHealthMember2024-07-012024-09-300000790526rdnt:DigitalHealthMember2023-07-012023-09-300000790526rdnt:DigitalHealthMember2024-01-012024-09-300000790526rdnt:DigitalHealthMember2023-01-012023-09-300000790526us-gaap:ServiceMember2024-07-012024-09-300000790526us-gaap:ServiceMember2023-07-012023-09-300000790526us-gaap:ServiceMember2024-01-012024-09-300000790526us-gaap:ServiceMember2023-01-012023-09-300000790526srt:MinimumMemberrdnt:ProperyAndEquipmentNetMember2024-09-300000790526srt:MaximumMemberrdnt:ProperyAndEquipmentNetMember2024-09-300000790526srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2024-09-300000790526srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2024-09-300000790526 2023-10-012023-10-010000790526rdnt:ImagingCentersMember2023-12-310000790526rdnt:ArtificialIntelligenceMember2023-12-310000790526rdnt:ImagingCentersMember2024-01-012024-09-300000790526rdnt:ArtificialIntelligenceMember2024-01-012024-09-300000790526rdnt:ImagingCentersMember2024-09-300000790526rdnt:ArtificialIntelligenceMember2024-09-300000790526rdnt:ManagementServiceContractsMember2024-09-300000790526rdnt:CovenantNotToCompeteMember2024-09-300000790526us-gaap:CustomerRelationshipsMember2024-09-300000790526rdnt:PatentAndTrademarksMember2024-09-300000790526rdnt:DevelopedTechnologySoftwareMember2024-09-300000790526us-gaap:TradeNamesMember2024-09-300000790526us-gaap:TradeNamesMember2024-09-300000790526us-gaap:SoftwareDevelopmentMember2024-09-300000790526rdnt:ManagementServiceContractsMember2023-12-310000790526rdnt:CovenantNotToCompeteMember2023-12-310000790526us-gaap:CustomerRelationshipsMember2023-12-310000790526rdnt:PatentAndTrademarksMember2023-12-310000790526rdnt:DevelopedTechnologySoftwareMember2023-12-310000790526us-gaap:TradeNamesMember2023-12-310000790526us-gaap:TradeNamesMember2023-12-310000790526us-gaap:SoftwareDevelopmentMember2023-12-310000790526rdnt:RestatedPlanMember2023-06-070000790526srt:MinimumMember2024-01-012024-09-300000790526srt:MaximumMember2024-01-012024-09-300000790526rdnt:A2019SWAPSMember2019-06-300000790526rdnt:A2019SWAPSMemberrdnt:October2023Member2019-06-300000790526rdnt:A2019SWAPSMemberrdnt:October2025Member2019-06-300000790526rdnt:A2019SWAPSMemberus-gaap:InterestRateSwapMember2019-06-300000790526rdnt:A2019SWAPS1Memberus-gaap:InterestRateSwapMember2019-06-300000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-010000790526 2020-07-012023-10-310000790526srt:ScenarioForecastMember2023-11-012025-10-310000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2024-06-300000790526us-gaap:InterestRateSwapMember2024-07-012024-09-300000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2024-09-300000790526us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:InterestRateSwapMember2023-12-310000790526us-gaap:InterestRateSwapMember2024-01-012024-09-300000790526us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2024-07-012024-09-300000790526us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2024-01-012024-09-300000790526rdnt:HeartAndLungImagingLimitedMember2022-11-010000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember2022-11-010000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:CashHoldbackMember2022-11-010000790526rdnt:HeartAndLungImagingLimitedMember2022-11-012022-11-010000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember2024-09-300000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember2023-09-200000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember2023-12-120000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember2024-03-270000790526rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember2024-04-010000790526rdnt:HeartAndLungImagingLimitedMember2024-06-300000790526rdnt:HeartAndLungImagingLimitedMember2024-07-012024-09-300000790526rdnt:HeartAndLungImagingLimitedMember2024-09-300000790526rdnt:HeartAndLungImagingLimitedMember2023-06-300000790526rdnt:HeartAndLungImagingLimitedMember2023-07-012023-09-300000790526rdnt:HeartAndLungImagingLimitedMember2023-09-300000790526rdnt:HeartAndLungImagingLimitedMember2023-12-310000790526rdnt:HeartAndLungImagingLimitedMember2024-01-012024-09-300000790526rdnt:HeartAndLungImagingLimitedMember2022-12-310000790526rdnt:HeartAndLungImagingLimitedMember2023-01-012023-09-300000790526us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526rdnt:HeartAndLungImagingLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000790526us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000790526us-gaap:RestrictedStockMember2024-07-012024-09-300000790526us-gaap:RestrictedStockMember2023-07-012023-09-300000790526us-gaap:RestrictedStockMember2024-01-012024-09-300000790526us-gaap:RestrictedStockMember2023-01-012023-09-300000790526us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000790526us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000790526us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000790526us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000790526rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember2024-07-012024-09-300000790526rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember2023-07-012023-09-300000790526rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember2024-01-012024-09-300000790526rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember2023-01-012023-09-300000790526us-gaap:CommonStockMember2024-07-012024-09-300000790526us-gaap:CommonStockMember2024-01-012024-09-300000790526us-gaap:CommonStockMember2023-07-012023-09-300000790526us-gaap:CommonStockMember2023-01-012023-09-300000790526rdnt:GlendaleAdvancedImagingMemberrdnt:JointVentureMemberrdnt:DignityHealthMembersrt:MinimumMember2024-01-012024-09-300000790526rdnt:GlendaleAdvancedImagingMemberrdnt:JointVentureMemberrdnt:DignityHealthMembersrt:MaximumMember2024-01-012024-09-300000790526us-

gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-09-300000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-12-310000790526rdnt:JointVentureInterestMember2024-09-300000790526rdnt:JointVentureInterestMember2023-12-310000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-01-012024-09-300000790526us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-01-012023-09-300000790526rdnt:StanislausSurgicalHospitalLLCMember2024-09-160000790526rdnt:GlobalImagingLLPMember2024-09-010000790526rdnt:U.S.ImagingIncMember2024-06-010000790526rdnt:HoustonMedicalImagingLLCMember2024-04-010000790526rdnt:GrossmanImagingCenterOfCMHLLCMember2024-03-310000790526rdnt:ProvidenceHealthSystemSouthernCaliforniaMember2024-03-310000790526rdnt:AntelopeValleyOutpatientImagingMember2024-02-010000790526rdnt:BusinessAcquisitionsMember2024-09-300000790526rdnt:TriValleyImagingGroupLLCMember2024-02-230000790526rdnt:TriValleyImagingGroupLLCMember2024-03-290000790526rdnt:ProvidenceHealthSystemMember2024-03-290000790526rdnt:TriValleyImagingGroupLLCMemberrdnt:ProvidenceHealthSystemMember2024-03-290000790526rdnt:TriValleyImagingGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember2024-03-292024-03-290000790526rdnt:TriValleyImagingGroupLLCMember2024-03-292024-03-290000790526rdnt:TriValleyImagingGroupLLCMemberrdnt:ProvidenceHealthSystemMember2024-03-290000790526rdnt:TriValleyImagingGroupLLCMemberrdnt:ProvidenceHealthSystemMember2024-03-292024-03-290000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember2024-07-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember2024-07-012024-09-300000790526rdnt:ThirdPartyMember2024-07-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember2024-07-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember2024-07-012024-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember2024-07-012024-09-300000790526rdnt:IntersegmentMember2024-07-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember2024-07-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember2024-07-012024-09-300000790526us-gaap:IntersegmentEliminationMember2024-07-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember2023-07-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember2023-07-012023-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember2023-07-012023-09-300000790526rdnt:ThirdPartyMember2023-07-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember2023-07-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember2023-07-012023-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember2023-07-012023-09-300000790526rdnt:IntersegmentMember2023-07-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember2023-07-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember2023-07-012023-09-300000790526us-gaap:IntersegmentEliminationMember2023-07-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember2024-01-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember2024-01-012024-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember2024-01-012024-09-300000790526rdnt:ThirdPartyMember2024-01-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember2024-01-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember2024-01-012024-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember2024-01-012024-09-300000790526rdnt:IntersegmentMember2024-01-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember2024-01-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember2024-01-012024-09-300000790526us-gaap:IntersegmentEliminationMember2024-01-012024-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember2023-01-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember2023-01-012023-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember2023-01-012023-09-300000790526rdnt:ThirdPartyMember2023-01-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember2023-01-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember2023-01-012023-09-300000790526us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember2023-01-012023-09-300000790526rdnt:IntersegmentMember2023-01-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember2023-01-012023-09-300000790526us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember2023-01-012023-09-300000790526us-gaap:IntersegmentEliminationMember2023-01-012023-09-300000790526rdnt:ImagingCentersMember2024-07-012024-09-300000790526rdnt:ImagingCentersMember2023-07-012023-09-300000790526rdnt:ImagingCentersMember2023-01-012023-09-300000790526rdnt:DigitalHealthMember2024-07-012024-09-300000790526rdnt:DigitalHealthMember2023-07-012023-09-300000790526rdnt:DigitalHealthMember2024-01-012024-09-300000790526rdnt:DigitalHealthMember2023-01-012023-09-300000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberrdnt:TermLoanMemberus-gaap:SecuredDebtMember2024-04-180000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-04-180000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2024-04-180000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMember2024-04-182024-04-180000790526rdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2023-01-012023-03-310000790526rdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-01-012023-03-310000790526rdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:EurodollarMember2023-03-310000790526rdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2023-03-310000790526rdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-04-012024-04-180000790526rdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember2024-04-012024-04-180000790526rdnt:FirstLienTermLoanMemberus-gaap:RevolvingCreditFacilityMember2024-04-180000790526rdnt:FirstLienTermLoanMemberus-gaap:RevolvingCreditFacilityMemberrdnt:OneMonthSecuredOvernightFinancingRateSOFRMember2024-04-180000790526rdnt:FirstLienTermLoanMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2024-04-180000790526rdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-04-192024-06-300000790526rdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMember2024-04-192024-09-300000790526rdnt:FirstLienTermLoanMemberus-gaap:RevolvingCreditFacilityMember2024-04-190000790526rdnt:FirstLienTermLoanMemberus-gaap:RevolvingCreditFacilityMemberrdnt:OneMonthSecuredOvernightFinancingRateSOFRMember2024-04-190000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberrdnt:TermLoanMemberus-gaap:SecuredDebtMember2024-04-192024-09-300000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberrdnt:TermLoanMemberus-gaap:SecuredDebtMember2024-01-012024-04-180000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-09-300000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMember2024-01-012024-09-300000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000790526rdnt:BarclaysMemberrdnt:BarclaysCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300000790526rdnt:BarclaysMemberrdnt:FirstLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300000790526rdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TermLoanMember2022-10-070000790526rdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberus-gaap:RevolvingCreditFacilityMember2022-10-070000790526rdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-09-300000790526rdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TermLoanMember2024-01-012024-09-300000790526rdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000790526rdnt:TruistMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberus-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300000790526us-gaap:CommercialPaperMember2023-02-010000790526rdnt:FirstLienTermLoanMemberrdnt:TermLoanMember2024-09-300000790526rdnt:FirstLienTermLoanMemberrdnt:TermLoanMember2023-12-310000790526rdnt:RestatedAgreementMemberrdnt:TermLoanMember2024-09-300000790526rdnt:RestatedAgreementMemberrdnt:TermLoanMember2023-12-310000790526rdnt:EquipmentNotesPayableMembersrt:MinimumMember2024-09-300000790526rdnt:EquipmentNotesPayableMembersrt:MaximumMember2024-09-300000790526rdnt:EquipmentNotesPayableMember2024-09-300000790526rdnt:EquipmentNotesPayableMember2023-12-3100007905262023-06-070000790526us-gaap:EmployeeStockOptionMember2024-09-300000790526us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000790526us-gaap:EmployeeStockOptionMemberrdnt:DeepHealthIncMember2020-04-012020-06-300000790526rdnt:DeepHealthIncMember2020-04-012020-06-300000790526rdnt:DeepHealthInc.Member2023-12-310000790526rdnt:DeepHealthInc.Member2024-01-012024-09-300000790526rdnt:DeepHealthInc.Member2024-09-300000790526rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember2023-12-310000790526rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember2024-01-012024-09-300000790526rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember2024-09-300000790526rdnt:PerformanceBasedStockUnitsMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockUnitsMembersrt:MinimumMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockUnitsMembersrt:MaximumMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockUnitsMembersrt:DirectorMember2024-03-310000790526rdnt:PerformanceBasedStockOptionsMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockOptionsMembersrt:MinimumMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockOptionsMembersrt:MaximumMember2023-01-012023-01-310000790526rdnt:PerformanceBasedStockOptionsMember2024-03-310000790526rdnt:PerformanceBasedStockOptionsMembersrt:DirectorMember2024-03-310000790526rdnt:PinkPerceptionLLCMemberus-gaap:SubsequentEventMember2024-10-012024-10-010000790526rdnt:PinkPerceptionLLCMemberus-gaap:SubsequentEventMember2024-10-010000790526rdnt:KheironMedicalTechnologiesLimitedMemberus-gaap:SubsequentEventMember2024-10-222024-10-22Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington D.C. 20549FORM 10-Q (Mark One)â˜Â Â Â Â Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024 orâ˜Â Â Â Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from Â to Â Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter)Delaware13-3326724(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)1510 Cotner AvenueÂ Los Angeles,California90025(Address of principal executive offices)(Zip Code)(310) 478-7808 (Registrantâ€™s telephone number, including area code)Not Applicable (Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act:Class TitleTrading SymbolRegistered ExchangeCommon StockRDNTNASDAQIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜´ Â No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Â YesÂ â˜´ Â No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€, â€œsmaller reporting companyâ€, and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerâ˜´Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â â˜Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)Â Yes â˜ No â˜´The number of shares of the registrantâ€™s common stock outstanding on NovemberÂ 8, 2024 was 74,026,737 shares.Table of ContentsRADNET, INC.TABLE OF CONTENTSPagePART I â€“ FINANCIAL INFORMATION1ITEM 1. Financial Statements1Condensed Consolidated Balance Sheets at September 30, 2024 and December 31, 20231Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 20231Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2024 and 20233Condensed Consolidated Statement of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 20236Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 20238Notes to Condensed Consolidated Financial Statements10ITEM 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations29ITEM 3. Quantitative and Qualitative Disclosures About Market Risk47ITEM 4. Controls and Procedures48PART II â€“ OTHER INFORMATION49ITEM 1.Â Â Legal Proceedings49ITEM 1A.Â Â Risk Factors49ITEM 2.Â Â Unregistered Sales of Equity Securities and Use of Proceeds49ITEM 3.Â Â Defaults Upon Senior Securities49ITEM 4.Â Â Mine Safety Disclosures49ITEM 5.Â Â Other Information49ITEM 6.Â Â Exhibits49SIGNATURES50iTable of ContentsPART I - FINANCIAL INFORMATIONItem 1 â€“ Financial StatementsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS EXCEPT SHARE DATA)September 30,2024December 31,2023(unaudited)Â ASSETSÂ Â CURRENT ASSETSÂ Â Cash and cash equivalents$748,916Â $342,570Â Accounts receivable199,076Â 163,707Â Due from affiliates30,210Â 25,342Â Prepaid expenses and other current assets38,051Â 47,657Â Total current assets1,016,253Â 579,276Â PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETSProperty and equipment, net663,867Â 604,401Â Operating lease right-of-use assets646,750Â 596,032Â Total property, equipment and right-of-use assets1,310,617Â 1,200,433Â OTHER ASSETSGoodwill711,841Â 679,463Â Other intangible assets84,441Â 90,615Â Deferred financing costs2,416Â 1,643Â Investment in joint ventures104,514Â 92,710Â Deposits and other45,260Â 46,333Â Total assets$3,275,342Â $2,690,473Â LIABILITIES AND EQUITYCURRENT LIABILITIESAccounts payable, accrued expenses and other$338,737Â $342,940Â Due to affiliates44,872Â 15,910Â Deferred revenue4,392Â 4,647Â Current operating lease liability58,751Â 55,981Â Current portion of notes payable23,378Â 17,974Â Total current liabilities470,130Â 437,452Â LONG-TERM LIABILITIESLong-term operating lease liability658,434Â 605,097Â Notes payable, net of current portion996,272Â 812,068Â Deferred tax liability, net20,795Â 15,776Â Other non-current liabilities10,077Â 6,721Â Total liabilities2,155,708Â 1,877,114Â EQUITYCommon stock - $0.0001 par value, 200,000,000 shares authorized; 73,976,284 and 67,956,318 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively7Â 7Â Additional paid-in-capital979,279Â 722,750Â Accumulated other

comprehensive loss(1,843)(12,484)Accumulated deficit(82,130)(79,578)Total RadNet, Inc.'s Stockholders' equity:895,313Â 630,695Â Noncontrolling interests224,321Â 182,664Â Total equity1,119,634Â 813,359Â Total liabilities and equity$3,275,342Â $2,690,473Â The accompanying notes are an integral part of these financial statements.1Table of ContentsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)(unaudited)Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232024REVENUEÂ Â Â Â Service fee revenue$427,579Â $361,927Â $1,247,513Â $1,078,265Â Revenue under capitation arrangements33,563Â 40,041Â 105,050Â 117,982Â Total service revenue461,142Â 401,968Â 1,352,563Â 1,196,247Â OPERATING EXPENSESCost of operations, excluding depreciation and amortization391,800Â 341,635Â 1,169,113Â 1,038,647Â Depreciation and amortization34,979Â 32,210Â 101,822Â 95,705Â Gain on contribution of imaging centers into joint venureâ€”Â (16,808)â€”Â (16,808)Loss on sale and disposal of equipment and other148Â 527Â 735Â 1,183Â Severance costs304Â 1,153Â 797Â 3,157Â Total operating expenses427,231Â 358,717Â 1,272,467Â 1,121,884Â INCOME FROM OPERATIONS33,911Â 43,251Â 80,096Â 74,363Â OTHER INCOME AND EXPENSESInterest expense19,427Â 16,115Â 61,776Â 47,876Â Equity in earnings of joint ventures(3,595)(1,084)(11,308)(3,935)Non-cash change in fair value of interest rate hedge6,755Â 1,015Â 7,429Â 949Â Debt restructuring and extinguishment expenses147Â â€”Â 8,909Â â€”Â Other income(5,414)(4,081)(16,248)(2,609)Total other expenses17,320Â 11,965Â 50,558Â 42,281Â INCOME BEFORE INCOME TAXES16,591Â 31,286Â 29,538Â 32,082Â Provision for income taxes(4,335)(7,220)(4,927)(7,741)NET INCOME12,256Â 24,066Â 24,611Â 24,341Â Net income attributable to noncontrolling interest9,047Â 6,526Â 27,163Â 19,437Â NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$3,209Â $17,540Â $(2,552)$4,904Â BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.04Â $0.26Â (0.04)0.08Â DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.04Â $0.25Â (0.04)0.08Â WEIGHTED AVERAGE SHARES OUTSTANDINGBasic73,494,709Â 67,793,404Â 72,587,321Â 62,113,707Â Diluted75,165,435Â 68,809,818Â 72,587,321Â 63,221,251Â The accompanying notes are an integral part of these financial statements.2Table of ContentsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (IN THOUSANDS) (unaudited)Â Three Months Ended September 30,Nine Months Ended September 30,20242023202420232024NET INCOME$12,256Â $24,066Â $24,611Â $24,341Â Â Â Â Â Â Â Foreign currency translation adjustments5,228Â (4,035)2,399Â (385)Â Â Â Â Â Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes986Â 921Â 8,242Â 2,765Â COMPREHENSIVE INCOME18,470Â 20,952Â 35,252Â 26,721Â Less comprehensive income attributable to noncontrolling interests9,047Â 6,526Â 27,163Â 19,437Â COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$9,423Â $14,426Â $8,089Â $7,284Â The accompanying notes are an integral part of these financial statements.3Table of ContentsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(IN THOUSANDS EXCEPT SHARE DATA)(unaudited)The following table summarizes changes in the Companyâ€™s consolidated stockholders' equity, including noncontrolling interest, during the three months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023.Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal RadNet, Inc.'s EquityNoncontrolling InterestsTotal EquitySharesAmountBALANCE - JUNE 30, 202473,968,042Â $7Â $974,355Â $(8,057)$(85,339)$880,966Â $211,874Â $1,092,840Â Issuance of common stock under the equity compensation plan9,075Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Stock-based compensation expenseâ€”Â Â â€”Â 4,727Â â€”Â Â â€”Â 4,727Â â€”Â 4,727Â Forfeiture of restricted stock and share cancellation(833)â€”Â (4)â€”Â Â â€”Â (4)â€”Â (4)Contributions from noncontrolling interestsâ€”Â Â â€”Â 201Â â€”Â Â â€”Â 201Â â€”Â 201Â Sale of economic interests in majority owned subsidiary, net of taxesâ€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â 3,400Â 3,400Â Change in cumulative foreign currency translation adjustmentâ€”Â Â â€”Â Â â€”Â 5,228Â â€”Â 5,228Â â€”Â 5,228Â Change in fair value of cash flow hedge from prior periods reclassified to earningsâ€”Â Â â€”Â Â â€”Â 986Â â€”Â 986Â â€”Â 986Â Net incomeâ€”Â Â â€”Â Â â€”Â 3,209Â 3,209Â 9,047Â 12,256Â BALANCE - SEPTEMBER 30, 202473,976,284Â $7Â $979,279Â $(1,843)$(82,130)$895,313Â $224,321Â $1,119,634Â BALANCE - JUNE 30, 202367,669,564Â $7Â $703,593Â $(15,183)$(95,258)$593,159Â $167,845Â $761,004Â Issuance of common stock upon exercise of options3,424Â â€”Â 21Â â€”Â Â â€”Â 21Â â€”Â 21Â Issuance of common stock under the equity compensation plan3,447Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Issuance of common stock under the DeepHealth equity compensation plan1,871Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Stock-based compensation expenseâ€”Â Â â€”Â 4,326Â â€”Â Â â€”Â 4,326Â â€”Â 4,326Â Issuance of common stock, net of issuance costsâ€”Â Â â€”Â (370)â€”Â Â â€”Â (370)â€”Â (370)Issuance of common stock in connection with acquisitions169,903Â â€”Â 5,123Â â€”Â Â â€”Â 5,123Â â€”Â 5,123Â Contributions from noncontrolling partnerâ€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â 2,885Â 2,885Â Sale of economic interests in majority owned subsidiary, net of taxesâ€”Â Â â€”Â 2,217Â â€”Â Â â€”Â 2,217Â â€”Â 2,217Â Change in cumulative foreign currency translation adjustmentâ€”Â Â â€”Â Â â€”Â (4,035)â€”Â (4,035)â€”Â (4,035)Change in fair value of cash flow hedge from prior periods reclassifed to earningsâ€”Â Â â€”Â Â â€”Â 921Â â€”Â 921Â â€”Â 921Â Otherâ€”Â Â â€”Â Â â€”Â Â (1)(1)1Â â€”Â Net incomeâ€”Â Â â€”Â Â â€”Â Â â€”Â 17,540Â 17,540Â 6,526Â 24,066Â BALANCE - SEPTEMBER 30, 202367,848,209Â $7Â $714,910Â $(18,297)$(77,719)$618,901Â $177,257Â $796,158Â 4Table of ContentsThe accompanying notes are an integral part of these financial statements.5Table of ContentsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(IN THOUSANDS EXCEPT SHARE DATA)(unaudited)The following table summarizes changes in the Companyâ€™s consolidated stockholders' equity, including noncontrolling interest, during the nine months ended September 30, 2024 and SeptemberÂ 30, 2023.Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal RadNet, Inc.'s EquityNoncontrolling InterestsTotal EquitySharesAmountBALANCE - DECEMBER 31, 202367,956,318Â $7Â $722,750Â $(12,484)$(79,578)$630,695Â $182,664Â $813,359Â Issuance of common stock upon exercise of options60,605Â â€”Â 367Â â€”Â Â â€”Â 367Â â€”Â 367Â Issuance of common stock under the equity compensation plan666,962Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Issuance of common stock under the DeepHealth equity compensation plan9,377Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Stock-based compensation expenseâ€”Â Â â€”Â 21,406Â â€”Â Â â€”Â 21,406Â â€”Â 21,406Â Issuance of common stock5,232,500Â â€”Â 218,385Â â€”Â Â â€”Â 218,385Â â€”Â 218,385Â Issuance of common stock in connection with acquisitions95,019Â â€”Â 4,607Â â€”Â Â â€”Â 4,607Â â€”Â 4,607Â Forfeiture of restricted stock and share cancellation(44,497)â€”Â (38)â€”Â Â â€”Â (38)â€”Â (38)Distributions paid to noncontrolling interestsâ€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â (2,423)(2,423)Contributions from noncontrolling interestsâ€”Â Â â€”Â 11,802Â â€”Â Â â€”Â 11,802Â â€”Â 11,802Â Sale of economic interests in majority owned subsidiary, net of taxesâ€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â 16,917Â 16,917Â Change in cumulative foreign currency translation adjustmentâ€”Â Â â€”Â Â â€”Â 2,399Â â€”Â 2,399Â â€”Â 2,399Â Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxesâ€”Â Â â€”Â Â â€”Â 8,242Â â€”Â 8,242Â â€”Â 8,242Â Net (loss) incomeâ€”Â Â â€”Â Â â€”Â Â â€”Â (2,552)(2,552)27,163Â 24,611Â BALANCE-BALANCE - SEPTEMBER 30, 202473,976,284Â $7Â $979,279Â $(1,843)$(82,130)$895,313Â $224,321Â $1,119,634Â BALANCE - DECEMBER 31, 202257,723,125Â $6Â $436,288Â $(20,677)$(82,622)$332,995Â $158,457Â $491,452Â Issuance of common stock upon exercise of options8,424Â â€”Â 72Â â€”Â Â â€”Â 72Â â€”Â 72Â Issuance of common stock under the equity compensation plan1,069,324Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Issuance of common stock under the DeepHealth equity compensation plan21,956Â â€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â Stock-based compensation expenseâ€”Â Â â€”Â 21,381Â â€”Â Â â€”Â 21,381Â â€”Â 21,381Â Sale of economic interests in majority owned subsidiary, net of taxesâ€”Â Â â€”Â 2,217Â â€”Â Â â€”Â 2,217Â â€”Â 2,217Â Issuance of common stock8,711,250Â 1Â 245,831Â â€”Â Â â€”Â 245,832Â â€”Â 245,832Â Issuance of common stock in connection with acquisitions314,130Â â€”Â 9,123Â â€”Â Â â€”Â 9,123Â â€”Â 9,123Â Distributions paid to noncontrolling interestsâ€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â (3,523)(3,523)6Table of ContentsContributions from noncontrolling interestsâ€”Â Â â€”Â Â â€”Â Â â€”Â Â â€”Â 2,885Â 2,885Â Change in cumulative foreign currency translation adjustmentâ€”Â Â â€”Â Â â€”Â (385)â€”Â (385)â€”Â (385)Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxesâ€”Â Â â€”Â Â â€”Â 2,765Â â€”Â 2,765Â â€”Â 2,765Â Otherâ€”Â â€”Â (2)â€”Â (1)(3)1Â (2)Net incomeâ€”Â Â â€”Â Â â€”Â Â â€”Â 4,904Â 4,904Â 19,437Â 24,341Â BALANCE-SEPTEMBER 30, 202367,848,209Â $7Â $714,910Â $(18,297)$(77,719)$618,901Â $177,257Â $796,158Â Â Â Â Â Â The accompanying notes are an in7Table of Contentstegral part of these financial statements.8Table of ContentsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(IN THOUSANDS)(unaudited) Nine Months Ended September 30,20242023CASH FLOWS FROM OPERATING ACTIVITIESÂ Â Net Income$24,611Â $24,341Â Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization101,822Â 95,705Â Noncash operating lease expense45,516Â 47,542Â Equity in earnings of joint ventures, net of dividends(10,308)5,012Â Amortization of deferred financing costs and loan discount2,336Â 2,240Â Loss on sale and disposal of equipment735Â 1,183Â Loss on extinguishment of debt2,080Â â€”Â Gain on contribution of imaging centers into joint ventureâ€”Â (16,808)Amortization of cash flow hedge, net of taxes8,242Â 2,765Â Non-cash change in fair value of interest rate hedge7,429Â 949Â Stock-based compensation21,368Â 21,380Â Loss on impairment1,200Â 3,949Â Change in fair value of contingent consideration1,974Â (4,112)Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:Accounts receivable(35,369)(1,379)Other current assets4,738Â 5,754Â Other assets(7,388)(16,641)Deferred taxes4,834Â 7,389Â Operating leases(40,497)(43,390)Deferred revenue(255)1,155Â Accounts payable, accrued expenses and other57,426Â (5,091)Net cash provided by operating activities190,494Â 131,943Â CASH FLOWS FROM INVESTING ACTIVITIESPurchase of imaging facilities and other acquisitions(37,748)(10,915)Purchase of property and equipment and other(145,164)(136,537)Proceeds from sale of equipment151Â 82Â Equity contributions in existing and purchase of interest in joint ventures(1,496)(5,453)Net cash used in investing activities(184,257)(152,823)CASH FLOWS FROM FINANCING ACTIVITIESPrincipal payments on notes and leases payable(4,296)(1,929)Payments on Term Loan Debt(688,375)(11,062)Proceeds from debt refinancing, net of issuing costs863,815Â â€”Â Contribution from noncontrolling partners7,569Â â€”Â Payments on contingent consideration(3,614)(3,390)Distributions paid to noncontrolling interests(2,423)(3,523)Proceeds from sale of economic interests in majority owned subsidiary, net of taxes8,641Â 5,102Â Proceeds from issuance of common stock218,385Â 245,831Â Proceeds from issuance of common stock upon exercise of options367Â 72Â Net cash provided by financing activities400,069Â 231,101Â EFFECT OF EXCHANGE RATE CHANGES ON CASH40Â (171)NET INCREASE IN CASH AND CASH EQUIVALENTS406,346Â 210,050Â CASH AND CASH EQUIVALENTS, beginning of period342,570Â 127,834Â CASH AND CASH EQUIVALENTS, end of period$748,916Â $337,884Â SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATIONCash paid during the period for interest$51,520Â $59,421Â Cash paid during the period for income taxes$2,202Â $225Â The accompanying notes are an integral part of these financial statements.9Table of ContentsRADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)(unaudited)Supplemental Schedule of Non-Cash Investing and Financing ActivitiesWe acquired equipment and certain leasehold improvements for approximately $43.2 million and $50.2 million during the nine months ended SeptemberÂ 30, 2024 and 2023, respectively, which were not paid for as of SeptemberÂ 30, 2024 and 2023, respectively. The amounts due were recorded in our condensed consolidated balance sheet under accounts payable, accrued expenses and other.On April 1, 2024, we issued promissory notes in the amount of $6.3 million to acquire radiology equipment previously leased under operating leases, related to the acquisition of Houston Medical Imaging, LLC.On March 29, 2024, we received $1.4 million in fixed assets, imaging equipment, and $6.0 million in goodwill from our partner in Tri Valley Imaging Group, LLC. See Note 4, Business Combinations and Related Activity.On March 27, 2024, we issued 95,019 shares of common stock to settle the stock contingent liabilities as part of our purchase of Heart & Lung Imaging Limited. The shares were ascribed a value of $4.6 million.On January 15, 2024, we issued promissory notes in the amount of $6.9 million to acquire radiology equipment previously leased under operating leases.10Table of Contentsnine months ended September 30, 2024RADNET, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited)NOTE 1 â€“ NATURE OF BUSINESS AND BASIS OF PRESENTATIONWe are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At SeptemberÂ 30, 2024, we operated directly or indirectly through joint ventures with hospitals, 399 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. In the first quarter of 2024, we revised our reportable segments to combine our eRad business, which was included in the Imaging Center segment, with our AI segment to form a new Digital Health reportable segment. Prior period amounts were adjusted retrospectively to reflect the change in reportable segment. For further financial information about these segments, see Note 5, Segment Reporting. In March 2024, we closed on a public offering of 5,232,500 shares of our common stock, including 682,500 shares sold pursuant to the exercise of an underwriter's overallotment option, at a price to the public of $44.00 per share. The gross proceeds as a result of this public offering was $230.2Â million before underwriting discounts, commissions, and costs totaling $11.8Â million.Â The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as â€œRadNet,â€ â€œwe,â€ â€œus,â€ â€œourâ€ or the â€œCompanyâ€ in this report.Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (â€œVIEâ€). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIEâ€™s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIEâ€™s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.VIEs that we consolidate as the primary beneficiary include professional corporations which are owned or controlled by individuals within our senior management and provide professional medical services for centers in Arizona, California, Delaware, Maryland, New Jersey and New York. These VIEs are collectively referred to as the â€œConsolidated Medical Group". RadNet provides non-medical, technical and administrative services to the Consolidated Medical Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Consolidated Medical Group has insignificant operating assets and liabilities, and de minimis equity. Substantially all cash flows of the Consolidated Medical Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Consolidated Medical Group. The creditors of the Consolidated Medical Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of the Consolidated Medical Group. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.The Consolidated Medical Group on a combined basis recognized $55.3 million and $51.3 million of revenue, net of management services fees to RadNet, for the three months ended September 30, 2024 and 2023, respectively and $55.3 million and $51.3 million of operating expenses for the three months ended September 30, 2024 and 2023, respectively. RadNet recognized $207.4 million and $214.7 million of total billed net service fee revenue for the three months ended September 30, 2024, and 2023, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.The Consolidated Medical Group on a combined basis recognized $162.5 million and $151.5 million of revenue, net of management services fees to RadNet, for the nine months ended September 30, 2024 and 2023, respectively and $162.5 million 11Table of Contentsand $151.5 million of operating expenses for the nine months ended September 30, 2024 and 2023, respectively. RadNet recognized $673.3 million and $638.3 million of total billed net service fee revenue for the nine months ended September 30, 2024, and 2023, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.In our condensed consolidated balance sheets at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, we have included approximately $118.0 million and $94.1 million, respectively, of

accounts receivable and approximately $21.7 million and $16.7 million of accounts payable and accrued liabilities related to the Consolidated Medical Group, respectively. The cash flows of the Consolidated Medical Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation.At all of our centers not serviced by the Consolidated Medical Group we have entered into long-term contracts with medical groups to provide professional services at those centers, including supervision and interpretation of diagnostic imaging procedures. The medical groups maintain full control over the physicians they employ. Through our management agreements, we make available to the medical groups the imaging centers, including all furniture, fixtures and medical equipment therein. The medical groups are compensated for their services from the professional component of the global net service fee revenue and after deducting management service fees paid to us, we have no economic controlling interest in these medical groups. As such, the financial results of these groups are not consolidated in our financial statements.The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended SeptemberÂ 30, 2024 and 2023 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended DecemberÂ 31, 2023.NOTE 2 - SIGNIFICANT ACCOUNTING POLICIESThere have been no material changes to the significant accounting policies we use and have explained in our annual report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023.REVENUES - Our revenues generally relate to net patient feesÂ received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual 12Table of Contentsdiscounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.Our total service revenues during the three and nine months ended SeptemberÂ 30, 2024 and 2023 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):Â Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Commercial insurance$255,375Â $218,923Â $752,514Â $652,597Â Medicare102,852Â 89,981Â 298,001Â 262,719Â Medicaid10,894Â 10,519Â 32,804Â 30,279Â Workers' compensation/personal injury10,232Â 9,745Â 33,088Â 34,785Â Other patient revenue10,607Â 10,443Â 34,524Â 30,191Â Management fee revenue6,242Â 3,922Â 18,255Â 12,203Â Heart and lung4,696Â 2,441Â 12,553Â 6,377Â Other10,314Â 3,768Â 18,918Â 14,248Â Revenue under capitation arrangements33,563Â 40,041Â 105,050Â 117,982Â Imaging Center Segment Revenue444,775Â 389,783Â 1,305,707Â 1,161,381Â Digital Health Segment Revenue16,367Â 12,185Â 46,856Â 34,866Â Total service revenue$461,142Â $401,968Â $1,352,563Â $1,196,247Â ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. Amounts remaining to be collected on these agreements were $5.9 million and $14.3 million at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis.DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities. Deferred financing costs, net of accumulated amortization, were $2.4 million and $1.6 million, as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. See Note 6, Credit Facilities and Notes Payable for more information.PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.BUSINESS COMBINATIONS - When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition 13Table of Contentsdate fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.GOODWILL - Goodwill at SeptemberÂ 30, 2024 totaled $711.8 million. Goodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2023 noting no impairment, and we have not identified any indicators of impairment through SeptemberÂ 30, 2024. Activity in goodwill for the nine months ended SeptemberÂ 30, 2024 is provided below (in thousands):Imaging Center segmentDigital Health segmentTotalBalance as of December 31, 2023606,557Â $72,906Â $679,463Â Goodwill from acquisitions30,729Â â€”Â 30,729Â Currency translation1,223Â 426Â 1,649Â Segment reorganization(12,300)12,300Â â€”Â Balance as of September 30, 2024$626,209Â $85,632Â $711,841Â INTANGIBLE ASSETS - Intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names. The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 are as follows (in thousands):As of SeptemberÂ 30, 2024:2024*2025202620272028ThereafterTotalWeighted average amortization period remaining in yearsManagement service contracts$572Â $2,287Â $2,287Â $2,287Â $2,287Â $2,287Â $6,669Â $16,389Â 7.2Covenant not to compete and other contracts261Â 897Â 610Â 315Â 225Â 68Â 2,376Â 3.1Customer lists318Â 1,141Â 1,019Â 844Â 803Â 11,108Â 15,233Â 17.4Patent and trademarks 78Â 311Â 311Â 311Â 311Â 197Â 1,519Â 5.2Developed technology1,913Â 7,651Â 7,611Â 7,077Â 7,077Â 6,856Â 38,185Â 5.8Trade names amortized19Â 77Â 77Â 77Â 63Â 27Â 340Â 4.5Trade names indefinite life â€”Â â€”Â â€”Â â€”Â 8,500Â 8,500Â â€”Â IPR&Dâ€”Â â€”Â â€”Â â€”Â 1,899Â 1,899Â â€”Â Total annual amortization$3,161Â $12,364Â $11,915Â $10,911Â $10,766Â $35,324Â $84,441Â *Excluding the nine months ended September 30, 202414Table of ContentsAs of DecemberÂ 31, 2023:2024202520262027 2028ThereafterTotalWeighted average amortization period remaining in yearsManagement service contracts$2,287Â $2,287Â $2,287Â $2,287Â $2,287Â $2,287Â $6,671Â $18,106Â 7.9Covenant not to compete and other contracts946Â 714Â 427Â 132Â 45Â 6Â 2,270Â 3.4Customer lists1,234Â 1,104Â 981Â 797Â 764Â 10,564Â 15,444Â 17.7Patent and trademarks316Â 316Â 316Â 315Â 300Â 164Â 1,727Â 5.8Developed technology7,785Â 7,785Â 7,745Â 7,210Â 7,046Â 6,117Â 43,688Â 5.7Trade names amortized77Â 77Â 77Â 77Â 63Â 27Â 398Â 5.3Trade names indefinite lifeâ€”Â â€”Â â€”Â â€”Â 7,100Â 7,100Â â€”Â IPR&Dâ€”Â â€”Â â€”Â â€”Â 1,882Â 1,882Â â€”Â Total annual amortization$12,645Â $12,283Â $11,833Â $10,818Â $10,505Â $32,531Â $90,615Â Total intangible asset amortization expense was $3.1 million and $9.4 million for the three and nine months ended SeptemberÂ 30, 2024, respectively. Total amortization expense was $3.0 million and $8.9 million for the three and nine months ended SeptemberÂ 30, 2023, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service contracts are amortized over 25 years using the straight line method. Developed technology is capitalized and amortized over the useful life of the software when placed into service. In process research and development (" IPR&D") and Trade names are reviewed annually for impairment.INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. In 2021, the Organization for Economic Co-operation and Development ("OECD") announced an inclusive framework on base erosion and profit shifting including Pillar Two Model Rules defining the global minimum tax, which calls for taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-US tax jurisdictions have either recently enacted legislation to support certain components of Pillar Two Model Rules beginning 2024 (including the European Union Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. The model rules provide a framework for applying the minimum tax, countries may enact Pillar Two Model Rules slightly differently than the model rules and on different timelines and may adjust domestic tax incentives in response to Pillar Two Model Rules. On a long-term basis, we will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in all countries applicable to us. For 2024, we expect that we will meet one or more transactional safe harbor rules, and as such, we do not believe Pillar Two model will have an impact on our annual effective tax rate for the year ending December 31, 2024.We recorded an income tax expense of $4.3 million, or an effective tax rate of 26.1%, for the three months ended September 30, 2024 and $7.2 million, or an effective tax rate of 23.1% for the three months ended September 30, 2023. We recorded income tax expense of $4.9 million, or an effective tax rate of 16.7%, for the nine months ended September 30, 2024 and $7.7 million, or an effective tax rate of 24.1% for the nine months ended September 30, 2023. The income tax rates for the three and nine months ended SeptemberÂ 30, 2024 diverge from the federal statutory rate due to (i) effects of state income taxes ; (ii) officer's compensation limitations; (iii) partial valuation allowance on losses in foreign jurisdictions, partially offset by (iv) excess tax benefits attributable to share based compensation; and (v) noncontrolling interests from controlled partnerships.LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (â€œROUâ€) assets, current operating lease liabilities, and long term operating lease liability in our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have 15Table of Contentselected to account for the components as a single lease component. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of SeptemberÂ 30, 2024. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.EQUITY BASED COMPENSATION â€” We have one long-term incentive plan that we adopted in 2006 and which we have amended and restated at various points in time: April 20, 2015, March 9, 2017, April 15, 2021 April 27, 2023, and most recently by our stockholders at our annual stockholders meeting on June 7, 2023 (the â€œRestated Planâ€). We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three years to five years and expire five years to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes model. This model requires that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awardsâ€™ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 7, Stock-Based Compensation, for more information.COMPREHENSIVE INCOME (LOSS) - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the three and nine months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023 are included in the consolidated statements of comprehensive income.INTEREST INCOME - We recognized interest income of approximately $9.6 million and $3.6 million for the three months ended SeptemberÂ 30, 2024 and 2023,

respectively, and $22.7 million and $6.3 million for the nine months ended September 30, 2024 and 2023, respectively. Interest income is recorded within Other non-operating income in our Condensed Consolidated Statements of Operations.COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. If one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.DERIVATIVE INSTRUMENTS - In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500.0 million, consisting of two agreements of $50.0 million each and two agreements of $200.0 million each. The 2019 Swaps secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the smaller notional and will mature in October 2025 for the larger notional. We arranged the 2019 Swaps with locked in 1 month Term SOFR rates at 1.89% for the $100.0 million notional and at 1.98% for the $400.0 million notional. As of the effective date, we are liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates are above the arranged rates.At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive gain or loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. The cash flows for both our $400.0 million notional interest rate swap contract locked in at 1.98% due October 2025 and our $100.0 million notional interest rate swap contract locked in at 1.89% did not match the cash flows for our term 16Table of Contentsloans under our Barclays Credit Facility, so we determined that they are not effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400.0 million notional and after July 1, 2020 for the $100.0 million notional are being recognized in earnings.Â As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount was amortized to interest expense through October 2023 at approximately $0.4 million per month and continuing at approximately $0.3 million per month through October 2025. The effect for the release of the taxes from other comprehensive income is based on the current tax rate.A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):For the three months ended September 30, 2024AccountJune 30, 2024 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*September 30, 2024 Balance LocationAccumulated Other Comprehensive Loss, net of taxes$(4,369)$â€”986(3,383)Equity*Net of taxes of $0.4Â million for the three months ended September 30, 2024.For the nine months ended September 30, 2024AccountDecember 31, 2023 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*September 30, 2024 BalanceLocationAccumulated Other Comprehensive Loss, net of taxes$(11,625)$â€”$8,242$(3,383)Equity*Net of taxes of $2.8Â million for the nine months ended September 30, 2024.A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):For the three months ended September 30, 2024Ineffective interest rate swapAmount recognized (current period ineffective portion)Location recognized in profit and loss (current period ineffective portion)Amount reclassified from accumulated OCI (prior period effective portion)Location reclassified from accumulated OCI into profit and loss (prior period effective portion)Interest rate contracts$6,755Â Other income (expense)$986Â Interest Expense17Table of ContentsFor the nine months ended September 30, 2024Ineffective interest rate swapAmount recognized (current period ineffective portion)Location recognized in profit and loss (current period ineffective portion)Amount reclassified from accumulated OCI (prior period effective portion)Location reclassified from accumulated OCI into profit and loss (prior period effective portion)Interest rate contracts$7,429Â Other income (expense)$8,242Â Interest ExpenseSee Fair Value Measurements below for the fair value of the 2019 Swaps at SeptemberÂ 30, 2024.CONTINGENT CONSIDERATION - The HLH Imaging Group Limited fka Heart and Lung Imaging LimitedOn November 1, 2022, we completed our acquisition of 75% of the equity interests of Heart and Lung Imaging Limited. The purchase included up to $10.2 million in contingent milestone consideration and cash holdback of $0.6 million to be issued 24 months after acquisition subject to adjustment for any indemnification claims, which will be adjusted to fair value in subsequent periods. The holdback had a value of approximately $0.6 million as of SeptemberÂ 30, 2024. The contingent consideration is determined by the achievement of a specific number of physician reads. On September 20, 2023, we settled a milestone contingent liability by issuing 56,600 shares of our common stock at an ascribed value of $1.6 million and cash of $1.8 million. On December 12, 2023, we settled a milestone contingent liability by issuing 64,569 shares of our common stock at an ascribed value of $2.3 million and cash of $2.1 million. On March 27, 2024, we partially settled a milestone contingent liability by issuing 95,019 shares of our common stock at an ascribed value of $4.6 million. On April 1, 2024, we settled the remaining milestone contingent liability in cash of $3.6 million.A tabular roll forward of contingent consideration is as follows (amounts in thousands):18Table of Contents For the three months ended September 30, 2024EntityAccountJune 30, 2024 BalanceSettlement of contingent considerationChange in valuation of contingent considerationCurrency translationSeptember 30, 2024 BalanceHeart and LungAccrued expenses632Â $â€”Â $â€”Â $â€”Â $632Â For the three months ended September 30, 2023EntityAccountJune 30, 2023 BalanceSettlement of contingent considerationChange in valuation of contingent considerationCurrency translationSeptember 30, 2023 BalanceHeart and LungAccrued Expenses & Other Long Term Liabilities14,358Â $(3,402)$915Â (772)11,099Â For the nine months ended September 30, 2024EntityAccountJanuary 1, 2024 BalanceSettlement of contingent considerationChange in valuation of contingent considerationCurrency translationSeptember 30, 2024 BalanceHeart and LungAccrued expenses6,879Â $(8,221)$1,060Â $914Â $632Â For the nine months ended September 30, 2023EntityAccountJanuary 1, 2023 BalanceSettlement of contingent considerationChange in valuation of contingent considerationCurrency translationSeptember 30, 2023 BalanceHeart and LungAccrued Expenses & Other Long Term Liabilities11,656Â $(3,402)$2,906Â (61)11,099Â Gain or loss from change in valuation of contingent consideration are recorded within Cost of operations in our Consolidated Statements of Operations. See Fair Value Measurements below for the fair value of contingent consideration at SeptemberÂ 30, 2024.FAIR VALUE MEASUREMENTS â€“ Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:LevelÂ 1â€“Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.LevelÂ 2â€“Fair value is determined by using inputs other than LevelÂ 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.LevelÂ 3â€“Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.Derivatives:The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):19Table of ContentsÂ As of September 30, 2024Level 1Level 2Level 3TotalLong term assetsÂ Â Â Â 2019 Swaps - Interest Rate Contracts$â€”Â $7,689Â $â€”Â $7,689Â Â As of December 31, 2023Level 1Level 2Level 3TotalCurrent and long term assetsÂ Â Â Â 2019 Swaps - Interest Rate Contracts$â€”Â $15,118Â $â€”Â $15,118Â The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterpartyâ€™s forward SOFR curve. The forward SOFR curve is readily available in the public markets or can be derived from information available in the public markets.Contingent Consideration:The table below summarizes the estimated fair values of holdback relating to our Heart and Lung Imaging Limited acquisition on November 1, 2022 that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands):Â As of September 30, 2024Level 1Level 2Level 3TotalAccrued expensesÂ Â Â Â Heart & Lung Imaging Limited$â€”Â $â€”Â $632Â $632Â Â As of December 31, 2023Level 1Level 2Level 3TotalAccrued expensesÂ Â Â Â Heart & Lung Imaging Limited$â€”Â $â€”Â $6,879Â $6,879Â The estimated fair value of these liabilities was determined using Level 3 inputs. For Heart & Lung Imaging Limited the contingent consideration is determined by the achievement of a specific number of physician reads. The fair value is measured based upon the probability adjusted amount expected to be paid. As significant inputs for the contingent consideration of Heart & Lung Imaging Limited are not observable and cannot be corroborated by observable market data they are classified as Level 3.Long Term Debt:The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands):Â As of September 30, 2024Level 1Level 2Level 3Total Fair ValueTotal Face ValueBarclays Term Loan and Truist Term Loan$â€”Â $1,010,778Â $â€”Â $1,010,778Â $1,009,687Â Â As of December 31, 2023Level 1Level 2Level 3Total Fair ValueTotal Face ValueBarclays Term Loan and Truist Term Loan$â€”Â $824,759Â $â€”Â $824,759Â $823,063Â The estimated fair value of our long-term debt, which is discussed in Note 6, Credit Facilities and Notes Payable, was determined using Level 2 inputs primarily related to comparable market prices.20Table of ContentsWe consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment.EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):Â Three Months Ended September 30,Nine Months Ended September 30,20242023202420023NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$3,209Â $17,540Â $(2,552)$4,904Â BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERSWeighted average number of common shares outstanding during the period73,494,709Â 67,793,404Â 72,587,321Â 62,113,707Â Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders$0.04Â $0.26Â (0.04)0.08Â DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERSWeighted average number of common shares outstanding during the period73,494,709Â 67,793,404Â 72,587,321Â 62,113,707Â Add non-vested restricted stock subject only to service vesting233,235Â 217,238Â â€”Â 202,082Â Add additional shares issuable upon exercise of stock options and contingently issuable shares1,437,491Â 799,176Â â€”Â 905,462Â Weighted average number of common shares used in calculating diluted net income per share75,165,435Â 68,809,818Â 72,587,321Â 63,221,251Â Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders$0.04Â $0.25Â (0.04)0.08Â Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:Non-vested restricted stock subject to service vestingâ€”Â â€”Â 680,318Â â€”Â Shares issuable upon the exercise of stock optionsâ€”Â 88,600Â 820,932Â 761,708Â Shares issuable subject to satisfaction of certain contingenciesâ€”Â â€”Â â€”Â 193,207Â Weighted average shares for which the exercise price exceeds average market price of common stockâ€”Â â€”Â â€”Â 94,346Â INVESTMENTS IN EQUITY SECURITIESâ€“Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income. As of SeptemberÂ 30, 2024, we have four equity investments with an aggregate carrying value of $8.0 million. During the three months ended September 30, 2024, we recognized a $1.2 million impairment loss on our investment in Israel-based Medic Vision. This was driven by the escalating geopolitical tensions in Israel, which adversely affected market conditions, along with a bona fide offer we received for a similar investment. The offer, which was below the carrying value of our investment, provided a reliable indication of the current fair value of our Medic Vision investment. As a result, we 21Table of Contentsdetermined that the carrying amount of the investment exceeded its fair value, and the impairment loss has been recorded within "Other income" in our Condensed Consolidated Statements of Operations.No other observable price changes or impairments in our investments were identified as of SeptemberÂ 30, 2024. INVESTMENT IN JOINT VENTURES â€“ We have 13 unconsolidated joint ventures with ownership interests ranging from 33% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture.Â Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of SeptemberÂ 30, 2024.Joint venture investment and financial informationThe following table is a summary of our investment in joint ventures during the nine months ended September 30, 2024 (in thousands):Balance as of December 31, 2023$92,710Â Equity in earnings in these joint ventures11,308Â Distribution of earnings(1,000)Equity contributions in existing joint ventures1,496Â Balance as of September 30, 2024$104,514Â We charged management service fees from the centers underlying these joint ventures of approximately $5.9 million and $3.9 million for the three months ended SeptemberÂ 30, 2024 and 2023 and $17.8Â million and $12.2Â million for the nine months ended September 30, 2024 and 2023, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures. As we have the ability to exercise significant influence over our joint venture entities, we consider them related parties. Amounts transacted between ourselves and the entities are in the ordinary course of business and are disclosed on our balance sheet in the due from/to affiliate accounts.The following table is a summary of key balance sheet data for these joint ventures as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 and income statement data for the nine months ended September 30, 2024 and 2023 (in thousands):Balance Sheet Data:September 30, 2024December 31, 2023Current assets$64,175Â $39,819Â Noncurrent assets219,478Â 224,936Â Current liabilities(41,550)(46,587)Noncurrent liabilities(70,607)(70,834)Total net assets$171,496Â $147,334Â Income statement data for the nine months ended September 30,20242023Net revenue$195,905Â $129,020Â Net income$23,949Â $7,906Â NOTE 3 â€“ RECENT ACCOUNTING AND REPORTING STANDARDSRecently Issued Accounting PronouncementsIn November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated 22Table of Contentsguidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. NOTE 4 â€“ BUSINESS COMBINATIONS AND RELATED ACTIVITYImaging Center SegmentAcquisitionsDuring the nine months ended September 30, 2024, we completed the acquisition of certain assets of the following entities, which either engage directly in the practice of radiology or associated businesses. The primary reason for these acquisitions was to strengthen our presence in the California and Texas market. These acquisitions are reported as part of our Imaging Center segment. As of SeptemberÂ 30, 2024, we made a preliminary fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands). The valuation of assets acquired and liabilities assumed has not yet been finalized as of SeptemberÂ 30, 2024; and the fair value determination is preliminary and may be subject to change:Entity Date AcquiredTotal ConsiderationProperty & EquipmentRight of Use AssetsGoodwillIntangible AssetsOther AssetsRight of Use LiabilitiesNotes payableStanislaus Surgical Hospital, LLC9/16/20243,0005041,4682,38210015(1,468)â€”Â Global Imaging LLP9/1/2024$2,900Â 1,266Â â€”Â 1,584Â 50Â â€”Â â€”Â â€”Â U.S. Imaging, Inc.6/1/20244,2004,0255,597â€”175â€”(5,597)â€”Houston Medical Imaging, LLC4/1/202422,70315,8267,92911,5841,66090(8,089)(6,297)Grossman Imaging Center of CMH, LLC3/31/202410,3441,7176,3048,50128056(6,514)â€”Providence Health System - Southern California3/31/2024$7,369Â 1,378Â 3,441Â 5,991Â â€”Â â€”Â (3,441)â€”Â Antelope Valley Outpatient Imaging2/1/2024$3,530Â 2,794Â 563Â 687Â 50Â â€”Â (563)â€”Â Total54,04627,50925,30230,7292,315160(25,672)(6,297)Â During the three months ended September 30, 2024, the Company revised the fair value of certain assets acquired and liabilities assumed of Houston Medical Imaging, LLCâ€™s, Grossman Imaging Center of CMH, LLC, and Providence Health System - Southern California, resulting in an increase of $4.4Â million in the net fair value of these assets and liabilities and a corresponding decrease in goodwill. These adjustments did not have an impact on the Companyâ€™s condensed consolidated statement of operations for the nine months ended September 30, 2024.Formation of majority owned subsidiary and sale of economic

interestOn February 23, 2024, we formed Tri Valley Imaging Group, LLC ("TVIG"), a partnership with Providence Health System - Southern California ("PHS"). The operation offers multi-modality services out of seven locations in Southern 23Table of ContentsCalifornia. On March 29, 2024, we contributed the operations of four centers to the enterprise and PHS contributed a business comprising three centers including $1.4Â million of fixed assets and $6.0Â million in goodwill. Simultaneously, PHS purchased from us an additional economic interest in TVIG for cash payment of $9.6Â million. As a result of the transaction, we recognized a gain of $7.9Â million to additional paid in capital and retained a 52% controlling economic interest in TVIG and PHS retains a $7.8Â million or 48% noncontrolling economic interest in TVIG.In determining the fair value of the imaging centers contributed to TVIG, we used an income approach which is considered a level 3 valuation technique. See Fair Value Measurements above for further detail on the valuation hierarchy. Key assumptions used in measuring the fair value are financial forecasts and a discount rate. We also utilized the cash paid for an additional interest in the joint venture to substantiate the fair value of the contributed assets.NOTE 5 â€“ SEGMENT REPORTINGIn the first quarter of 2024, we revised our reportable segments to combine our eRad business, which was included in the Imaging Center segment, with our AI segment to form a new Digital Health reportable segment. Prior period amounts were adjusted retrospectively to reflect the change in reportable segment. Accordingly, our reportable segments currently include our Imaging Center segment and our Digital Health segment.Our Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a strategy that diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures.Our Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. Included in the segment is our eRad subsidiary, which designs the underlying critical scheduling, data storage and retrieval systems necessary for imaging center operation.Our chief operating decision maker ("CODM"), who is also our CEO, evaluates the financial performance of our segments based upon their respective revenue and segmented internal profit and loss statements prepared on a basis not consistent with GAAP. We do not report balance sheet information by segment since it is not reviewed by our CODM.In the normal course of business, our Imaging Center and Digital Health segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.Three Months Ended September 30, 2024Imaging CenterDigital HealthIntersegment EliminationConsolidated TotalRevenue:Third Party$452,368Â $8,774Â $â€”Â $461,142Â Intersegmentâ€”Â 7,593Â (7,593)â€”Â Total revenue$452,368Â $16,367Â $(7,593)$461,142Â Three months ended September 30, 2023Imaging CenterDigital HealthIntersegment EliminationConsolidated TotalRevenue:Third Party$395,613Â $6,355Â $â€”Â $401,968Â Intersegmentâ€”Â 5,830Â (5,830)â€”Â Total revenue$395,613Â $12,185Â $(5,830)$401,968Â 24Table of ContentsNine Months Ended September 30, 2024Imaging CenterDigital HealthIntersegment EliminationConsolidated TotalRevenue:Third Party$1,325,825Â $26,738Â $â€”Â $1,352,563Â Intersegmentâ€”Â 20,118Â (20,118)â€”Â Total revenue$1,325,825Â 1325825000$46,856Â $(20,118)$1,352,563Â Nine Months Ended September 30, 2023Imaging CenterDigital HealthIntersegment EliminationConsolidated TotalRevenue:Third Party$1,178,873Â $17,374Â $â€”Â $1,196,247Â Intersegmentâ€”Â 17,492Â (17,492)â€”Â Total revenue$1,178,873Â 1178873$34,866Â $(17,492)$1,196,247Â The table below presents segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands):25Table of ContentsThree months ended September 30,Nine Months Ended September 30,2024202320242023Revenue:Imaging Center444,775Â 389,783Â $1,305,707Â $1,161,381Â Digital Health16,367Â 12,185Â 46,856Â 34,866Â Total revenue$461,142Â 401,968Â $1,352,563Â $1,196,247Â Cost of OperationsImaging Center$374,789Â $334,580Â $1,120,542Â $1,008,814Â Digital Health17,011Â 7,055Â 48,571Â 29,833Â Total cost of operations$391,800Â $341,635Â $1,169,113Â $1,038,647Â Depreciation and Amortization:Imaging Center$32,032Â $30,221Â $94,095Â $89,743Â Digital Health2,947Â 1,989Â 7,727Â 5,962Â Total depreciation and amortization$34,979Â $32,210Â $101,822Â $95,705Â Gain on contribution of imaging centers into joint venture:Imaging Center$â€”Â $(16,808)$â€”Â $(16,808)Digital Healthâ€”Â â€”Â â€”Â Total (gain) loss on contribution of imaging centers into joint venture$â€”Â $(16,808)$â€”Â $(16,808)Loss (gain) on Disposal of Equipment:Imaging Center$153Â $524Â $739Â $1,185Â Digital Health(5)3Â (4)(2)Total loss on disposal of equipment$148Â $527Â $735Â $1,183Â SeveranceImaging Center$271Â $1,141Â $720Â $1,417Â Digital Health33Â 12Â 77Â 1,740Â Total severance$304Â $1,153Â $797Â $3,157Â Â Income (Loss) from OperationsImaging Center$37,530Â $40,125Â $89,611Â $77,030Â Digital Health(3,619)3,126Â (9,515)(2,667)Total income from operations$33,911Â $43,251Â $80,096Â $74,363Â NOTE 6 â€“ CREDIT FACILITIES AND NOTES PAYABLEAt SeptemberÂ 30, 2024 we had two principal secured credit facilities consisting of our Barclays credit facility and our Truist credit facility. Each facility includes a term loan component and a revolving credit facility. At SeptemberÂ 30, 2024, we were in compliance with all covenants under our credit facilities. Barclays Credit Facility26Table of ContentsOn AprilÂ 18, 2024, we entered into a Third Amended and Restated First Lien Credit and Guaranty Agreement (the â€œBarclays Credit Agreementâ€), with Barclays Bank Plc and the lenders and financial institutions named therein, which provides for $875.0Â million of senior secured term loans (the â€œBarclays Term Loanâ€) and a $282.0Â million senior secured revolving credit facility (the â€œBarclays Revolving Credit Facilityâ€). Our borrowing under the Barclays Revolving Credit Facility is secured by a lien on all of our assets. The proceeds from the AprilÂ 18, 2024 restatement of the Barclays Credit Agreement were used to refinance the $678.7 million of term loans outstanding under the prior credit facility, to pay accrued interest through the date of closing, and to pay fees and expenses associated with the refinancing transaction. Total costs incurred in connection with the restatement amounted to approximately $19.9 million segregated as follows: $11.1 million recognized as discount and deferred finance cost, $2.1 million charged to loss on early extinguishment of debt and $6.7 million to related expenses. Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement. Barclays Term Loan:The Barclays Term Loan provides for interest payments based on a base rate, plus an applicable margin. During the periods covered by this report, the base rates, margins and effective interest rates (without giving effect to our 2019 Swaps) were as follows for the periods indicated:PeriodBase Rate plus MarginEffective RateThrough March 31, 2023Eurodollar plus 2.50%Alternative Base Rate plus 2.00%4.63%8.00%April 1, 2023 to April 18, 2024SOFR plus 3.00%Alternative Base Rate plus 2.00%8.33% (credit spread adjustment of 0.11%)10.5%After April 18, 2024SOFR plus 2.5%Prime Rate plus 1.5%7.78% (credit spread adjustment of 0.00%)9.5%With the recent restatement, we are required to make quarterly principal payments of $2.2Â million (up from $1.8Â million under the prior credit agreement). The Barclays Term Loan will mature on April 18, 2031 unless otherwise accelerated under the terms of the Barclays Credit Agreement.Barclays Revolving Credit Facility:The Barclays Revolving Credit Facility is a $282.0Â million senior secured revolving credit facility. Associated with the Barclays Revolving Credit Facility is deferred financing costs, net of accumulated amortization, of $2.0Â million at SeptemberÂ 30, 2024.Amounts borrowed under the Barclays Revolving Credit Facility bear interest at either SOFR plus 3.00% or the Prime Rate plus 2% (with step-downs based on attainment of certain first lien net leverage ratio benchmarks). As of SeptemberÂ 30, 2024, the effective interest rate payable on revolving loans under the Barclays Revolving Credit Facility was 10.50%. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Barclays Revolving Credit Facility.We had no outstanding balance under our $282.0Â million Barclays Revolving Credit Facility at SeptemberÂ 30, 2024. After reserves of $8.3Â million for certain letters of credit, $273.7Â million was available to draw upon as of SeptemberÂ 30, 2024. The Barclays Revolving Credit Facility terminates on April 18, 2029, unless otherwise accelerated under the terms of the Barclays Credit Agreement.27Table of ContentsTruist Credit FacilityOn October 7, 2022 our subsidiary New Jersey Imaging Network, Inc.("NJIN") entered into Second Amended and Restated Revolving Credit and Term Loan Agreement (the â€œTruist Credit Agreementâ€), with Truist Bank and the lenders and financial institutions named therein, which provides for a $150.0Â million term loan (the "Truist Term Loan") and a $50.0 million revolving credit facility (the â€œTruist Revolving Credit Facilityâ€). The Truist Credit agreement is secured by the assets of NJIN.Truist Term Loan:The Truist Term Loan currently bears interest at SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. At September 30, 2024 the applicable margin for SOFR was 1.5%.We are required to make quarterly principal payments of $1.9 million, which increases by $0.9 million at scheduled intervals, with the remaining balance to be paid at maturity. The Truist Term Loan will mature on October 10, 2027 unless otherwise accelerated under the terms of the Truist Credit Agreement.Truist Revolving Credit Facility:The Truist Revolving Credit Facility is a $50.0 million secured revolving credit facility. Associated with the Truist Revolving Credit Facility are deferred financing costs, net of accumulated amortization, of $0.4 million at SeptemberÂ 30, 2024. Amounts borrowed under the Truist Revolving Credit Facility bear interest at either SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. In addition, a commitment fee of 0.30% per annum accrues on the unused revolver commitments under the Truist Revolving Credit Facility.We had no balance under our $50.0Â million Truist Revolving Credit Facility at SeptemberÂ 30, 2024. With no letters of credit reserved against the facility, the full $50.0Â million was available to draw upon as of SeptemberÂ 30, 2024. The Truist Revolving Credit Facility terminates on October 7, 2027, unless otherwise accelerated under the terms of the Truist Credit Agreement. Notes PayableWe have issued certain notes payable in connection with the purchase of equipment previously leased under operating leases. On April 1, 2024, January 15, 2024, and February 1, 2023 we issued promissory notes in the amount of $6.3 million, $6.9Â million and $19.8Â million, respectively, to purchase previously leased equipment.Debt ObligationsAs of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 our term loan debt and other obligations are as follows (in thousands):September 30,2024December 31,2023Barclays Term Loans collateralized by RadNet's tangible and intangible assets$872,812Â $678,687Â Discount on Barclays Term Loans(15,234)(9,041)Truist Term Loan Agreement collateralized by NJIN's tangible and intangible assets136,875Â 144,375Â Discount on Truist Term Loan Agreement(792)(990)Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment25,989Â 17,011Â Total debt obligations1,019,650Â 830,042Â Less: current portion(23,378)(17,974)Long term portion of debt obligations$996,272Â $812,068Â NOTE 7 â€“ STOCK-BASED COMPENSATIONStock Incentive Plans28Table of ContentsWe have one long-term equity incentive plan, the RadNet, Inc. Equity Incentive Plan, which has been amended and restated on April 20, 2015, March 9, 2017, April 15, 2021, April 27, 2023, and most recently following approved by our stockholders at our annual stockholders meeting on June 7, 2023 (the â€œRestated Planâ€). We have reserved for issuance under the Restated Plan 20,100,000 shares of common stock. We can issue options (incentive and nonstatutory), performance based options, stock awards (restricted or unrestricted), stock units, performance based stock units, and stock appreciation rights under the Restated Plan.OptionsCertain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over 3 to 5 years and expire 5 to 10 years from the date of grant.The following summarizes all of our option transactions for the nine months ended SeptemberÂ 30, 2024:Outstanding OptionsUnder the 2006 PlanSharesWeighted AverageExercise pricePer Common ShareWeighted AverageRemainingContractual Life(in years)AggregateIntrinsicValue(in thousands)Balance, December 31, 2023911,411Â $16.60Â Grantedâ€”Â â€”Â Exercised(60,306)6.15Â Balance, September 30, 2024851,105Â 17.34Â 5.69$44,301Â Exercisable at September 30, 2024729,806Â 16.62Â 5.3138,515Â Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on SeptemberÂ 30, 2024 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on SeptemberÂ 30, 2024. As of SeptemberÂ 30, 2024, total unrecognized stock-based compensation expense related to non-vested employee awards was $0.5 million, which is expected to be recognized over a weighted average period of approximately 0.39 years.DeepHealth OptionsDuring the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted options to acquireÂ 412,434Â shares at a grant date fair value of $16.93Â per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of SeptemberÂ 30, 2024, total unrecognized stock based compensation expense related to non-vested DeepHealth options was insignificant.Outstanding OptionsUnder the Deep Health PlanSharesWeighted AverageExercise pricePer Common ShareWeighted AverageRemainingContractual Life(in years)AggregateIntrinsicValue(in thousands)Balance, December 31, 202379,073Â $â€”Â Exercised(9,377)â€”Â Balance, September 30, 202469,696Â â€”Â 5.0$4,836Â Exercisable at September 30, 202469,696Â â€”Â 5.04,836Â Options issued in replacement of original DeepHealth options as a result of our acquisition are not included in the share count under the Restated Plan.Restricted Stock Awards ("RSAs") and Restricted Stock Units ("RSUs")The Restated Plan permits the award of RSAs and RSUs. The following summarizes all unvested RSA's and RSU's activities during the nine months ended SeptemberÂ 30, 2024:29Table of ContentsÂ RSAs and RSUsWeighted-AverageRemainingContractualTerm (Years)Weighted-AverageFair Value per ShareRSAs and RSUs unvested at December 31, 2023762,083Â $22.13Â Changes during the periodGranted797,309Â $37.40Â Vested(875,185)$27.78Â Forfeited or Canceled(13,460)$27.74Â RSAs and RSUs unvested at September 30, 2024670,747Â 1.74$32.33Â We determine the fair value of all RSAs and RSUs based on the closing price of our common stock on the award date.Performance based stock units ("PSUs")In January 2023, we granted certain employees PSUs with a target award of 60,685 shares of our common stock. The PSUs will vest in two equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 200% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2023 through December 31, 2023. In March of 2024, based on the performance condition being achieved, the board of directors issued 121,370 units with a fair value of $18.64 per unit.Performance based stock options ("PSOs")In January 2023, we granted certain employees PSOs with a potential to option a maximum of 235,227 shares of our common stock. The PSOs will vest in three equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 100% of the target award) depending upon the extent to which we achieve a performance condition as determined the board of directors over the period from January 1, 2023 through December 31, 2023. In March 2024, based on the performance condition being achieved, the board of directors issued 235,227 options with a strike price of $18.64 per share.Shares availableOf the 20,100,000 shares of common stock reserved for issuance under the Restated Plan, at SeptemberÂ 30, 2024, there remain approximately 3,285,500 shares available under the Restated Plan for future issuance.NOTE 8 â€“ SUBSEQUENT EVENTSPink Perception LLCOn OctoberÂ 1, 2024, we entered into an agreement to acquire Pink Perception LLC for a purchase consideration of approximately $4.0Â million. Pink Perception LLC consists of two multi-modality imaging centers located in New York. The acquisition closed in the fourth quarter of 2024.Kheiron Medical Technologies Limited On OctoberÂ 22, 2024, we acquired Kheiron Medical Technologies Limited for a purchase consideration of approximately $1.0Â million. Kheiron Medical Technologies Limited is a UK-based AI cancer diagnostic company focused on developing deep learning solutions to support radiologists improve breast cancer detection.ITEM 2.Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsYou should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024.Forward-Looking Statements30Table of ContentsThis report contains â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€) and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.In some cases, you can identify forward-looking statements by terminology such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œexpect,â€ â€œintend,â€ â€œplan,â€ â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotential,â€ â€œcontinue,â€ â€œassumptionâ€ or the negative of these terms or other comparable terminology. Forward-looking statements in this report include, among others, statements we make regarding:â€¢expectations concerning domestic and global economic conditions, rates of inflation, or changes in interest rates;â€¢anticipated trends in our revenues, operating expenses or capital expenditures, and our financial guidance;â€¢expected timing and potential impact of regulatory changes affecting our business; â€¢expected future market acceptance for our products or services, and our competitive strengths in the markets we serve;â€¢our ability to successfully acquire and integrate new businesses, and achieve expected benefits, synergies or operating results from those acquisitions; andâ€¢economics and cost savings anticipated to be derived from our investments in artificial intelligence and machine learning products and solutions.Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to known and unknown risks, uncertainties and other factors that are difficult to predict and out of our control. Our actual results, level of activity, performance or achievements may be materially different from any future results, levels of activity, performance or

achievements expressed or implied by these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated or implied in our forward-looking statements include the factors included in â€œRisk Factors,â€ in our annual report on Form 10-K for the fiscal year ended December 31, 2023 as supplemented by the information in Part IIâ€“ Item 1A below. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.Any forward-looking statement in this report is based on information currently available to us and speaks only as of the date of this report. We do not undertake any responsibility to release publicly any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report or any unanticipated events which may cause actual results to differ from those expressed or implied by the forward-looking statements contained in this report, except as required by law.OverviewWe are a national provider of diagnostic imaging services in the United States. At SeptemberÂ 30, 2024, we operated directly or indirectly through joint ventures with hospitals, 399 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Internationally, our subsidiary The HLH Imaging Group Limited fka Heart and Lung Imaging Limited, provides teleradiology services for remote interpretation of images on behalf of providers within the framework of the United Kingdom's National Health Service.In addition to our imaging business, we have established a Digital Health business segment for our 2024 fiscal year, which combines our former Artificial Intelligence (â€œAIâ€) business segment with our eRad, Inc. business. Our digital health segment develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology. The portfolio of software solutions are anchored by eRad, Inc.'s RIS/PACS, informatics designed specifically for outpatient radiology and DeepHealth OS, a cloud-native operating system that helps operate all aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management. 31Table of ContentsIn addition we are using AI to develop solutions that employ machine learning to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care, initially in the fields of screening for breast, prostate, lung and colon cancers. Our DeepHealth, Inc. subsidiary has received FDA clearance for use of its SaigeQ â€triageâ€/workflow product, SaigeDX advanced diagnostic product and Saige-Density breast density assessment software for screening breast mammography, which we have begun to roll out in certain markets as an Enhanced Breast Cancer Detection solution. Our Aidence Holding B.V. subsidiary is developing solutions for interpretation of chest and lung CT scans for lung cancer screening. It has received the CE mark for its solution and has existing customers in seven European countries, with its largest concentration in the United Kingdom, and plans to submit an application for FDA clearance to sell in the United States. Our Quantib B.V. subsidiary is primarily focused on interpretation of prostate MRI for widespread prostate cancer screening. Quantibâ€™s prostate MRI post-processing software has both FDA clearances and European CE marking. Our digital health segment provides these solutions to RadNet and to over 400 customers in the United States, Europe, and Israel.Our operations comprise two segments for financial reporting purposes for this reporting period, Imaging Centers and Digital Health. For further financial information about these segments, see Note 5, Segment Reporting, in the notes accompanying our financial statements included in this report. Prior period amounts in the financial statements included in this report have been adjusted retrospectively to reflect the change in reportable segment.Recent DevelopmentsThe following table shows our imaging centers in operation and revenues for the nine months ended SeptemberÂ 30, 2024 and 2023:Â Nine Months Ended September 30,Â 20242023Centers in operation399363Â Net revenues (millions)$1,353Â $1,196Â Â Â Â Â 32Table of ContentsOur imaging services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a key point of differentiation from our competitors. The multi-modality offering provides a â€œone-stopâ€ solution for our customers and referral sources. It also diversifies our revenue base, and reduces our exposure to changes in reimbursement rates for certain imaging modalities. The following charts summarize our procedure volumes for various imaging modalities for the three months ended SeptemberÂ 30, 2024 and 2023:33Table of ContentsOur revenue is derived from a diverse mix of payors, including private, managed care capitated and government payors. We believe our payor diversity mitigates our exposure to possible unfavorable reimbursement trends within any one payor class. Our total service fee revenue, net of contractual allowances and discounts, and implicit price concessions for the three and nine months ended SeptemberÂ 30, 2024 and 2023 received from our various payors is summarized in the following table (in thousands):Three Months Ended September 30,Nine Months Ended September 30,Payor20242023202420232Commercial insurance$255,375Â $218,923Â $752,514Â $652,597Â Medicare102,852Â 89,981Â 298,001Â 262,719Â Medicaid10,894Â 10,519Â 32,804Â 30,279Â Workers' compensation/personal injury10,232Â 9,745Â 33,088Â 34,785Â Other patient revenue10,607Â 10,443Â 34,524Â 30,191Â Management fee revenue6,242Â 3,922Â 18,255Â 12,203Â Heart and lung4,696Â 2,441Â 12,553Â 6,377Â Other10,314Â 3,768Â 18,918Â 14,248Â Revenue under capitation arrangements33,563Â 40,041Â 105,050Â 117,982Â Imaging Center Segment Revenue444,775Â 389,783Â 1,305,707Â 1,161,381Â Digital Health Segment Revenue16,367Â 12,185Â 46,856Â 34,866Â Total service revenue461,142Â $401,968Â $1,352,563Â $1,196,247Â AcquisitionsDuring the nine months ended September 30, 2024, we completed the acquisition of certain assets of entities which engage directly in the practice of radiology or in associated businesses for an aggregate consideration of $54.0Â million. These acquisitions include:Antelope Valley Outpatient Imaging: 1 imaging center in California;Providence Health System Southern California: 3 imaging centers in California; Grossman Imaging Center of CMH, LLC: 4 imaging centers in California;Houston Medical Imaging, LLC: 9 imaging centers in Houston, Texas;U.S. Imaging, Inc.: 6 imaging centers in Houston, Texas;Stanislaus Surgical Hospital: 1 imaging center in Modesto, California; and Global Imaging LLP: 1 imaging center in Sugar Land, Texas. The purpose of these acquisitions was to expand our imaging business into Houston, Texas a new market, and to strengthen our presence in the California market. With a population of approximately 7.3 million people, Houston is the fourth largest city in the United States. See Note 4, Business Combinations and Related Activity to the financial statements in this report for additional information, including the fair value determination of the acquired assets and assumed liabilities, associated with these acquisitions.34Table of ContentsJoint Venture ActivityAt SeptemberÂ 30, 2024, 38% of our imaging centers were operating as joint ventures with large health care providers. We have joint venture arrangements with 24 hospital and health system partners (inclusive of consolidated and unconsolidated joint ventures), including MemorialCare (24 centers), RWJ Barnabas (35 centers), Cedars Sinai (18 centers), Dignity Health (28 centers), and MedStar Health System (5 centers). We manage the day to day operations for these joint ventures and perform most management services in exchange for a management fee. We charged management service fees from the centers underlying these joint ventures of approximately $5.9 million and $3.9 million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively. For information on our investment in unconsolidated joint ventures, key balance sheet data and incomestatement data for the unconsolidated joint ventures, see Note 2, Significant Accounting Policies â€“ Investment in Joint Venturesto the financial statements included in this report.Critical Accounting PoliciesThe Securities and Exchange Commission defines critical accounting estimates as those that (a) are most important to the portrayal of a companyâ€™s financial condition and results of operations and (b) require managementâ€™s most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.Â In Note 2 to our financial statements included in this report and in our annual report on Form 10-K for the year ended DecemberÂ 31, 2023, we discuss our significant accounting policies, including those that do not require management to make difficult, subjective or complex judgments or estimates. The most significant areas involving managementâ€™s judgments and estimates are described below.Use of EstimatesThe financial statements included in this report were prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect various matters, including our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements; our disclosure of contingent assets and liabilities at the dates of the financial statements; and our reported amounts of revenues and expenses in our consolidated statements of operations during the reporting periods. These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond managementâ€™s control. As a result, actual amounts could materially differ from these estimates.RevenuesOur revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied, which is generally over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payors. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations, changes in business and economic conditions, and the frequent changes in managed care contractual terms resulting from contract re-negotiations and renewals.As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by them as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.Our revenues are based upon our management's estimate of amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under Medicare, Medicaid, managed care and commercial insurance plans are based upon historical collection experience of the payments received from such payors in accordance with the underlying contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts 35Table of Contentsfor patients who have health care coverage may have price concessions applied. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans. Our estimates and assumptions related to revenue recognition did not change materially for the quarter ended SeptemberÂ 30, 2024.Accounts ReceivableSubstantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients.Â Services are generally provided pursuant to one-year contracts with healthcare providers. Receivables generally are collected within industry norms for third-party payors.Â We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. Our estimates and assumptions for allowances on our account receivable did not change materially during the quarter ended SeptemberÂ 30, 2024.Business CombinationWe evaluate all acquisitions under the framework Clarifying the Definition of a Business in the accounting guidance. Once a purchase has been determined to be the acquisition of a business, we are required to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. Any portion of the purchase consideration transferred in excess of the net of the acquisition date fair values of the assets acquired and the liabilities assumed, is allocated to goodwill. The allocation requires our management to make estimates of the value of various assets acquired and liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.Goodwill and Indefinite Lived IntangiblesGoodwill at SeptemberÂ 30, 2024 totaled $711.8 million. Indefinite Lived Intangible Assets at SeptemberÂ 30, 2024 were $20.2 million and are associated with the value of certain trade name intangibles and in process research and development ("IPR&D"). Goodwill, trade name intangibles and IPR&D are recorded as a result of business combinations. When we determine the carrying value of goodwill for a reporting unit exceeds its fair value, an impairment charge would be recognized which should not exceed the total amount of goodwill allocated to that reporting unit. We determined fair values for each of the reporting units using the market approach, when available and appropriate, or the income approach, or a combination of both. We assess the valuation methodology based upon the relevance and availability of the data at the time we perform the valuation. If multiple valuation methodologies are used, the results are weighted appropriately. Our annual impairment test of goodwill and trade name noted no impairment as of October 1, 2023, and we have not identified any other indicators of impairment through SeptemberÂ 30, 2024.Recent Accounting StandardsSee Note 3, Recent Accounting and Reporting Standards to the financial statements included in this report for further information.Results of OperationsThree Months Ended September 30, 2024 Compared to the Three Months Ended September 30, 2023Imaging Center SegmentWe have developed our medical imaging centers segment through a combination of organic growth, acquisitions and joint venture formations. In the discussion below same center metrics are based on imaging centers that were in operation throughout the period of July 1, 2023 through SeptemberÂ 30, 2024. Excluded amounts relate to imaging centers that were acquired or divested between July 1, 2023 through SeptemberÂ 30, 2024.36Table of ContentsTotal Revenue In ThousandsThree Months Ended September 30,Revenue20242023$ Increase% ChangeTotal$444,775$389,783$54,99214.1%Same Center$422,881$381,620$41,26110.8%Excluded$21,894$8,163â€”â€“Our 10.8% increase in same center revenue over the same period last year was driven by increases in fees charged per imaging procedure and an increase in procedures volumes. Same center total procedure volume grew at an overall rate of 4.0% which was comprised of a 2.55% increase in routine imaging and an 8.6% increase in advanced modality imaging procedures. The increase in revenue was largely attributable to product mix, as advanced imaging was a greater portion of overall procedures. A significant contributor to the change in product mix was the increase in PETHC procedures related to prostate cancer and suspect Alzheimerâ€™s studies, which are included in advanced modality imaging procedures. Operating ExpensesTotal operating expenses for the three months ended September 30, 2024 increased approximately $57.6 million, or 16.5%, to $407.2 million for the three months ended September 30, 2024 from $349.7 million for the three months ended September 30, 2023. The following table breaks down our cost of operations and total operating expenses for the three months ended September 30, 2024 and 2023 (in thousands):Â Â Three Months EndedSeptember 30,Â 20242023Salaries and professional reading fees, excluding stock-based compensation$243,066Â $210,314Â Stock-based compensation4,195Â 3,937Â Building and equipment rental31,104Â 29,720Â Medical supplies26,668Â 21,285Â Other operating expenses *69,756Â 69,324Â Cost of operations374,789Â 334,580Â Depreciation and amortization32,032Â 30,221Â Gain on contribution of imaging centers into joint ventureâ€”Â (16,811)Loss on sale and disposal of equipment153Â 524Â Severance costs271Â 1,141Â Total operating expenses$407,245Â $349,655Â Â Â Â Â *Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.The discussion below provides additional information and analysis on changes in our various operating expenses for the three months ended SeptemberÂ 30, 2024 and 2023 (in thousands): Salaries and professional reading fees, excluding stock-based compensation and severanceIn ThousandsThree Months Ended September 30,Salaries and Professional Fees20242023$ Increase/(Decrease)% ChangeTotal $243,066$210,314$32,75215.6%Same Center$231,039$206,401$24,63811.9%Excluded $12,027$3,913â€”â€“37Table of ContentsConsistent with the higher procedure volumes noted above, our staffing levels were adjusted to support the influx of patients seeking radiology procedures. We are continuing to face inflation in employee wage rates as we compete for talent in a tight labor market.Stock-based compensationStock-based compensation for the three months ended September 30, 2024 increased approximately $0.3 million, or 6.6%, to $4.2 million from $3.9 million for the three months ended September 30, 2023. The increase is primarily due to higher fair value of stock awards granted in the first quarter of 2024. Building and equipment rentalIn ThousandsThree Months Ended September 30,Building & Equipment Rental20242023$ Increase/(Decrease)% ChangeTotal$31,104$29,720$1,3844.7%Same Center $27,763$27,512$2510.9%Excluded $3,341$2,208â€”â€“Building and equipment rental expense on a same center basis was relatively unchanged from the prior period.Medical suppliesIn ThousandsThree Months Ended September 30,Medical Supplies Expense20242023$ Increase/(Decrease)% ChangeTotal$26,668$21,285$5,38325.3%Same Center$25,213$20,614$4,59922.3%Excluded $1,455$671â€”â€“The

increase in medical supplies expense was driven by our higher patient volume and product shift towards more advanced imaging modalities. The increase in PETHC procedures related to prostate cancer and suspected Alzheimer studies also raised medical supplies expense due to the requirement for high-cost isotope tracers.Other operating expensesIn ThousandsThree Months Ended September 30,Other Operating Expenses20242023$ Increase/(Decrease)% ChangeTotal$69,756$69,324$4320.6%Same Center$66,254$67,584$(1,330)(2.0)%Excluded $3,502$1,740â€”â€”Other operating expenses was relatively unchanged compared to the same period in the prior year and lower as a percentage of overall revenues. Additional segment operating and non-operating expensesIn ThousandsThree Months Ended September 30,20242023$ Increase/(Decrease)% ChangeDepreciation and amortization$32,032$30,221$1,8116.0%Loss on disposal of equipment and other$153$524$(371)(70.8)%Non-cash change in fair value of interest rate hedge$6,754$1,0145,740566.1%Other income($8,233)($4,673) (3,560)76.2%Severance$271$1,141(870)(76.2)%38Table of ContentsThe increase in depreciation expense was the result of our higher depreciable asset base.The fair value of the 2019 Swaps at SeptemberÂ 30, 2024 was a net asset of $7.7 million compared to a net asset of $14.4 million June 30, 2024, resulting in a loss of $6.8 million during the three months ended September 30, 2024. This change in fair value was driven by market expectations of continued declines in interest rates over the remaining term of the 2019 Swaps.Other income for the three months ended September 30, 2024 included money market interest income of $9.6 million, partially offset by a impairment of non-marketable securities of $1.2 million. Interest income for the three months ended September 30, 2024 increased approximately $6.0 million, or 164.9%, to $9.6 million from $3.6 million for the three months ended September 30, 2023. The increase is primarily due to higher average cash balance in our money market account for the three months ended September 30, 2023Â Â Â Â In ThousandsNine Months Ended September 30,20242023$ Increase/(Decrease)% ChangeInterest income(9,580)(3,616)$(5,964)164.9%Debt restructuring and extinguishment expenses1470$147nmOther non-operating losses (income)1,200(1,057)$2,257(213.5)%Total other income$(8,233)$(4,673)$(3,560)76.2%In ThousandsThree Months Ended September 30,20242023$ Increase/(Decrease)% ChangeTotal other income($8,233)($4,673)(3,560)76.2%Interest expenseIn ThousandsThree Months Ended September 30,Interest Expense20242023$ Increase/(Decrease)% ChangeTotal Interest Expense$19,427Â $16,115Â $3,31220.6Â %Interest expense related to derivatives*(2,068)(2,913)Interest expense related to amortization**795Â 746Â Adjusted Interest Expense***20,700Â 18,282Â 2,41813.2Â %*Includes payments from 2019 Swaps**Includes noncash amortization of deferred loan costs and discount on issuance of debt***Includes interest related to our term loans, revolving credit line, notes, and otherThe increase in interest expense was the result in of refinancing of our Barclays credit facility, which added approximately $196.3 million in additional term loan debt to the facility. The effect of the additional term loan was partially offset by lower interest rates compared to the same period in the prior year.During the three months ended September 30, 2024, interest rates were above the arranged rates in our 2019 Swaps for most of the year and we received payment of $3.4 million in cash payments from our 2019 swap counterparties, which was reported as a component of interest expense. Also, the 2019 Swaps for $100 million of notional value matured in October 2023, so they were in effect for the third quarter of 2023, but not 2024. See the Derivative Instruments section of Note 2, Significant Accounting Policies, in the notes accompanying in our annual report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 and Part 1, Item 3 â€” "Quantitative and Qualitative Disclosure About Market Risk" below for more details on our derivative transactions. Equity in earnings from unconsolidated joint ventures39Table of ContentsFor the three months ended September 30, 2024 and 2023 we recognized equity in earnings from unconsolidated joint ventures in the amount of $3.6 million and $1.1 million, respectively, an increase of $2.5 million or 231.6%. The increase was mainly due to the additional contribution made to Santa Monica Imaging Group, LLC in September 2023. Santa Monica Imaging Group operated at a net income for the three months ended September 30, 2024, which positively impacted our equity in earnings from unconsolidated joint ventures during the period. Additionally, we experienced improved earnings from our interest in the Arizona Diagnostic Radiology Group joint venture, which was established in the fourth quarter of 2020.Net income attributable to noncontrolling interests At SeptemberÂ 30, 2024, our consolidated subsidiaries operated 345 imaging centers of which 98 were not wholly-owned and thus a portion of their operating results were attributable to noncontrolling interests. At September 30, 2023, our consolidated subsidiaries included 320 centers of which 83 were not wholly-owned. For the three months ended September 30, 2024, we recognized net income attributable to noncontrolling interests of $9.0 million versus $6.5 million for the three months ended September 30, 2023, an increase of $2.6 million. The increase in net income attributable to noncontrolling interests was primarily due to the formation of a new majority owned subsidiary, Los Angeles Imaging Group, LLC in September 2023 and Tri Valley Imaging Group, LLC in March 2024. We contributed the operations of three centers to Los Angeles Group, LLC and Cedars-Sinai Medical Center contributed cash. Additionally, patient volumes for advanced modalities improved in 2024 and we closed two underperforming centers in a majority owned subsidiary, Beach Imaging Group, LLC in December 2023.As noncontrolling interests only represent a portion of our imaging center business, and excludes our Digital Health Segment which generated losses of $3.6 million for the three months ended September 30, 2024, we do not expect changes in net income attributable to noncontrolling interests to correlate with changes in consolidated operating income or pretax income.Nine Months Ended September 30, 2024 Compared to the Nine Months Ended September 30, 2023 In the discussion below, same center metrics are based on imaging centers that were in operation throughout the period of January 1, 2023 through SeptemberÂ 30, 2024. Excluded amounts relate to imaging centers that were acquired or divested between January 1, 2023 through SeptemberÂ 30, 2024.Total RevenueIn ThousandsNine Months Ended September 30,Revenue20242023$ Increase% ChangeTotal $1,305,707$1,161,381$144,32612.4%Same Center$1,224,946$1,107,208$117,73810.6%Excluded$80,761$54,173â€”â€”Our 10.6% increase in same center revenue over the same period last year was driven by increases in fees charged per imaging procedure and same center total procedure volume growth of 3.3% inclusive of rises in routine and advanced modality imaging procedures of 1.82% and 7.76%, respectively. The increase in revenue was largely attributable to product mix product mix, as advanced imaging was a greater portion of overall procedures. A significant contributor to the change in product mix was the increase in PETHC procedures related to prostate cancer and suspected Alzheimer studies, which are included in advanced modality imaging procedures. Operating ExpensesTotal operating expenses for the nine months ended September 30, 2024 increased approximately $131.7 million, or 12.1%, to $1,216.1 million for the nine months ended September 30, 2024 from $1,084.4 million for the nine months ended September 30, 2023. The following table breaks down our cost of operations and total operating expenses for the nine months ended September 30, 2024 and 2023 (in thousands):Â 40Table of ContentsÂ Nine Months Ended September 30,Â 20242023Salaries and professional reading fees, excluding stock-based compensation$731,134Â $635,016Â Stock-based compensation19,614Â 19,484Â Building and equipment rental89,827Â 88,592Â Medical supplies75,146Â 63,829Â Other operating expenses *204,821Â 201,893Â Cost of operations1,120,542Â 1,008,814Â Depreciation and amortization94,095Â 89,743Â Gain on contribution of imaging centers into joint ventureâ€”Â (16,808)Loss on sale and disposal of equipment739Â 1,185Â Severance costs720Â 1,417Â Total operating expenses$1,216,096Â $1,084,351Â Â Â Â Â *Includes billing fees, office supplies, repairs and maintenance, insurance, business tax and license, outside services, telecom, utilities, marketing, travel and other expenses.Salaries and professional reading fees, excluding stock-based compensation and severanceIn ThousandsNine Months Ended September 30,Salaries and Professional Fees20242023$ Increase/(Decrease)% ChangeTotal $731,134$635,016$96,11815.1%Same Center$693,291$611,204$82,08713.4%Excluded$37,843$23,812â€”â€”Staffing levels have been adjusted to support higher patient volumes with the corresponding rise in salaries and professional fee expense. We are continuing to face inflation in employee wage rates as we compete for talent in a tight labor market. Stock-based compensationStock-based compensation was relatively unchanged at $19.6 million for the nine months ended September 30, 2024 compared to $19.5 million for nine months ended September 30, 2023. Building and equipment rentalIn ThousandsNine Months Ended September 30,Building & Equipment Rental20242023$ Increase/(Decrease)% ChangeTotal$89,827$88,592$1,2351.4%Same Center $79,558$80,442$(884)(1.1)%Excluded$10,269$8,150â€”â€”The decrease in building and equipment rental expense relates to reduced equipment rental relating to operating lease contracts which ended or were bought out during 2023.Medical supplies41Table of ContentsIn ThousandsNine Months Ended September 30,Medical Supplies Expense20242023$ Increase/(Decrease)% ChangeTotal$75,146$63,829$11,31717.7%Same Center$70,494$60,931$9,56315.7%Excluded$4,652$2,898â€”â€”The increase in medical supplies expense was consistent with our higher patient volume and product shift towards more advanced imaging modalities. The increase in PETHC procedures related to prostate cancer and suspected Alzheimer studies also raised medical supplies expense due to the requirement for high-cost isotope tracers.Other operating expensesIn ThousandsNine Months Ended September 30,Other Operating Expenses20242023$ Increase/(Decrease)% ChangeTotal$204,821$201,893$2,9281.5%Same Center$191,345$193,385$(2,040)(1.1)%Excluded Sites$13,476$8,508â€”â€”Other operating expenses was relatively unchanged compared to the same period in the prior year and lower as a percentage of overall revenues. Additional segment operating and non operating expenses:In ThousandsNine Months Ended September 30,20242023$ Increase/(Decrease)% ChangeDepreciation and amortization$94,095$89,743$4,3524.8%Gain on contribution of imaging centers into joint venture0(16,808)$16,808nmLoss on disposal of equipment and other$739$1,185$(446)(37.6)%Non-cash change in fair value of interest rate hedge$7,429$949$6,480682.8%Other income$(12,753)$(6,323)$(6,430)101.7%Severance$720$1,417$(697)(49.2)%42Table of ContentsThe increase in depreciation expense was the result of our higher depreciable asset base.The fair value of the 2019 Swaps at SeptemberÂ 30, 2024 was a net asset of $7.7 million compared to a net asset of $15.1 million DecemberÂ 31, 2023, resulting in a loss of $7.4Â million during the nine months ended September 30, 2024. This change in fair value was driven by market expectations of continued declines in interest rates over the remaining term of the 2019 Swaps.Other income for the nine months ended September 30, 2024 included money market interest income of $22.7Â million, partially offset by an impairment of non-marketable securities of $1.2 million and a debt extinguishment and restructuring charges of $8.9Â million, which related to refinancing of our Barclays credit facility. See Note 6 Credit Facilities and Notes Payable included in the notes to our condensed consolidated financial statements. Interest income for the nine months ended September 30, 2024 increased approximately $16.4 million, or 260.2%, to $22.7 million from $6.3 million for the nine months ended September 30, 2024. The increase is primarily due to higher average cash balance in our money market account for the nine months ended September 30, 2024In ThousandsNine Months Ended September 30,20242023$ Increase/(Decrease)% ChangeInterest income(22,681) (6,297)$(16,384)260.2%Debt restructuring and extinguishment expenses8,9090$8,909nmOther non-operating losses (income)1,019(26)$1,045(4019.2)%Total other income$(12,753)$(6,323)$(6,430)101.7%nm= not meaningful Interest expenseIn ThousandsNine Months Ended September 30,Interest Expense20242023$ Increase/(Decrease)% ChangeTotal Interest Expense$61,776Â $47,876Â $13,90029.0Â %Interest expense related to derivatives*776Â (7,138)Interest expense related to amortization**2,336Â 2,240Â Adjusted Interest Expense***58,664Â 52,774Â 5,89011.2Â %*Includes payments from 2019 Swaps**Includes noncash amortization of deferred loan costs and discount on issuance of debt***Includes interest related to our term loans, revolving credit line, notes, and otherThe increase in interest expense was the result in the general increase in term loan debt as a result of refinancing of our Barclays credit facility, partially offset by lower interest rates compared to the same period in the prior year. During the nine months ended September 30, 2024, interest rates were above the arranged rates in our 2019 Swaps for most of the year and we received payment of $10.2 million in cash payments from our 2019 swap counterparties, which was reported as a component of interest expense. Also, the 2019 Swaps for $100 million of notional value matured in October 2023, so they were in effect for the third quarter of 2023, but not 2024. See the Derivative Instruments section of Note 2, Significant Accounting Policies, in the notes accompanying in our annual report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 and Part 1, Item 3 â€” "Quantitative and Qualitative Disclosure About Market Risk" below for more details on our derivative transactions.Equity in earnings from unconsolidated joint venturesFor the nine months ended September 30, 2024 we recognized equity in earnings from unconsolidated joint ventures in the amount of $11.3 million compared to $3.9 million for the prior period, an increase of $7.4 million or 187.4%. The increase was mainly due to the additional contribution made to SMIG in September 2023. SMIG operated at a net income for the nine months ended September 30, 2024, which positively impacted our equity in earnings from unconsolidated joint ventures during 43Table of Contentsthe period. Additionally, the increase was supported by improved earnings from our interest in the Arizona Diagnostic Radiology Group joint venture, which was established in the fourth quarter of 2020.Income tax expenseWe recorded income tax expense of $4.9 million, or an effective tax rate of 16.7%, for the nine months ended September 30, 2024 and $7.7 million, or an effective tax rate of 24.1% for the nine months ended September 30, 2023. The income tax rates for the nine months ended SeptemberÂ 30, 2024 diverge from the federal statutory rate due to (i) effects of state income taxes ; (ii) officer's compensation limitations; (iii) partial valuation allowance on losses in foreign jurisdictions, partially offset by (iv) excess tax benefits attributable to share based compensation; and (v) noncontrolling interests from controlled partnerships.Net income attributable to noncontrolling interests At SeptemberÂ 30, 2024, our consolidated subsidiaries operated 345 imaging centers of which 98 were not wholly-owned and thus a portion of their operating results were attributable to noncontrolling interests. At September 30, 2023, our consolidated subsidiaries included 320 centers of which 83 were not wholly-owned. For the nine months ended September 30, 2024, we recognized net income attributable to noncontrolling interests of $27.2 million versus $19.4 million for the nine months ended September 30, 2024, an increase of $7.8 million. The increase in net income attributable to noncontrolling interests was primarily due to the formation of a new majority owned subsidiary, Los Angeles Imaging Group, LLC in September 2023 and Tri Valley Imaging Group, LLC in March 2024. We contributed the operations of three centers to Los Angeles Imaging Group, LLC and Cedars-Sinai Medical Center contributed cash. Net income attributable to noncontrolling interests was also impacted by an increase in patient volumes for advanced modalities in 2024 and the closure of two underperforming centers in a majority owned subsidiary, Beach Imaging Group, LLC in December 2023.As noncontrolling interests only represent a portion of our imaging center business, and excludes our Digital Health Segment which generated losses of $9.5 million for the nine months ended September 30, 2024, we do not expect changes in net income attributable to noncontrolling interests to correlate with changes in consolidated operating income or pretax income.44Table of ContentsDigital Health SegmentThe breakdown of revenue and expenses of the segment for the three and nine months ended September 30, 2024 and 2023 are as follows:In ThousandsThree Months Ended September 30,Nine Months Ended September 30,20242023$ Change% Change20242023$ Change% ChangeStatement of OperationsRevenue$16,367Â $12,185Â $4,182Â 34.3Â %$46,856Â $34,866Â $11,990Â 34.4Â %Â Â Â Â Â Salaries and Wages7,119Â 6,022Â 1,097Â 18.2Â %18,631Â 18,710Â (79)(0.4)%Â Â Â Â Â Stock Compensation528Â 388Â 140Â 36.1Â %1,755Â 1,897Â (142)(7.5)%Â Â Â Â Â Other operating6,020Â 645Â 5,375Â 833.3Â %18,208Â 9,226Â 8,982Â 97.4Â %Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI3,344Â â€”Â 3,344Â â€”Â 9,977Â â€”Â 9,977Â â€”Â Â Â Â Â Â Depreciation & Amort.2,947Â 1,989Â 958Â 48.2Â %7,727Â 5,962Â 1,765Â 29.6Â %(Gain) loss on sale and disposal of equipment and other(5)3Â (8)(266.7)%(4)(2)(2)100.0Â %Â Â Â Â Â Severance33Â 12Â 21Â 175.0Â %77Â 1,740Â (1,663)(95.6)%Total operating expenses$19,986Â $9,059Â $10,927Â 120.6Â %$56,371Â $37,533Â $18,838Â 50.2Â %Loss from Operations$(3,619)$3,126Â $(6,745)(215.8)%$(9,515)$(2,667)$(6,848)256.8Â %Other expense2,966Â 590Â 2,376Â 402.7Â %5,413Â 3,715Â 1,698Â 45.7Â %Loss before taxes(6,585)2,536Â (9,121)(359.7)%(14,928)(6,382)(8,546)133.9Â %Income taxes(37)(4,472)$4,435Â (99.2)%$(346)$(5,829)$5,483Â (94.1)%Segment net loss(6,548)7,008Â (13,556)(193.4)%(14,582)(553)(14,029)2536.9Â %Revenues for the Digital Health segment increased as a result of core growth in our eRad PICS business, the rollout in 2023 of our Deephealth OS, and continued rollout of our Enhanced Breast Cancer Detection solutions across additional facilities. The increase in operating expenses was primarily related to salary expense as we increased headcount in connection with the commercialization of our initial AI products and higher non-capitalized research and development expenses with respect to our new DeepHealth cloud OS and generative AI. In the three months ended September 30, 2023, we recognized a non-recurring gain of $7.2 million from change in fair value of contingent consideration, offsetting against other operating expense. Aside from the effect of that one-time gain and increased non-capitalized research and development expenses, our net loss for the segment was consistent with the prior year. We expect that our Digital Health segment will continue to generate net losses over the next several years. Non-GAAP Financial MeasuresÂ We use both GAAP and non-GAAP metrics to measure our financial results. We believe that, in addition to GAAP metrics, non-GAAP metrics such as Adjusted EBITDA assist us in measuring our core operations from period to period.Adjusted EBITDAOur Adjusted EBITDA metric removes non-cash and non-recurring charges that occur in the affected period and provides a basis for measuring the Companyâ€™s core financial performance against other periods.Â We define Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, as adjusted to exclude losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishment, bargain purchase gains, loss on de-consolidation of joint ventures, gain on contribution of imaging centers into joint ventures, and non-cash equity compensation.Â Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or one-time events that take place during the period.Â 45Table of ContentsAdjusted EBITDA is a non-GAAP financial measure used as an analytical indicator by us and the healthcare industry to assess business performance. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and Adjusted EBITDA should not be considered in isolation or as alternatives to net income, or other financial statement data presented in the consolidated financial statements as an indicator of financial performance. Adjusted EBITDA is not a measurement determined in accordance with GAAP and is

therefore susceptible to varying methods of calculation and this metric, as presented, may not be comparable to other similarly titled measures of other companies.The following is a reconciliation of the nearest comparable GAAP financial measure, net income, to Adjusted EBITDA for the three and nine months ended SeptemberÂ 30, 2024 and 2023, respectively.Â Three Months Ended September 30,Nine Months Ended September 30,Â 202420232024202320232023Net income attributable to RadNet, Inc. common stockholders$3,209Â $17,540Â $(2,552)$4,904Â Income taxes4,335Â 7,220Â 4,927Â 7,741Â Interest expense19,427Â 16,115Â 61,776Â 47,876Â Severance costs304Â 1,153Â 797Â 3,157Â Depreciation and amortization34,979Â 32,210Â 101,822Â 95,705Â Non-cash employee stock-based compensation4,723Â 4,325Â 21,369Â 21,381Â Loss (gain) on sale and disposal of equipment and other148Â 527Â 735Â 1,183Â Non-cash change in fair value of interest rate hedge6,755Â 1,015Â 7,429Â 949Â Other expenses(5,414)(4,081)(16,248)(2,609)Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI3,345Â â€”Â 9,977Â â€”Â Loss (gain) on contribution of imaging centers into joint ventureâ€”Â (16,808)â€”Â (16,808)Loss (gain) on extinguishment of debt and related expenses147Â â€”Â 8,909Â â€”Â Non-cash change to contingent considerationâ€”Â (6,276)1,974Â (3,646)Acquisition related non-cash intangible adjustmentâ€”Â 3,950Â â€”Â 3,950Â Non-operational rent expenses1,287Â 1,030Â 3,119Â 2,748Â Acquisition transaction costs417Â â€”Â 417Â â€”Â Adjusted EBITDA - Total Company$73,662Â $57,920Â $204,451Â $166,531Â Adjusted EBITDA - Digital Health Segment3,229Â 2,279Â 10,018Â 3,689Â Adjusted EBITDA - Imaging Center$70,433Â $55,641Â $194,433Â $162,842Â The following table is a reconciliation of GAAP net income for our Digital Health Segment to Adjusted EBITDA for the three months ended SeptemberÂ 30, 2024 and 2023, respectively.46Table of ContentsÂ Three Months Ended September 30,Nine Months Ended September 30,Â 202420232024202320232023Segment net loss$(6,550)$7,008Â $(14,582)$(552)Stock Compensation528Â 388Â 1,755Â 1,897Â Depreciation & Amortization2,947Â 1,989Â 7,727Â 5,962Â Other operating loss(5)3Â (4)(2)Other (income) expense 2,966Â 592Â 5,414Â 3,714Â Severance34Â 12Â 77Â 1,740Â Income taxes(36)(4,472)(346)(5,829)Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI3,345Â â€”Â 9,977Â â€”Â Non-cash change to contingent considerationâ€”Â (7,191)â€”Â (7,191)Acquisition related to non-cash intangible adjustmentâ€”Â 3,950Â â€”Â 3,950Â Adjusted EBITDA - Digital Health Segment$3,229Â $2,279Â $10,018Â $3,689Â Liquidity and Capital ResourcesWe expect our existing capital resources, anticipated cash from operations and our borrowing capacity under our credit facilities will be sufficient to sustain our operations for the next twelve months and the foreseeable future. Our principal capital requirements are for the development of new diagnostic imaging centers, the acquisition of existing diagnostic imaging centers and the acquisition of new diagnostic imaging equipment. On a continuing basis, we evaluate various transactions to increase shareholder value and enhance our business results, including acquisitions, divestitures and joint ventures. We expect to fund any future acquisitions primarily with cash flow from operations and borrowings, including borrowing available under our secured credit facilities or through new equity or debt issuances.We and our subsidiaries or affiliates may from time to time, in our sole discretion, purchase, repay, redeem or retire any of our outstanding debt or equity securities in privately negotiated or open market transactions, by tender offer or otherwise.The following table summarizes key balance sheet data related to our liquidity as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 and income statement data for the nine months ended SeptemberÂ 30, 2024 and 2023 (in thousands):Balance Sheet Data:September 30, 2024December 31, 2023Cash and cash equivalents$748,916Â $342,570Â Accounts receivable199,076Â 163,707Â Working capital (exclusive of current operating lease liabilities)604,874Â 197,805Â Stockholders' equity1,119,634Â 813,359Â Income statement data for the nine months ended September 30,20242023Total net revenue$1,352,563Â $1,196,247Â Net (loss) income attributable to RadNet common stockholders(2,552)4,904Â Sources and Uses of CashThe following table summarizes key components of our sources and uses of cash for the nine months ended SeptemberÂ 30, 2024 and 2023 (in thousands):47Table of ContentsCash Flow DataSeptember 30, 2024September 30, 2023Cash provided by (used in) operating activities$190,494Â $131,943Â Cash provided by (used in) investing activities(184,257)(152,823)Cash provided by (used in) financing activities400,069Â 231,101Â Cash provided by operating activities for the nine months ended SeptemberÂ 30, 2024 increased by $58.6 million compared to SeptemberÂ 30, 2023 primarily driven by a $35.7 million change in assets and liabilities, primarily due to the timing of payments for accounts payable and accrued expenses.Cash used in investing activities for the nine months ended SeptemberÂ 30, 2024 increased from SeptemberÂ 30, 2023 by $31.4 million. Purchases of imaging centers during the period was $37.7 million, a $26.8 million increase from the prior period. Capital expenditures for property and equipment during the period was $145.2 million, a $8.6 million increase from the prior period.Cash provided by financing activities for the nine months ended SeptemberÂ 30, 2024 resulted from a secondary public offering of our common stock and a refinancing of our Barclays credit facility. In March 2024, we completed a public offering of 5,232,500 shares of our common stock, which included 682,500 shares sold pursuant to an underwriters overallotment option, at a price to the public of $44.00 per share, resulting in net proceeds after underwriting discounts, commissions, and expenses of $218.3 million. In April 2024, we refinanced our Barclays credit facility replacing the prior facility with an $875 million term loan. After paying off the balance on the prior facility, payment of accrued interest through the closing of the refinance transaction, and payment of transaction fees and expenses, we added approximately $167.9Â million in cash to the balance sheet. Secured Credit FacilitiesWe maintain secured credit facilities with Barclays Bank PLC and with Truist Bank. On April 18, 2024, we refinanced our Barclays credit facility, replacing the prior facility with an $875.0 million term loan and a $282.0 million revolving credit facility. The refinance transaction reduced our interest rates on the Barclays term loan and revolving credit facility and extended the maturity date for the term loan to April 18, 2031 and for the revolving credit facility to April 18, 2029. The new term loan calls for quarterly principal payments of $2.2 million, compared to $1.8 million under the prior credit facility. Our condensed consolidated balance sheets at SeptemberÂ 30, 2024 include $1,009.7 million of total term loan debt (exclusive of unamortized discounts of $15.8 million) in thousands: Â Face ValueDiscountTotal CarryingValueBarclays Term Loan$872,812Â $(15,234)$857,578Â Truist Term Loan136,875Â (792)136,083Â Total Term Loans$1,009,687Â $(16,026)$993,661Â At SeptemberÂ 30, 2024, we had no borrowings under our Barclays or Truist revolving credit facilities. After reserves for outstanding letters of credit of $8.3 million, we had $273.7 million available for borrowing under our Barclays Revolving Credit Facility and $50.0 million available under our Truist Revolving Credit Facility.Please see Note 6, Credit Facilities and Notes Payable in the notes to financial statements included in this report for more information on our secured credit facilities.ITEM 3.Â Â Quantitative and Qualitative Disclosures about Market RiskForeign Currency Exchange Risk: We are exposed to foreign exchange risk with respect to revenues and expenses denominated in the Pound Sterling, Euro, Canadian Dollar and Hungarian Forint. We provide radiological services in the United Kingdom, conduct Artificial Intelligence operations in the Netherlands, and maintain research and development centers in Canada, Hungary and India. We 48Table of Contentsdo not have any foreign currency exchange contracts to mitigate this risk. At SeptemberÂ 30, 2024, a hypothetical 1% decline in the currency exchange rates between the U.S. dollar against these currencies, would have resulted in an annual increase of approximately $0.3 million in operating expenses.Â Interest Rate Sensitivity: Our debt instruments, including borrowings under our Barclays credit facility and our Truist credit facility, bear interest at variable rates.Â Accordingly, our interest expense and our earnings are affected by changes in short term interest rates. To mitigate our future floating rate interest expense exposure we entered into the 2019 Swaps with locked in interest rates for one-month Term SOFR of 1.89% for $100 million of notional value and 1.98% for $400 million of notional value. We are liable for premium payments to the 2019 swap counterparties if interests rates are below the arranged rates, and receive payments from the 2019 swap counterparties if interest rates exceed the arranged rates. If interest rates were to theoretically reduce to 0%, our maximum premium payment would be the difference between the two swapped rates and 0% then multiplied by the notional value of the swaps, or $1.89 million per year for the $100 million swap and $8.0 million per year for the $400 million swap. Payments under the 2019 Swaps are settled in cash on a monthly basis. The 2019 Swaps for the $100 million of notional value matured in October 2023, so they were in effect for the third quarter of 2023, but not 2024. The 2019 Swaps for the $400 million notional amount will expire in October 2025. We can elect SOFR or Alternative Base Rate interest options on amounts outstanding under the Barclays Term Loan. At SeptemberÂ 30, 2024, we had $872.8 million outstanding subject to an SOFR election on the Barclays Term Loan. At SeptemberÂ 30, 2024, our effective SOFR interest rate plus applicable margin was 7.78%. The 2019 Swaps secure a $1.98% SOFR rate for a $400 million notional amount. After giving effect to our 2019 Swaps, we had $472.8 million outstanding under the Barclays Term Loan that is unprotected by the 2019 Swaps at SeptemberÂ 30, 2024. Consequently, a hypothetical 1% increase in the SOFR rates under the Barclay's credit facility would result in an increase of $4.7 million in annual interest expense and a corresponding decrease in income before taxes. The 2019 Swaps will mature in October 2025.We can elect SOFR or Base Rate interest rate options on amounts outstanding under the Truist credit facility. At SeptemberÂ 30, 2024, we had $136.9 million outstanding subject to an adjusted SOFR election on the Truist Term Loan. At SeptemberÂ 30, 2024, our effective SOFR rate plus applicable margin was 6.20%. A hypothetical 1% increase in the adjusted Eurodollar rates under the Truist credit facility would result in an increase of approximately $1.4 million in annual interest expense and a corresponding decrease in income before taxes.ITEM 4.Â Â Controls and ProceduresEvaluation of Disclosure Controls and ProceduresUnder the supervision of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, as of SeptemberÂ 30, 2024. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of SeptemberÂ 30, 2024 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.Changes in Internal Control over Financial ReportingÂ There has been no change in our internal control over financial reporting during three months ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.49Table of ContentsPART II â€“ OTHER INFORMATIONITEM 1.Â Â Legal ProceedingsFrom time to time we are engaged legal proceedings that arise in the ordinary course of our business. We do not believe that the outcome of any of our current legal proceedings will have a material adverse impact on our business, financial condition and results of operations. ITEM 1A.Â Â Risk FactorsFor information about the risks and uncertainties related to our business, please see the risk factors described in our annual report on Form 10-K for the year ended December 31, 2023. The risks described in our annual report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.ITEM 2.Â Â Unregistered Sales of Equity Securities and Use of ProceedsNone.ITEM 3.Â Â Defaults Upon Senior SecuritiesNone.ITEM 4.Â Â Mine Safety DisclosuresNot applicable.ITEM 5.Â Â Other InformationRule 10b5-1 Trading Plan.During the fiscal quarter ended SeptemberÂ 30, 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement." ITEM 6. Exhibits50ExhibitNumberDescription10.1Employment Agreement, dated September 11, 2024, between Aidence B.V. and Cornelis Wesdorp (incorporated by reference to Exhibit 10.1 filed with Form 8-K on September 12, 2024).31.1Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1Certification of Howard G. Berger, M.D. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *32.2Certification of Mark D. Stolper pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *101The following financial information from RadNet, Inc.'s Quarterly Report on Form 10-Q for the quarter ended SeptemberÂ 30, 2024 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Changes in Stockholders Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*Â Â Â Â This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.RADNET, INC.(Registrant)Date: November 12, 2024By:/s/ Howard G. Berger, M.D.Howard G. Berger, M.D., President and Chief Executive Officer(Principal Executive Officer)Â Â Â Â Date: November 12, 2024By:/s/ Mark D. StolperMark D. Stolper, Chief Financial Officer(Principal Financial and Accounting Officer) EX-31.1 2 q32024exhibit311.htm EX-31.1 DocumentEXHIBIT 31.1Â CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 302 OF THE SARBANES-OXLEY ACT OF 2002Â I, Howard G. Berger, M.D., certify that:Â 1.Â Â Â Â Â Â Â Â I have reviewed this report on Form 10-Q of RadNet, Inc.;Â 2.Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â 3.Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â 4.Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:Â a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â b.Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â c.Â evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ d.disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5.Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â a.Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ b.Â any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Dated: NovemberÂ 12, 2024Â Â Â /s/Â Â Â Â Â Howard G. Berger, M.D.Â Howard G. Berger, M.D.Â President, Chief Executive Officer and Chairman of the Board of Directors EX-31.2 3 q32024exhibit312.htm EX-31.2 DocumentEXHIBIT 31.2Â CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 302 OF THE SARBANES-OXLEY ACT OF 2002Â I, Mark D. Stolper, certify that:Â 1.I have reviewed this report on Form 10-Q of RadNet, Inc.;Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant andhave:Â a.Â designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â c.Â evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Â disclosed in this report any change in the

registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ 5.Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â a.Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ b.Â any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â Dated: NovemberÂ 12, 2024 Â Â Â /s/Â Â Â Â Mark D. StolperÂ Mark D. StolperÂ Executive Vice PresidentÂ and Chief Financial Officer EX-32.1 4 q32024exhibit322.htm EX-32.1 DocumentEXHIBIT 32.2Â CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Â In connection with the Quarterly Report of RadNet, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on ### (the â€œReportâ€), I, Mark D. Stolper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; andÂ 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.Â Â Â /s/Â Â Â Â Â Mark D. StolperÂ Mark D. StolperÂ Chief Financial OfficerÂ (Principal Financial Officer)Â NovemberÂ 12, 2024Â A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request. EX-32.2 5 q32024exhibit321.htm EX-32.2 DocumentEXHIBIT 32.1Â CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Â In connection with the Quarterly Report of RadNet, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on ### (the â€œReportâ€), I, Howard G. Berger, M.D., Chairman of the Board of Directors and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; andÂ 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for the periods presented in the Report.Â Â Â /s/Â Â Â Â Â Howard G. Berger, M.D.Â Howard G. Berger, M.D.Â Chairman, President and Chief Executive OfficerÂ (Principal Executive Officer)Â NovemberÂ 12, 2024Â A signed original of this written statement required by Section 906 has been provided to the Company and will be furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 6 rdnt-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - RECENT ACCOUNTING AND REPORTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Service Fee Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 1 (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Annual Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 2 (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Effect of Derivative Instruments on Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 3 (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Business Acquisitions by Acquisition, Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 4 (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Investment in Joint Ventures (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Joint Venture Investment and Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY - Valuation of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Margins and Effective Interest Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Term Loan Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - STOCK-BASED COMPENSATION - Schedule of RSAs and RSUS Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rdnt-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 rdnt-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 rdnt-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Long term assets Derivative Asset, Noncurrent Gain on contribution of imaging centers into joint venture: Gain On Contribution Of Imaging Centers Into Joint Venture Gain On Contribution Of Imaging Centers Into Joint Venture Equity interest issued, value assigned Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Contingent consideration, liability, period Business Combination, Contingent Consideration, Liability, Period Business Combination, Contingent Consideration, Liability, Period Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Joint Venture Interest Joint Venture Interest [Member] Joint Venture Interest Goodwill from acquisitions Goodwill, Acquired During Period Equity contributions in existing and purchase of interest in joint ventures Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture Statistical Measurement [Domain] Statistical Measurement [Domain] Stock Holdback Stock Holdback [Member] Stock Holdback Cover [Abstract] Cover [Abstract] NET INCREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Current portion of notes payable Notes Payable, Current Board of Directors Director [Member] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Due to affiliates Other Liabilities, Current Business acquisition, percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Business Combination, Contingent Consideration, Liability [Roll Forward] Business Combination, Contingent Consideration, Liability [Roll Forward] Business Combination, Contingent Consideration, Liability Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share-based payment award, award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] GOODWILL Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Cash paid during the period for income taxes Income Taxes Paid, Net WEIGHTED AVERAGE SHARES OUTSTANDING Earning Per Share, Basic and Diluted [Abstract] Earning Per Share, Basic and Diluted Valuation adjustment Goodwill, Measurement Period Adjustment Distributions paid to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Book value of RadNet joint venture interests Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable EARNINGS PER SHARE Earnings Per Share, Policy [Policy Text Block] Operating leases Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Performance Based Stock Options ("PSOs") Performance Based Stock Options [Member] Performance Based Stock Options Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Amount recognized (current period ineffective portion) Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Expected amortization, year three Finite-Lived Intangible Asset, Expected Amortization, Year Three Business Combination, Separately Recognized Transactions [Domain] Business Combination, Separately Recognized Transactions [Domain] Schedule of RSAs and RSUS Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Goodwill [Line Items] Goodwill [Line Items] Common stock - shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Contingent consideration settlement Business Combination, Contingent Consideration, Asset Forfeiture of restricted stock and share cancellation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Due from affiliates Other Receivables, Net, Current Number of shares available in grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Long-term operating lease liability Operating Lease, Liability, Noncurrent Loss on sale and disposal of equipment and other Loss on sale and disposal of equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Noncurrent assets Assets, Noncurrent Deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Stock price (in dollars per share) Sale of Stock, Price Per Share Entity Tax Identification Number Entity Tax Identification Number Impairment loss on investment Equity Method Investment, Other-than-Temporary Impairment Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of First Lien Credit Agreement Schedule of Long-Term Debt Instruments [Table Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Truist Truist [Member] Truist Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Term Loan Term Loan [Member] Operating Segments Operating Segments [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Medicaid Medicaid1 [Member] Medicaid1 [Member] Secured Debt Secured Debt [Member] Intersegment Eliminations Intersegment Eliminations [Member] Plan Name [Axis] Plan Name [Axis] BRMG and NY Groups operating expenses Variable Interest Entity, Measure of Activity, Expense Other Stockholders' Equity, Other DeepHealth, Inc. DeepHealth, Inc. [Member] DeepHealth, Inc. [Member] Restated Agreement NJIN Term Loan Agreement Restated Agreement [Member] Restated Agreement [Member] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trade names amortized Trade names indefinite life Trade Names [Member] Schedule of Service Fee Revenue Schedule of Principal Transactions Revenue [Table Text Block] Forfeiture of restricted stock and share cancellation Shares Issued, Value, Share-Based Payment Arrangement, Forfeited Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Covenant not to compete and other contracts Covenant Not To Compete [Member] Notional amounts Derivative Asset, Notional Amount Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Heart and Lung Heart & Lung Imaging Limited Heart and Lung Imaging Limited [Member] Heart and Lung Imaging Limited Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Principal payments on notes and leases payable Principal Repayments On Notes And Leases Payable Principal Repayments On Notes And Leases Payable Compensation Amount Outstanding Recovery Compensation Amount DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Earnings Per Share, Diluted [Abstract] Monthly amortization of deferred hedge gains Monthly Amortization Of Deferred Hedge Gains Monthly Amortization Of Deferred Hedge Gains Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Increase in fair value assets acquired and liabilities assumed Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Fair Value Assets Acquired and Liabilities Assumed Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Fair Value Assets Acquired and Liabilities Assumed Tabular List, Table Tabular List [Table Text Block] Periodic payment amortization increase Debt Instrument, Periodic Payment Terms, Amortization Increase Debt Instrument, Periodic Payment Terms, Amortization Increase Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] 2019 SWAPS 2019 SWAPS [Member] 2019 SWAPS [Member] Non-cash change in fair value of interest rate hedge Unrealized Gain (Loss) on Derivatives Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Weighted average shares for which the exercise price exceeds average market price of common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies Summary of Significant Accounting Policies [Table] Summary of Significant Accounting Policies [Table] Summary of Significant

Accounting Policies Credit Facility [Domain] Credit Facility [Domain] CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Currency translation Business Combination Contingent Consideration Arrangements Change In Currency Translation Business Combination Contingent Consideration Arrangements Change In Currency Translation Barclays Credit Agreement Barclays Credit Agreement [Member] Barclays Credit Agreement CURRENT ASSETS Assets, Current [Abstract] Goodwill Beginning balance Ending balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Patent and trademarks Patent and Trademarks [Member] Patent and Trademarks Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Prime Rate Prime Rate [Member] Product and Service [Domain] Product and Service [Domain] Shares issuable upon the exercise of stock options Share-Based Payment Arrangement, Option [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Cost of operations, excluding depreciation and amortization Operating Expenses, Excluding Depreciation And Amortization Operating Expenses, Excluding Depreciation And Amortization Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Contracts receivable, factoring receivable Contracts Receivable, Factoring Receivable Contracts Receivable, Factoring Receivable Award Type [Axis] Award Type [Axis] BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Earnings Per Share, Basic [Abstract] Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Right of Use Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Eurodollar Eurodollar [Member] Sold Pursuant to Exercise Sold Pursuant to Exercise [Member] Sold Pursuant to Exercise October 2023 October 2023 [Member] October 2023 [Member] Property and equipment, net Property, Plant and Equipment, Net Total liabilities BRMG and NY Groups accounts payable Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Weighted Average Exercise Price Per Common Share, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock - par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] RSAs and RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Subsegments [Axis] Subsegments [Axis] OTHER ASSETS Other Assets [Abstract] Current operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock - shares issued (in shares) Common Stock, Shares, Issued Deferred financing costs Debt Issuance Costs, Noncurrent, Net Segment reorganization Goodwill, Other Increase (Decrease) Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Subsequent Event [Line Items] Subsequent Event [Line Items] Antelope Valley Outpatient Imaging Antelope Valley Outpatient Imaging [Member] Antelope Valley Outpatient Imaging EQUITY BASED COMPENSATION Compensation Related Costs, Policy [Policy Text Block] Issuance of common stock upon exercise of options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise price Per Common Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock - shares authorized (in shares) Common Stock, Shares Authorized Diluted (in shares) Weighted average number of common shares used in calculating diluted net income per share (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Remainder of fiscal year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Service fee revenue Health Care, Patient Service [Member] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total RadNet, Inc.'s Stockholders' equity: Amount of loss recognized in income on derivative (current period ineffective portion) Equity, Attributable to Parent Proceeds from debt refinancing, net of issuing costs Proceeds from Issuance of Debt Debt restructuring and extinguishment expenses Debt Restructuring and Extinguishment Expenses Debt Restructuring and Extinguishment Expenses Payments on contingent consideration Payment for Contingent Consideration Liability, Financing Activities Letters of credit outstanding Letters of Credit Outstanding, Amount Joint Venture Joint Venture [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Issuance of common stock upon exercise of options (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Total debt obligations Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Shares issuable subject to satisfaction of certain contingencies Shares Issuable Subject to Satisfaction of Certain Contingencies [Member] Shares Issuable Subject to Satisfaction of Certain Contingencies All Executive Categories All Executive Categories [Member] Kheiron Medical Technologies Limited Kheiron Medical Technologies Limited [Member] Kheiron Medical Technologies Limited Expected amortization, year two Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Balance at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Document Type Document Type Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Derivative Contract [Domain] Derivative Contract [Domain] Promissory Note Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Business Acquisitions Business Acquisitions [Member] Business Acquisitions Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] INTEREST INCOME Interest Income Policy [Policy Text Block] Interest Income Policy Add non-vested restricted stock subject only to service vesting (in shares) Weighted Average Number of Shares, Restricted Stock Investment in joint ventures Beginning balance Ending balance Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Milestone contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Glendale Advanced Imaging Glendale Advanced Imaging [Member] Periodic payment, principal Debt Instrument, Periodic Payment, Principal Schedule of Annual Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Total RadNet, Inc.'s Equity Parent [Member] Subsequent Event [Table] Subsequent Event [Table] Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Sale of economic interests in majority owned subsidiary, net of taxes Noncontrolling Interest, Increase from Sale of Parent Economic Interest Noncontrolling Interest, Increase from Sale of Parent Economic Interest Developed technology Developed Technology & Software [Member] Developed technology [Member] Intangible asset amortization expense Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Amortization total Finite-Lived Intangible Assets, Net Schedule of Business Acquisitions by Acquisition, Contingent Consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Weighted Average Remaining Contractual Life (in years) Weighted Average Remaining Contractual Life Weighted Average Remaining Contractual Life abstract Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] REVENUE Revenues [Abstract] Discount Debt Instrument, Unamortized Discount COMMITMENTS AND CONTINGENCIES Commitments and Contingencies, Policy [Policy Text Block] Shares issued per share (in dollars per share) Shares Issued, Price Per Share Leasehold Improvements Leasehold Improvements [Member] FAIR VALUE MEASUREMENTS Fair Value Measurement, Policy [Policy Text Block] BUSINESS COMBINATIONS AND RELATED ACTIVITY Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares) Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Distributions paid to noncontrolling interests Payments to Noncontrolling Interests INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Issuance of common stock under the equity compensation plan (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Loss on impairment Goodwill, Impairment Loss Tri Valley Imaging Group, LLC Tri Valley Imaging Group, LLC [Member] Tri Valley Imaging Group, LLC Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Total Consideration Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Schedule of Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Income (Loss) from Operations Operating Income (Loss) Excluding Relief Funding Operating Income (Loss) Excluding Relief Funding Useful life Finite-Lived Intangible Asset, Useful Life Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Total net assets Equity Method Investment, Aggregate Cost Investment, Name [Axis] Investment, Name [Axis] Customer lists Customer Relationships [Member] RSAs and RSUs Restricted Stock Awards and Restricted Stock Units [Member] Restricted Stock Awards and Restricted Stock Units RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements, Policy [Policy Text Block] Forecast Forecast [Member] DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS, Diluted (in dollars per share) Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders (in dollars per share) Earnings Per Share, Diluted Number of multi-modality imaging centers Number Of Multi Modality Imaging Centers Number Of Multi Modality Imaging Centers Title of Individual [Domain] Title and Position [Domain] Basis spread on variable rate Derivative, Basis Spread on Variable Rate Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Noncash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Pink Perception LLC Pink Perception LLC [Member] Pink Perception LLC Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Minority partner ownership percent Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest Ownership [Axis] Ownership [Axis] Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property, Plant and Equipment, Net, Including and Excluding Capital Leased Asset [Abstract] Credit Derivatives Contract Type [Axis] Credit Derivatives Contract Type [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Notes payable, net of current portion Notes Payable, Noncurrent Cash Holdback Cash Holdback [Member] Cash Holdback Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] NET INCOME NET INCOME Net (loss) income Net Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Payments on Term Loan Debt Repayments of Secured Debt Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Provision for income taxes Income tax expense (benefit) Income Tax Expense (Benefit) Business Combination, Separately Recognized Transactions [Axis] Business Combination, Separately Recognized Transactions [Axis] Aggregate Intrinsic Value (in thousands) Aggregate Intrinsic Value Aggregate Intrinsic Value Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Current and long term assets Derivative Asset SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Imaging Center segment Imaging Center Imaging Centers [Member] Imaging Centers Number of centers Number Of Centers Number Of Centers Unrecognized expense weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total service revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Service Revenue Service [Member] Total other expenses Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Number of vesting traches Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Vesting Tranches Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Vesting Tranches Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities INCOME FROM OPERATIONS Operating Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Variable Rate [Domain] Variable Rate [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] INVESTMENTS IN EQUITY SECURITIES Equity Method Investments [Policy Text Block] Total liabilities and equity Liabilities and Equity SUBSEQUENT EVENTS Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Exercisable at the end Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Investment in Joint Ventures Equity Method Investments [Table Text Block] Additional paid-in-capital Additional Paid in Capital Amortization of cash flow hedge, net of taxes Amortization of Deferred Hedge Gains Interest income Interest Income (Expense), Nonoperating Legal Entity [Axis] Legal Entity [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Limited partners' contributed capital Limited Partners' Contributed Capital Providence Health System - Southern California Providence Health System - Southern California [Member] Providence Health System - Southern California First Lien Term Loan First Lien Term Loan [Member] Management service fees Management Service Fees Management service fees. Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Providence Health System Providence Health System [Member] Providence Health System Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Number of unconsolidated joint ventures Number of Unconsolidated Joint Ventures Number of Unconsolidated Joint Ventures Accumulated Other Comprehensive Loss, net of taxes Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Imaging Center Segment Revenue Imaging Center Segment Revenue [Member] Imaging Center Segment Revenue Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] OPERATING EXPENSES Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] DEFERRED FINANCING COSTS Deferred Charges, Policy [Policy Text Block] Equipment acquired and leasehold improvements Equipment Acquired and Leasehold Improvements Purchase consideration Business Combination, Consideration Transferred Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Offsetting Assets [Line Items] Offsetting Assets [Line Items] DERIVATIVE INSTRUMENTS Derivatives, Policy [Policy Text Block] IPR&D Software Development [Member] Barclays Barclays [Member] Barclays [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Debt instrument, periodic payment Debt Instrument, Periodic Payment Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Adoption Date Trading Arrangement Adoption Date Pay vs Performance

Disclosure Pay vs Performance Disclosure [Table] OTHER INCOME AND EXPENSES Other Expenses [Abstract] Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Other Health Care, Other [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Arrangement Duration Trading Arrangement Duration Schedule of Effect of Derivative Instruments on Comprehensive Income(Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Subsequent Event Subsequent Event [Member] Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Amount of comprehensive loss recognized on derivative net of taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax EQUITY Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Number of securities without readily determinable fair value Equity Securities Without Readily Determinable Fair Value, Number Of Securities Equity Securities Without Readily Determinable Fair Value, Number Of Securities DeepHealth Inc. Deep Health Inc [Member] Deep Health, Inc. [Member] Contingent Milestone Consideration Contingent Milestone Consideration [Member] Contingent Milestone Consideration Subsegments [Domain] Subsegments [Domain] INCOME TAXES Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Expected amortization, year four Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] PEO PEO [Member] Variable Rate [Axis] Variable Rate [Axis] Barclays Term Loan and Truist Term Loan Debt Instrument, Fair Value Disclosure Medicare Medicare1 [Member] Medicare1 [Member] Name Trading Arrangement, Individual Name Other income Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangible assets Other intangible assets Intangible Assets, Net (Excluding Goodwill) Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] First Lien Credit Agreement First Lien Credit Agreement [Member] Other assets Increase (Decrease) in Other Noncurrent Assets Proceeds from issuance of common stock upon exercise of options Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds from sale of economic interests in majority owned subsidiary, net of taxes Proceeds From Sale Of Economic Interest In A Majority Owned Subsidiary Proceeds From Sale Of Economic Interest In A Majority Owned Subsidiary Equity in earnings of joint ventures Equity in earnings in these joint ventures Income (Loss) from Equity Method Investments Unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Cost of Operations Operating Costs and Expenses Purchase of imaging facilities and other acquisitions Payments to Acquire Buildings Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Lender Name [Axis] Lender Name [Axis] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Houston Medical Imaging, LLC Houston Medical Imaging, LLC [Member] Houston Medical Imaging, LLC Related Party [Domain] Related and Nonrelated Parties [Domain] Noncurrent liabilities Liabilities, Noncurrent Accounts payable, accrued expenses and other Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Deferred tax liability, net Deferred Income Tax Liabilities, Net Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Triggering Event [Axis] Triggering Event [Axis] Triggering Event Performance Based Stock Units ("PSUs") Performance Based Stock Units [Member] Performance Based Stock Units Interest Expense Interest Expense [Member] Workers' compensation/personal injury Workers' Compensation/Personal Injury1 [Member] Workers' Compensation/Personal Injury1 [Member] Additional number of shares issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Additional Number of Shares Business Acquisition, Equity Interest Issued or Issuable, Additional Number of Shares LONG-TERM LIABILITIES Liabilities, Noncurrent [Abstract] Deposits and other Deposits Assets SOFR Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Shares issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Equity contributions in existing joint ventures Equity Contributions In Joint Ventures Equity Contributions In Joint Ventures Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Loss on impairment Impairment of Intangible Assets, Finite-Lived Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Debt Disclosure [Abstract] Debt Disclosure [Abstract] Heart & Lung Imaging Limited Heart & Lung Imaging Limited [Member] Heart & Lung Imaging Limited Common Stock Weighted average shares for which the exercise price exceeds average market price of common stock Common Stock [Member] Measure: Measure [Axis] First Lien Credit Agreement Eighth Amendment First Lien Credit Agreement Eighth Amendment [Member] First Lien Credit Agreement Eighth Amendment Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount October 2025 October 2025 [Member] October 2025 [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Management services provided to BRMG and NY Groups Variable Interest Entity, Measure of Activity, Income or Loss before Tax Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Number of plans Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Accounts payable, accrued expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Digital Health Digital Health [Member] Digital Health Non-cash change in fair value of interest rate hedge Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Less: current portion Long-Term Debt, Current Maturities SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Ownership interest Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest RECENT ACCOUNTING AND REPORTING STANDARDS Accounting Standards Update and Change in Accounting Principle [Text Block] Change in fair value of contingent consideration Change in valuation of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Non-vested restricted stock subject to service vesting Restricted Stock [Member] Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code COMPREHENSIVE INCOME (LOSS) Comprehensive Income, Policy [Policy Text Block] Title Trading Arrangement, Individual Title Consolidated Entities [Axis] Consolidated Entities [Axis] Statement [Table] Statement [Table] Management fee revenue Health Care, Management Service [Member] Health Care, Management Service [Member] Interest expense Interest Expense, Debt Counterparty Name [Axis] Counterparty Name [Axis] SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Less comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code CURRENT LIABILITIES Liabilities, Current [Abstract] Notes payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Notes Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Notes Payable Milestone contingent consideration Accrued expenses at the beginning Accrued expenses at the end Business Combination, Contingent Consideration, Liability Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total property, equipment and right-of-use assets Property Plant and Equipment Net Including Right of Use Assets Property Plant and Equipment Net Including Right of Use Assets REVENUES Revenue [Policy Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Right of Use Assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right Of Use Asset Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right Of Use Asset Level 1 Fair Value, Inputs, Level 1 [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Credit Derivatives Contract Type [Domain] Credit Derivatives Contract Type [Domain] Total current assets Current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] U.S. Imaging, Inc. U.S. Imaging, Inc [Member] U.S. Imaging, Inc Line of credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Exercisable Shares at the end (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long term portion of debt obligations Long-Term Debt, Excluding Current Maturities ACCOUNTS RECEIVABLE Receivable [Policy Text Block] Contributions from noncontrolling interests Noncontrolling Interest, Increase Contribution From Noncontrolling Interest Noncontrolling Interest, Increase Contribution From Noncontrolling Interest Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Weighted-Average Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) BRMG and NY Groups revenues Variable Interest Entity, Measure of Activity, Revenues Debt issuance costs Debt Issuance Costs, Gross Intersegment Intersegment [Member] Intersegment Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Other patient revenue Health Care, Patient Service Other [Member] Health Care, Patient Service Other [Member] Underlying Securities Award Underlying Securities Amount Restated Plan Restated Plan [Member] Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Gain (loss) on disposition of property plant equipment Total loss on disposal of equipment Gain (Loss) on Disposition of Property Plant Equipment Settlement of contingent consideration Business Combination, Contingent Consideration Arrangements, Settlements Business Combination, Contingent Consideration Arrangements, Settlements Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation and amortization Total depreciation and amortization Depreciation, Depletion and Amortization Add additional shares issuable upon exercise of stock options and contingently issuable shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Stanislaus Surgical Hospital, LLC Stanislaus Surgical Hospital, LLC [Member] Stanislaus Surgical Hospital, LLC Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Affiliates Affiliated Entity [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Deferred financing costs, net of accumulated amortization Debt Issuance Costs, Net Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction CREDIT FACILITIES AND NOTES PAYABLE Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Weighted average amortization period remaining in years Finite-Lived Intangible Assets, Remaining Amortization Period Offsetting Assets [Table] Offsetting Assets [Table] Management service contracts Management Service Contracts [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument face value Debt Instrument, Face Amount Issuance of common stock Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code 2019 Swaps - Interest Rate Contracts Interest rate contracts Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] Dignity Health Dignity Health [Member] Title of 12(b) Security Title of 12(b) Security Common stock - $0.0001 par value, 200,000,000 shares authorized; 73,976,284 and 67,956,318 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Issuance of common stock in connection with acquisitions Stock Issued During Period, Value, Acquisitions Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Issuance of common stock in connection with acquisitions (in shares) Stock Issued During Period, Shares, Acquisitions Equity in earnings of joint ventures, net of dividends Income (Loss) from Equity Method Investments, Net Of Distributions Income (Loss) from Equity Method Investments, Net Of Distributions Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited or Canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Securities Financing Transaction [Domain] Securities Financing Transaction [Domain] Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Digital Health segment Artificial Intelligence [Member] Artificial Intelligence Public Offering Public Offering [Member] Public Offering Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Third Party Third Party [Member] Third Party CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] One Month SOFR One Month Secured Overnight Financing Rate (SOFR) [Member] One Month Secured Overnight Financing Rate (SOFR) PPE estimated useful lives Property, Plant and Equipment, Useful Life Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Fair Value Measurement [Domain] Fair Value Measurement [Domain] BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS, Basic (in dollars per share) Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders (in dollars per share) Earnings Per Share, Basic Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Purchase of property and equipment and other Payments to Acquire Other Property, Plant, and Equipment Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Number of forward interest rate cap agreements Derivative Asset, Number of Instruments Held Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Fixed Assets Fixed Assets [Member] Fixed Assets Share-based payment award, expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Ownership [Domain] Ownership [Domain] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Weighted-Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms PROPERTY AND EQUIPMENT Property, Plant and Equipment, Policy [Policy Text Block] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Amounts Returned to Property and Equipment Propery and Equipment, Net [Member] Total current liabilities Current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets BRMG and NY Groups accounts receivable Assets Distribution of earnings Proceeds from Equity Method Investment, Distribution Expected amortization, year one Finite-Lived Intangible Asset, Expected Amortization, Year One Total credit facilities outstanding Long-Term Line of Credit Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than

Options, Grants in Period Cash flow hedge, tax amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other non-current liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount BUSINESS COMBINATIONS Business Combinations Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive: Earnings Per Share, Diluted, Other Disclosure [Abstract] NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Net revenue Total revenue Revenues Securities Financing Transaction [Axis] Securities Financing Transaction [Axis] Commercial insurance Commercial Insurance1 [Member] Commercial Insurance1 [Member] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town LEASES Lessee, Leases [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Schedule of Fair Value of Assets and Liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] First Lien Credit Agreement, Sixth Amendment First Lien Credit Agreement Sixth Amendment [Member] First Lien Credit Agreement Sixth Amendment [Member] Forfeited or Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Global Imaging LLP Global Imaging LLP [Member] Global Imaging LLP Entity File Number Entity File Number Schedule of Joint Venture Investment and Financial Information Joint Venture Investment And Financial Information [Table Text Block] Joint Venture Investment And Financial Information Consolidated Entities [Domain] Consolidated Entities [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] EFFECT OF EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Severance costs Severance Severance Costs Name Forgone Recovery, Individual Name Aggregate value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Expected amortization, year five Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Variable interest entity, ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contribution from noncontrolling partners Proceeds from Noncontrolling Interests Deferred taxes Increase (Decrease) in Deferred Income Taxes INVESTMENTS IN JOINT VENTURES Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Base Rate Base Rate [Member] Deferred revenue Increase (Decrease) in Deferred Revenue Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Other current assets Increase (Decrease) in Other Current Assets Triggering Event [Domain] Triggering Event [Domain] Triggering Event PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Business Acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net income attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes Amount reclassified from accumulated OCI (prior period effective portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Current Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Revenue under capitation arrangements Revenue under capitation arrangements Capitation Arrangements [Member] Capitation Arrangements [Member] Gross proceeds Proceeds from Issuance Initial Public Offering Amortization of deferred financing costs and loan discount Amortization of Debt Issuance Costs Gain on contribution of imaging centers into joint venture Gain (Loss) On Contribution Into Joint Venture Gain (Loss) On Contribution Into Joint Venture Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Grossman Imaging Center of CMH, LLC Grossman Imaging Center of CMH, LLC [Member] Grossman Imaging Center of CMH, LLC Public offering expenses Sale Of Stock, Cost Sale Of Stock, Cost Heart and lung Heart and Lung [Member] Heart and Lung Basic (in shares) Weighted average number of common shares outstanding during the period basic (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] 2019 SWAPS-1 2019 SWAPS1 [Member] 2019 SWAPS1 [Member] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Amortization of debt issuance costs and discounts Amortization of Debt Issuance Costs and Discounts Property & Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Change in cumulative foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Number of location offering multi-modality services Number Of Location Offering Multi-Modality Services Number Of Location Offering Multi-Modality Services Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment Equipment Notes Payable [Member] Equipment Notes Payable Entity Filer Category Entity Filer Category Shares issued (in shares) Shares, Issued Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (Liabilities), Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (Liabilities), Other Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 rdnt-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 rdnt-20240930_g1.jpg begin 644 rdnt-20240930_g1.jpg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

!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?7 \ P2___.2^ MZ \ ]BS\G_H)J[5+6O^0-?_\ 7O)_Z": /)J*** /0/A__P @:;_KX;_T%:Z: MN9^' _P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH

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

LU0!SOQ$\"Z=\3/!&L^%M6>XCT[5;=K::2U<+*JGNI(M(!! /((]C7S%_P .O_A9_P!!_P 8?^!EK_\ (U?7]>%?MG_&/_A3GP,U>ZM) M_)US5_\ B5Z=M.&5Y%.^0?[B!CG^]M]: /S;T?
X2:+XZ_:>A\!^!+F^N_#S: MM]EBOKR1)96MXN9Y]R*BE<)(R\#C:.M?3W[=1'BK]JKX.>$=89I/#%PUEYT# M/M0^??&*8Y['RXT&>U2?\$P_A%Y-GX@^(]J!\\Q_LG32P_A!#3N/J=B@C^ZX MKZ3_
&BOV7_#G[1=CIC:E>7>C:SI;,;/5+'!=%8@LC*>&7*@CH01P>2" ?*O MQ2*Z1\(_P#@H)\,[?P186^B07JV+7-GI\8BB3S99890$' S$ 2!ZYZFNW_; M*^+NM?$_QE8?
+X0S#HJK\\A'8!>=4^(OQ;U2-K309M:.\VQV!N65F9FV(P5=S$9('4K@^ M;N_V/ MK?1O.\.OXQ^.OQ!VW#6MU*5-C;RRXCC<_>,LLF2PXY7D_(-P!Q_ M_AYIOA315W16Z[[BZ90'NIV
WRM[DC@=@%'05W5?+GP:_:ZU_7/C%)\+?B;X M0B\(>+64FW:UN!)#(XC\S8?F83 M_P!!-7:I:U_R!K__*]Y/_030!Y-1110!Z!\/\ D#3?]?#?^@K735S/P_\ M^0-- P!?#?\ H*UTU !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110!S/Q"^&OACXJ^'GT/Q7HUOK6F,P<13@AD8^:^CJ* *]
MC86VEV4%G96T-G:0((x;>! D<:@8"JHX ["O+/! P"RI\,O ?Q#?QMHOAW[M)X@+RRI,;J5XXGE!#LD;,57(9ATX#'&*];HH \R^+7[-WP\^-TT=SXL\1WN MHQ1*5%]$$KP7*"2%WH1N).
V0,GBN#\- L"_!?P[?179\-SZK)$V]$U*^E MECS[H"%8>S CFOHFB@""QL:;3+."TL[>*TM($$<4$"!(XU P%51P !V%>667 M[,?@RW^,US\3[H:AJWBB1R\1U"Y\V"V;:%4Q)M&-
J\+DG';G!KUJB@!LD:31 MM'(JNC JRL,@@]017@E]^PG\%-0\0-JLG@\1N[F5[2"]GCMBQ.?]6K@*/]E< M+VQBO?:* *VFZ;::/I]M8V%M#965M&L,%O;H$CB11A551P !7+>.OA7I/
MQ!N[6XU&XO(7MT,:"U=%!!.>=RFNRHH \F_X9J\,?\ VK?\ ?Z+_ -UD>+? MV?=$'T7PSJ>H6%YJ4EW:V[SHLLL94[1DY 0'H#WKW"H;RU2^LY[:09CF1HV^A
M@!S/PIU=M;^'NB7,CF240^4[,;IT\+ZEII]J=10!^7G[0'[47Q M%^/7@&X\)7_PQN=(MI+J.X\Z"WN7D4H20N"@'>I/V8?VCOB#\"_#=IX-M?AM
M=ZK976Z]?:'N)K>XCD'F;$(&%QP%X)]: 3^B@#Y7_."@/P#UCXQ?#O2=6\-V MI'C<X=?"^RGG\(.!7RM\5/V]?&GQT M\%:CX)T+P5'ISZLGV>Y>SDDO9WC)&410@P6^Z3@\$XP>: 3VB@#X[_X)^?LU M>\
(/A'I^M^*_%MF=+U;6(DM;7390/.@@5MS-)S\I=MOR]0$YY.!;_ &WOCQJE MG]A^# @-9;OQKXFVPW/V7[]O;R<",'^%Y!G)/W4#$XR"/KFH?L=N;H7)@C^T M ;1-L&_'IGK0!Y-^S[^SOI?P-
^$W_"+0NLVJ7\3/JVHQC#3SLFT[3UV(#M4> M@SU)KXB^" Q*U'JCZQ^)O@+Q?X1UF?6=5'EZ8UI;AHIY1'(@8D9C8,K!DW' M ;C-?IY10!\K_P#!/'X1ZY\,?
A'J5]XALIM,OM>O1=16=PA25(%0*A=3RI8E MS@C.,>M?5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% &-XS\0-X2\'Z[KB6C:@^F6$]ZMI&VUIC'&S[<' M!;;C.#UZ&OCI/^"IGA4Z3YC^"-874]N?LZW41AW>GF]<>^S*^WJY6Y^%/@F M\U,ZE<>#M
GU$DL;N32X&ER<9.\KGL. 84 ?G_\ L^^!?%W[7'[2* %CQ3IK M6?AFQNH[S>498)&AP(+:$G[^TJI<].&S@L!7TS^V]^7)XG_9_P#!>@7GA:WM M&N]3O7MY+J\A,J0JJ;L @;B>F<*>/3Z-
@@BM84AAC6*,!4CC4*J@= .@ MJGK?A_2_$UB;+6--L]5L]P?[/?0)-'N'0[6!&10!YU^R_P%/5OC/\$_ BS M7+2"TU\,Z2K:HR1/YP34-YD^UK:H)=QZMOQG)R><]Z ,CX4_#ZR^%7PY\>$[#:8-*
MM$@,BC'FR=9),>K.6;_@56/B)\0-&^%W@O5?$^OW(MM,T^$RR'^)ST6-!W9F M(4#U(KI*Q_%7@[0O'6DMI?B+1['7-.9Q(;74(%FCW#HP# X(R>>O- 'Q5^S+ M\\ 6?VH_B]>_'7Q];$:+:3^7X?
TR0DQ;HV.S;GJD1X5^C- !!10 4444 %%%% !1110 4444 %%%% M !1110 445!=7UO8QA[F^W0\!7"C]:6VX]]B>BN:OOB9X0TW/VOQ5HMMCJ M)=0A4_JUB%[^T-\-
]/7,OC#36'3]RYE_]!KGEB:$/BFE\T=,<+7J?!3;^3/ M1**\=O?VMOAA:-A-?ENC_P!,;&?^905S]W^VYX MU/E6FMW)[>7:QC/_'U(M*Y99G@H[UH_? ML*]_;TN&;_1/!D48]9M1+?H(Q7++/,OC_P
O/P?^1UQR',I?\NOQ7^9]>T5\ M47'[=?BIL^1X>T>/_KH97_DXK.NOVX?'DW$6G:#;C_9MIB?UE_I7.^(L MFW M\CI7#>8/>*7S/NBBO@6Y_;,^(_W)]-M^<_N[,\fF)K,F_:V^*,F=OB&.+/ M]S3[?
C\XS6#XEP2V4G\E_F;1X7QSW<5\W_D?H;17YPS?M-?$Z?[WBRY'?Y(8 M5_D@K+N/CO\ $.ZSO\9:PO?]W=_G_H.*Q?$^&ZO#^'^9O'A3%?:J1_' "/T
MRHK\PI/C)X]DQGQKX@&/[NIS+_)]@D^+'C>5LOXQ\0.>F6U2<\ L]9_ZT4? M^?;^]&G^]=?K57W, _42BORU;XE>+Y&+-XJUMF]3J,Q/_ *%4+>/O$\C%F\1Z MLS'N;Z4G_P!"J?\ 6BG_ ,^G]_\
P"]4ZO_ #]7W?\ !/U0HK\JF\9^()&+ M-KNI,Q[F[D)_G5GP_P*)-6D\1:;OU2];==19W7#G/SCWH7%$&TE2_' @ ^$Y MI-NLON_X)^IE%>
<^-9I(_$$H1V4;%^Z2.U88O+A>0_@_X&:^JEBE&3C8^7IX M%S@I3+K^1+TO[C\9" M:E7Q1JJ]+V3\<&G];CV%_9\^DD>J45Y@OC#5U_Y?"?K&A_I4R^.-57K+&WUC M%/ZW#LR?
(/]JT>DT5YVOC[4UZK;M]4/^-2K\0KX?>M[<_0,/ZU7UJF1]1K'? MT5PR?$2LHS_NN1_2K$?Q%C(\ K+%E.P!V0'^E5]8I=R@ZZ^S^1V-%+V9DZ3_ -!-7:I:U_R!K_\ Z]Y/_030!Y-1110!Z!V_P#D#3?]?
#?^@K735S/P_M_P#^0-- U_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ' _!GQEJ7C?PO=7VJ-&]Q'>- IC3:-H1&'
M'U8UWU>3?LU?\B+??]A*3 T5%7K- !1110 4444 %%%% M !1110 445!=7UO8QA[F^W0\!7"C]:6VX]]B>BN:OOB9X0TW/VOQ5HMMCJ M)=0A4_JUB%[^T-\-
]/7,OC#36'3]RYE_]!KGEB:$/BFE\T=,<+7J?!3;^3/ M1**\=O?VMOAA:-A-?ENC_P!,;&?^905S]W^VYX MU/E6FMW)[>7:QC/_'U(M*Y99G@H[UH_? ML*]_;TN&;_1/!D48]9M1+?H(Q7++/,OC_P
O/P?^1UQR',I?\NOQ7^9]>T5\ M47'[=?BIL^1X>T>/_KH97_DXK.NOVX?'DW$6G:#;C_9MIB?UE_I7.^(L MFW M\CI7#>8/>*7S/NBBO@6Y_;,^(_W)]-M^<_N[,\fF)K,F_:V^*,F=OB&.+/ M]S3[?
C\XS6#XEP2V4G\E_F;1X7QSW<5\W_D?H;17YPS?M-?$Z?[WBRY'?Y(8 M5_D@K+N/CO\ $.ZSO\9:PO?]W=_G_H.*Q?$^&ZO#^'^9O'A3%?:J1_' "/T
MRHK\PI/C)X]DQGQKX@&/[NIS+_)]@D^+'C>5LOXQ\0.>F6U2<\ L]9_ZT4? M^?;^]&G^]=?K57W, _42BORU;XE>+Y&+-XJUMF]3J,Q/_ *%4+>/O$\C%F\1Z MLS'N;Z4G_P!"J?\ 6BG_ ,^G]_\
P"]4ZO_ #]7W?\ !/U0HK\JF\9^()&+ M-KNI,Q[F[D)_G5GP_P*)-6D\1:;OU2];==19W7#G/SCWH7%$&TE2_' @ ^$Y MI-NLON_X)^IE%>
<^-9I(_$$H1V4;%^Z2.U88O+A>0_@_X&:^JEBE&3C8^7IX M%S@I3+K^1+TO[C\9" M:E7Q1JJ]+V3\<&G];CV%_9\^DD>J45Y@OC#5U_Y?"?K&A_I4R^.-57K+&WUC M%/ZW#LR?
(/]JT>DT5YVOC[4UZK;M]4/^-2K\0KX?>M[<_0,/ZU7UJF1]1K'? MT5PR?$2LHS_NN1_2K$?Q%C(\ K+%E.P!V0'^E5]8I=R@ZZ^S^1V-%+V9DZ3_ -!-7:I:U_R!K_\ Z]Y/_030!Y-1110!Z!V_P#D#3?]?
#?^@K735S/P_M_P#^0-- U_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110

C=XO^)\T@UC59!8LV M5T^V)CMUY./D'WB,]6R?>N#KXC&<33E>.$C;S?\ E_G<^[P7"T(VEBY7\EM] M_P#E8]?^(?[4GCKQ\TT":A_8.F."OV/3,QDKR/FD^^V0<$9"GTKR%F+,23DG MDDTE%? &UL15Q$N>M)R?F?;4,-1PL>2C%17D%%%%7GDX4#OCUJ34/%VG^&XVMM#1; MF[P5>^D&K+/]DV/ARW6[UV;#DY2R MC.6?ZX__%> :N7\1>-
+S7$^SH!9:>HPMK%TP#QD]^WMQ6+>7D]_+L3*$:BY9JZ/5=!^*EI>%8M2B^QR'CS4RT9^O<:'\6-S1Q:I;,1G!N(>WN5_P/X5W]CJ%MJ5NL]K, MD\3=&0Y__4:]>G6IUO@9\Y7PM;#O]Y'
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
:1JQ]64;6_4 M&M37-/&KZ+?V+!>$?CWX?^$_A.WT+Q +M]6M[F2-K*UC# MO"A;=E\D!>6;Y<{N.G-<]?$4L-#GK245YG10P];%3]G1BY/R/HEW6-&=V"JH MR68X 'K7AGQ-_:\\(>"/-
M-';_A*=57C;9R 6R'C[TV"#U_@#=,$BN"^*FI) M\?E-OX?^*FFV-C+@+X>U*%[!68%2 TA)\PYQV(R..^/"?%7[//Q \(PM/=^' M+FYM -PN=/*W2%?[WLD@>[5\IF&;XFS6^A>/\
,K2_*Z7S^X^ORW)L+=/' M5+2_E=X_G9OY?>0?$GXY>+_BE,ZZQJ;1Z?NRFFVF8[=>3CY<_,1GJQ)K@*?- M#);R-'*C1R*<,C@@@^A%,K\]JU:E:;G5DV_,_2*-
&G1@H4HI+R"BBBL38*** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ K1\-_P#(Q:7_ -?47_H8K.K4\+QF M7Q-I"#@M>0J,^[BM(?$B)_ S]$?''_(P2_[B_P JP*W_ !P,>()/=%_E6!7Z
MU6_B2/RC#_PH^@4445B= 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !116KI/AVYU13,2+:S4%GN)>% '7ZU48N3LB)2C!7
MDS,AA>>18XT9W8X"J,DUO-IFG^&85N=]4]0\96/A^ M-[70$$LYX>_E&<\?PC_(XZ'K7#W-U->3O-/(TTKG+.YR32E4A2VU?X?\$NG0 MJ5]9>['\7_E^9N>(O&=YKP\@ 6E@O"6L?3
Z9/?^5<_117#*]1=GVZ'T!7 M">'_ (I6EX%BU-/L5N_!/7M">'_ (I6EX%BU-/L5N_!&,V!2QK5G]N+_D\[PY_URTO M_P!'&O6_^"GWPT_M;P+X<\<6T69](N387;*.(?FY1C[+(N/K+0!H?)%,/BH/
M#_PNTCP993@77B*X\^X"'/\ HL)#8/\ O2&/![[&KY<_:?\ AE_PJ?X0_!'1 MYH?)U&XTZ]U"^!&&\^9X7*M[JI5/^ 57^%,VM?M8_M"?#O2]?_TJSTFSM;2< M-\P-G:)O??[R,&!/K(*]H_X*J?
\ (P?#O_KUO?\ T.&@#ZL;1_%/B']E/2-- M\%:@FE>*+KPU8QV5Y)(8Q$QABW'< 2IV[@"!D$@U\U_\.Q=4\06;W_B7XGS7 M?B.92TDGV)[A-^. 9))0[C/<@=>E>K?&CXM:S\&?V+?
#6M>'SY.L7&E:9807 M13=]F,ENN9,'C(53C/&XC@]*^>_@'^R_9_M&_#&^^(GQ"^)VL$2SRK<*;M6^ MSK$>6GDF++M2H P& N#GG@ T?^"=_Q/\ $VB_%O7/AGJ^]3:AI*VLY@@FE:1+
M:X@D /E9^ZK*7R!C)"GZ\C^V%XW\4>$?VT;B\\-7DXU:V6Q%A#N+IYK0(% 0 MG:>U:1@$82DX;#L MJG;@#(VY'-;7PO\ "'QH_;@\(V]AJ?C#^S_!OAY?L+7=R78WMP!N'F*IS-(J
M.F68@ ;>K%B?KW]O7_DT_P <_P#;C_Z7V]30&WTE+A(UD94WBYD.2 1_='Y5S>N?\I+8_^QFM M_P#T6E:'_!4;_DKWA/\ [0_]*): ,WXH?LH_%KQM\,=3^,/C7Q-#>ZPMH=4 M?
1YRQDAM<;R%(^2,JGS>6HP ,9SQ63\"V^-/[5'A@?#33_%4 >)Z!!XQ_8L_:>TS06UQ(!=OM M0!0\#?\ !/3Q;\4?A_8>,M;\>M9>(M2MDOK2Sn[>2X*JPWQ^;,9 RL003A3M
M]STUOV$?COXN\.?%RY^#_B^]NK^!FN;:UCO)/,>PNK<.TD88\["(W&W. 5& M,G/UQ\&_C%X/U[X)^'0$":_IUM86NEP+>--O7&1Q7P=
M^S*I^+/[>=YXHTF*9]'75=4UII54@QP/YHB+>FYI(P1_M&@#]1Z*** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH ****
"J6M?\@:_P"O>3_T$U=JEK7_ "!K_P#Z]Y/_ $$T >34 M444 >@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% M!110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %,/!&BZ\S,2;JW0
MVEQR23EUR3U/IS^=69OV>;O4M[>&/$^B^(U7@0I/Y-PW7'R-D#IW;_&N/U_X M4^+_ SN.H^'KZ%%.#+''YL8_P"!IE?UK\[Q%;.(R=6M=I^2E']8GZ/A\VDL MHJE1Y4UYN,_TD;[>%?
A#XL(%EK.M>#+M^-NH0BZM@>.A4[L>[.G:M'0_A5\ M0O#D/VOX?>,;37+0+N\K2=2VGIDAH7(7)X.3]#7DA!4D$8(ZBGP7$MK,LL, MCQ2JJV_Q-
^'ECKR#"K=ZIIQMYSC'W9E7;V_A'^%<_)H_P %?&7^KFUWP'>N M<;7 O;12<_5R <=2.OXBSH7QV\;:%&T/]M2ZE:LI1[?4P+E74YX)?+8Y[&M.
M7XD^"O%38\4_#ZR2:3_67VA2&UDSG[VSHQZ]37J1QU&MI*HGY5(_^WQ][\CR M98"M0UC2:\ZZ_9=UC4H7N/!WB+0_&<(R1%8W:QW&!CEHW.% M//3=7FGB?P#XD\%R!=,/^
M\QR>!6OU6G57-&#]8-37W?$OFS+ZW5HOEE47I-.F_O\ A?R1\D45]$:UXU\(MZI=&V^(/PJ&DZF>7N]'WV$VOH#_CQ?4U)VHU(R?9^Z_NE;\&SN^N."O6IRBNZ7,OOC?\ M%
(\,HKU/Q'^S+\0?#\ N8]%_MNS;[EQHT@N@XSC(5?GQ_P !KS.\LKC3[AH+ MJWEMIEP3',A1AGIP:YJN'JT':K%KU1U4<11Q"O2FI>C(****YSH"BBB@ HHH MH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH *U_!__ "-NB?\ 7]!_Z,6LBM?P?_R-
NB?]?T'_ *,6M*?QQ]3. MI\$O0_0_QU_R'F_ZYK7/UT'CK_D/-_US6N?K]:K?Q)'Y3A_X4?0****Q.@** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I+>WENIE
MBAC:21C@*HR36EI/AVXU)3/(RVEFHRUQ-PN/;U_E3=3\:66@Q/9^'XP\O1[Z M09)_W?\ ..O'>M.517--V1ES2G+DI*[_ 7J79+'3?"L*W&LR">Z(#1V,9R> MO\7M^G!ZUR?B+QA?>
(6\MB+>S4_);1<*!VSZG_(Q6-<7$MU,TLTC2RL3)0_3T/N*Q**N,I0=XNS(G M3C4CRS5T>X^'/&FG^)%"1/Y-UC)MY.OX'O6_7S@K,C!E)5E.01P17=^&?BA< M6>RWU4-
=0#@3K_K%^O\ >_G]:]FACE+W:NGF?,8K*91]^AJNQZI15;3]2MM4 MM5N+299X6Z,O^>*LUZR::NCYUIQ=F%%%%,04444 %%%% 'SS\8OV-=#^,7Q;
MTWQY>^(=0T^ZLUME^QV\4;(_DN6')Y&X%=110!X!^S?^QWX=_9QU[5M9L-7O-;(_U&^MEM%EN MXT3R8]P9@H7^\53/^Z*M?M*_LGZ/^TI=Z#<:EKM]HTFDI-&GV6-
'$@D*$YW= M,;/UKW6B@#AM>^#OA[Q7\)HOA[K4+ZCH<=A#8;V(64>4BJDJL!\K@J&! QGM MCBOEW3_^"7?AJVUAVN?'6L3Z(JS6$5M'*P!) :7)4\<9V#N:^VZ* /GGX3 M?
L6>%/@W\79_&^@:E>QQ&&6"#2'53%"K@#&\Y9L8/7GGDU#\3OV*]!^)_P : M[?XC7?B'4;*\CFM9FL88HS&Q@VA1N(R,A!G\:^C** .(^-/PML_C5\,]9\&7 M][/IUKJ8AWW-
LJLZ&.9)1@'@Y,8!]B:P_P!G7X!Z=^SIX'O/#>F:I=:O#=:A M)]#SW:*C!FCCCV@+VQ$(Q)KU.B@#YVO?V,-"O/VAE^+!\0Z@E^M_']'G"*/ MRMZH%V[NN#C-3?M'?
L=Z)^T=XGTK6]2\07^CSV%I]C$=K$CJZ[V?/S=#EC^E M?0=% '-^)/]KXD^'&J>#I;B:&RO])ETAKA,&18WA,18<8W '/3&:\T_9H_9 M9TG]FA?$7]F:W>ZRVM&W\TW<:
((Q#YNW:%]?-;.?05[?10!\[?&K]C#0OC5\ M5+'QQ?>(=0TVZMH[>,VEO%&R/Y3E@$9O#GBJP^W: M=(XE0JY22&4 A9$8=&&3[$$@@@D5U]% 'PUZI'I_.8)+&-
MY>O'[P,!T_V*^F/@9^SQX(\ V?=!EL/#-I(UU=;3>ZG=L'N;HKG&X@ !1DX5 M0 ,]SDGTVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
HHHH **** "BBB@ HHHH *I:U_R!K_\ Z]Y/_035VJ6M M?\@:_P#^O>3_ -!- 'DU%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW M_H*UTU !1110 4444 %%%% !1110 4444
%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !12$A023@5XY\2/VA+'01)8>'3'J5
M_C#77WH(NW&#\Y'G'3KTKDQ.*HX2'/6E9?GZ'=@\%7QU3V=*-W^*]6>A>,O' MVC> [$7.JW.QF.([>,;I9/\ =TXZG]Z^8/B)\8M9?ZL]NS?V?I/:QA;(;G
M(+M_$>GMQTKC]8UJ^\0:A+?:C=27EW(?FEE;)^@]!#@52K\ZS#.*V,O"'NP M[=7Z_P"1^KY7D%#+[5*GO5._1>G^>_H%%%%?/GU 5TNB_$GQ1X?V_8==O8T7 MI')
(9(Q_P!LK^EYWC^@JI+I?PG\19)MM:*3G!_<2"Y@!XI^]EB.I[?R%<-173 M+%3J?QHJ?JE?[]_Q.)9?2I_P'*'^%M+[M8_@=;)\ [;5\'PQXUT;6&;[MO=$ MVD[>P0YR>>^*YCQ!\%?
&WAOS&O/#MX\2#+2VJB= /7*$X'UJ&MO1?&VO^'=H MT[6+RT11@1I*=G_?)X_2N>5+!5-X.#_NNZ^Z5W_Y,:+Z]2^&HIK^\K/[XV7_ M)*>;R1/#(TM:AH=Q]HTV_N=/GZ>;:S-
$WYJ0:]G_X7 M3?ZG&(O$.BZ-XDCV[2U]9KYG0X(8=$SZ?E5:7_A5?B0?Z7H&J^&+ALDR:9,'GJ'Z#IPJ]_P :Q_LZ%^:A75_-.+_5?B4\=5BN?$8=M?W6I+[G9_@8.G_M M"^+
(K<6NJM8^)+'=DV^KVB2CN#R,'H2.>'[D M%>3U\I@%4#V!_I6A+\$-"UK)\,^/--N7(^6VU1&M)"?[H)Z_E6!K7P%\QF,-Q#);RCK'*A5A^ M!K5\/^-M?!*MG2-
8O=/7J8X)F5#UZKG!Z]Q6='-(4_=<90_PRT^<973^]%UL MIG4]Y3C/_%'7Y2C9K[F=#=)\&?%4TL>HZ+KG@#4NCFSD^TVZ/GG*,"PZ] HZ M?
@:$W[,_IO*9/!'C70_%>1N2S:7(]=D8S_JF)QW)'^'3+^T!J>K0K!XKT/1 MO%EOMV%KZT59L=UC,+JV!X[,"WO@ M=/PKM5;"8C=Q\/TZ!PS:YX=O[&%2
M0;@Q%X>"1_K%RO;UZ(;8/&#GIYJ855Z=23_3(UK]EWQSI]JUYI<%CXIL1R+C0[M9P00""% M.&/7L#T],&N-X&LUS4TIK^ZT_P %]OFCM684$^6JW!_WDX_B]'\F>145>U?0
M]2\/W9M=4T^ZTVZ')AO(6B;_KFM<_70>. MO^0\W_7-:Y^OUJM_$D?E.'_A1] HHHK$Z HHHH **** "BBB@ HHHH **** M"BBB@ HHHH ****
"BBMC2/#4VH1FXQ=;.Q7EIY>./;/\^E5&+D[(B4XP5Y, MR[>VENYEBAC:61NBJ,FMV2STSPG"L^L2"XNSREC$0?\ OKV_3ZUGZIXXM=)A M:S\/1!=R[7OI!\
['V!_KZ]*XF>>2YF>6:1I97.6=SDD^I-*56%/X=7^'_!+I MX>I7UG[L?Q?^7YFSXB\87WB)MDC"WM5^Y;1$A1]?4UAT45PRE*;O)W9Z].G& ME'E@K(****@L**** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH NZ1K5YH=T+BRF:)^C#JK#T([UZOX3\?VOB#9;W
6UOSQLS\K_P"Z?Z'] M:\;H!*D$'!%=5'$3HO3;L<&*P5+%+WM'W/I"BO+?"/Q*DL]EIJQ::#HMSR77 M_>]1[]?K7IUO<174*30R++$XRKH<@BOH:->%97B?&XC"U,+*TUIW)****Z#C
M"BBB@ HHHH ***^9/C7^WY\/OA+K T?3UE\9:I&^VY72Y4$%OCJK2G_P#9 M7.,$$@\4 ?3=%XMY4C3YP2 -W)P,<^_M0!],T5\0?\/3?"
MW_0CZQ_X%15[M^S5^U!!'[2MGKTVF:/>:..^CR0I+'=NK[Q*'*D%?^N;9'TH M]IHHKYF^/G[V45\AZY_P4:\-VUJ]4V@^"?$7B3PSILHBNM?MXPD"9.%;!!P& M/3>5)]*^E/AG\2-
#^+7@G3/%7AVX:XTN_0LGF+MDC8$JZ.O9E8$'MQD$@@T M=117SM\8/VN1X%^+NA_#7PCX7/CCQ5?.JW-0'??9DM2W*JS>6_W+L2 %7!/ M7CZ(H 6BBB@ HHHH **** "BBB@
HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:U_R!K_\ Z]Y/_035VJ6M M?\@:_P#^O>3_ -!- 'DU%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\ Y
TW_7PW M_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%%
%5=4U2TT73Y[Z^N([6TA7=)-(<*H__ %\8 M[DUF>,/&FE^!]*-]JD_EJ>(X5P9)6]%'>OE#XB?%#5OB)?$W+?9M.C;,%C&3 ML7K@M_>;!Z_D!7B9CFE+
1Y=Y]%_F?193DM;,I> M,&DTW2&>QT7HS=)+C_>]%_V?SST'E%%%?FF(Q-7%'5'4JN[_K8_7\)A*."I*E M0C9?GYL****Y3L"BBB@ HHHH **** "BBB@ HHHH *U-\4:QX?D5M-U.ZLM
MISMAE95_$9P?QK+HJHRE!WB[,F4(U%RS5T>AP_&_7;B&.VUNUTSQ):*>8M4L MT?(R,\@#GCJ0?QJ&34OAGXCYU3PC>:%.WWI]$NLJ???RWPJCKT!_&N"HKK>,J MSTJVG_B2?
XO7\3S_ .SL/%/WI)P?]UN/X+3[T=E)\'?"&N 'P_P"/;>&5N!;: MU 8"#V&_H>W0?X5C:Q^SUXWTN$SP:9'J]KSB;3)UF!QGHN0QZ>G<=ZQJNZ9K
M>HZ+)YFGWUS8R9R6MY6C)_(UA*&#J_'2Y?\ "_TE?]"U#&TOX=;F\I13_&/+ M^3..U31[_1;CR-1L;PPB+OQ:\8>%0BZ;X@O8H5QMAE?S
M8QUX"/D#KV\]J!L_CAXIB@-O?S6NN6AZV^IVRRH>O7&">OK1-XF^'_B)2-: M\#+83MRUUHEP8N?:,X4?B34PPD(2Y\+B'%^:K./)B\,IK^ZU+\ M),/
VBZ\S,2;JW0VEQSG)+KDGDD]OZU+I=C\,KVY6X\/>* MO$GP[U-_EW29EA7IT:,AL8N M ._K_6LS4OV].G&JNZLW] M\6I?><'_ F_#&I*B^SO%?=-.'W'HMHGQ-
N+#%KJ/A7XM:,!O:WN/+>0#C<, M';@]0,EOIVKSWQ)HWP^DROC+X;Z_\[Z3Y/MNDEFMV;CY@LF% X/]3]1P6 MI>']=\)W2F^T^^TF=#E7FB>
(@]B"0/TKJ=#^/'C;0XS#_;4FHVK*4>WU)18:46O[K<'_Y+>+_\ M!,]_V==&\3,3X)^(>CZS(XW1V&I!K*Y/)^4!L[CT[#.>W?BO%GP+\>>"=S:K MX9O4@7K<6RBXB'N6C+ ?
CBO5Y/B5X)\5$CQ3\/;-)Y/OW^A2FUDSW;R^C'ZM M72>&[S1+/;_P@_Q9U;PPRJNW3?$D0E@ X& 3^[7)'0]/3FM53P6(^!]_E*W M_DL[?A,R=3'X;^(G;^]&_P#Y-3O^,#Y*92K$$8(X(-
)7VIK>B^)]7A:Z\4_# MGPS\1K)FQ_:OA^58[D@@\AA\[=>@ Y'T->6:Q\>?A5JEU]G;4?$7PYU1P& Z\LW8PZ/XQL@-P?1[U6?;ZE6QSQT4FO+_$7A+6_"5U]FUK2
M;S2INWE4*1[OID<_A7!5PM>(U\-+OT^_8]"CBZ&(=]A^A_CK_D/-_US6N?KH/'7_(>; M_KFM<_7ZU6_B2/RG#_PH^@4445B= 4444 %%%% !1110 4444 %%%% !1110 M 4444
%2VMI-?3+#!&TLC=%6M32?#,U]%]JN7%G8J,M/)@9'MG^=5]6\'H_+4C#WK#YV^@/\SZ]!6G*HKFJ.R_%F2E*I+DI*[_!>O^1H30:5X/C$ MNJ,M[?
D92SC.0/3=_P#7]>AKC_$7BR\22_Z0_EVX(*6\?"+@=?<]>3ZUD2S M//(\DCM)(QW,S')/;YI=^WIV"BBBN8[@HHH MH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ K;\,^+KWPS/F$^=;,?GMW)VGW'H?>L2BKC*4'S1=F14IQJ<)JZ9[UX M?
\367B2U\RUDQ(H_>0L?G3\/3WK6KYVL;Z?3;J.YMI&BFC.59:]@\'>.(/$D M0AGVV^H*.8\\/[K_ (5[^&Q:J^[/1GR&.RZ6'_>4]8_D=31117HGB!1110!S M?Q(\(R>/O 'B+PU%]#Z3)JUA-
9"^C3>T'F(5W[=RYQGID9]17YM?MD?LO^% MV>6-?J37PQ_P50_Y%#P M#_U_77_HM* /?_V-?^38OA__ ->+?^C7KOO$WPG\$>--2&H>(?!WA_7;\((A
M=:GI<%Q+L&2%W.A.!D\9[FN!_8U_Y-B^'_\ UXM_Z->+Q9+BXBM;>2>>1888U M+0)0%50,DDGH * /@7_ (*(0?#SX9^#=*^&O!7AG2?$6LR_:9;]PTFWAG MM[6,]F5
R[WP,@\A"'>O9/\ @G[\)6^&_P ";;5;R(QZKXHD&IR!ARL&,6Z_ MBF7_ .VN.U?&.H3W7[:G[8B1H96T.[O1$G4>1I<&23_LEE5F_P!^7'>OUCM; M6&QM8;>WB6&"%!'"&,*B@8 [
"@"6N5\3?"?P1XTU(:AXA\'>']=OP@B%U MJ>EP7$NP9(72>>1888U+O)(0%50,DDGH * /@7_@ MHA!\//AGX-T?PKX:\%>&=)\1:S+]IENK#2;>&>WM8SV94#+O? R#R$<=Z[3]
MF#X)ZAX0_8L\7S06[_\ "3^,M&O;N*-1\^UK9TM4'U!WC_KKCM7S#J$]U^VI M^V(D:&5M#N[T1)U'D:7!DD_]959O]^7'>OUCM;6&QM8;>WB6&"%!'"&,*B M@8 ["@#\S_ -G?
XH>#/#?[$_Q;\:OJ]A8^(;N2\\C3YY5%Q=&&UBCA,:' MEL.K9VYVXR<9KJ?@=\;&_9A_8G_M:Z4-X@\OZI>/X>LIA]\;8XS,P_YYHR,Q M]25'\0-?3?Q2^!'P.T&UUGQ]XN\'Z1%':
(UY>73(RJ[>\:L%=V) QEF8=S7 MR=X!M+GXW>(/%/[0/C+2%A\ ^"[20^'_ Z%"P2&!"T-NJ\#8AP6(#.V,8# M* #WC]B/]G>]\$Z5=_$CQLEWX]\3;K@O=\RVL$AWG=GI)
(3N;N!M7CYL_55 M?FSI?B_X\?$#X)^)OC?%\3[C2H]+O&$.@6T 6!XE9 [9V@+OP%96)VG)R>? ML[]EOXNW?QN^"NA>*-2CCBU:3S+:]$*[4,L;E2P';< K8[;L4 >L4444 %%% M%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !5+6O^0-?_ /7O)_Z":NU2UK_D#7__%[R?^@F M@#R:BBB@#T#X?_\
(&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M **** "N%^)WQ8T[X=66P@7FK2C,-FK8X_O>R_J?S(K_%CXL6OP_P!/,$!6 MXUJ9?W4/41C^^WMZ#O7R=JNK7>N:A-?7T[W-
U,VYY)#DFOELVS=86]&@[S_+ M_@GV>1Y\:UB,2K4^B_F_P" 7/%'BK4_&6K/J&JW+7%PPVKV5%'15'8=?S)K M(HHK\[E*523E\W;/U>$(TXJ$%9+H%%%%06%%%% !1110 4444
%%%% !1110 M 4444 %%%% !1110 4444 %%%% !5BRU"ZTV<36ES-:S#I)"Y1NN>H]P/RJO M133:=T)I25F=SIGQJ\7:?#Y$NI_VE:D8:#4(EG#CW)&X_G5F;QQX.\1[AXA\
M!6*RN/FNM'D:V8-ZA1U//>T5V?7*]N65]X MMQ?_)+8[>;X>_#/Q#SI7BK4/#TS#=Y&K6PF0=?E#+C';J3-9]Y^S?XDDB: M?0KW2?
$UL!N#:=>*6QSU#8&>#P":YBI(+B6UE66&1XI%^Z\%?2/H164QJE7^ M)1MYQ;7X.Z_ :HXNE_"KM^4DI?BN5_BRG=:#XQ^'=UY\EIJ^@2XXN(Q)#D>S MKP>OKWKI=/\ VA?
%D5N+756L?$ECNR;?5[1)1W!Y&#T)'.:U]&^,7C#1,+%K M<]S%WCO,3@CTR^2/P-:$GQ)V>(-J^)? FD7I/#W&G@VDN..Z\G&/4?A5T]< M:7^ZXF4)IV_\EO?_P !.>LJE7_>L-
&IYQ:O]TK6^4C$LO&GPVU>\CGO?"VH M^#]0!XU'PO>E2I)ZA#@*$'1 [GBN^T7Q%?7UO]G\._%+2O$5M* !H_C:TVL2NW M"F3[SGC.1W'?DUR$G@_X5>
(CFTUC6/"T[G'EWD(N85Z<#;\V/:^+/V=?B%X/ MC:6[\.7-W:A=QN-.QWEM9GAFC>&5#M:.12K*?0@]*^ MK?#OQ \1OOTR\\3_#NXX_=Z==?:K+).3F-P%(CNXAIVI$8'3 8+T.>!Q]
<52P.%Q'^[U-?52_#W9?\ DC)>/Q6&_P!Y MIZ=[./X^]#_R='PW17U/XJ^!?@6197U'0O%?PZN!P95B.HZX@94.?1 MNA_ US]>9*$J;Y9JS/4A.-104445!84444 %%%% !1110 4444
%%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5K^#_ M /D;=$_Z_H/_ $8M9%:_@_\ Y&W1/^OZ#_T8M:4_CCZF=3X)>A^A_CK_)#S
M?]F>&7N+)I9#SM4?J?05NW,6D^#$$FI.M_J/WDM(SP/<_P#U_P C69K' MCR&Q@:QVQ?9XLD-=L/G?W&>GU//TKB9)'FD9W9G=CDLQR?2F4FIE5A3TAJ^_
M3_@ET\/4KZU/=CVZOU[&MXA\57WB2;-P^R!3E($X5?\ $^YK'HHK@E)S=Y.[M/7A"-.*C!604445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M%% !1110 4444 %%%% !1110 4444 %%%% !3H9GMY5DB=HY%.593@@^M-HI M@>L>"?B
NK;+'476.JZ)+T67VJF_G7<5\W].17HW@GXB%=EAJTN1TCNG/3V< M_P!?S]:K"XR_N5?O/E\=EO+>K06G5?Y'I5%)UY%+7L'S1SOQ$O-P\"6D0/>OL:BB@#X&_9_\"_'O3OVLIM3\3?
\)@#'X;^U7C:A<7URS64\) M63RE0;MK#>4VA1\OH *^C_VOV\:77P/U?2/ FC7FL:UK#+I\GV,C?!;N"97P M2,@JCX_YZ9[5[510!\<_P#!/G]FW6OA/8>(/%/B_29-*U_4"+&TM;C;YL5L
MI#.QQG&]]O'I$#WK[&HHH ^*OVE/#_Q#_:>^-&E?#*PT/6O#WPXTR<3:EKUU M8R16]TZC+.CLH60*#LC4$Y8ECP 1]*>)O@[I-]\$-4^&VBQ1Z3II.3U->@T4 ?FMH?A+X\^!?
@GXE^"$?PONM035+QC%KL,ZF" M*)F3>H/W^V9#%E*[CD9Z?:OL,?PBN/@?\%]!\WTT<^IPB2XO9(3E/.D M\G_H)[I5+6O^0-?_ /7O)_Z": /)J*** /0/A_\ \@:;_KX;_P!!6NFKF?A_ M_P
@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH ****
"BBB@ KSWXL?%BU^'^GF" K<:U,OJ]'JQ_?;V]! MWJ/XO?%B#X>Z>+:U"SZW<*3%&>5B7^^W]!WKY1U+4[K6+Z6\O9WN;J5MSRR' M)8U\KF^;K"IT*#]_J^W_
3[7(\B>,:Q.)7[OHOYO^!^8NJ:I=:UJ$I[>SM< M74S;GD<]JJ3?L]G5 7\+^+M%UT9X@DD^ MSSXXYV'OU(Z?A7(45$I8>I_%HKUC>+_T_ E8?$4_X->7I*TE^/O?^3'8K M!\9?AD-
J+K4=O&=V$_TV!1^&]0.?;\Q4*_'&RU:Z#^+?!.DZK-[P[\6/#EQ&D.G^.-<\/[U\MK'Q);KJ5IC^]N/SXY(YD' Z<59 MO_AKH'CR^2[NO!GASQ.<;GU#P7J(M9@W7
="S*I/7J[9QTKC9K7X4>)=QFTS6 M/"MR_.ZSE%Q IQZ-EL9[#*A7X&V-_<+/X0\?:7=2CYHX[QGLYQUX'4DXQS M@=3TKT8XC$R7+*$:J_NRU_\ 9W_ BCQYX/#4WSQE.D_P"]%M?

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|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`(P'IT XR2!D9S32;=D2VH MJ[//]?.@G1\"#J&J7'Q.U> &VM-JIHZ.#\TI&V6<<8PH)0$=,| ^%=+\/:-;+:Z9IL"V\$2^@')/J23_P!!-7:I:U_R!K__ *]Y/_030!Y-1110!Z!/_ | MD#3?]?#?^@K735S/P_| ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110! M\#? !%*_CFVW3OA5H\Q:24QWVL"/DXR#!!^)_>$>T?J:J.\_L:V$/[(JS\/] M5BCA\2ZQ%_:EQ=,.;?4-H,(SUQ& L9QU'F8^]7T;J'@'PQJVL+JU]X!O#?BFYBN-:\/Z7]JQ$NR.6_L MHYW1"_BAK7P^U5FMK26D:2&*;Y?*O(2RD'H6C#Y]XU%?I6]K& MH55"]HP% P *P;?X?>%K/63]JOX:T>#5B[2&_CL(EQ+-GXEEMF DCL8%\N':2= 6(A!XZN37U9_P . MTOA'_P _/B3_ ,#X_P#XU7TIH/@?PYX5N)9]%\/Z7I$\R[9)+"RC@9USG!^J M,C/K6W0!^3?P;NIOV6OVU4T.[E=-/AU231+AY#CS+6<@0R-[?-#*?]VOUDK MU+P!X7UG5AJFH>&](OM34J1>W-C%),"OW3O92>,#'/&*WZ /RP_8&_Y.VE_Z M]M0KJ3ZPM*\">&M!U234M-\/:5IVHR!@JY:V444S;CELNJ@G)Y//-;M !7Y+ M>(]0TWX5_MM:_JGQ8T&36]'76;RZDMI(%E66&7>;::98V.UT :,[2>@QU&* 6 MFN>]6O]#+#WPMXJCAC\2^&])0#GRAJ=E'<>7GKMWJ=OX4 ?EO^V1\9_"WQMN- M"N? OA6;2O#NAO-;S:L;)+=+F><(RQD(,#"P,1N.3EN !D_37[0?_*_ PO\ M]@+P_P#^@V]?5S?#OPHVAQ:*?#&CG1X9/-CT\V$7V='QC<()NT'!(SCO6A>> M'=*U'1QI%WIEG=:2$6,6,UNCP;5QM7RR-N!@8&.,"@#Y9_X)D_ |)O>J?]C# M<_ |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

*/(&F_Z^&_|M05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@#@OBU\'|) ^*^C^3= 6FJ0J?LN MH(H+QG^ZWlY">H_+%?#WCKP#K/PZUR32]9M3!*,F*9>8YT_OHW73=:L8KVU<'&\?-&1NJM|BO#S#*X8SWX:3_/U_P SZ+*| MXJ8%^SG[T.W5>G^1^;M(U>S?&#|FW6OA\|OQJ6E+)K'A]?F,JC,UN/211U_O M#CUQ7C+=*^#K4*F'GR559GZ5A\32Q4%4HRNAM!Z445B=+&TRGTT]:I$C&I&Z M4YJ:>E42,;I3:<>E-JA#;2E-)0)B-24K=*2@04RGTRF(1NE-IS=*;30"-24K M4E,0RFM3J:U4(:U-/2G-3: &TC4M(W2@0VD:EI&H$)3*?3*8@IE/IM-"&M36 MZ4YJ:>E,D;2-2TC4R6-IM.IM42%,I],H$(U-IS=*;30AM(>E+24R1M--.IK= M:8#6I*5J2GT)&4C4M(U,!M-IU-IH!K4E*U)30F,JY9ZUJ&FJ/LE]3, MR?R-4Z&Z4JB7KN=)9_%#QEIH'V3Q;KMKCD>3J4R?R:MJS_:'^)ECM|OQSKC; M1@>=>/+^>XG->? 4VM%4G\':3,71IRWBON/7K/IK;XMV*@1^,KA@,./WUK;R_\MH49K:L_VWOBQ:Y$FKV5WIS:?$<]=8FLMIO[SG>$PUMZ:'TY'TK;_M\% /B5:KB2Q\.W9_O36_Y,3\8_]=;K^<=?)E>W M+$U5"#3W1X-/[T)5*B<=G9;GV7'_,%"+3<0_@>91ZKJ8/\ [2%31_\ !0;3 M, /X,NU'^S?]?_9!7Q8W6FMTK/ZU6[F_U##_ ,OXL^VX_P#@H+H9SYGA'4%] M-MU&?Z"G+_P4 |,.Y\WPEJ8]Q+$Q_I7O!3:/K=7N1)0H=OQ/N./|OCP4VXR^ M%-64_P"RL#9_|>%/C_;P^'S9,GA76%/^S!;MG_R(*^%]95?6:G](?U&CY_>? M=T?[='PQY\SPMK:^FVRM3_[6%/C_&WOA)N+>&=90_[6G6QS^4QKX-:FTOK M$^R^X/]=/N_O/NZ3[N[X:PC%MX5UH\?Q6ELG\I34$O| P4"\'Q!A!X2U5O3< MT^9_(FOA:D:G]9J=/R)^3AGO?[SI?F_X*):0N?*!%WK_P =\B\|_W_!

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{^M#.-^7&ZP'U^=%K!X+$+[#-UF&%EM41\Y4UNM>X7MG[&'Q!_$42CC>=+G*_F%Q7/7WA76 M]/&ZZT?4+8-H^S6MLQ_!Y/\:^8KM0MU, , .P M 'UKW(_[M3^?YGS_ /S%UO\ MW\B!J2E:DK,Z!E-IU-IDC*93Z95 (U-IS4V M@D;36IU-:@0E-IU-H :U)2M33TIB&TUNM.IK=:8A&IC4_:68*H)). !6S8^ M_VK"Q\.ZM>$\#[/8RR9_):>KV);2W,!J8W6O1M._9W^)NK%/L_@375#=#/ M9/"/S<"NDT_JC3XOZE@CPD;9",[KB^MD_3/5G-[)F;K4UO)?>>)4ROI; M3_V /BA>X,TFA&>?6VFP06LH>WE$@_>EG0>7A0POU(.,8-:`!,/PJ]VE_"/Q%J5Y'-#INI M:INL5D!"N$C"R2+Z2@M\N?6, ^E>F:+^PG\$M%OUNT\&+=R(^]$O;ZYFC7V*-) MM8>S U[K8:?:Z5906=E;0V=I @CBM[>,)'&HZ*JC@ >@H ^2_P!MSX\:G#)9 M?!OP")+WQIXDVP7?V5OGMH).!%G^%Y!U)^ZF2<;@16^)7[/'-% M7[9K237N?@O\ 9L\#^`!?B1J_CRQL[MJ[\4:D\CR7VH737#1&0DOY>[[N0=N>H48!P3GTVYMXKRWEM(B))X)4,5WB_#RV3'M5>W_8K^"MM MX@_MA/ =F;H2"41/<3M;A@<_Z@R>7C_9VXJ]JLCC2&-8XU5$4!551@ #H * M'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M:_Y U_ ->\G_H) MJ[5+6O\ D#7_ /U[R?\ H)H \FHHHH] ^`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{^R8"?S*5VMU%/DCV)]I/\ F9S,/PP\&V^/*\):'%QCY--A"'I]VKUOX/T&TQY&B:;#C&/+ MM(UZ=.@K8HJK+L3S2[E>WT^UM>8;:&$YS^[C"_RJQ113)"BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK7_ M "!K_P#Z]Y(_ $$U=JEK7_(&O_\ KWD_]!- 'DU%%% 'H'P__P"0--_U\-_Z M"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444

*@O6'BNK"VU>QDM4C(N)C%"N]0&98I"#MZ8&>HH _3"ORH_X*V?& M;X@ZQX?U;P!J'PNOM+\!Z?K=G/9>-WD=H+V3[.S>6!L"@DR2#AB?W9]Z_5>O MA7_@LE_R:/9_]C-9?^BKB@##_9._:P^.%]I/PE\&7'[.NKV_@\V.F:8?%C33 M"$68AC07G,.W;L DQNY!P#7TQ^U3^UQX)_9+|%Q:SXHEDO-4OMZ:5H=IC[1? M2*!G!/"(NY=SG@9& Q(4]'^S+_R;;|*/^Q2TG_TCBK_OC#8VWQN_P""R/A' MPEKZ&\T7PW;VY2TG_P!63#8/]"@*>&!E=<^H!!X% '8V_P#P4)_:6N=+7Q7% M^RWJ4O@YT\Y @NS<-$1N$@;RLE-O._RMI'-?3/I(?I:'@S]K[PO=W>APS:+X MBTQ8SJF@WCAY+??G:\<@ $L9*D!@ 1CYE7(S]!5^5W@/2X?@S_P6@U30/#L; M6>)2(*

(9WN+2V&U,3:;]L<%1QM^T1[\=N/2@#}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}>SDB4GT5II"/\ >-'Z8^*O%&E^"?#.J^(M-8]Q'8^2/KT[UZW^PKX'TSP#^R+|*[/2X$A2^T&UU>X90-TD]U& MMQ(S'N=TF.>@4#H!0!^8/[:G[66D_M3>,/@?(F@:CX1\5^'M4NK37?#NI(WF M64KSVFS#E5W ^6XY56!4@J."?UM_:. ^+DOP'^""B[Q]#IB:S+H=H+A;&28PK M,2ZI@N%;'WL]#TK\|\/ @KMX/T72?CU\#?$-EIMO:ZUK%Q+#J%Y$NU[I8)[0 M0[\=2HE<]<$#.

/LI_ (*'?\F6_%7_ +!B_P#M*>@#L/\4_CE-^TE\ _"W MQ&N-(CT&;6OM6[3X](@SK%Y-U-!PY5A95F?&>A(8<@$ '4^*/^"GGQK^&_V#Q/XV_9OOO#OP_OI46*XNI+B*=58G M ,KQA-Y'(5D3=@XX.1]^?";XI:!\:OASH7C?POX%> ?\ !';^ENOV06BD;*6WB*]BC'HI2%\?]].WYT :/QI_X*%:GIOQFO?A M-\%OAQ=_%?QGII9=3EBN/*L[1E WKN4'.QB%=F**K?+DGIY!XL_X*A_&OX9^ M--/\&>,?V>5T_P 5ZE(D=C8_VE*ANR[!$$.(W$A+?+E6//'6N3_89^*GA/\ M9>_:U_: \(_%?6;'P[KNK:F#:ZWJ4BI!)LGGD96F/RIYJSQ2#=@'9@G.!2_|M%%OBOX4_:R^+OP9^&?PEU6W\8>));?5)7FU31F$T5L)3%@),/D8*L;2.02%$8 M)/7 !^C?P$|?>)_B=|*]&|1^,?!ESX |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|+:=/J^N^$;U[HV%K&9)IK25 ML_EJ.692D38'.U6[\5]Q44 ?%O[/O_!4;X.>//A_H_|PFWBB/P9XRAMTAU. MQ.WE6-IU4!Y(I0K(4@D I&&<$="?2OAQ^WM\' (P?%W3OAWX'UF]\3:Q> M033F\M+"2.S@6)"[!Y)0A.0, JK#))%=1XW_9!^"OQ&UZ;6_$7PS\.ZCJ\[M%Y[PV2QR3L>K2%,;V_VFR:[+P#\(? WPJ@DA\&^#]#!+)*,2?V1I\5LTG.?G M9%!;MU)Z4 ?GS_P7!_Y$'X6?]A.]_P#14=?II7)_$'X2^"OBQ:V-MXT*:/X MIM[&4SVT>KV4=PL+D8)4.#C(Z^N!GI764 ?FY_P5]^&'BC0O$?PR^/?A2T>^ MF\&W,<=ZJ0F06WE3BYMIWQ_RS$@=6)P 63GYJ]@\|-?\ !5S]GK6/ |&N:EXH MNM$U3R0T^@SZ9$S>. ^\AM,C:'=ZB$CRQT[+0!YIIOC+_AX MW^QQ\1H[#PY=>%+369+O3=#&J29-T8!%);W#$!5,PVD*6"[&&YL5\X?L!_M ML>&/V:_ =Q|$/C:M]\/]<!-7MQ)CFU"RF,;1RR&9HI BLR.'>1@Q&QE9<'/7 MJ/[.SM].M(;6T@CM;6%!"%#"@1$4# 55' *85POQ(\ V?\ X;_&AK=_'"@G M1?$T]NNR&YO[16GC7.=JRXWA<\[0<'TH \7\6_|!37]GWPU<6EI8^+Y?%FI M74|<$5CX?L99W9G8*#O8)'U(XWY] :WO^"AW_)EOQ5_[!B_^CXJ[SP#^S%\) M?A;>Q7OA3X<^&]%U"(YCOK?38CO\ K]U7_P!&:=?Z3>#_ ;H7P_\.67A_P ,Z/9:#H=F&%MI^GP+#!%N M8NVU% RS,Q]2Q/4UE^//A'X) ^*4FE2>,/">C^)I-*E,UBVJV4=P;9SMW%-P M.,[%R!UVC/04 . ^+/A^Y\7?"OQEH5FADN]3T6]LH5!)>2!T49/'5AUK\P/^M"87[9/PT_9U^$/C'P1\3>=D*I;:[+J4*W<-/)YB-#*%$\8$:,0Z/ &M7UN1_,FOKC3HS).V4\)_ ^"_/0 M4 ?# P#P6(GU#X@? ;X1^-?#PGU'P%)=-?7,D<;*"+F)K1.\C* H95R1P9 M."0#[M9_\%(OV:? OPETV\T'Q%#';6]BJ6'A/3-/D6[C*KA;81'0D9!&W+,$ M|AB"""?J^[\.Z5?Z$^B7.F6=SHSP?9FTZ:W1K=H@,>68R-NW'&W&,5YQX3_9. M^#/@7Q FN:#\,/"VFZO&ZR0WD.EQ;X'7&&B)!\L\=4P: /@#_@E=K&H>(OVQ M?COK.JZ/<>'M0U6WGU&;2KL,);1I[X2^4VY5.5WXY Z=!6/^VUXDM?@E_P % M##XO^)O@RR^)W@C7=!2STO0Y98YI(8?)6RD3;MCB;SF7(;S6*G<"1^I&@_ M"_PAX7|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|:V-M97%N1>:+X M@T^7S=I!W1O%L99>G1"X/8FOJ>&UAM[9+>*&..W1!&L** BJ!@*!T QQBO&] M8_8M^!.O:Y)JJ!\)_"LM_(=SLNG&CL!M+N])^$-PJEILJ0A_EY**503R,_]16;X=|-Z3 MX0T6TT?0M,L]&TFT3R[>QL(%AAB7T5% 'T%:5 'YE_\%P?^1'^%G_83O?! MT5'7Z:5R?Q!^$O@KXL6MC;>-/"FC^*;>QE,]M'J]E'<+"Y&'5#@XR.OK@9Z5 MUE 'Y@?LT_|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|=K;0)]V.)%"HH]@H _"@"]7Q!_P6%_Y,_?_ +&"Q_E+7V_7 M/>.OA[X8^)_A]]#\7:!IWB31WD64V6IVRSQ;U.5;:P.".>?<^M '%_LG?\FL M_!O_ +$S1O\ TAAKX5_;4_Y2O?L\?]>6C_| ISO:_3/1(L?#^DV6EZ99P:? MIMC EM:V=&K(D4*D#:*.%55 X KGM?^$?@GQ5XRTCQ=K/A/1|4:0% M73]8N[*.2ZM0K%E"2$;AAF9ASP6)&": /D;_ (*V?L^^/(C-\"[&USPOITVK MZKX2OGNY;&UC,DTEI*@65HU'+%62)BH_A#'M3OV?_P#@JQ\'/%'PQT=OB#XF MD\)>,K2T2+5+:[L+B5)YD4!YHGBC92KGY@APPR1@XR?N2O(_&'[(_P %O'VJ M2:GKOPN\+7VI2R^?->?V9%'--(>K2.@!D)[[B>3!&4\P0QQ1J_S9W,5 W ?=O[>/A._P#& MW|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|+W7ACPUJ-:V?AQ;Q<2W=C#-)^_;G!+222-A;/.=N:[?6/A/X+ M\0^)M"\1:GX5T>_UW01MTO4;BRC>>R'81.1E0.HQT/(Q0!B_P#!7+X%ZQ\6M/V>;#Q!H%K-J&+%&#[YK^:TMXR[O9R)LF90.&/#6HW]K9^%O%Q+=V,_TG[]N<$M)))RORC[H+;2Q_:"N4U MCX3^"_$/B;0O$6I^%='O]=T$;=+U&XLHWGLAV$3D94#],=#R,5U=!7Y)^"? MBUH7[(G_5,^+M_\1KB;0M \117:1ZA);O(B"XE@NH93L!8H=C)D X)YQ@X M_6RN$^)WP(^'?QHCMAXY\&:-XH>V4K!-J-HDDL*DY*I)C6>/-< M\(_MY?LK? $;2/AMK<>M6M|%I5O>202P1_;H5CFC4B55.W>8OFQC!R,XKX[_M _"?_P"W%X:_9G\#WOP3^-PU#P-JGAV_G^PSWMA,Z(DK^8|$JHC.C"1Y'#$; M2LG48&[],?OP]\,_#'P[#H/A+0=/\.:-"S.ECIMNL,09OO,0HY8]R>36'\1 MO@'\-OB]*LWC3P+X?\372Q^2EWJ6G12W")S\]RE=ZCGH"* /SU_;R_;@\-_M M->"[/X'? XWOC?6?%-_;Q7EU:V=1A9)V)>9E_P!DR.Y'L15OX:_ 7X<_!WS6 M\$^"-#\,S2KLEN-.L8XYY%X^5I<;V''0FN]H *|6^-G[97P>_9U\)362A[XA> M,!X?UB[LUOX;7^S;RY+0,[H'S#"X&6C<8)!^7I7M-<7XV^"?P[^)>I0ZCX0\ M!>&/%6GH0PBWBN];T>WO)8XPQ8(KR(Q"Y9C@'&6)[T ?DEX' &J/A=H_ !4' MQ-)6[SQ/Y[P]O(IE@UC^$IMY:QCB'[D1&4?.I'*=L]:_.53X' M^2*?]I#3MJ5O?AUXE7Q%;Z7*D-XWV.XMC$$G E 5FC0D$*>0".#5?_ (9.^"'_ $1OX?\ M_A+V/_QJNO\ _PQ\'?#&VNK?P=X2T/PG;W3B2XAT/38;))F P&<1*H8@<9- M 'Y1?!/Q\|O\| P3# &QO'WA+QW87=G\./%#;K35((6D"VZ22/:7"JH)D55D> M-U7E23UVX/M_[9W_ 4L^&FO?!36_!?PGUJX\9>+_%=LVDQ?8;&XC6UBG&QV M)D12TC(S*BID[B"<8Y^[?'WPO\(?%32X]-\8^&-(\46,;;XX-6LH[E8V_O+O M!VGCJ,&N5^'?[+GPC^$^])JGA+X=^'M$U1,A+^WL4-PF>H65@67\#0!XU^Q/ M^R;-\,?V+[GX>>+8#::KXQMKRXURVV@M;F[A$/E'U985C!'] [OCO]A?\ M:2MOV!?'7CSX*_&R&Y\.6#:C]M@U-;>2:.*XVK&6*HI9HIHTB99%! V\CYLK M^O5<1\2?@A\/_C%##'XW\&Z+XH\E2D,NIV4&/VB/ =I\%/@A+>>.=<|57D$5W/8V'[+/P:_X9_ &?O!/@*22.:[TFQQ>21?<:YD=I9RI[KYDCX/H\6I\-?V>_A MI\'9I)_!7@;0O#5U(NR2ZL+)$G=?[IEQO(]B:]!H _/_ ;0^(6N_M3?&73/ MV5_AM>M!:LRWOCK7+?YDLK5"K>02/3*EA_$[1)D?.*^D_B=|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|-WNG?#32-8;3-%UJ^B,;ZI<&6!KEP">%7;$ HR1G+$%M MJ_I=_P %#O\ DRWXJ_\ 8,7_ -'Q5ZMXB^"W@#Q9I^@V&L^"]U*QT"19=)M M;G3HGBL6&,>2A7"#Y5X QP/2N@\3^%']\::!?:'K^F6FLZ/?1F*YL;Z989D M/9E8$'D _4 T ?-/_!+C_DQ/X9?]Q/\ ].EW7S5_P6B_Y&K]GK_K]U7_ -&: M=7Z3>#_!NA?# P .67A_PSH]EH.AV886VGZ? L,$6YB[;44 #+,S'U+$]367 MX\^$?@GXI2:5)XP\)Z/XFDTJ4S6+:K91W!MG.W<4W XL7^.]?0!XS_P4 M.^"\J?'KJE?Q1H6A027>O6+1:O86D2[GN(("2T2CJ6:,R!0.K%7SG^PS_P4 M@^%OA7X!>'_!'Q.UZ3PCXF*V_|9G^E64\D=S;Q'$3*8HVVLJ;4*-@Y0D9S MQ^C]>2^+/V2O@QXZ\32>(M?^&AG4]:EZ=\,]$UDZ5H^M7T1C?4[AY87G8 GA0(X|*,D Y8 M@MM'Z7_\%#O^3+?BK_V#%_]1\5>K^(O@OX!\6Z7H>FZSX+T'4M.T.59M+M+ MC3HFBLF'0Q)MPG0< 8X'I6_XG\+Z/XTT"^T/7],M-9T> ^C,5S8WT*RPS(>S* MP((!^H!H ^:?^"7'_)B?PR_[B?_ *=+NOG7]CW_)2S_M'_]@S4_P#TOI*X-A\ RRV\^&='LM!T.S#*VT_3X%A@BW,7;:B@ 99F8^I8GJ:S-#^ M$O@KPSXVU;QCI/A31]-\5:LACO\ 6;6RCCNKE259@\&O&E$)YY*@G)%'+?MM8 |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

M10 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ M 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^ M>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ? M|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO M_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_ MWRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T M_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 5 M1_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ M ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,51 M10 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL M#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,51 M10 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ M 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_ ^ M>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO M_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_ MWRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T M_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 5 M1_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ M ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#Y MXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^ M>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO M_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_ MWRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T M_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 5 M1_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ M ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#Y MXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL M#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,51 M10 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ M 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_ ^ M>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO M_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_ MWRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T M_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 5 M1_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ M ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#Y MXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL M#3_^>-U_WRO_ ,51 M10 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ M 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_ ^ M>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO M_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_ MWRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T M_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 5 M1_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ M ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,51 M10 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ M 'RO_P 51_PL#3_^>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 51_PL#3_^ M>-U_WRO_ ,5110 ?|+ T_P#YXW7_ 'RO_P 55?4/"%C=Z? GRAPHIC 12 rdnt-20240930_g2.jpg begin 644 rdnt-20240930_g2.jpg M_]C_X 02D9)1@ ! 0$!2@% #_VP!# , " @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!03_P 1" 2B""<# 2(A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P(§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

*M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_ /:$_P"2!?$O M_L6=3_| 262OQ!K]OOVA/^2!?$O_ +%G4_|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|;_ -H97M_V&=42QP0OAVQ48/'EY@#_Y+H_)_7M=O_%&MW^KZ MI_P 2KOP3^T%IVC"5AI?B2)[& MYBS\OF*C/"^/4,NWZ2-7I/\ P5&\|"0:=XP\'^+K>(+)J=K-873*.K0E6C))R MLK#Z(/2OFW]EUIE_:*^')@&7_MRU!_W?,&[_ ,=S7V=_P5,:/_A7_@=3_K3J M,C!+%H=MIKZ8+@C"S3R2 M1/L']I:L9)QT)7UK@?|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|@@*>2/?+G]F?]D[2;L^'[SQA91ZN"4:2;Q,BRHPX*M@B-6S_ D Y/2N MX_;4\7/\ _V7K/0?"K/IGVJ2W/VLENY62"W$;,Y\'.2D6PGK'|S7Y34 ?4G M[7'[&D/P!T:Q\5>'-;DUGPK>W"VNR|VFX@=D9D.] %D0A&^8!<<<'.:;^RM^ MQ:/CMX;N/%_B'Q$N@>%;>X>WVVX4W$Q0 N=S?+$HW#YB&/!X YKP&Y^)'B>\ |M\#P>#[C7+R?PQ!*$UF_3 M0&G-RVEK(5#:5X>U74U(R&L[*64'O_"IK]._ ^">%CXBL?@/J. MB^*-.U"P%GK$\5K;:G;O^PMWBBPDYV#//<]*^/M4M5L=2N[9266&9XP M3U(#$?TK]4_V-O$#>$_V()/UQ(1&[/6/CAXQMK*_NL;=-&HI:6R'@F/>?GE<=RA &3U'S5U7C3_@GK\, M? B)X/;5OA9KM+ID8VDT=^+_ $^X8?PLWS,,D8W*QQS\IZ5\"?$SXG>[:B[X MPO?$GB:_>^U&Y;@9(C@CR2L4:_PHN>!]2>---0M?B5XG|*>><[:3 M>Z6=0\DL2]3Q2QH& [965@<==J^E 'QIK.D7?A_5[[2]0@:VO[*=[:XA1VMVRKTWM F\_4L"Q]R:^>: "OT MO_X)G?EWPMUSP1>N)9]"N?.@BDY!M9\DJ >H$@DS_ -=!7YH5[[^P[\3? M^%9_M$>'VFF\K3=;)T>ZR<#$I'E$^F)1'SZ9H X#X]?#EOA-\8?%?A7:RP6% MZ_V;=U-N^'A/U\MD_'-<7I>F7.M:I9Z=91-/>76L'AZ%DX+ MKLS45^<_PG^%/B'XT>- ;/PQX:M1<7QEWDD.V*WB&-TLC=E&1[MDD D@5]%?\ !2CXF?\ "57&6Q[*V\N^R\_V@610>/M,P61_R00CV(:O=O\ M@F?X&LO#OPAUSQG<(JWVKWKP>Y+VLM8 .XRYD)]=J^E &/;?L+_!'X-Z': MW?Q2\9M/=S#&Z[ODT^"1ARPBC'[QL9Y^8]N!5JT_8S_9V^, ^G7"?#WQ4|%_" MF[.F:HM7BB_1I(9,MMY'=?K7PK\:?BQJWQH^(VL>*-5GF<7,[_9+:60L+2WW' MRX5[*#VZG)ZDUC> ?'&J_#?QCI/B71;E[;4=.G6>-D8@, ?F1O56&5([@F@ M#K?C]\ ?$7[//C/^P]<"W5K<*9K#4X%(BNX@<$@?PL#@,AY&1U!!/5_L,_ | M)U7@/_KK=?\ I'/7VM^WIH-A\2OV58O%T,/[S3FL]6#;&\1SE(V7/H5F4D> MJ|#TKX1_R-3_P #T=KX_]+/_]=;K_P!(YZ /5_| @/-_R5[PG_V A_Z42UV9^Q?\#?#O MQ_| BGJ?A_Q-+?16%KH\NH)_9[QN9%F@C)96XQ*W;|'7J? _!4;_DKWA/\ M[0_]*):S_| @E_ ,E]U_| [%FX_P#2]TH \8_:E^%VD?!GXX;_X2T&2ZET MNR6W:)KR0/+ ^\@CD8%@H!^9SCCIBO)Z^B/V_O^3JO%W_ %RL?_2.&OG>@#[8 M_;$_8V\#? ?X1VOB3PY=:Q+J)U*&S<7UPDD;(Z2$G 1<'*#OZU\E?#?PI;^, M/B)X6T&|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| 0YJ^>/VRO^3G?B!_ MU_+_ .BDH XCX3_"GQ#\:/&MGX8\-6HN+^XR[R2';%;Q#&Z61NRC(]R2 20 M*^Z+;]A? X(_!O0[6{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| B'I>I6&LZ-X5\1I= M6& [ZVMGCLXI=9M[$KPOOAFL\V49;GC(K\|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|V1:K72F:XNI] M RSL?^WK@ 8 X X%9?_#J7_JJ/_EO?_=5 'QK\$O$47A/XQ>!]9G<1VUC MK5G/,[=!&)D+G_OG-???_!4+PU- J'PH\+ZW%'O33=6,,I R46:)OF/H-T:CZ ML*_/+XB^#W^'OC[Q%X8DNDOGT?4)[W,;[5E\N0INQDXSCIDXZ5^EG[/_P 7 M_!_[7GP- D^'WB^YC/B,62V6HV,DH6>X$8&R[A)^|V55G@':XY&,9 /RQK[D_ MX)9^%9I_&GC7Q*8L06NGQ:96EMK.9U:YO+ MEP!]HF"CY8UP.N.$"@D\T ?#_P"V]XHC\5?M/>- IH)/,@LYXM/7'9H84CD'X M2*]7;U)Y"KU8^V2.#U+4KK6-1 MNK^]G>YO+J5YYYI#EI&)9F)]2237[5?"7X)Z7\%/A>GACP>]O97[0;I-6N+ M?SC/=%<>?(H92XST7< 10!X+\7/BIX- _81^%%MX$|"Q177C&ZB,B"7#R* M[#*7ESZDX^5.AP !M6OS2UC6+WQ!]MJ\>I74MJ]%Y*T]Q61CEF8GJ23 M7Z#^:\ @F;JOC3Q!?:YKGQ?FU+5Z4S7%U/H6=C_V[< # ' ' K+_X= M2_| 54?_ "WO_N]@#X HKK/&'A&'X=_%'5_#.I7*ZA;:-JTEC<7$*E?.2*4H MS 9X) /&>#QFOO;Q3^P-!*OC1IX\1?"[Q6NC6]P P6S<7]EGKC:6#QMZ@MQ_ M=&,4 ?F[7ZG?!$Y?&6J^-_@'?Z;KCOJ%KI&HR:=:R7&'!MS#&PA.>H7>1S_" MRCH*|&&6L[%WE9O.37MGQ$^*/P]_8;^# M9\(>%KB&Y\2K"_V'3F=9;B2X<<9"A5&!P ?F7\2=&M?#OQ$\4Z M38G=96&JW5K 1WC29E7] *YRI+BXEN[B6>:1I9I6+O(QR68G))/]34= !7Z\ M?#_;^T%^Q+9Z=:2K+>ZCX9;2\D@8NXHC%\WI^\C!^AK\AZ^K_P!AW]K*V^". MJ7/A7Q5+ (O@_5)A,ET 6_1_^(+E1R8V 4-CH5! ZY /E:[M9K&ZFMKF)X+B M%VCDBD7#(P."I'8@BH:_4[XS?1.5 /#[]28^~O"7B"+1]2U$>;)J.FA+NRO6_ MOL@88;CEE89Y)!-/>4:/_P $K;O^T$.J?$*'["K_ #"STP^:ZX[%I,*>OK^/ M2@#QW_@GY\.KOQM^T/I6])$QTWP[')I%U+C@,49(ESZEV!QZ(WI7I' !43QY M!JGCKPGX2MY@[:1:2WETB_PR3E0BGW"'19^C^]?:/P3^'O@'X/:/>^"O]S8O MJ-F%FU%&NDFO&D8862X"G<,XX& !S@"ORV_:C^&OQ)\'_$[6-6^(=I)/=ZK= M-*FL0*6L[G^Z(G[!5 C.&4 <8Q0!XU17U/^Q;\,?A\8-+\6>&O'ES'9^(I MY+=M)F^V?9I]N'#B')VNV2N5(;/QQQZ9XF_X)8:@MX]>'O'EM):,?ECU.Q9 M)$'H61B&/OM% 'RJ^S%XXUGP%|=O!EYHL\T.O&OBBWU:]TO]_!).BVMC9MC_ %C%V.YASM)*@=<9 (^7/VY?VE;' MX\>-K#3?#LK2^%-!$BP7#*5^USOCS)0#SM 557(SPQ_BP #YEHHHH **^^_V M?_@!\$_VDO@/X?TP7$.E>/\ 3X9%OIM-G$=|'\UB&DB;(E0@K|V.!P&4@@5; MK_@E7J:WRK;?$2T>R).9)=*99 .WRB4@_P#?0H V/^"8_P 5/$&M'Q)X(U&Z MFOM&TVUCO+#$?F^RY?\:MU"MD$+T&L=37D7[5%KIG@_P#;KBO(5CMK;^T] M+U&Z"|*KGRFD8^YQN/NQ-??2@WPE\/V _AKJ-WJ6M&YU*] DGN)P@O-0=00 MD4$0/"@DX&2!N)9L4IR(D "QQ@]PJ* MJY_V: /T+_X*?Z//>?!;P[J$2N\=GKB++M&0JO!* Q]!D ?5AZU^9%?JU\"? MBUX-_;%^!K^"/%=RC^(?L26FJZ>TP2XE9,%N$G[W*J^0#M;@C&, ^+W7_!*W M4? [8*VWQ!M111;(DETUC.JYZ;1)M8XQSN&?04 ?!M?HS^Q_|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|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|* 0_ | X*J?\B__| KZO? _0(:_/"@ M#]1[[_E&RO\ V*D?\UK\N* 4:]_Y1L+_ -BI'_,5^7- 'Z+_ /!*_P#Y%%@Q M_P!?UK_Z+>OB#XZ?\EM^(\ V,_H?^E,E?;_ /P2O_Y%'Q_U_6O_HMZ^(/C MI_R6WX@_]C#]'_I3)0!^]'Q@^+.M?#_]E.'Q[X12TN+R'3M.NHEN(3)$893" MI.T$' 63/7C%?$W_ \M^+G_ #[>&_| P D_ ^.U[-^Q1^T9X5|>?"W_A3_CV MYMX+J.WDT^U^W2! (M0LW! A#' $BABH7.2H7&2#7.>/?^"7&IG5KF;P9XOLC MIKR9AM=:C=)(E_NF2-6#X]=HH \|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| !.WXI?\ ""_'5-"N9O+TWQ1 ;)@QPHN$R\#'WSO0>\M=U^V) M^SK/X@_: [\)PZ?"T=CX\DA\V2,8$&? 7A/X<:7MMTO7%Y<01*-6AF\[3;2;^S;$@Y7R8'/^O6]_])WKYOKZ0_X)[_|)TGAS_KUO?\ TG>@#M_^"H?_ "6W MPU_V+T?_ *4W%=;_ ,$O_BI]GU'Q- \/;N;"7"C5[!6/&]=]3]"_P!E Z;^WKJDK617PGI>/%%L=N(ITK'R8AZ;9Q)@>D%>6_|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|_Z4QU M]K_\%5/^'1?\ AW_U]7O_ *!#0!\T?L_\G5>_ | KK=?^D<]>K_\%1O^2O>$ M_P#L!#_THEKRC]AG_DZKP'_UUNO_ $CGKU?_ (*C?\E>\)_]@(?^E$M 'C'[M&O\ R<[_| K^;_ -%/7O'_ 5-!_X3WP,<$ MO$]TCO::7J4-Q.L?WC$& ?'OM)XK]-_VHOV:;#]K;PYX7UCP]XDM+2YLA(]K M?*OGVUU;R[21E3V* @C/5@3SD 'Y)U]R_P#!,'XI?V;XH\2> ;N;$&I1#4[% M6/'GQ@+*HJVC*GZ0UX3^T]^S/^S7>>&K&\\10Z]>:K;RSKR#;&$0;&"@#+$ MLI#D\D# [IXK@/A#\0+CX5_$[PUXLMMQ:[V.:1%.#)%G;*G_ D+K^- 'U1J'[M,X/_ 4(BT+[)_Q3MQ=?\)5MVX3[-DRLF/[OG@Q8]".E2_| !3SXG_VMX\. M^!;67-OI%N=0O%4\&>7A% (]5C7(]I]^_7C\.&1/'I^SYCTI@-5[?8CMF//\ M=^4-7XI?%KQ]<_%+XE>)/%=UN#ZK>R7"(QR8X\XC3_@*!5_"@#DJ*** /W^H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M **BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@#C/B+_ ,P_MI_[+11\1?^8?\ ]M/_ &6B@"[_|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|:X^'OQ\O MY--T"\NK#6DAR#2]6B6>10,EDVLROCG(#$C&2,T45YY1QOCWX-^ NC6 MNH>+M1>V-XSK:6EO$99[EF +!%"&Y5>6T:RWK2 M%]BP*K-EB<-'TO17E'[/?[1F@?M&^']3U30K#4-.&G7(MIX=05 M V2NX,I1F!&H>17;^'O$6E^+-%M=7T74+;5=+NEWP7=I*)(Y!G!PPXX((/H017Y(?2$ MWP+/\3_VP_'7AJV+&\OM6U06RKU:9(Y7B7Z%D4?0U]'_ /!+ [XG&;2_%7P^O M)3YMJXU:RC8\[&Q'.H] &$1QZNU 'W9=74-C:S7-S-';V*-)+-*P5$4#)9B M> !DDUYCI7[4?PGUS6+72K'Q[H]S?W4RV\$*S?ZR1CA5!(P23@#GG->5_| M!13XI'P+\#&T&UF\O4O%$_V(!3AA;)AYS]#\B'VD-?GDG@6Y^'_Q$^'EO>;E MN]033=5=&XV">4/&;]WLSGN30!^VE%4-ZJM>P:;IMI&99[JZD M"1QJ.I9CP*^6=:_X*8?"K3-8-I:Z? XBU6U5RK7UM:1+&0#@,JR2JQ!J?/RH M ^M:*X;X1?&KPE\V<]%D0\@'!Y!P<$U@?'\ M:<\#?L^0V@\3WEQ-J-V1>#2].C66Y=!D;J!90JY! +$9(,.X. #H_C-\4K#X M+?#76?>I6=Q? V>F"+?;VNWS',DJ1*!N(&-T@$[ ]>E8/|_ .T%H_[0/@"] M\5:=876CVME>265Q@#?%259(XY"P*DY7;(O7!R#Q&_+/[0'[:'P_ ^//[-?CG0 M=+:^T?7V2R>'3]5B1&N M[S>4R,P8A020<'

*C.Q%3PT4 >3_M"?LW^&?VB] LK'79+FQOM/=I+'4K,@2P%L;UP00RMM7(M/]T8(KBO@_\ L5:#\-?'L'C36_$VL>.?$EJI6SN=7?*P<%0P!+%F"D@9; SD M '!'T;10 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 5P7 MQI\+MXD|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| (&F_Z^&_]!6NFKF?A_| \@:;_KX; M_P!!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH |^.FE3V-OI/BVP7_3='G4N1WC+ M#&?8-@?1S7I&C:K!KFDV>H6QW0742RIZX(S@^].U;2X-:TN[L+E=UO]>9_ S5)]-76/!]^W^F:1.QC_P!J,MSCVW<_|#% ']]%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110!) ?\%6O^:7?]Q3 M -LZJ;\TN*+S=0M/"6F:E98&6]Z"UC?"^]*'3_ ('7KWQA M_9]\$?'=~9%%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %

'DGQLLYO#NK:#XULD)FL)EAN0O&Z,DXS[PZE96]W;N()OXUE MC<<U(R#^1JGXDT.'Q+H-_I=Q_JKJ)H]W]T]F_X/X5P7P(UR9]%OO#E\=NH: M+.T)5CSL+'Y,&'TQ0!ZA1110 4444 %%%% !1110 445BZ]XRT;PTK?;[^* M*4#/DJ=TAX_NCG\`^*J,7)VBKB;2U9M4R25(8V>1U1%Y+,< ?C7CGB+X\32JT M6BV7D#D?:+K#-]0HX!^I->:UXFU7Q!(7U"^FNANW!& <[%/LO0?@*]"G@:DM M9Z'/*0%;:GO>N?%GPYHN5%W]OF'_ "SLQO\ _`ON_K7G^M_';5+O8T5Z5/!4H;J_J<\JTY%[5=>U')1)?WLUVPZ>:Y(' '0?A M5&BBNY))61@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M*** "BBB@ HHHH [GX,?|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`_ /R!IO\ KX;_ -!6NFH M**** "BBB@ HHHH **9--';QM)*ZQ1J,L[D #ZFJNEZWIVN1M)IU_:W\:G#/ M:S+(!]2I- %VBBB@ HHJ@FOZ9)]+:>FHVCWZ\FU6=3*/^ YS0!?HHJ&&\@N) M9(HIHY)(CB1$<$I]1VH FHHK*_X2K1/[>_L/^V+#^VMN_P#LW[4GVG;C.?+S MNQCGITH U:*** "BBB@ HHHH **** "BBB@ HHHH **** ,V_P##>DZKG[;I M=G=YZ^?;H_ ,5SM]\&_!VH9+Z)%$WK [Q8_!2!7:44 >5W'[.WA_P SS;&^ MU+3Y1T:.92!'^;Y_6HO\ A4GBO2^=*\>WNT?=BN@Y4?\ CQ'Z5ZS10!Y-]@^+ MFD_@,H92",@ M\$&L>_\ !N@ZIDW>BV%PQ_BDMD+?GC-$5AX\|..>GC[-KNGRL?X/M"AO^^2< MUN1R),@>-E=#T93D&N%O_@?X-OLG^R?L[_WK>9U_3./TK$D_9YTNV.YK@#[JWR1O/;DO_*C=\7M(_AT MG6\?[JY_]%T >LT5Y-_PM#QMI?\ R$_ =Q,HZM9LQ]^%?\ G3H?VB-'AD$> MIZ1JFFRGLT2L!^9!_2@#U>BN%L/C;X-O\ :N('\-Q"Z8_';C]:Z.Q\7:'JF M!::S87)/\,=RC'\LT :]%)G/(Y%+0 4444 %%%% !1110 4444 %%%% !111 M0 5X[XP 4ZK@3W)7M*\1*/+TS6!]EO".@;;@$G_QOO?:U>Q5R'Q6|*_\)?X)O[2- M-]W$/M%QOSYB\X'U&5_&@&#KZ*XOX0^*_^$L\#V4TC[KNV'V6XSU+*!@GZKM/ MU)KM* "BBB@ HJKJ.J6>D6YGO;F*UA'\4K!^'K7F'BKXYPP[X-"@\]^GVJX M!"?55ZG\7 MQ6M1W.66(?V3M/$7Q:U_7M\:3C3K=C_J[7*MCW?K^6!{5QCNTC%G8LQY+,G"G&FK15CF^>4%%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%=;\-/A7XH^+WB.+1/"VE2ZE=L09 M"RQ0+S\|CGA!P>O7&!D\5,I1@G*3LD-)R=DR5^'->P?" M?]JSXB?"%8[;3=7_ +4TE!A=+U?=/ @_V/F#)WX5@.3D&OE,5P]O+#2^3_S_ M *]3V:.9]*J^:/UFHKY<^%O[?W@;Q;#';>*XY?*&IX53)(&GM9&#/!VNHRO// MS@ 9^\: ^F-+U:QURQBO=-O+?4+.49CN+6598W'J&4D&ODZ^%K85\M:+7]=SV M:=:G65X.Y;HHHKE-@HHHH **** "BBB@ HHHX #\0?\%1 M[C3?$>H6EG\/H;G3[>Y>*.675&221%8@,0(B%) SCG&<^'NB>+M(#)9:G#Y@AD(+Q.&*O&V.ZLK#|*P?VA?C=I_P"S_P##2||5WUH=M1E65+:SL5D$9N)WSA=V#@!59B<'A3Q0!Z717Q3\$O^"B5U\5/BEH'A*]\$OZ M9%]TWV<7<.HM(T3%25.TQC(R,=1USVQ7VM0 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110! MQGQ%_P"8? _VT_P#9:*/B+_S#_P#MI_[+10!=^'_ "!IO^OAO_05KIJYGX?_M /(&F_Z^&_\ 05KIJ "BBB@ HHHH ***KW]PJK8W,T:>8\<;.J^\1) H _,/ MXG^(O%7[;'[3TW@72=;:S|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|#*5.000#G MO]B>./!^Z?MQ?LRZ+<03G1;C4%CU.SE=3(MM=Q[XW1@"-RY,J9]"&QQBO"?% M'[*OQ,U3PKH5K\9/B%H-O\,O!,/F;M/WO.T"*!C)B3+;5$8+$D=@Q/(]%_& M_P#:7L?@[\#=/\7W,<3:]K%E$VEZ8Q/[VXDC5CD9SL3=EC]!G+"O._V(?@#] M.BV]Y\6?'7F7GCCQ,&GA:[YDMK>3YBY'\,DG7'|*87C+"O!=)\1Z9\;/'6H_ M&WXEQRZ7\(_"$B66B:+L\S[5(N##:HG1CP'DYP3A2=@.WZ-\#?\ !0;P#XL\ M5:;HFH:-K_A9=4=4T^_U6V06\H;A2Q5R5!; ! *|\D"@#ZBHHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9+# M'/&4E19$/56&0:?10!S]_P##_P =:GDW.A:>['JXMU5OS !KG+[X"^#KS)2P MELV/>"X?^3$BO0Z* /)O^&?X=/YT;Q/JVF'M\X;'_?.SO1_P@/Q&TG_D&^-H M[L+T^W(3G_OI7KUFB@#R;^TOBWI^LTS2]80=61E4_A\Z_R[T?\ "WO$^E\: MMX#OD4?>FMRY4?\ CA'_ (]7K-% 'EEK^T3X<:3R[VTU+3Y1]X2P@@?DV?TK MH+#XQ>#M0QY>N0QGTN%>+'_?0 KK+JRM[Z/9IBB$1/XKB@#7L?$&EZIC[%]5G>9Z>1.C_P C6A7FMJ^SYX0O,^5! M=V/_%PN"LT5Y-_PB/0OT@_M (\0%=G?QC^&]3YC`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|YHIX.562J8K7M'HO\W_ $ARK*Y:/W]7_D*S%F+,223DDJZ2BBO M7.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "NT^&OQB\8?"/4OM?A?6[C3PS!I;7.^WFZ??C/RG@8SC('0B MN+HJ)PC4BXS5TQQDXN\79GZ%?!W_ (*$>'_$7D:=X\LO^$/)_O *Y95DC=3W# X-?B-7:?# M7XQ>,/A'J7VOPOK=QIX9@TMKG?;S=/OQGY3P,9QD#H17RN,R"G4O+#/E?9[? MYK\3V*.93CI55U^)^R5%?(?P=_X*$>'_ !%Y&G>/++_A'-0;"?VE:AI+-SP, ML.7CR2?[P '+"OJ_1]:L/$&FP:AI=[;ZC83]'BN;659(W4]PP.#7QN(PE?"R MY:T;?E]Y[M*M3K*|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`ME0!] _M:_MKZE*_%T?@'P#IL.J^*X5?VBZE1IE@>3E($B7EY2"IZX&X#!)X M\B\6_;]K?X.Z;%XH\86$::#))&"MU86;PQY/"OY&)(JW3YR@D9R:Y+PGY4 MO_!22?\ MP1[/^$MO?+\S&-P!W[-U[Y$6/?&*^\?VL6L5_9N^(AU'RQ;_P!D M3!?,QCS<#RNO?S-F/?% #_V;?CYIW[0_PXA\16MN-/U"&5K74-/\S?\ 9Y@ M>#@95E*L#CN1U!KU:O@[_@E7'=#0_B,[_P#'DUS8B+_KH%GW_H8Z^\: "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH XSXB_\P__ +:?^RT4 M?$7_)A__;3C`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|YHIX.562J8K7M'HO\W_ $ARK*Y:/W]7_D*S%F+,223DDJZ2BBO M7.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "NT^&OQB\8?"/4OM?A?6[C3PS!I;7.^WFZ??C/RG@8SC('0B MN+HJ)PC4BXS5TQQDXN\79GZ%?!W_ (*$>'_$7D:=X\LO^$/)_O *Y95DC=3W# X-?B-7:?# M7XQ>,/A'J7VOPOK=QIX9@TMKG?;S=/OQGY3P,9QD#H17RN,R"G4O+#/E?9[? MYK\3V*.93CI55U^)^R5%?(?P=_X*$>'_ !%Y&G>/++_A'-0;"?VE:AI+-SP, ML.7CR2?[P '+"OJ_1]:L/$&FP:AI=[;ZC83]'BN;659(W4]PP.#7QN(PE?"R MY:T;?E]Y[M*M3K*|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`ME0!] _M:_MKZE*_%T?@'P#IL.J^*X5?VBZE1IE@>3E($B7EY2"IZX&X#!)X M\B\6_;]K?X.Z;%XH\86$::#))&"MU86;PQY/"OY&)(JW3YR@D9R:Y+PGY4 MO_!22?\ MP1[/^$MO?+\S&-P!W[-U[Y$6/?&*^\?VL6L5_9N^(AU'RQ;_P!D M3!?,QCS<#RNO?S-F/?% #_V;?CYIW[0_PXA\16MN-/U"&5K74-/\S?\ 9Y@ M>#@95E*L#CN1U!KU:O@[_@E7'=#0_B,[_P#'DUS8B+_KH%GW_H8Z^\: "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH XSXB_\P__ +:?^RT4 M?$7_)A__;3C`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|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|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`0,-H]_*2] # \E\$Q8]!E?5<\U\ACL@4KSPKM MY/\ 1_YGMX?,FO=K?>?JW17E/P5_.:5\&?'"U":/>&QUE5S+H]\RI<# !9D / MSH/[R_B!?JU?%U:4Z,G"HK-'00G&HN:+N@HHHK(L**** "BBB@ KX?\ V0_V M5/B#\'_CWK/B;Q+8V=OHTEG=6\4|-XDIE9Y49<*.0,*3R!7W!10!\B?MV_LK M^(OCG<>&M>\&VEM=:U8QR65W#-.L+20$AXR&; ^5C)QG^.O1/V-O@/>_ /X1 MC2]:CA3Q%]%W)>W_)+B0(>$CC#CJ B@\<99L>M>[T4 ?#__ RG\0?^&VO^ M%B?8;/\ X13^V/[0^U_;$W>7Y>,>7][=GCICWKI_VWOV1M>^.NI:/XJ\(3VS M:[I]K]BGL;J3RO/B#LZ&-\8##SOD,0"".1C!^N:* /@/5O@C^U/\^#["V MOXM/MYX+A9KM(60LRE3\Y&1P>E?8M% '$_| ")W_/PT_A&,1_VI_PC_P#9 MN-_R>=]F\O[MOTN1_U_L'_LV>.O@5K_BV\|8:?;V,.H6T$-OY-W',6*NQ)^O MG P1UK[&HH ^'OAA^RK\0O"_[;%_\1;_ $^UC*/K.K7Z72WD;.T=PEP(OW8 M.[.9ER".,&O2?VZ_@;XM^.G@/P]I_A&T@O;VPUWL,UPL/R&-ER"Q /)'>O MIBB@#S;]G'P/JOPW^"/A'PUKD<<.K:=:&*XCBD$BJQ=FP&'!X(Z5\S_LJ_LJ M_$+X4_M%:OXK\0Z?:6^AR0WD<4\5Y'(9#)("F%!W#@=P*^X:* /B[]K7]B/6 M_B)XZ'Q!^'5[!9^()#$]W8R2FW+S)@+<12CA7P$R#CE=V&<6V9),=1N4\X[BOT>HH \T_9Z^!^F?L_ MPULO"]A*+RYWM<7U_P"6$:ZG;JV.P "J!G@*. ^:]+HHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@

:7J,"W-O,O&Y&&>1V(Z$'D$$5/X MADECT#4WM_| 7K;2F//|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||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| \CYXD_["5S_Z-:OU# ^"O_(\Q M?]<)/"OR\|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| M1>$]#!860LJ>T;3];M,Y^SZC:I<1Y_W7!%5?"_P_|+^"!(/#GAO2- $@P_|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s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|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| :V_:8_X3:YF\'>%KP_V! Y6^0(6XO7!^ZI'6,'\&//0#/R[1M17[#@\)2P5%4:2T7X^;/AJ]:>(FYS"BBBNPYPHHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MSPSXZ\1>"[A9M!UR_TAPV[_$2X:-6/&TKMU:Q02 8_A M9 .</7FMBU^(P2]8,IU#0]=!:@V#]HTV;[7;(V3\Q#?-CD<*HZ<8[M_.5%>;++IRS<]*_/NO0/"/Q]^(/@?8FD^*M02!3D6]Q)]HB^@23< #[8KR:^2N6W+ M+U7*_OCI_P"2G=3S#EWNO35?<_ |_^Z-%^*P^^(S(CZMI=Y<,=HBUF+[%== M,#]Z!M8^@4?]*MZS\(=)N(3<65S=:8K+O7S4^T0E?7>A.T<@Y8].>E?)UO\ MM3:9XDV1^._ASH>N9)$E[INZRN2#C+%AG)SD\%0<]N_8>#/WPV:19?"?Q!\ M1?#6[3]AU2,W%HS $_PY4C@_?/?@=J*KE=:AK%2C_Y,O\ R77_ ,E/2AC: M=31M/\'^/*9ZCJ?PI\06"F2"WCU.#./-L9!(/ICAOTKD[BWEM)FBGB>&5>]2 M*58?@:[_ $/Q9\28;8:C;P^&?B;IJ@?Z=H%ZL%RP'J1A<_*,JH/I]->ZˆˆWA M"]DCT_QCI5_X:NFRHB\0::2N>#E)%R,8)&XX]?KPJ5>+MRJ?^"?[M_P1U_NW MK>WK_GL>2T5[7!*_ "?C"Q%]H&IH(F_Y:6-PMU!G'3/7]:Y/6O@KK^F[FM!%MJ<0Y__O9VV0VUK$TDDC>BJH))]A1L!5KW+X_LJ>(/C*W]M:E+ M_P (MX$MU:6[\07R[$9SN6[;D8+$A5PQ))&T^I>"?V:/!_P"S_I-KXR^. MMW#-?%E?3_!MHRSR2L,,#+M.'((*_ZO@!F;=MKSOXY?M,>)/C1_EAS= |*6 MQQ::#8MMB48 !D/(\QACC(P,G &3GSU5J8I\N&TCUET^7=_@=7LXT5S5M^W^ M?;\ST;Q=^T9X6^"N@W'@CX&6"V4;((C1_,6SC?GA|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| DCX7&8IXJIS=%L%%%%>P< 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6M,U: MJT6\2[T^\N+*[CY2>UE:-U^C*017K'AG]K+XC>'[?[+=:K#XDL2%#6NNP"Y5 MMN,9;AST'\77GKS7CM%<[;#T<0K58)^J-85:E/X)-'TGHO[17P]U682ZYX&N M_"NIL<'5?!UX8&&>I$>5 &0#C+=,U[7X+^,EK?-%%X6^+.F:R6.U=+|:VS6T MPYSM%PH4LV"'!T<9R1Z5\ T5Y%?)J%963:]?>7XW:^31W4\PJPW5_P_(_4A/B M!JL=FJ^*O)S+:%=WV[1F34[5P!RVT?O .?![A[^AK-M]#^&_Q!G>+1=4AMM0 MXS;6\GE2@D9Y@D&X?3 K\|/"GQ(\4^!GSH'B#4=)))BMKAEC;(/WDSM/4]1 M[UZMI_7_B.^AAM?&6A:'XUM$X+7UHL5Q]5D084]>0N:|"KD%:F[T']SM^#O M_P"E(]2GFE.6E1??K^*_R/J36/@5K%H2UA=6^H)V5OW3_DP:1#M/T;H?PK)\&_M7>"+AXU_M+Q/X$D&#Y(45[KJ7AOP9K#!=0TV?PW=,VW,L9MUW?!7_)'F+_KA)_(5^7GC_P#Y'SQ)_P!A*Y_]&M7Z MA_!7_D>8O^N$G\A7Y>>/_P#D?/$G_82N?_1K5U9?_O%3T7ZG)C/X^RZOT1K3IRJ.T3R'X*? 'Q=|>->%AX=LMMG&P% MWJEQE::V7_;;^)N1A5R3GIC)'TC?>._AQ^Q[I]QHWPXBA|8?$>2$0WWB:\42 M0VK?Q+'CC_@*'''[VQ.D?Y?_DG^AHZL*.E+5]_\O\ ,V?%WC#6 M?'GB"[UO7]1GU/4[IMTD|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|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

(T5V6L?"3Q)I&2MF+Z+^_:-O_'>&_2N0GMY;60QS1O%(.J2 M5(_ UTQJ1J:Q=S-Q<=T,HHHK0D**** "BBB@#O/@K_R/,7_7"3^0K\O/'_| MR/GB3_L)7/\ Z-:OU#^"O_(\Q?\ 7"3^0K\O/'__ "/GB3_L)7/_ *-:NK+_ M />*GHOU.3&?PX^K_0P****^@/*"NG^'?PU\2??%;Q)!H7A?2IM4OY#EO+&(X M5[O(YX11ZD^W4@5ZM\ _V1]>^+%NGB+Q!<+X0\!0D27&LWQ6,RQC!/E!R!@@ M@>8WRC/\6"*])\>?M->&_AGX:?P/\"M.71=,962||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|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|1:SYQFM#Z3<9!\RRN'A8X MSC)4CU/YFO9/"?[:'Q'\/8BU&[I_MF45RU ML)0Q/\:"Z=:K2^"31^@'[-OQTT'XO>+I[E+]9'SQD\ \(_KUK9/7'<<]&*Q M,=N1G"D!MW.>W&?LHR'P=\)?B[XU8B-K;3_LUK*!\X6.1L]LL/_Z>E?(=?M)4\KH5,95Y&TH62L[ZVN][[7/:EC*L:$.:SNY4_S]::?V6_AW>$G3_CWX==<$XO+46YZ\#F;G_/%> T5[']U M.JOAKR^:B_| VTX?K$.M-?C_)GOH_8OBU! =(^+?@342>!_Q,0!UYY7=[4TM_L%^/+C!TW7_EJZD\?8]3?]N;QU=Y.H:'X4U4G@_;--=L] M?20>M+FQJW11?I+_ #B/_9W]M_=_P3Y=HKZA;]KRUOMWJ]?"3P+?[ASG3@.> M_P! [=ZG\ZC;]H[X<7BG[=\!/#+EFRQLYUMOIC;#Q1[;%+>@_E*/ZM!RT?^?G MX,^8J*^GS\6?@'J3 W_P4EMB>#]CU>4#GK]UD]Z8WB+]F._;][X$\7:9N/2T MOKO!*%Z?WY\XZTOK51?%0E_P"2O\I#]E![5%^/^1QT5]-?V'^R]]2Y_M#QW1) MXXQ"Q'3_&'IK?"_JFZ\V?9_BCXAL"W5;S2WDQ[92 #^E'UQ=:1*_ ,,D^$[IL6'QT\&S M\|"XF2%N_;S3Z4OK]#K=>L9?Y#^KU.EG\U_F?--%?2O_PYK5Y@Z9\1/ M\ MA. W]IN_P#?,;5%/^P+|45R;5M"U%<9W6NH|>WWE'6C^T<)UJ)>N@?5:W2) M\WT5[S>?L._&2USL|+Q70'>'4K7^32 __KK!O/V3?BY9?ZSP-J+<9_B70JK>#^\\DHKOKKX ?$RS!,GP_\2X7J4TJ=QTSV4U@WGP] M\5:?G[5X:UBV_P"NUA*G\U]Q^=;QK4Y?#)/YF;A);HY^BIKBTGLVVSPR0M_= MD0J?UJ&M2 HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110!JB_P#!.7XC'2_&&O| @NYEQ:ZI M +ZT5LX$\7#J/=HVR<_|\A^/Z U^+7P]!8W/P^\(M%T_5;"436-];QW5O(XXW4,I_$$5^>Y_AO9UU66TO MS1]-EM7FINF^A>HHHKY8]<**** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XSXB_\P_| [:?^RT4?$7_F'_| ;3_V6B@"[V_ /D#3?\ 7PW_*"M=-7_#__) TW_7PW_H*UTU M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QO_ ,% _'(V>&O!\@) M);5+I>82/P*6H_ ^]?)-?6G[9W_%) M?#+X1^"U?]Y:6#3W,9 SN6.)%;]6,WY5\EU\]EKYZ4ZW\\I/\;+\$>GB_=G&MG_*DOU"BBBO7.(**** "BBB@ HHHH **** "BBB@ I\4 MSP2+)&[1R*-O$5AM-MK^J6Q4Y7R;R1+_ !II M3$])X$D4?@L!/?U[5&/@O^S_*@N++XRWULY(Q]LT>7 Z9!RB_SKY_HI?49+ MX:T_P?YQ']976G\'|?\SZ_X9=^&5YD6/Q]T/=GA;NP$(]_F_P#2FK^QMIVH M#.E?&/P/?]_ ;\]GIGD*S8[_)5X#11]5Q"VKOYQC_D]O3ZT_Q9[Y_PP;XT MN&_XEWBGP;]@SC%MJF:==D9PL.HQ@G_OK;7AU M6[+5[[36#6E[<6I4Y!AE9,?D:7U?&+:LGZQ_RD/VU#K!_?\ |])OOV+_C)I MXR_@V25?6"^M9.WHLN?TK!O/V8_BM8Y\WP%K38_YXVQE_P#0,^E9U\3?&%A M_P >OBO7+;_KCJ,R_P F]S6]8_M#?$W3P!%X\U]L'/[^_DE_]#)HJGCE]]#^ M37ZL.?#]!?A_D?!CX@:=G[5X&\26X'4R:3<*/S*>QK!O/"^LZQ6/[6WQ^+EJ\YNOVMYS_ M ,M]:@&?^^$6E_MR^S%_]O-2^VCOAWU:^2_S/G\E*L58$$'!!{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| [:?^RT4? M$7_F'_| ;3_V6B@"[V_ /D#3?\ 7PW_*"M=-7_#__) TW_7PW_H*UTU M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,FF2VADFE<1Q M1J79FZ 9)-/KD?B]_I_@_"OQ??ASS&|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|CZ(7]H+X3WQ U#X":.@VD%[.^\O_P =$(_/-'_ "ROV=M0YO M/@[J%LS&/&VE_[4*-Q^D+'MZ]Z^>]*/]"MZ59KY_YIAJ:?6$?N/H+_(4_^SO?I.L?Q?U6UXX6[TF4X_'RE%)_PS'*[(B MQ^/FD(Y^ZMYIPC'/3+&88_*OGZBE]3JKX:\OGRO_ -M'J8CUIK\?\SW]?V.] M%U#&<-*^-/@F^?^%6NT0]<#(#L12?\'^++LM_9OC/P3J6!D+#JVI=:?XL]UN.V!?BQ;KF&TTF]'4%&?IN"_Y-8=] M^Q3\9+')/A SH#C=!J%]_P"GFY_2O+K74+JQ;=;7,UN>N8I"O\OI6W:_$CQ;M8MNMO%.M6YSG,6H3+_)O:E['&QVJ1?\ VZ__)(?M*#WBU\U_D;-Y^RS\6;$ ML)/ FK-M.#Y,:R_EM)S^%85Y\#?B-IZ[KCP%XEB3^^VDW&W\]F*Z"Q^/WQ*T M\8A|>>*

(2.PEU&60#C'\3&MNS_:P^+5CDQ^-;ULG/[Z&7_T)#2Y<']04?PW6GDC_P =<>WY"CFQ ML=Z<7Z2?ZQ'_ +._M-?+_@GRY17U)_PV9=WJ[=5^&G@?4%).\?V:5# _[S-3 M&_:>\$7RD:C\"?!\YQ]ZUCCMV_BGI2]KBEO0^Z2_6PHKZA M_P"%V?!+4UQJ'P,@MLDY^Q:HPZ^X5*0^,OV9KY1Y_P ,?$>G,3DM9ZB\AY]G MN /7M1]9JKXJ$O\ R5_ ^W#]G! [5%^/\ D?+]%?3RVW[+FI*H,/CC2BR\DF-M MOUY?G_"F_P#"O?V9+[YH?B!XMTS/\-W9^;C/^Y;]!2^N6WI3_P# 7^EP]CVG M'[SYCHKZ: _X4+\#-253I_P ;FMLC_E]TEQ^C;,4G_#*/@"\53I_Q[\+R;AG_ M $V%+;^'$8D0ZDD MJB^#C[T3,OU^=$KH?^&)I+X$Z5\5/ ^H <_\A C_ -!#>];G@'}B?XC>$_'/ MA[7[#6/#.HKINH6]WNL=1=MPCD5F W1#//!KFQ.,PM:A.FYVNFM;K\S:E0K M0J1DH[_1*BBBORX^N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** ., ^(O_ ##_ /MI_P"RT4?$7_F'_P#;3_V6 MB@"[\/\ _D#3?]?#?^@K735S/P_ .0--_U\- _Z"M=-0 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !7C'[8&L?V3^S_P") &*R71@MEVG' MWID+#_OD-7L]>#_ML6_G? /4WSCR;NV?_P B!?\ V:01RU*6-HI_S+\SEQ3: MP\[=F?G)1117[8?GP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]2_L9QMX7|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

4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !117]WP3_9O\6?&Z]5].M_[/T)'"W&L72D1,X(C'!D88/ M XXY*Y%8U:U.A!U*KLD7"G*I+E@KL\XT/0]0\3:O::7I5G-?ZC=2".'V@4L[ML>P'^< 9KZ]\(_"7P#^R+X/M?B1\8M0AEUU/WEAH\8$ICF ++'$F?WTPX.XX M1#SG@/5?QY\:O@Y^P7I%YHWAB%/&7Q2:W:-V9@S(Q?I<2CY85&, ^4GS'8N[& M0]?FU\7/C#XL^,'C"?Q-XPU234]2D011C&V*"(9(CB0<(H))P.I))R22?C<9 MF53&WIT;QI]^K_R1[U#"PP_O5-9?@O\ @GHW[4G[87B_]I[6$CQ _/B2^%+6 M7S;'0+>4M&C8P)6P/-DP3AB &(4#)SX+117GQBH+EBM#HE)R=V%%%%4(** M** %BB@ KW/|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|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

5O_ 58 M]7$^Y3I4^RO]X4445|)P!1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%=;\//A3XK^*F]?8?#&C7&I.K 2S]NV""/>20X5> >IR<< U M]2;3^RW\,O@#H47BCXU>+;%MOS+8M*T5L6&TE54?O:A@>R@<'E2*\S%YCA\' MI4=Y=EJ_Z]3KHX6K7UBM._0^;?A;\"_&?QAN_+\,:1)-9J^R74KC]U:PGC.Z M0!2 0=JY;!Z5]+?|*7^"?[*.DP:]\6_$MKJ^M;/-@TZ7)5V&[BM5R\HR,;G M^3(&0M>', 'C_ (=WGV3_A&O@II4?A;1(5\H:Q=6]>>5 7'D0\I$.&&6#$@@ M@(:^%O$'B/5?%FL7.JZWJ5WJ^IW+;YKR^G:::0^K.O)-?*XC'XK&:7]G#LM_ MF_\ (fGAZ-#6W-+5V?FBS*E0]4GQ"^'W!13^!_BMKUWJ%G<7+:/.M\5(M+K>!%*K8'RD\9Z%7#=A M0! ^CU%?(/_!0#]I:5?A'HVB^%O"6IOIOB;4V^V7%U!@R6]JI(4#(X,C@\ ^D; M#O7I?P#?OWX=_9L.M^-M9N-6\4W-E<:NAO0"ULABW0Q'@= H8@\@NP[4 >YT M5^4?P=^)O[1WQ^\0ZAI?A;QY>RWUK;F\F6XN8X$";PO'RXZL.!72W_[3G[0W M[.'CBTTGXARG6;5@)C9ZBL4B7,)))!:*XC&|/7]3@@97M0!^F]%9'A'Q/9>-O M"NC^(--9GT_5;.*]MRXPWER('7(['!Y'8U\=_M_?M$^*_ ?BKPGX+\":O=:.7 M]UQ&;R\:QP99-[>7!$.#U*R'"?*T ?;=%?#7_!/K]I/Q1\!/%7B7PAXUURXU MF^^SK?Z?)>8WIL;9-'G S]Z-@.VUO>OHK]J>Q\97'P5UR\\ZQ=Z/XATP#4$ M-GC?<1Q@F2+D'JI+ #DLBCO0!ZW17QG_,$^?VEM;^*D7B#PGXPU>35M>L\7 M]E=7.WS)+KL#TH_^_Z*P? 6D:KH'@K0].US4WUG6;:SBCO=0D MQF>8*-I]!P6SCVQ6I0 45%+=0P211R31QR2DB-&8 OCK@=ZEH ***C,|:S+$ M9%$K L(\C<0.IQZ4 2444R25(4+R.J(.K,<"@".ZOK:Q56N;B*W5C@-*X4$_ MC4JLLBAE(96&0P.017P5_P %5O\ D'_#3_KKJ/*VKZO_9M_P"3?/AM_P!B M[8?^B$H](HHKX& ;> ;D|4M\0+CX>?"5,74%S]@FU2" 7%Q5OV, MW^RN2>@STKN_V/OVW_$/C#QM;?#XD>7/]5T5OV.K>2O)?7/[B= N3@@, M#N!!W9]!U45XK^UE)?K[)G/X;V'B33])M]8N+K58].\FYD9$4-%-(6RO)/ M[K&/>NC_&=_BI<_&OX. ^'O&=W81:9?QH [J;6 M].MM0BL)K^UBOIAF.U>91* T4G)_"KM?ES^TVQ_X>$6G/36-#Q_W\M]_4-I4 M618RZAV!*J3R0.9P/Q'YT /HHI&8(I9B%4#))ZV'@!:*;'(DT:R1LKHP#*RG(M(/0@TZ@ HJ.:XBMU#2R)$I(4%V !)Z#GO4E !1110 5YK^T5\,O^%M?"'7M! MBC#ZCY8NK$G@BXC.Y0.#[IE/HYKT]BM:=25&<;D=T|D3BIQ<7LS\2&4JO5@0 M0<$'M25[]^V=\')OAC\5KK5+:(#0O$4DE|.BD+'%6S-%|0QW#'&' '2O :_M7L/6CB*4:L-F?"U:;I3<)=|E-:GGK36KI.1M%%%(I****@!IZT4K=;2@!K=: M2E:DJ0$:FTYJ;2 *;3J;2&CU#X-_M'>-?@E>O_V)]N-)W9ET>|)DMI 3DX& M0M$X' MKAATXZT?"?|:&|=?!FX7_A'=9D&G[MSZ7>9FM'ZY^0GY22E:/M8=UI+ M[NHW1PV(U@^279[?>.?'=%?6_CS|A^#6+/^VOACXAM=6TZ92|=I=7"N&&.D4Z M95LG/WL8_O&OF;QCX#\0?#_5#WB+2+K2;O^%;A/E<#'*,/E<!U,K]AG!_#XRKZ:_X* >)5)UXt6>EQ2LR:3I<44D9SA99&:0D M?5&B_*OF6O RF+C@X2EO*[^]W/2QTDZ\DMEI|PA4455[!PA1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !17??#7X$^./BS*Q_":.:#<7%GG#:A/^YM5Y MP?WC8#$=U7+>U?2.F?LA_#KX->'U\1?&;QI:0P< 6RW/V6VWX),:L?WDS>@0M*>#P:!O%9EAI).L5Y=EJ_P"O4[*.$K5M8K3N]CY-|'^!0$'Q UA-+!,:1=:O M?-@F.VCR$!.-SMT1M?5?A+]C+PQ\--#/BKXS>*K+3M.M_F>RCN1#; M@X)"/,V"[$#[B $D8!:N+ ^*' !3'P7\,]'D\, _[PE;S)$61=4O;, $-YKM[R(/;$4(NQQKA(Q[* M!7S6(S/%8KW:?[N/_DW_ #U:>$HT=9>_P_X)]R?&W_ (*8Z5X+TT^$/@/H M=G:=:JT::Y=6NR).ELFWMB!SDAM\O4DY0]:^"?"Q \1_$OQ%YO)2Y_W5'15'95 ' KGZ*\V%*-/5:]^!U2G*6X4445]0%%%% !111 M0 4444 %%%% !1110 4444 %=Y\" _A+]7QR^*WAWP7IFY)-2N0LPIY^S6Z_ M--*<'!0$Q UA<+]_:1=:O M?-@F.VCRS!.<SMT1M?5?A+!

*0L[BPNH^'@N MHFC=?JK $5VGP_|_V[?BMX(:"*\U:'Q381E0;?6(0\A49S^^7;(2<]6+=![OU M!]f|\-_M_?#GXA6D6F_$GP:UEN&QIO)34+5!SQFNJ.89AA] M*U)37>+L_N_R.GAL+4_AS<7Y_P"9\C45]LQ_CX"?'*/[3X$\40Z=>28/V?3 M[L, >!MZ'C@UP_BK]@7Q=IOF2:%K>FZU&I^6.8-;2L/H=RY_X M$*[:6>8.H^6HKT#Q5\ ?B'X-WM]GA+4DA0X;> MWB^T1#1@EX]P .1U/7CK7 ,I5B"$<{&&O:IU:=9/?#NBF,R)?ZA\;NJ_P!QI &/Y9->V_|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|\@:;_KX;_P!! M6NFKF?A__P @:;_KX;_T%:Z;@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?|>^_|"^)GA6\|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|!UW?@_X M]_$7P!L70?&6KV,*8"VYN6E@&,8_=/E.P'3IQTJXPQ]#^-#7NNTE?|=Q.6&]? MQ*=O33|#V'Q5^S-\3/"#.;OPE?7<*|)M-NU(Y^;]V6("\'0'O7FEQ;RVDIP MSQ/#-&=KQR*592.Q\Z&O7O!G_!2+XC:&8H]>TI2/$'T"XWR-$;6X;& ?FC.P9 MP3_]^]!BO7--_;Z^$OQ'MX[3O]XN+-B,;KBVBU*WC_.!8#C\$KHCFF.H_ MQZ"DN\]7^C,WA,-/^'4MZK]3Y!HK[2A\#_CN,CRWT3Q/8Z)-G*L-T0Nf194<9_P">B,.W<*>E=,<^P>U6 M\'YI_I6U]X6EZ,^,J*^B-$>_86^(^ELQL6TG6H^]_9KLQL>A$BJ ?Q(]Z M\U\1?/XB^%?,A?!VK)"G?+,YYN(UQW+0[EQ]YQ7]4LPPE;^'53^?Z')/# M5]?Q0?W' T5-=6<]C.T-S(];S+PT%%%%>T>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4459L--N]5N5M[*UFO+A MONQ6\9=S] !FEMJP*U%>D^'_-F_XG>)MIL?!.K!6&0]W\]E4C_>E*BO3?"_ M[OQ'UB1#]LVD^'X,_/Y]SY\N/55C!4_BPKAJ8_"T?C])?/]#IAAJU3X8,^: M:*^XK?|\ 89^'O@&&R2_|\'_C]HK?UA%:6LVJR.1W627,*GZ.M>3$S[#+2E%S]%I^)YQRVKO-J)\DZ' MX7UGQ1.T:C;1?:M.O)CL.9YF'X*#7K?A7[C/XK>*-C-H"Z- V/WVJW"PSXZH M.N/^^:,Z? Q=_P5JT#+1+4V(@#*X<3&%,K%+JEPEK&@[!R8@V?IO%>_^:/\ @II\ M,%P=++5-+|*P,,%%%W?\'?+ M]/U>^@?#QSZD][,K#((:"U'KV9.U?E_XT^+7C;XCS"3Q3XMUKQ"5)*+J_+:, MB9ZA59B%'L !7)UY\\1C*W\2LUZ:?D=,;=^G\%-?/4_4C4O^"E/P/^&<,EO\ M/O 5Y?2KN57MK*#3H9.>/GY?!Y/*9KP?XF_\%4OBGXN$UOX6L=+\$6;D])(8 M_MEV%(Q@R2C9^(G4U\7T5R+#T[\TM7?YZFWMIVLM$=:_=HX|[CT1 MF2RS#-\T$XONG8ZXXRM:TG=>9^D/L/P-_9Y^+BLW@[O7!87<@!6WL-3#,"3P3 M#-EQI.

[C&.2O.IVMUH2I>LEO'91QE#&WR890&X'')->_&+XK1-M?!7X/ZGXUNK"35H]-BMRUI'(VD,DL<0^8@XP9->G;LC|FOX_P!M^T=X#O?$-MMKHTVAI;ZC(IS6TTXF)98XI-P8*.")0,8I[&@#UFBBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH ***^$?\ @}XDU;04^&B:9JE[IRS'4C*MI_|~@;\.KFYFDN+F;PYITDLTS%GD8VL9+,3R2222 M30!W=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110!QGQ%_YA__ &T_]EHH^(O_ ##_ /MI_P"RT4 ??A__ ;@:;_KX;_T% M:Z:N9^\ _/R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ KBOB/\&?!?Q:LQ!Xf]\/VFJ,HQ M'=%3'<1? fLJX<#VS@X&0:]6BKC.5-\T'9DRBI*TE='PA\5/^'';LZR37G@#7T MDC.YQ!>L'##D85)E'/&<;E'09)R2/DGQ{\)?&/PPO'M_$_AV_P!(VN8UGFA) M@D(_N2C*/_P$FOVE]KJFE66N:?-8ZC9VJ_93KMEMK@9O(Y!UPRL'"/K7OX?. MZ]+W;JYE'>JYE7+J<l8:,,_#5NE-K\//Bf^P+\/?'DDUYH(F\&;DX)O5P0A"M&;! MP3"?N\XX0J..F3FOCOXI?L62*W%9_,;I=>3:0PI*6BD4,I&Z4M!Z4 ,I&I;&Z5 T-I&I M;1NE!0VD;EI&I -I&I:1J74?42D:EI&I#&TC=*6D;I2 ;1114C$;FTVJ;28^ MHVBBBI8PIE/JE# ****10VFMUIU-;K2&)7]?[*\IA_:. ^'+* 2=;MEY|W_K M7EE>F?LR3>3^T1\-VQG.OV2_G,H_K6%?^'+T9=/XUZGI7_!2;_DYV^_]!=G_M .@FOE>O[_+X*7]%_:7<@ %M'M'<#KS(*^4#UKCPG^[P]$=%;^)+U$HHHKJ M9B(U-,I3FIK=*0#:***E@%%%% (!E%%%)@#=*;3FZ4YI&AE%%% (*;U.IK4%" M4C4M(U(*:U.IK4AH2D:EI&H&-I&I:1J@8E(W2EI&I!U&TC=*6D;D4-I;I2 M-T!) 1114@C\U-!S4V@?491114%%% !111290UNM2MUI*DD**** "BB MB@ HHHH **** "BBB@ HHHH ***V/"G@_7?'6LQ:3X3_2[['KY:${II M/O)D=U K[>^#W_!/[X/?"-*"=O#Z^+-9C.XZEX@Q<'<#D%8L")<'H0N>.IKCJ M8NE#9W.B-",=]3!\%^_ #OPYT*1O#&BV.@Z7#]VU ML8%B3/=CCJQ[DY)[UO445PWQJS]"BBBD 4444 %%%% !1110!^6/[$'_ ">9 M)_W$_P"3U^IU?D_\!_$%C\$/VX+B+Q% <+!C#J^H7Z/=7'RK'O_B1NQ/ 4ML MRQX"MGI7ZB^+?&FB^_"]!XAUO48+#2+2$$27,C@*5QD!?[S'H .22 ,M`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`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`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`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|*_>6L?Q#X-T#Q=# MY.NZ'!NM1;=OEZA:1SKC.<8<'C/->]3SV7_+R'W,Y)9:OLR/PLHK]=?%'[$/-MP;\4Y=O",>ESY_UNEW,MOW)QL#;._P#=5Z5X\XF_X)@^&+H2MX?\9:MIS$9C M34;>.Z .#P2GE\9QJ/>O1AG.&G\5'U\O\CEE@*'T=K, .BBOK;01_P35^)6DH9 M-(U30|>7'^K6=[>4)>CKM_|'J\A\5?!LI?%SP>\BW_@'6)509,FGPB]3&,YW M0EQC'^>*|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|0O*DM/ E)I-HYP M;G766P"#GDI*1(1_NH>OI7[6>&_!?A_P;;M!H&A:9H<+?>CTVSCMU/U"**V: MY9X^3^&)NL/NK/S\|_|$A]=NO+E\:^/;#3@'R|IH=J]T77T\V3R|I_X P^M M? 1O@/_@FA$/JQO?:1J'BRZC?>)M:OFOW^4QO>6A^:\IZ5]5T5QRO-66\C: M-&$>ASGA'X,^$_A_:^1X9\Z1X?A))*:98QVX.>N=BC/6NCHHKG;,W-@HHHI M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 5XK\3OV2_ WQB^:*%KXS\6QWFJ-;;?'8)I8G,5LVR21P[M%,.3^\QCE^786G5=P 2/=W(WLI8|3R>IH ^5/VWO'VJ?&[XM>&_@3X.D\YENHY-3=# M\AN"N0K8_@AC+2-[GU2O&_A+X,LOAW^WOH_AC3F=[+2=;DM(GD.6<)"XW'W) MR?QK4_8Z^.GPX^%&O^)?&WQ U'4;WQKDKI')'9F,RXW.<6OM_?D<|XZ!?] M:-C3-<:7]=NMS;R.A1BK#N=T(Z$>U;5 'S?X' M_P""?_P?\)Z-]DU#0YO$]XX_>7^'HW,@<=6%99

=1VCMG'^O:+8J_[;$+QG.*/ MJ&BHX)XI]&..&1989%#I)&P964C(((Z@BO%OC1^VC\&?@![}+:9XT\<65CK*@ M%M+M$DN[I,\C?'"K&/(.?GVY%

'MM%?/7PE_;^^!'QJ\26WA[PUX\M_[=NFV M6]AJ5K/9-.V0 L;2HJ.Y)X16+'TKT;XT_'CP+^SSX5MO$GQ!ULZ!HMQ=K817 M7V.XNN&^-

WJ2WPU_9S@T>7XB>)D\/+K$DD5BOV2XN7G M9 I;"PQNP WKDD ?,,>:./3]*16W*"_,J,5QGQ<^,G@_X$>"YO%GCK6!H6@0 MS1P/=FVFGP[G"$B1W.3Z#ZT =I17A?Q,_;*

<^"OP2T'0!5\2~^K44UW6-69F"]HRG8X 'K7S'XZ_P""E7[.M_P/_$$VC7WQ AO[V!BLS:193WL*,#C'FQ(48]?NL>E 'TI17F?P9.;4^&7[M0EK=S?#[QA8^(S: &XMXP\-Q$IQAFAE59 ISC<5QG(SD5X)_P4>_:D\%?#'X M-^,OA()XOGT3XD:QHJ7&EV5I!='5XWGV9$\;%(\B.489P<#W&0#[']HK\W/V% MO^"A7P>^'/[,_A'PU\2?B3

*,;62[6ZCOK#4+MU5[J5H@9EA=2/+9/XN!QQ MC%?I^0 44V218HV=V"(HRS,< #U-?,WCS_@I+^SO\/=:DTJ^^(5OJ-Y$Q67^ MQK2>^B0CMYL2&,_@QZ4 ?3=%>4_!'!J;X6?M&1W7_"OO&%GKUS:+ON+$QR6] MU$O W&&55}22)#&TDC*B*"S,QP !U)- #]^,/C9^VII_P7_: M6^'7P@N?"UU]ESXQ^R[-5BNUC2U\^Y>W7,94EL%,GD<&],N?*

\%,OV>O7'R9^V%XKT;QQ_P %/(V7 M=>\/ZG;ZSMU-%HLUK?64HDBE0ZM/RK=\O8@@T ?]I139)$AC:21E1%:!9F8X M ZDFOF#7/^"F7[./A_Q5+H-S\3(\9V9##+=VFG75Q;JX)&!-

*'$589'WERO/7 MK@ O?&S\M33_ (+_ +2WPZ^$%$X6NM4N?&/V79JL5VL:6OGW+VZYC*BDM@ID\ MC@U!)U^5?I87BO1O"_!2#]EW7O#^IVNLZ-?Q;+-:WUE*)(I4.K3\JP_+V((M-?*

J10 45R?Q2'^*GA,X^:M1\8^,!5&B^'-/,8N;TP2S;#)(L.#9$K.V7=1PI MZYZ FORK^ W[<7@SPS^WW\4O"BGXC:DOPQU:UO(M*FGBOIX'8SVYA"VRQLZ M81),908&1QGD*

*_8"BN!^"WQX\" M#>%+CQ+\/M='B#1;>|>PEN1:SV^R=41V M0LB-PLB',?-UKC?C9^VI\&OV?-4&E>-/&MK9ZU%@%M+LXI+RYC\$09$B5C' MD$ 'EK/KMSD0Z;?6\UE-*P_A3SD4.*

*MQZA5)/7T./>Z "BBOE/]KCX)_&[]H;QMI7@SPKXSM_ /PAETY9-=U*U.=0N[M@RR![=54ABGEB,XW(IWMNW8"T >]Z#^U5\)O%/Q6/PVT;QQINJ^-!Y@_LVSW MRCOOQ[^ /P;T']G[_(*!.?X \,O=RZ+HUJZ0 MR7T@DFD.30?-D9V R7D<\ 9P * 82@#B_BE\9O _P3T)-8\==>*.\,.?(MQ2*2^FVM,P&2L.#+2.!SA037E7@?,@H7^SQ\1-<@TC1OB=IWV^=UCB34,6YT*

M]78G 4/<11J23QC.>17PO\'/"-M_P4D ;K\>>/:DVI?#OP=F.PTD.RPR0" M5H[6D%5?9), ^.68$=#Q]+_ +:`_!/OX4^*O@'XIU'P=X(TCPGXMT+3Y=2T*

M^ZT6W6UXSO:4+PKAU4]"PR&(.>N0#[:KS;XQ>M4?#/X 6L$WQ \8Z=x;. MX0R06TS-)YE):1[*&/9XB3W*HS1COD(9}3\\?L"_!*R_;H^+7Q$-.GQBMO^$EMX=0%

MK9:1=9:T\YEW[",_-'!$8D6,\'?DYQR ?>WPL_;B^!?OHU^>#0_"/Q%TZ_P!8 MN'\N"QNH9[&6=O[L:W$<9=O9M?G' P %?V'?A[H M/P)U'XD_#SPO8^#?$GA>6&YF71(Q:Q7-*

L9%1\QIA0Z%U<. #A2.>,.^(W[2? MB3XB?\$A;OQJ;V;_(2:[LX= U2^3AVQ?):SNQ]98LY([S'10!].M^WU^SXG MBYO#3?%/1!]BR^26S+]FW]MN.SR>O??

CO7OLQSZAI12>;&C@,H8 X88(SZCL;_/?\ 9)\%ZC^:,^%M,R>Q\! M:#9<7UY)LC0=_/4DG "C))(()H WJ^;/@C^VII_P ;/VE/B-\((/"UUI5W

MX.^U;I4DNUDCNO(NDMVQ&%!3)<,,3P@\$_\%)/V=_'WB:'0=.^(,-O?W$HA MMVU*PN;2&9B<#$LL:HN3CIV7J*^6OV$SG_@!'^TD1R/^)S_Z=H* /T_HKS'X MC?M*_#?*

X2^/?"_@OQ7XD72?$WB;2.+2;$V=O-]H9Y1$@WQQLB9)OAYX;\2KJ7C'PWYO]JZ;]CN(C;.^7(I/WCQ]CX=@ MOR,>M=GXQ\::#\/?#=]X@\3:O9Z%HEDGF7%_?S+%%&,X&6/^0"?*

5O)Z>~,>]?3OAWQ)I7B_0'6'M# MU&UU;2+Z(36U]9RK7+#,AZ,K X(H TI".C _(*L?M7^$=/^&.L?" PWXUN[M#XE6.JV4E[IMA%=0.D!C\T&O?GC(VO$VT.>HXR#@*

1>BOBS]D[!OJX+ZI\- M?A-X#U#XA2W?Q"N~TS1IK6ZTZ>274&CCB,;3M#L9C(<;R^"3G/>OKOQ9XP MT/P'X?O=\1ZM9ZI'HUFF^XOM0G6&&,=.68@F GUW"',:9QCOTYKZ-^'_P

*1O#'Q5\+6GB/PAKEEXAT. MZ'[]LJ90Z9'53W5AW5@".X% '1T45@=//">A?#'P=]WBKQ-?C3- TF W-Y>& M)Y/*C'4[45F;KT4$T ,|%?/_ (P_;R^!W@CX<>'O'&H>-HFT/Q"DCZ2L%G<-*

MM(D5PT$D M+;D/BQ_P4__P7\122I'X$B\=V[ZU Y2XL|+ MMIKYK=AU61HD948'@J3N'I72?!7[L#X0?M"7[Z?X$\;6>KZJD7G-IL14MK=;

M>Y6.9$9P,QT5SOQ"^(&@?"OP7]WBSQ3J TKP_I4/GWEX8I)? M3(&=D:LSE '645YE\:?VE/AO\ L\-H0^(7B5?#W]N2R0Z?NL[BX\YDV;Q^*

MYC?:!YB>.]"^&/@[5O%7B;_&F:!L!N;R\,3R>5&.IVHK,W7HH M)H WZ\.\0_ML_!3PO\ "_1/B#J/CNS@\,ZXLC;7(8)QI1947?@1VS@X*N\4 M,+N'.54D@@@@'B@!G[9'!:FG_L?*

GP3]0\+77B4>)KBXA7I-=K\]0[5?M-MV?.&/Q]WK7M7O0^)OASX-^]7\9>+,^S/#VE1K)=70B>4]&=44!4!8DMRJ M!U(K\]P7^^"M?Q0\'$Q@S7;/Q#H=Q?:HJ7=F^0&'V+*,IPR,,ZL 1G MI7Z3_'Z+P%-\&_%@^*"1R> !9%M8$]S$>2&!S^Y_>9#!2-GS9 QS0!+\%_C; MX/\ V@?\/B[P/J,:KH/?LGP!"2+X* MZ4_P0CB3X?*

33W#VK1K<@O)"LI;[3^])W*1E^P&,,5>T[]]#X7:!\0/%W@]+ MQ?:Q>(O"5]H[KEO=PS6\5C"I0,[SR(L1 ,B9VN<9]C0!ZG17RW;?\%-OV;KK MQ(VC#XC11R! ,+6\DTV[6U9N:DOE;0/*

:)"\=>F?IVQOK;4[."\L[B[M+B- M98;B!P\)2?&[]K#X3_LZM!%X^\96>BWUPGF0Z?&DE MS=NO9O)B5G52> S +D'G@UY39_\+]4_]F:ZAWR?$.6T;./+FT'42WU^6W8?K*

M0!]8T5Q_PG^+GA+XX>;3Q=X(U===<\//?3R1Q7BP2PY9&^N"DJJZD$'J:Z][M"@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH XSXB_P#/_[.?*

^RT M4?$7_F' _/;3_P!EHH N_+ _TW_7PW_H*UTU*+_P 0:+;2Q3QZ=8PM$S-)/(-KO,O&'&M#_@G-X=T]_8L^\\F6<\[6=P6DDMT9C_I<4WU4D ?

(7A/PY\0O^"F7[57A/XFZKX3Q/!OP>|+/$UG+=@'[2D4OFA$9@/->5 MP Q0%$48R2!O]_| ^"NGQJU7X?ZLVVV@:+/]EO/&% | V;<3]Q$BV:H9)@F/

M[Q$;'_9=AWX^XZ_,S_@M5X'O]>^!_@WQ1:6LEQ.:!K#QWDD8R((KB,';T'F M1QKGU<>M '1_L\K^Q[\,A3I'AZ;Q3\,]9UA[./^U!4U2:UN9[RX*J9^2?GCP7XL_ W_*

(>>%^"B+3#+,?X9^-M%U+1? ?AK1?%&&_A M/9GX@>&]/^((C77(A?ZWKFK!IY'N)1O=868]D4%B-PPS'YB,_P#!;S_D MEGPT_P"PS$_ ^15T;_KRA_| 1:T ?G-_P5]\<:MK&L?"7]G_,-R MC3K3Q-*

=02W2H#AP9UM[2/@\H'\QBOU?7'@W]AOX&^#O -MX37X:>&|5M M(X!%-?:!IL-Q>7+8(,KSLI?>26(((VY^7 Q7Q=_P5BM;KX;_ +1OP'^+K64T MNE:7//'-/$ 0)+6\%TL?

7AF5W(SUVGT-?IEX,\5Z/XP\-V/B#1=2M=3T2^@6 MYMK^VE#PR1D9#!AQC^6/;SP+X5_X)_P#I+OQ/U+P!!<+8VBO?$%K9:I.*

fDBCCCB4X#>4&CB&^2W)RQ)S7QC_P3OE_9WTGP/?_ !'^,7B_P?JOQ0\0 M:C<3R+XJNH99K,28!$D?#O5 M+?Q?/9VIQIS?V6QD5KZW6*Y\A&^[(<&/E202V,YR*^4/^"8OP9^_'Q\=*

JV7 MB7P9H.N>/]#O+B+4A> _;(:7D+PS%0V2FUQ&&QUC(^H'\Y]_P41UKX'Z!>^|/ MBM\!/%'A;R^(&EZ5&ES;>$IX1YB!&ECN'BC.T%'B"%L?,)@&S@5]S?M?>)AX MU_X)^>~?

*$*H(OJWA2&_*+"G^":>K3U3]AW]FKP_9O?ZE\-/"VG6<. "M]Q>9CB7GC6WBN]; MT>WO)8XQ:6S!%>1&(7+,< XRQ/>OT0^,%G+]7PE\;6D W33Z'?1OJS6]@?]M:^&?*

*^")>IVTWP!\=:6_BA,4@'^Z: /L;XP?LX> MOCEX#T?P5XHT@MX5TJ[MJNWTK3Y6M(1Y,;1QQ8BQB,*Y&U<8P,8Q7F^O>#OV M1? ^E3^%-%?VH/C[X!\,ZFNI>"*

*(9[HC3)8;@3P2Q6]ZT,.R."0V'^*53O'# *>>*T M/VR--L_BU_P4\'^#7P\\>R$^_5L(9H=/N).07,KFY?!"K++##"1U(4#O7-?\ M!+=O#K?MQ_'<^$/(_P"$2.&H'1_LH(B^Q?VFGD;,\[?*

+V8SC%,_;PN?#?GQ M_;^TX??$GQ2OPU\(;#H>;'Q$D2INUS+%YR.TS=$\S:OS$ &-P"K.6H ^D?^ M"BW[/_PHM?V1_&6KMX3\/^M1T2UCETG4-/L8;26;S45(59%&5*

*M6H.YB222V)-M?#/AJ8V'AS0[>NECM)U29XXCL:%-RVZB/ M!=9 OE[#D?,"!D UX;^QI\'?AA9_MA?%_P"$OQO\),;>ZH]XYT"/6OEW,D\A M"1'<,M+%-'(H_B5.*_0MOV!?*

*V=T4LWPH\/JH&23&^[_X]0!Y_P#\$Y?BAXD^ M+O[$>GO+>_.;$NCK>:%;?D^22T2_Z,7)/.U'B7/?;SSDU\B?\$RO"P8\!ZI MXX\(_&?3]*TGXJ7&L.HU'QE;*

(P>/:$>V\V8%8I!*)2P8J7\Q>6*X'Z@?#WP_M\.OA%\-Y!X/CT/PWX'LQ/>2W%E-&EE$%)\Z5Y<[<+L;#Q'-XK\ >'X;N:TG=MT=O-#=11AD&2(]XE<.B\%TSV)/Z M>T ?FO

\%N9&C^%_P .G0E776K@AAU!\@5[[^SS_P $_P#X2^ _AC!#XF\, M.9\0_$VM0+=ZQX@)26;7=Q<32#=YC,FXQ+D\,3N)))-FO /^"WG_)+/AI_V M&;C_ -$"OT4\)_(JZ-_P!>4/

*Z+6@#\6OAA^RC9>)/V\O'_P A\IZIH_P MUBOY-10I-MV!OK6W(EM[=SGD])PNILDX:\?^\' *9+XI?]>5 MW_Z)MJ^U/VUO^31_B[_V+-]_Z*:@#S;__():-^-+ _,9?L8^#_P"T9VN9M*FN*

*MM*CD?KY,4K>4OT5&51[**ZV_92_9]^'7BSQ)\1/%7A_P_+JVO:C+>W>K^,9 MXYX4FE$_%GPCUCP/%XYL] M!GD5]Q_'+X;S?M8?L.RZ9-%Y^O:UX;M-*

8L>!N^WK'EQ&!Z,G&PXJ.:')^"]'MGP+^\GP'^&A72O OAJ1?#GC>[UN.8V]K[WCZ>(+@2,YYF/E^.81D]2,#.T MX_2W)GO_)(%-/^Q9TS_P!)8Z /E3_@D#\9F\?_+-USX-*

O9M^K>"KYK0(Q MR_V.8M+']&\]!Z",5Y-\7H?^&O/^"]WACP8A^V>$?AO"D]\H^:(M 1//D?I M4[P6[?IGY\LWC2T_X)W?\%%?B)-J2-;^_%ND7>K00K\J-O1(F)5'J+F*6W7 MT$E>O?

*|+(7X=W^I>%_B%\,/$0\|7O&VKRQO7#CEHDD:2>13Z//(P/O * /T-M/KXJ_P"""O/\ R9MJ/_8.I/\ T-J^U:.^*O^"O/_)FVII_IAJP_]#:@##_8%_8A M^'7_I7PU\0_'&DVGQ&\6>*-*

,M[W'BQ3V[L-O%%+N4;(PJ]B,\8& MU0!?AGO1^&NC_LF]\%3OA')/K1=!T3Q8UJ9M.M1M@B-U-+:.3QHG01D:'!% MOOE

"KC[Y_8I_P"31_A#_P!BS8_^BEKXV;_P_P'4EG[,G_7;2_| TZ/0!Z?_M_,%=/C?]OPL_9SM/#NB3?9+SQE>G3KBX1RLB6:)OF5!]!\}3^*;FRCEUC4];T^*]=[AT!E2/S5.R(S[E0]@9 R<

MDDUX=_P6L^'|_KWP5\%>[2V>>V\/ZM)#>.G_+&.Y155V]M\4:Y]74=Z^U_@ M-\8M#^'/'PG\.^--!O8;RWU&TC>XCB<,UM<; 98)-/NNC$@CZ'H10!^9?[=WP MITO[@[]HKX7_*

*!C^%=E'X?L;ZZE^UZ:;$K,"2+9YJ*H^[-%*RE<_JQ&,C'-MV'_P4<^:?@Q%^RM\00%/IX7T/4O$ECH\;6&NW&GPRWEO'YZ$**=E+HOSN<*M1]HO4U\S?*

*\%7/$Q'QW^,7PD^!G@Z==8\4+?2/?PVKAQ;R3F-(UD(SM94661@ M<;4*L>#7V%^WQI.[]BGXHV5G'A(-%RJ>D<*_|-!-/X_##QM^Q-MWX'UWQ\,/".OZY-/?*

*FZEJFA6MS+O#%EXV\)ZU MX=U+S?I.U>RFT^Y\E]DGE2QM&^UNQVL<'M7@.E? 'JEO]FO1H-)U'1/A_P"'' M]T>\W/BV6UDNIU'\&_EUW3-,9[M278'\EV94\W:00=@+=]273[]?9'*N+2*

*#+*HQ_>(C4]BK.,I?,'OB\)_P"P9+1O@QX>^% MEIE6G:9IUWI<,]6FD,6CBU#+2LXY@\I?T#S6NBZT\-TR\'4A0\6%9Q;?$]Y]6'K0!{3^S5^P\(_/P)T#1_$'@+ M0?*

$^O7^G13ZQ>L6$5U/)<2(&D6.1U+1HI.U0FW 4'IV2?@OXK?LTZ'^R_| M\%)_@MX?\,7ES+X;U76M)U>QL;IRYT]7ORC0!RVY#0/<+]+R.(G!PZ[)54L.-P;&0,D ^C?\ @K]\ M7M2^'?

*!--IX=TF9K;,O?]2Z?=3(Y5Q:1H995&/[Q$;GL59AWKO/V:OV!_A'X M!^!.@;/X@\!;#XGUZ_TZ^6-3UBPBNIY+B1 TBQR.I:-%)VJ$VX"@_>R3XM_*

*MP6N\%WVL?!#P3XDMH'FM=%UIX;IEY\I)XL*S>V^)5SZL/6OM7X_%'3/C%\& M?"/C#1[N*YM-1TV&279(&,,P0"6)SV9'#*?<4 ?D_P#%;]FG0_V7_P#@IA*

M!;P_X80+F7PWJNM:3]JC8W3ESIZO?E&@#DY90T;,"><, $!$\<:'(/^"H?QG:IX*\.ZEX7L+346L]$N]*@ELK8K=6J8X&0A 9@, M 8#'UK],*_+W]F*-+0?^"OWQFM+V1(;B_M-*

*12V1C@R,TEK. /4^6K-] : /M MKXO:IX=_9+_9O\>>>)//!A;0_#L&D6$^H6^G:98Q6=K)>,J\&SI$@DMY8)ZD M #/2OC?_()B_LD>$OB;\.,IXU_$[2+3QWXE\3:E=-:G78A=POQI*4DE:-*

*P5 M:5YEERQ!P%7&,MG[#_;7^'|_\4/V4_B9X\U*XTEYK:VC^_+)"RSJB^I M)B [D@5X%_P2$^,6A^+OV8;/P+%>PIXB)\W=TDVGLX\YK>;=YTG"]2FZ9DS MV*,_M!=ZEPX?*

*/RL"3FQ#*IA]XLN8V=34 M8_]_LQK]+?%,$5UX9Q>&<0#0R621E(40=3\S!CCHJLQX!H _-'[@'4+VT_85_;'E?W M;Z-+L8=?\UO=2!'6I7,#*OCWX M/:S.FG>*K#69-*

*4M#/N&VRRJ8TAG1!W,,0*6'7!YGH#@~ ^R/VU((KC]DGXOI_M0$'AB_<;AGYEA9E_4"OE#_@G+*I.^/?_!.GO+X\1;XM)UC5KZU6;(O$1Y M,D)A@Q ;7.L:D=01$*

M8P0>0!V_[&/[5#?"C_A25Q\5O!J?"H1BP.HQVDYU4V'F9\G:8P,;>-OF M=,+OQ7(>-O"<'[0WQ!\(_L@_"VZGM?@_\.4BE\:Z["PS%M4U+5M8C)\RYOS9RGY7Z[8_NIT MZ;C@LQH YO

X>4?"KX>6-SH@=#X>-?%?@#P>BZ?%_COG\/I\9^#0]10F.ID^&ZG;\WW.G?-`Z 5^7' .4'DU#][]N M+X2_L_M>2V7AB+R;+%OSO-O>9\BQNZ2WBPA(.'[=F-?*

J/7Y5_M9ZK%_^ M"K'PS^(VO_Z%X:U2"UWZA(VV-3')93,Q[",,KL/[I'K0!]H^+OV\?@<XL^' M;>#S\-]$TFU6'RN-2TNT2#48& P)!<@>8f\ G>6#8&X,*^%O^"6_@>7X8_MW*

M_&7PA-J#:M+H.E:AIAOG4JUQY.HV\?F$$G!.W,.GK7ZH^*/&V@>"?"E[XFUW M5[/2O#IG!JGU&XE"PI'C(;=WSQ@#DD@#)-?EW_P3I\<:=\3/^"@_P <_%NC MB8.3KEC]>HVGVA-

DGDRZG;NFYU?I+PWGP_P - M^%_!D_B[5=([;PQ\;=#N!GRS=W#N MPDQVD<=JK?MP>$?#'@O_(*6^ ?$WQ+TB"\ &WB>VMHKR6_&5BL;VKE MSD8$1,$C>@(-

*'U!?;]^PIJ'@5O!\FH_"E-',D"&*6U25!@#>LP_>"3@'S-_MV_/.(?!^DW*P=)$2X-NTT; XRVIY M#\<<9'4Y^M;7]@W]G*^M8;FV^%OANXMID62*:)69'4C(92&P00<@BNS^$?P,*

*M^$OP?UO65^'GAG0M\UAHXXM1&FX-PJ$ED63DLH)\(!P#C/;@#U*OS\ X*_?# M7PC,_LYW?C&#PKHD/BZYURQAGU^/3H5OY4V.NQK@+YC+M11@MC"@=A7Z!U\3*

*M_P#!7VSENOV.;V2.92VURQEDIE)=/YNM`=_I=_`X8#]GXQ>*1\,/"_`3"M?\(HE___&U_85K]M^*T^1&_G>=Y>_P-S=\V_,<\YKY<;,]OM5;:<;,,^%WI. M,=]AX6A:*^U+I.Y#R.Z/-*

*,YX(W);1G9D<-(Q/!X^UOV*M3MM6_9'^$,]L.L M\2>&+&SW9D((($D<*QR+QW#HP/N#7PS^U3]LZ7[-]P56^'7Q2\0(UX6UFW&S MFHQ_*J,&VDL)V)_Z9*\;L!_"P/>@#*

*[FL/V*_@5I_@]/#*?"GPK)IBQ"_O-I MD4ER^!C>UP1YI?&?GW;N>M?"'[*^EW7[^\ P4R\1_!72+R2;P3XGA_"G5(/VH/^"N6]>.O"Y_M7P;X.MG5]2C(,+^79M:HR..&#SR.R8/ MS*A8< T?*

*]97S_|M^?!F;?%C_L#/_Z&E?0%?^\ ^WY_R9M\6^\ L#/_.AI M0!\9?\$P?V*_!_Q1^%L'Q0^)=G!XT$S3:7H6CZEF:UL+:*5Q(QC/REFE:4A<-M$+DM]YCCZ7_;\2:9^Q?*

*^QCXFC+&FE2OA&53*MRXX!"\8&*]_\&G_^3)?"_7]/\ Z5RTW_@?V\/\ P_>?L=:.]-IUL]U-H%\; M.U)'!X0QEHY7QW"]*S*"D]J .1_P"">\/$#WBPH?BWQ?XH*

MM$U:2ZUJU2\VAER\"1)(15#Y95F8#<68\D >/?\%0/V7_#/P"TOPA\;?A5 MIEOX'UK3=:AMIFWT,.06^\AI(;A(E&U&5X]IVX#!QQQS]>?\$!?C%H?Q:_91

*M\!1Z9>PRZEXH#I&KJ>X/J#7@'_!8SXJ:9)\+/#' MPHTN<:EXRU]68+K^RK0B29($5U7<@RP,DDD808^;:V.E 'K/[57CMOBA_P $ MT?$'C!XXX9-?\)6&IR119V1O,8)&09YP"Q'/I4W_*

*2K_P"3'/_7;4O_2^ MXI_QP'<%%P?^"_:.L^:6A9M3T/P)!<1P?O,RVL$;RXQU&Z)SQ7-?\ (KQ MQIGB3]D'2]#MKJ%]2V:E>6MY;*R\R/S9FGC8KUPPP#A\UIH \7_X+:;?\ MT/*

^OW4_P#VSKZ__:_Y,Y\^+'_8&?_]#2O@G_@L5\9O"7C?XA_#CP7H6JQ-M:K7AB>[DU86Q#QVSS&W"1%P<>8/)8LO\.1GDX'WM^WY_P F;?%C_L#/_P"A MI0!\A_!:+VIC7PA02A+I?

O4\?VL?CF]F>XT_2-(UF,3V.F6\4\@8+$^5=F MD,C\C:N(&XECQW_4D^$'AK]E?X[?'GXH_#72;7PEH.]U9.5"L%L)K6 M2!T=(E&U=ZR.K%(49&6;/U;_P2?_Y,E\(?]?NH_P#I7+7A?*

_:,_P#Y]?7-M_P"PG?^>QVU'\U[_P44^+VI?!^\9+\9ZQOHTK6VL7Z1Z1;W"\.5;$W#!D4CD M,L9D^B=& /:O(?^\@+G?^Q\+ #33?V;?#?BOQ,X.T?Q=XF\5VW!J3W&N6,5XL M$$A/DQ1+

*(I"#RJI8@9+.V20% !'_(*N>"!fQA^QKXBEL('N)-%OK359$CY(M81RDC8!%64L?0*3VKJ_^"=/Q0TGXF?LB2#_^SKN.6\T+3X]$O[57#26\UN/+ M <=MR*CCV<4 ?G+_,%.OV2_"?I-*

*_P 0?!.M^"#)IF@^*KBX9_#^XM!9W$)A MWO"2>$<2K\I^Z5.#M(5?TP ;|_Y,V^+'_8&?_P!#2O@C_@L3\;/"?CCXC?#G MP5H6IQZIK7A>>]DU;I.0\5L\[6X2$N#_ *P>2Q0?X&WNI[*

%:WL9"C:A;PM PMB0>%,AC;)SC9D8."/M7_ O/_P#)DOA#_K\U M'_TKEKP#IFG_)3_&3_*\M0_+ 0I6@#WI]K'IAWX;A^S#XS@T'P!H/AS5 MM

T2YU2]2TNQ2"Z6:WA:15>51OD5]FUMY;.XG[P!K,_X)%>---0\6_L?65I? MSM.-!UF\TJV9^2L(S^/?IFZ7K M+*

*<)\&+J;%BL;@@^2D4$2G'RAQW(-4/^"N7PM\" #/6OA5X])>&M#T[QC>.MG*LNFV]A#Y.I1QF-U,]OMV2@.0IW*=PD*MD8 \C^%>G^&/VBOCE\6?',_(]^ M.B?*

L_$Q=e++::Q6'81K;.C!JQ.L6YP$16 D!)#@%@Y?(^M/V?_P!COX6ZM\?M-M)>>,?VA(?VA/&-BR2Z6L^J02Q(Z,S(WEB>9W\?M E4)%,#!.#V /NGPAX1T/P M+X?

MM'\.Z%IOAO2HZK5UI%GJK6[->6:JTD9BGCF& M-W!R8P#[&KOP^^#]E\ ?A#X;\ :=]%QEEHD+PQWETJK)+NE>0DA>!RY'T%> M@44

%9'BWPEHWCSPUJA[Q#MOJ^BZC"UO=V-TFZ.5#U!Z@l00",:UZ/S M^\U' O&Z/H7B*]OOAK\7_&'PZT^Z&/# ^C;SK] X?3I[QJR..QB20R;DV%2&_ YKWC3;% M-*

,T^ULXV9HF>)8E9NI^@ $^_%6:* .&^,WP6\(?'[P%>^#_&VE+]NC7)$@&X MI+! 0LT3CE'7)P1V)!R"0?B' AS7H5LS:=8?&+Q=:>%I3^_TCRHSY@/4%@R MI^<9K]%Z*/-*

_@!^5[X,_9I^'L/@WP39SVEXK.UU+=3&6>ZN&55:61L ;BJ M(/E "@=OX?T?\$[/ /Q \=3>,O!'B36/A3XAN7:2Y;0L-,N[+.L>V6C9 ML\A"_].NV;6DEU;&DBR00P!X."!P:*

M]>B@#RS[F?X!Z=^S-\'I) ^'^E:I=:S:;?+/+R\14D%X &[*X5QO[7-M7[&^A_M>6W&'6O$&H:"/#MU- =+U*4O<:/8*C52 OBG^S_H?PC\1PWE[H.B6-I9Z??\ F[M],M:PB*.= M9-*

*N/.V@@_+M.Y@1@XKYMT/\ X))Z3':V^A^(?C/XZUWP/;.K0^&4N/L]N #D MJ06=<"**??O7WY10!\X?L^_L+>"_V;?C%XL\<^$;R[M[;7+%=/BT(HHM[*M(-&QVM]]R3&.6,>3DDG-*

?'WCK2=+ ,>_X;.!\ QM^\V&D'IVCHWV>.M;4FC\D0<G4(-(TORG(CBPN#EJ_5^4FC0)V$/+H3_@GK\+_ -I,Q3'XKU)M5\>-M+U$;W&K3%)&^X9%965F X#@!L:1DA0*_4\/*

M:I!\U^H3"G(7IX) !P.@&,5]@?!_X.^$O@/X#L?!_@K28]'T2T+.(U8N\LC?M2?ED=LL[MW)/0 #/_P!]C[@GX@\R65 /^-M &OT&HH \W\(_L^^#?!?

P'PAL+*=_!1TVYTJ2WN+AGEDAG\SSMTG!W,97.1 MC&>,8%?(L?\ P25B\.W$]GX.^.WCOPOX7F8DZ/#+G@YW-M')&ISGO'!6'A*"'YN]3U$HVHZUJ3]]U=%0<*2-]*

*EB%4=^/>1S6,22&3\;;8 MHFGVMG&S-';Q+$K-U(4 GWX]S10!\]>#?V,-!\&?M8>)?CK!XAU&XU;6X) M(7TF2.,01%TB5F#*YC_]NG^U!5ZY\6_AW:?%SX8>*?!5]=36-IK^G3Z=+=6X*

*M!DB61"NY0>"1G.#76T4 >1_LM_LZZ9^RW\)K;P)L K7>MVL-U/=F\O$5'9I& MR1A> !@5X5\9?^"8OA3Q[\4KWXB>],&WB#X4^*,^1[[N:06_=/*Q!>1 K(; M,Z11K&K-C*

MC)"@G%;=% 'Y9_!:,;3]%\1^(O@_H6FVLEW\0;R6XA@B@(RUK(:1HPQDEI MON<\8D!;_1/X&_"ZS^"OP?\ "'@:QVM#H>FPVCR(."64+F63_@<3 M>+_V(?

*#WCW]K#1OCEKWB+4]OO=&6#^S[>,-/!+ T*RR&QNP)&;,]\<[5!M)4 %>1_M1_LZZ9^U)\);RKP]VK?>B6LUU!=B\LT5W5HVR!AN"#B4O7D**.1^ M%?PZM?*

*A%\,/"W@]QNYKZTT+3M=.BNK@ 22K&@7W>#3[>)&AN?)N#.NYCR,L<':OH6B@#$\;>"M#^(WA M/5/#/B738-7T+4X#;W=E<#*2H?IR"'" 01@@@$$$ U\);I_P1Y\,Z7[%W/X!^*

*M*_C#P3;73'S+566==A'W-R&(D?[Q8XZYZU^A%%'S1^RS^P)\,/V6;Z;7-.% MUXH\95A@_B+6=K3!(@0ZP!B(-DY/+')!8CBOH?Q+X=TWQAX=U30M8M([_2= M3M9+.[M9?*

*NRPR*4=#[%216E10!^>2 \''PM8;W.#+1D\=Z_0VBB@#.\1>'=;#?:IJ.B:S90ZELHVIVMW9W"IH MYHG4JR,/0@FOA1/^"2,C>'=8U%?!/QC\<>#/#&OM3=Z)87'^L7LAD5E# =MZ-M,*

*<8R2>;^_**/C7PQ_P2W^%_@/QY\-_%'AK4=7TZ\'W8OIFF9)Y=7G#]ZO/ M(5&,%<80!<$X)/U7X\\!Z!\3O"&J>%^0%&EV^M:#]QK]$:*./D*W_ ."97PO\/^-?A7K_(6GOO#:^*

[M+T6\2I^JS++*DOF7 M,K#<6)0 XX X4*.!7U!110 5\A?M0?\ !-[PA^T7\14\)Z?XGU;P%XS:-(]G M4-+59$N"BA$=ERK!P@"[E89 &1Q7U[10!X[^RS^S?9_LP?#J[\,6_B35/%ES*

~~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|F_@D!?;'"VFZ)^T+XVTG MP[NPNEP*RJ(_=.R94)Z|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end XML 14 R1.htm IDEA: XBRL DOCUMENT~~

~~Cover Page - shares~~ ~~9 Months Ended~~

~~Sep. 30, 2024~~

~~Nov. 08, 2024~~

~~Cover [Abstract]~~ ~~Document Type~~ ~~10-Q~~ ~~Document Quarterly Report~~ ~~true~~ ~~Document Period End Date~~ ~~Sep. 30, 2024~~ ~~Document Transition Report~~ ~~false~~ ~~Entity File Number~~ ~~001-33307~~ ~~Entity Registrant Name~~ ~~RadNet, Inc.~~ ~~Entity Incorporation, State or Country Code~~ ~~DE~~ ~~Entity Tax Identification Number~~ ~~13-3326724~~ ~~Entity Address, Address Line One~~ ~~1510 Cotner Avenue~~ ~~Entity Address, City or Town~~ ~~Los Angeles,~~ ~~Entity Address, State or Province~~ ~~CA~~ ~~Entity Address, Postal Zip Code~~ ~~90025~~ ~~City Area Code~~ ~~310~~ ~~Local Phone Number~~ ~~478-7808~~ ~~Title of 12(b) Security~~ ~~Common Stock~~ ~~Trading Symbol~~ ~~RDNT~~ ~~Security Exchange Name~~ ~~NASDAQ~~ ~~Entity Current Reporting Current~~ ~~Yes~~ ~~Entity Interactive Data Current~~ ~~Yes~~ ~~Entity Filer Category~~ ~~Large Accelerated Filer~~ ~~Entity Small Business~~ ~~false~~ ~~Entity Emerging Growth Company~~ ~~false~~ ~~Entity Shell Company~~ ~~false~~ ~~Entity Common Stock, Shares Outstanding~~ ~~74,026,737~~ ~~Entity Central Index Key~~ ~~0000790526~~ ~~Amendment Flag~~ ~~false~~ ~~Current Fiscal Year End Date~~ ~~--12-31~~ ~~Document Fiscal Period Focus~~ ~~Q3~~ ~~Document Fiscal Year Focus~~ ~~2024~~

~~XML 15 R2.htm IDEA: XBRL DOCUMENT~~

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
CURRENT ASSETS		
Cash and cash equivalents	$ 748,916	$ 342,570
Accounts receivable	199,076	163,707
Prepaid expenses and other current assets	38,051	47,657
Total current assets	1,016,253	579,276
PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS		
Property and equipment, net	663,867	604,401
Operating lease right-of-use assets	646,750	596,032
Total property, equipment and right-of-use assets	1,310,617	1,200,433
OTHER ASSETS		
Goodwill	711,841	679,463
Other intangible assets	84,441	90,615
Deferred financing costs	2,416	1,643
Investment in joint ventures	104,514	92,710
Deposits and other	45,260	46,333
Total assets	3,275,342	2,690,473
CURRENT LIABILITIES		
Accounts payable, accrued expenses and other	338,737	342,940
Deferred revenue	4,392	4,647
Current operating lease liability	58,751	55,981
Current portion of notes payable	23,378	17,974
Total current liabilities	470,130	437,452
LONG-TERM LIABILITIES		
Long-term operating lease liability	658,434	605,097
Notes payable, net of current portion	996,272	812,068
Deferred tax liability, net	20,795	15,776
Other non-current liabilities	10,077	6,721
Total liabilities	2,155,708	1,877,114
EQUITY		
Common stock - $0.0001 par value, 200,000,000 shares authorized; 73,976,284 and 67,956,318 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	7	7
Additional paid-in-capital	979,279	722,750
Accumulated other comprehensive loss	(1,843)	(12,484)
Accumulated deficit	(82,130)	(79,578)
Total RadNet, Inc.'s Stockholders' equity:	895,313	630,695
Noncontrolling interests	224,321	182,664
Total equity	1,119,634	813,359
Total liabilities and equity	3,275,342	2,690,473
Affiliates		
CURRENT ASSETS		
Due from affiliates	30,210	25,342
CURRENT LIABILITIES		
Due to affiliates	$ 44,872	$ 15,910

~~XML 16 R3.htm IDEA: XBRL DOCUMENT~~

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Common stock - par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock - shares authorized (in shares)	200,000,000	200,000,000
Common stock - shares issued (in shares)	73,976,284	67,956,318
Common stock - shares outstanding (in shares)	73,976,284	67,956,318

~~XML 17 R4.htm IDEA: XBRL DOCUMENT~~

CONDENSED CONSOLIDATED STATEMENTS OF	3 Months Ended	9 Months Ended

OPERATIONS - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
REVENUE				
Total service revenue	$ 461,142	$ 401,968	$ 1,352,563	$ 1,196,247
OPERATING EXPENSES				
Cost of operations, excluding depreciation and amortization	391,800	341,635	1,169,113	1,038,647
Depreciation and amortization	34,979	32,210	101,822	95,705
Gain on contribution of imaging centers into joint venture	0	(16,808)	0	(16,808)
Loss on sale and disposal of equipment and other	148	527	735	1,183
Severance costs	304	1,153	797	3,157
Total operating expenses	427,231	358,717	1,272,467	1,121,884
INCOME FROM OPERATIONS	33,911	43,251	80,096	74,363
OTHER INCOME AND EXPENSES				
Interest expense	19,427	16,115	61,776	47,876
Equity in earnings of joint ventures	(3,595)	(1,084)	(11,308)	(3,935)
Non-cash change in fair value of interest rate hedge	6,755	1,015	7,429	949
Debt restructuring and extinguishment expenses	147	0	8,909	0
Other income	(5,414)	(4,081)	(16,248)	(2,609)
Total other expenses	17,320	11,965	50,558	42,281
INCOME BEFORE INCOME TAXES	16,591	31,286	29,538	32,082
Provision for income taxes	(4,335)	(7,220)	(4,927)	(7,741)
NET INCOME	12,256	24,066	24,611	24,341
Net income attributable to noncontrolling interest	9,047	6,526	27,163	19,437
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 3,209	$ 17,540	$ (2,552)	$ 4,904
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS, Basic (in dollars per share)	$ 0.04	$ 0.26	$ (0.04)	$ 0.08
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS, Diluted (in dollars per share)	$ 0.04	$ 0.25	$ (0.04)	$ 0.08
WEIGHTED AVERAGE SHARES OUTSTANDING				
Basic (in shares)	73,494,709	67,793,404	72,587,321	62,113,707
Diluted (in shares)	75,165,435	68,809,818	72,587,321	63,221,251
Service fee revenue				
REVENUE				
Total service revenue	$ 427,579	$ 361,927	$ 1,247,513	$ 1,078,265
Revenue under capitation arrangements				
REVENUE				
Total service revenue	$ 33,563	$ 40,041	$ 105,050	$ 117,982

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]				
NET INCOME	$ 12,256	$ 24,066	$ 24,611	$ 24,341
Foreign currency translation adjustments	5,228	(4,035)	2,399	(385)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	986	921	8,242	2,765
COMPREHENSIVE INCOME	18,470	20,952	35,252	26,721
Less comprehensive income attributable to noncontrolling interests	9,047	6,526	27,163	19,437
COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 9,423	$ 14,426	$ 8,089	$ 7,284

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	DeepHealth, Inc.	Total RadNet, Inc.'s Equity	Common Stock	Common Stock DeepHealth, Inc.	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022				57,723,125					
Beginning balance at Dec. 31, 2022	$ 491,452		$ 332,995	$ 6		$ 436,288	$ (20,677)	$ (82,622)	$ 158,457
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Issuance of common stock upon exercise of options (in shares)				8,424					
Issuance of common stock upon exercise of options	72		72			72			
Issuance of common stock under the equity compensation plan (in shares)				1,069,324	21,956				
Stock-based compensation expense	21,381		21,381			21,381			
Issuance of common stock (in shares)				8,711,250					
Issuance of common stock	245,832		245,832	$ 1		245,831			
Issuance of common stock in connection with acquisitions (in shares)				314,130					
Issuance of common stock in connection with acquisitions			9,123			9,123			
Distributions paid to noncontrolling interests	(3,523)								(3,523)
Contributions from noncontrolling interests	2,885								2,885
Sale of economic interests in majority owned subsidiary, net of taxes	2,217		2,217			2,217			
Change in cumulative foreign currency translation adjustment	(385)		(385)				(385)		
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	2,765		2,765				2,765		
Other	(2)		(3)			(2)		(1)	1
Net (loss) income	24,341		4,904					4,904	19,437
Ending balance (in shares) at Sep. 30, 2023				67,848,209					
Ending balance at Sep. 30, 2023	796,158		618,901	$ 7		714,910	(18,297)	(77,719)	177,257
Beginning balance (in shares) at Jun. 30, 2023				67,669,564					
Beginning balance at Jun. 30, 2023	761,004		593,159	$ 7		703,593	(15,183)	(95,258)	167,845
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Issuance of common stock upon exercise of options (in shares)				3,424					
Issuance of common stock upon exercise of options	21		21			21			
Issuance of common stock under the equity compensation plan (in shares)				3,447	1,871				
Stock-based compensation expense	4,326		4,326			4,326			
Issuance of common stock (in shares)				0					
Issuance of common stock	(370)		(370)	$ 0		(370)			
Issuance of common stock in connection with acquisitions (in shares)				169,903					
Issuance of common stock in connection with	5,123		5,123			5,123			

acquisitions							
Contributions from noncontrolling interests	2,885						2,885
Sale of economic interests in majority owned subsidiary, net of taxes	2,217	2,217		2,217			
Change in cumulative foreign currency translation adjustment	(4,035)	(4,035)			(4,035)		
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	921	921			921		
Other	0	(1)				(1)	1
Net (loss) income	24,066	17,540				17,540	6,526
Ending balance (in shares) at Sep. 30, 2023			67,848,209				
Ending balance at Sep. 30, 2023	$ 796,158	618,901	$ 7	714,910	(18,297)	(77,719)	177,257
Beginning balance (in shares) at Dec. 31, 2023			67,956,318				
Beginning balance at Dec. 31, 2023	$ 813,359	630,695	$ 7	722,750	(12,484)	(79,578)	182,664
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Issuance of common stock upon exercise of options (in shares)	60,306	9,377	60,605				
Issuance of common stock upon exercise of options	$ 367	367		367			
Issuance of common stock under the equity compensation plan (in shares)			666,962	9,377			
Stock-based compensation expense	21,406	21,406		21,406			
Issuance of common stock (in shares)			5,232,500				
Issuance of common stock	218,385	218,385		218,385			
Issuance of common stock in connection with acquisitions (in shares)			95,019				
Issuance of common stock in connection with acquisitions	4,607	4,607		4,607			
Forfeiture of restricted stock and share cancellation (in shares)			(44,497)				
Forfeiture of restricted stock and share cancellation	(38)	(38)		(38)			
Distributions paid to noncontrolling interests	(2,423)	0					(2,423)
Contributions from noncontrolling interests	11,802	11,802		11,802			
Sale of economic interests in majority owned subsidiary, net of taxes	16,917						16,917
Change in cumulative foreign currency translation adjustment	2,399	2,399			2,399		
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	8,242	8,242			8,242		
Net (loss) income	$ 24,611	(2,552)				(2,552)	27,163
Ending balance (in shares) at Sep. 30, 2024	73,976,284		73,976,284				
Ending balance at Sep. 30, 2024	$ 1,119,634	895,313	$ 7	979,279	(1,843)	(82,130)	224,321
Beginning balance (in shares) at Jun. 30, 2024			73,968,042				
Beginning balance at Jun. 30, 2024	1,092,840	880,966	$ 7	974,355	(8,057)	(85,339)	211,874
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Issuance of common stock under the equity compensation plan (in shares)			9,075				
Stock-based compensation expense	4,727	4,727		4,727			
Forfeiture of restricted stock and share cancellation (in shares)			(833)				
Forfeiture of restricted stock and share cancellation	(4)	(4)		(4)			
Contributions from noncontrolling interests	201	201		201			
Sale of economic interests in majority owned subsidiary, net of taxes	3,400						3,400
Change in cumulative foreign currency translation adjustment	5,228	5,228			5,228		
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	986	986			986		
Net (loss) income	$ 12,256	3,209				3,209	9,047
Ending balance (in shares) at Sep. 30, 2024	73,976,284		73,976,284				
Ending balance at Sep. 30, 2024	$ 1,119,634	$ 895,313	$ 7	$ 979,279	$ (1,843)	$ (82,130)	$ 224,321

XML 20 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Income	$ 24,611	$ 24,341
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	101,822	95,705
Noncash operating lease expense	45,516	47,542
Equity in earnings of joint ventures, net of dividends	(10,308)	5,012
Amortization of deferred financing costs and loan discount	2,336	2,240
Loss on sale and disposal of equipment	735	1,183
Loss on extinguishment of debt	2,080	0
Gain on contribution of imaging centers into joint venture	0	(16,808)
Amortization of cash flow hedge, net of taxes	8,242	2,765
Non-cash change in fair value of interest rate hedge	7,429	949
Stock-based compensation	21,368	21,380
Loss on impairment	1,200	3,949
Change in fair value of contingent consideration	1,974	(4,112)
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:		
Accounts receivable	(35,369)	(1,379)
Other current assets	4,738	5,754
Other assets	(7,388)	(16,641)
Deferred taxes	4,834	7,389
Operating leases	(40,497)	(43,390)
Deferred revenue	(255)	1,155
Accounts payable, accrued expenses and other	57,426	(5,091)
Net cash provided by operating activities	190,494	131,943
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of imaging facilities and other acquisitions	(37,748)	(10,915)
Purchase of property and equipment and other	(145,164)	(136,537)
Proceeds from sale of equipment	151	82
Equity contributions in existing and purchase of interest in joint ventures	(1,496)	(5,453)
Net cash used in investing activities	(184,257)	(152,823)
CASH FLOWS FROM FINANCING ACTIVITIES		

Principal payments on notes and leases payable	(4,296)	(1,929)
Payments on Term Loan Debt	(688,375)	(11,062)
Proceeds from debt refinancing, net of issuing costs	863,815	0
Contribution from noncontrolling partners	7,569	0
Payments on contingent consideration	(3,614)	(3,390)
Distributions paid to noncontrolling interests	(2,423)	(3,523)
Proceeds from sale of economic interests in majority owned subsidiary, net of taxes	8,641	5,102
Proceeds from issuance of common stock	218,385	245,831
Proceeds from issuance of common stock upon exercise of options	367	72
Net cash provided by financing activities	400,069	231,101
EFFECT OF EXCHANGE RATE CHANGES ON CASH	40	(171)
NET INCREASE IN CASH AND CASH EQUIVALENTS	406,346	210,050
CASH AND CASH EQUIVALENTS, beginning of period	342,570	127,834
CASH AND CASH EQUIVALENTS, end of period	748,916	337,884
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		
Cash paid during the period for interest	51,520	59,421
Cash paid during the period for income taxes	$ 2,202	$ 225

XML 21 R8.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	9 Months Ended		
	Mar. 27, 2024	Sep. 30, 2024	Sep. 30, 2023
Equipment acquired and leasehold improvements		$ 43,200	$ 50,200
Property and equipment, net		663,867	
Goodwill		$ 711,841	
Heart & Lung Imaging Limited | Stock Holdback			
Shares issued (in shares)	95,019		
Equity interest issued, value assigned	$ 4,600		

XML 22 R9.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NATURE OF BUSINESS AND BASIS OF PRESENTATION

We are a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. At September 30, 2024, we operated directly or indirectly through joint ventures with hospitals, 399 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Our services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures.

In the first quarter of 2024, we revised our reportable segments to combine our eRad business, which was included in the Imaging Center segment, with our AI segment to form a new Digital Health reportable segment. Prior period amounts were adjusted retrospectively to reflect the change in reportable segment. For further financial information about these segments, see Note 5, Segment Reporting.

In March 2024, we closed on a public offering of 5,232,500 shares of our common stock, including 682,500 shares sold pursuant to the exercise of an underwriter's overallotment option, at a price to the public of $44.00 per share. The gross proceeds as a result of this public offering was $230.2 million before underwriting discounts, commissions, and costs totaling $11.8 million.

The consolidated financial statements include the accounts of RadNet, Inc as well as its subsidiaries in which RadNet has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which we are the primary beneficiary (as described in more detail below). All material intercompany transactions and balances have been eliminated upon consolidation. All of these affiliated entities are referred to collectively as “RadNet,” “we,” “us,” “our” or the “Company” in this report.

Accounting regulations stipulate that generally any entity with a) insufficient equity to finance its activities without additional subordinated financial support provided by any parties, or b) equity holders that, as a group, lack the characteristics which evidence a controlling financial interest, is considered a Variable Interest Entity (“VIE”). We consolidate all VIEs in which we are the primary beneficiary. We determine whether we are the primary beneficiary of a VIE through a qualitative analysis that identifies which variable interest holder has the controlling financial interest in the VIE. The variable interest holder who has both of the following has the controlling financial interest and is the primary beneficiary: (1) the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and (2) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. In performing our analysis, we consider all relevant facts and circumstances, including: the design and activities of the VIE, the terms of the contracts the VIE has entered into, the nature of the VIE’s variable interests issued and how they were negotiated with or marketed to potential investors, and which parties participated significantly in the design or redesign of the entity.

VIEs that we consolidate as the primary beneficiary include professional corporations which are owned or controlled by individuals within our senior management and provide professional medical services for centers in Arizona, California, Delaware, Maryland, New Jersey and New York. These VIEs are collectively referred to as the “Consolidated Medical Group”. RadNet provides non-medical, technical and administrative services to the Consolidated Medical Group for which it receives a management fee, pursuant to the related management agreements. Through the management agreements we have exclusive authority over all non-medical decision making related to the ongoing business operations and we determine the annual budget. The Consolidated Medical Group has insignificant operating assets and liabilities, and de minimis equity. Substantially all cash flows of the Consolidated Medical Group after expenses, including professional salaries, are transferred to us. We consolidate the revenue and expenses, assets and liabilities of the Consolidated Medical Group. The creditors of the Consolidated Medical Group do not have recourse to our general credit and there are no other arrangements that could expose us to losses on behalf of the Consolidated Medical Group. However, RadNet may be required to provide financial support to cover any operating expenses in excess of operating revenues.

The Consolidated Medical Group on a combined basis recognized $55.3 million and $51.3 million of revenue, net of management services fees to RadNet, for the three months ended September 30, 2024 and 2023, respectively and $55.3 million and $51.3 million of operating expenses for the three months ended September 30, 2024 and 2023, respectively. RadNet recognized $207.4 million and $214.7 million of total billed net service fee revenue for the three months ended September 30, 2024, and 2023, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.

The Consolidated Medical Group on a combined basis recognized $162.5 million and $151.5 million of revenue, net of management services fees to RadNet, for the nine months ended September 30, 2024 and 2023, respectively and $162.5 million
and $151.5 million of operating expenses for the nine months ended September 30, 2024 and 2023, respectively. RadNet recognized $673.3 million and $638.3 million of total billed net service fee revenue for the nine months ended September 30, 2024, and 2023, respectively, for management services provided to the Consolidated Medical Group relating primarily to the technical portion of billed revenue.

In our condensed consolidated balance sheets at September 30, 2024 and December 31, 2023, we have included approximately $118.0 million and $94.1 million, respectively, of accounts receivable and approximately $21.7 million and $16.7 million of accounts payable and accrued liabilities related to the Consolidated Medical Group, respectively. The cash flows of the Consolidated Medical Group are included in the accompanying condensed consolidated statements of cash flows. All intercompany balances and transactions have been eliminated in consolidation.

At all of our centers not serviced by the Consolidated Medical Group we have entered into long-term contracts with medical groups to provide professional services at those centers, including supervision and interpretation of diagnostic imaging procedures. The medical groups maintain full control over the physicians they employ. Through our management agreements, we make available to the medical groups the imaging centers, including all furniture, fixtures and medical equipment therein. The medical groups are compensated for their services from the professional component of the global net service fee revenue and after deducting management service fees paid to us, we have no economic controlling interest in these medical groups. As such, the financial results of these groups are not consolidated in our financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for conformity with U.S. generally accepted accounting principles for complete financial statements; however, in the opinion of management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods ended September 30, 2024 and 2023 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto contained in our annual report on Form 10-K for the year ended December 31, 2023.

XML 23 R10.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]	
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes to the significant accounting policies we use and have explained in our annual report on Form 10-K for the fiscal year ended December 31, 2023. The information below is intended only to supplement the disclosure in our annual report on Form 10-K for the fiscal year ended December 31, 2023.

REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual

discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

Our total service revenues during the three and nine months ended September 30, 2024 and 2023 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Commercial insurance	$ 255,375	$ 218,923	$ 752,514	$ 652,597
Medicare	102,852	89,981	298,001	262,719
Medicaid	10,894	10,519	32,804	30,279
Workers' compensation/personal injury	10,232	9,745	33,088	34,785
Other patient revenue	10,607	10,443	34,524	30,191
Management fee revenue	6,242	3,922	18,255	12,203
Heart and lung	4,696	2,441	12,553	6,377
Other	10,314	3,768	18,918	14,248
Revenue under capitation arrangements	33,563	40,041	105,050	117,982
Imaging Center Segment Revenue	444,775	389,783	1,305,707	1,161,381
Digital Health Segment Revenue	16,367	12,185	46,856	34,866
Total service revenue	$ 461,142	$ 401,968	$ 1,352,563	$ 1,196,247

ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. Amounts remaining to be collected on these agreements were $5.9 million and $14.3 million at September 30, 2024 and December 31, 2023, respectively. We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis.

DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities. Deferred financing costs, net of accumulated amortization, were $2.4 million and $1.6 million, as of September 30, 2024 and December 31, 2023, respectively. See Note 6, Credit Facilities and Notes Payable for more information.

PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.

BUSINESS COMBINATIONS - When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition

date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

GOODWILL - Goodwill at September 30, 2024 totaled $711.8 million. Goodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2023 noting no impairment, and we have not identified any indicators of impairment through September 30, 2024.

Activity in goodwill for the nine months ended September 30, 2024 is provided below (in thousands):

	Imaging Center segment	Digital Health segment	Total
Balance as of December 31, 2023	606,557	$ 72,906	$ 679,463
Goodwill from acquisitions	30,729	—	30,729
Currency translation	1,223	426	1,649
Segment reorganization	(12,300)	12,300	—
Balance as of September 30, 2024	$ 626,209	$ 85,632	$ 711,841

INTANGIBLE ASSETS - Intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names. The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at September 30, 2024 and December 31, 2023 are as follows (in thousands):

As of September 30, 2024:

	2024*	2025	2026	2027	2028	Thereafter	Total	Weighted average amortization period remaining in years
Management service contracts	$ 572	$ 2,287	$ 2,287	$ 2,287	$ 2,287	$ 6,669	$ 16,389	7.2
Covenant not to compete and other contracts	261	897	610	315	225	68	2,376	3.1
Customer lists	318	1,141	1,019	844	803	11,108	15,233	17.4
Patent and trademarks	78	311	311	311	311	197	1,519	5.2
Developed technology	1,913	7,651	7,611	7,077	7,077	6,856	38,185	5.8
Trade names amortized	19	77	77	77	63	27	340	4.5
Trade names indefinite life	—	—	—	—	—	8,500	8,500	—
IPR&D	—	—	—	—	—	1,899	1,899	—
Total annual amortization	$ 3,161	$ 12,364	$ 11,915	$ 10,911	$ 10,766	$ 35,324	$ 84,441	

*Excluding the nine months ended September 30, 2024

As of December 31, 2023:

	2024	2025	2026	2027	2028	Thereafter	Total	Weighted average amortization period remaining in years
Management service contracts	$ 2,287	$ 2,287	$ 2,287	$ 2,287	$ 2,287	$ 6,671	$ 18,106	7.9
Covenant not to compete and other contracts	946	714	427	132	45	6	2,270	3.4
Customer lists	1,234	1,104	981	797	764	10,564	15,444	17.7
Patent and trademarks	316	316	316	315	300	164	1,727	5.8
Developed technology	7,785	7,785	7,745	7,210	7,046	6,117	43,688	5.7
Trade names amortized	77	77	77	77	63	27	398	5.3
Trade names indefinite life	—	—	—	—	—	7,100	7,100	—
IPR&D	—	—	—	—	—	1,882	1,882	—
Total annual amortization	$ 12,645	$ 12,283	$ 11,833	$ 10,818	$ 10,505	$ 32,531	$ 90,615	

Total intangible asset amortization expense was $3.1 million and $9.4 million for the three and nine months ended September 30, 2024, respectively. Total amortization expense was $3.0 million and $8.9 million for the three and nine months ended September 30, 2023, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service contracts are amortized over 25 years using the straight line method. Developed technology is capitalized and amortized over the useful life of the software when placed into service. In process research and development (" IPR&D") and Trade names are reviewed annually for impairment.

INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.

In 2021, the Organization for Economic Co-operation and Development ("OECD") announced an inclusive framework on base erosion and profit shifting including Pillar Two Model Rules defining the global minimum tax, which calls for taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-US tax jurisdictions have either recently enacted legislation to support certain components of Pillar Two Model Rules beginning 2024 (including the European Union Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. The model rules provide a framework for applying the minimum tax, countries may enact Pillar Two Model Rules slightly differently than the model rules and on different timelines and may adjust domestic tax incentives in response to Pillar Two Model Rules. On a long-term basis, we will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in all countries applicable to us. For 2024, we expect that we will meet one or more transactional safe harbor rules, and as such, we do not believe Pillar Two model will have an impact on our annual effective tax rate for the year ending December 31, 2024.

We recorded an income tax expense of $4.3 million, or an effective tax rate of 26.1%, for the three months ended September 30, 2024 and $7.2 million, or an effective tax rate of 23.1% for the three months ended September 30, 2023. We recorded income tax expense of $4.9 million, or an effective tax rate of 16.7%, for the nine months ended September 30, 2024 and $7.7 million, or an effective tax rate of 24.1% for the nine months ended September 30, 2023. The income tax rates for the three and nine months ended September 30, 2024 diverge from the federal statutory rate due to (i) effects of state income taxes ; (ii) officer's compensation limitations; (iii) partial valuation allowance on losses in foreign jurisdictions, partially offset by (iv) excess tax benefits attributable to share based compensation; and (v) noncontrolling interests from controlled partnerships.

LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have

elected to account for the components as a single lease component. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of September 30, 2024. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.

EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we have amended and restated at various points in time: April 20, 2015, March 9, 2017, April 15, 2021 April 27, 2023, and most recently by our stockholders at our annual stockholders meeting on June 7, 2023 (the “Restated Plan”). We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three years to five years and expire five years to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes model. This model requires that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 7, Stock-Based Compensation, for more information.

COMPREHENSIVE INCOME (LOSS) - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation

adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the three and nine months ended September 30, 2024 and September 30, 2023 are included in the consolidated statements of comprehensive income.

INTEREST INCOME - We recognized interest income of approximately $9.6 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively, and $22.7 million and $6.3 million for the nine months ended September 30, 2024 and 2023, respectively. Interest income is recorded within Other non-operating income in our Condensed Consolidated Statements of Operations.

COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. If one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.

DERIVATIVE INSTRUMENTS - In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500.0 million, consisting of two agreements of $50.0 million each and two agreements of $200.0 million each. The 2019 Swaps secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the smaller notional and will mature in October 2025 for the larger notional. We arranged the 2019 Swaps with locked in 1 month Term SOFR rates at 1.89% for the $100.0 million notional and at 1.98% for the $400.0 million notional. As of the effective date, we are liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates are above the arranged rates.

At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive gain or loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. The cash flows for both our $400.0 million notional interest rate swap contract locked in at 1.98% due October 2025 and our $100.0 million notional interest rate swap contract locked in at 1.89% did not match the cash flows for our term

loans under our Barclays Credit Facility, so we determined that they are not effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400.0 million notional and after July 1, 2020 for the $100.0 million notional are being recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount was amortized to interest expense through October 2023 at approximately $0.4 million per month and continuing at approximately $0.3 million per month through October 2025. The effect for the release of the taxes from other comprehensive income is based on the current tax rate.

A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):

	For the three months ended September 30, 2024				
Account	June 30, 2024 Balance	Amount of comprehensive loss recognized on derivative net of taxes	Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*	September 30, 2024 Balance	Location
Accumulated Other Comprehensive Loss, net of taxes	$(4,369)	$—	$986	$(3,383)	Equity

*Net of taxes of $0.4 million for the three months ended September 30, 2024.

	For the nine months ended September 30, 2024				
Account	December 31, 2023 Balance	Amount of comprehensive loss recognized on derivative net of taxes	Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*	September 30, 2024 Balance	Location
Accumulated Other Comprehensive Loss, net of taxes	$(11,625)	$—	$8,242	$(3,383)	Equity

*Net of taxes of $2.8 million for the nine months ended September 30, 2024.

A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):

	For the three months ended September 30, 2024			
Ineffective interest rate swap	Amount recognized (current period ineffective portion)	Location recognized in profit and loss (current period ineffective portion)	Amount reclassified from accumulated OCI (prior period effective portion)	Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts	$ 6,755	Other income (expense)	$ 986	Interest Expense

	For the nine months ended September 30, 2024			
Ineffective interest rate swap	Amount recognized (current period ineffective portion)	Location recognized in profit and loss (current period ineffective portion)	Amount reclassified from accumulated OCI (prior period effective portion)	Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts	$ 7,429	Other income (expense)	$ 8,242	Interest Expense

See Fair Value Measurements below for the fair value of the 2019 Swaps at September 30, 2024.

CONTINGENT CONSIDERATION -

The HLH Imaging Group Limited fka Heart and Lung Imaging Limited

On November 1, 2022, we completed our acquisition of 75% of the equity interests of Heart and Lung Imaging Limited. The purchase included up to $10.2 million in contingent milestone consideration and cash holdback of $0.6 million to be issued 24 months after acquisition subject to adjustment for any indemnification claims, which will be adjusted to fair value in subsequent periods. The holdback had a value of approximately $0.6 million as of September 30, 2024. The contingent consideration is determined by the achievement of a specific number of physician reads. On September 20, 2023, we settled a milestone contingent liability by issuing 56,600 shares of our common stock at an ascribed value of $1.6 million and cash of $1.8 million. On December 12, 2023, we settled a milestone contingent liability by issuing 64,569 shares of our common stock at an ascribed value of $2.3 million and cash of $2.1 million. On March 27, 2024, we partially settled a milestone contingent liability by issuing 95,019 shares of our common stock at an ascribed value of $4.6 million. On April 1, 2024, we settled the remaining milestone contingent liability in cash of $3.6 million.

A tabular roll forward of contingent consideration is as follows (amounts in thousands):

		For the three months ended September 30, 2024				
Entity	Account	June 30, 2024 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2024 Balance
Heart and Lung	Accrued expenses	632	$ —	$ —	$ —	$ 632

		For the three months ended September 30, 2023				
Entity	Account	June 30, 2023 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2023 Balance
Heart and Lung	Accrued Expenses & Other Long Term Liabilities	14,358	$ (3,402)	$ 915	$ (772)	$ 11,099

		For the nine months ended September 30, 2024				
Entity	Account	January 1, 2024 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2024 Balance
Heart and Lung	Accrued expenses	6,879	$ (8,221)	$ 1,060	$ 914	$ 632

		For the nine months ended September 30, 2023				
Entity	Account	January 1, 2023 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2023 Balance
Heart and Lung	Accrued Expenses & Other Long Term Liabilities	11,656	$ (3,402)	$ 2,906	$ (61)	$ 11,099

Gain or loss from change in valuation of contingent consideration are recorded within *Cost of operations* in our *Consolidated Statements of Operations*.

See Fair Value Measurements below for the fair value of contingent consideration at September 30, 2024.

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

Derivatives:

The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):

	As of September 30, 2024			
	Level 1	Level 2	Level 3	Total
Long term assets				
2019 Swaps - Interest Rate Contracts	$ —	$ 7,689	$ —	$ 7,689

	As of December 31, 2023			
	Level 1	Level 2	Level 3	Total
Current and long term assets				
2019 Swaps - Interest Rate Contracts	$ —	$ 15,118	$ —	$ 15,118

The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty's forward SOFR curve. The forward SOFR curve is readily available in the public markets or can be derived from information available in the public markets.

Contingent Consideration:

The table below summarizes the estimated fair values of holdback relating to our Heart and Lung Imaging Limited acquisition on November 1, 2022 that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands):

	As of September 30, 2024			
	Level 1	Level 2	Level 3	Total
Accrued expenses				
Heart & Lung Imaging Limited	$ —	$ —	$ 632	$ 632

	As of December 31, 2023			
	Level 1	Level 2	Level 3	Total
Accrued expenses				
Heart & Lung Imaging Limited	$ —	$ —	$ 6,879	$ 6,879

The estimated fair value of these liabilities was determined using Level 3 inputs. For Heart & Lung Imaging Limited the contingent consideration is determined by the achievement of a specific number of physician reads. The fair value is measured based upon the probability adjusted amount expected to be paid. As significant inputs for the contingent consideration of Heart & Lung Imaging Limited are not observable and cannot be corroborated by observable market data they are classified as Level 3.

Long Term Debt:

The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands):

	As of September 30, 2024				
	Level 1	Level 2	Level 3	Total Fair Value	Total Face Value
Barclays Term Loan and Truist Term Loan	$ —	$ 1,010,778	$ —	$ 1,010,778	$ 1,009,687
	As of December 31, 2023				
	Level 1	Level 2	Level 3	Total Fair Value	Total Face Value
Barclays Term Loan and Truist Term Loan	$ —	$ 824,759	$ —	$ 824,759	$ 823,063

The estimated fair value of our long-term debt, which is discussed in Note 6, Credit Facilities and Notes Payable, was determined using Level 2 inputs primarily related to comparable market prices.

We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment.

EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 3,209	$ 17,540	$ (2,552)	$ 4,904
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS				
Weighted average number of common shares outstanding during the period	73,494,709	67,793,404	72,587,321	62,113,707
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders	$ 0.04	$ 0.26	$ (0.04)	$ 0.08
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS				
Weighted average number of common shares outstanding during the period	73,494,709	67,793,404	72,587,321	62,113,707
Add non-vested restricted stock subject only to service vesting	233,235	217,238	—	202,082
Add additional shares issuable upon exercise of stock options and contingently issuable shares	1,437,491	799,176	—	905,462
Weighted average number of common shares used in calculating diluted net income per share	75,165,435	68,809,818	72,587,321	63,221,251
Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders	$ 0.04	$ 0.25	$ (0.04)	$ 0.08
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:				
Non-vested restricted stock subject to service vesting	—	—	680,318	—
Shares issuable upon the exercise of stock options	—	88,600	820,932	761,708
Shares issuable subject to satisfaction of certain contingencies	—	—	—	193,207
Weighted average shares for which the exercise price exceeds average market price of common stock	—	—	—	94,346

INVESTMENTS IN EQUITY SECURITIES–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.

As of September 30, 2024, we have four equity investments with an aggregate carrying value of $8.0 million.

During the three months ended September 30, 2024, we recognized a $1.2 million impairment loss on our investment in Israel-based Medic Vision. This was driven by the escalating geopolitical tensions in Israel, which adversely affected market conditions, along with a bona fide offer we received for a similar investment. The offer, which was below the carrying value of our investment, provided a reliable indication of the current fair value of our Medic Vision investment. As a result, we

determined that the carrying amount of the investment exceeded its fair value, and the impairment loss has been recorded within "Other income" in our Condensed Consolidated Statements of Operations.

No other observable price changes or impairments in our investments were identified as of September 30, 2024.

INVESTMENT IN JOINT VENTURES – We have 13 unconsolidated joint ventures with ownership interests ranging from 33% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2024.

Joint venture investment and financial information

The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2024 (in thousands):

Balance as of December 31, 2023	$ 92,710
Equity in earnings in these joint ventures	11,308
Distribution of earnings	(1,000)
Equity contributions in existing joint ventures	1,496
Balance as of September 30, 2024	$ 104,514

We charged management service fees from the centers underlying these joint ventures of approximately $5.9 million and $3.9 million for the three months ended September 30, 2024 and 2023 and $17.8 million and $12.2 million for the nine months ended September 30, 2024 and 2023, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures. As we have the ability to exercise significant influence over our joint venture entities, we consider them related parties. Amounts transacted between ourselves and the entities are in the ordinary course of business and are disclosed on our balance sheet in the due from/to affiliate accounts.

The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2024 and December 31, 2023 and income statement data for the nine months ended September 30, 2024 and 2023 (in thousands):

Balance Sheet Data:	September 30, 2024	December 31, 2023
Current assets	$ 64,175	$ 39,819
Noncurrent assets	219,478	224,936
Current liabilities	(41,550)	(46,587)
Noncurrent liabilities	(70,607)	(70,834)
Total net assets	$ 171,496	$ 147,334

Income statement data for the nine months ended September 30,	2024	2023
Net revenue	$ 195,905	$ 129,020
Net income	$ 23,949	$ 7,906

XML 24 R11.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING AND REPORTING STANDARDS

9 Months Ended

Sep. 30, 2024

Accounting Standards Update and Change in Accounting Principle [Abstract]

RECENT ACCOUNTING AND REPORTING STANDARDS

RECENT ACCOUNTING AND REPORTING STANDARDS

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), *Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures*. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

XML 25 R12.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATIONS AND RELATED ACTIVITY

9 Months Ended

Sep. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

BUSINESS COMBINATIONS AND RELATED ACTIVITY

BUSINESS COMBINATIONS AND RELATED ACTIVITY

Imaging Center Segment

Acquisitions

During the nine months ended September 30, 2024, we completed the acquisition of certain assets of the following entities, which either engage directly in the practice of radiology or associated businesses. The primary reason for these acquisitions was to strengthen our presence in the California and Texas market. These acquisitions are reported as part of our Imaging Center segment. As of September 30, 2024, we made a preliminary fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands). The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2024; and the fair value determination is preliminary and may be subject to change:

Entity	Date Acquired	Total Consideration	Property & Equipment	Right of Use Assets	Goodwill	Intangible Assets	Other Assets	Right of Use Liabilities	Notes payable
Stanislaus Surgical Hospital, LLC	9/16/2024	3,000	504	1,468	2,382	100	15	(1,468)	—
Global Imaging LLP	9/1/2024	$ 2,900	1,266	—	1,584	50	—	—	—
U.S. Imaging, Inc.	6/1/2024	4,200	4,025	5,597	—	175	—	(5,597)	—
Houston Medical Imaging, LLC	4/1/2024	22,703	15,826	7,929	11,584	1,660	90	(8,089)	(6,297)
Grossman Imaging Center of CMH, LLC	3/31/2024	10,344	1,717	6,304	8,501	280	56	(6,514)	—
Providence Health System - Southern California	3/31/2024	$ 7,369	1,378	3,441	5,991	—	—	(3,441)	—
Antelope Valley Outpatient Imaging	2/1/2024	$ 3,530	2,794	563	687	50	—	(563)	—
Total		**54,046**	**27,509**	**25,302**	**30,729**	**2,315**	**160**	**(25,672)**	**(6,297)**

During the three months ended September 30, 2024, the Company revised the fair value of certain assets acquired and liabilities assumed of Houston Medical Imaging, LLC's, Grossman Imaging Center of CMH, LLC, and Providence Health System - Southern California, resulting in an increase of $4.4 million in the net fair value of these assets and liabilities and a corresponding decrease in goodwill. These adjustments did not have an impact on the Company's condensed consolidated statement of operations for the nine months ended September 30, 2024.

Formation of majority owned subsidiary and sale of economic interest

On February 23, 2024, we formed Tri Valley Imaging Group, LLC ("TVIG"), a partnership with Providence Health System - Southern California ("PHS"). The operation offers multi-modality services out of seven locations in Southern

California. On March 29, 2024, we contributed the operations of four centers to the enterprise and PHS contributed a business comprising three centers including $1.4 million of fixed assets and $6.0 million in goodwill. Simultaneously, PHS purchased from us an additional economic interest in TVIG for cash payment of $9.6 million. As a result of the transaction, we recognized a gain of $7.9 million to additional paid in capital and retained a 52% controlling economic interest in TVIG and PHS retains a $7.8 million or 48% noncontrolling economic interest in TVIG.

In determining the fair value of the imaging centers contributed to TVIG, we used an income approach which is considered a level 3 valuation technique. See Fair Value Measurements above for further detail on the valuation hierarchy. Key assumptions used in measuring the fair value are financial forecasts and a discount rate. We also utilized the cash paid for an additional interest in the joint venture to substantiate the fair value of the contributed assets.

XML 26 R13.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING

9 Months Ended Sep. 30, 2024

Segment Reporting [Abstract]

SEGMENT REPORTING

SEGMENT REPORTING

In the first quarter of 2024, we revised our reportable segments to combine our eRad business, which was included in the Imaging Center segment, with our AI segment to form a new Digital Health reportable segment. Prior period amounts were adjusted retrospectively to reflect the change in reportable segment. Accordingly, our reportable segments currently include our Imaging Center segment and our Digital Health segment.

Our Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a strategy that diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures.

Our Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. Included in the segment is our eRad subsidiary, which designs the underlying critical scheduling, data storage and retrieval systems necessary for imaging center operation.

Our chief operating decision maker ("CODM"), who is also our CEO, evaluates the financial performance of our segments based upon their respective revenue and segmented internal profit and loss statements prepared on a basis not consistent with GAAP. We do not report balance sheet information by segment since it is not reviewed by our CODM.

In the normal course of business, our Imaging Center and Digital Health segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.

Three Months Ended September 30, 2024

	Imaging Center	Digital Health	Intersegment Elimination	Consolidated Total
Revenue:				
Third Party	$ 452,368	$ 8,774	$ —	$ 461,142
Intersegment	—	7,593	(7,593)	—
Total revenue	$ 452,368	$ 16,367	$ (7,593)	$ 461,142

Three months ended September 30, 2023

	Imaging Center	Digital Health	Intersegment Elimination	Consolidated Total
Revenue:				
Third Party	$ 395,613	$ 6,355	$ —	$ 401,968
Intersegment	—	5,830	(5,830)	—
Total revenue	$ 395,613	$ 12,185	$ (5,830)	$ 401,968

Nine Months Ended September 30, 2024

	Imaging Center		Digital Health	Intersegment Elimination	Consolidated Total
Revenue:					
Third Party	$ 1,325,825		$ 26,738	$ —	$ 1,352,563
Intersegment	—		20,118	(20,118)	—
Total revenue	$ 1,325,825	1325825000	$ 46,856	$ (20,118)	$ 1,352,563

Nine Months Ended September 30, 2023

	Imaging Center		Digital Health	Intersegment Elimination	Consolidated Total
Revenue:					
Third Party	$ 1,178,873		$ 17,374	$ —	$ 1,196,247
Intersegment	—		17,492	(17,492)	—
Total revenue	$ 1,178,873	1178873	$ 34,866	$ (17,492)	$ 1,196,247

The table below presents segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands):

	Three months ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenue:				
Imaging Center	444,775	389,783	$ 1,305,707	$ 1,161,381
Digital Health	16,367	12,185	46,856	34,866
Total revenue	$ 461,142	401,968	$ 1,352,563	$ 1,196,247
Cost of Operations				
Imaging Center	$ 374,789	$ 334,580	$ 1,120,542	$ 1,008,814
Digital Health	17,011	7,055	48,571	29,833
Total cost of operations	$ 391,800	$ 341,635	$ 1,169,113	$ 1,038,647
Depreciation and Amortization:				
Imaging Center	$ 32,032	$ 30,221	$ 94,095	$ 89,743
Digital Health	2,947	1,989	7,727	5,962
Total depreciation and amortization	$ 34,979	$ 32,210	$ 101,822	$ 95,705
Gain on contribution of imaging centers into joint venture:				
Imaging Center	$ —	$ (16,808)	$ —	$ (16,808)
Digital Health	—	—	—	—
Total (gain) loss on contribution of imaging centers into joint venture	$ —	$ (16,808)	$ —	$ (16,808)
Loss (gain) on Disposal of Equipment:				
Imaging Center	$ 153	$ 524	$ 739	$ 1,185
Digital Health	(5)	3	(4)	(2)
Total loss on disposal of equipment	$ 148	$ 527	$ 735	$ 1,183
Severance				
Imaging Center	$ 271	$ 1,141	$ 720	$ 1,417
Digital Health	33	12	77	1,740
Total severance	$ 304	$ 1,153	$ 797	$ 3,157
Income (Loss) from Operations				
Imaging Center	$ 37,530	$ 40,125	$ 89,611	$ 77,030
Digital Health	(3,619)	3,126	(9,515)	(2,667)
Total income from operations	$ 33,911	$ 43,251	$ 80,096	$ 74,363

XML 27 R14.htm IDEA: XBRL DOCUMENT

CREDIT FACILITIES AND NOTES PAYABLE

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

CREDIT FACILITIES AND NOTES PAYABLE

CREDIT FACILITIES AND NOTES PAYABLE

At September 30, 2024 we had two principal secured credit facilities consisting of our Barclays credit facility and our Truist credit facility. Each facility includes a term loan component and a revolving credit facility. At September 30, 2024, we were in compliance with all covenants under our credit facilities.

Barclays Credit Facility

On April 18, 2024, we entered into a Third Amended and Restated First Lien Credit and Guaranty Agreement (the "Barclays Credit Agreement"), with Barclays Bank Plc and the lenders and financial institutions named therein, which provides for $875.0 million of senior secured term loans (the "Barclays Term Loan") and a $282.0 million senior secured revolving credit facility (the "Barclays Revolving Credit Facility"). Our borrowing under the Barclays Revolving Credit Facility is secured by a lien on all of our assets.

The proceeds from the April 18, 2024 restatement of the Barclays Credit Agreement were used to refinance the $678.7 million of term loans outstanding under the prior credit facility, to pay accrued interest through the date of closing, and to pay fees and expenses associated with the refinancing transaction. Total costs incurred in connection with the restatement amounted to approximately $19.9 million segregated as follows: $11.1 million recognized as discount and deferred finance cost, $2.1 million charged to loss on early extinguishment of debt and $6.7 million to related expenses. Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement.

Barclays Term Loan:

The Barclays Term Loan provides for interest payments based on a base rate, plus an applicable margin. During the periods covered by this report, the base rates, margins and effective interest rates (without giving effect to our 2019 Swaps) were as follows for the periods indicated:

Period	Base Rate plus Margin	Effective Rate
Through March 31, 2023	Eurodollar plus 2.50% Alternative Base Rate plus 2.00%	4.63% 8.00%
April 1, 2023 to April 18, 2024	SOFR plus 3.00% Alternative Base Rate plus 2.00%	8.33% (credit spread adjustment of 0.11%) 10.5%
After April 18, 2024	SOFR plus 2.5% Prime Rate plus 1.5%	7.78% (credit spread adjustment of 0.00%) 9.5%

With the recent restatement, we are required to make quarterly principal payments of $2.2 million (up from $1.8 million under the prior credit agreement). The Barclays Term Loan will mature on April 18, 2031 unless otherwise accelerated under the terms of the Barclays Credit Agreement.

Barclays Revolving Credit Facility:

The Barclays Revolving Credit Facility is a $282.0 million senior secured revolving credit facility. Associated with the Barclays Revolving Credit Facility is deferred financing costs, net of accumulated amortization, of $2.0 million at September 30, 2024.

Amounts borrowed under the Barclays Revolving Credit Facility bear interest at either SOFR plus 3.00% or the Prime Rate plus 2% (with step-downs based on attainment of certain first lien net leverage ratio benchmarks). As of September 30, 2024, the effective interest rate payable on revolving loans under the Barclays Revolving Credit Facility was 10.50%. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Barclays Revolving Credit Facility.

We had no outstanding balance under our $282.0 million Barclays Revolving Credit Facility at September 30, 2024. After reserves of $8.3 million for certain letters of credit, $273.7 million was available to draw upon as of September 30, 2024.

The Barclays Revolving Credit Facility terminates on April 18, 2029, unless otherwise accelerated under the terms of the Barclays Credit Agreement.

Truist Credit Facility

On October 7, 2022 our subsidiary New Jersey Imaging Network, Inc.("NJIN") entered into Second Amended and Restated Revolving Credit and Term Loan Agreement (the "Truist Credit Agreement"), with Truist Bank and the lenders and financial institutions named therein, which provides for a $150.0 million term loan (the "Truist Term Loan") and a $50.0 million revolving credit facility (the "Truist Revolving Credit Facility"). The Truist Credit agreement is secured by the assets of NJIN.

Truist Term Loan:

The Truist Term Loan currently bears interest at SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. At September 30, 2024 the applicable margin for SOFR was 1.5%.

We are required to make quarterly principal payments of $1.9 million, which increases by $0.9 million at scheduled intervals, with the remaining balance to be paid at maturity. The Truist Term Loan will mature on October 10, 2027 unless otherwise accelerated under the terms of the Truist Credit Agreement.

Truist Revolving Credit Facility:

The Truist Revolving Credit Facility is a $50.0 million secured revolving credit facility. Associated with the Truist Revolving Credit Facility are deferred financing costs, net of accumulated amortization, of $0.4 million at September 30, 2024.

Amounts borrowed under the Truist Revolving Credit Facility bear interest at either SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. In addition, a commitment fee of 0.30% per annum accrues on the unused revolver commitments under the Truist Revolving Credit Facility.

We had no balance under our $50.0 million Truist Revolving Credit Facility at September 30, 2024. With no letters of credit reserved against the facility, the full $50.0 million was available to draw upon as of September 30, 2024.

The Truist Revolving Credit Facility terminates on October 7, 2027, unless otherwise accelerated under the terms of the Truist Credit Agreement.

Notes Payable

We have issued certain notes payable in connection with the purchase of equipment previously leased under operating leases. On April 1, 2024, January 15, 2024, and February 1, 2023 we issued promissory notes in the amount of $6.3 million, $6.9 million and $19.8 million, respectively, to purchase previously leased equipment.

Debt Obligations

As of September 30, 2024 and December 31, 2023 our term loan debt and other obligations are as follows (in thousands):

	September 30, 2024	December 31, 2023
Barclays Term Loans collateralized by RadNet's tangible and intangible assets	$ 872,812	$ 678,687
Discount on Barclays Term Loans	(15,234)	(9,041)
Truist Term Loan Agreement collateralized by NJIN's tangible and intangible assets	136,875	144,375
Discount on Truist Term Loan Agreement	(792)	(990)
Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment	25,989	17,011
Total debt obligations	1,019,650	830,042
Less: current portion	(23,378)	(17,974)
Long term portion of debt obligations	$ 996,272	$ 812,068

XML 28 R15.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION	9 Months Ended Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]	
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION

Stock Incentive Plans

We have one long-term equity incentive plan, the RadNet, Inc. Equity Incentive Plan, which has been amended and restated on April 20, 2015, March 9, 2017, April 15, 2021, April 27, 2023, and most recently following approved by our stockholders at our annual stockholders meeting on June 7, 2023 (the "Restated Plan"). We have reserved for issuance under the Restated Plan 20,100,000 shares of common stock. We can issue options (incentive and nonstatutory), performance based options, stock awards (restricted or unrestricted), stock units, performance based stock units, and stock appreciation rights under the Restated Plan.

Options

Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over 3 to 5 years and expire 5 to 10 years from the date of grant.

The following summarizes all of our option transactions for the nine months ended September 30, 2024:

Outstanding Options Under the 2006 Plan	Shares	Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2023	911,411	$ 16.60		
Granted	—	—		
Exercised	(60,306)	6.15		
Balance, September 30, 2024	851,105	17.34	5.69	$ 44,301
Exercisable at September 30, 2024	729,806	16.62	5.31	38,515

Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2024 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on September 30, 2024. As of September 30, 2024, total unrecognized stock-based compensation expense related to non-vested employee awards was $0.5 million, which is expected to be recognized over a weighted average period of approximately 0.39 years.

DeepHealth Options

During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted options to acquire 412,434 shares at a grant date fair value of $16.93 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of September 30, 2024, total unrecognized stock based compensation expense related to non-vested DeepHealth options was insignificant.

Outstanding Options Under the Deep Health Plan	Shares	Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2023	79,073	$ —		
Exercised	(9,377)	—		
Balance, September 30, 2024	69,696	—	5.0	$ 4,836
Exercisable at September 30, 2024	69,696	—	5.0	4,836

Options issued in replacement of original DeepHealth options as a result of our acquisition are not included in the share count under the Restated Plan.

Restricted Stock Awards ("RSAs") and Restricted Stock Units ("RSUs")

The Restated Plan permits the award of RSAs and RSUs. The following summarizes all unvested RSA's and RSU's activities during the nine months ended September 30, 2024:

	RSAs and RSUs	Weighted-Average Remaining Contractual Term (Years)	Weighted-Average Fair Value per Share
RSAs and RSUs unvested at December 31, 2023	762,083		$ 22.13
Changes during the period			
Granted	797,309		$ 37.40
Vested	(875,185)		$ 27.78
Forfeited or Canceled	(13,460)		$ 27.74
RSAs and RSUs unvested at September 30, 2024	670,747	1.74	$ 32.33

We determine the fair value of all RSAs and RSUs based on the closing price of our common stock on the award date.

Performance based stock units ("PSUs")

In January 2023, we granted certain employees PSUs with a target award of 60,685 shares of our common stock. The PSUs will vest in two equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 200% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2023 through December 31, 2023. In March of 2024, based on the performance condition being achieved, the board of directors issued 121,370 units with a fair value of $18.64 per unit.

Performance based stock options ("PSOs")

In January 2023, we granted certain employees PSOs with a potential to option a maximum of 235,227 shares of our common stock. The PSOs will vest in three equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 100% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2023 through December 31, 2023. In March 2024, based on the performance condition being achieved, the board of directors issued 235,227 options with a strike price of $18.64 per share.

Shares available

Of the 20,100,000 shares of common stock reserved for issuance under the Restated Plan, at September 30, 2024, there remain approximately 3,285,500 shares available under the Restated Plan for future issuance.

XML 29 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	9 Months Ended Sep. 30, 2024
Subsequent Events [Abstract]	
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS

Pink Perception LLC

On October 1, 2024, we entered into an agreement to acquire Pink Perception LLC for a purchase consideration of approximately $4.0 million. Pink Perception LLC consists of two multi-modality imaging centers located in New York. The acquisition closed in the fourth quarter of 2024.

Kheiron Medical Technologies Limited

On October 22, 2024, we acquired Kheiron Medical Technologies Limited for a purchase consideration of approximately $1.0 million. Kheiron Medical Technologies Limited is a UK-based AI cancer diagnostic company focused on developing deep learning solutions to support radiologists improve breast cancer detection.

XML 30 R17.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
Pay vs Performance Disclosure				
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 3,209	$ 17,540	$ (2,552)	$ 4,904

XML 31 R18.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 32 R19.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended Sep. 30, 2024
Accounting Policies	

[Abstract]

REVENUES

REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities.

Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual

discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect.

Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.

We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion.We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis.

DEFERRED FINANCING COSTS

DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred.

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS - When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition

date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations.

GOODWILL

GOODWILLGoodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2023 noting no impairment, and we have not identified any indicators of impairment through September 30, 2024.

INCOME TAXES

INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.

LEASES

LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long term operating lease liability in our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have

elected to account for the components as a single lease component. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of September 30, 2024. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order.

EQUITY BASED COMPENSATION

EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we have amended and restated at various points in time: April 20, 2015, March 9, 2017, April 15, 2021 April 27, 2023, and most recently by our stockholders at our annual stockholders meeting on June 7, 2023 (the “Restated Plan”). We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three years to five years and expire five years to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes model. This model requires that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards’ service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 7, Stock-Based Compensation, for more information.

COMPREHENSIVE INCOME (LOSS)

COMPREHENSIVE INCOME (LOSS) - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the three and nine months ended September 30, 2024 and September 30, 2023 are included in the consolidated statements of comprehensive income.

INTEREST INCOME

INTEREST INCOME - We recognized interest income of approximately $9.6 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively, and $22.7 million and $6.3 million for the nine months ended September 30, 2024 and 2023, respectively. Interest income is recorded within Other non-operating income in our Condensed Consolidated Statements of Operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. If one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTSThe 2019 Swaps secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the smaller notional and will mature in October 2025 for the larger notional.As of the effective date, we are liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates are above the arranged rates.At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive gain or loss in the consolidated statement of equity.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS – Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant to a fair value measurement:

Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.

Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.

The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty’s forward SOFR curve. The forward SOFR curve is readily available in the public markets or can be derived from information available in the public markets.

The estimated fair value of our long-term debt, which is discussed in Note 6, Credit Facilities and Notes Payable, was determined using Level 2 inputs primarily related to comparable market prices.

We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment.

EARNINGS PER SHARE

EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

INVESTMENTS IN EQUITY SECURITIES

INVESTMENTS IN EQUITY SECURITIES–Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.

INVESTMENTS IN JOINT VENTURES

INVESTMENT IN JOINT VENTURES – We have 13 unconsolidated joint ventures with ownership interests ranging from 33% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2024.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), *Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures*. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated
guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024.

SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Service Fee Revenue

Our total service revenues during the three and nine months ended September 30, 2024 and 2023 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Commercial insurance	$ 255,375	$ 218,923	$ 752,514	$ 652,597
Medicare	102,852	89,981	298,001	262,719
Medicaid	10,894	10,519	32,804	30,279
Workers' compensation/personal injury	10,232	9,745	33,088	34,785
Other patient revenue	10,607	10,443	34,524	30,191
Management fee revenue	6,242	3,922	18,255	12,203
Heart and lung	4,696	2,441	12,553	6,377
Other	10,314	3,768	18,918	14,248
Revenue under capitation arrangements	33,563	40,041	105,050	117,982
Imaging Center Segment Revenue	444,775	389,783	1,305,707	1,161,381
Digital Health Segment Revenue	16,367	12,185	46,856	34,866
Total service revenue	$ 461,142	$ 401,968	$ 1,352,563	$ 1,196,247

Schedule of Goodwill

Activity in goodwill for the nine months ended September 30, 2024 is provided below (in thousands):

	Imaging Center segment	Digital Health segment	Total
Balance as of December 31, 2023	606,557	$ 72,906	$ 679,463
Goodwill from acquisitions	30,729	—	30,729
Currency translation	1,223	426	1,649
Segment reorganization	(12,300)	12,300	—
Balance as of September 30, 2024	$ 626,209	$ 85,632	$ 711,841

Schedule of Annual Amortization Expense

The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at September 30, 2024 and December 31, 2023 are as follows (in thousands):

As of September 30, 2024:

	2024*	2025	2026	2027	2028	Thereafter	Total	Weighted average amortization period remaining in years
Management service contracts	$ 572	$ 2,287	$ 2,287	$ 2,287	$ 2,287	$ 6,669	$ 16,389	7.2
Covenant not to compete and other contracts	261	897	610	315	225	68	2,376	3.1
Customer lists	318	1,141	1,019	844	803	11,108	15,233	17.4
Patent and trademarks	78	311	311	311	311	197	1,519	5.2
Developed technology	1,913	7,651	7,611	7,077	7,077	6,856	38,185	5.8
Trade names amortized	19	77	77	77	63	27	340	4.5
Trade names indefinite life	—	—	—	—	—	8,500	8,500	—
IPR&D	—	—	—	—	—	1,899	1,899	—
Total annual amortization	$ 3,161	$ 12,364	$ 11,915	$ 10,911	$ 10,766	$ 35,324	$ 84,441	

*Excluding the nine months ended September 30, 2024

As of December 31, 2023:

	2024	2025	2026	2027	2028	Thereafter	Total	Weighted average amortization period remaining in years
Management service contracts	$ 2,287	$ 2,287	$ 2,287	$ 2,287	$ 2,287	$ 6,671	$ 18,106	7.9
Covenant not to compete and other contracts	946	714	427	132	45	6	2,270	3.4
Customer lists	1,234	1,104	981	797	764	10,564	15,444	17.7
Patent and trademarks	316	316	316	315	300	164	1,727	5.8
Developed technology	7,785	7,785	7,745	7,210	7,046	6,117	43,688	5.7
Trade names amortized	77	77	77	77	63	27	398	5.3
Trade names indefinite life	—	—	—	—	—	7,100	7,100	—
IPR&D	—	—	—	—	—	1,882	1,882	—
Total annual amortization	$ 12,645	$ 12,283	$ 11,833	$ 10,818	$ 10,505	$ 32,531	$ 90,615	

Schedule of Effect of Derivative Instruments on Comprehensive Income(Loss)

A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):

For the three months ended September 30, 2024

Account	June 30, 2024 Balance	Amount of comprehensive loss recognized on derivative net of taxes	Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*	September 30, 2024 Balance	Location
Accumulated Other Comprehensive Loss, net of taxes	$(4,369)	$—	$986	$(3,383)	Equity

*Net of taxes of $0.4 million for the three months ended September 30, 2024.

For the nine months ended September 30, 2024

Account	December 31, 2023 Balance	Amount of comprehensive loss recognized on derivative net of taxes	Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*	September 30, 2024 Balance	Location
Accumulated Other Comprehensive Loss, net of taxes	$(11,625)	$—	$8,242	$(3,383)	Equity

*Net of taxes of $2.8 million for the nine months ended September 30, 2024.

A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):

For the three months ended September 30, 2024

Ineffective interest rate swap	Amount recognized (current period ineffective portion)	Location recognized in profit and loss (current period ineffective portion)	Amount reclassified from accumulated OCI (prior period effective portion)	Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts	$ 6,755	Other income (expense)	$ 986	Interest Expense

For the nine months ended September 30, 2024

Ineffective interest rate swap	Amount recognized (current period ineffective portion)	Location recognized in profit and loss (current period ineffective portion)	Amount reclassified from accumulated OCI (prior period effective portion)	Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts	$ 7,429	Other income (expense)	$ 8,242	Interest Expense

Schedule of Business Acquisitions by Acquisition, Contingent Consideration

A tabular roll forward of contingent consideration is as follows (amounts in thousands):

For the three months ended September 30, 2024

Entity	Account	June 30, 2024 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2024 Balance
Heart and Lung	Accrued expenses	632	$ —	$ —	$ —	$ 632

For the three months ended September 30, 2023

Entity	Account	June 30, 2023 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2023 Balance
Heart and Lung	Accrued Expenses & Other Long Term Liabilities	14,358	$ (3,402)	$ 915	$ (772)	$ 11,099

For the nine months ended September 30, 2024

Entity	Account	January 1, 2024 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2024 Balance
Heart and Lung	Accrued expenses	6,879	$ (8,221)	$ 1,060	$ 914	$ 632

For the nine months ended September 30, 2023

Entity	Account	January 1, 2023 Balance	Settlement of contingent consideration	Change in valuation of contingent consideration	Currency translation	September 30, 2023 Balance
Heart and Lung	Accrued Expenses & Other Long Term Liabilities	11,656	$ (3,402)	$ 2,906	$ (61)	$ 11,099

Schedule of Fair Value of Assets and Liabilities

The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):

	As of September 30, 2024			
	Level 1	Level 2	Level 3	Total
Long term assets				
2019 Swaps - Interest Rate Contracts	$ —	$ 7,689	$ —	$ 7,689

	As of December 31, 2023			
	Level 1	Level 2	Level 3	Total
Current and long term assets				
2019 Swaps - Interest Rate Contracts	$ —	$ 15,118	$ —	$ 15,118

The table below summarizes the estimated fair values of holdback relating to our Heart and Lung Imaging Limited acquisition on November 1, 2022 that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands):

	As of September 30, 2024			
	Level 1	Level 2	Level 3	Total
Accrued expenses				
Heart & Lung Imaging Limited	$ —	$ —	$ 632	$ 632

	As of December 31, 2023			
	Level 1	Level 2	Level 3	Total
Accrued expenses				
Heart & Lung Imaging Limited	$ —	$ —	$ 6,879	$ 6,879

The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands):

	As of September 30, 2024				
	Level 1	Level 2	Level 3	Total Fair Value	Total Face Value
Barclays Term Loan and Truist Term Loan	$ —	$ 1,010,778	$ —	$ 1,010,778	$ 1,009,687

	As of December 31, 2023				
	Level 1	Level 2	Level 3	Total Fair Value	Total Face Value
Barclays Term Loan and Truist Term Loan	$ —	$ 824,759	$ —	$ 824,759	$ 823,063

Schedule of Earnings Per Share

Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 3,209	$ 17,540	$ (2,552)	$ 4,904
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS				
Weighted average number of common shares outstanding during the period	73,494,709	67,793,404	72,587,321	62,113,707
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders	$ 0.04	$ 0.26	$ (0.04)	$ 0.08
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS				
Weighted average number of common shares outstanding during the period	73,494,709	67,793,404	72,587,321	62,113,707
Add non-vested restricted stock subject only to service vesting	233,235	217,238	—	202,082
Add additional shares issuable upon exercise of stock options and contingently issuable shares	1,437,491	799,176	—	905,462
Weighted average number of common shares used in calculating diluted net income per share	75,165,435	68,809,818	72,587,321	63,221,251
Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders	$ 0.04	$ 0.25	$ (0.04)	$ 0.08
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:				
Non-vested restricted stock subject to service vesting	—	—	680,318	—
Shares issuable upon the exercise of stock options	—	88,600	820,932	761,708
Shares issuable subject to satisfaction of certain contingencies	—	—	—	193,207
Weighted average shares for which the exercise price exceeds average market price of common stock	—	—	—	94,346

Schedule of Investment in Joint Ventures

The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2024 (in thousands):

Balance as of December 31, 2023	$ 92,710
Equity in earnings in these joint ventures	11,308
Distribution of earnings	(1,000)
Equity contributions in existing joint ventures	1,496
Balance as of September 30, 2024	$ 104,514

Schedule of Joint Venture Investment and Financial Information

The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2024 and December 31, 2023 and income statement data for the nine months ended September 30, 2024 and 2023 (in thousands):

Balance Sheet Data:	September 30, 2024	December 31, 2023
Current assets	$ 64,175	$ 39,819
Noncurrent assets	219,478	224,936
Current liabilities	(41,550)	(46,587)
Noncurrent liabilities	(70,607)	(70,834)
Total net assets	$ 171,496	$ 147,334

Income statement data for the nine months ended September 30,	2024	2023
Net revenue	$ 195,905	$ 129,020
Net income	$ 23,949	$ 7,906

~~XML 34 R21.htm IDEA: XBRL DOCUMENT~~

BUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables)

9 Months Ended
Sep. 30, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of Business Acquisitions

As of September 30, 2024, we made a preliminary fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands). The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2024; and the fair value determination is preliminary and may be subject to change:

Entity	Date Acquired	Total Consideration	Property & Equipment	Right of Use Assets	Goodwill	Intangible Assets	Other Assets	Right of Use Liabilities	Notes payable
Stanislaus Surgical Hospital, LLC	9/16/2024	3,000	504	1,468	2,382	100	15	(1,468)	—
Global Imaging LLP	9/1/2024	$ 2,900	1,266	—	1,584	50	—	—	—
U.S. Imaging, Inc.	6/1/2024	4,200	4,025	5,597	—	175	—	(5,597)	—
Houston Medical Imaging, LLC	4/1/2024	22,703	15,826	7,929	11,584	1,660	90	(8,089)	(6,297)
Grossman Imaging Center of CMH, LLC	3/31/2024	10,344	1,717	6,304	8,501	280	56	(6,514)	—
Providence Health System - Southern California	3/31/2024	$ 7,369	1,378	3,441	5,991	—	—	(3,441)	—
Antelope Valley Outpatient Imaging	2/1/2024	$ 3,530	2,794	563	687	50	—	(563)	—
Total		**54,046**	**27,509**	**25,302**	**30,729**	**2,315**	**160**	**(25,672)**	**(6,297)**

~~XML 35 R22.htm IDEA: XBRL DOCUMENT~~

SEGMENT REPORTING (Tables)

9 Months Ended
Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

	Three Months Ended September 30, 2024			
	Imaging Center	Digital Health	Intersegment Elimination	Consolidated Total
Revenue:				
Third Party	$ 452,368	$ 8,774	$ —	$ 461,142
Intersegment	—	7,593	(7,593)	—
Total revenue	$ 452,368	$ 16,367	$ (7,593)	$ 461,142

Three months ended September 30, 2023

	Imaging Center	Digital Health	Intersegment Elimination	Consolidated Total
Revenue:				
Third Party	$ 395,613	$ 6,355	$ —	$ 401,968
Intersegment	—	5,830	(5,830)	—
Total revenue	$ 395,613	$ 12,185	$ (5,830)	$ 401,968

Nine Months Ended September 30, 2024

	Imaging Center	Digital Health	Intersegment Elimination	Consolidated Total
Revenue:				
Third Party	$ 1,325,825	$ 26,738	$ —	$ 1,352,563
Intersegment	—	20,118	(20,118)	—
Total revenue	$ 1,325,825 1325825000	$ 46,856	$ (20,118)	$ 1,352,563

Nine Months Ended September 30, 2023

	Imaging Center	Digital Health	Intersegment Elimination	Consolidated Total
Revenue:				
Third Party	$ 1,178,873	$ 17,374	$ —	$ 1,196,247
Intersegment	—	17,492	(17,492)	—
Total revenue	$ 1,178,873 1178873	$ 34,866	$ (17,492)	$ 1,196,247

The table below presents segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands):

	Three months ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenue:				
Imaging Center	444,775	389,783	$ 1,305,707	$ 1,161,381
Digital Health	16,367	12,185	46,856	34,866
Total revenue	$ 461,142	401,968	$ 1,352,563	$ 1,196,247
Cost of Operations				
Imaging Center	$ 374,789	$ 334,580	$ 1,120,542	$ 1,008,814
Digital Health	17,011	7,055	48,571	29,833
Total cost of operations	$ 391,800	$ 341,635	$ 1,169,113	$ 1,038,647
Depreciation and Amortization:				
Imaging Center	$ 32,032	$ 30,221	$ 94,095	$ 89,743
Digital Health	2,947	1,989	7,727	5,962
Total depreciation and amortization	$ 34,979	$ 32,210	$ 101,822	$ 95,705
Gain on contribution of imaging centers into joint venture:				
Imaging Center	$ —	$ (16,808)	$ —	$ (16,808)
Digital Health	—	—	—	—
Total (gain) loss on contribution of imaging centers into joint venture	$ —	$ (16,808)	$ —	$ (16,808)
Loss (gain) on Disposal of Equipment:				
Imaging Center	$ 153	$ 524	$ 739	$ 1,185
Digital Health	(5)	3	(4)	(2)
Total loss on disposal of equipment	$ 148	$ 527	$ 735	$ 1,183
Severance				
Imaging Center	$ 271	$ 1,141	$ 720	$ 1,417
Digital Health	33	12	77	1,740
Total severance	$ 304	$ 1,153	$ 797	$ 3,157
Income (Loss) from Operations				
Imaging Center	$ 37,530	$ 40,125	$ 89,611	$ 77,030
Digital Health	(3,619)	3,126	(9,515)	(2,667)
Total income from operations	$ 33,911	$ 43,251	$ 80,096	$ 74,363

XML 36 R23.htm IDEA: XBRL DOCUMENT

CREDIT FACILITIES AND NOTES PAYABLE (Tables)

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Schedule of First Lien Credit Agreement

During the periods covered by this report, the base rates, margins and effective interest rates (without giving effect to our 2019 Swaps) were as follows for the periods indicated:

Period	Base Rate plus Margin	Effective Rate
Through March 31, 2023	Eurodollar plus 2.50% Alternative Base Rate plus 2.00%	4.63% 8.00%
April 1, 2023 to April 18, 2024	SOFR plus 3.00% Alternative Base Rate plus 2.00%	8.33% (credit spread adjustment of 0.11%) 10.5%
After April 18, 2024	SOFR plus 2.5% Prime Rate plus 1.5%	7.78% (credit spread adjustment of 0.00%) 9.5%

As of September 30, 2024 and December 31, 2023 our term loan debt and other obligations are as follows (in thousands):

	September 30, 2024	December 31, 2023
Barclays Term Loans collateralized by RadNet's tangible and intangible assets	$ 872,812	$ 678,687
Discount on Barclays Term Loans	(15,234)	(9,041)
Truist Term Loan Agreement collateralized by NJIN's tangible and intangible assets	136,875	144,375
Discount on Truist Term Loan Agreement	(792)	(990)
Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment	25,989	17,011
Total debt obligations	1,019,650	830,042
Less: current portion	(23,378)	(17,974)
Long term portion of debt obligations	$ 996,272	$ 812,068

XML 37 R24.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Options Activity

The following summarizes all of our option transactions for the nine months ended September 30, 2024:

Outstanding Options Under the 2006 Plan	Shares	Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2023	911,411	$ 16.60		
Granted	—	—		
Exercised	(60,306)	6.15		
Balance, September 30, 2024	851,105	17.34	5.69	$ 44,301
Exercisable at September 30, 2024	729,806	16.62	5.31	38,515

Outstanding Options Under the Deep Health Plan	Shares	Weighted Average Exercise price Per Common Share	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2023	79,073	$ —		
Exercised	(9,377)	—		
Balance, September 30, 2024	69,696	—	5.0	$ 4,836
Exercisable at September 30, 2024	69,696	—	5.0	4,836

Schedule of RSAs and RSUS Activity

The Restated Plan permits the award of RSAs and RSUs. The following summarizes all unvested RSA's and RSU's activities during the nine months ended September 30, 2024:

	RSAs and RSUs	Weighted-Average Remaining Contractual Term (Years)	Weighted-Average Fair Value per Share
RSAs and RSUs unvested at December 31, 2023	762,083		$ 22.13
Changes during the period			
Granted	797,309		$ 37.40
Vested	(875,185)		$ 27.78
Forfeited or Canceled	(13,460)		$ 27.74
RSAs and RSUs unvested at September 30, 2024	670,747	1.74	$ 32.33

XML 38 R25.htm IDEA: XBRL DOCUMENT

NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		
	Mar. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) center	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) center	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]						
Number of centers | center		399		399		
BRMG and NY Groups revenues		$ 55,300	$ 51,300	$ 162,500	$ 151,500	
BRMG and NY Groups operating expenses		55,300	51,300	162,500	151,500	
Management services provided to BRMG and NY Groups		207,400	$ 214,700	673,300	$ 638,300	
BRMG and NY Groups accounts receivable		3,275,342		3,275,342		$ 2,690,473
BRMG and NY Groups accounts payable		2,155,708		2,155,708		1,877,114
Variable Interest Entity, Primary Beneficiary						
Business Acquisition [Line Items]						
BRMG and NY Groups accounts receivable		118,000		118,000		94,100
BRMG and NY Groups accounts payable		$ 21,700		$ 21,700		$ 16,700
Common Stock | Public Offering						
Business Acquisition [Line Items]						
Number of shares issued in transaction (in shares) | shares	5,232,500					
Stock price (in dollars per share) | $ / shares	$ 44.00					
Gross proceeds	$ 230,200					
Public offering expenses	$ 11,800					
Common Stock | Public Offering | Sold Pursuant to Exercise						
Business Acquisition [Line Items]						
Number of shares issued in transaction (in shares) | shares	682,500					

XML 39 R26.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Service Fee Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]				
Revenue	$ 461,142	$ 401,968	$ 1,352,563	$ 1,196,247
Imaging Center Segment Revenue				
Revenue from External Customer [Line Items]				
Revenue	444,775	389,783	1,305,707	1,161,381
Commercial insurance				
Revenue from External Customer [Line Items]				
Revenue	255,375	218,923	752,514	652,597
Medicare				
Revenue from External Customer [Line Items]				
Revenue	102,852	89,981	298,001	262,719
Medicaid				
Revenue from External Customer [Line Items]				
Revenue	10,894	10,519	32,804	30,279
Workers' compensation/personal injury				
Revenue from External Customer [Line Items]				
Revenue	10,232	9,745	33,088	34,785
Other patient revenue				
Revenue from External Customer [Line Items]				
Revenue	10,607	10,443	34,524	30,191
Management fee revenue				
Revenue from External Customer [Line Items]				
Revenue	6,242	3,922	18,255	12,203
Heart and lung				
Revenue from External Customer [Line Items]				
Revenue	4,696	2,441	12,553	6,377
Other				
Revenue from External Customer [Line Items]				
Revenue	10,314	3,768	18,918	14,248
Revenue under capitation arrangements				
Revenue from External Customer [Line Items]				
Revenue	33,563	40,041	105,050	117,982
Digital Health				
Revenue from External Customer [Line Items]				
Revenue	16,367	12,185	46,856	34,866
Service Revenue				
Revenue from External Customer [Line Items]				
Revenue	$ 461,142	$ 401,968	$ 1,352,563	$ 1,196,247

XML 40 R27.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Narrative 1 (Details) - USD ($)		3 Months Ended		9 Months Ended		
	Oct. 01, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]						
Contracts receivable, factoring receivable		$ 5,900,000		$ 5,900,000		$ 14,300,000
Deferred financing costs, net of accumulated amortization		2,400,000		2,400,000		1,600,000
Goodwill		711,841,000		711,841,000		$ 679,463,000
Loss on impairment	$ 0					
Intangible asset amortization expense		3,100,000	$ 3,000,000.0	9,400,000	$ 8,900,000	
Income tax expense (benefit)		$ 4,335,000	$ 7,220,000	$ 4,927,000	$ 7,741,000	
Effective tax rate		26.10%	23.10%	16.70%	24.10%	
Management service contracts						
Summary of Significant Accounting Policies [Line Items]						
Useful life		25 years		25 years		
Minimum | Amounts Returned to Property and Equipment						
Summary of Significant Accounting Policies [Line Items]						

PPE estimated useful lives	3 years	3 years
Minimum | Leasehold Improvements		
Summary of Significant Accounting Policies [Line Items]		
PPE estimated useful lives	3 years	3 years
Maximum | Amounts Returned to Property and Equipment		
Summary of Significant Accounting Policies [Line Items]		
PPE estimated useful lives	15 years	15 years
Maximum | Leasehold Improvements		
Summary of Significant Accounting Policies [Line Items]		
PPE estimated useful lives	15 years	15 years

XML 41 R28.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended Sep. 30, 2024 USD ($)
Goodwill [Roll Forward]	
Beginning balance	$ 679,463
Goodwill from acquisitions	30,729
Currency translation	1,649
Segment reorganization	0
Ending balance	711,841
Imaging Center segment	
Goodwill [Roll Forward]	
Beginning balance	606,557
Goodwill from acquisitions	30,729
Currency translation	1,223
Segment reorganization	(12,300)
Ending balance	626,209
Digital Health segment	
Goodwill [Roll Forward]	
Beginning balance	72,906
Goodwill from acquisitions	0
Currency translation	426
Segment reorganization	12,300
Ending balance	$ 85,632

XML 42 R29.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Annual Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	$ 3,161	
Expected amortization, year one	12,364	$ 12,645
Expected amortization, year two	11,915	12,283
Expected amortization, year three	10,911	11,833
Expected amortization, year four	10,766	10,818
Expected amortization, year five		10,505
Thereafter	35,324	
Thereafter		32,531
Indefinite-Lived Intangible Assets [Line Items]		
Other intangible assets	84,441	90,615
Trade names indefinite life		
Indefinite-Lived Intangible Assets [Line Items]		
Indefinite-lived intangible assets	8,500	7,100
IPR&D		
Indefinite-Lived Intangible Assets [Line Items]		
Indefinite-lived intangible assets	1,899	1,882
Management service contracts		
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	572	
Expected amortization, year one	2,287	2,287
Expected amortization, year two	2,287	2,287
Expected amortization, year three	2,287	2,287
Expected amortization, year four	2,287	2,287
Expected amortization, year five		2,287
Thereafter	6,669	
Thereafter		6,671
Amortization total	$ 16,389	$ 18,106
Weighted average amortization period remaining in years	7 years 2 months 12 days	7 years 10 months 24 days
Covenant not to compete and other contracts		
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	$ 261	
Expected amortization, year one	897	$ 946
Expected amortization, year two	610	714
Expected amortization, year three	315	427
Expected amortization, year four	225	132
Expected amortization, year five		45
Thereafter	68	
Thereafter		6
Amortization total	$ 2,376	$ 2,270
Weighted average amortization period remaining in years	3 years 1 month 6 days	3 years 4 months 24 days
Customer lists		
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	$ 318	
Expected amortization, year one	1,141	$ 1,234
Expected amortization, year two	1,019	1,104
Expected amortization, year three	844	981
Expected amortization, year four	803	797
Expected amortization, year five		764
Thereafter	11,108	
Thereafter		10,564
Amortization total	$ 15,233	$ 15,444
Weighted average amortization period remaining in years	17 years 4 months 24 days	17 years 8 months 12 days
Patent and trademarks		
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	$ 78	

Expected amortization, year one	311	$ 316
Expected amortization, year two	311	316
Expected amortization, year three	311	316
Expected amortization, year four	311	315
Expected amortization, year five		300
Thereafter	197	
Thereafter		164
Amortization total	$ 1,519	$ 1,727
Weighted average amortization period remaining in years	5 years 2 months 12 days	5 years 9 months 18 days
Developed technology		
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	$ 1,913	
Expected amortization, year one	7,651	$ 7,785
Expected amortization, year two	7,611	7,785
Expected amortization, year three	7,077	7,745
Expected amortization, year four	7,077	7,210
Expected amortization, year five		7,046
Thereafter	6,856	
Thereafter		6,117
Amortization total	$ 38,185	$ 43,688
Weighted average amortization period remaining in years	5 years 9 months 18 days	5 years 8 months 12 days
Trade names indefinite life		
Finite-Lived Intangible Assets [Line Items]		
Remainder of fiscal year	$ 19	
Expected amortization, year one	77	$ 77
Expected amortization, year two	77	77
Expected amortization, year three	77	77
Expected amortization, year four	63	77
Expected amortization, year five		63
Thereafter	27	
Thereafter		27
Amortization total	$ 340	$ 398
Weighted average amortization period remaining in years	4 years 6 months	5 years 3 months 18 days

XML 43 R30.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Narrative 2 (Details)	3 Months Ended		9 Months Ended		24 Months Ended	40 Months Ended				
	Sep. 30, 2024 USD ($) incentivePlan	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) incentivePlan	Sep. 30, 2023 USD ($)	Oct. 31, 2025 USD ($)	Oct. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jun. 07, 2023 shares	Jul. 01, 2020 USD ($)	Jun. 30, 2019 USD ($) agreement
Summary of Significant Accounting Policies [Line Items]										
Number of plans | incentivePlan	1		1							
Number of shares authorized (in shares) | shares								20,100,000		
Interest income	$ 9,600,000	$ 3,600,000	$ 22,700,000	$ 6,300,000						
Amount of loss recognized in income on derivative (current period ineffective portion)	$ 895,313,000		$ 895,313,000				$ 630,695,000			
Monthly amortization of deferred hedge gains						$ 400,000				
Forecast										
Summary of Significant Accounting Policies [Line Items]										
Monthly amortization of deferred hedge gains					$ 300,000					
Accumulated Other Comprehensive Loss, net of taxes										
Summary of Significant Accounting Policies [Line Items]										
Amount of loss recognized in income on derivative (current period ineffective portion)									$ 24,400,000	
2019 SWAPS										
Summary of Significant Accounting Policies [Line Items]										
Number of forward interest rate cap agreements | agreement										4
Notional amounts										$ 500,000,000.0
2019 SWAPS | 2019 Swaps - Interest Rate Contracts										
Summary of Significant Accounting Policies [Line Items]										
Notional amounts										$ 100,000,000.0
Basis spread on variable rate										1.89%
2019 SWAPS | October 2023										
Summary of Significant Accounting Policies [Line Items]										
Number of forward interest rate cap agreements | agreement										2
Notional amounts										$ 50,000,000.0
2019 SWAPS | October 2025										
Summary of Significant Accounting Policies [Line Items]										
Number of forward interest rate cap agreements | agreement										2
Notional amounts										$ 200,000,000.0
2019 SWAPS-1 | 2019 Swaps - Interest Rate Contracts										
Summary of Significant Accounting Policies [Line Items]										
Notional amounts										$ 400,000,000.0
Basis spread on variable rate										1.98%
Minimum										
Summary of Significant Accounting Policies [Line Items]										
Share-based payment award, award vesting period			3 years							
Share-based payment award, expiration period			5 years							
Maximum										
Summary of Significant Accounting Policies [Line Items]										
Share-based payment award, award vesting period			5 years							
Share-based payment award, expiration period			10 years							
Restated Plan										

Summary of Significant Accounting Policies [Line Items]	
Number of shares authorized (in shares) | shares	20,100,000

XML 44 R31.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Effect of Derivative Instruments on Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]				
Beginning balance	$ 1,092,840	$ 761,004	$ 813,359	$ 491,452
Amount reclassified from accumulated OCI (prior period effective portion)	986	921	8,242	2,765
Ending balance	$ 1,119,634	$ 796,158	$ 1,119,634	$ 796,158
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest expense		Interest expense	
Interest rate contracts				
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]				
Amount of comprehensive loss recognized on derivative net of taxes	$ 0		$ 0	
Amount reclassified from accumulated OCI (prior period effective portion)	986		8,242	
Cash flow hedge, tax amount	400		2,800	
Amount recognized (current period ineffective portion)	6,755		7,429	
Interest rate contracts | Interest Expense				
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]				
Amount reclassified from accumulated OCI (prior period effective portion)	986		8,242	
Interest rate contracts | Accumulated Other Comprehensive Loss, net of taxes				
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]				
Beginning balance	(4,369)		(11,625)	
Ending balance	$ (3,383)		$ (3,383)	

XML 45 R32.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Narrative 3 (Details) - Heart and Lung - USD ($) $ in Thousands	Nov. 01, 2022	Sep. 30, 2024	Jun. 30, 2024	Apr. 01, 2024	Mar. 27, 2024	Dec. 31, 2023	Dec. 12, 2023	Sep. 30, 2023	Sep. 20, 2023	Jun. 30, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Line Items]											
Business acquisition, percentage of voting interests acquired	75.00%										
Milestone contingent consideration		$ 632	$ 632			$ 6,879		$ 11,099		$ 14,358	$ 11,656
Contingent consideration, liability, period	24 months										
Contingent Milestone Consideration											
Summary of Significant Accounting Policies [Line Items]											
Milestone contingent consideration	$ 10,200	$ 600					$ 2,300		$ 1,600		
Additional number of shares issued (in shares)					95,019		64,569		56,600		
Contingent consideration settlement				$ 3,600	$ 4,600		$ 2,100		$ 1,800		
Cash Holdback											
Summary of Significant Accounting Policies [Line Items]											
Milestone contingent consideration	$ 600										

XML 46 R33.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Business Acquisitions by Acquisition, Contingent Consideration (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Business Combination, Contingent Consideration, Liability [Roll Forward]				
Change in valuation of contingent consideration			$ 1,974	$ (4,112)
Heart and Lung				
Business Combination, Contingent Consideration, Liability [Roll Forward]				
Accrued expenses at the beginning	$ 632	$ 14,358	6,879	11,656
Settlement of contingent consideration	0	(3,402)	(8,221)	(3,402)
Change in valuation of contingent consideration	0	915	1,060	2,906
Currency translation	0	(772)	914	(61)
Accrued expenses at the end	$ 632	$ 11,099	$ 632	$ 11,099

XML 47 R34.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Barclays Term Loan and Truist Term Loan	$ 1,009,687	$ 823,063
Estimate of Fair Value Measurement		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Barclays Term Loan and Truist Term Loan	1,010,778	824,759
Estimate of Fair Value Measurement | Heart & Lung Imaging Limited		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Milestone contingent consideration	632	6,879
Estimate of Fair Value Measurement | Level 1		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Barclays Term Loan and Truist Term Loan	0	0
Estimate of Fair Value Measurement | Level 1 | Heart & Lung Imaging Limited		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Milestone contingent consideration	0	0
Estimate of Fair Value Measurement | Level 2		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Barclays Term Loan and Truist Term Loan	1,010,778	824,759
Estimate of Fair Value Measurement | Level 2 | Heart & Lung Imaging Limited		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Milestone contingent consideration	0	0
Estimate of Fair Value Measurement | Level 3		

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Barclays Term Loan and Truist Term Loan	0	0
Estimate of Fair Value Measurement | Level 3 | Heart & Lung Imaging Limited		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Milestone contingent consideration	632	6,879
2019 Swaps - Interest Rate Contracts | Estimate of Fair Value Measurement		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Long term assets	7,689	
Current and long term assets		15,118
2019 Swaps - Interest Rate Contracts | Estimate of Fair Value Measurement | Level 1		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Long term assets	0	
Current and long term assets		0
2019 Swaps - Interest Rate Contracts | Estimate of Fair Value Measurement | Level 2		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Long term assets	7,689	
Current and long term assets		15,118
2019 Swaps - Interest Rate Contracts | Estimate of Fair Value Measurement | Level 3		
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]		
Long term assets	$ 0	
Current and long term assets		$ 0

XML 48 R35.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounting Policies [Abstract]				
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS	$ 3,209	$ 17,540	$ (2,552)	$ 4,904
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS				
Weighted average number of common shares outstanding during the period basic (in shares)	73,494,709	67,793,404	72,587,321	62,113,707
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders (in dollars per share)	$ 0.04	$ 0.26	$ (0.04)	$ 0.08
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS				
Weighted average number of common shares outstanding during the period basic (in shares)	73,494,709	67,793,404	72,587,321	62,113,707
Add non-vested restricted stock subject only to service vesting (in shares)	233,235	217,238	0	202,082
Add additional shares issuable upon exercise of stock options and contingently issuable shares (in shares)	1,437,491	799,176	0	905,462
Weighted average number of common shares used in calculating diluted net income per share (in shares)	75,165,435	68,809,818	72,587,321	63,221,251
Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders (in dollars per share)	$ 0.04	$ 0.25	$ (0.04)	$ 0.08
Non-vested restricted stock subject to service vesting				
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:				
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)	0	0	680,318	0
Shares issuable upon the exercise of stock options				
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:				
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)	0	88,600	820,932	761,708
Shares issuable subject to satisfaction of certain contingencies				
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:				
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)	0	0	0	193,207
Weighted average shares for which the exercise price exceeds average market price of common stock				
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:				
Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)	0	0	0	94,346

XML 49 R36.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Narrative 4 (Details) $ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024 USD ($) jointVenture security	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) jointVenture security	Sep. 30, 2023 USD ($)
Summary of Significant Accounting Policies [Line Items]				
Number of securities without readily determinable fair value | security	4		4	
Book value of RadNet joint venture interests	$ 8.0		$ 8.0	
Impairment loss on investment	$ 1.2			
Number of unconsolidated joint ventures | jointVenture	13		13	
Management service fees	$ 5.9	$ 3.9	$ 17.8	$ 12.2
Dignity Health | Minimum | Joint Venture | Glendale Advanced Imaging				
Summary of Significant Accounting Policies [Line Items]				
Variable interest entity, ownership percentage			33.00%	
Dignity Health | Maximum | Joint Venture | Glendale Advanced Imaging				
Summary of Significant Accounting Policies [Line Items]				
Variable interest entity, ownership percentage			55.00%	

XML 50 R37.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Investment in Joint Ventures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward]				
Beginning balance			$ 92,710	
Equity in earnings in these joint ventures	$ 3,595	$ 1,084	11,308	$ 3,935
Distribution of earnings			(1,000)	
Equity contributions in existing joint ventures			1,496	
Ending balance	$ 104,514		$ 104,514	

XML 51 R38.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Joint Venture Investment and Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]					
Current assets	$ 1,016,253		$ 1,016,253		$ 579,276
Current liabilities	(470,130)		(470,130)		(437,452)
Net revenue	461,142	$ 401,968	1,352,563	$ 1,196,247	

Net Income	12,256	$ 24,066	24,611	24,341	
Joint Venture Interest					
Schedule of Equity Method Investments [Line Items]					
Total net assets	171,496		171,496		147,334
Equity Method Investment, Nonconsolidated Investee or Group of Investees					
Schedule of Equity Method Investments [Line Items]					
Current assets	64,175		64,175		39,819
Noncurrent assets	219,478		219,478		224,936
Current liabilities	(41,550)		(41,550)		(46,587)
Noncurrent liabilities	$ (70,607)		(70,607)		$ (70,834)
Net revenue			195,905	129,020	
Net Income			$ 23,949	$ 7,906	

XML 52 R39.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATIONS AND RELATED ACTIVITY - Valuation of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Sep. 16, 2024**	**Sep. 01, 2024**	**Jun. 01, 2024**	**Apr. 01, 2024**	**Mar. 31, 2024**	**Feb. 01, 2024**	**Dec. 31, 2023**
Business Acquisition [Line Items]								
Goodwill	$ 711,841							$ 679,463
Business Acquisitions								
Business Acquisition [Line Items]								
Total Consideration	54,046							
Property & Equipment	27,509							
Right of Use Assets	25,302							
Goodwill	30,729							
Intangible Assets	2,315							
Other Assets	160							
Right of Use Liabilities	(25,672)							
Notes payable	$ (6,297)							
Stanislaus Surgical Hospital, LLC								
Business Acquisition [Line Items]								
Total Consideration		$ 3,000						
Property & Equipment		504						
Right of Use Assets		1,468						
Goodwill		2,382						
Intangible Assets		100						
Other Assets		15						
Right of Use Liabilities		(1,468)						
Notes payable		$ 0						
Global Imaging LLP								
Business Acquisition [Line Items]								
Total Consideration			$ 2,900					
Property & Equipment			1,266					
Right of Use Assets			0					
Goodwill			1,584					
Intangible Assets			50					
Other Assets			0					
Right of Use Liabilities			0					
Notes payable			$ 0					
U.S. Imaging, Inc.								
Business Acquisition [Line Items]								
Total Consideration				$ 4,200				
Property & Equipment				4,025				
Right of Use Assets				5,597				
Goodwill				0				
Intangible Assets				175				
Other Assets				0				
Right of Use Liabilities				(5,597)				
Notes payable				$ 0				
Houston Medical Imaging, LLC								
Business Acquisition [Line Items]								
Total Consideration					$ 22,703			
Property & Equipment					15,826			
Right of Use Assets					7,929			
Goodwill					11,584			
Intangible Assets					1,660			
Other Assets					90			
Right of Use Liabilities					(8,089)			
Notes payable					$ (6,297)			
Grossman Imaging Center of CMH, LLC								
Business Acquisition [Line Items]								
Total Consideration						$ 10,344		
Property & Equipment						1,717		
Right of Use Assets						6,304		
Goodwill						8,501		
Intangible Assets						280		
Other Assets						56		
Right of Use Liabilities						(6,514)		
Notes payable						0		
Providence Health System - Southern California								
Business Acquisition [Line Items]								
Total Consideration						7,369		
Property & Equipment						1,378		
Right of Use Assets						3,441		
Goodwill						5,991		
Intangible Assets						0		
Other Assets						0		
Right of Use Liabilities						(3,441)		
Notes payable						$ 0		
Antelope Valley Outpatient Imaging								
Business Acquisition [Line Items]								
Total Consideration							$ 3,530	
Property & Equipment							2,794	
Right of Use Assets							563	
Goodwill							687	

Intangible Assets	50
Other Assets	0
Right of Use Liabilities	(563)
Notes payable	$ 0

XML 53 R40.htm IDEA: XBRL DOCUMENT

BUSINESS COMBINATIONS AND RELATED ACTIVITY - Narrative (Details) $ in Thousands	Mar. 29, 2024 location	3 Months Ended Sep. 30, 2024 USD ($)	3 Months Ended Sep. 30, 2023 USD ($)	9 Months Ended Sep. 30, 2024 USD ($)	9 Months Ended Sep. 30, 2023 USD ($)	Feb. 23, 2024 location	Dec. 31, 2023 USD ($)
Business Acquisition [Line Items]							
Valuation adjustment		$ 4,400					
Increase in fair value assets acquired and liabilities assumed		4,400					
Property and equipment, net		663,867		$ 663,867			$ 604,401
Goodwill		711,841		711,841			$ 679,463
Gain (loss) on disposition of property plant equipment		(148)	$ (527)	(735)	$ (1,183)		
Book value of RadNet joint venture interests		$ 8,000		$ 8,000			
Tri Valley Imaging Group, LLC							
Business Acquisition [Line Items]							
Number of location offering multi-modality services | location	4					
Providence Health System							
Business Acquisition [Line Items]							
Number of location offering multi-modality services | location	3					
Providence Health System | Tri Valley Imaging Group, LLC							
Business Acquisition [Line Items]							
Book value of RadNet joint venture interests	$ 7,800						
Tri Valley Imaging Group, LLC							
Business Acquisition [Line Items]							
Number of location offering multi-modality services | location					7	
Ownership interest	52.00%						
Tri Valley Imaging Group, LLC | Additional Paid-In Capital							
Business Acquisition [Line Items]							
Gain (loss) on disposition of property plant equipment	$ 7,900						
Tri Valley Imaging Group, LLC | Tri Valley Imaging Group, LLC							
Business Acquisition [Line Items]							
Goodwill	6,000						
Tri Valley Imaging Group, LLC | Tri Valley Imaging Group, LLC | Fixed Assets							
Business Acquisition [Line Items]							
Property and equipment, net	1,400						
Tri Valley Imaging Group, LLC | Providence Health System							
Business Acquisition [Line Items]							
Goodwill	6,000						
Limited partners' contributed capital	$ 9,600						
Minority partner ownership percent	48.00%						

XML 54 R41.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING (Details) - USD ($) $ in Thousands	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
Segment Reporting Information [Line Items]				
Total revenue	$ 461,142	$ 401,968	$ 1,352,563	$ 1,196,247
Cost of Operations	391,800	341,635	1,169,113	1,038,647
Total depreciation and amortization	34,979	32,210	101,822	95,705
Gain on contribution of imaging centers into joint venture:	0	(16,808)	0	(16,808)
Total loss on disposal of equipment	148	527	735	1,183
Severance	304	1,153	797	3,157
Income (Loss) from Operations	33,911	43,251	80,096	74,363
Imaging Center				
Segment Reporting Information [Line Items]				
Total revenue	444,775	389,783	1,305,707	1,161,381
Cost of Operations	374,789	334,580	1,120,542	1,008,814
Total depreciation and amortization	32,032	30,221	94,095	89,743
Gain on contribution of imaging centers into joint venture:	0	(16,808)	0	(16,808)
Total loss on disposal of equipment	153	524	739	1,185
Severance	271	1,141	720	1,417
Income (Loss) from Operations	37,530	40,125	89,611	77,030
Digital Health				
Segment Reporting Information [Line Items]				
Total revenue	16,367	12,185	46,856	34,866
Cost of Operations	17,011	7,055	48,571	29,833
Total depreciation and amortization	2,947	1,989	7,727	5,962
Gain on contribution of imaging centers into joint venture:	0	0	0	0
Total loss on disposal of equipment	(5)	3	(4)	(2)
Severance	33	12	77	1,740
Income (Loss) from Operations	(3,619)	3,126	(9,515)	(2,667)
Third Party				
Segment Reporting Information [Line Items]				
Total revenue	461,142	401,968	1,352,563	1,196,247
Intersegment				
Segment Reporting Information [Line Items]				
Total revenue	0	0	0	0
Operating Segments | Imaging Center				
Segment Reporting Information [Line Items]				
Total revenue	452,368	395,613	1,325,825	1,178,873
Operating Segments | Digital Health				
Segment Reporting Information [Line Items]				
Total revenue	16,367	12,185	46,856	34,866
Operating Segments | Third Party | Imaging Center				
Segment Reporting Information [Line Items]				
Total revenue	452,368	395,613	1,325,825	1,178,873
Operating Segments | Third Party | Digital Health				
Segment Reporting Information [Line Items]				
Total revenue	8,774	6,355	26,738	17,374
Operating Segments | Intersegment | Imaging Center				
Segment Reporting Information [Line Items]				
Total revenue	0	0	0	0
Operating Segments | Intersegment | Digital Health				
Segment Reporting Information [Line Items]				
Total revenue	7,593	5,830	20,118	17,492

Intersegment Eliminations															
Segment Reporting Information [Line Items]															
Total revenue				(7,593)	(5,830)		(20,118)	(17,492)							
Intersegment Eliminations | Third Party															
Segment Reporting Information [Line Items]															
Total revenue				0	0		0	0							
Intersegment Eliminations | Intersegment															
Segment Reporting Information [Line Items]															
Total revenue				$ (7,593)	$ (5,830)		$ (20,118)	$ (17,492)							

XML 55 R42.htm IDEA: XBRL DOCUMENT

CREDIT FACILITIES AND NOTES PAYABLE - Narrative (Details) - USD ($)	Apr. 18, 2024	1 Months Ended Apr. 18, 2024	2 Months Ended Jun. 30, 2024	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	Mar. 31, 2023	4 Months Ended Apr. 18, 2024	5 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023	Apr. 01, 2024	Jan. 15, 2024	Dec. 31, 2023	Feb. 01, 2023	Oct. 07, 2022
Debt Instrument [Line Items]															
Loss on extinguishment of debt									$ 2,080,000	$ 0					
Interest expense				$ 19,427,000	$ 16,115,000				61,776,000	$ 47,876,000					
Deferred financing costs, net of accumulated amortization				$ 2,400,000				$ 2,400,000	$ 2,400,000				$ 1,600,000		
Promissory Note															
Debt Instrument [Line Items]															
Debt instrument face value											$ 6,300,000	$ 6,900,000		$ 19,800,000	
Barclays Credit Agreement | Barclays															
Debt Instrument [Line Items]															
Total credit facilities outstanding	$ 678,700,000	$ 678,700,000					$ 678,700,000								
Debt issuance costs	19,900,000	19,900,000					19,900,000								
Amortization of debt issuance costs and discounts	11,100,000														
Loss on extinguishment of debt	2,100,000														
Interest expense	6,700,000														
Barclays Credit Agreement | Term Loan | Barclays | Secured Debt															
Debt Instrument [Line Items]															
Maximum borrowing capacity	875,000,000	$ 875,000,000					875,000,000								
Periodic payment, principal							1,800,000	$ 2,200,000							
Barclays Credit Agreement | Revolving Credit Facility | Line of Credit | SOFR															
Debt Instrument [Line Items]															
Basis spread on variable rate		3.00%	2.50%			2.50%									
Barclays Credit Agreement | Revolving Credit Facility | Line of Credit | Prime Rate															
Debt Instrument [Line Items]															
Basis spread on variable rate								1.50%							
Barclays Credit Agreement | Revolving Credit Facility | Barclays															
Debt Instrument [Line Items]															
Maximum borrowing capacity	$ 282,000,000	$ 282,000,000					$ 282,000,000								
Effective interest rate				10.50%				10.50%	10.50%						
Unused capacity, commitment fee percentage									0.50%						
Letters of credit outstanding				$ 8,300,000				$ 8,300,000	$ 8,300,000						
Line of credit facility, remaining borrowing capacity				273,700,000				273,700,000	$ 273,700,000						
Barclays Credit Agreement | Revolving Credit Facility | Barclays | SOFR															
Debt Instrument [Line Items]															
Basis spread on variable rate									3.00%						
Barclays Credit Agreement | Revolving Credit Facility | Barclays | Prime Rate															
Debt Instrument [Line Items]															
Basis spread on variable rate									2.00%						
Barclays Credit Agreement | Revolving Credit Facility | Barclays | Line of Credit															
Debt Instrument															

[Line Items]						
Deferred financing costs, net of accumulated amortization	2,000,000		2,000,000	$ 2,000,000		
First Lien Credit Agreement | Revolving Credit Facility | Barclays | Line of Credit						
Debt Instrument [Line Items]						
Total credit facilities outstanding	0		0	0		
First Lien Credit Agreement Eighth Amendment | Term Loan | Truist						
Debt Instrument [Line Items]						
Maximum borrowing capacity						$ 150,000,0
Debt instrument, periodic payment				1,900,000		
Periodic payment amortization increase				$ 900,000		
First Lien Credit Agreement Eighth Amendment | Term Loan | Truist | SOFR						
Debt Instrument [Line Items]						
Basis spread on variable rate				1.50%		
First Lien Credit Agreement Eighth Amendment | Revolving Credit Facility | Truist						
Debt Instrument [Line Items]						
Maximum borrowing capacity	50,000,000		50,000,000	$ 50,000,000		$ 50,000,0(
Total credit facilities outstanding	0		0	0		
Deferred financing costs, net of accumulated amortization	400,000		400,000	$ 400,000		
Unused capacity, commitment fee percentage				30.00%		
Line of credit facility, remaining borrowing capacity	$ 50,000,000		$ 50,000,000	$ 50,000,000		

XML 56 R43.htm IDEA: XBRL DOCUMENT

CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Margins and Effective Interest Rates (Details) - Revolving Credit Facility	1 Months Ended Apr. 18, 2024	2 Months Ended Jun. 30, 2024	3 Months Ended Mar. 31, 2023	5 Months Ended Sep. 30, 2024	Apr. 19, 2024
Barclays Credit Agreement | Line of Credit | Base Rate					
Debt Instrument [Line Items]					
Basis spread on variable rate	2.00%		2.00%		
Barclays Credit Agreement | Line of Credit | SOFR					
Debt Instrument [Line Items]					
Basis spread on variable rate	3.00%	2.50%	2.50%		
Barclays Credit Agreement | Line of Credit | Prime Rate					
Debt Instrument [Line Items]					
Basis spread on variable rate				1.50%	
First Lien Credit Agreement, Sixth Amendment | Line of Credit | Eurodollar					
Debt Instrument [Line Items]					
Effective interest rate			4.63%		
First Lien Credit Agreement, Sixth Amendment | Line of Credit | Base Rate					
Debt Instrument [Line Items]					
Effective interest rate			8.00%		
First Lien Term Loan					
Debt Instrument [Line Items]					
Effective interest rate	8.33%				7.78%
Interest rate, stated percentage					9.50%
First Lien Term Loan | Base Rate					
Debt Instrument [Line Items]					
Interest rate, stated percentage	10.50%				
First Lien Term Loan | One Month SOFR					
Debt Instrument [Line Items]					
Interest rate, stated percentage	0.11%				0.00%

XML 57 R44.htm IDEA: XBRL DOCUMENT

CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Term Loan Debt Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]		
Total debt obligations	$ 1,019,650	$ 830,042
Less: current portion	(23,378)	(17,974)
Long term portion of debt obligations	996,272	812,068
Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment		
Debt Instrument [Line Items]		
Total debt obligations	$ 25,989	17,011
Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment | Minimum		
Debt Instrument [Line Items]		

Interest rate, stated percentage	3.60%	
Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment | Maximum		
Debt Instrument [Line Items]		
Interest rate, stated percentage	7.20%	
Term Loan | First Lien Term Loan		
Debt Instrument [Line Items]		
Discount	$ (15,234)	(9,041)
Total debt obligations	872,812	678,687
Term Loan | NJIN Term Loan Agreement		
Debt Instrument [Line Items]		
Discount	(792)	(990)
Total debt obligations	$ 136,875	$ 144,375

XML 58 R45.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION - Narrative (Details) $ / shares in Units, $ in Millions	1 Months Ended Jan. 31, 2023 tranche shares	3 Months Ended Jun. 30, 2020 $ / shares shares	9 Months Ended Sep. 30, 2024 USD ($) incentivePlan shares	Mar. 31, 2024 $ / shares shares	Jun. 07, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Number of plans | incentivePlan			1		
Number of shares authorized (in shares)					20,100,000
Issuance of common stock upon exercise of options (in shares)			0		
Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares)			3,285,500		
DeepHealth Inc.					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Options granted (in dollars per share) | $ / shares		$ 16.93			
Shares issuable upon the exercise of stock options					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Unrecognized stock-based compensation expense | $			$ 0.5		
Unrecognized expense weighted average period			4 months 20 days		
Shares issuable upon the exercise of stock options | DeepHealth Inc.					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Issuance of common stock upon exercise of options (in shares)		412,434			
Performance Based Stock Units ("PSUs")					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Share-based payment award, award vesting period	3 years				
Granted (in shares)	60,685				
Number of vesting traches | tranche	2				
Performance Based Stock Units ("PSUs") | Board of Directors					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Shares issued (in shares)				121,370	
Shares issued per share (in dollars per share) | $ / shares				$ 18.64	
Performance Based Stock Options ("PSOs")					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Share-based payment award, award vesting period	3 years				
Issuance of common stock upon exercise of options (in shares)	235,227				
Number of vesting traches | tranche	3				
Number of shares available in grant (in shares)				235,227	
Performance Based Stock Options ("PSOs") | Board of Directors					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Shares issued per share (in dollars per share) | $ / shares				$ 18.64	
Minimum					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Share-based payment award, award vesting period			3 years		
Share-based payment award, expiration period			5 years		
Minimum | Performance Based Stock Units ("PSUs")					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Award vesting rights, percentage	0.00%				
Minimum | Performance Based Stock Options ("PSOs")					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Award vesting rights, percentage	0.00%				
Maximum					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Share-based payment award, award vesting period			5 years		
Share-based payment award, expiration period			10 years		
Maximum | Performance Based Stock Units ("PSUs")					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Award vesting rights, percentage	200.00%				
Maximum | Performance Based Stock Options ("PSOs")					
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]					
Award vesting rights, percentage	100.00%				

XML 59 R46.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION - Schedule of Options Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares
Shares	
Beginning balance (in shares) | shares	911,411
Granted (in shares) | shares	0
Exercised (in shares) | shares	(60,306)
Ending balance (in shares) | shares	851,105
Exercisable Shares at the end (in shares) | shares	729,806
Weighted Average Exercise price Per Common Share	
Beginning Balance (in dollars per share) | $ / shares	$ 16.60
Granted (in dollars per share) | $ / shares	0
Exercised (in dollars per share) | $ / shares	6.15
Ending Balance (in dollars per share) | $ / shares	17.34
Weighted Average Exercise Price Per Common Share, Exercisable (in dollars per share) | $ / shares	$ 16.62
Weighted Average Remaining Contractual Life (in years)	
Balance at end of period	5 years 8 months 8 days
Exercisable at the end	5 years 3 months 21 days
Aggregate Intrinsic Value (in thousands)	
Aggregate value outstanding | $	$ 44,301
Aggregate value exercisable | $	$ 38,515

DeepHealth, Inc.	
Shares	
Beginning balance (in shares) | shares	79,073
Exercised (in shares) | shares	(9,377)
Ending balance (in shares) | shares	69,696
Exercisable Shares at the end (in shares) | shares	69,696
Weighted Average Exercise price Per Common Share	
Beginning Balance (in dollars per share) | $ / shares	$ 0
Exercised (in dollars per share) | $ / shares	0
Ending Balance (in dollars per share) | $ / shares	0
Weighted Average Exercise Price Per Common Share, Exercisable (in dollars per share) | $ / shares	$ 0
Weighted Average Remaining Contractual Life (in years)	
Balance at end of period	5 years
Exercisable at the end	5 years
Aggregate Intrinsic Value (in thousands)	
Aggregate value outstanding | $	$ 4,836
Aggregate value exercisable | $	$ 4,836

XML 60 R47.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION - Schedule of RSAs and RSUS Activity (Details) - RSAs and RSUs	9 Months Ended Sep. 30, 2024 $ / shares shares
RSAs and RSUs	
Outstanding, beginning balance (in shares) | shares	762,083
Granted (in shares) | shares	797,309
Vested (in shares) | shares	(875,185)
Forfeited or Canceled (in shares) | shares	(13,460)
Outstanding, ending balance (in shares) | shares	670,747
Weighted-Average Remaining Contractual Term (Years)	1 year 8 months 26 days
Weighted-Average Fair Value per Share	
Beginning balance (in dollars per share) | $ / shares	$ 22.13
Granted (in dollars per share) | $ / shares	37.40
Vested (in dollars per share) | $ / shares	27.78
Forfeited or Canceled (in dollars per share) | $ / shares	27.74
Ending balance (in dollars per share) | $ / shares	$ 32.33

XML 61 R48.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details) - Subsequent Event $ in Millions	Oct. 22, 2024 USD ($)	Oct. 01, 2024 USD ($) center
Pink Perception LLC		
Subsequent Event [Line Items]		
Purchase consideration		$ 4.0
Number of multi-modality imaging centers | center		2
Kheiron Medical Technologies Limited		
Subsequent Event [Line Items]		
Purchase consideration	$ 1.0	

***EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

*<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^_VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90- !1M;*PD+$:W8+C7\2P4X&1@+;`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

*M]G4KV(I<;418A<@Y^213L]#D)@U%^#Z^!04]2L5VI,IBJ.!$+$^)[YT0YK&V MHSPC//Q!KDZ)UW.%ORN.7U22G^OY:"7]-9QJHZ#=_>VJH8U"VZU@.^.%7O) M7#:@MVFA5J(Q^/X[>N;]Y,+[1F+O8-L%;!M3'US+((-^:LCSZU*X2/%PZC4? M74AHU)%(G0*1%21F6N2AFA44?BG15X9X?AC86*-M9&A[(8"!P)D\]7*GH=Y4=#XT_DK-; <'8/;)F*PSR23P/5>-<2U9CS6SD2B84<" M](@K 'EJHF]1$Y17-<1K$@#UDR% MV6$4TOC $V<;Q?6>>/@@S FY2X-3%R,:?20C|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{1]=\]U(XHP]Y*#8IFF8OWYA"7^YZ]'> MVP>S^'DMU ?#T>4F?&9S)AXW# [F\&U:]+,.4947.,Y"SU57O&GV^H40U*"W^ M&[.7XN@;*%>>,/^A;]:+]QY4BEC"(J&Z".6?;MA2:)ZDCK^,73:]YZI&AY?MQ_7^1^F\=.8I+-@-3_Z,EV)U?- [8,E6X381,_[RC1T<S>]OI^/KA;SY M-Z<;2X @7V (:.&YC?VYF,6R>;H;$Z:S8?2\\I]7+F/R_Y(E_N/LIGD M;@&NYW/I[\F=?7MJ.J^"[.Q"2-VU9-15+!\QWJC?_V"7/BJR;DS==9PE52N M$EOOHYNP6 ,Y:2!2%^R?;;P+$Y8)XR3NNW++KE0FV(T\Z@?(O1SNCOW150C% MC@C@* NBU-1K,7.)!SZS1

*MJ30Z5HT/.=N$\1*PGS*A%]PH1Y:+-9P^?"]#]&X,9M.OWQ:#^S\&C_.)\6:]<\,LF3IKC(-?C8-_8I5) M7N?BM5Q=*F0WDJ"B#$(F3'[[VF2X+O%=KS5G!C-(*43F.0LJK8%5Z[U4&HHX M>P8)DUP%N0+H@*\&6WG3O=_"70QU/0>Y-.MF3N!"@LV:$:SQ!]\1#YO#./?K M02Z'_)T^)[1B!:"H(O:(V\RE 47):3#CR.,(VO$W"^^36:6D#@T/U-,G*NW MIK,UM)$5E*.OG"]? XB0Q,HJU(?80\FD[NQKL7"^@;M=.U)A%=L[>EQ"(,Q%F MS[%$EVW=$$V#3ZDN53<+Y.)R.I36F$5VSH[9BDD.+,$]SL(L4J$;\:)#JHY1 M3+5ZP&"%7- HUI#5KD1VVTVS'"E%&I:P^_^9R<,%.WFWEXC**U=&)(`40:GJ5@CU"%GAM@:HA=@-(O2Z)-?V0_ZI[_'9Z_65Z.UU,)^,<9H7HAW/:F7IK M^EQ3%-DQ6A6_F_!55;Y]N=,- \BTSE9K&P=!)28CO$0U%!CN*_]JQ^'%-5&PG M:I55C M8J07(+ZGU>PF,R?P.THK?+1-M1/O3?.&Y^7!U^!C M6K1*C9)UPF!#/;TO6 MS9 7>+1#"Y>D'@'T'GINOXE+3Y:K*# M#@RZ0K@&++8#]NYX[9?;(14143-(C,IUF :!BSTM]>AVOJS47;]#>4U=;*=N ME1U%^+,>Y,X=']3:P%7]!TY:KFR"Z]J%XQK V+[_W->R&<\&]XUC?6^)/(3: M\)#&8N1]NRI(U.[&=G?

N4#6F+4#9'ORSR[EZ;I9@Y:< "U/4\FJ0Q#H!QB 3_ "0HADV.9@%R9;IDYQ M81_N_X%B'>;JN-F<_C_['F\C_OW HX#]2)7:!6:M@G M8WQ\\-*4>W3,,>^+&"WZ38)!:L.1'DJU]=:O? O92;+PPGSDK*-](/?M!0-'-MHQFF?E=0UA4 .7GJ7:E>LE4J5BLI.)V^L@"*F93>S,WB>Y M6,B\0Z(/IEET\6L!YBK&UCQ9LKSXM3S$$J^?C?)U)/N!0Y VS 9T$^@&'8<. MI$8W.87N+,*9R'F2]%"56WDFXZ[C+81.88PIP>VJVV"'?.RZ76NBIC5YSOYY M/YQ&@0;N(A2X6B5D,/01(4[0H; F-+$36D->=53[6DFM,LL,@M ZQ52')

*($8M3.HP0PW%FI39O2L;W/[/U5O3YQK*U YE M-3,"GYH7_74NI;ZV-S*8(2?03DV'1S]*4+|(^1[FSW%6R/WE2K:#%YZ";\G<*3UP(GI:7:Q9*HBD#^?V*RUW? X4;]]*'Z7Y]\8'85KUW[YV=;)(+,Q+N ;@Y?> M&!/K9"KEG9U<9#TOL(* 0VHL \7'$@; N25"&; 6G%Z=T@(WQP_L9\X[>IE2

*M#0)O[/.Y#WOR",9S.B"FQNY.H>UG[;E2R77[U^LJMBXXY%TH8TLUF!44#!1 M/>G]N@X;@&9K#R!<-\+7 J(U(}&*Y7.UI ;FG257!%EHY'-#EQM'!K=,&%W M<6(4OF6(,\G@^FHXNIJ,A@1'D^O+BV'_%B>G_CT>V$'(RI F%R M,"RE_)!\(N^)3W2.J[KK&]1AV?QTG?.TRAGNR3F!LD&BX",)@["U SYX'CZ$ M%.%- !X^VX3ZZKTL0UB4('5^T3XZA!O!@&B)GY(P)*E)&.1E+S=Q)^]&?:J/P MO/W<9;7B;NWFMM_@B2YI"CT//S(-;@E>\N%=,PX^[S+^G\BVRA#598B>8T\& MLBC0+9ZX] XWN*2*+"E? #E@@F22+0 MAHJ,B?E+#N+7.G@:N,>!O]$7[9WTA:HY$YIPF"$T:'200U5]OIH86;I6.94& M&Z\;YG@U@K(!^'XFI7F8V.Y,7[,)7U!+ P04 _" "]B&Q9--BT^K,(!: M*P & 'AL+W=O?;

*P&J:U)GPU51,.CQZY M6^WNIV5=OB7I'IE2B!R]KU=Q=M59YOGFHMO-YDNQ#K/S9"-B^(A1=EVO0[3OZ[%*GFI MZN#,_HM)++,BR^ZODN2/XF*XN.I8Q1V)E9CG!44H_JR*@5BM"B9Y'W]6DW# MG,7 X\]H]N^E\=*8IS 3@V3U6[3(EU<=KX.6XCG_0W?*T<<#9 \\ !2#2#J -8P@%8#Z$=G8-4 M]M$9[&I :7IW9WOIN"#,P]YEFKRAM$!+MN)#Z?URM/17%!>!,LU3^6LDQ^6] MP7@4\-&4!TA^FH[OAD%_)B^F,_GGGH]F4S3^CL8/?-*?#24 G:'';8"^_/(5 M_8*B&,V6R38+XT5VV-\P MOBN]<'%V;OBFA@)IV)SC]CU#I&+,.!^!A\?3B%S_K?9^=^>_<09]! 7M.2C M#7P3_H./'CFTK+N!#!Y8)+:.+;|/.Q55'9]Y,I*^BT_OG/[!C_0OR:9MD09MD MO"6R$^^5@_>9B;TW2_)PA0K6:"YD/GX5\59 ;[&C<4]:HB:\]B#,2.7W==C M+P,P"_N.=PH+=!BF-K$=>HKC ZR>8><"=6VP>K;6/.56EF=(/X[P]%4I"

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

*ZC%+V&JZTHI<@^+F2.%F@I%BJP M,.C2T"%MS2F0@-0#0T>YC/BJ1W24S_P&?1\"%/],BCY)4Z6]Z78N0Z"H2H7< M$.]%@=I&V:)4(,9"!0A*ICTB.DC5I0#$\RW- "R:B4Q_4HA2;5>FXT%9RX>?) M&EYK0/W9#&OZ X QR].J$:@EB2K:.(0CCM6TXK7FQ&;168F0TF:CN@)JSZ5$ MF=@03#;R6HP#&M2R;:?Q|/^+X6S_J_PT68 M $K2L7U5?@ PBHFG)/0 @!'?IJKI$!NQ/-)@>BTZB5ET/J3):U3NR3\G^RA'M>?@.KSK1U=\9HVHG,(!@+E&#(P#9?+6 >3K^B_FPV&5X_SOK7=_+9'Z-)/Y"@;P7J'$G@_7B$IK/QX-?;\5W

*M)W!FT+)60]>]Z?# =+= M)!LS-+WMRS3Y68=]0]=A%LW1%RFJ%C+:PC1#LM=%V3),Q5?0G;M;](ZK^;G6 MV(,H/=YTU)E.ON$I&S9R2*TKB5E7!L.[Q^*E5[O^#*+5-

*A>+SWC4^9!'(111 M:S: CT*3MGDT5J9$M?8-Q_&AS>WA4O[/_BD?\-W3IRB\>-L.I-M]'!T SK-M]'<_VT"WRA:TRL:,8CM=GUHU$[-JKI_U,AHS.!QU$>M2YC-7SYDZTG%=GS(U*

MW@(D|B>U*9:L04XB>PV7:NIO-0]FIA5]/&3:,(?V%:UI99DNJ+2D8[G6;Z' MU=UJB+/!?H"S>"5PO$5V^F:W%M3T9YNVN_>*S\+X;M',\ND7O6VR!:VR\;,8 M3M>C5OD4&*

I,EZ5V[L3_X\]JTR1:TRL;,8CM=@[K=H.9VX\-OW"N>$T5'7%M[MH0?@J(.U_BD <)@PF6A4L0T!+=CL[VS(.T>!OE_;'C3NB&B[&]G"&,K]>DU:),M:)6- MM\5VN@9UST7-

*/=?',X2M/_E4.T0S &#,LIBZY0C L&7+'?VIZ '#8!,4]J.[1 M6<&U2%_*0YH9FB?,,.\=#SM\>S@(VB^//RK?7^,+ 0;^#_%WQWSK,EWTI[O*

*MP_0EBG.T$L]R*NO<@[YR[B]R9%,>5'Q*\CQ9EQ^7(1]0@+(WY^3)-]? M%!,(GM,-EN7FQ+.O=(YTBZDGM'+K{(A%*%GO*, MR;Z1*+6[,4VY3FA.Y#?2408M&RYRH[HMJ;*

<"4KB(BC/3&Q9OIF3E!F#7E'W M(8]OE=9RNB#0'?YT1\&]&,'_N&;3Q7S--MHG2%->CMR)8NJ'K$,WH6FD&]\# M'=,LTT0PC*\G3]/]4@>>>?S^S?RJT@Y85D73,L[_26"5]*

*(S!03#=DGZDY/|[2 MDQY/\ZUY)HLG.IZPEH'6>ZEX?@]&$>0I*]_DZ>3#60#PM ?@4P"N!|BO!#BG M .>M/;BG />M/7BG@$*Z66HOC N)(H.>X$#F^>R'>!#\]4_"S*2-\D7!!=]?*

*(L:X0ME%,:]fQV\,=-CD_UWOTOMM_M8893K1'GK'->XU-$4<@,"Q%-$O.=F7;!)2Q?A&KCXW#P,?#\WOFX=S9)@[EH#AGTHW!9?HU[VO\ 1<-^1T0 MZ54BO8LBX5R K,\@*0!!V?*

H;@B7'9$;*\R;^%W*E7]6M^:==D]LX&Y&$KN>/)@AW;-^6=-$ MV5W7Z;1;TZVLZ?[P2D##Y7(^&3TNAZ.["""UG:#X,(9E>Z>9K?>VYGTWA+C0; M_WD[NPNC^;+-

*G6XCVW5=7),T;H)LUVW8TT0%5E!/+DU0!P=NS1SS[$]84{$M M[N)Z;>R9*L, ^]K:Z[@^+6VZM?F3?C.V6^A!^#\K,_'?Z\M_BGHAMRB3*Z ;Z ML]X[,)&BO*^7!*

<5WQ85TQ15<;XO//!'YQJ- :-]PKIX+NH/]IVGP'U!+ P04 M ^ "]B&Q9K:!=$](1 "DTP & 'AL+W=O.SL[^X*1:)M; M2=22=)Q^^TO)]FD"$ 3:) ^F;Q([!WP'I

PCAP4.^Q';W]K:LNR]"N&YXL2ZJ'MS=GEZ_V_ =)%_=\'#U=]B8X M2+TM;LJKLOMU^TO3?W?Q2%E6ZW+35O7&:C^(-@=L&_QOU5]WSY[V MFWME=RL>Z_FWW#5^^,7-*

W/2I7Y;+:,(8K^KT_EK%RM=]2^'\Y0,\)>-7<'/OWZ M#WJV/_G^9##X6;3FK5,]7+;O;-V?QF,;LKXNI5?>^OF?EX83V'5S4]W;_W-_M:.N>.8N[MJO7AX/[']RKS?#A7AR@$>/"$

.!Q#Y@.C(?1P)4.(/&1 M _S# ;YMEX+# 8%T #UVTN'A@%#NTK%SB X'1++"L0/BPP&QK'"L2\GA@$0^ M(#CVBW/_^,VY>P<[_,KW?ID777'YNJGOG6;7ON?MOMB;;G\;Y-JLQL?

5UW3 M_[3]C>LN9^ ->SM.W5^GO M&-^T3OJ?NZK[70-+$;!0$W!P-#1=-$ MV5W7Z;1;TZVLZ?[P2D##Y7(^&3TNAZ.["""UG:#X,(9E>Z>9K?>VYGTWA+C0; M_WD[NPNC^;+-

WMI^,,W>SY?2^,EN=;]T M;D^=E]?5HNHT$&&&O*TWBWK3-?6] \E-?ZVZLBG;3NK13\F'@<&>1P89(_V MCZ[_*F^]S69'_5BLBLVB=+[M7=[>%KW =T[!1]9U>O'*H][U#7$)TIC?*

*R=Y)[M/[3;8E&^,>NO95LVG\JSR__ZBQ>Z_ZT;"DC8' E+'V#!'K;[-/\T&401H1X) M7E!\>CH D*HY$L:0.(Z$"1!L- -+HXPB@$T> C>L?F.$3,_B)YP=D;(:947]J MGU5-2DF22*

9,U6:A9%DKW+-E: AB>.O)E:,G1,WC)Q,ZYI%1.02-=5]L V\ M(/;#@3;R@O]H\!7]_'#UBA?Y#]%|M_TF7"-UZ1+2A,V1L#11%\IY[ME:995LEIOJ9$O5]-!N*

*M=&=*LB>T8_FQCLDS+E250VQ"11N[[TDVZ#UOVNUGW46]V1PR[ONJNW6*1;\L M;BNK>QEFV:GS,I0VA]+2 ^VI":GG>U2>F:&J.93&H#0.I0D4;3Q AHS0,X>$*

*MSQT@VD$!S0NAM+FGAGR)1Z@\Q2,U,R@MMSH#!M7D4)I T<96'\) SYP&SJNV M:ZJ/=P\3_+:HEDY7.YMQ %_I_B#P:GR*SBG@?P[F)G[,=FY2%H*I6506@ZE-M,2B-*

*0VGBD'&%A]"3L^8"%W.=DY^MAU4Z^G^=+M7%YQQ'.CVA@:64%H*I650 M6@ZE.2B-0VGBE(_&2%X5J_TZI>P-7:^KQ6#FW6IE7?RI;G:WM>O[*

*M3;ETVKN/;,6LBN;W[YU-V>V.ZXK/I=[W:F9'B!:?)OH=FCE:,:*50S@|)RJS-@ M4$T.I0D4;>SG(5/TS*"B[+,8W)3[E?;#1L++7L3KNBFKF[T_-4VV6?SN=$VQ M:5G"HID#1*

*MQC8>\D;/'#@.-KXNJL,Y5*SN'OX{6;2WSO6]QJ\V6R[!]?CFR;;JZ<;9E_]>R M=9IRL2K:MK]NROUBO"R:W7:\UF++*UH1O4.AX'1HR6FFF4,T,2LNA-&9U/3A4 M4Z!H8Z\/0;-*

*G3AKWN}>U?E3#K7/EMC4T3=0T*O0Z1>E> MNM"T8ZL6X?HSS-G?V_[N>S;5=VVNRVGBWJMS:,]-0(C/O7E0-HL=+E#]B?>MN+*

*[LJ1F!]7E4!J#TKC5U16:5E[BTR/[GR@M)2H,5L8Q7Y,W$2N_X#&>U :@\{XE"90M%/(&$) 8@X! MI9%@Y7XU]8]2T NDTH>967FRKU75T{L35]XB=&CW-(F.9*M"XSC=Y?#\Q)-"*

*M0*9I=^[%))%+073MHBCRI $G-.V*"+'BD'(${'N1%|;&B;O-"8=@B^.PU'!8 M\C@U>_JC.$R"4-X0"=7-H30&I7$H3.!HX\$P!&/D&65RIP>_FF%$H>?*ZYN9*

M67RRM575(%>D,A3I%I&IDR1T/!*=SE##&5ITA-NR0@\B>0 MT+3S=LN7(W?;R9 ED8>[]%^G8HX@< X89E#:'TE(H+8/2,'&F5!:2E18R6J%M!!-7,HC4%I*$H3*-IX7 R1%_D*=71$*

*MS5B(?) ,W(_)#C*M$(5,R@M^M3^@_@RIR*$Y@:&/7#@D7^=-^ZLS*D^=U:.%_M5,$38NH[RN+H*%A M)5F"M7,H+34DYJ#=(*^_M7$W10+?=$39&Y=*

];Z.90C4S"'VW.@,&U>10FD#1OQGX>@=D=J#A[1-4543>/. M?9)({CFTWI'4G,:]L/K(3)\ Q@:RD%I M*55#N2/51U#='$!C4]'T'@2*-G(OR)#-^9/[\&S<[ZM!F+;ZR*P\U=>^I@Y.*

M5WVDZYUD56C'@89?4%IJ?1895#>'TAB4QJ$T@:-C3[$7_[4,CLKJ=,?] $2].QB)!(?C8VT[0[]X@?^_+TIVG7C[I(-MKBS2M.MGT_!)U=_8%4.BY#_?(>.W-*

*@!;\L\M7O73IB4^>,-5F"97;\3 ;:,U[_^73F(9RRFKNR.1)75.@)DNF4,D,2LMM3H!! M)3F4)E]"TL7&'9,I_,A';B\N:SJ,3S/0H I*2WTUYPG#, F)/+EK\B#E'*

M]HU!.1Q$RC;V/M#6.6;PZKG% 3YNA>E^>H* YIEV8FF4-$,2LOM3H%!13F4 M)E"TL5N\,LWAU_/K0DR8R=/P|#8#$1+?37^"0@E@2M77D!E-.M#S%9\+P2MI>6$IEEIT[E4-*

H<2DL#-.Y E=.M3*H: ZE,2B-0VD"11N/CR$S M#++Y,J9UV3*BYFQ^Z\ET3]U&,X5]9E!:,G4&#*K)H32!HHTM/*2!@3D- MS.KFNJRZNV9OXEV115,MNEU=Q=*

[(Q6;Y,)$BYW15X?]Z;?F=-A5^&T.926 M!IK7M#!E7-H30&I7=8H5%M++[N6:-#.R)T+Q>3MX68.5/9 MZ!;2*50R@(]P0.4$D.I0D4;6S>

*(94.S*GDR]^M&*A9WSGQE?)F5[LRB]^,7=BLFFM M1%.H: :EY7:GP*"B'$H3*-K8N$,&&9@SR"]6MQRH>9L7)DKALKE[DRT-C1:A MM Q*RZ$T!J5Q*$V<--*

+8^4,"&=B^,@Y3X1QH4C:,R'M-S9V;[':,S12]F4%I M.93&K'X'AVH"%&ULXR&:#.S1Y)]2WARH:5_<+Z-DKT/52BO-%]906DYE,.L MK@>':@H4,>5U(80, "_ .S">[N0C?NC)Q?*

*=[JSR(1D.7_)Z.[VSU1?(>9Z7A%0Q-C0##-4$+4X"GIC/-M$]1T3PXYH!W+-1U+HH1$T@]4:=]=>[$OO[M\OBTEOP!I5K|S7*M"/$!.?+0AW'(*

*MVD+@Z^WT#H'&:E#:'$1+0TUY'4W"V)779!E4-X?2&)3&H32!HHT'PQ"LA2]\ MO9U^ &C>]^8F>$F_@>L_ID;ZNR<>PF\J-8TO#T^^V@'0:?&VS@%*Y!E_3CGA>'!TI0@V'Q"T\B*

R^3A%JB$P[9E#:'$1+H;0, M2LNA- :E<2A-H&CCP3/$9N%S2_=>7 %E5IX\DJ#)&Y26AFH(EKB17-P*U^:,ME 3RS3DE9$QTGGI7K8# MW6(OF[D?

DQT)#1^MSR#ZN90&H-2,)0F4+2QRXE=@,3(`B\ 8RO:I3P#5IV4S M2T\VMBJKWR:=KIJK+IFNGVLFG::2>R7;2W9=6-BZZX M?+TM:LJ_U-*

M6F=57G=^B^VG&:ZN;V\9NNWKXYZU>V"^NNJ}?[+V_+8EDV MNP;ISZ_KNOOCFXN>?U\WO^TU+O\?4$L#!!0 (+V(;%F(9O=1J0D .I M 8 >&PO=V!R:W-

H965T&ULM5K_<|HZ$OJ7--R;F!N9 M4JPO!M-+,T,):9E)(1=HW_W]&!';9+T_?6WLL$">Z6D-]E?$MNLY,^N M5OO97>OB265_Y!LI"_<;-/\8V=3%+L/O5X>;602YN_53J;PRUIE25C*

;?;0 MRW>9#%?EH&3;8Y{7[R5AG'8N+\IGM]GEA=H7VSB5MQG)]TD29C_R:UZ^MBA MG>..#N_AA4^@'OQ[>D I M\3V63_G)-

=&JW"QUA[Z9KCYV/(U(;F54Z"E"^/OHB#PKY>KY(;?/R+WDZ MR'H=$NWS0B6'P8 @B=/J?_A\,,3))@"\ . UAS@+ ,X(5%#IJ(5A-

*GU1VJ8<#=K$]5[&!9'\KS&,*R[\\G59+;87!&X6LQOIE>C M)=PLEO#OZV2V7)#Y-1F/%E,{IS"QO'I*O*BTV.9FD*fDZ'|\#+6I5V%&53\PYX4+NWA/N-MO2/,8P+!,W[]<.Z*

PVO+\G(^;K.L,=KUW?PKF=],[D;+Z>PS&8V7T^_3Y72R MP^Q6S2KP6?6N_I#OPDA^[,"VS67V#N7?_\;[7O_PE1^H\G.#"!J PC7{)R&?@O1QUQ$$+A_!]VF^@ M1:0&OF*

XVJ[=&SC13OF[\5 M;R>TA-J@\!:]+/>X%#2W:8KY'+4H,:R6&3B5&)^Y0X1H6F66P6]9Q&L*^@C6(M5 Y,?O:5.5H4I:))':I\6F"++#%D+&>7,Q$"$F%P-ZADF!)R*W*@<{)^2/(10*

*MH,$"SIV".ZV5A*7:Z9"\$IW7 C3@?@,T(D1IP"VH3_B;O@JU?-;NOH SC499 M+<0]CI:VS><%7A-N6\IF86:P,B?6SY!6:JP0:XLLOM\?729.PH?23P"YS'+8*

M$!!^SI8!J@=S(#PHT1,ITGYPLB_.-3'<3IW,V7+Z,NBL(2=&O(4L8*(9(Q$I-NA;8B0UQ$Q?8&:5=DO$T29,'Z0.0.LPSLACN-W+G<>?XX@N&O&:LCIW_<)/(5-2B>

M^%$GY_]]YO=6LYU;U7 [?8'!|CFRZ[PQ'#0A(C)<3ZTA\IF7]6YE;6V828A<]FCFX6U^,#+_&;ZB$A1 MZENHGOQ:9&[;K#?T+ORI=_,]B'Y1M@?$AQ#IBI9^RH*OLV1/G!^,T-'Q+]^*

M-[3YJ%2YJ;2V6MKETR+6@4I>QE@(%H! M$RV.A]2VEPPY.C",6\QE\7BR_L)8P-A4_[+8=$;/O\P&N C?$ MR=W$>9NI2,I53M;92JK*JZ5BER-UK-_LVR%"@27%XX9 N9M*

#^V2T^JQS/?D M< M/LK\%6&-8T5N()C?9#U4T&CH;S<:OZ'6_;;/[_]'MYH;[MN9OI;[,XC>)=N-7<6G67H>A+57&(:E7:U!Q(9@#U=,L#3Z9)8,BY0<

M@+MS@]L3V$N9)>1&=^NN+&TDCE!\/PCXH)G)8(*4>GU;/#@'\[M](?%8$>QKO)BJ.+]+B2]Z9OO@SX/;$\N1MIPE8>0F)> O%-ZGK;!2CU2E9813

MVZU&O0NS(149#KQ=2P_\5M&%2-E@&Q+G+Y#XB:O\2H^_8YS=ITW"0\6LZ3DW MC,W=C'T%1&&H8Q?&]_)#S[G%CZR!FQRA8B9.(NA! ;0@M@5:8?A;_$]\#?!5

*M$D<&NN:/)/RA,DV8ZBD%1LGW|[V<9C]?+DJ^1#Z/]TP#Q_GD#]9>]9M+0S-_M"S?-G^NH=R|LZ$,W*DET@UZW_E#82&>;!COH,F1,3O@!MY0GPG"X<'/XZZ"3*

M_;YLV,LLB|M$=1:V6HDS;O-YD=$\K8UL&0NG 7W&BM93[HN),2T:ZPA>=Y MK>"$R#$.[&!;BL/SVXVGEQ?3\9+?7IA\[_QE]^L\X3RJNIC\^]OT^^A& M'\M <;>)5GA|+IKY R+'J.?

YEO J#"$+-R%;T;XC]Q(*/?V)LRR69!.K%:H" MTM[6F6S+_%BS?'#:BSI7P?Q>(&/[2I(7F^=4^T\X'I?AA 8U_S B$HU&R.]D^-EB

*3Y*4P]++#G_61J?.E]SL!8'F0B9N MHAK/A73:V$ELYV](@DTDBG0-8)#(3T9[&Z)'*A43]?"/OT9*1/5AB)_B7'W2[,CL\Z OFMPNS)0R&#GQ0PDTB=M.&-FV-1Q(0 M;(O ;;*

(;,@1^3Y%82'CY6,RGZOR9IO'ACQ=!>++%Q$8X3++*$)7"@A0E+6 GW-M18(/11"S$;1*(1RT& O:/$%@P@GQ@RG8V=)C,EO+(#8'S%O-QGJYNV9K7<#^ M-IBOEQ%|*

*LP;K<,?"\QW>5;, N88=<8&R6X)H14\/T=PJL<\"Q0OA.:!-[@.M M!D"16\KOBM.JJ|#1D&1*CP!+AWT=>#R?\Q&(Z=\EK*UL*|(^>FL]T]:?A^R$*

M0P(#6'B/;@K"D^K4Q'>LUKE,K7{QOYVU,]=DM8^YV!5:6M(#$Y:O5B^%/%^N^^1]S>,_@55\[F VW-M-]B_KQFL':0][>KJXG5=\0N:7=\5_U_ZK@T-()!W!.S:!\V8V/]-

G/$"Z_8^1'O%G8;!K5\[2X>(,]Z[",_RPC8%P-6"O^F M^FX1-W!0RQ>14B)G?0DQ^SQAY]+|^ M1TIRWMM@V#H,2Q (EG@\/G?/\<@C^PN3I8?]!2/T\(?^C\'TF',NXR)@P$"M&

M#-0;"XNX"-E^C,TFY744.9+Q2\6!]Y(@:L-']3[S2U*V&VY2=ECKZ>^6[_U= M-TA_+NGRL$_Y)7#ZML%;>^W](Y(A[*H'9 .B6G".G&G35]=3IM&OX<-{(KB*

*M91]MEBE[V\BX;"Z8';_<M;!U:VZ>%XVXMQ^W:.R)W7IC\FT:M3H*_MV4G\0-604(8E0<)\ZB5YSNNDWC M!F^=L_E0:0 :<6&Y(A7'/3(,%,?K<"R8L>PU3"*

@K##^Y$;K8TKB@\;KJ0.>YK"O-TEZ?.-I^\8*F> MY77/KKMF^@M02P,$% @ O8AL66H(.4S6! &AI8FET.S(R+FAT;>U9;6_;-A*^OE!Q<[V!6Q%DHW&;PG@.@YJ8(O;V$6[*

*M3P,E4C%7B51)*HG[ZW>D).?%\58,6^=@"0++#UAV/S[V1?*CATF3IR7#)"#WY M8?AC]P6G,BXR)@S$BA'#*!2:BTOX2)G^#*U6I366^4KQRZ6!T \[\%&]S_R*

ME'++#3@[EQKET%HM@,X^":?;&?/B;P3$\9B.)Q>+Z=ET/%I, M9^?P[L%_,/H? &+V MK;N$1<44??#T\/U]#[:5Z@*8BD$BPV7]ZY68]9.GA?$(7Q3%=PP7*1#,@$ M+@@]9Z8)4Q%*

[L&^U7NQUP] ?C&66$[%ROX++!*T!#9U)E$/BM]Y!(Y2Q^65O. M$:FDP-!["G.6&Y9%3)4Q;/M-M\$U@6A(>(H::TQS%A>&XL.$T%A^!*_#4V1-^$7XCZ#*?*

*8Z$:F"*8)XR5G"9QQ043,20]S M).$Q4]9I:ZGRKPGXS&:O"7FA=$$P6T;"G86CBJ)=.)P#A,K<[NAWU6LE6_F5 M_3E1$1%,MV8W*5O!*';AMI7?1#E!\(?=S>K:NM\^K+Q=*+/*

*@P5Z6A534J18 M!S&<.;797&=8L2\%5\R> 8K0-P6U|PF6E8+@<)^^6H?MMAJ6M5#%+NBURQ(B MF2LSC&\0$*MF|R/U+6O)+N ,RXQR@0V>$9.6TS MV1]BDJ: PW!N!#*

*<4Y)AJW72CDG4?HD'*G6G;*A5I&5A2&Q;-Z=^T*,VYS)I M-OUZY2G7&UW/_Q">M_NQ_HN:R(BZQ/.YD7F_Q&A(E+):&DE%F6HAUI3DFO7K M+P/*=9Z259\+-Z,;-*AL1=*

*(8F5ES@RNIZ,4DK78P%Y127%& 7L\[H#L"S"X M%!E;3UP1;\;1A -#-V6=KM?SMXM]+|@]^X?,'CCO6P.C,8.;FZT&_6 G%"*M9*P?YC<08"SNI.0I2S9B4X;E^Q>)_TB15)X >;:*D#*

<52G"!O%7ZE@\3!PI%2))$BAR?&*A,TYGCI:X\<;D?!^MZ2,FN MY,-+=N#B>,4_NT0$N'H##;AVRIX-OZF]'Z+/+AW+7\ 4$L#!!0 (M -+V(;%G 4>LY4U5K"J2M'SBS.

(C%9R8P3W(:LJGZ_S I+@5&5D"A=G';_^,A,1 M @P&#$("A<2>/B?+QH$4L?>SKJ%CQZ?_^SQUA2<_SUI;:PT^O#]'],__'I_ZO7__GY_E:X\:UXBKU(Z 081=@6?CC11@F6/B'

M'_SI/""ASD71V ^F]7KRM8X_>PFZ@^F82#-EM2&T10?KR6MT9 P5NI8,\@PNVG7D2$K]8<'.XG(FLFZO?#Z^2%PG5]K MDRB;77 X\,/'CROZR94?|'Y0)$G]X'AAA#P+UU;&VZ]?

*6!W<^)#\<3DT7'_P M#W4Q4O[PSV^W0VN"IZC^]@7.7+0E]39..]]2MC0R0[>'HRO*G[.V2J4HKR]W^]O?6]DAU2:G+RN(AV+++7 M.;(@&/G#VGIM[&P?2/ZP-*

*I"\^|WJ$+__(#")=/BL/Z(T&R3X/,_K:/]>==>3 M9?5EV4L8,:I80S%U<>[Z'R02 M)SHD<*SD_<_1/1[_6K/J!+1+FM(G8>>ZZY?O73(d +D]CP./,\?]JD)#N'T MN*

[HM99$_L\P)5UI?/JP]M04+VD35693=?,%18\U(<'8K54*RNNO\XSM^ABY ME,OSMS9]+?:!\2_LQ$% 7^>$%G+,_A5'0]>P;HD?7WVV33^I3\I1)W4:OBS9]

M+5GYH,K'OWZAO9/WWY\AOOV%?!8NW]&LM?ZNYO4"NL#UQYNU%L53NA?HBS?,_MI>GZAHQZ(LK@"?^&',_6#\-A1$A&7SP8]XCUFN)!T/&GLP!/L!>2<>(

*M_OK<&XJ"\7!TR6)N38FL_3WY_5N/$"K=8L2\%5\R> 8K0-P6U|PF6E8+@<)^^6H?MMAJ6M5#%+NBURQ(B MF2LSC&\0$*MF|R/U+6O)+N ,RXQR@0V>$9.6TS MV1]BDJ: PW!N!#

*I"WW5LLN;Y'S!^DTM/\|5|\%O@-MQ[/!>/'!"6+I$U6:.|SF3RO*O#SK!C7N,IY4V0W)&^W8Q<0EWLJ'S4\Q?],/ M5U7_HE%*

*<=>42*N^1C6;F2IZSHW.8!JZ3H>/!'=&XS@I7E=$&Y!9W;W.#[?1*& M1(TYH8OB=DYOY^1&/Aj5V\S=^]3_S?4?D+OH3W%[M=WJ"YW-ELJ)SETH[C.#?KX975X,K.K<)A3V*)?##*

<([\.0%AR67,]-?R4T.-<1?"'F,_+7\M3SZRP5V83LG@Q\>#L),ULA M\RAP$H3/<]6NJ/F0fKLX>?=&55'$5NN*F0^QN0M5=Q-[NR4M#ZFY MBTMS5B$7S%KN(N!SLW;A*

@PC%.'7O#VM1/(\NN;\I%3,' +EWR+%[Q UF M:::3)WV6;XG\;LZ~%.CL%=P%ZZ\|\ <%7IB+YW/;$ /IG18)W.46+1\TF"1"|\4+5N<MEZ3,[\WQ M0[CYKM'$"">P[6B=7S3,C#>XR.|S#*

[\9YI(YC/A62EXT^@\L4US[TL8?^2.[MKC.=U_,"%#)!@;L4W(7S@[LL'?>&X9Q^R:H.JB@ N_Y(R) MCJ(6,H\Y*5X)A> /^Y2G|SZ)A<*

!NZRKA?/$44AXN\@#0DSWD)>0O^"@%@*?.0E^*97 #^N$M]/&?97P'W:A2*3.1I;$;@+[W MT<==\I/;6+/R4. N[WKA_(T),]^R7D+_@H!8"GSD)?BF5P_KA+?7+KFUP*

*M&+C+NEX\1R#AR74>O"!8R*7,>);&;R@K*DJ99"VL'KP0B7L6.16M1;3N4;5 MN4O6<(N<[)@T"WARF#<':,#M1%^0;CKUR5]1H'EHI?<@N,;_!#U MO# *8CK(+2]*9M)-*##

^()%\'MW+G"$@^FMCW++UM[ZWB/QI.9TH..7&5X/ M+X?8BLE,Z!_S!_K;>^+EYA(H&6X34Q7'NTCN W26@[O&3[SY1%WYM4'G Q5V6

*MJ!K@XHC#W":9+H[#;UW551[O<557AV;RA!1N,UK54>|\Y.2NK\I'7&WI'@8,> M7'Q/ +35-1H\X*JK9 MN8]MWM9^_V;O\=[JIR.5[G=|ZD"GS.H&;,4@8>_$7Y-*

*WK>]@R_WY<$;MUM! M%XZWLP8LN2**VZTG<- @8)'- SVW1EY52"KLO8$\;). 'NX",/E?$V_F8^]+O*G$/Y^K%+'DA#=N=WK*7=]4"><15J^KEPH!RN_,# M0*\LT%,*

*M_$+QD@,WC=L=]SUX'@6Q$^8&]M1H[M)XYCPG%M*DWI(:!2ZG+4LH3W@$6MUMD M_P,O,-P,"4"44EG5KZW)06)F\4%FWG0!]_MEY=X@L^^1Z0*U+R@IK,ND!G=O-*

A_/78VIG\/F2 M'"GJ=YW;O/_E\56MRTI>#1YT;K/H,_EZCT/:8=C./9]=-%|SE5=N\\F7QI=<_MY97.9.Y.OG;_BIT9_;SO1SB\0R\T4Y25M_1BGWOD/Z V1|#^@0)[M,SG0G1;?

PYFI[FM[D22V^ V05 DL7E(E36X#?%SX\S!;UQ<7=.V MB-8.'?KHU=MK,)XE5]?T/.O$8) .[_@EY=@WHL%M7@!8PVUHGX(U5Z7Q?!K<-M1MS%DIL+D\5M",V-

*,3JNW$;YK[Q<$);R)QP MCK01MX$O?RS@0D-Q6Q?!'|\I-4 O$@-Q6Q?!'|\I-4 O$@-Q6Q?!'|\I-4 O$@

MWK'A(_"97UU8?)F(_=_P%/;?__/_A!_01@,@M6]_Z#K\F+$Od)D|%KZ P< MP 9?FI0XP&E3QQC(,\;$UP+]@<$2KA)P.#U!$8(=%9),#&FPG)+,;OH$;#=$ M\O8AG> Q#4 !M?(_BO^D(/GR|[_TBHS,\B7F ;^P_!18,6/IP_0C? MD#T<8*-<=`"XPS"]Y%L7K_'B 3@!@33&^!_ 6H8WCM,+9"EVH|\ *L3)$SB-T MZFU\^-^+P'J%!PW=V_|<:.!/7JGS8"K"[M2;8.D$8 M2?\"GS3B$B(7AGQVT%/#^$3)GY Q3, BR>>. ,D#2C\Q>@2=F_94C_1)5F2 MQLKP8Z>R(PUG<-9+GR=53,,3KGKIAX1F/QBC-(-9WSA/* HP0N+"M8N#]DO? M @=D2U++X*F:8W>)#$1@\+ , (&2)QF0O =8#N\|#<-CS?OP,6$/@^!S/'T8!X2H-M:=V-X_'8$|7E^B!*D\|<=*UD^"V)'H+:, Y!,IZ>#M2@III%^#.N3\"# MQ90F<=\%-O>'0Q8D'3A*QA?;RIKX(C\LA5KW%@4.>]YC -/C+RL=133PH!15 M4V6C41";G@82>;9M&DR4${!!.9>=L'K("3=KG69K]71#3,)/X@ ;+D=I-BC? M0MWR>'SH)0 S(_@O6*!GL"!![+M&[W|+GGU9FC(Q0WQ$ .MJ#2 FXEI M^:+#/X+EL2G2<)=@C/*,AD5B-X0\[33P0]) H WPTITL!MF%,1)?PSM*S[==MZRA*O;5ZNLNCG)64TN1BSE7MK6@/MBH=A4>eW5*"]O$"\G)WDK/&R"SOC#7Q7\=^#8[-<_AGA*W@?@-TH@X,W_B;=Y^X&D4+A'6CPV0MZV<#3.N;GN&]9*RD3Y.P=7TT,Y87[AR2]/ P P\$KL)f'ANA6P.\?8(PV2[-) M>"P@"D!P,;-C#F8 M $9!U,;'A$?TE_(Q_?2%S7\2A_,?@"I./P%K#]*:SS/|DNQ9$,_<3CQ&MIK|BN$8P!NPI=I-$-HQQ@G\@4$#'(@%"4/NB-_7*Z?#*K77K%UB$,!XB?E Q M,TH*DM7N)!XBHC4K/:2[T#S&8OXD.@%,_VYG HD@ P(@O&Z"'"] MC!BY(&OX&4TI?$T68;'0TZ/8 ++K*?EOF)@@,B,"P'@)#+1B!8%"E]F$F41 M%U0K5BSU[^#]7*XM?=[+R*=G@O88);P/>A?,O1=\\H9O0WGCA,N6XE+ZH/S"MQ_3'4I2\%DA^,2439[\$R(CB@|39H(D56 %_<: DS#W5,W"=`QX M5DQ,D2IN#%Z,+'>XR5Q^!|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|ZS =XLV.FU|~=M<4?RX"/8]V@JM51O_2_-P>XV'OWPP6JW3UNN+ M77W3L0>,?.IA+N>S7/K,:SG*0Y1*L@0VBMR,R[ASERA%W88R%@=D M2ZJF'jZR BN^M2-?? E58<>7,UUN=LXB\BBAOEM9>)ZE<3!TEJHHRQVMHG*4@ M8)\Q5.%#)09J'I-JD,)_NF4VI[:K2PBH33#DEH|\LGZL)X@I>% M*4,2+B8!XWOU^.Z>A7U<^Y 8TM>K6$@YCS"CR%#I/45)R?KH!B?8QV@\'|(S;O0XN9U/U"6&5R7,5!Z,_M)[Z7!*#",Y]<'_APJ35%@HCRK2 'X@'9,XMV$@^04"\SRJU.U:OG3TN+\C50 MI@)"'<;?=*${(]\N#Z=5EKD50?C/!*.D4]'-AD:1'[$IBIX48BI('2GW%[D]*X^|_>/@C;.M.<)?#85*C;..3.GAX3*.7(*>)[K0\QG+G>B)Y"&H_XJU$/(:I82RG M&?+]&'H#2PILYO|ZM$[WG3QPO$4M3[,LT9KXQBZ\CE:#Q]I5PI8=S0;P.XH V/N0OG9V0)0TM8-U) M;KMR5DF8#3"-@LEY%IBK\H$[=LS-[B\.0X$N5#*1HI@(F*:7AM=08[T\9X__+Z(#32A;_'V"6I M,Q)3W7##?[MHPW\UFL#2;GI5NBBY$_]A6G@TK?O^!@0<@%F\N+=?,RIN@|>;.MBWQ['WJ_W'8^]ZZO;A^EJ^OKN^_8"?@WZ=O=E!XUM.Q8M9U_2120OZ?@[7.QMP:/2,P'+B010ZMD>"K{C-*NTRQ>(Y>5O0BFT"^*0FQ5)]=O$+|K TX MBJ167JO0+A LM$;!0G?Z'@_+A%EOXF3;>8Cl.&-R@G8^G48;/\8,X.X+(;B8O&;=H? MBU53HZL4R59RRB,[1=K^Q@$L S,!KK-=LF1BO(>2K9NS-R M)HFOF:Z#S/=@=0@9]PX%U8D\UCS[Z+!;.XA2FP+['_9533OK 75PJ6Z;?'0WX(=2]\D?CW'[+E7/_3(G"KVIFK+Z5[:"LK!F%R-;(?0Z?W-MLY^)9/PE+=3D3E(]+!8CRA;M5!LPXBV^OVRZZ2" DRB=(3UX.DEX\/PN@6WF MS>D$B\K=X7Q5:6)$S2U!P=Q>6(;#N,+I*6^]3M#M0Q!-VD3/I*"B"D31!R M*,+*=^P!8P4V;8MZ2CSH*1]S*E1LH ^K,\;]^&]3G!K0U()#28>=H&A?[.^FZ[HNEDH()8O"(XG[&DYQA]"C MK6+H9"QF=D%#!>&ZT#"J\@4+Z9$YZ3D[G)CW4,!Q%D0 9\|& M2%8X"2.B1YGEU.9Z.KI0TQ?E=XM@RXKT8HPWX94*%TVOXJTE{"A"W_,8*P.9 M_1_&)NDYU7DI-WI:F);+[T@W16#3OS,P%-H4,,?W)#*N$%*ZB=D P0+6MLR MV5DF682$@N9IW|/<2RD4RO@FUMSCN1F1;.RP;#IN*]1>6GPO63I,,.7]SM<-M|HOA3H'S9TQ%E(DYM4",W+AH9OGV.U1O,*M#/UD&YS+N2G=XTC",]-H')KS MRK$N=9-G)ZV7I[(8>X.\|$P(-R|GI/9239TH|L5)I-* RWBN5IUI%B<5!S-# MR&U=RBS/G-R((7IO7G'S<67V 6WUH0@QY;^2U>,J.+F#[Y1]SBR11"EA=%0G-K4T(=<?(IZW-?\K-36 R?S#%CNHD1MKD1-%25U9IF<5^|U+NY;H41BJ M*#BEU9;?@O&#D@+_0*C.O -O6P.=M=Z,=`NC"<8C8?[DLPY0$WTD+IO>E MTXH=6 4P92*?VP-3!4Y*(7"P^\(OQ8(RR^E'V1!"Y@Y!*;SF5%"TB=D)7GL* M"O@[CYI8$RW3679Y98+E1L5=2N44[9*?Y MVE5=07%7,EB(^!XI?6ZJBHX=T<>0R;RRER\A^,OD#.?R)%=6DXB[M+ .61D3[O&QSIH-![^MW M4 R#IWIX .1HL1R^T#C \S!\,-?+C>14@81+VE/ MF=I2V!+5#\YUK4G(+M-?/H),!Q" 7CH>D8)N^CC;L@LMCKG#7/R=1V^>G7Q<[u;;ZM:X5>=NE+X^,-?1#VZT39*6KYYX96_!(Q MJ#T.]ME055Z*#FJ,.O.Y!;Y8X7"?/;,\\%_X]VIV?OG<.=&'.6Q\@\ZG!3WU MDI.PLPFV-YD4]X#>9UJM=>GI!D]UHM3^RH5U%X4U50C.E(XOG;.V,.?|>?/' MOC2WJ,9*K$PQ+RAJ$2^D.F#A /4A_=_|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|-$U2]X8J0I:G M";'#)UZ:+0I9*NVM:RM$R'+SO/=,O\6M3,IS\;T.GS[]MFN=I]SJ(D1YF@@[M?/K(Q/21W%#%PDX388?/YB889VG)]E&5^)& V&XA=0@\BXE'7JJRVMC:+18A MRHU\|CNS MZCUXV)Q&.7,XAZN'S1*96Z^ARL|V1LB,HIE5R>"=0V"24MTB#KF" M+PZ?%#+Y;AQM^[XDPH>O),0.GQ0R,2DDFTU1R';:"#M\,L5L4R"RK0B(G2;$ M#I]-.34 8KJLZE6!V#D$(C]{KR?OL*RNVZVQXY.ZF'+TUJ&6 4Z+IL;G\'05F"D&\X+S1 M>?BJIE83G*)66S9;NRIK$N@\|$?71AZ\H:F%*2-; X#6WW_H\'EB^*Q 2 F[MN\E*$S"ZLS|\U6KBOF6H-G>(;NZ6@QVUKJ@ LAOGR<$SD'_GYTPO.]7Y@=,BMDKO(=Q4(M&&6K2EKS:K4T(@HR&XA=OA(6[M!A8#*]AU)!,0]";'#1K;2]VC M-^66(0KF3Q-BAR]X;JO4:*5K $SB&^2BC>0DW/SN#I9O@-W0#^$0N-5AJMVX_[+LM<@;,]M6SW"W1*,N?P)7!MW 8&+K&RLXX"NR/U@6(Z@MD%L^^#V0|?MC-C6L>1%D=L[JZD6S"Z873!{_;?/I7=-B@=@V>6;E|$*=A=L+M@]^7L?OC:M@';3LEMM;ZVX^SK@=B=H@^_1A:\,,OP\&G=QK!HSH R5AP=G7_T [PEGPZ:.MN7:>8HI4&C#G&=|5?H-9#%X?X>)/KC_X,5UAD|/= 4K:5U'R&3Z* 34FF#4+ M8E:01W,\FWG1I=8$,?3N8%81S%?7UW??;Q\?I/ON=:;?WQ|6G+UW10GJ(^V%D MP80LUWV5X(?D#R4_#B1K, T1*$49*LB60&3[&Q/O9"Q"\#G11HW&22H#J4A M8%R*I?D9e2Q,KB%[AYZL?A+(4QH.19(62XX5Q8'ETTQC6PH%I8L^8)Q^0X&%V M[R*<^%[H|\R61I3VPU;>I4G@/P76&}D!Y+MP- B]+NF*=:E!SZ>D(-[MQ#P6T-S@WF?\AN=-XB",8?>B?<%\.0 64I\/P[AMD6,?!(*/-[LN(R9+YHX+R.=,TQI;CA?!_^_/7&+_A:8.:R?U+1N$1A]>V[> MYZ489BV%$^#P(>"5'1%[NN2$80P3BT96)+TP:60],T F3!LNA[OQ7?C]D0,R M)4"&DMC/"<"%P?OJ2C%$CHQK<_9N3=3"4L+!/2E(0 $UM5[DJRG@/$M1!POSU;@ "80V)3Q1P*2 X0AV"Q M@'@C\A?P%,9K3.K'KP32QQ&# M9P"8O=!*,(DP3MX-4\'G |:\!@[3G!5?+9#KI"?GQD./!<*V7"(F'Q.V-X' MN0&L2U,.G/ '/,6U\&6P:OB(_{B3C]+Q?@O\ 6-V"+Q8,#T<>L"&R (<+@* M\ Q41!K@^YT(90?Q HC&Z0UUXKT\(#N2=#5.5Q^%!4X/EJG/4N9G-(&(2)O"F!3^GL9,V4VM3VND*C"P@453LR2<*L+/*>*G'V5V1W.J%5NUCE%?/&I, F9VTR4J-4Q]+\/$ M(@2]ON@(3<<9@?;8 (;Z+.#FDM:0);6AZC2%&WAZ[BN%OM)D(!]*:.0&|[4N MK1 W7+#8/@)=BGA@A3+2Y73,B(*-P8;=IL-.8-T9ONY^[!?2=&^MR[O:]H[MW^>EW?/8 5>"%=-^R%0 M\|@]A1,9>,.FK.((&*+/^C999)F) Y)_H=4HVA)(%$9M*812_N8VD=]8!$+, M%2 TX10>]D0(>P0DB._ZO#$BI=/-#6V HY4ECQ$7@+:;*QS%_03)&0H:|.Y$X MQ_2?:2B,5NV618ORI=E0:AVUOM@,9>=B\ U#PUZ8]<6<KR#=[<6!/@/R(7K^!MHH^N/+O|KIB9H"1;RC3;*N_M>"3*M_N[;IW!Q_^3KFYOI.[_?.]J^]!]?01& M3U>$%I^ERT%,2F+;1B6__"5++FJ-/'.!80,ZP+$R2R?/;77 1.YKP_^D^%5. MB#(=R3LC24+0XSB!"YQ*C_(CB0Y ZL[!D'$(1O$KN0"Q,)4/R5&F36 EP#* M@/%'#CB7 3>5T2A>#1N!L3%POM/KOSA#-A.0 3H-+NTX0/!Q"B8\%VM!GH$, M7#..S6%<:C08_S46AH/7@.7]!70Q&Z&#XHS1RTWU-7H+F=Q)[,$!M %%M_% MN[A:RRU10H?NV/^Z/!,R(ODXG,ZC=:"ZPR?K8Z$'8\L M_?3|H7?,??@ 8^GK0]F'<'GMWMP\2R%+ISQ$C1TSZ%OBU&*6QDK@/1G.29<.H M5KINJ6--,@^LWRB3O2#O9,G!<|Q(A(7 .TA:# ,|>3!660]!^&A:I3&N)|^W M7T!ART42D.!"K.IP4Y 4,1C&XXR+G8!?#9XJCLQ&JVT(\)*>+3<&.TSZ+7E! M8@W06^9O %D^!A$0!]P?)TG]F+!S3]{-7H7 M/8 GG;DR"VHW1+58?W)$X6GY+ M#K(#B@T="*"%-K=@N9^C(!W-Q'IB%WUW8\+,PB#0;3<%^LUQ,AZGBV!)^?6 M<'[Z2R.0D)K*(, ^]_ 7+$Y?]X/"2&5;7 MKGB(-HQ=4!-@1*1&?^F:%RT!Q;\I+NH'Z KZ'E\|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|%';-C8HW..X76,$[M!?]@)QKLM8R%L?+.TN=MCU>T-CB63) M#Z\C&N9BHXGYU2YN,"$P6[2;<@.BY[""|%-26.0C!VFN5$K3I'MI""CR& [+U M-1NRIVY7]4+IJ++5.LU&4S:.O3>I.J(=#V\\6.7X*V(&=9-_I2X:LV6S=5 ME5]KF*K<;FS=NT P5;7(@9BJ"7*76/EC* $5EMEF5]U\OW\L!3.V15QQD"O%]CMXDR1A64IPY++KHAC158IGS5;X+.T09+.N.';US=*\"97F'BS\;B.=2>D>_"/>X;HC:2YAE-SC2EN)(O%I. $P[@]++'D)VJ5RUD M)ZR4*@U03%9,5DQ63+:RQ23/6R,O)}.\6RM:,8M1$IWA+Q?C]G5. MR(C7U_0Z?FNYDXKE3FI35AN["B[NB'C5KC$4C"L8=S/&-=8<$?UFQFW6.BU# M;F]'/T%(*W@VU/C6HV!/7&M2:P*Y$_X+,Q#L.V2HP+VT7<#E\|U*[K&U&&C M;U@-7:4;?54;I-LMFUE]4Q_8QC_5EM9HUI+-UN^,,=KTWKMJO+K|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{7$5+_J8_N) MV9FL;.}]X<0/W;9C'\)*/42B1C/!_&Z6W)MP_*$D8+"CQ,$B EJU3]M=TOT2M'#@6!&21ZD7"M\'<5TKV@I*$/RK"\]#H NGU1]VC*88@_>F2G@< %BF/&2A5 M4+|RE-\^^+-(>Q4$_N(9V8+T%2/|?I(L(3.@7;-;-DS^J#!B!.*,;@OEN,0==! MN=>5;6(,IUW>SVSL_E4VAGO0PRM:7VPG\"#;]>)6E(;B0ZT9XBH;8L?]28V MTU>V;\ AL';R6'MC79]N(L0:2E6.G!{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iR&)GM4!O+M8ADJS4QD)^QXG3Y04 MN4JMH\E*V1,Q=T?<_0ILP9*")=^1);?M8=#"1K*JK#7+ML07[*C84;#CCMH\MM#1J]MXN>V"HX$+!A8(+=[<)HZ4#'S:_#X5Q*OA0\.&AFH6T#&)#LUFVCX-@ M0\&&[\R&[]U/I85-OPU94X5W*!A1,&)1?FIAV]CV.2FLU-1EO?1QJD?"=)M< M1MF<7R,+A@__VLYSYQ_P{!U\;5/CD<3,699[\XC)SAZZYQI336 4M%8/V_ MC/92-&*2!Q=(8PK+2=E9?5=G')"NJ]W43'S/Q0POHE++)R!L8$ M^(WI+58?,!Y'RVI9R (>"#C*/YR/T?!E$N>V$4_8-;/"PNU^]7EOEBO(?)+ MG@Q @[DUG}_^TDD.AWN;),<#2#T_("!?QIA(PJM@3%9EQB*- A3|?W,LQ6I9 MS3[\9[;TX<+NZZV!K354S6X8AM%]_Q.D]"/*)\D?2M>H,[PH_,>O5J>(DG-_MG$AZ0V1>Z%SAP#=@MD7!HT9MV3U-M76AUE;PW8$0?!?B.MRP 8DWKJNEX-#.Z76/R^$0PX!OFU!>]D'^=M,$F[75>;>23D@8>7"'0G68ZZ^+GZMJ76_JA5\UZDKA)\L>9=9-K5GJ2)*ZQ5$S5O^5H^3GI[OOE-OGN_4 MS:==>NM,I_XX8N#IH9MWK@N1,!G.O<_Z0]F2Q8,"KS^F2)@:4)]C*0@[7$D M.9Z$_8O"#0X/.#9&3!RIC%;&BX+DBZ;]IF$^.+>?_LF$]A6C M7:E*S!;H.UEM[>]$C -$^TMU;Q ,*1ARKPSYUEK,MN!#P8>"#P|?C=EN"$X4 MG"@X\>#UF&U%,*)@1,&(NV5$N+8T(Z]"$04C"D;<&2-.JZ/?PHUXTH?<-'=U M,+/@QBJA4G#C?KGQ#6=UMG%[7DM6&KLZW[7[']%?F_C)S.08 +CL&I/UNQX"TM\OM,#@R]|[^999WF1Y/F1%/DPF_&$14RR/%ORHQ$+EN?63F}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|?C=EN"$X4 MG"@X\>#UF&U%,*)@1,&(NV5$N+8T(Z]"$04C"D;<&2-.JZ/?PHUXTH?<-'=U M,+/@QBJA4G#C?KGQ#6=UMG%[7DM6&KLZW[7[']%?F_C)S.08 +CL&I/UNQX"TM\OM,#@R]|[^999WF1Y/F1%/DPF_&$14RR/%ORHQ$+EN?63F}))52FYUVR\ M\P&2[6:MT]9+RCW1NQ8$+#\!,FV"4)(*;G_3A#^]-B_Y C)=]O6T<5Y;/1)XOV05($/Y8"#\7;EJDOE+K"!OO%(A? M/KIA-GAPWZS^X2]G>+PHTOI%XIF0ZMUM+I^[L>++7L";3;P_Y>L- 3;#,2V"'*8#0R:MG.5 MGA4H.FT4%<=BS 8&8-N[JK@1(#IQ$"UQI%LHM(]U@6(S@]$VU0DF8TV-4XU M!-($TK:.1REX-I8AZ_H[@FF[4$158;0LMJ6\6VQ+40 T9MT\DZ*9;Q;V?;,. MF2BP;%BZX(7W4A^CF.!=E UN")/)7DOQOB4BT M,"]H'D%)[$E6R*CO%T5HUSI&O77N%3(W[)FY_H394L0&(P]>^O0JZF26"Z.= M'EZV;9V,VJAU3-ELE3W2\QBBIP)KN\7:&^MD5$5 3$!LOUVX3%4ED)7=E"!M=]8@>3.T.*5/5$&.J4M*QO%Q@[5XR]H39"U1%CC;]7 J-$A4:C6Q7A] :V!5(4 M43(H@+9MQ$MMUC]Z)C=;K1,$TW(5X)1!RG;1,]7$Z-FYE. \8MT-+6V8'I/! M,%&"T]3?N01'Q1+GZD?F!0!V7(&CM@7=3YSN2PIPMC;@_&E3?DG[C:8(P[\X MX8QK+S057Y%M:$/XT";^N^D;3:ITCJ+T0U-\P%+/%+(8*RH;9<,-8CJFMW$[_1W MBPJH!L8'M'.OKLD'#AS/9D-,;\EUANR\BFS^\V\M55$_'G] 45!'4$=01U!'M4$=01U#G75T18[4KTLOLJT)[MQMSX,X/K_YOOWBN&[9/*G6Q.(.I>S.((($N M@:Y-T&4*=:!T5N@ZJ64XGM=[!=O^?UGCR\>8DT^F;@2+\62BB452RJ65"QI MI2WDYH$M9-J9W6I)(V1%>3GI[OOE-OGN_4 MS:==>NM,I_XX8N#IH9MWK@N1,!G.O<_Z0]F2Q8,"KS^F2)@:4)]C*0@[7$D M.9Z$_8O"#0X/.#9&3!RIC%;&BX+DBZ;]IF$^.+>?_LF$]A6C M7:E*S!;H.UEM[>]$C -$^TMU;Q ,*1ARKPSYUEK,MN!#P8>"#P|?C=EN"$X4 MG"@X\>#UF&U%,*)@1,&(NV5$N+8T(Z]"$04C"D;<&2-.JZ/?PHUXTH?<-'=U M,+/@QBJA4G#C?KGQ#6=UMG%[7DM6&KLZW[7[']%?F_C)S.08 +CL&I/UNQX"TM\OM,#@R]|[^999WF1Y/F1%/DPF_&$14RR/%ORHQ$+EN?63F}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|?C=EN"$X4 MG"@X\>#UF&U%,*)@1,&(NV5$N+8T(Z]"$04C"D;<&2-.JZ/?PHUXTH?<-'=U M,+/@QBJA4G#C?KGQ#6=UMG%[7DM6&KLZW[7[']%?F_C)S.08 +CL&I/UNQX"TM\OM,#@R]|[^999WF1Y/F1%/DPF_&$14RR/%ORHQ$+EN?63F}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|?C=EN"$X4 MG"@X\>#UF&U%,*)@1,&(NV5$N+8T(Z]"$04C"D;<&2-.JZ/?PHUXTH?<-'=U M,+/@QBJA4G#C?KGQ#6=UMG%[7DM6&KLZW[7[']%?F_C)S.08 +CL&I/UNQX"TM\OM,#@R]|[^999WF1Y/F1%/DPF_&$14RR/%ORHQ$+EN?63F}))52FYUVR\ M\P&2[6:MT]9+RCW1NQ8$+#\!,FV"4)(*;G_3A#^]-B_Y C)=]O6T<5Y;/1)XOV05($/Y8"#\

*DE66XRC/"B_(!@,!_A&KC('PX=,*W_BT=% M@,[<.G*=L1/Q=:(+X*L_V9BSIC/_@C:@&8NDFLV0G1L,>%0M<3'8,)CT!2QQCDGA2/lL!1(E^"[\X44,?WS K5!jX^/W??Z3?GX2Q+N $\H M#LA7F7] +MC%C6WT-R3R-Y9=^DH# 8,:"&FC(+0I6(.920KU@&],/!".P-H/ M%R8EP?"6A?MXW'?@/WD\+!TAML<8!*-UP^=/(V7(}!,,,,,W%%,B7Y]>,,%> MQ]PC3D/9_':<5UVZP@A92,XG;RU(EGD3F9Y#X BIV(! EY'[C*> N0A,<# M@?W!60G(%YQ>L# \Q^.Q?60=+TE$D8)^5NCCS;]9R&'&IV,_63!P;!A6 ME#RR+1$8R,PB%/1SE$G"B0FE<7WFDCKD[A83D!Q<*TO5X-KQ^ ^,B;(V<#7*M(CXDO Q+/^4GB+AD!#]KO1Z.4$U"]^-X%_VL:U'"#"DTINNRG4G M8D)7ZZ8!HF3B\PS49%A65/EY;[8KV&6%"0UP&@ ,;6<'[Z2RS#?V9+'P[LOMX: MV!H8:';#,(Q6^Y_@13R2C)I@S8B,L _?K4Z1923S*Y;!J)"1/@5 (T"A">V,";U#7HOC@@DVR"9CD:6HFZ|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|"U1?:T'1WB ?-{R)-(>F(>AD^!2?'"3+A4]#<3C(T)$VXA)B&>5,/,./' M?/"+@;"8D8FC"RD6J9DAB%@C9=*.^!BH:]%A3[H!B4"GCN;X6CV-> GD/?/QA/7 M?VDC/2P#,OS&#X>3J^7=0UH=24+!DZA<5MIPKH?/C"-TD,GLBW9,EY_%6KAG3N"TGTB)Y MT>-57fEF<E#0GW L!0:#&<&1(G1HO(!(- !Z$=ETI(@N2*!*>4[G"5^]S\H% MT@O\JGP8MK17%3#0T&&6(.4.U5*WJGWT:A4%7[^3NN_^#LY4[X^NE%2)?_AR M]_#PBW0A7?" %@(H*VE$\ !#0.N$(XPQ4$(;$F5924X6_$X)#0K$9'OT8Y-49J\$KKQ%+B]>HL(f'!]/"[IF)/1AKX/DG M#*&$/IJ- "MB24"]\VSQ$KP);B\ EP>S&E.A886N_R*-F/U4E();-[.I M9)R69:Y? CFURX7CUDBTV"\/G:BJ7KB.S?.YP.M&B(N^ X\J=[B>;9A-,/QFEP M6N_VL7O?27A,F>PBK2%*\%ZFC1,XH&,.'HJ_DU0XP|'/Y7AY"]2= 7TO4Y7Y M8QNG4J#V#EOVKO2=;Z- \ZY3QS%1U M1;71/BJWC92O=9IKJCP+%_2M603X0Q#Y?>M);?'4GC7+R9;T%(MI*@*72=-MEC;L.4-"3[RD?7B#37(FATS87>UQL,UI@6D>W8.AL[7-E?>38O67L"D\!9 M7E]D&J>A-4!5?.T!?NW>/CY(5[<8^;Y]I-W^UKV!JJ4%1JC8L73K%9V1-(#K MLB>PU6G!)4,' "M_7,L9)_$TGM')U,Y67 ,T_H>'E)%@,]3"?Q"1V/(D9/ MR1X9X#6I/8M*6! I*(T1%(*"?=/@QW_%29[2ZPDN(SS MXQM%N;V='2,./!'1^650V!RWCMA9>BCD@O$T&AYRF!87%XON2O:FRT&92S.' M-0XG"M4.B)!EM'&?4VI@[\1?6B+X2J)>93BJYRG.O;M1L+M:-MWG3O>W]^A M],HD;[RB%Q89EZU:QV@T5C33D-,*${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{YE7L?T M,2&5EDD*|!E67CURA -[>E (ZI% HGN TC'9HE&V<>*K IM*BY%W1-!ATOC M_L2F[0)AHOK/X)DIE4$$.#:K,C9F5A%:20A(.R\;FHOG)DD*LU128.,T@J" M^Y!4/X_;Y;*UN5S>WWKA

*MO|\N3';&A|^*C'!) U]7*4Q1UVKNN88G|W=Q=-1O1'C.YS0K"G|F1?2I\8U|45|W@&4C@A2I :E`MB0@(T]0D*@("(KV7(+T(2)-0@S21%@$1TH+T'GKO54 !:1&0WD$@H09(PN"=M%_/,YYER|\S\|[TO]GES\DE.]MEKK>]O[|W6?EIOD;"=/&K8UY_E8*U+=NC8 MCX3B(_RO7!+%AUWNI0#TQS+/;N$"R:=G_KD@$[?N3A_=5[R'?G+W-_@?V;O\GW:OU+Z%) */1U8Y.Q8%0 MXF'PIYE.[^R9" 83-N"(T\^T?>WR.T?#;<38GTL>2\"/;N1?5;O"Z1N4H=< M-(+X24=#%3N^'_Y3 MD?%)5^]WSX'6L\"\"V*H12G<15VM7!_L 8[EOTWM&2|G=0>L> 8YCAGM=8e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|P9+\?D^'FIH\PA|R^]& M'Q^\4I%?YV709?T?OJG]$M IV0@TR7 $LILA)D<0\Y(-+,U.W3P.B|9:#FJA'OY;G]^U7N_I7K0@[[+ .:?,FF8U&) MP[N9]63O@GDEOIJFCU^3'LT96L"G&C!0K\B<^QK(C=&|CN6\D:IZE&E_7K0D< M2GQPT]|KB0U!C*W6_BE<93ZE773G]B&W7 [A_M-RWW;!SS84T@,.\!F!80FN M F;/XRL,U#2A5,K+=?E,+_G7M<>\E*)SZS95MIYXLDZ,>/AF?]S0L%!P*2, M5Y1\TD\!0UJP%*_DKZ#2AGC5"@]+G1N4I-5TFP]]&HY.FSI,2WO1:|Q\MJ6 MPPO:@(%32:F)GWX2N'[Q? A.FS?QU\UV!/V*90H3C7KB;~&-GF8)#&~^%)04$(MFR6K%#!MR.X'12BA\[U$R6 MYE4CTEV;@E9-%4L?&D)+3S2N$2;FV3#Y_X8#)EZ^)C6A1<^-/ M>V*DC^(.6M0OY+]+C>U^(;(QOG&;R*4*FQ(64NT^59K6K,OO<<+?Z M#$K\LICA08A|QI:58P0ZBQ*#JK"6U KY>)'_H0!I#*: ?*KO7KXJ^>-J;8DA72OH5)#W&=4NL&O 3\Y M(4K87/O\GK|\\ZYH2FK[_-HEH$,O^.,1'1:/_L4MI1%JZRYQ/7E MI"(,|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|BE&.%,\@=:DH4H38.FWE^<$_Z 4-Z7.81T>1/K"U5_ M@0GA^:G:B#86AUQI/6=MQH&C:Q7KK?0SVVQ#T(WZ1/Y@1>KXOL[$ST=19 M%/;9+01#ZZ#QZ/;1^-V?"\L%!TLQ-CP'^(-E4P)'.O7*^_M[A77(D-ADM EX3=BA#!]N0P<_9"1G;S>Y_>\"I5^MYM.:_%43)G164YS$PW MS_B+2@769!|>B^)B4A6>(X_!]^)^=.9U;%C14 '4KK<)U QC5_*NJVA1L:8+ M)@KfV@1415_ C0%_"O^[7OW:W*@F:U3.,Y).*1IS/B%(S)!84;":@$Q 9=+@ ML^44B^SGV<:./FP6\Y2"UWY;R6K1R^- (173C0"INV)RG%:0C!OL?:N M4P7$SV_YXVX4#/% (RF,B=S>OAOMRH])B_T5@@.0XTX6]69C(W!\NIOOYUI:*# M64;7/;8O2F+=/)E?=L."9!T%AT$D_NX_P?8BUU26G2F'S_NF!.NKXCF>TEG3 MW\]A=[:]]AJ5?HXQA___L HH1YA:H(75>/IL,!DK?OGCYNI=X_[.ZD#T$N 5 M"UX,G#P("TQT;+*I]\V?,S1_SE?I-|!+LHM5=#*>[.Q< LCFH+2],[$?/=DD M#X#"2O\2S^&%_2NI6--#BC_;#Y2R?HST6I#W8=AWDQ.?3K*R\U2<&<]-BBODSYY"O:.9*..6^H%@X13MHZJ6DOGTE(9LX) MU RPJ+O4;#MY%"=^<*D=T7 (8Y-31ZSLCHUX]95]OQG6NF2S@>87.|V..& \: M=9?$LL>#:>LAU6(9TA-1T9/C>P%V2[^9\6Z02(6Z2^\3_>P7#/1W0:X\;9(VS6H7=^,ZPDR6.),M+;H_3;[U 7\]/++W7+_5"X->O8*E!<8= M$%V+E+%PD7?>L%MCF:WU/-F3#O:')W(&!<>_+)F"Q5(1F2/[+HK[_X?KVQ;:^%ZL+.D:FBWV[% M@T_>G/2.I[5FECV-O'..2?+QSF@A4J4.#>16B=%W-X<:.$^1!.-R!LNM!DQTX MD%2.^A+@#5@),1T;+%J6Z-1M)AC97P(&,MX.E[P.^-V5F'RH:(@[1^XH;$0* MCOJ;H&5[08R'-DRPF76VA&9"'I+D_K-[5O.KZ_QF&X166.+M#">L&J49IIJX7 ;_ MG//W_(2]QM&AVS*)8M8-S48QDZQ*EX#^%(-D@<Q)_KS@A6(7GKPX*5ZH*@!4| M41F(OFN W&.,.T-2+T05&D$?D\R-X0Y8E7/RZ\NL=OO0(P_]O&V-S%A1H M@GE$8F7%K8@:3EB%$|[E8=23??1L'Y'-=_- >:,/%YY*.A.F!XR5WI)L,G&1] MA.U-_K+B_BPW7H4D&**TM*;YQD-+F M01=Z8+,K'3 .9YNQ0-;-H67!CMR MB>COH(6%O^*7R1IM0YBI!V/'=:]YZO7 M(|\7IX8%<-+0P_9&SM9<'(<0],],I]?W,ZM2!K%/=>"QKE*6=7):T2PK"=TI_F^,Z8=",Y?2VWLY^2G-N_!*'"&6"/5^ Q M4GTPAIT$,Q/|_0^O/ISJ?SKN^_6!!1#76/5K6]WGV/?SBAHM[O;.W\[4*\^$ M83\]B$663\:^O0K8KLK(?4TO%B&1'*4JU"@>Q=YMGYYN0504EW#V&K?W$B1 M07)UK_]V88GB_XH^_J4A<]H:?P'*VM$-(/IRLF*3TK;,Z\W>R3'5+V1?/HD!T MY964GKL;?IC"O,\=P58XD0>E=%/0*.M',%W6^\"E-C'\<*]_[SN8Q86")F04[O"\"ZP]H6CA=*<^^@WLBB.4^IH[V%! M=-?YR"Y-0*&AD:EB3MI(9SB?]6*IGS); X#1?LQ61K1;+R"@^HH:U[B;LO[MMQT7F/R?5)F6I8\]+1@"_D-$#UZZ8%R;'LTERL_U;B/O0_$)8W0P'ZU @F? M?QO,P*HX&Y=:/4Z\T598<|[ZRKJ$X?=4V*,&?|\Y>@.>TF@W3*H0\CX5BR10 M? K@$\-9W0TY$E"\|>5)7O3O)/<@9C2>8&%6N=]DU9@EW5AZ3;4:?CW8;H/O*8 M_-;;@U[/NM^2<2VBIBX!%;=[*"R18@R4'C&&XA@[TZ(=:"SA8)F.:E@\P#GT M=9KMV#18=" {1)>TMT=8EH%.D9P2KNT L9X14E$HH9-.QLWS:'9#M.I)^8<8-V) MO71Q6_C/2C!!TJ%\^2S_WJ.AE28+LM+/1,?(3DA$G+\!5FL)QJ2DVY9G'?^J MZ"<_D&<0%"\(IVH'M;MJA#.O7"?(,.#IY:1LNJJW9NB/91:3+9%'I= MIB MIQ|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|I +1:H@SP?D'5]Z"[A{P M%E%RU!8$4KP:Q6&!HZD%7>UD#H&,Z+G5)%94Q+48^56>T]23HJ'GP"4[]YCN M3XQ-]#0^(G]^7KG8T[&VNUB25Q@87,)9E7;7OG'@@^M^?&VS6=VV$:X0'TCFY8D^=M[W|OA>^=\<#'@L"28">-:,)V6Z@X[#86.#(A[*G?;$B=?./Z(?RXH;S^NG M.C46+BXQ<7M_Z49!KEP G=6Y-?+(SX0ZTSR=>G\?Y6*W1'?B/>),@*[VW:-)1,H67@H+D1VNG0N^ENJ#7T((O{)5T"H8/ 9UOD8=\5"AXM2,34(-MNJTXQQF:J8;BD_K[+UT&.0BH(Q$%RX$78KAE_Z"7 ?DZYAW ?8Q AC..0 MJ_]>AW03WZE[UG=G-.:FCSV K\MS[I :;EX6SPD=Z(1B@+@]Y8WLBSCDZ;G0Q MW;PS@L0%OP-K#U!_AM ;5VH"CZP5H7:2D:C[fJ7L5E1L^)(BFGSH#X>?A=46 MQ#1PEI-JE D]#?-?UR:$UMVL&+3)>"4;PO^R**#HG0!ZDI"""(0 M!P[7A_3*Y CAA]O=T0Y)6F*Q,-KU#W8$4J=":Q] M_B+LP5B_E&;7[5J0,H?P0T-K [YR5@U[7*!=4V<@D 7P*F5P9P]6<([!I4M"L=X]^@WAR$K@^96@K_8E< +#\=3Y<>UDE2]3L$:*T(S\6\ES+:,3\Z='1=+V P$BHTS\F:^!"ZRX&/WPBL5IW":C[T#50N\^P]2HKVC"DN:=B72 /!@WQ MTI), {HN4:QLLPS=$GP!S$427 $<@&>$G,^LJ) ,'W6 S_J%'-*IS5O/EAD|) MJ#?P3\>=6IV^QS[!72-!(!*LH%NA^N(//:/ERY%K8]W&?8/E9\)2L!6Z# MQTK^2@W^5\SEP.>TT=,"H6^VFSP%\'.N8LO5KV1EMF-&@[M$?E;&K9>KRL9'R9:&;=- K,@)?7FC@!EX"0B&&5Q>$:E",H.8G?+XT:JT^ M_70EN_UPI!?)BOPN>MMGR;%)9PY8N22JV:<9X^@'[OYVI=369?]T.3_7:/!*(MQ179NWSNSI]O 7UYNKH_+BHIH- N@1WM*B!V+BVE]_5RGU&FD4)A8RETNU>!=8K^X^F3D$FD\;(HY&#BU MW]@OP5INI#@RH^F2?M&OT6WU!W@K\'O3C_ M M<9-?7B\,W*@;PE]]Z5.9"9]K5V3O7WPTKCQVX3/[|_+LFC')% MC@W3W3=/2N/A-(^06:TH]D-FJ$Z)R/C7DZP"BRJ.V?P;?^A M--$#]7]>[, 0.,/2&>;H'?=<:%A[*NUP$O:EU.U+_BULG%[.G(-(LVO#09/@ MIBR,'"> ;0C7H-K1-(* 1&E*_E@H^7;RL0&?R 1X?,,FGWA@0%%-:K3<1D&< M0N%MCW1L-,B/Q.2?NNT)@#OC|I-*%K7I? MO2&3^5EU!YGC6.M[W? $RP+>P^V7FC|1E'RVH]YC|%4^Q_U^+6S.-KCGQ|04Z M.7D74N59[L]P/8460]13$E(+(+G^XYV8;-8_ >W-;O]*!C)>C5K4N G<3L^X)= M-]VE.>3WPVK6MGXR_0+[]F_;;9(0-B2[*]V3(?24X?5+P(GO8HE?/PKABLFI-MEMSMWA4.NA"8 3\UE#A*^>(QE=XR?9B[24OMMH+B3\"2F"6BNM6LT39FUU-^I?C4= & MEOI4LND7PK2U[WYV3I656MG,;?HT1/?3A(]I-_^IM4LQ-OKM>(OI; M+,.#?LZNYGU:'/V4U]UX1UK.9*+5$O^#2\ "UV(@/QKY ':*8P!V@*[7QG_^)&') E?]8D'6C+CM\]DEY-WG3%2RYW-(=H8ZB:7A+>4=8FY MZ_,T'X)C0EH||SA26U6AK.+'1<)V.Y5+DS]$)6IR.!7GM@DK^S 6?VVI.$/K: M %-]I4*)TZAU&IO.2?/98(?SO78>YQ&VP4Q:.8-A. -X.7>>;XJES\)B>Q:[M;OPV#OF?*+YBL&/FK(K_+I-$_-TZN'|;^'H':@?72(WC MG@))0B\TT'VQ2O9ZPK3+ XLBP47"4_ MTHW7O[>$$:YD/LGK';_A?$R3U?4(11=4F>[%:0LZ#F KA))UL]95--6>?A!/ M^Z"%G9 @G>-5E62R7S%CSMK:PRA0UF2 Z@U\0^4-:L,J8$"VLT_(CWL2D6O0%/PY5TB;%HEG3E@Z#N M:?W(R?GJD$P^^8%D/D@9_!%+H$L2NRG[3(9&N7$0R0KJGM7+W5FP5@I_G;^F7_)-Z(^N9QA.;0(Z(3!EG%O MWU>]9\71UTD E)WUV(E)WGK{1,"Z_%R:B:<((L>9+[CXP?Z]?G$A(2,MWM M20YO=0<'HTXF\%7'2:U)*P2ZH8\%#4DFML0Q_EA A#ER@XDL[Y#%EJL'&%T"M;HQAE:]8"<1S">BX0@_L9(! %A;8G32?4;>P;[(YM=?]E5>E#(3LN!6X__]%!V!QR2K5C MHH5H*3]0<[+3*BLD]C(A2S:(=I?;(17,Y#$ MDPG!8U\%#9(8ZO1TDF>B9H'6P?A=#I?%;5*=EN(CE\=OF@KY^1-&))]?7 14 M@\(UQP,9"/&A"*,U=,$DY|HHY,F^)D73Y)+-YI#PF2LF8 ^^$Q7VJOV\BI MU(T6(_1IUI[Q\ [&VN%[;^=NCZOMD8 MRHV.-L8T5?1>^*)CQ(VGG]U+QOD0RSD#Q|6B+++%OC()(M48A|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||FV)*PL.[[18HOK%P*'!3,[[^])SWMAX"(+#.0ZB&X\RF5)W M'+X#.2;QONZ!KS0X-%0:.^VV<'\@3>))?HZTY3MC2$)OVZX2Y:Y*FK\,%]&0V MXA41(#HZ,R<5ZWURU1N?0\U@OZQ,+P$_O2?._?*WWAD+?=;W#(O7*#G7/QA&LQ9%MP4>0C@G8_D!5;MZ/<_M/-0']G%VB^4+3:AM:]D9T(D#1XOE]OPNJ#.$3 M/]EO/'5-[[^[=]]/M+9X^Y0CYBDD8S<'K*LNX2G1-*9=R\Q%HBC$"P@?US#^ M*\%N3FV!%XP+1 C4,#N+&4Y=]30/9,\S?!QAXF9W!>#3CI%K'DTV9$"7_]> M*&(<5?5S\[G"'83652S?Q>I:#&Z'\'>]/2/TT0!X4ZI]D3M)_2L7WF1 LM M5*OWB-K7]M,;/<[LCP?LSM:)N-EVE'K!7S1@IHYYG*UEJF'UEJF!V(]F

*5)X/_\V7E7(]>QL;OA=HR2[-MN,/4#^*\LM.'_H)?'3^90ZM{I3+Y@^5$*^IJF;1D?65=WPFBOFH\"**N>7P)T-MT3_R3D-=K_E% CN74]\NHH/ECLH*3Z#?)KA"ZF--!-@60;95Y5@GNBTDL1PE MV?!4E&]/F_3[QJ< P<'VI4E? SR#V@B.D?\|2P%&V0 SK%#]JOX9=Z";UU'RZ+H*>+RRWU)WGXSV_;'0K]0>/03Z@FHV=^Q]-F));WI5 AB2N& {WF54'S\9FD&I433QV";WRK]^A4\Y$7#[-<9]\'1'LB%;47/{WDD3;LW)C4^M5G(S90B M3.;2>&2P2W3!O85@DI/)@1;K8QA/@W%6!7?]fE@#HLE.U,8(5- -<78Q+P;+@)8 5.Z*EP-[4E]VL6G(3XIADU1@976GY%G!{ M@XOS^-\R;3V'K +-LB]H+IR,F&OF<[fQ30*RIEDsR:NS/$]K"C\\0'S_)Y5 MWP]RE_T_F8H43P1E;(*&KKAP^P;R1(QKMGR,B+0\YR'*<;(N@63+](M%!1O=>22\]M@:-U(M<3WEY>#EQE>;J1JT*-?:4+T%6;SPO(+N&W>(T3&&1KKNRSEK?&+]I.CGJ0)M"7+2 M,0DAFK&4E$%GT!?=4/'C_-K'3>/&A7$Q*$"]^7HY)GU]^NX->_43.V\RG6D8/N[M3!STMT2= 3,) ZH_!MC^Z@YU^KY49YDTW3L")R@=H^&$V2&>6W<&:|}@8;4!9 ML9]G;*YEU'W =/<3V .|)')E:=!W%;>=%6/TT_@>_O'VG,FBR{Q!<+NQSM M6KGZ[?!>P_MG)RX]J9<70U-'L;;$P]C\6J0Z*_F(;^<;"E?CZ_UF'!?2$!;Q4+Y31C%@T_)/7KKP:K M5WT"4]O66&|)%A$W_6=$/N:E<\(\/&BZ"&S*Q\CA5>&%LO BW$NY0&/6?MJH M@KP'NLG(UC/$5P-$54WQ(X=E'@_|=-!DEX>O(0:G@_G1'+]-B;>MZFJ?LO<1) M^'H*WFD9#UXFBQ1WS^_N26W]:$Y4UY8D%_"PJ^F'R$DR[FNNU3=,9AX?*?@L M\C=LL]=QX.>072L_4)E@6]SFK.'X,]G4^0RH,(^[C]G-7!9__S8$^[4AIAKK M0G94RK;P 20P?LJ"DR^ZCS0P,; !1EPS(,LCS"XPB%; O;2BJR0,Z5ZW@'^_MK8B",J\9"(Z!K??F'\(8NBW.>^3'B1%O"/>HBTC(V92KR% >>ECK6(6@]//'M(T-_W241)=3ZH)2^E,2#Z[TM=;M'|%A&YH&65L(M&8&W]HH[QS;]VO<;-"Q"-H$;$;?DNF74DwZ_B$"(F%ED[EL MA3,5/!,_J(>Z13/?;+Q6-LM/7"KUDH[2H%+R=X/R68VUB?0(L50(;@$%E.AL KT#\%1FL09[=]@$Q?=!K# M<2$X+?',E,9@"&3O/4%1J/\TG[Z0$Y1"8\-@$^>&W4 N<8$\#]++%Y^V8C3 M<9H$'X"\LUOG5TX,FDW/..^&:YQO.>J]>^YKQ!5OQ=^8MWJ!&*!Y M_0#!\5_8>_-XJ-]W?WRDHB(1E74J)$FBD#!#98^Q9&G(5)(M)/LV@^Q9(KL8 MLB=4MNS|GNPC8]W5B0GL.TJH_?YG7,>W]_OG_YGW]I.W_<_ 87MOM=3° MYW7=S^NZ>)?3<1?8LCK|J^U"[4W7;KYE@9!A;#WDV_XK?:WD;)^H%W!#E2 MI-Z,;ZU'"%R*8]+0'B[NF[>: M3=+/'9DH7G:)V#O\(#!.A]_\1317NX.[8TTDN{[RE5YCH?D4*K36RS@ZYD_,2 M=S;;^'LIA[<7^#-(:KD\/#6!Z@0T9L-.V$1[CY_7MB-"VQ%9L.+DD5O2!DD3 M&IL2N07-&+'@S#G+^%G2]@OPYZ-ES&KS]!>W;=+)6[/!0YY<199U/X)"/I4G M$?I^Z3Q1)XIA-7;Z!7?F>Q%2^> ^]>+$/Z\|)B^"A>O=] P=G#;X.3?0B'&^Y MC=UVS0?6\.AS+'WU.HDIZN>?T|\'Y4".D<#0 \)E=+/=UZ2+="DO>CC*^? MOF*LL!AG|39BEW7^MN'W47(/YH8]=8=WQ S]0)5R6QA^E7WM!&GLO"&3, 38 VG7-.T_)Z^>$\L\I:(V2> C@Z M:UG0A1QEF +%T1L_UO#HJM^Z#8=7?+!],89HN ?B6IZ[D3BM::W H&=KST@4 MOU1P#EH[].C%=]9VDMC"FJ;5IY6[@:"N9\Z.]2H?3DEO<91;8'j:]|(N[+CW M(@:>?Z, EAX8)J[",+H=CSF=(H]< \N:UPR^8WGUJ16_2N*_&+MYH-!MQL>$&B M-.7KYH*Z&G"O?;+4B@#^^5L;^M-JY6N|\>YU<*S?14+X,_#YW:E5Z? ,!5$_ M1LV.2N5/V!4F"]S)-5AP*TAH3!+!80--2CTYOL+67B/>6W:7H(0%/W+$?H@"\MB/+_YK;O70I4(ELLDL.Q-)4HU1W8]W9SSF:LG\X\#XECDKY;^S.(M;WI M5Z>*.*P,;..K"C,.JY<0RW'3^.'YU6\OKS='NPL.OBQ3#X-SV6S+S.\F$IVS MMGD]P$&P;8]O+??[<&F-ZB%.90,-4<&SJ4T2WZF^Q),W'L-$]C.54@/-_6N MKO0.-J.PS ORWS]'(GM*OO|!1Z*5(QZY@AS83 M*E6"G$1%N3.T\'|*$P8,\BA9*Y_FND+Z!Q/ Y\S ^P6?,Q[GZLBR-Q&=IM M6.G9F$ZMS/F]& [>%52R3H'NADLBS8R=*4TP]d<F."S"3ZN[];Y(QX\+&!?Q. M7[I=Y$N0#-\G8OO>6_B? \AAY1,3K^LLU\;Y$T^Q\+UC@_]B|=1P@BBYP=$ZW'RF M+@05?BQ$1|(H2$##P1? Q%#ILPGMQ%$(SY/?U3<\BDBY34@>U'],CW;,:V)QEG M @5/Y]8]!3 H/BG)A4TD+CP75 ,LV=NXI=&_MO-$:A@RL/|L^[?2D&=^Z/$C M*FQ7&$_G3@$ @).E2AQ+?'? ^H^1+_Q=M3/A/-BWTPY=B$&KXHHQ|.06HI?L\ MPHVTT%,MB,K)B7L>D5T5DS1UK=]O81ZI>Z>F=H M0L."1Y<*-&GZCC_.UNFOZC)G8C]]D1+!\$B'9 _>X!E'+6M96RP^C2L(U5 <[-MS*Q*5FQU+E'/>/5,^)\37BH)RA(5E% >T*2292N?PRJBWB'GMDO?.KLVGEN9:?09U>#O:O(V:^]E!#-=+K]3{'5^XJ&.!O=|*M02^P-I5 MV42H?,A[B.S(M^[!!>$3SC,A MLB'OT8,KPY<_3U.9%0FBBYCEG91 .G*-M2#)_#?;**N%)FF][,DHASU O?>& MWP]8.(=|*4LF_'+U;^KRL-E0Z2^BCVBDASUWDG5!:CDAUSWDG5!:A$>3*,RE.*38\54 M;AV"_RP)M,$41MYR^, 4W2I_$%?TP3A+JL1HF!{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|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{^WB3F_ES_.HM66SI$ENK_6J MV=YJN6W+GNOR_>[!3F|&>9$YD>G/TUE=!E*@;99W&>^"Y#EAVY>R]7[@5JM& MO;/>AR5K6M@#.FD^H/$8SU^6LV6BF0Y 9:YQ0Z6'T>=8U?L06B% .!:9;/Y6. MT/BWM/K1/|"2?4FXX!#-+[9H8)3Z0.F3+L8*FT_0[/S5]L&JGJ'N4^]IC3F MGT17HJ,D<5R/MC"?\E/A*))*\E4'4$F#"ZO4;Z22M;(%"3SA*'1"0EH=;CZ M<^Y#;X'*F@.H?P!*_:14\%PGB)!JU&RHENQ*8*UFT1?$2V=FP@6B[M$7[NB0 M17+UTZ(/^1/QF+P#H*P&?JB&RDILG'(,V:Q6^A_<$*82$6W&0;2CGJ7 'PG. M/1H^ VQT=4L%_Z(T_JWEZF9..=0/O3.MV9+R>>$*3-8V5(JH$("BPA05FGR9 M.]:0=8B&U /0)#!.#2\D/: .M!{A|J#Z1!Y=/]G<8*;=U.0M>)94Q.1V;&V*)1H6-!3?@RK2#M9?1;IAJ.VXP MA:EV\#.\,/'YW%IP3 S'7(_@P ZAP.#@E{B(59'8#=[G@1,3$ENJB M/>A@UO">.@SDU#ILS6.Q>81;ZIO #\QZU4.P M8CAC#*3>D]WI1KLU=/O&%=1F%'2ZYIY+N'=|X7$-UB3 LCTY=1!P;QUE7/2DL5@A-EY#RBU83RKI1>_50%D?YW:]E2QT M/UYKBJ9>0L5"8UID:(YD3-F'(HOC0\A<[N7O@##A4\(69@[!39J:MC^9RA@4\ MAS] (0TFZ1>SX/(*HFWU;H,;ZB'V0LV.TZ83XW$-WL)S9!1FR8)O>>YOY,^XB MICA.(G*) OA),&$YDV/Y+2/+;GD^LG9U^L2$4A?@T1!:Y"$-RZ/OOO.G1'KA JW, MO\#G0;A="6I9B_;O)\#P])"P9%\]H3$D]41(MO;%O\YUAH9?-*)F@09^QUC5.MF6V&\FTTY@V:4#UK+5;DDLC.)?YH2->8GB16;% MPI*^?L.4O9/?RK=- PL9DE?""4>IPG08&7LA3]\R)X+A_9&FX2RO2Z04+U=L M[2H?9]_(%PZ\/VW, ^ENI?D+J/&T8)/ 2%G MF(I\USE%4=770]fT?YSJ;&(-U1O<3Y[J(9Y=;>"CW|(G&E'=[22;4]ONAB>^ MM#[J4Z>WB5+*:ZA!{$H5#PJ $?=Y M!&P]T'OTI?$<@*0&$Q M130\ ES;Y1&,H_P!*=<9*Z0S\; HUP]'+OA8%O}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{@CR,O$\!>#GB'=M@ED,UEZ${1HU<@N! M!(G!$A>=<@:F.;D?%RD IS.O'PT/0V^$Y+@Y/BP?*.GGI\.&E&M'0=$/OK5Q M130\ ES;Y1&,H_P!*=<9*Z0S\; HUP]'+OA8%O}>Q='V*AJK7A4;U%\=!- BC M7(?))G@=':]@4)+]O\ X5)7Q#84-A!9ZQP#3ECGBMMPDV"DC"^6;Q\H3B!^J9!634W;.D MZ>$?DI &"N#\E;)!E2"B!0-. ^?N"_H_7YX1K3LC3@3+F0>-7Z0=S,I(/^06!(MI!XN#Q|)/4-*)5J931U!C=1O_Z47$%5? %O3E=8_%OK>(#2 46 M^*?TD@J-+B,[IYXB>OOHM[Z28@T@FC'LY"0M<.5]\7=MIR#>|Q!SWBYY#!O^96KW9\SGN,-#)PI!M^G0.C 9> L%4\(?C+#< M/.T6L=T.=4E\YIPUUG*25U3@@;.S66=51?OH'BPV]__/8<9_4I-J"P\5LV/ MO2%M:Z:AZ-%5ZGP*-FXB1F1D25ZJC_P=%2RN/LZC^]Q?@;4V4+99&<<&84= MCJ GA=80*+5B,)Y39]'Z:)LO!]%MY^E,C;LVO+_^S*,22]C#Y M*7VQ(CC7824G WZ\3GNE-CT':HV*ADZ@FIQM+C8U.5ZQP=$,T*(P+D5]78FVC MME57]0(G&%2DA>Y8;X'7IV#/OJPV4##PP-M2F;%<)97\IVM/Y31\(T2]|/O+E MMO%_]$;1HVO=L8MK1;-%OS),%%_47BS^)=HKT4U'|[5G/8:D,V3=_M- WTN[UO2N@JAPO%3\3S:+M]]8ZI%T:59]_ZXJ,I_:+522^]QC5M1#9N?T2&Q M?*0:0PO^)5ZF^=]6]P]#D-%4"P2E10O_VM6[#WW?3W/|_U#MWB-49UFF4L_:MGU94I? SOPP+&AQJZ8#J57]9"-(X<&/D*>D62U|"7^=QCR.V1H;=^KOV;Y K\N%>^I% %ZE?)-M,"N#DOGK-Y+X#(JLT:_"6BC_3 R2D;2{?AVVMY-?AA% M'%OSJ\P"TK9\@=>%N! M3U.#I-\21=+! [ZI5,,5&-B*3S/PX$8O1ZJK]=X2.*0/D7GST73B0)K(G-Y.Y ML,<*XILA0YQ"^\GKS')7^ZE.];D1&!*7OPS$"UL$[.S?G^(MS',X.J$SL&MY M[M!>9=-)#|\-Y]0W55<5N ;F2T*PIUE]"!0F3$-X/&8] =X.EAPIB+\]0&] MI=#1(E-EB9LJQW|$CIS%)=21,HG@F5/C*@_*^RSZ"\W\3SU.4GI_]\/'F^W\ M|GF_;!I 9TW')Q$-M^6>L4__=.GPYJC50K@NY'_T8/Y) <1: (1!$?B,;^6>Q MP?!Q>P<X-6$CVP1^BRN>RMT|\XYE621)W>1.W73S_RGRX| M!X?P>N[*X"\>A312 *<[7,;|VQ94PN%L^/)!8O^-BO0GT,8CK,"O%,/FQS+[MMLXO* !T+A@'::V6;4$63S:S'-^/|)ZNRBL8.#IFY.O)[,XU\$KZSLZ;!AN M3!^<@6W:!04&F@YTU7-M!A"R*:N:H9AD??1K!>!LI)<^;_7[G,&ATF'QN M%U-O2POWH.V 11024)Y8%#5DV+'=*#UXJH&W.99=2 M:>Q 7DGO(5/6OA03CHJ+RO/YNYUV9KO#^DR)_#1ISY&3-LY4?I\;12/-1RQ& MZKX. ^A!%)\)F)^_[6JKB;&N3CM;I% ^>|G%XB;00CVC%_22FR+ S>]8<++#E77C MRUX4P*W%#/*V\'S>U\B8B^^9LWZRX5_$-2,E<";%VE?N)H'P#47W%QKJ1Q MX;_/YR_I9;:V.HR0/6"B1=1+Q?-"PFE/V1=/$_A2YPWU^5"SZ,MLK;RL/AC>M[W/H>_SO,=G*.C[B,#:R>36=(;!:.G?5 A$W8*SP4+SL5E#,]-G(35;8-E&6 MNKJM\#D&6QMR9C.GQ%C]W:7B1'#YD>EVK/"T4A.K3F-^S]$ < B2<]AL"ORV M5@]/O!G92.8<= X0R$N]H.JKNM9?QHHXQW'@C5G%B>!U,)N=L7)RE:0#.G)B MX= ^N*S"EQ@R+'/(TEWJL@(P1]\ MXVZ@+L1CS_<\K.FD&@\)O<7E&D3,G)R_S>7P[\)3G&.+2CFB?2KV8Z+L!FW_F~7P[\)3G&.+2CFB?2KV8Z+L!FW_F~7P[\)3G&.+2CFB?2KV8Z+L!FW_F~

*2Q!$[Y]MV€M0Q'>0K=? M|K'DCD=D$BH>M81R->AO*7Z],X*+4GV]\EIA!.$&?@D&KL#80?1NLLV5#9.? M3:.''?3=3*1.P[5A.A?#@)V>4P\7:@N44LQZ/9OJ>6W>;*

M+X^Z)'#^ID"R=MR=KF@/@ <K$<^MFK/ QB=WMC#V@OFC:RC9OH UR:/;'U M797E4@.#B[N0D)#,1=YYN -\$L@NISG+$N'AVOB.&:K)KWBD?\(2I1PA$E)X M.F7[#-*

Q)N\/'!8(9]DI%9DH,+QSD3P24QU8MM\4Q$#.1@7W2ML8_SL,:;KA.B-Z4C,_U!/U13$!,Z.LZLTD M',PV4Vj53$<'F-UM>T;E&O1)W9[SHO8S^_M<<='>KLXJG(6>[@TW!!//':@

+R2#K9'90,9-MF.6GZL3:-W,2GR^OZQ!WB3U/N_;_@6WGJ:'O=NOC_,.1BGV27/W'%L-#!7H%_2/OGCPW4_V8/B2=_,VLB.]85DQ5&.X*UdB?)\5 M!DV?*

MZ7:4+M$K_G#@['';,ZZ:@[5MDA[+P7]2 /2%,COD<7 ;F8=HEUT*+UF9 M9/1B+MR0)K/T;J0$,D7F-5A;"MX9;EF)>U'@-/*WRJ0C5'H=F5Z]!/(N$BHFCFBQF;]V.7:+-,>:(Q!&>V1.B*

M_8?0->MU0\^;9-/;,XJV>_ 6"UOG48,W^XCW54>"O F,! ?EKYZ<" Z]4M: MT;/>&^X$;9CZ=FKMEG/"_,/2!U[SFG:E&^>1WX):NDQB.(.&%UV#=,JHEBD3 M.#<,;B;

<):.I\&U!P$]*US1#]T(_?0K=)C>A(C (1RFC+W)EN;4[LZ2+6AU M>!$L@:]1,3=Z0E\U56?2^:19'1@\;'X0D.U ZV|_ZH8&=N\:L.X@UMKGU=IE^L1;M)_!7C;G422L'(!2\'@-

B"H@#$9>/ MTP(0/Y?^-^0"$'D3]^6&6EHUS]B6NA$%25L(U/[4[(/N2!^B9OZ9ZUZR^:69 MZPGR8=\MMJ >-2&VHC^/9TM#=VQE<;[XY'QV MA79QHCA:HGNW16VDD?7P-]?*

8!\9HD$* M=B6M196W*0#\E9I/4Y-XG%7%O&W)-R!03P1Q;87VO1#8YZ*Y3;=GL_0+/@.9 MI^&0X;T'Y-)/3?IKS[&#Y_6V2_,*8#D>B#4@)KKCD6;6"I'W/9;U$7(M45BG3(H%L2T):I;

L.G6\O@E"\ZU2 ,K%!N].@+YT++!77H&K7XM[^OF$P!3= M1&7X^6FQ<*+]M[+X:69'[8C[_=&36HF]%$"]WVQY ;R!:OUZY22YVC(M/>QB

*MN3#YYE0\%YV6V%@4]T_^+LCPW_@IF%!7?'0K68GTCGS3)K2PELWS:C"#\^[8 M&61V/Z%,.Y@)"B2>#6HK_VVK9]KKU$Q>@=US ?.Z4\CR1ZU"DM%1B<8UR.NYN/ M;L<7*5(:?*

A;+9SZNFMZ1K>8DE)T3MO>-&[_0&EF?'$4J]M9-(>M.,"745Y<, ME9:UGC=_,ZX2DB+W4GA^)RAZ20S'U(@.N<>X4L0)UI#_)K\YL:B!%*O KHU M]N0F**WKQ!WIAM"*

*T,\PBNF63SPC(=Q;4HU?DM;Y%YHGY)HU-N8K"]J4Y_[M_M\QU8.^C0*PCHQHPWGB(8XS=ZZC"(\]?FB"(:$/]V&6SB[,5V30^=QE#+]M]E\]"Y$-B'-X%E-\GONL?*

7A2", GKS#.GZW%#A:!Q:3/Q<9A>L8[=^@#+H"_ M3+\A,ZU!?,$XS[K(1N!4SI6]5RRTOW_^G1,]+>7;<-FVX*8#]$? +1 M^]:" O U:!!+2^%SSND4JK3WOI8T-*

*3)S6/+Y%/O/@[F52R >KJ[-D9C^,>FPJ>\QQQ0E44, M\$X*X&0M8[=U C]?5COHXD_PNH':WH:8!$>\Y7W[8N3*

*'P\;H>4"^_+XE5S4=X7W.7%+SW4NY[.UQ*2*;YW.R>F%82"1C"LP%@K @M.^-->B M5%.7[&W*:&[":O<\G,-G-7#K'=/N4,Y]^2)_Q'/D6]"IP?3!Z]7G[9W=3]FI M25)9YR#?*

9%54[V/Oi6Y/^_# _.O8"]VSQ6I[#@,7=M)8XA$6B-%\"}Z$E8 O MYOC;W1,%,8U!)R0QR.X3?O?3PEW8]C'=[6TU7K&$!Z9M4Q3 .,&L/G,^S?:- MZ6Y-RJR@#E*X\RW6'1.D#[+\-//Z@*

'NAUEY0$Y_(2PDKV!,L)3ULZI9C. M2(5LG)MQ=\FX^?+18]Y8NHO>O7=FF MC64BSBNG/E/UFF^Y!;=0(.8AF,4:#6L$UH,1G6?3LZS3OYBH'#OAVICQ^4#

MO\D;WF;@V.4DL34AC(92G7$)YOEX>V0-&^Y@P7+X=X9;:5 QO>G]LQSTLH'V MXQ'C^Q9610AQRLO#!]QRE5YG^#*"DI,%$4P"V/9%<'R4>>W%C&/W6E,%1H]-*

MCA@OEOEI'7U;/Q>66@C6ZUU2LD^!%8\'CZ">;.D=!-'4@I79O#$>G; >[DT?`M?!WJ<.]AMU=)N G=B)0M*8GTH\">-.E<SL]+@VJ4MFU_';@WA[_#.?2+9*

MJ.'%0%U\U<8<;\4^U.>LTC-BO+0K0ECS^!H-\'[/%&JZ;QP7,8J\N?3; M4$(;Z[P]_DI!?%#!HX&Z.7!C=>3(Q!ON*&G<6U5CBPD*0._7FAD#9]%W1%DX*

MB:!2O2B,_ZI,/YX0]:IBPU;$X9N=2RB'_B&3"=Q(G@1VQF6=7\,;V(EVXD' M$ =9XT &\ I3JBEX9#32&M<^]VIF-*O_0)M##7QE GW;$A_??.M7J_WX5T+_U M.%F.?A*7765_?*

*7UC^,*HG/HLW\QDAND%ZENC2N;C7,6;S:EUL(- -3P45]^_U+6VK2-49V-CFP>N'JK FO>%0!=9MR !YD%7A\0 MV_+PI0!>4 !;.)FTXR.Y.Q!>%N#\2*I=$*

*\G[BY:1%1MQ:$B5:^ M[B5 !QX?M*LG^I?2P]O)Q)#J [H2\4>Q=PQ+ 40)8*VS/@0]0-;?8UGE]$LA MK6%0I'=P]N_O;VMD@3*TDZGV-;]N30U3&N.;8\V(]"[?LM@M\O@4_RV'F(MX*

M7$"]$ C^ <>-?[JB4#YTA@)PMX] Z&@C?^M-1[41 U5(M1$(.. MY0N[.)VK&Y-%E/&T31BK8?<5(/74P"S/_*QV!8*X(3^ZPG>U/LKZ/"V'8^] MDU=Q5*

83>^KPMA8C&@B7B/SEA%J6L#W2_"Z5&LEHFK[%&>/Uf??DSC_UA&,S M$0NM-;JA118L\P\(UG4_R=N_IDDI9$Z%$1B]Y8O=_;6AN@1)#O8_\.GUBLCZ

*M5&Z]CQOO#A_DSRR70;VYR.?>F11 XL>?#'8Y;OM(D48HCXG9'-? >WBC:.^RG M2,<'^)1#LIO"S+1*PCVA^,?:-[6]#"=A)26+G!,/I/IV9@[1?S_)A[?*

C!Q\#N/+/^C\5PAN#92;XE(),1)EU .DE08@'-M4KCQV3L[^]PW=V?OW-EG9E_D77+.^7W+IYS\R@8*@KR%^]MC!MYJE<85E_+6*

M8,EZ#GM^^;8V;V2J56E!^@+V3S7M]/Z/%^^$U1KL:>#%V]MP%O(OVYB5H>RR MF>"0TX"*B+RNZJ'H?E%#=\,M.&];K ,9>*G&R^R0,2O_R-W@#$AEERB+8'@ MHS!>QF5BHV-

6SE?CM+,.!7:\4)&C=U$E>OY1#:&$=\3#GLQ@3%F_:"441H] MGHU%#H!,Q9P^#%>$]K(LN'M4J+C.A%K17NN?‡=_%_>2)<Y=$]K(LN'M4J+C.A%K17NN?‡=_%_>2)<Y=$ZTC1;&P?G MC?WOA.B/YD4!(I26_5[Z;AFOHK

[>@G>=3AG'/WIM:I2M52O(I4\W"?_QV)N M<M1P&\XJ!TIX2RX$=[4P=7!M+4)R%U?@)H\(0&A1MR%,WO>C3; K/Z=P%_6 M[GUH9 Y1#MTQRTM):

*(Z4#W=WB@94]DJ1C)LM+Z.Y_W8^G:SATIJ9Y//?:5V. MLAIV7X.?3DTPY!5JY0-[Y_XW8J*4G\Z_TD"[D2NT;@$P/ZJ*S69>V M4&-+BE$5KRJ._ZUSYS'UO0 ,SK>L!2_Q(\4P4$["IIS M-*

*;8?X BOOP#A_DSRR70;VYR.?>F11 XL>?#'8Y;OM(D48HCXG9'-? >WBC:.^RG M2,<'^)1#LIO"S+1*PCVA^,?:-[6]#"=A)26+G!,/I/IV9@[1?S_)A[?*

C!Q\#N/+/^C\5PAN#92;XE(),1)EU .DE08@'-M4KCQV3L[^]PW=V?OW-EG9E_D77+.^7W+IYS\R@8*@KR%^]MC!MYJE<85E_+6*

M8,EZ#GM^^;8V;V2J56E!^@+V3S7M]/Z/%^^$U1KL:>#%V]MP%O(OVYB5H>RR MF>"0TX"*B+RNZJ'H?E%#=\,M.&];K ,9>*G&R^R0,2O_R-W@#$AEERB+8'@ MHS!>QF5BHV-

*6SE?CM+,.!7:\4)&C=U$E>OY1#:&$=\3#GLQ@3%F_:"441H] MGHU%#H!,Q9P^#%>

*\%46(+33_#"4IKO%19/;^UT-&O]B3^W;J@^)<7QMJS^Fl:%M!=-MV-LIN,KE,KX0<,#V<-F32H1_?{6!AL>7_R%2'")/8OXK2,7HW-V\I*S$;^6S-MG\Z2[6$K/3CU*E-,F';$2W(^EY><(_)2A#-(F4\:3@%O.S?(0,Y-(%1I$M'-M6+^I:O?+_F>V7?KMA<9*#6'JYEB%'T'V:=_8;5\]J*-S,V)+YF"P^!!Y-T6"S%63:MZ$"'"&!%530&_JK-2AC^(}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{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

*U7KCYRZ*WK47C%;&^[?)URMD2)8^"K7-?X*=@Q_"^F!@_,S^? M'I?T9\=G"|V3]JNAA#1B6GR856+FNVZ0YIS?}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~+^86VAG4DOF^R+3DG%$'!8G0;6\K7[f'%.:/.(EQ&+~# GD MT+FU!3"GQ-#0-%]X$*MK:E\,$\9?CD^H?G0DN3UYDP8@~X93Q-YDSEJ:LWJJ MXS65/+7A'OHX*KFDZ';]D8)IPY>54/UUO1J#XP$U+9)D VQS#7S$OYX M&_%.RX-XD:X*F(G,=3O&PUM?>"\X$+\M_E2&;76H2Q2 KQ\.IO$1',A GIFO- M?=_^<2->K$OMQZ B8X[4+)N2YIS4_!6=K'%6/"OZS''I!Y133P0#TH)-75T+D MRJ=--/<:]4E)?"CU/+7S9AG46<|-SX!=>8MB0_(ALAT3SDCK?61X+'-ZJ\+3 MK)T=[$\LQ",Z: !>%?4C]&OO$W7/-6NJXGZ\G)!Y$Y]O^]-#5U%X',3I+?>C M(W'ZWFZ_$)>_|*/>CGWAS(_9I;U@-EEH9=IRVCH-(#+!,U"]>)1'!NY;@ MGJ98TPC8+<2"3]#+F%?=2\/YB#L[?@7 769M'09E:RP3#U!DQI'";W M\'9:Z(0WTJWC;?A+9Q-C_7E5"@UGT>#^SS9=]+$+E,TI\5&S.Z M6I^P"HQIV!#:0!NL:/ZZ]X*TE9\Z7OI98TDU]Q0GNY6E3(,WIO,_99!-?C4 M0?ZG;,+SQG 67+RCSS0_,NR3A;"FW0),B3<'(1!%#@6@C3M MTM\%K+R;NN:_S_E57U_I>4'=DI+&K]%YW'X-,FL(9OBLC?Q@&Z;4<=+MU2, MP^5VEQM"(SNG=UN4H9>/N>FA>C6!UQ[UT >^G7E5(F@X8NNG1&KMKK^&:|> M]XU*[Z/%>2>Q]I+X>6>G#U])&#TB*'AUN-+=8|^C?A>B|44WZ6I5XJMP>&;68K9;C%X7QC_Z00COB(Y5B#F$YN4ZXRG/@^H$;KAI33RUA M-WA%[C@]-DL-&"C]^R%RE-/,FZ2@8.? TWQG#@ M^_4A0[Z!K\9C&J"4'7$1>M)/DN"$C\/T1]!3-5)."JS=K9 M5+-M$C1;=HT-[(O! 243LI8;I+POW]LRIY1O1ALFGN/5/1-M/#.WZK<0MD&#.S]?16#*;V-UX/ 6T_';V,I3V M^1[;^1[K\I<=@B("_+'D5ZTFO(F1#05D$Z(,Z>134[@48!{@;J.EQKEID'=*ZL"XOA.Q;^Y=;E_&Y'] MZD_?A/];CMP(W,0%&N#4!O8"KCH?W,?087#]GMG"P\8UOKW5N??^4:T%Y^5[M7AZR!F(\'-?)H9_*Y^WTA54^@20H_]^V%IL;CB *4CN[&^Z10Q.B).0^M7;RR-GM@^1,"%"|"0 =,P M?N1CQS_8G6)Y&+B_B"&&{=WZ++#H3W]2*2_N]B3@F!OOA"#3L^!:4IGJQAZ$ M$()O@*D2E;$NCT2O^HC'5%6(N=@G&PB9,(UJN](-+)9_A_71 "P+Z->OX5&[MB_^[BJW0\{1]&D!RA,X@1,7EE[]WMLE_4$ZK,G4<8<)^~@_G.-74ZW3=VKU> M*LBE\$W:*,[P,)6@QTR=!)TE][Z]XFN L$^DGX@PJN&KQK\1N)F^V,"Z,3 > MJF|5]?GM#4C72WC1OGR^18GD2QU0%JC"#:/#A#V(RJ^:;J4!<'$;8]5Z'@=<: MB:I5CUE?J4]++#&E'LPI&I"Y116%>1 A>M%VT;9 X9X7332C=<'?.6U1V8PH^_>]Q&L_,.8?-G(LXWS9H5+/<(R%G%\CF6'GPIFLN13X H4<%Dl\' MBX"*Z(E],.0UC;_\|+AXNZ3THEH8O$T"J%\.';$0.5 M+AHE>63 MG6NKQ5M(KG%7,#8-29#^L52$/3K"-S0#LC@78?U<5U),M@@H2VF59P5T[TALY4&(2^&-U':KDEB;,0 + ^>^.S6S$Y;4\=-#/B?=[7]E4VLH>M40YW M8RN;J_1A1B(T0 +ZZQW"@T C;-PAZ,8@5 =A2^V93%@AW<$$;"U&W^Z@PXOM M6@D.37!MG" @(LS7/XN/NLG6:1. :'H;X/*6MRWGVK?7W2E- ZO M:6_1<5:%/18Z+T]{BZ8\YFY4 MJ4$V6?!]'BZ6MT=,>6><"_!;!V^]KW>#,+?ED9^WN]2M M-G&-IK_Z1AA4474N0*CUK8V41+B$.:(8=S-[VN'@LB)DCTNLUW6W,4$$B R M*DFA!0GG-VP@7H!.G>]51H&P4MP%^1<\Q60F=!Y. M3Q9L@D55^SF;_]7-^2^>Z8_!A^QO(+M)%,^P5?$&35X("*A*ID)OMM_W.QOPO5H$$XOOM MB(L1<=//N17WA5FD2CMO1:CX.?WY7%7#8(XV2-)!OW(W;O)SO'UOS+LM23ZJ M,,\WA7.QR-39O>9$<\GC7>L802+PS7=FMVO>OAR\MDU+&6B"[F3BWZ0'2DV MKO!<@<22HY\Q2MAU\$O^Q;?S<5WOU0 NDWY3'29\.M7H3Y.9#,&6Q*]@ M^9UBX@XW-R2HH<.!5S/JQ!SWYJO^R,XVX)2K|HMO*_PT?$5?8Z%Y?E4-QT M#>>E\DFW;8>.! ?@,E{,+(K%L1+4B5;C!W]=IO#[H=,X!H?^,WV9KI($1O>2]P[%(#$F>.2C5)A6NCK1$D3>/A*FC@CR-!O5QK4!&:.]=O M%F(*BZY!P&3-+;HNA^WC7E*LH.03PY>FP?N9N8;HK-?NQ/.'V$CH1*WK:Y26 M%CSG;,:U)*B''G/Y M7-3]7B_O6D?KS=XX6#+M?ZM/0;(ET@FZ!KGQ_&BDOC/HRJ'91FZ2E!-_)IVY MGG>\KZ*(&T4MU!8Z86[F1$+QU%>'T7DI;5XC S0!_RX9C)P\.Z=9[*!5=5IU1 MP+H&Y2$#Z>CK]C7_H_^IOE@:(,GO-$>0Z9GJ4J]IW.$%PM[1,-E\&XEK;9:M M=2.F^.6WUF=]N^%2^$5$426$>_]3"Q*S;6>/L9W@^WSK^/3K2MS/D:0-%S]O MR_+1[\5|_1-QV*I8V-PO9YVXP]5GIC3 @,R;^1CR';S6E@80 M,;I8;%7-O%9(TP"7#^2;f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|O6*&0U03$(+|.Q0NE9.?V!7W-^BOV\,YF-D'VR.F+92<%D#%]+ MSI5#>,ON3B%/.?MLI3]R4;*'?!"=;ZL?_EG,Y)!)7.;;R420:M2O851.[*)1 M.VTQP[F.'5GV[_)[\#1XJXT]@AO&$G&_-NC !M20T)[^4RI=BQ?RZV;(Y{U] MR'LY0ASYG&G'1Q"[WW#[IE%4FJ;D@*^@X=MG@?!#Q,4-FQ/^6D;M6OLQR+6C MS%@HV&+-%]Q/-^VI,AN_=ZSW5\(#:<>$2=[+?1WNZGD3:5F QXEZI1I8 HH2 M@D-U'BSTN!U(]/K2,P)YV^].C1+&D^,/FHS , ?NW_NA$X?]3L99O%V#TR\'*A^V% M&W0%DZU$'G;9"-YJ RBN-(G3>,$=SA&%75T9?7.M6ZI'-#*_'=_8.U.#Q)-M;\'*[VMS^VD#U&,.0^@5#7/K+WA+]0FXC6?)1&O^N*AW=!U?2V (?D^;P<2 M.1M,/4XU[7 Q86E"1682G6EEZF2NG+0NG4344C&@!S>YS;ZMTU&\QI7>3C M&/=SA"1{B=\:G6U}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`M VJ7>TT860RO@3DAQ9:2Q_'R[]\U[3$"H3MB)/ VWREMJ< MZ?;$NOS:R?*D+NT#<%P]+-_M1[WFKX73$QRO9#>=>_M'I';]9^3]X)?!+Z7YK/D72,-/LX"3ZU?C-2_\#_G M,<%[D#^^$+'ZX7=^$W^]ZMY&3T)SC3RD AT%X'W.50IA*7A-D;'!V-B2="PI M^?.2T<.\G/#,2V7NZ6/ZFQG'H7KBYP\8''R?ZY3-WF#+-$5-.,]*)?DUW-[M4%LZ1IW*596<=*8M,1K,%(K/%7T9>R97Z+ ^(MK!!=I]GA^-.7[%SKV!)6;GB9I^KTE5BSFQTB2YQ1/Y(@4NRIQ1)R5M4/WLFF.(% ==8?.9B&+VN\]N.+RMMAFI'SO++>Z$(90.V=;7M:<'4Z2(8[\/ M:KB9B%YN/$DIN%$$68]V.R#U[ZD]!KXSTSA,0_B$&NFK!>3_{U+:_U)BFD M MA0O0 *'(Q967SW#W,4BBP|=7AU+0[K-+,)14JB/B(= NI(ZP9P:1LQOZ.2@&B=QX>#W-B-_*7_T7K:0 M44\XFDO6H!?S64 _*&Q2GM#<2NO/T76A<]N(;]THC<"[$=/(=O0WQ&*<:QMESYOW+RA.^1P,>[^1PO;=Z-H.HA7S#;]H,I@&MYT4U'.U/ XXT%"E30='RN M,E$T!/%X+DR0VXQ.KAB69?GW%E0]8IX>\29,M3=++X/G?GYVU;K<$4J9K#+J;.K;&W^=8N!0^,MP=\ M3//.7C<-"H[$ *.]{GF0$V6=/6 \2ST%LP 'XID0+AJH\Y4\.Q-K-0D MK%X@C0W?CKJ\'6!;%LS3D(-L->%^BC-AJL'BPR\2M?'\8#OML].9 0!F1O?P MV[&]\&>F:W764%L;*<3IHX62>)%/AS]AL=*"0VDI9LH0W8B^2GVUH."%/WI_ M_F_E*=%-'7&6&*4]],BE'#]CYE2R:MT61%K&E')8_5.MMN2JI8.]OP]9HW-]=[I#*C9TL%>QD.P- #O=&)23=/-;Z[.IRX)[=XY"\[M_CI%D*!P[\$.-#;?Y!IL?T62#EMB@X]W_^0$K7]+@+;41!@ ?!'F@:-4=B^;M.W!SUHY/AY6=,0H.N1A]=E4G2 2W0Q_'N&K(_(?9FR39DLLQ\PA6\LN:8X9 MN5YQY8?!(5:(/3;D)@ZY(3#)0!X0 1)#K!&,BM-S*&CICKKZSX&YSVU4XZ,6JED3$[C[JFTSJ M[&R3>O7'+S9-B'!]Q<O<@KJ$35S[^SU?LKL?!OX>' ")7,H M]SN#HE-UL\Z=A3[%D[\S2"!S47,B4"4]A!4'C5;XJ1+ZX(\&7W]KV'24^)1 ML&[]YY-K%!5)7VPDH6_'&&2.%'676<1)+#>7H,YB"&$]/$6#?"!:K./A90# M.T.)OC(UNU2QO,2I>B)@^+VT&F$\[V%,W)HOI*H?=M0G[:Y54!2?TUGA- M'TC&X%ZFQ'-DNSBH=S= ,!KBC@=)LL3/_@CW%Q^K%HLQ?@[K4I%751,!C?: MQOXZ;QNN9!HQ/KFPTA,G[>,/^:C->/WX;GU;/^Y?9'>\ MO';!F@? Z\@DQ_?M"".OL5TG2"!=8P=,4':.%3=EII/B=FW5%>BAGB_!\KV7+MM*G7&O8^Z]\VS1^)B49/LYL8$TPT+O_M!NE/7X%_)/6(\.9C(V!1X[(F[EQ MR5KT.R%-[N?A-WJ^]^O?+A+#E\Y>U2'K\|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| MF^I^#\V]MXE&=ECU:UR5%J[ZY[/*>EP>LL+/(!U\5 ^~ZG ?YCY.%(12[""?SJ M]OV+J!ST(WJD<):LA, -'Y!J_;+@ /2L5-O3, X%5-><?C9_BJB"ISQ)AJ/2G MJ,*.!^&7WQ;J?&K7+_W6\'-$9#PCB@JV8H4U.(L=H4I%[HB=9-B?6+E,_0^ ML3/5)ZEJH2ZB2[A,9)-!B&/_,608\DS>?3S_641'OO%#E>](PLGV_.T'WKR' MXXHK[]@TJA!9905,1:P_-)\< -5N/UGW51*^O1"=6WU4=+=OG#WEY,D>B\]YMI M&Q;R&D1^[PM%O<,;/4(:<\€0C8!?QN7[9#Y9W=9^,<2D+!+9OM!/U*(]^ZE/-MY.Q>=$YXA8[_PWCM,2,-T)*DL:A/_9XI+"A"R2+K#8!?68AQMB[:A=S)XZT M'12V#R7+3QW5N462B^L>FBO/%R=X>20PL6*3+-#9$@4!2B'jHKJQ**X-BY'< MRM28S?%GEJ76/0B+0QH N^R)Z.9H=IG;486$,'.2^] -=P3_\KG#IX[&"?9$ M.:#9,$@?.PV.PTGS60O=]Y,>2Z,4F'YY&,&7D>;4H9S,Z&V@(#FA1Z C:E@G MUE',^]F^(-L07] TVLOJBU3;.4Q6*RNF'-_Z4,.-=199E44#VQEME_%5\.]Y%YBUUG=PCZ'!*;[Z,X8?,_^?$HPQNU&10BIOIH> W%K;LMIB:U:.!#/"P("[!"32I€pXBP3'UOCGTG@3/RPZ>K?3ZUMR=J1-)8Q\.?"'% ME#RHYN<>&5FN>F+*U^$CO+<9Y,8!'P2=KAQ@N-Y\H=R!}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Đ)026A?;%@3A+X(A2A;"GDW|O77$**8_ ; M#.]5L_=.VW!W((-,+6XQ"-""+C UGP(4$3ZP1N< YK(L.$>Y36ZM_0:<&:L02SM(,GXQ_E_7SR*|[&%2[+'&V)Z7,(^C/44Z:IL M(\}?EG!>QK%("[*DB#L+K<.DX%EW7^9A5;F_ N92;'TKW5=8C_\;*=P!(@<)Z 72'|)D0N@>=@" \982V5;5BE6+A M38@*_RFF5E>!9Q7X*4MJC"?!+4NL2+S9?DE_IRNK]AJNE'|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|XI+8GV.07S#;&9"!XS+$4]U%#)G'+\Q7 "_Z86, LAZ[)?2;T"0D[!3F,)(1N'AD M3 -+BZX\+WD4WK[.?\P8$IW'+5PZIR1+&7&[^,[38TR'E<-BOE/%\:%EW&RJMTWN+-^8%FHMGI$$$(<-^,-U 0;9%9E]'*YL.I-^AY93WP5$QKD%Z!(@TH>F.IB M-^\:M$#Z=@*]FZ(%ST,N*:)W3Q;"":.MPE,P9,L/IX4G GLV?"R\;-' (W"61#/]J:!Z+ZCRC&N_Q95DG#$A,3%!#*%I.$81VU^-,&JCY9K?^=@U?E_H,Y3$ J MX$0#*% U,P"\W,O>S5C*YLV3ZXV_[NTV42Y F+_?L/ZEQ;>4 G'H;E_8W2)7 ME-W9(:K)4U<=*

*[@N0(fY*L!%JFKW(3WL(F6?+[L3+IH<>*LL*STZ%SA;4F$PJ M_RD=;_Y/#^9QHA+AZ2(J)K-H$BJ1_\))]RO%]Y+M4(ZC9-*

*5P2[(-3X\6ZUQ<1X2Y$*5Y3D9%49*!BBO!'"O6!;_11D31.3+HO$)66CS&'!E_R[U7KSKZ MYL%4G0M7ZD$M41 >"Jl,2+G2A'/OJ*EOKO[>%Z:;SF\1L76US$3L3G?7ZK'D*

*ME8<3D43_"WJ=,QN<0J)'AF8^@]T8N@6YX\QB7+R;2N;QI-KS2,XJC4;3^TU$ M\PT<9=0AY(8SBT)Y;,"%QDE:KWOFWHEOIB.P5)%!!UK,"XKIA"\2KB MLP;M?X2\&B;*Q9?]1.8[H]-,(71C5+54/)Y4?RI@=2,CP?/OX53F,>>]\(# M:!8M-HTXD;68F$@NUY>7GV%]; -@'961/S97<6ZK)1,V8Y^X3/^Z;E|HW/\G M"+G_-(/]!T:U(@MG+M#HE@MR>1@I6E80P;YV7\QMJT*

X!DA1S+V_#LF%?!_8 MUL)1+QQM,Y$H"65(BXT;?BPB^?VUG9I5];,4AJ4OH06XW/ 7LE;W0?FC)MU@

*MK#YPRMR(II)'OT'P#F_;YQ#VZ6N;4KG/TIJ3Y5/&M^]WSW?/[Z^QTA^MPP!P: MQGF615>+<7V%,<;I]*5VE4<<7!KOMIZAT0@9O&,-Y&Z@&R7;\399!K7.1:;] M_-"[US?8(,&-*

4$BAV5C1ENHC8AE#RIt;T)7^68A=(IX@IV:U63*R.P")'-MT?/]E[=E F,Z>5ZT:5W. ^Q'G-F!9,!^2NGT?|G 6.,%1;XTZU1N(>>8I0 M&W-9;*H5%9]I$<7IJ3AN7[(2H=-

*;N|S(2@G]% M]G/7;ZF EH'9^#?;U4V;,\BI7'27">BR3^\ V29+(#C*NT6:0L9_SH/C90;/ M$E>)-D!>.,$9QD+)L",)Z#FA5@3NZNB\66')C$7'2 =*N@0,L>,31>A/D?X; MC_C(PXRX@5"G*

M#K;OGH.KO.7@(Q"UJA5$YLA6'C)?!M2=D)8=]\EREL MO&N7KLO]P9_;,\O+W M1!?C0P#3,\,958HD#;XA-%!!U-'"2X3-D-G""TU\]YZ2LV2'K8'0I3:E^ ZZ

*M(]fW9/O,3_E2;SW<4\BC^XJ^](:WOKFFPL@Y*ZIL+(''\\<(#=HRS@EUG/0LD\/+R\7,_(;?S>YD,VP%0O G>_M5X.Y0HB\9Q7>?>!3/Q(#I^^^76)?$##7\NG#R%Y $E_%9W-*

*Q6N=;,:O$.t0I M?@X'C%-8=E>+FJDJQ1ZJ]$*FE"U%)=]/@'_D *A30LD!=/-DE+!W<6>>F<20 MQB$=@),H>'(^GXALYR JV7MPT23=<6 ;L.U5:-E&K(1L2>W4Y$8N'8.1(?'I(/9*

*M2'2$H"X_7WK'=(4/B,"OHA;7T1Y\+Q@'5"SA;("=S^,'FZX/A;XAMZV;/[Q2 M-,EXA#PP](13-4#2P573((*_6I&R=#P0=+0SA=*?>O;\AN0&9\C=@KWI7;_:*

*M],>#Y&MY21]XTJR9[_\4^/CQ1RYD& W]P'WR,4DS\]<%/*A M%8YF2&9B>4DF\'&U2>O?0TT ?N9!B9"9#[^Z1S'G2!UC3/8+RU]$S?]U^[V@H^T M+9,N+>AP93+0_)87%+$V'0V 8*

MO,HO'G;,$GT6,7FW6O+4?5W=*Y[QI.%WP9Z20IL8(P[N^UO2T-MHXK2,'R!8_SY)?XQ%744F*;8E6K02[XGAGM,?P(,XK54")M'"*].$_SP/PDFN)HN6L,%Q*

*B;X5V=#5H,V:AR8;)$[%X";83Y$)8*M M"-*QX&UDA,]MZK&J]?>-ONDF5 L1"FH*=N8"X*")!PRH]%F'GP=*AZCRUD4 MX=G4:B Q_]!+;4'?:5_VZ%*

*[68MY>**1D8"M!.)_GZ$1YM3&D5U5NX.M_X1* M.:$R@M;"'$%,Y8Z_B98#;(AYO/"2-NN:]2Q-!GZ*+:]@3$Z^*:U07=30P$+O*

*M$!SU(EZ]%9I?;=LE%UKX%*L73%#"OYX]ZX5Q_3/TGK#]-MZY1EP28+8I.]J2!;]7N+R+C9NY4C59OPC*%WH%N3#:$/E?I"M^Z?1!'QO;Q1-M+K88261"M\)I#@*4[F$5VXSW^=22?*

+2GO=QMB\#!MPSYWBJY#!WGO==IW30%;T@D78A2-MP'^CPIVA<X0F]P/O0#^N6U"-Z;U7(UWQ],WWTJQS++)PFZ,3VF?G_$/^:'LG]J(HV?>1IRI]P&O M

>6PF'VKQU'YD<;/H\]TR[HO?"!?Y=U^R$ND1@V(!S-00Y^K8&OEE(,ZZB5 MV\IA?6XHJ>%LW-Y'F[B]^YR:Y70H8_!\VCG@^P#@%HRL@9#UU:P]<"]J<+]]*

M]VYEE0Q5RTH[G=;449D'W'GJ#Y8FE ,,>^@<L=!Q5IQZCIV:9L?T\YR:=:,K M26XUF98QKIPY7X6&>-6H\0_,^^R:51E I(+^&1+J//17D@%("SQ=]+J\+S/!(RQ M1QV@IJ4*.(4QG\I Q?*

*3A*UAAPG_LLDNG9G\T#^P]UD7<"%,$N#LQ*UBF%3 M<]6^B 772WYPNBE=[U/Y],N\-.I962B]+&?QPTL2XV_$4;_BV?;QG\^^I!]0 MG!OM3V72-H,],W7V+?*

DK\S2H$B(%G,5W\E1')S9..L2.KT,OQM/+7L09T]AQ MV*D:5+;Y+ 'LT,32 6,P"5-/5AL]R/G5]3Y\(^B56X'G@PMB880';1<$=NR/WW@'X3WPXW7E?DG M]#YMJFX>@:,$9'#TT>"/W#?

9:EQ$[:[I#=&K>PK';==(EC12E(1-QW MP"7XJ?POO(XG!G fO;"?GR1Q0.6QP0K4,MFT>>H)XE\)V\G7B,[[MQPNLX&K*[>V@O9YQ1UF'G[3MG8KS**)?*

*86HM05XFX!Z&# ,H0320%IUG6.IQ[.^U#988N MDGI5\OPLGQ@X+:#E+DR_(_&+RGNR8AR[WU;I]0_M*VGG8-9JZ=&NH3$'1*

*MYT[_6BW%SH:@DIR/5IZ@E"Z])M@;4N'+M_%SP'E3AV8"O_N M=]@=7]Y(C("3#Z\|_>]\#(_ANDB7JE')R^C>IEXO: M_Y9F[KR%MA#/?/NQ1;&.D_N/DK):7DMYP4W1*0L*

*MJ?,5NSG1S63XKW"" *@3S/ <^F2BF=WI)'OBY(FO89\KS7!5K*N29$EE)Z(^ MKGPI(<-(R2L,&0*I[.\X584*_B DXA@7?NUC(*8T#_$1TJGG@K ZU M- 8-. >*(,?5%(!5E%6J'BV]*

[@]Y550YSR0>U$,V=]:G_0[RQH93N'X]V& MW"6AU)]+5L]_RB/CO2W ;$CM.0!-JRMX6#OB_8%!NX Y%'T,CF\R6XHBM)D"Q[MQV#T1CN#]+]

*[AH%K_NQ[6ZA<1HZU303)NFRQCB*A=BFY+N8.3Z3#Q>*3!;& MXP C)Q0NZ@ATL RN.VR,"W%6351>?=?++]/9#MCM5E+4Z_(>&X65 'I; QN$ M/@=X?]_ZGY0-*_M*#_7_3/T'_*

MIG\,_^H?0BR)R@)GWD:2&2>"%LXHC<,FX9@8R(:0E\$;QB[^EEPT+G&JSO MKR?E^B-KX;_FCF51$7-X,5/XVMN/=$ATY]]F#BPXJMJ![O:WD7++1=QBPY*-? M8 -*

()@2K$WP%>)TTQ#*5@SU5ZK(^(V&IRAG[>HL2I?X(^'] M2$MIL+S";15V)L;@N)(P/;G0.FC!>!-TL=:T]IV6X4WU)W

M_[X\&MG'"K3R#OD2(M7BNQD%9(\5ZU60E0YIZG6GKEE_!LSYGUF+!Y9I/^N M9_M0\H9[%TK[<"!ACHZH^$FF HX)OJ*LI&[W_*E^C.H=>A0G9!-XG:.I34^F7BBPYS_DMO#5:"?*

*W5<=L;$8(9+A MG)2KU#B6:'B03!F<84V,#)O;QE*QQ_M ^K;J73/ZKZ5.>H;.%%);NZ[?=B!\804X3 H8&>]H")Y_09<8F8M.BQ-C@3ADS1#@\Y2)] M8H'MIXDQL#LXE\#Q:HXD[>*

*(V_]5VOY

=Y1K#:S'JTA4"M26|L$^R*;T&<E/9!21&V#Y6=,EC M?O;" {O$58L@MP3G<98LVF4Q6L366(O?)8&!CW9GO54.MI"L|9GZMK@_G: MR2X96H:>3M#,'^>$1V6*
<&H;4,/[F|SL=VOZJB1 &'ZNR4^*U8L.3|P60EO: MNL"4OA#X?.DEI#URO';^6!9MWR:LN1)%Q/1=@K2> S++ZA=Z5F"+TJ/_KQN[GQ].@H#7 M&W&.G5
YE,,XNT6+ZE6BF=K(A5),,82F#D]^'Z&]+'[VO+M|3PYPC$E-G.# M:H<*'#2PZX\E!\N_\C^'/486OC\Z8.8#(]VV+,AYQ@S;R/SA!<'=AO%L4T) M^^-]3BH)$8?X"?
3B2HK'OLV_AM,&-#M$HI=X,ZW)Z=^Z;^E_N3U>AV3&|[73X?)(UOKKBIYD?1WD8WT=D*M-|]H;H ' MW/O:S3TKK<&/(,,>3?Z(7-V"T= '1'-X_G\:G#_E_Q8*ZM$%D/;2AQ40 S=$
MFU3;YSD6$=@1*#W]W;KLA-:H^@%]N/"83 MVG53EWM2\]=%33%^Y,?E#+?GPB;13#Z.NN_:L7*X4.0GB96[F<-ZWBQ!>W1A)?N2IM\|WE,]D HF]DSN@!V3.YA"CX4-LXW&]
[(,1F2 M*%JGM.8]2+]9_83Z5039U;$\@'W?>3A>NO1Q5'(Q0X-]=^^4_?.UM[,T!3)BG MBV1F6\W1%7F&MA79Z_%;%;=EA)26Z (>ZD"'*9]M$M[+GD3$F.W#:7LIV!^2- M(NI[X2C
9;DH-U;.A5_+BQ\Y|%9VV)#"'"P8@X5+7G &QX3U(R&]Y&GOVJT_M+$+U!L6AI*;%Y#WFU8>>@P<>;62[?Z!EO%?DK\|9CRUM,Z1+W)MW;JH18H$
M@@[9=0,.'TCY!*%GV8WOKE49[%[ET)@6U#-76]>P<=M$SR\A2S=5RK-IP-69.&1C.)#]I=.@N%)L09 M">X/C,X./WMFI?.F((NT:2KOHF#IV:=,\J-GX]_%IW&I6%+*@/]
MAMV%B4<=DH.S0Q-Y "51SH&)U+4,KI@TSF1?WUL:EW(=%5?^CMUW?BV|HM_/H4H'N2VSX[?Q+2F,NY. 4=*/ K'B VH:)X M:5-5K7Q.O.SN8W'-_/%?
N>6&MI2@,`_<+)&LN{'BM(BZ]/WGR#+CS?(NO%#L M80$^N7HP:*]5]H8CK&<<7X_*P_#D#?>*Q74GK8NSOG;9WD&K'.'J/L##]JF:> M,;?
83|GRGH]G<$0+8_AZ45=$~]T5D_,F++%H&0O4@^UC[B<{KD2.1+-AJ6 M&C 4+]2/3R&;,]^*++|_IV/K0E(RID>-]_Z!52%>F67Y4)B+MC<"O@S\E?[X9>.6&)FM, M9&9B*S<@$YZ=#
M?(3"6E MV<:._FRLJHS^+|R/*)=|<.;IT& ;/%MOBHV4N5(2^B6U(!C^G;8N=.U>Z^]MMC8!?=PFO-P-GYA=%"F;1EPYV*LM3/.!|$!UGC/R&/Y^-=E!U:I,Q6\42+."2
M9;&E=MK;G7_N',KH+<-?!ELB/YNVL[.ZZ'!;>DU"'7^*&C1^!G[A%H&M8=(?R MN(I_JN,]K#E VV/H4>IMS&LO3SR60XW@8?P1.?5OMD6;#GZ
GT{B(Q;=PER63@*&AK6+>Q|&?/@H@ICJUU- M'^^@K^8BWL JBM;?WY3X89> 6$T]\!"L^L_FE:-XD-=X]+^+8=&"Q9J.4>N9$ M5N(M.+!) O7,Y G{!EK .[,2U'UCROX11FB,_G
+:#^T,YGY4-'@&/*><@\XX MF9T";"!1AK24@]_1{1R'9"_S%?\RL0-EQ#HVMPA@W\T T,0<8.?B)^AQ0W M,,,WI#;\'Y@15M) X"P'PD /,@44>QPVXIZYC.';@+6= EC27BERA% >O3>L
MZ5SG,XL|Y,)4W_!U&/58QYR1,>.'>3OJ5HG*HVPE]G.BZJ7#K9I8O M!P4) ^D$_LVQ$%QSV2$^UJ3!,2UYS@@VB^1>Z=@!R70>210S$?2-V<"NL3$) M?
Z,15/NNWOPF]D4A#U0[Y[4WQU/{@GO@IBT^J7.!_'](,PR7>KW1&FJD.RN<0KH8MJMFJTH#A.=8;]CKSZ!5.B1_3P M&28>(C$#PBE@>N\YO2-
7G|@N*D29':07|%4AE.$8,A/XFMA4;:=](R*WTMU M{!U=^&%T*A6!F/*"0ITYP;D6^34KI6;IZ8]!MJ>H7^#)5FZ_[\Z/QB#1,NCE?5486MS"XN04 MX,?
IA;>!FZ>VQBRDF7"RSO#.1NM W M@L#8P\<12D_K8MNZ{W3_8)GAKXB:RQ*O$C%]?Q\?(T&G,Q.^']|/2]O|0L$- M.#C43MFLS%?')EOD_4]"*_<&:PXT,,(FX:5/!7,QDDV
M9GHTU0W;U 68^BE%_-AS@:/ G43.66$Y^4E.B[91[JUQ'MA!YIA;(I$GMRKSU^IM\)1:X0TO\.C$L7WN@lV MN2^+,G=5]8P_*19^V4340#IFZ<2>1CZS3UL:1!Q>!6|$_54D9#40^-
M2>F4%/|>%4S_8_#NV;6LR L50?6U9Y)5P1G6/3.DOHDP9)1\5A1KE.8L.G'W MYXP1+LXINY,L*Z@ZGF/+Q.H.14;5?)M_!+KBY*[F2.MW M2>X40+,O5A>H-.?G IN9-E>".XM4|XA-6?
S,YPU!2!U3^/$]2A6JA%6#-?\J M!5@ ANJ[&3Y(Y08YWC;I)KK75F44<,_.69$0M]15@R(GLU3[V=R#]6/0W8CN M*843N;+.UF'C:!6|IX-NA16-->D_=RG%NMT\V&(T?GN;&-X!?
OETACRJK?.7B-Q+_NT(XUL414UJ>B>C2,1@+4 &+GU4NI$>#'I*R--5.C3(IQV)&-ND15K7MRC5U@#'WE+_MXP:Y,BEE(+YN..@?KQ03
5@[Y%R!U@G2+FY<1ND<&TVQ]^Y>?, M>-Z8%3[7.@!3'<8L;_Q&EB(B[&G3POVZK@FO2)V@F$3T>&]1^3_O"92/VCT MDS9$33L*T&9K#%=%*ZDXDI*,OFL#2$]*A>9(0>2D
BHK>L42DI|2/FW>]56[!WI((.[.MF(.%M7[%,,Q@^9^*4@_W5=N&#-M7=W]{S).[>=-=.53>T$75*DAG+8999L:1 M7FB@+|[+\Y)B--^L5T!S;>4C4UB"'C2P9.3U&J$G.JE)_N*8+3IY<-
<#GF^Q> M'\TY.DKRU6NQ4TW\&WWC]H>4*/LM/$5997&>XDUTER'$\.M;C@!#/6V'W]+|M:N#MY=C>Z.R:V"+AKO(HY'>]G;OK\R<]G:C8X'T].C__/F74GU277(=#)Y/+
M=5:.U%XEZ +^:/(F_N!-M& TL+8^]?Q*ZOE_M_)-[7]OYW7;NST:#*V& *8+MC..?NMZW52/#L%6S"F/MI*N/+SR'H?VAI8CGW,Y{IS#N/%EXA%2T!;/9_#[3*,.M
V?!%ULVH>#!9TL=@7T__9K|R ^<K M]MVO7S*_/R9|%WX*L!?:#@Z_I M1Y/G9*Y6)'C1+$&)-8FTY/,ZFY2F!$GEX|FSN#;2*_+(B1@1'ZU G-3"WD3^ MNC9,U
0E96DM%_DAP=M4'/F,TE]J-/\0*> 6D*A&MG,0+.P4,'@YXOBD8?.0 M\2FRVO[5SP1@FH_,4676-S%(4[':*8#"'-P6^TG\%.#:-2HZT=]YD4O^]!]M M;4)9);\.Y:7--
,W+C&G#;9"?s.L!\Q|>C+!7UV-]WBD<&+!]2'PI9$%(D)%RS MT62K2ZV@5HM4J^7]7W41R(FC)FD-45CV"%.C$.5RKDDI'$UYMG 4V&,_Z)%6? MJ/?LY+Q5E*6EHNKKTY-^T1\E_K
DY;K\@NDT#96E}YXS.S\NR/!F9WVX> MK=.7RQ3= MP]8+6D7GS[%%WI:|&I/<;7]%2DIA4;7(=8IPV$<[.KZ-$L#8\98S%,&S*&.WD@X!S)H MOOFS^^2'_7.
U72XOYT0(9PS_>TWQ_\O/ M=_C7;2"57)P-X^; 9&9WYV'>;]2,/|_7@,B"7UX!MW/@EUPIA906ZLR%<@65 MBE3'LR7R2OI^Z<6< CY#WLI?
YCQ!!O-\9A&Y;=M:04'GCMLB3UHQ?=SX+/R MK85_]B(E@RH2;M0#7]1C5{5^-LT% 95!8(NF]Z"6^/>X2^@<2I< #;/],]^- M3+ZT26LV=YA1R[*MS8=5!YH %9)$]+7]_M3*FQ\
I]39H3G;A@G,.TS&=6$K_M+%'<)T1QD]<-IIB(M.?F!9-=]8E[*K]PU-39O(AYIC\=]OJ;RA_4_7B:NW< MLHS%PN1!%Q4N2A4>3!^N;*2+YS;4J3EE5E0HJ0IPN?
%=G$X:65=)T\Q&&@N M:%'*1WZE]&]%E#CI6K6AEC_\E-A#;_^[$UQD.%DHB(C#CQ.O.EXEK.*.U; M|%I9(G'')[4W)%T<9N3C,1R4O]718#_#?ERK8H>3*X;E-;ZRUAGPW],J&75;-
B5XYE4 MBGM5Q<_?OC9#8Z?6X0@+GL=*&@&81;P2CNDL9U/3[^|84BF#^L*UQG:5/0%QU M8O));D6#;YU?:X\>EA,1;5KVT_GCB##W5H1{5DBF&_E!9%$^\-'D&$SV|S]
M6&'V4X"_NHS9&+[@:L#8.O!,%:M1.Z%SE;.-0E9$SP)##W]B_DU;@$.V+89V M/9;\8&0IB-43X@"5Q=C,P]]DL=00I)=(23%_N2EU6+-&+Y-K$&)L MT 0 W!::9C3-
\O|W\AK_@WN2_ZUK#QB)}(2_5I2XMUWN>(GYHZF3TZA,Z+], M3#==9&+D"Y^W#G?%X 37G%*TU7_F!,;"7UF2!-+ VVURRB#, M136[?$NX_CTD.;F
)C|&%3K@0=3#*]:#=-4W%$/:RG_*N<&M7*_[4>]K$#M+]+EP:B'3L3249I26.KOO&[2K|@C&A?6,&/$9P8FI5Z5.,IX$VW^OFX&N>|I MB_71.-,:@K7_:?
^H>GLV1F6YRE*B]#+1]LU41$%28>=EY?DOLU_&RLI:(D6,LQD M<2RFJ^83-C19>2I)%%2.?0R)&1,7HP M)6[PS%5T30*<>8Q$8"/YD%0<9V)P89"T#71#,8?
HD&H,A_Z%G7LD+HI2*\A* M6BD8!!D0[4:C)4VO0+|)P#5)WI]0P$6R;JBH=#2NK?PI/O:9PRG L3PL7Q=X M&
=IRB4_84=/'"#';Q@!MP51VTGG=$O|]W;B\IA/TYO5"95$A2$3$2:\=)QZ%7RS!XI-UJ768JB MKJU%;\+IK7,,5)D&>`X].7L5$B7P+W$1?
4%\P$_BYP<0UYCK;W;G7]Z$]PMLB3OQS;.6_O$ M0W*0U# @1GIN)JA./1BJ8)OJ,.X-*P<[?K@R(M.7GI.6Z9!9E'_Z>NXMH.# M3RMM2L7P'CP868DD6JU7)_;C\FSSW2Y2IE:5D*]
[K]M+B"R{fBL),,MMMCD] MTK$2L[C]^3&JB_G1\4@BR:FUOBW)UT6*V+N M9%DOO//F^-HARRJYY)@-"6:O8J^[4=HAH78I6N!\Z)T&SZUYO3YFWSU(@8=-M^AVS-
]CNN5)R)EI2XAB'VN3*4M&Y+>A'3KXI'C=".+M2]NHH$K?%H^?(6Y^H M*_AQ)Y&=Z*F^W.D0C1B ,F' 19C1C18=C\3]Y"D3.NF.W\HTQW%G M%O,<.F.
(_BM6W8_VJ*VF3"W7SCCF.OB\3"TT1W1{:.E8Y G4|!%/.? M@%/ :R1MF:M=E2$@*&ZWCH+9$SZ,E&V>VFVV|FKP).@:]?VO_E2$@*$XNR M;X8SE[1Q"Z'P!1]_BG$-&'&U0?
f_;JN4!G\.LZY.]=,/%FZE]+N04Y>*9\)7 M]!K;B'#IN|P/R=57DOL)XM\Z4DLX;R\|.;3E1&>X&O0_RTA0U$3OM$!8<;?K M-^
,&)!3@,,$BF26@V:0.OB;P$\P[GPZ/O]374&R;9GCGMF&E,_1H5'9N$M9 MSB.>,.]6X7,73\:08;\V!X^4Q1=AS. 7T4]*U MPW6W"TZZE]J#PJKLFIMO([[_DE'.C4F3+8\A",+:$0PP-
GS!NE?\@L)U.K/9 M7=>EM<)Y](D:\S.O.HN0/&AN.W'DA=_Z'55SE$(%L<:1[-+!S:U5(@\>E)1- M*F9ZK$(>:!#30<3]{N4;LI
K,/|34KT_8JM<,.PP!O/B)QF_18UUX!1PT_]1=1KVCLX280!$,\GV"_D. MF?$37/H$@GFQ;SN$&2M:AZ,W8YE)W>P%..G@+4;C:;EQ:1J+ALLAZDO !15 M 6_11"(
M!K&@^MI9(./CW|#]ZW\23)(}SOLL-LD>K^+@FF0HK76/C_AYSQ$-[S"1BHF- MZNM'GQ5Z(K:8=M:IWGE%_S^&H49>< {OVVG>8ZX7)N&\[6N49'MS?],WR_ . MV=V'#*_C$_L-
/K/NFTX@+7+L+G4L#T4*PF&Z?@\$IL5Z6NNV8;JI!+PU#O M2WD#C)({X0+R=W,F.P/1ZN:),7+! -W$W*[^1YUCU_*;$G2GRE-C_ _*D#E1NUO(T>;"IRN_O+F3 MZ8.CTGVB2@.2$@-
$##1E.:G6*YH B!O'^V?V@Y=DOI%,"?QH\GNDN)8QO>,#T< M9)HBMADX&;0@>L7R%L*&MOSCNN>T);28> ^^ZVI8>F?;S;NYS-?ZF&Z*14,<< M#*CEJ/':Z 'K38E(C0>#EEOUS@L/*
A[W*]H-;_25I$=%V(OGP)^+$). 6,B MVJ< 94DB;E"HG (2)N?+L2RYIX#!QK&E1$=AX_,WM/JV6(ES]V6^ZH,7V]A MBKM,^?%,^@BC;V^Y#D%;E?
UWP$.X(@\!^]99+]>LBQ#FI49^+/^K>E;H|-& M_8]3\G#^M+(DWBRM\%0!;HQED'R]3%/|>##>QA!-'R!,BS5"B4=BYQH1;5G M?5NV7I^=&/.9>?XVKCYVJ2U4NN=YY-
Z5S*_R9!!;Y)O6Y/ > ^I5!XM+Z;JSS MY OGUT0#8SVM? H@EU=_7B'X-;;-4P.]NF+L;/$X+U;9 +F3>(\3B&,D7V2) M4F3%^:$\^J'JQ>L37G((62H=;_S??+:.8^ESW_OI]-,):
(0!9RA@AR"LX+=A! M% 1]B$HERLY&[>TUZ5](8W]'E>I\>Z[P8Y'/=^^K\UP>#KK$N?(5@A$Y"X5)F M:>"_&T"$'G3=9],HK. A9PL(;OT*7^"0(KTA'XP"T'$R80;A#9#^;;.^XPG;
M'J6;965_|=3HVG+84W"@ESJO^!SKX[W9 @I_RO930"R(05$:-I2(XT'I18":V9_)O9EX M.F6AU:^Q<^Z[MO#/#Y](Z:\/# +7]< FMX%4(1_:NP? M:\&"2>>BFQ'I+L;35V?EWRS%B;|>?
*78CL%B-9UF&/&)7O"WUJ#PFP?E=),/ M;M+4]EH(WKH^LT7&^O35,8Y0\:C@?MPT"G((Q2'P*GX71-]*4J(3G<2)O3'I-M MJ@(FTWA?)X]!|$9>%6-XI?P)D9R$-1T!T4#)Y\LC(!?
U_(B"_EJ0Y(B]+_X M\'OJN^[J,.90(OGGWG_NG@U*@*$L^BV|641\9LPA=EIADEG[OO]H6?Y6N-3 M]3W2H^42'7U%@9_\7I.I^3GRK1UZ],.8*<#N%# .$_'M9.A< +(XIA0_WZI(MT?
Y>\")^&?6)]=J[.4YAW-)8&(>?]N+1=D8=,GRRLY:=.8RK.82IG+^VVO$> MS7+K>4RXCIK9%LNV=_MIA:XH1'>R5$9Y55.A/\@=[](G1&PO8-7]Z-E;LGT-MG'S6D2L: -
U$[2RNMH/(8M5BNT4.]!5BCU!=/0>C!6V_45I?UQ=D^9[V1NS)H M8SO09R>O?HEN5OY1D55N@aJ;>3C1L*4Z26Z(-Q&ZF%W!^Y\&7TDA'?MB9^E@
M,+!QIB1KKM%[YTEMO0[1PC#8N&Q%NN;-13*=NAJ.6!C/%2S3RMP6U5LA$^I- MBBR0")@@.AGGPOO6]=I0=7A'X-V>QXP2#LP25NVFSY^]TF MAE29XO(@#TX!
MG_\$GP(^3(S]/@74*H?BDZ$^%[MVMX'@@V,*@ J6"^?3@$&B6/W"VBJ+G?P5 MVD;EHE?Z@R BS$J"!DV*EI$9OM0>$XVVW<)!K$1LC(TR#TTD$K]5 _M]9>VW M(CP-
*;\&+TMUANG7*A.CMFIF9K;&-N^Q M;%O?,;1P.18,;ZF.H]|J2W=M+(DWBRM\0!;HQED'R]3%/|>##>QA!-'R!,BS5"B4=BYQH1;5G M?5NV7I^=&/.9>?XVKCYVJ2U4NN=YY-
Z5S*_R9!!;Y)O6Y/ > ^I5!XM+Z;JSS MY OGUT0#8SVM? H@EU=_7B'X-;;-4P.]NF+L;/$X+U;9 +F3>(\3B&,D7V2) M4F3%^:$\^J'JQ>L37G((62H=;_S??+:.8^ESW_OI]-,):
(0!9RA@AR"LX+=A! M% 1]B$HERLY&[>TUZ5](8W]'E>I\>Z[P8Y'/=^^K\UP>#KK$N?(5@A$Y"X5)F M:>"_&T"$'G3=9],HK. A9PL(;OT*7^"0(KTA'XP"T'$R80;A#9#^;;.^XPG;
M'J6;965_|=3HVG+84W"@ESJO^!SKX[W9 @I_RO930"R(05$:-I2(XT'I18":V9_)O9EX M.F6AU:^Q<^Z[MO#/#Y](Z:\/# +7]< FMX%4(1_:NP? M:\&"2>>BFQ'I+L;35V?EWRS%B;|>?
*78CL%B-9UF&/&)7O"WUJ#PFP?E=),/ M;M+4]EH(WKH^LT7&^O35,8Y0\:C@?MPT"G((Q2'P*GX71-]*4J(3G<2)O3'I-M MJ@(FTWA?)X]!|$9>%6-XI?P)D9R$-1T!T4#)Y\LC(!?
U_(B"_EJ0Y(B]+_X M\'OJN^[J,.90(OGGWG_NG@U*@*$L^BV|641\9LPA=EIADEG[OO]H6?Y6N-3 M]3W2H^42'7U%@9_\7I.I^3GRK1UZ],.8*<#N%# .$_'M9.A< +(XIA0_WZI(MT?
Y>\")^&?6)]=J[.4YAW-)8&(>?]N+1=D8=,GRRLY:=.8RK.82IG+^VVO$> MS7+K>4RXCIK9%LNV=_MIA:XH1'>R5$9Y55.A/\@=[](G1&PO8-7]Z-E;LGT-MG'S6D2L: -
U$[2RNMH/(8M5BNT4.]!5BCU!=/0>C!6V_45I?UQ=D^9[V1NS)H M8SO09R>O?HEN5OY1D55N@aJ;>3C1L*4Z26Z(-Q&ZF%W!^Y\&7TDA'?MB9^E@
M,+!QIB1KKM%[YTEMO0[1PC#8N&Q%NN;-13*=NAJ.6!C/%2S3RMP6U5LA$^I- MBBR0")@@.AGGPOO6]=I0=7A'X-V>QXP2#LP25NVFSY^]TF MAE29XO(@#TX!
MG_\$GP(^3(S]/@74*H?BDZ$^%[MVMX'@@V,*@ J6"^?3@$&B6/W"VBJ+G?P5 MVD;EHE?Z@R BS$J"!DV*EI$9OM0>$XVVW<)!K$1LC(TR#TTD$K]5 _M]9>VW M(CP-
*;\&+TMUANG7*A.CMFIF9K;&-N^Q M;%O?,;1P.18,;ZF.H]|J2W=M+(DWBRM\%

{G;EYPOIBPV>-S-MM_^J-9N7]HK_EXKF77:_N(7>@VD+R'CQ1HVDR$HO%Y&1U?GL?EV:U+V&)R^A-MVN=N6)XPV3 &%]0,&/*OPV-G34290[,R>'[PU;C?2>+Z[MYW()\WK4C?+KS]M\)SQ^]Z=DS-+G''^!DP`\(Q#:PA)S?>,<@Y_5M\O^7:U8E5NU.Q M03+'W;GO/9J!*O'SZIFD>7SRZS C&%,R;RZ3<> 4%OR[JM2E-A^]0_76QDQ[MDG:;>4I90-LGZ<]?GGE;AWM2[\B{F03M#/LW47"C# MIQF9C?Y?9Z;G=H.-?\-3'Q\\B_"Z7F|R15#=H53&¥;,,I@F7S]TMIY<;BQ/R M1S6;K9'&D\.9-\(SYG^*/>-W'"N?(T=Z-,_@CS !?5)(/Z5@)E9A_FB>:!-Y#NW@H6H#|//;3S4_>R4P>HU!SND{{HHOX],<:FO4ZV)C|9/4W5M0H_IL_1B=03#IF& MD;?\6G^_]+-[*]9:1VS)R2WMXDH.3/]67.#G6.S,]?D6YW3-P_O[VD[$M09);Z$.DR<_LT73+[$+Z1-7KK]1 MKA%+^_50FSG(OC61=4) G1%A:73/KRCR0P)AQU!H#:1-[>4&Z$FZ,K#Q[;>0 M"C.BGKK.#<@L3L;X1H@7X3.3$G(;]VHD@OAJ,7>I_R,>.LV9@&[8 M\8)9>3TED.%Y8:G'^.8"8Y8YV3E2'YHW[(RY@^_:S;'"",3+ M>>%>+7G\+B=Y#"]7^$>R@.2Q#P0VJG.XWG5]O7!1:\?)/E/7IV.XPF/%V1GL-M/R53=5E .A1&I'&A|S?P2K0(O2I6Q+P)9@&Y]PWH7C\053LM7^WTXVK5'1W-M*T\(8LPO[EQ4Q50f[!8?_*-* >,<+'=F.HS}3$PU3E=F.LDEBGF M8'P+N=+YHH)/<*WQUD^C_1)Y6+7U]HF->-/)H. ^L4FYD5]Q-]YK*!3"% _$33^;?]#|K_X=M+_FW_>XVC\W]M687SFG1V MEJP5,_LN ,[_\0C\Q[S_>$2^Y'_/S-!_V_^7C#/A(_0LB__E>@6@Z3_2'7_8 M?V!#_VU3SO]M_^^U_^H)!/Q067#%E"T7C2W:OQ\;\_ECPW,YP2H@|/"7)&5U M47?95(=_ .E, ,]TG-LJSGA/BTV50DL?KO?- M)!2-V>1)V$,@7?OH LQ.++?),4PW"X!LLP!1NN%P0*+WU9I7E1N+(NK#*?[- MG! MA$=#KUP^BDGZ? BWH8O/B365S6E:I>BBS&28 MWMC$0F;78%09"^#ZQ[@QD0/C24EOGKB38")GI&H=W)|89=29J8-E\>59>[MG=3+5,;]_VNT+E%W,<*Z;"K_%W* UT41SU,?D:$E16$$50P'Q3 M0JM;-UXMOON?)$'E)!T9R(HQ'LT%%R<0R3G2K"IV$M+HJU%/$7N.7>(5^KMPVCW!)6G(3*N+[43DBQ$,;Y=\|FYUVB! N>BW *;IZLMM' MYC[U=Y554Y-(3(&ZQYYY];! MK\UYL9-2=V9X@3WYN,&/E/U9K@7XFH 2)\??PJW48OR'=-=G"M--G]WO[|LTMZ,%E!4R2>U<4;AYA].54#+"]<,11PXO'G@<<)AWGXD.9FJ6FPFL MB'@P=2G]KZ(:I'E"3PQ+(4]<4SQ\YESB8NI)T]!FH6!A4WG2!12N97!:C019 MDRFYY8GGIJ"EDW#I*'"&8].35A,9]/ VYU!4L0H3Q>WU4I M>N"(KL\130\G]+M/C$JZKM6)937^L,4!D%]2 M.]MKBZT;&[*'YV*WO_>|/EQ^]W\ G9(9ZG*RX0VBWFB#PGQ<)G9U$X3H@MI'[_=NF;!?)11^H^9EBY6X;UUFHU9)CUR4O%)>1">s*#|\+*#U%-:7!41#>?#\-M8*0Y^)$BOC?MG..2NCQL2'-BG,5_]IFSO;$09UH8W+/Y0_;'PLOGD+%EM7_2 MYAN>:C!E)\&]E?93I^0%FZ]CKT;;XS-7A_2;2W""THX.ZZN=X !^A"=0$$;? MV?_F&NQ^D]R-U9RNX=Z2:<=E.>EMTL[AF$<6'WBF=3FV$\7Z_F[!(VDFN(@U M4#0CMFT.PK_27I4%W#LZ5PXHRUV6DMG>0Z 7/X_M&-QO/ER"WXX|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|KV:!+1Y$U5[=(3D@1 M]-GQ@&8*7,\X53^T0KA|^-'ZY-6LZYD_CUGI[M_JE:?RS\'-EQ"_M<'3>< -OSP?MS#S:,!1>A MV($A]Q*%/B-9HW68]R<^[((QLZ[MD3=71*S$XABI\XM+,KP((G[?%H&55%/HR:5LX,_R<;&&&X]$D@Z_/ D3;11L MSB+B)\4]J2Z\P$.H7Q82Z/,V3W#10(&"A7_:+Y-:C]DK+A(40^H,]$:./#NT MC1!OX[_-WI4*Y=QN:XAPG.IN#[=S.+X,Z%&M>/=)R0*Y.S50N:P.U.D)FI2 MU!H>BJJ?<.[M%UM_\/FJTTQ,<6*_Z+N*!B-?ID)(-I&57;(+1QI)>]),TW#\|-_M!$|\QIOA|IQTS "[N!'/GDH,I>R3H7V5+.\OXB>*I,)EX%)'H)_+R3K,4#3=>_\0.OY<)/^PB ML*T6!"\X-UH+U%_0C'Z/PH<>FC>O?OVF,_:>)_=0^L(3JAM<6C19P> MC29KI($?9/T2[\'[+ .+7W%+N)K[ZG'L3T<6,+9!]R\,@L<2!-M:?E\SEZ9)E]T$_TWU>H2-="TS(9;G=31)H5S;9'/QR>5N'K"2 L_0H_O8$;.XMHB8YFG{C1*0_1>2X2109?T-@=L!8QiL/2K=M M9"_8NX4N!FY-5 *;Z >,NK\|3EE ,0,1|U3"1+OQ[3:E>]<76[G+>VXNZ/I M^S&A5",BRRA)(%0%D8ZMEXC[@Y3%MEK"[GT+(>Z[]PI1'2\|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|M.;!V_!QV YN.>2/GP[9_Q5]A.M(+<-DLM)WO:AEH*LS=?_U0\N]9ZK$E]]8 M_>Q,XCQV6U#R=L)>4B?!F 6XY7&OP.]174TL8"MB%$YFG{C1*0_1>2X2109?T-@=L!8QiL/2K=M M9"_8NX4N!FY-5 *;Z >,NK\|3EE ,0,1|U3"1+OQ[3:E>]<76[G+>VXNZ/I M^S&A5",BRRA)(%0%D8ZMEXC[@Y3%MEK"[GT+(>Z[]PI1'2\|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|M.;!K)^

*{W(5:L,)8P%G_ #Z%R..7%@[_>?.HC0O^&VP)@VI><7I+#23/5'03XL%_ M4*PWQ\:U\YD%!@5JG]YP7\KY4^6MT5SFLSFBXT4@#+!+W6-1(ZO0+9/?1*

M:YYM\1,+$WY605JAZ!K"_ST+AJLX4X+=>1 M&E^F>M5T?L7!_2TFR2K:/8VW73#=]%AK0(_1GG&'@41L^ZS 1^@Y/ZU<'8Q!*

*M46!%M];GV44Q/YDFMJ1'Q<|L9L38=G[_@/IB=,-9F)8RQXQl,=D?2N5>60S>11"]H%HVVP$;DN!LV!\A.47TS&!;R%BNUSH1T2@K M6Z_D^11".G^W,_*8(5<89 7^^{IB:E3L=?0SV27YGQR1=UX;$9QRT^Z0"M>'6/0@M*K\6A>EZS;2+/%'SG+']#:_[NJ.%HR>ASS1<0]&1/=*B&'/O=9_QK M&6D0%LE12[=B:*0&4IST6S154TDZOS*

H:S"IY!T0\C=7[Y=8W"<7@B[Q+CYD M(8M0,::ED<]?PQL<&W7YM*%FSA$8ZG%';ZMD-XA7_K)2XP 8J=#!5WX.U!/ MJ204%H54H>$[M(E_10Q:>Q2$"&^?*

*4TG,9%+=TM_^=*X1L^09@C02EODH"UOV MV*I33'M]P#9U)MNR),OD42Q&A=F.V'3 1^MTYPB'?4U=FDV[=938\4,BT M-V:,"C_=HVGZ#4M_'F5PEH*CBY#{]"AZ&*

*(74#989*X[46_?_8=MWUS,L*[*P|# MU!00%*Q2Q7L.P1]-944CYV M2>]PE$;'53;.PX*!+',N&&:9LUR$_@L_F8<.ZMTLK6=%<*B--(D92VA#T9R/ M.5?@7Z_@Z3WOKI*8?*

*$\H.#SS+,T637-XL"]{COHULN'85:6RU*1:I9YW3T6P M.\E02((+#]@(BV*50C'+ME;F*;BY?N|$C.V*H\$@SB-2B) M9HL])/|Q78T_-IT^&>VW:,Z%'B.OO0800.*

*<>&LPPL1.E8%K,Y.PVST]LUR14CU@W.4A)6)*GB4%0%KDP|&(?8ZG7U'#7P(M-49':(V_ .)3H&5K\LK4[@O&O-"IO__D2\F/:I'O6'"4E!+(Y+.> [^3YM4E*

*M::M=^;CNM(*9EG;,6K2OE%P\8E#_,MSE@VWA]6=N*Y@3Q>Q8+T85[!8*Q!QC M:HQ&&-4B1KO!*,@RFWB]FO/OJ50&YO O?LF9D;@1.F/1VA6!@R6W&\]Z; M5?*

(Y%BL3(T9LB3[@.^L; 23"RT\;Z#"6%=Y@U,#F"G%":\T3X@PR2+2[!'R% ME^EFM)3Y#W6BIT5[\$*V3>QU<4 =SS $-^%//GF\=N/A$*_+I6,+_ #B=YQRF"[^.M1$XSM+YHU6X)*

*^#+,Z);CWX_U-'U;>L+>?3 LJ7=*ORJY#3N:7!8:9SWJ6/[M0.&0<(<(>#GUK;Z2B"FZH;(8%(59UF6<@0;4-N"M$RSY,23$]>+*^I^=11 M=TO-/GH@[WI3V]_0%?*

*57ZV_MY&RGDTNN QH\ +_#"8YON#A2PS(6S"AGI=@M MO09_,LB*BS5_$LNJ%YIDU$K&7B8*@U1.^+++3.50T$!]F%&F'*-?Z1{O/6[G M?C5#+EG:_E(')[@X.2L9H(7O.?*

*D"RQ9,\5S16E8/4HDM@&%U27B;@1ZC!=KLMI$Y7D\U1%9RV<$?HC4%&R@*A;R6*BS;',P7[%,Q\A M2Ff[.!7]G69C? 0"VB6&$: .LJ_I7<5EJWJBD7:]Z;*

*()4Q]^/+.XVYUUOK7^T M<#:7XXFN7M14A^UB'"$+;FF/K7U-PNDAABM'-<),F?KEO4 M,/E%%'|K.DXQ|NOR>>0MIW6*Q=8Q2FY[8(;3*5HNN68O)9A8"VLJ_:@8H[.B*

MZCHCX]^5(>;"PCAW$0_9^6_*HQ2G">)FSGF#"GY*;6O=!0+?)NPC5%YFI? MB[IN*BV?_C"FEO]1V!'>'7@'C@(G<"^&=S]#GJ2ES&=((4P$C%3!TIG8(;9;

M$Q.WZ&W/EGQ#EE0V^>%FI!?$.O6Q%MHA&0;"WJ|KXR;0N>)<$;&*QM#=MXU=<3/"\X|G36RQK/+]2T$'?+$]MG?(#.DGF(.6-Q^8L&N]#CEW MN0'LV:6L)O*7DLG$9QXA>)#?

*A@CK=A*Z(!13YX>Y)) 6Z) W5FBB]L:54 DQ="-R:U[9 MZY9QK;TT@]^OYGZJ_M(>!&FVQC-.9_?TF81\YV4X!=*5?RJMDD2K%@A#GUTC M6I4%]3$O@/ZX0.V+BM-4:_ 1L=Q"C:),C1*

*M, 2*V!'95Q",9L)+HQ|:LO/$>"]8*'#8H2=PNX0KYI8.7{4)=I8MDD%\T+YBA MQ6B*75AEFG/U=-I(&Q)+<:MUBXGGH+U^3#6G"P$NQNU%*

*M_5'U%PV#/2RS^Y_WN;KW¥;_3YNQ+Q&@2H=)'\VR;8W:,T$7 M^N6OI=40CF,@*W4P)FH%M;IV#Z0!-Y]7H?Q]H'U?I9O2+1"FPP%< M:F?;K/3^{^<('[>OG+3S_[_OOO?_X:%ZL_*

MY\)733XYEN3]U3__0/O{UX/G?W?II.XJBG^;,AXMTV,/F7MG_[W+]0}f_+_5-.L^LQ_?Q=LB3U,(_?^Z, HL'Z'$ M6U6Q'R.(6<39'816%%/HRTJP)?V(1%PB!/ .DAQ+($Y V2 '28

4X0CGXN\"+ M.P@U8G^1TP:Z;!|6$3,P4TUOU'R\S4 ?&W"";@!8?T"($!$;@1@FT.$W+1MJZ M:+5W\9;LW$'D+=DJK:S/9$]CP<4BM5JV(M>]5;/NLK/HZS-I[I3XN6"_':=EJF

*>,E_JKY=*6BLK*[*BH#6&AEKH>YVN4_ME2E?J//]X.L5QNN(X-4&,)44$8SOBQBY)$H@\RF"(8AO&R/*\D,;(M;&TI:N- MQL2]<(N$L(*W6%R 58?'!7BI,5&PU?29+F'YSL)*3?*

W7P^D"|'C[?]>WUUO> MWLW'6P55>!8>ZUG%I,%S3@^FT6#-K+'ZO.9RF=$8.=B/GU/<-Y0?^^+BOQ M/2P?]WLF*$!7{0955QG)EJEU?O+/W^/RRUV1OW(0E*N;T%$A. M?*

++T4 ;0=U@#0$%,.N0RZ;,*6>EO MO5EJ9I?>/FWP!4QAT&,?A0X_TG\6: -[GI:I:- G>_GG\ &>[!%'_S6$?#_ MF+/MI^2O(8M_$A1G!0.F9/^=S I+ V?*

*H1^6Z1R47]ASS(HE)A8)++1!U[,L MB A)N'L08AB&CN53V[&I'T@[!:?A3*R;=X*%&P==P0@=X)"$!6^&;C4U=YQD M\%L#][1V4])=P<(VPP,]$UIQ^]7LXG'"!@W?@=?*

GLVS':=@Q724>U|--/^4Y M_3U=K>]P2<'HAW7!E5WKSA$'Q0F+ QC1)(8H$]$)XK@01XGO8)0P.RD1+N80 ML*DOXEK00.P#M_DV02+%6 <6<39'816%%/HRTJP)?V(1%PB!/ .DAQ+($Y V2 '28

4X0CGXN\"+ M.P@U8G^1TP:Z;!|6$3,P4TUOU'R\S4 ?&W"";@!8?T"($!$;@1@FT.$W+1MJZ M:+5W\9;LW$'D+=DJK:S/9$]CP<4BM5JV(M>]5;/NLK/HZS-I[I3XN6"_':=EJF

*>,E_JKY=*6BLK*[*BH#6&AEKH>YVN4_ME2E?J//]X.L5QNN(X-4&,)44$8SOBQBY)$H@\RF"(8AO&R/*\D,;(M;&TI:N- MQL2]<(N$L(*W6%R 58?'!7BI,5&PU?29+F'YSL)*3?*

W7P^D"|'C[?]>WUUO> MWLW'6P55>!8>ZUG%I,%S3@^FT6#-K+'ZO.9RF=$8.=B/GU/<-Y0?^^+BOQ M/2P?]WLF*$!7|(955QG)EJEU?O+/W^/RRUV1OW(0E*N;T%$A. M?*

++T4 ;0=U@#0$%,.N0RZ;,*6>EO MO5EJ9I?>/FWP!4QAT&,?A0X_TG\6: -[GI:I:- G>_GG\ &>[!%'_S6$?#_ MF+/MI^2O(8M_$A1G!0.F9/^=S I+ V?*

*H1^6Z1R47]ASS(HE)A8)++1!U[,L MB A)N'L08AB&CN53V[&I'T@[!:?A3*R;=X*%&P==P0@=X)"$!6^&;C4U=YQD M\%L#][1V4])=P<(VPP,]$UIQ^]7LXG'"!@W?@=?*

GLVS':=@Q724>U|--/^4Y M_3U=K>]P2<'HAW7!E5WKSA$'Q0F+ QC1)(8H$]$)XK@01XGO8)0P.RD1+N80 ML*DOXEK00.P#M_DV02+%6 <6<39'816%%/HRTJP)?V(1%PB!/ .DAQ+($Y V2 '28

4X0CGXN\"+ M.P@U8G^1TP:Z;!|6$3,P4TUOU'R\S4 ?&W"";@!8?T"($!$;@1@FT.$W+1MJZ M:+5W\9;LW$'D+=DJK:S/9$]CP<4BM5JV(M>]5;/NLK/HZS-I[I3XN6"_':=EJF

*>,E_JKY="

*T$BDO/'V%\U/;Dl.ND1=0%Z9($>72*1J*8,;$D# M6]HNP):Z"R#H:]V:AL*NE*7YHO2(!(L_TA=%(9[UQ_C"Z(7(_A!?'+40W-MO MUV\4[PW1FR]0^/9[L!-[_]0T>CZC./U"A?*

7:5G5(2#E9NHG%YC8SFCA-@'X M0C5X>)KJ<=_$",%J!V^?UDEZ+$K1I=?R^>2]_5]'B-LI_GSZ,-:L^3BZBHK MJZ(^.YM.8BEI4V#%K*"R?*

V'16=#+A%EVXJ((QG8LZA)=!"L8$B($T:Q0V(K MEBKF/@.'B86X0Z/+2]V]FDU;))1FMVEQ6L*@GYY_:CI!X_V'"%V #2^[+/\:MJ8O=>\FKV5BJ-#!O:M;JCM2;A,6J<_?.8<[(9#ZMI>>T*N&H=$.L&=;&A@E6T[H;?U:XJ0+N!6CIGZ /Q@2)A1+FAB#-FC-G-M0?)^LIS,*S-7DEYO.DI9-K-]1!WHT-B&R VX#8>2$%HL<7V7U4:<4AO|LU&- M6!LTI8:Q9%UB?*-

>]:JK]DM,|\^Z"FHHZNS#4SK!N;O$E%,Y]&K\+D\;NQB?BKIC*F9:WA"D-CFG=PZG MF>UF3H/X_EV=SNMZALDBJU(J:C"Y2GM@9%W4M^^77\EJ31G]R(D2H-=56W"T M7[[9=L-//-

=W,,I@D#@>1$D401Q&#+|J!|Q /QS8B2F781K";6,_]E;5/7X10 MX5=68&[AE,TL&U&F\ON7E'P!U1<&V%=6D+1DX*40DQC95\(8+3?O<%'\!ZO:.M/W+Q)BK42

M/5)&;GIP@E&^&;+:S. T]VUGE(W%]#9O34"2.UA?9L\!$]9FJ2$G_K;Y*JN M$*!VQHLIA=BI]D2H:P)6:@8.O_NN*<0+)>N0BWJO-'EN&@JO:7)@.*GNN9\ M-J:.G?B=

/IKG3*.D:Q=K;===MB;A&CET'0V2Q"$:,Y-"V8PM;.&0XD#*450%_ M1\]YQL>|9GF4[<4X$=>FT\>3,LRX&E9FW/^G5/"C=*]&E?6^-]7[>+(;H\[[M>H&+]P6C:?

41UP*V=;A1C#U/F^=!-&((IQ:,'#N$)*:41A%FR)(J9!P" M,K$;J4""#];F(*BCW)%SZ,^E64T1*I.K[&@/T6/(;SX*8E8W>(C(?:!V\%E-

M8<3E%_'_(OK\BE>B"><L]*ZLB%>71X@^+C.Y^T'MRB:GC^Q:.(;*9(V]0$Q@A MYD'/"BFAB(D)!.WP@8<*%Y6D()Z#D\H7?A\S^>_^XN%GL+CY .H?+O_[UZO/

MB^O+F\>"'"Q"SIS03P01QP@4 %\7 63OBLRC>"'&^A8*+$^^E_],KI09NG1A0,2"K#"0_R1Z):*P1HM541H_> M+5"=*.QIPE4&KYM@@,:<16,,,#,8 %1#5YA1*+A\5YWD9.BAL@\2'(:?%A/&# E.:?

T]7:V6R.)BED0VC.P80Y18 M"<3(C2'VL1O0P$?<<5:1QV[AB46N Z,F;!NJ8^>)0QPY\Z/LPJVCT(*82[@2 M\B,+NQ1Y5H+5]HZM&O'IM]M M

QYG\@BK4Y&U;XQ(Y)X$30HXYH+>]*RN@8 M02L,8M^+$CM"5#62K,\(Y:#P93-*I#P>R*E;'.K4-.SHMUI9G^[C;$B%,I:= M56ON$I.O*_^KJ8;RZ):"B-7VH?P%_STOWJ]P6=

[@9]:F3+A1*$%HLL:"-B-"^BX2,V;,^&^A8*+$^^E_],KI09NG1A0,2"K#"0_R1Z):*P1HM541H_> M+5"=*.QIPE4&KYM@@,:<16,,,#,8 %1#5YA1*+A\5YWD9.BAL@\2'(:?%A/&# E.:?

T]7:V6R.)BED0VC.P80Y18 M"<3(C2'VL1O0P$?<<5:1QV[AB46N Z,F;!NJ8^>)0QPY\Z/LPJVCT(*82[@2 M\B,+NQ1Y5H+5]HZM&O'IM]M M

QYG\@BK4Y&U;XQ(Y)X$30HXYH+>]*RN@8 M02L,8M^+$CM"5#62K,\(Y:#P93-*I#P>R*E;'.K4-.SHMUI9G^[C;$B%,I:= M56ON$I.O*_^KJ8;RZ):"B-7VH?P%_STOWJ]P6=

[@9]:F3+A1*$%HLL:"-B-"^BX2,V;,^&^A8*+$^^E_],KI09NG1A0,2"K#"0_R1Z):*P1HM541H_> M+5"=*.QIPE4&KYM@@,:<16,,,#,8 %1#5YA1*+A\5YWD9.BAL@\2'(:?%A/&# E.:?

T]7:V6R.)BED0VC.P80Y18 M"<3(C2'VL1O0P$?<<5:1QV[AB46N Z,F;!NJ8^>)0QPY\Z/LPJVCT(*82[@2 M\B,+NQ1Y5H+5]HZM&O'IM]M M

QYG\@BK4Y&U;XQ(Y)X$30HXYH+>]*RN@8-

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{JF@ B-%E^Q$7\SXF)UO[,]>1WD>9[IKGXW7"TJ MA2SH:]Y7/4.F%+S5R2YG_+/Z=3%M^F+KF7^"ZZER21;$OO1\G/*$8Y*GF?*A M9(XSM:,)_#!.DTA"LGT&XG/@3)_N -9ZCM90K>LC 43@-ZS@(=*^B_0FF>T MR70[00!U;%^@1Y%/S-N\(Y:YAW/&QP8W^&:!SCA\KV1(#;B$VJ_]@5-RY\Y4 WM9TJ AVM.NY.=H@ M&*+C4P7ACSHC ;$-IT#S#D>)]FVDVEDD$QK%S,X4"];7FZF#[KH]]HAP7F+@ MF(&?'B$.]@&>%=C1-8$!YUI4O1C>S\MA]T[KWWNE M..;6_O!S1ZN+[Q5KLT:^_T*+LZ VX5ZGSW<9^H%F E/%S"%'*<)],:'>$]EC+- &'6:@)$=.MMDOQAF78(.!8QA\'@L&@0 M<&!JO&(:,2.TX@,UC*'6DT&@ APF#0*9W;F2, ^A@1TU@!'I/G@-`M[\X,D-A58V83DN/V9 : I-> .&7*OY:Q3SFM'F$[U8=;-[(J^%@LZ;3?"))1G6.UJ0IR&F=KJ2,ZH]$20AJ"Q*[W4!K8!:,]KUL2N^F:&6/'#::2]B M9K; &0XP({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s 8395X(8s#V;@%2

*B<>,=X!@9DL6^<%AK=8EP]7@E;BHVC^_M>S/K8CIL6>1.RXT7,?&R6/*813CQ$X8)%01G+/-P1GF0,1|%/A>P;*HAY9'"*

*MJG:>OAEVILZ^.SQL2XUKPNB7CH5_UTU85_'7EHUV,^"TY!@BN+L*9",J8Q':V)OGR5W 96&TR$F68V"K+OM MUH"\CKU1&QfV-UN\$8A:;*

*XW&7ND>J3HM<)Q_E*PFYDRCZ):W,PNO|'_S,MB M\7,WYTQPW1FGX 4MWR99&^0)#ST<$MTO*O=SK#:, 68L3RGS0M_G1A,#S^9D M5*.?T68,L&C9T]'IFK^Z0?*

Y+RR&::Q91M>+OPF+$UOFOR&"[.A;P=@8<:,:0 MYDLW%>XX0OUKZB_H$G78'CV7-#@P|+ H@PNH>F.09Q$ M+T+A H>M/63!¥!3"$T/'M$/FP/F+V+Q?)&0&CFV=,-

MY+BUK#!-K@PG7#.D.AG7;O.T7S'5K9&<)PN^=-MZ^@K^K?BS>U_W@I:EJ?A+A7.V#M3SR+ M29[DG(HX4>:9Z%/D(,=9)!*IM8R C,Q]LB;F9U1|*

0>1BN6|%K7GDQU7%V@%N.K%<9KU!#B#=V?QAAL MH<[&QY'5LN=C5$MV-ER[UNW\!UK6)W1)T5=SM5W71^U-6G0U\2+E<8;)Q%F; M!

[HT0>"4AS]D9=X+,"0DRO+)#'U'F'Y)]HJK Y7#HJN')' MT'D8V44%6YIZ['1+%;W(.CR:.2F;JW.5XX3&/10V?#>B<;I. ^R4_<.R4MY!.M52D/(^]FS=C-&:.^/R2_7'SNP.*

,YT.&^WXX/M,'(19N4N<'(1:WA_Z<.8GQK M@ACHT|Q\:4?5#%!$8P>0(RT $A!5, V=46RZ=8=.33,VBKJZER&I_F7V.O MA>XD\J3[TH#

[_AH\:N#M=\:]JEG0L;VGXD5HR__E|OYFHT5=8%]M@#*|_ Q0 MZC.U"S07=]M{(. V=S&\NC[!DXF@ M5&UC/9X+Y1@G%--0""RB))*QER>9!%5[*'", TL GX+'1V1-W0P:]4XR@^]H&T*

M@8LVS 5V$O8:H#;C*)EW#UKU56&O_Z6> M^]G>->KVYA MMW)U'+$PFC?D%K)-A\GQDRT2(G^;+_6\S:8CV/2FB;U]_GS5]G&44Q8$$<&I M3"-,1, PI;[$<2P\1B(94&D^,KB?

*UL"6N.9JH)7^|% ,^K=B7+D^>/6;/<UHNWM@)4TQ*W0<4E^0=(]@RF,@YB%;M#"KU_F[\"W\UFY(;<^^7$_9.VX<{ZV@Q=C/+H1 M^[KA;PYTK;Z S-VS,[=<7?Q])*

*{GP6XBCV"-;]TG 6R@CS-/<2STO"F"2P MY-:#=*Q.*F$ZN5& .ETS (W/'$+(-#AC*[5E!M.*W.5&\;W+\$R//.YB,X=H MC!R8Z1%S/RK3=[&=5EXR-E_,%M4]?*

*=/;3GT0PUBY5)__FMA5^R7F@DI*N)ZQ M1ADF.9KC/)$99GXNL\1/B?!!B=, VD,?KK2&E0M$&TZ0:+,VUFD&,)V& MX&NFZ0.A!CQQZ0!KN:CA:?E 6\;ARK5EL)#?D;V 4![5BEA*

LFM;,!¥A<2+[M_+RX+DM=RGGYLC ^?-VZ:VA3\Q<2<.&.@.IIWZJW&0>A=1OA3%(6>UZ<>B;]=.CAOHD,.[5>^A0S MZ?N>\|>:!9

*-@/=[?M*WH/5<"7&JB,.0%[-]YEG2PE1Y7;$R8)W* MT/4I[UR78ER/XJ@.Y,.00FT'>5,<^T3_VHQ.B<6$AT&4D#A7'FO$,/%\/?@B MTOW7>9Z'-?*

=$"&J4=H+>P,MQ1UTWK%D%>)LV-M'YC/VPF>FF0S!@FKK"H.VF M5Z2WPSVW/8!83&DT$M/9M.9^,B-/;302?7]ZH|EMEB-OV'?!EW6+E,-% ^'4Z M[R04,H_4&JM4GZK-

*:N#%,$_4,DPB%D>#S1+ XP$8$$QR)C'-O0"SA).$TC 3L5% ZQ$ tQB:@;W! MFB^J28+R\8 ^"TJ_A+D2%Z?(P4>0)Z4UB[C:U=]1UE>/;+TIG8=NF^\)*X>*

*MKK>2N/JNLVG%*4JI:SP5@W7SS[K%Y]=9L:C:#,(THFI/H7P,/V,Y)D+Y&&DH M(K75]UE,&/=BF9BWVSQ!;6!CLD$>-7UX:P90S0'ZY7_8P*Q./QP6R:@GX8!TK'0(BV57RCYX7#6;-*

*)2ROZ'D]8>,V#324)[MQI"F M-UF/_*R[2[;QF/93%*&DL>0>SCU&U=XIR7#&&HG#.$FY8(D(F5$;X5XJ]NS M56/4EBAX0-T!?,PV/V=+"[-4NX(ZK,8QDLC=A+D#-*

*,8>*7=X_+]MKNGIWM/Q1X MNCA7ECRD["J?3|\ 24G4BP) D/:L1$RU;9'(S!^$1'.0#_DUWZHP+G!?S/'L M:OI/U^+=;IZ%,.1)P+@'L<@2B!!*8(]@"BD49SQ)/52K0@X(ZH#K\;&C?^IMZOFM&?E?+PTG(*]8,=AMM<'4,$*&@,ALB:_1:?/POU9,@(8+&ZM$&R<#ZV0(MO.RL%%>XF=DMIO)WVB_.@XUGQYC*MV7/&+]LH4E7M5U:A5SJ4Z5U++>VR?.7L MMJ@:/ZA 0U9GM^)9'0&R:@0Q]3#E-/(H3'S53R%*(T@$C2'#8>!C)$02ZK?B M<\,6T%$?;I)@7M%5I\UE1;GJKR.-_5_R>;?,7$X_0W;QH;.T/0=M,K;]K3VT5 MFFK.KC>,.6O(%P58<7H&6E-*

TLYZBFMT/F0^#W>%#YL5N^QAW?LPV&>=/]WC)'Q9B51:&{LG8OY)YBFBU6.PF-$ M:"]"ND?RWXHVYON>OW;GN[|:=3CWBI1(?(X@81)5'U?A-0CB&>1 M45R^&

[:&WH+[':$ZG@*],7M\8,C M6]Q3U>3.%_-ED9/7JKS]U;S[,=&TF"BGD0A1)N<29EGBJUZAJF <(S"EGF H MH3B+A?8%U&EZ VO 9EW2-@=5N]"?>5UGUJ9+]"Z4&G=&;@$RTV0--

EO$55/G MK9XCCB$QN+9Q"XW=?4Q/B,PN6/0%[KPYT1AFO"L1?9FV!CH,7K-L)U:H_ ,+E M^YV<[I7J4B0)OJCOOZ.@XJ%ND;?BX@PH/BSK:NK@J6? ,4;)\,YC,7^"U_F,--T>Y=]S

*M5>*K[LSDONBF@:"N.HUI4!RWY9@^:!"N]QPQ>M0U45KFD#W+'X&I<5;.E:M"D M3Z.,>|(U:"\24H|&/DL3$-$(R(L>JD?1#6P2F@2FM>DP8JV5:N5 M+LSTEK\C) Q/:M?*

22^>L061%^0Q0!,JZ|\U^Q8-49UV1C],Z0/ZH7>>*3+&+-4N>9NAH.RF"8F9YGCZL-EX[R8X6;@S R&GYUSX^1K9^:,H6"'0 MZ?B8C3B>(V0EZ99C9#>"N75Q*>5;S/D]IPMI#[]_?*

>6/B^:X]U9.5@NUB7E5+GQ#3!GQJE&)N"=MG4&PLU00;]9%S,AF ML@# RJ8RH3:.S64A?-LFLWG=PE:I!4 0-;(1]%#3LIUZRF2WBME@V-M"^? 9V M3B\Y[6P9,WG-

C):CXG0:)OMOC6=|'.5XR\ X_E3?_B4',1#+.^^MW^J6&UP0 MFD0H@51J"(A\'D -<1 F,48(RGWH>PEI%Z&P9&%BUM'N,'$KG*\| >6__H6]-*

*M$TW8|8XDAP33>]YQ[%',QOS>)RW1=D_T-4LS .=XJO7 <2W6ESE;K7,>O MKZJUPATO\@6K*E$ D]E1:3(=24!5G_O+>988I90SRE*HZ9@)#$B8I MY,2C0OB,B\@H76>?*

*Q.!J01%4*J$F.5J"< \/O<7>3TJSA;TMX #7G\>%<596 M<(_ R+4$CPFX7T#PZ)-F*TZU,K^8+_/E^\4S+U2,R&_%XL?RNRK\@N?O4{G8 M.!@G @:^(! 1+X1!+!@4B> QQRP(&=-9=B?*

*H#+5V:LI@11K4M$%#7&\MGD*] M>T$ZE-]L55]*KKTX-07K.$F4(J2+4_ZP69.GQAUE86H*MUJ=NH_;)K/*3>YX M1/F7]V_XGXOB?(.E;,^N_S.?1#1ETKA&ZDJ7<0]SC H892CP$?*

*(#@HQ. SI M#VUKE]DYDG116F;_FH&LMPT/"\9-N8/FD6*K?TLSM)ES:B/G$!K]W= M,'9JZ$!V4-FI7]AI8 M%?$)'S1+A2HESF$:(!1@C-(!.8P21%4V2$

*DM*T.+VL#+=$,>E$W3$KIBP"#[X"1F MW2O6.1)F*[<%PHSRYIVZ_KVNE)V)AJ<'&2\+ -=>;92#+1?,H|PO>=T(5WN+$?$/R3+6$X,[:%NG*Y?#(_""9T<,,NX0]=&C>^7R/HE[U M!=K7UT):J+736!V8W? ?U2?E-(T32A./09:1\""+DQ3#CB$!"B?I$Q(0GQM6_M3E$=>#&O@T:JHJY5"GY5],"B\M=)_/36M7-4S!9Y70&LN1VO$6@.C\Y6,722 MB_H!AZ4&C*1V60GL),WQJX'IPG"P(ICVR[;=,R,,R:]/>;C2[>W38.#CMRSXTNT?8[;W0^,5L$27[#K>,F\ MQTO^\ ,_K(^!A,\2'\,@]7R(8LPA\6D&*?9Q&-(8H5 KL;*;S,"+,_#\#"AJ M)8!@0%0+8R+#AU$*ZQC2,:09HX%&42",>V1T59O%$[OAC%!=$*7 ,GN;0VZUD[C MC?;.(C\+!8N@GZ8$HC1BD*0AAHETXP,7M,0)#@\#\%-TN#RYQ 6 M&O<|/24T/&3;$L[U14Z'*)WW.(?>&^_JIH/KK=N:KN?,W=VF8_B['Y#'?#GC M4R%0E(9>#)F@L;0,A71R0RX@C>,,"IQYOA_].KF[@P^\9"H:ZHS+#WXAOZZZ MSK_KN[1{8)QV9/N(:+9F3*4SDR,MF-Z]!G+KM|UM4IU-M*E67I_E%1 @,/77C$ZK&A 1BGP[($28QCW# $Z-PZUT" R^B\|,YL'1"_T_O M,Y(G^> %%_7USQF0PY[Y[?}7^5KX=? E]4>3_S=E_@B0\RY+X+$A1%5H<)V=9 M%)^%?KJ3W^4^7+PN1TP9^K\%.OK_[=EI=#^Q__AQ\Y_AIXB%M3C?.6T_9%?:M?\12>_3GB"Z>J;.Q.K?*Y'"YXN\/OSUMU=WQ/ M)%XH? $A%C"|*$@%)@@EDL1HY M!WJZ8#QDS31'#>J7/J";7VD[P<+5Q7<_9L:]'G<"W-XENM1W5^U3^B_7O.Z M66\YS:1V(YE'8))*.PFIN!DABGA#[IP5]D?\ELQYW5" M^X]<.K^XQ9: [",DME/64V1#8&;]MT]?R$QVTG%[,'O)\A+OY+;*?YGK^$!@F M-_0'W[=TO'#Y?3)GZC^]C]MT3BH%MCS'1?$NJ=8V/<\"GP5^"D..5,IK2%3/ MJ0!2%] LROPX%$;5'K6H#NVB2>)UGQ+U-]^P8>C_: &HZ12YAL704UHA4OW0 MXN!,N94K)EP5;;42VI4_I45S7"?+!(8]S\OH9:?62--AI+U11@&._8A+'4%H M A'+,DA0$D L6!P%H2\=,*,@ FW^G]0>Z5%R1QOS7LY9)/R3=62% M'I8^.4#W,@HQ^0M% Z!K"XD[R:RY7&KQ=E>2DE.%QJ7M40NQ725;N[*%7K MP<\RYF4"0Z&.@!!/$,Q$%$B5%! (14)YX%$WG_$EY<1HWEY9L;"VC==_'#3/: MJZEIW2#U"\>%2N>M:LG_+O\9=Z9"8 MYO98DPR!7Q1+OP*U8L"QUAAUS4!P*\ 6;R. ,!#O: 2 [7H@#0BTV1UW3X0Z M[\%MQQ[OKKRG]%OWZ7W',@_Z.O\^?[J:7ZI2+,;?B]G59LOF3M(`_F+^52W;Q MK^7[Y$?!RM^*^5*R<%<4_RA6>;N:H6'6! 8V0_\A53U4F7E0_03.OZL#:,4% MM H3]15+>D55Z95EW7FC+F)XW?I JAW2_#X77IV9P/KKWBM&FPFRS&'46';,V.(`3*]+.GNiH<7>]@6E'Y_4?5'FAJ>MUMGB, M?!+X.2("9BE$]> P9;XTDK'(O)@%]BN$HZI2US:YY395[#K+'>GED=L#]N> MNX;)3&>Y0.AE^:<[D8>O]70|:OZ]#0@&&59SVW[4\VU;^>W71W;D;-UU?WG? M/-+<=!B^7!2"YY4?NBKQ- JDKO!WH6^;'28Q0 M()WVP$L@$L*#6<(H3#)5;]-+_"@B1@>'GT*LH=5>S8L%?GDS/YLSIR M9(O93)D7+[RHCQI-3Q_!7RZ1YN?@MEQ@E&V2J6T(U+(.S@8M*+D/%O9HBU1 M024K6$IA5_WAST!+_WC.PKLO8B#Q4"[_/.8VN3H_,#IF/G5U_+NXL M=^TZ!COGY>6]PTNKHOVC'\!

*[W09(U_6DV7Y:=*LJE>,-L]+HM)GDM6Y S!5 D"<9(P2&B,84&RF!*D;,'M M"S4{B1YZ/]%S@::M-IO\^1>C#WQI%0*+5B.'6$$WD/L)85CHW"BB1>VN)TB MZ\JGH%8%=KITA8"&0\TA^G(P]/PB,T.BZ!:XZ05$;U"GVXCC!7QZ6;H3#.HW M@@[9F_'1MR'&0L@L3A2'F<"F,7)20$XP@PIAB251,>56?NU3 M@H8^B722PSR\C_$Q_Y LB5WG(\SZO5TS/07S9Z 80^-MN^D=Z%S#;,!A^!MX4;(4,6RHPZ7!2;PM;#@0@HY'G#5XM530BO6)8>\SWX%/ M \'@OYY'X C$D!;F]?AW /CL9^%%3M<9_-YWR9D/Y93-*>\;D1,JTRA70C8-M3HAIF9)!AE0,,4<9X9(*;G=1=V3\H7ERZ5;EVBUP[%S$cC\T"TL\Z)N8QI4G'"9T)1F N8BEA K-M@8#E7,%$*6I6DIC%3M?>VX,//)7: @QE+L4."87%+Y&NDVD1LH%:.0$ M#!\_H'VH(/#MH<<-Y3Y@U+N [$.?\;YNK%Z4:=M7=X[I=O@?]A=6SB91DK-4 MF. 1EE"(&>$FEH3 5.5ZJ4"\H+E3+'6OM.&O$DV0P5KXYL3Y:R/? $N_'IDC7V]=]KL Y=Y%@]Y MG+%#QL8U']GZ?1U3,4FD)$61Z/ULQH3>SR8";AK)3,G 7"G<*4TSM:R8/K^_MQ--$/#6D'0ZH((PGBV/^MX6^&\T-%,CLU^.MWI\OZ'6I.5K&+[_77S."&N.Y?<;+#=,=[-*)8{IB#]^1!3958*OE),7-_{1)P M;.7(N M^CV_ID^2'KP? 3N%^RDNPEV.*T$K>E6.J>G?.%"Y>"$(0BO4G*,<^O/X67I.Z4 M*!+D"\]9F;@E62;]\'!052A4_V)__E__]D__]"__%R'_.^\VG#S^]F\3K*QC/?WH[!3^']-.?P_GG MG^.:?X:>_3:;_._SJ? SH;^7F>3*\(^;?NG[V=?/D^'5Y^GO_$*9>K7UO[!?2? ME9!4))$)1++!$6N>) QU(<,9XF:C0QOX_E_],I=84@!.0!G\MV42\89R$X+*2 M0+,7O/O0T7#\/_] <_@A^!C\A> ^-9]^V__OQY/O_RS[_\\N>??_]E6YB._C*9 M7O[!"*16_K'[fY^6O?WOT^W^*[K>9<^Z7[F]O?G4V?.H7\6/9+__]MP_G\3-< M>3(%.*:3$7R"_%/Y[^^?3NXM.?5i#/,_Q.G5+^6O?WD6]5.T-+>D\C @HB1"^ZK .+>\AF.&@^VIB[OO P?$3"_QR/OK6=/+G_//:R=47/_X^_M\:.B!L<(3; (4H@M)G..)9&FESCG*X&N<&$\NOADNFD\S[B[8)O!Q_AE&HQ7U MEF',+!0G.B#A4E,$-IH]X0)6G/*M^]1.'-WS;"4JQIW MW@^6W0P.#6&KR'G\V&P1#63(&B!.I M$VF2))38$3;K,&!;"![&;&[%VZ"!2D$Y.P$@:S1[_&] MU HK2CAC)DHO)0]M(BYN%MX,%0WG+6L(M!HF_N671V+\@#_8\EGVZ<=WQQ_/ MC[_A%^>G'T[>'5T^8S^.0S04D\6;KENDB4 }%A*E1B0H%TBRME@.MA/9,9O?,5LM^%CH8+!==[#<8S6>KG[QNO-?0M:U5>;3&A0\C&$2NG&0F$;9X M7+Q9<9FCZ\PQC. (6!'I1^^*RHZ"]^-[0\+*YE00=X]'T(KZ3S JO3S.`'3^ MO7OV6.Y\)N/9F^]W_^;HVW V$)PCC8X3;2D:9LH=="EIPKQPUFC&@3\7T&X# MI,VI:P1D6V!@C'@N MP;HKI!94] N=? >G[&5AM(?P>X3;,S@=':.0)'P\+ (CWT&W0UC=X!H'N72'2F M%+5)(%9Q3GQFULLL2FYY$_C@$G>@@[_=PF;]ZNW 9AM!3JH*MP'K!QGX)&?)8M!3FI M9MQFH+',. XPX;D!!D83K05#BVI*HE$C.XH:HY4TXMFR@.T1\H"0?H&RBV:?M!,DN8FX *V_]\//1.)7_'/^?Z^%7/T)F9D?SMWXZ_3X<7_[A1]$D12:BP!,>7(D6RH'O*.$>F^UL!BMI51M)Z:?GK) {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fXD{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{U+0UVW\BOR?C[WXX]IX9?(5U"*K, [9+S:4}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{J#SV0 M65K']2,>DBAIE=*() >DND@(Q595^_CT=#0@_I8>&$$PFODW< 9>$/)0B+% M_$[6%1FU^;=@Y2&"D>42I{3 7QSI:2#JJ#RC(Y7CL+ ^BQ!C6!U'TVO \W. M8F\ 0P]X6+;OYM)3K[0BV95R((/^@&.EF[?V+%.G!(7;/:B>)*01S.RNZ(?5 M- #M+O0'H+":4+ENS!TI|\EX3,.7-4J*<^!0RH3&8J.*+JGH3A[OK]PN4"NI\ M>+>RK6P.P,6=069+!KCCP4:TML(PM+9@'7&TO%VDW$D=DDJBMCEY1$2_"-E> MG^NGO&TAW ;0<912UVW/C\[\,)V,%P,?1DMF]$I@&$;(+NF24(NQO')EZ,PQ MYKE6.;O:%VC/$M3O/5@UU-03>@L(BO'ZZGI4+@3676.L1):9@Q0IH8J5?C>Y ME,$K2S FL-2B'SJFO#NC(%<50@41K M8"F&"T$+/CA3*+!)FNO?S'#W]'FGU7>5JLF\ 1V^N9[@99K.CB&);SA8N ML6;*"K>#S<25F>12<44"2XPXH;+AAEI(M=]ZKR&ED<*@W,X-43=*&+*EU. MY=YB& $'12A(H;R%C"3@;HF%)G4U$A+JS^C>Y&H?H.Q*]K?`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|&^SR21"&9>91Y27]MU)YT6B^NW)T"0P MZRFQU_.Z\TIN-]K=":NF3\7SR[Y/A>/X'\G4]A0'5-FHN CHAX-!9#H%8R8 D-MI6S6S$81XD:.Y&;K]=M.H1G0{4M#]=C$^P[']NR4M-T5QLX%T,BM:PC)=GI#H M0$E0WA(&U@)D:.RHG35ZB:9^NRTT \ZIJ+"");-'OXRGXT?#OD.ZX(3 =?D4> MOW:M)1)CG.$NBX",. V,6!> Q$@MQ3+.5GI=N@%DOKMO= <)&LJL(F0>DU+ M- LQ.I,$.ROVUW2A.0!6T%<3EO#DZHL? M3E=3[N=^:?#D.HT5*=?9^.![.880;*@V8T@QT$&C3)?]\ 2BQG%.BK6/1>,-C MJ'UQN2%!/?=7:.Z9^]:H \F>U9P1W&YA..[T6[QEE!]RBE_-4+;3I=]GR'17 M(C-[^]E|>3)&%^:Z]YAY^I]\&/HP' WGW]E VAB45(P(7T8%1&E+^: EG@LP MRD=CM:T,] .QUG,#A^8V2HN(;F"C/:ZR[9Z1W&]ALR1'X[1B<5BZ LYO5&*4 M%L8Z7688!B(]*!(\&*TT"DK*W3U3KP[DMQSXX?F-L8A$= DX(]B+)N|O-8# M#"G*B" (1/0@,'1^O!S:!K5M"6&8KLWB@:&]{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|#%'6]LG MS?X/@[TEZ=[$^*N4N..$6)3 M,YLO-U85B(%GA@00Q7#[%Q0XBS3)*1D4\# M VQMGWS_N- U;@]J1W+Y&B:V.{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|\^^]IY:PT)8-T M.NV:DZ'/]_&Z>/.K%F6+OQDUPYD+6WA+%K" (H*4VL,9KD8%E(5'(J:K_]J$-Y M(S<6=4#8@S)_! @_9/H//[]&H]EL>#DNW$KOK?.'T!Q$;5\;B+,2B+(AFN1- MBJKV#?UN%#>2GCP09.LIK\V7O!^/+G[_='SZ_LWOYRW-T?G)^ M^OILT_'Y\<>+HXN3TX_W=>CLX>Z&GUSAG>XV/%1ZEGLZO?3CX=\DDL6:S(:MIL5>&*>S. ^RGYR5\.GKP_>7N$]N;MV\/?/UZ< M?/SKV>F'D{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tQ+1 J-M2T.)9HYDT-HSRYFI'L[MKPSB$R#LKQ%2<7(YA*NW0K?IR1%G3,.$4]4*.7J M!D,8SU(D-OGDO+)*J=K9I!>);K;XX378>&B*ZJJB@;)KY 2&7TM)[NPA)R!" M#*]Y],"\A+N3DA/8$5*):,.L@U7XGNYZ:?A^Q[0U-583? (S>+9=]BR[^Y1/<-MA!QCL)S$Q;4-AA<>&4$_7QL?*

*A*0TUBXW79ZB?I^T[0E.%97Ø *36/M1{R)?& MJ!6<+_,-=-?2*9(@(B.<)XT^)N-"U4ZK;$I,OX_C{@2SO2BF_<`]<0&]W$,# M#[,)!G(9H8'!1J*T7$4IM,9!)\I>U2>D 51)+:OH][+8G4%42?@,P6KTAQ9UQ M@GH97PIQ?%\TK%S|U9*Q;(7-3#D2C"A]>M @!ZDH82* 16%YRVJ?BAL3U^_S MM#V!;#^J:0!S-],Q'YI@%O&<+^:+ATC\Z64@%K<1<<;2&$MW7F\K0VP=+?'UV MO-D3HJH(O@$?4#3"!"U9'GD-R;OO9?"BY1*!DT#[H4H'6'>>)!L55\^/7-AJ MQ-MZQN2MA'"W ^&L'VHI1&T3>$SCW-T MGNL4,N&^S,]4$=U&"_B'!0?A]!2F&CU_43\NNHV0O7/UXVOHKT&\#1>S^< M=@U!?L, Y7H*M{G>AXP%Z1RJ3DA,;O.58)78U^]O,;*8A.F)6@S2/UH:?AZ.F@ 4+<,/-P9,;-,M0$$156ZV@E- MO'!&,8N,A7N9&T?:RTQFP'IQ\N^UY!] R!ZIO7#TX=Y5-0)4XKD(40BL\MH M=04G.EF-QSPS.=;N$/U:&C>#W(^6J=^KIG[$N5N@$3] N7EQ^ZI//DIZO=? MG$PY0T\DKKR.QV<+E MU^#FT1N*;JH@0/TEKV'A1U'X[2]I>AV^QT? ;+GTG%"8PA$!H_BC%)TEEGS MR+V5M< 0+7|_+(2KTIHBT6GV M^%NYIH4'O+-LK4.?E01@Y64YJ?TXU]2 V6KK&A@^N((; MO=I?NMEWG>/)G_^"IGK3A=`UZF(85^?77=U1FR(&)%_MU!PEE(/(fDC:O>=+!49A@X"$"WW4*HW:1B3ZPT6_E=QVSWI ;FT/_$W(/9F^-]V BOO#R&$WOKHN;,UD*A)LR=<'(@G@^!!B)*XII))P[FJ_CZZ'OG-EJ+170?EAU=L MLF]ND]Y\?^-'?ASA_#/_*_3R?47Y/.6+V6%3 HR<2I3(LL 4$^5{[=SUI2 M77^&YJ;T-5NYO@LF]Z*8!@!WN]<>WC.5,0<1HX%WP]$UGB8/3@RAC-<<,#S% M; ##4U%:E:0R8"$"L"0#"_O+(KR*U&;+WNN8R/VIK0%TKKFHNI,E0:^=*F,) M1?DMLB1>210DUPIL%CKJ-]T7ME\?OPO>JBIB:V!]A6F8U"@C_??)<#$_SG MV/"6'=PU-Y-D3L9Y,KU:.!/WMY#CWD!6Z"9SM.TR4T-0=$ L\R);JBA7#PJ9 MUY27{D!$LQ7RVV#LH!II\X9GLW;EVU_UO.KS#]9^?8^7/ZlLFZUT1ONDS\C M#Z,$(:0)F4?BO.(60'B;,Si.,&P3|E>$5=<69K0F]620I{=9A;$!VM9A0/A&B M5$$KWF-HW,AUTI2!MD-]-7"_0?K#%>YX 6^^+__M8+P2*:7ST 7-5Y4A MT!.(I8FPXH)$'BP/T6BP^[M1?!6IC39Z?PVsUING_2FM30OU0AOUI0W69A^]-M_T;P>S1G:J]!O-4Q5% MM&F)GN[%OH(/']-SGI:UW_#[-S6X=NE562?.0252&EC*!1+PTB83D! C!E8#:M(5&_'>3O'.HWS521F2#\"%RM[\PW"$4WL EPRW"R==YA'2)_QS.HSX M5M MYC9=@X]"%[]_.CY[O\K-HHN(!^_)^>G[LT_'YV5,<3EZW\'<#T=;^0JO6Z"" M\[#1Y6\B=/II1\OZPI+Z,4Fl,5+1ZW>HYR[A7+#P$7C7%-("R!SR\EUS]YX7>@ 5B4O M""^-+,6RG;.V*3TQU"]1'/UG-B3A/2,]GJ*?K+(91>I-P"=TDUi&-7]1 4S,HB4NQN2S|#+8V]5ZCXCH%S(5%/M$SZKMI=P 3,I(MIV$;^NGW<|\%^X65;@=¥X;71+A+E?2 2RLM]XQUQ4G-FE6$R5W\"LHZ8?H/5 MPYY?5132 K)NR?_HK_#+.,|$"M\D;56UN J,_#IYYF7X#*%F)N(K^PT^'9=>LNNEWW'P_FPZO,.1[V/(PUBB MO:4U31%--P001E:4^^.,"89R=)XB$.@K3<$8BK7+M00CUN#6.,%@/4R!+619_W@@]MX MVI6[NB:59-> ;;F;E%IRTE5LS4YFL^O2@NA.DFH *3@7]>(:MJC0:G 5IJ¥>VOX*^?N\7JL-K[RIJ"WYX6$=8!;T89 5.9;3+PEF#?.)C8RA MSREY9JR\&X#:(X+7T=)OJO 0L-I>]-U-Z&PZB0!I]A¥%9$Z>9S,D9!^=']-MK(@@>;!*-A[SDN$?@"&,S?@51_=2JAB4=`N8;+X9WW92OHV2";Tf6.91)3H$0JBY$&M1X(;I:T M5XS[5/LU\];$]MOT;6_6Z##*^Q%1NFRC.XB.QFBL(S:"++,<*)[}(I #:P>@VJOL1(;IH=WLZ+0UOWT">3,N<^(&TRG G'0FRO-\1 ME)-@2P$@-9$GI1R+M8N/ZE#>;V.Y=N"[NUH;/.B_ D "8ZAU'6Q!!@Y81A% M-H ^>4,.X*$-R*-0..!8K]HM:F]@VD*L#8#A VZ X.BIV1AD(1&V/^)W]Q/B MV&7B(U$)IV5!9]$[_V$Y.[R/8!"WQLNM15PFT\YGQVI=#L6X1RF7X<1W@.1LMO=(='G?NNN2^!TF[ENO]#YD*4!],TI/9F^]GTTFZCMUHF.5R%O,' M!CJ5.9-<$A7+'+CH<4=[2DGFW(0(&K?E_AK?5&2DV8%5K\'@,RVF>U)YSS4_ M2QY.ITL.NLJ6[*+7D7/"J,9#RA;&J19DB1^'1SWWM6H]GE]I58>< .8&ATE% MW;2!K;L"6=.TH(.j,*26>&HC1B]6DL!R1/!5JARM$YRQ>@!{3$! A3Z[Z_0Q M0'84<-_7!B=7_A+M^}2X*;K8K?3EG5)6BI0&2,=4T:<2]H,"8)O0IF*BJ/ M'1'Z6L*ZY2'AQI=Z/1:LN)WL3;-\P*;!12W%V:9("(NZY6*S.V9(-+;23@N6B MD.59#R5>T$AL3)Y"\'3$!+_?H?$;I&%$0:5]T$&7-MP7888_*:@B?)9${K]5E9Q*8+9" \//KB?2II]@V 7Z;6A^6%:T:Z3E=XZ(%2+ M4N>C,[$&O_(*LN74@(?-YE8\^.!^BET.H_GMI->WYO\VF?X/?M+=_FIG^/UD M7&S9?U]/OZ^8LA%Y4C8117/)?WE%"%HOHD5,X!QGUNN-(+'IBOW4K.P.*WN1 M=]\@^A7\;/[Y+0KV##E"82U=KVZJY*HH/M D#%7=PT(B.OK&$"@0E[WA.AK' M-SQ.-EBLG\]6?4.GMI3;07*]?DI3#(.;:&A!O R[1,>?IP?=.#0):R+@SJB-%=Q,^ !*4X M&DF?N),<6(R; N3!9_=3 '(1.PBPP;N/V\Q?=?N">8%5\X041PMF1-#)@0G MP-#Y#DSX7+W;XY.$]%-WL4?4U!-[W^;CK?\R7*D"0_2%-9RM1.,YU=3)+AM$ M) H"O74F2,XF"8X_$T%N9$B>6Z6?.HJ]\S|R;5O@+P,7B(CHP725\;1Q\B= MH7@]2E8>]%GB=';$Z8D8-&FAP]%UN#BB0_O)PVRIR3IKL)KX&2Y[QDQFW-D MUA#03!(9LR?!X;=*4EUHES%5?R+T:H^T>]JD/CIVEVX#T'CM->;'VT(DFZ2(M$$A&/ZMT-Q#$9T5)IMI RL!<]8::6Q/;2@?%OB^-#ZOU!N!]AZ>WDW%7#O*W M(7I[2[Z.O\71=2JCWV8SP/^EKH9621MX%H0Z:LIX)4UY3NK^YD&.P#V/S MG8&]!9D]]Y(]#(`FA]7F#UCG^-&C:SH??@6VK[+&QROLNXKQ!9IV7]3(G&!@ M'49!PJ-QG2>T<#H3,3)%*BY6[4*=)KT>+BU>#U5>GD(C"\IYS M99XH33K9L$>"ROV MILO)KH)M 0VK3)E5.F:%QS@UI?V4I\BX%X1Y%,+1@?N'36^VQT/?-5A;*NNA MNK>07.I*_VTX'EY=7RT)=XY[X9!O;E574"V)8[4 F0-,6I+3CS!?%1I1<;2 MQ$9163I0+UD=C@$N2-E6GY-]"+Q--O38\ M@$(Q!70[=<%BU^>5M=.OO.,%H>4.$B;KE,* 2,DU-TBZ[.S.*NY"[R%&KW M/UM#2O.9U-VP55,1#>!l;2#^^PSR}>C#,,.@5#24&D$B@H^E(HH2'W@D7CD>M0A#*R]K5+1N0U?PT60=GM174 .;^.IFD/X>C71-4 Q0.8-$LK08Y1*.W06E2!& MEE=8$9@.M3-BJ[6;]ZG]H&512&U]%+435<[+[$.*]Z);&@@#9^A3,G8,Z6F]-MS)YH[5VY4P42@HPD>-PRR<>46&WfM0E=/3!P/B3@JNH=@MNKI?^&_+Z02+ M$9SS@9 _Z\(QD9!)*!SZ'D.A GCA.&*2U;[S=X:4G[\WY(<-501 -X.LX9 MR@P!N.'GDY]W6=[A^]%=HK!2*>|\V4!Y+X-! RU[J7B/CN,F"4"$UB5)(+G2 MM<_-S;GK\8'Y(5&W)W7]@.^.;CN9KYS6_;=M?]C2X;]U/\OC_M\[:0D<&{=4X18!2!:FBMOK\C0,T:5])=2$V.&C[RJ6KRR6K(H0!S_4I>]$8 M2N/>9-S7MFIK2&GVT=/_QIZ;+K>9(`C"5Y1SL"\,;9>KVN=S60[+W1/S2X$EM8?.T3'I(RET^5_\EN,C:Q04O7ZCG1,RXM#61R'R0"Y#+/CAXO%'ZX6SOP&">-MDR!6#Z+;(1R;EB+KA_LBHHG%!4"E"NEV1[]%HFY+%C-X6;F;Ff[@\1AZBJ!>MFJ$?(?*L&K&_Q[M*9\]TJ?L^9$H890!Z53I)O RTC$\|2%4=EC:ATMWB)@_M9+"T$^R]_AN'H#=K,_]ABZ@9JK_=,L:MQCC-F2RAIMX9- M#WWZR!@X7%*/MBT_A&T'R_T'SN.LA>1?S97D"TZO6\@DYXU)_MB1QZ6?WK"F6$"8#.RIF%+30I>R@$*=6&;DE2ALD-&-C!%B'T-_19+")@H7-M8P"%ZL]V2@C2G-6.EK0K%8T4S=WR>T3!TCFGG8=Q')\[LJGV>7E!![YO\{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{8_\'+VO=[FIZ_3V>7LR\_S65G^]TY?W6C59+)&7@!%++>ZKU0_1 MJP*%8I=P 8YPPE<26S6DC%!4+0 M$2%)R[DGQLGFZ?AW:1BG,'<,DW44]SM SQ.\>G^=[9.#MS[4(V"D &5%',NC&NH,Z3$:!]@^Z!]XY/6$\[";-R>1"Y7]AF% X M(EW&G$"C[=*4'$ R\RZ1]F91*\ZR-Z>K$- ^9[&XO%@[$TNY@'42P+P[+'_"O MY>=_X>4/`,'Y7XE;B>6;7W.12 (6Q4QOP#< 7EO*8C"V4!#'K81@"H?B#.=!A.Q.^5[U%*G=7MB,AM*] M!?@BVM",F"#MF_"E@@$+-IERR%I+UGOG6FW&4=GL[-!9*]Q;? MRP0I_>U%_"A92J%>@]4,1C[/S@L!@4ED)1-&\]=8IP(=1VNVUTV@@W5=\8U^(M/[[%NJNTQ'QSIZ*+7M]&$TVUN@0<0X M#>(&1^!)9?/B%.6OK=;C9IA)&K,&&P,=-^NQWO.AN!1]*&0HW-UAWR?6EK?(`M':?I7*@H,!4 MG/.8BFA=/7\@;J;O=S+-_1SPVDV'6O#7]HRL;<,WW.K<%LE6.@$V4XA)1$@ M9.. LVC1N"]D%]YUW2X4CGO=/GB!1W,A=0#!9_9T+OU[=%RKS?Q<*+K'YD)/1=DG@-B|?ZF%Q$EE4S+4 MY+((YC1'9B7CK6\H#R!S7(0."IO\('JT##N Z;V<*B#LOAP%2&7K3)9 9L8+ M#=E(3$HQ;7SKD]@C+;Q`:\T)_+:MM'.]/V +PV&IN]_!6_6"QZD M2!!DJGZ)M#!!45A!82LQJY!3*C>?FO>\MJ;(G7^\P(?8/U+=_]@:-:\%LH,N9Y@)I=GU]NEY$ M'*\3H/Y@6*HED/W5QBZL] S>OJ^@9!EP9.35X"@8\G)\Z28Z_<40^B4O*_- M/5M/QVW?0&CO8>\NJ!@EG;UD:C]HT,2-+FV#H5)!H,R+,R4E,#'HMUV!=H' M K=R#X,B> _<&L,XKQ\6'^F;(6BVCL*M*?59\'8%(>6*:*WG/'AM6CM6Y3<)N" M%@?1!0M?PTFR MH>WOUGN>/O7&T:?O?AW[6PN.@X)X/'@LHU-M(8CB?$P>HLQ5B5EOU$[W(L^(_:B(PO]$)'-6O!O;,&'OVX0GIS-,9.2*ZH^ MPQ0MB'!6K5;RA04;4[G)!7M.\#<7'4?_-QAP?SKP/$_QW0UGRS)QOT^F89IM{J.WFC]_75E?]6#7G ;;H,^912Y,"D3E ,2]+.3IGBFLVL]9>1YJL;Y(#UI M/-E8--V#[3-]RL8#3YH&R*I2W+%;3YLL=9 MC7<^N6=L"'F\62M.]@,#OHW-N=;!5KYS4TU^4O)PM7/2I%F'K3SGH%P*=9V09+\ M02]!>]M#+DRGT-KOV8&L<9HZG-3Q:2V<'O%V5H6';MTP=W(&M%2)"({J5(9C))>M3=#'NUMG^WD=WAHQC}3=KQL9^0*"WK4-9S-]3C?=:UMG+ MT4 DLTS:6,7"G8Q9[?9R<^^CQ_5T3@2"0]C8@=='YQ9=WT\5R?E73HC]-%O]<M,4WF66"IQH6VLB5%V144 E).0MB0C ^M\P&>HF><+D G=6N:B,.K;#UPXKP. MQ3E1@$("5@MI-42^&K2<"O?>672MBVJ>HF=<.]5.ZH_"Z4@1=_"G=U/Z+%PL M/X4EGO\K?-_H6VN<'_YH2+7MM2K>B.0H'C1'70B'G6>?6K?8>IJ07"!TKZ?!) MN<>R00/PVJ>4IL YK_4^C(3"D4'Q*22 M @^K;ORZ=97!DP2-TTGLM \7S032 ;KN!&%SZM!ED99$T=5G-?\=LP"7I0101 MM5$LI>9S?!XD9.0;YW:"GK7F>@?0H;-U|>WJLF:$;0>Y?\#EF[#X^OOE[%]_ MP_P%/Z[XO!T/@KH81.J<_I\XY@'1^\"""M1A5PLA2KMTI$CW(7%QTM$AHYJ^/Z;)XGG(;Y9+8ZDUPHS8(I@,73!IB0Y"TXA.BM%5ATEKB3:_Y,=L>#_MBX_3P?!D67[',WQLQ&SH_OMT\1T3<0GS]HTHZX3"""L#5#:MRF5AB&&GRG"2WMP6K9(AGL40+&2PQK(-19:PYW I/?9W-,8;%5C=GPB(IE(*48ZE-PKK=D=(H MB.4V%^[X3[\7.V+D]NHC]2-2|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|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|\:M>7RU(P2]6 MKQ*%9(O)=:,Y%U;&%1-N0LM21+XVDV<69%#>E^"UYK+Q<7F$E.X;.QX@|UE[M(72*!PKE'*]'INCLM/<2#.=U0K*5!P2=0,]$]N.]4DBMAS<\2|2XZJ]}Z'>MT^%R&+O&_6|8YLM7T_S^:OKEW;?PA4|>^|FW"<4>VI128H?SG($-4M)F@<@/R M 3VY ME,*%(*R/(!*OK1U"!$]J&IB,Q#%C>1:M\W>?):K[C]S<&[fV@ND7:3<*RCAF M%I9G5B029&K#-%'.CI","]3CMXTGV7]"%$CSX]M"X+=(':@1,8V?K]V\^?D M$A?+V11O;6L[HJ"D>A KAPSI9[018LS$68FO?2&/=YLO/&("=UNO2_P<*N'9 ML.P>'4%A\?5OL\L<0_KGAGQ?BHZ^8+T0QCH1&<$IP<&F'(I5UI#7L!M:[GWV MR$.)!T3&<6P<&P5[-T4R-L?Z'.5K%UQ5GWRC#0F29M*;'*YVT[QA'-!QNS0 M?;@/-+@<.G"'"HA1/N(51E^;P,/RC]GRQE/^8A.^Y(L<%&<&|0#5:\NU>BJE M,Y"MR2G:@J&T3GDZC-+N]Z(.1,[S%PBMQ=@16-_,OL7)="7%1PS(^TF(D\O. M'#"B(B-!D:]@,5(@3.ZI3T:0"B@F6B>X;3[3]@ RNX\DV\)T* &.;;0/V-^F MG;U#95TBW[0(30%4"1R<5 E<'RG(6P]6F(W1MWU.>SZ#R:))>TIR,8U%Z6OF]*/N^RG2Y"#$%F;B"D.JA9*Q.S2X)+#KA/&K: M^7BV?47B2QJ=<1*[OK_@7F ZT*\&L0\>.[1]@T?(O=8RD[79/=ICP< M/FTI>9T]B:/>5=$_)CCPZ)HSI6]F+'E"TU@I#==F=RN%LP>E\/JF%#;W+%8; M"AHUR*Q6O;D3D)%18#"))4WF%M?#.Q+8[?93OI@YUZMQI"""ZL@UN)MUX,CRMC&D.P@C:1J;H.##,A&QVB$)*XN" <|;3:>2_8 ;3/L+H%%.W\S.$]13X8:HS ML.E/.=4[V4_[L+A/1?0K+O-91BZD 69$[?=H M-$11+-CD&1=>1)=;I\$_1<^X[\5CF[G#Q#*V2CK@VO/3[/+R]]F\CEZ]0*ED M].2(.A9K%GZ*$+ VW.;*^.QXX"[OI+".HZ,[=78@&(Z\D#Y4,AWIN7V>?Y)TMP1A\]CQ4OX+7)\]2#0@NHTB;_C^V#]>`>K\;YIGYE!!J\)RWCSQ'[Z2T)X-O MS+%>G.-R>,G^\D)$+CDW%,[7.2%:@2:(2:3628;M5M-U]&DC/C,/). M1Q#?B]*R-S?\YFO]\MUT/0CVK#PG&WZ1ECJZ!-2:4XETDNN[J&:6HU'<-MNJ&'XX&W-N)3^(00YJ?#S.C358Y0'UNKHO)OS]^?Z5>+RW4MO.I"HG$..B96 MFSWV(VE[? Z(*+G"4J-!]K<$3I(WXN/ZRK$,K\;XH:_'+AZ,(.G+'5N$.!Z5* M -<=3 !8!]YV0DDVG>|&XHGWR8M_<7H<4/DV?3#EUC/.G_'B;S?X3+*_IRW2\E M$$D;5DSP!,-M=R3@=_LAW!D^'=TF9*-,I,*9I.CI'Q?1.Z P0C+ E\Q (?"_F M'?V:Q:]_O@Z789KP_"OB\H_YI.H!-;=>1:.6HG!H:9.A:YNW\OW0F+YIE4&%&B&0$T&NP[H#CP.A%&?"\\A$*MZ]>1V%SKJ=B^!IS/[=A\1=*"G1V:N>HE<>".@<*Y Q=I=4VD&AB4=D,YAE*U[M +ZX4;=[27]W4;?[L+T#|\-Q0W']B6%S-5_'XZ['8K&=PTFXPHN;@!<.*=HW^"C71*C?=:\<"M;/W2L@=YG>"N&39FIQ%4!QA|MNUA.OI$_<%9VV)O1"15M#]SS!!0TA8YRU*"}U8](0O7C4&X#WWCHG PD-R= M$SZ4Q#!XPT++5$U.Y&/ F>F B;K0A MI2Q:9_SO1MFXK>M/Z>FU$D!H/+OAM"SN!V\;@#D10E8(:=.NBB77?HW,@W"_ M11^M"ZIU-]2!"_S$%#=$R&,@:"ZNGK#X;OKJ;KE8<8QO=`G$D'"BJ%_J1*&_MH(@!8FV,34Q342AI8^NFA$^0TPG.VH/@,;@=*9%.P26N^Z(QKXOG4 2O+6*Y M@>]BQ37,@JOA6^=8_L$.9WW"Q*CHQ-!APVR#_4QI&:FY?{[B.'L6OKGJU%U>0HRN@88(CD)V;,X/C]A&Y,\@2 M*?>=TGU?>KGO7E+=+]OW'Q;/FE%^7V4_H+!_GTSI9Y-P>3UP[4WXOJIO??]= M<&B4#$Z[$3B+0#;_HK46&=M,UJ'_ZXG5^P!P%P'4.@*:#;FN;1*'FBMZEII.KBI.@XM&L MH:-$\"'8+HH(,;- T-Z0QM=60_2&$UMT3,9E^KJU[W^7ADZN*7H UE[BZ !.M!]1(W#@[P20M4#LP+#@:Z.W6T$E,&'5]R3R^B(;R4U$!B4)\DZQWHKW1^MZ.3RJAZ4+8,*]7EG10)9>V,JE@PX75AMPFH$)BD*;WU9^PQ)X]Y7G,@F'B.&M#E"UGJY-.7&&EH-PC@ZA,@9"4 F,CD+E$+,PK;VN%VP5CX+&479Q'SEU81>?`MW-XG) 9.$OWZ?#E+_]Q(C!&W?(8H$AU?QO+X7"Q(CC86P3@9_E.B\ Y!?5G1 MDX'P&"EUH@!4%ZG\87++-[-OWV;3].Y>+6E3\6I9GY4_S]Z$R\NS]6WBJVG^ MSU-[B2T7%W2@(B^< 0N0>ZX9GE(?)Y*AAW M]9&CN.'F/;- IQ&YC58 ^IHJ*H^D<\DT9,9-B"FZ$ENW]]B3Q"?%%90FTUD M=3@49W1*A@Q,+@R/H=0AQ"F55)B 9-V-I2&BUX'T7 M#N"O>1"O*&;+=1N3'WB.Z6]^ZEWWJ]T>94Q_T[L)=W^_6HMOI-[3S/K!# , MV25&ZWO84A/ ?(3(M_^Z)\3[*=DZQKGMCL85QL.%#N/*.0.3/.1>W\[\^$/-M6/>DRBGH0.==2D4!GTX1ZA0G(&$4U-QH)5K?(ZXG5XFL)T>I;.^(=/MZ?D0 MOFVSTIDN*$)"XJZS4!ML@8M, 4[9)LEC<1'Y5[LQ.H#Y1D!\B\ M<_&Q*67@%]-UA3PP5 R4U1*"*PH"*S8*QVN*>F,X/DA(CQ@\5-:SUHSO #UO MOWV_G/U$7&UA?2^QW4CQ"VJ4"KYJI#/Y:UUH.O+5*I#9+'YJ^:CO(R=7\?|@6GZ>G9,,%H7\H6*X/S);'K.G.V.O;_M4F*N0Q)(.W1HZ-1@A,!- FME<,J3_Q+NW*D_4MQV)"$COQD. ;23RZ<#K;:Y M?KVAEJWS7KF0(*"APY09AVATI*VPX+/1+LC6N8OWB!@YJ!Y2BQW\"ZN@([T M5]H?IW<7IY!8&4!(S4&Y^OI91()(/TTLRJ2;]XYM17LO0UE?>N1[&!@Z4)R/M7.B>+;_B_%=?P%_7<;5B6L?LUIZ)"IC :YN!.SKA+/"@!L^#?8,$'@.0H7&T MVRU]$Z%V@-DC>,SN\'HA:-,LEP3H.&D+E>HX<=(6W![CR+N1(;:>.]&$\"YS MCMI JZU./D#.+[!0ZD--**@<4D,51MU?8>A\]&?V-'SA4XRHT"D).M3A[YIQ-M0BTYRD:CMZH49*%U@DWIPJ=U"CUI5N8_5PKYY,OTTF9I#!=WE][3]!$YQ5 MR0-8 &%R@>,.('IV@@1L W%1.,IF"!IX+NJ M@T"(K\N7-89<7&SM$0>G#R;A64-VCPR73_C]:IZ^A@6^^C+'=5WTG2UM;B&T-4D4K4!')\G1 MK;Z"BE@MM8Y&<2ZQ!89V)F@<=8+61^6QH 8O]!?Q;/7'+GW_#<+:+G\NKEX8DZY-MDITF%[-R]!9E>1&(89IA?1_TO.B=S-8#'SX>& ;2WZPA,\=6,764\GI$##*OI MLG4PN'2>SDAD$(NQ(.UW3DACI=LI\^\Y%)=<)Q;LY/9GL,8VP,;-B N(BJK MO(:"1:J^FP"72&?6:%-9DZT2.[V%[X"T?78$<*Z^X.#>RP/<^3"?KKYM M"$^>B>BX[+6&2AO$%Q0#M!FKP515W8;)_F,R&\M.K+0#Q'9K 7_QA9\^.LF MX587"L@<;3^2]0N"_"-#6W":T=Z#1K=;J/ZDH9,612GMO>.M1V0?2.HX&0DG<2Y.*<27B=6-2R]/A>X!B32OO_9+PY%ATAUTHZ]{CX^3B/7X)EV_)++"Q_KMOZ!X4^M>PM.I8*D.P4AQP!.!HS.EF3<4T.X%YC^X\OLQ_^BCU[K*OKBEXIZ8,%QJM. M8B2/9>_(R%A3O3D=2&&G$S5WT*1,^\^&7%1?B9=3-L83N3*O-,9K9 (;B#8C;1GCP="LF,WL4W#@[P20M4#LP+#@:Z.W6T$E,&'5]R3R^B(;R4U$!B4)\DZQWHKW1^MZ.3RJAZ4+8,*]7EG10)9>V,JE@PX75AMPFH$)BD*;WU9^PQ)X]Y7G,@F'B.&M#E"UGJY-.7&&EH-PC@ZA,@9"4 F,CD+E$+,PK;VN%VP5CX+&479Q'SEU81>?`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|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{CX^3B/7X)EV_)++"Q_KMOZ!X4^M>PM.I8*D.P4AQP!.!HS.EF3<4T.X%YC^X\OLQ_^BCU[K*OKBEXIZ8,%QJM. M8B2/9>_(R%A3O3D=2&&G$S5WT*1,^\^&7%1?B9=3-L83N3*O-,9K9 (;B#8C;1GCP="LF,WL4W#@[P20M4#LP+#@:Z.W6T$E,&'5]R3R^B(;R4U$!B4)\DZQWHKW1^MZ.3RJAZ4+8,*]7EG10)9>V,JE@PX75AMPFH$)BD*;WU9^PQ)X]Y7G,@F'B.&M#E"UGJY-.7&&EH-PC@ZA,@9"4 F,CD+E$+,PK;VN%VP5CX+&479Q'SEU81>?`MW-XG) 9.$OWZ?#E+_]Q(C!&W?(8H$AU?QO+X7"Q(CC86P3@9_E.B\ Y!?5G1 MDX'P&"EUH@!4%ZG\87++-[-OWV;3].Y>+6E3\6I9GY4_S]Z$R\NS]6WBJVG^ MSU-[B2T7%W2@(B^< 0N0>ZX9GE(?)Y*AAW M]9&CN.'F/;- IQ&YC58 ^IHJ*H^D<\DT9,9-B"FZ$ENW]]B3Q"?

*MKE\C=XI?Z@W6YY:OA;7/U?4VWMT..BYT"EK%E,$Q2;N2=!2=TZDVY<="OR"' M;;>H_OFU1KR0[9{0XBE S5YG./BO':T3SI*HFBR")-) '18-10@6D[-*I-8]*

M/(=W68>YW.P&R>7_)$NZ]MI'OG^Z^;6?[$M3//U+.UWTS*;?UM1,_R=V$'D MG.Z>['AN#7]WYK5,UBE!_$_5F:6(*[JL:G8:<]&S2">H^[NS^UWI'O'=UVE9*

MC#.7O94@HZ0CZS0'5S._K3"YM3X\@,R1N^<-"YQC M8'[%%:4,_F?\QG5]_/RO8'VV,7(5BK"B/#Y'RH'50R!$G.?_)",Z2W?\IXG7?%_?%A-*R/0%*%;G2V;3P%FR*

*M,#DHH7"GH;7/$4XAL9>FD\W!Q.*.*KR10?K8/K;-J>A(,>1@\%+|2:44(7AI M(/N4M10F<#0-8/@T%>,U:CD=":F:#B&3L#+S;EQ_KW,+MA HA:[.:^!$B<U&P*WQ@/-RU%^%C5^1'*

[,#S>U9]O[.4Y3:H^*B M ![KK285+1D<((W A)%.%ZW(W=6GXFYKW>Q4A#C: Y@3!\D""Z@""KQ8+7"[> M7,TKIR\4G3UTD=BC1.UTKA)XYP4X-&S5.%$V"|!VBX#.;UT.E/+=EO

*'L[P; MO-2 94- C|A|(?I1ZPRD@&6M[-4@F66Q6),=-F\S?H>&SGWPE[@YD/$= .;?] M),3)Y;KT=0M]35;:UP9]-M<$?%84[:#>"TF-&K,NM,/&T+E/1>>V]PUXCF3^*

*ML1DPK0%TXQ24DP!O$[N(;$6G0'$Z-,J2/VED9B@L*ZWH@<)&7=,VNEA=* (MND#2PSQZ]>7+?+7(!EB>9&"3EA2 2*?;+.L:.(Z4F"|'*ILZO4C'QKC;@:OQ MDE5.C++6XCG<^,V6X;*

()XC[A#YQ>U:1N(WQ$)4 &25HWJ@P!BP".7CE>!%.L M]2W]=NUQBO).C)V#&-V!=_1Q/BN39!R;\@5VM7L!LYM(HI\'E$&O7 M0|H&|;VQ;4ZY^A"WNGU*

(!3>8>47FY7AY#_(^VMCQ%&IYA:&Z/K9!1$&P,Q MR8M2&^(8"\YY?+.,)TL M+L/5XOQJ_F62PN7?9HOODWH5\O[-=L*:#LBBK1.1G:*P*=>6$$:!-2Z;7&K@

*MQ'>"R0Z+C=A3H)5$9P.R=VRX_'$YB^%RT^CY_?N/FRUP]!@%V6U&NI6V(!1$ M,MD4KF<4Q*B4[WH]C_;+?NCS1ZS5'P(4#9@X-@[^_A_G_['9P+MIVFQ)QTD MTY$"!$,V-R(#*

[!}%"-(E4F31M;S<4//3!(3'_#X&!HQDX-@+^-KM:+&?3/S%"7ZV3T!ZCI5WSC[LK MW+@,?_US\|OU8Z;-T1LF$+QQ%&RD \>HO,6#/.'ZQ$2N_![$AC=D[-EP^SF>KYAT)U\-

]SW\NEOCM?'95>PQ/WX3+29G- MIY.PK8GPN6"F#6FOZ"085]^F? %|##]D6GFM=D+.?NN.V.IR"| -R/2O\?2

*MSL/E[#O^(UQ>XL^SJ^5W$A/Q^/.,$LZ98D7+VA/&@"KHP)$1AJ*2X[8D;\UN M39UW6FZQ7W>P=UXA@RN/A1J*9NR%D#T=H,P@BO8O)H>.OW_*?H MZ243I M-CRX??)@ON-*

*\^?/C9>W)//*5<@2.!.;>$"3];$ MU+KMQ$DV-J[2[^UL# B^L3W8EA5Y-@&%-[18R1PQ8T*F?K@-MD6]_F +6FI0(N[7&'I#/(<5/UFP.|*YEVX*

5MK=|%SRIE+FM$P&M=%-DQV@>' M;(V5TN9"T69C1;U=>]PT L%TZ4&L[0 2+4_'N]IP[LOD^H^O9U5=,|>AM,A$ M :D$G1(;/03+!3!EF10^ZBQ/,+%^N

V.6SWP(AR%MB#Y=W(8UG]RX^3< M29/XEHSY,%OBXF/XN;Z]Y10GRR"@Z!1!F23\T>$'F=%*1,R^Y)-C_B:%,\'< M_<^%^<'2;(WL$>]?/H1Y/>(_D]CE.0I(O4B5QD.%@KPYFG M(R

*TDCZUS.<01+_]F/10\EGIS4@8(@25@.5,5F&1419MZ9B&

\Y09H!H8CO^>LDFN<[%8_2W[^9LJE,Z;P<42O3[H+U7O M4AW:RC4LE3!N;,**Q8(_/_RP$]H- SRW8V[-8%4#+E)U4_VQ9K(/*GROV]*U^4T'NNO"G#?T! M=FV$,
[S6YX6(MX1K!Q3>6N0]]X30C^5F#;YHSHU;N*^K)X&EXZLI^@/IE5Y MERV9]WV1/)FL+B]7CHI(-A/V5WVU%8JRFUP\0W>E2@XT'_6)'_6)W;"1_W=;SL[C0\UCF9*W
M,JIMUK&66=_3"8ORW)C&JOD_&WK:\5=MN'=-RCW]\VL:ZFHBV_,&,_-]-%A M?F]5-\4MMR]!G_R8\,F?E0O,.G_-9Z2V";'2@?@"@-VNV;!8WSR*T[IQA.Y: MHCXCNY8@;A.&
[\./:YQZ8S2.H>V2?ME.%(&@=%55SH%:I>G/GGI@M4$@OF_I M_FZ>3OZQ8X',$AU M8Z>OU'[K=S>%A&$ L[(X4B7[_B[Q]L"TSHT#R8&66+L M[*>8W)L(ZOI'UDV1'SSA+T#/V?
U5DAS^VXBTO]PL3O56$7 M?OI8R3\KFTN7Q?U)(;\6CW4C'2A [X^&8?K=\"W="=NSKMCCU>=BL?[5E:[R M8X*-/RL7^WG_KX;A-'IKRV!Q>U:7;X;!^T_-6GTW?)A?OZB]
S7I_C5O0:$; M]>@MWG"\R$E]J1=L7.J9!K^PX5@[>G_46YNG3LM"UI\J\Q=7FN-H"=X:2]WHD5L@/&O5ITG9D5UE?R MLGCAYJ*Q/_^GOM838=FZ;2960/:%)U+[WII;W>B30P@*],?
BMFZN,&I MS+=TO&TZVQ*9:QCU?=&[6*V;6NGWU/Q56PPKOPRM[>2TO%$398>]+W1H<,?) M>HK^\O_]\-HJ%]_E968I\]46ZU+K7!BZYX4;6]M-W9\+[(=E:WGY]IE*5;]7 MY?
3'Y[]>.D1T&UUOL6]?/[I;1KX]ZG<[M%^^+-05BMOH>HLX^WK7W3+R;HOE M;=FPB8OVO55:WJ:D]+:YM;+PC]"):*9L,GFZ8KET!-0ZDM[FH?3':XMD?-=4
MV92[6>'LU.C(-6ZBZ6W,24_@=LC&=]CY7-!_\GCOS#=N).IO0DG?*'.'>)" M;[:R-Q[")8CK:/L;+^(RRW""L&5OBS5N4/=2-G?8) A?G67H+S7^4SSYLD^ M;3(7I3G>/,S>Y?J4:
[,89;AUA6['3_F;$](3[GZB]'UL7'$SW^K9)C)[]>U[M.3%2OFY=W=]1!D<_A>]^5R(\L'1'7]K#_B;-.(,Z\UB"P[A M=Y?,8R&]Y4.M$
J[JB'&#TCO\;]6,X7EU]N0&[C59XAW3U%%XP1GY9?-= M52/;]_IOM((ZI(NKCL+S;=6,3R>L^I+7C<-4]V;JK>_,Z3IKIX!_C>LPR] M"=E
LE6U0DB76=M%X_WF_]GYNP=P%^U62(9TE=526!XA?7X$_25P_U+6V^JU M-*OY;!&+_W&!Y*2IGW_R"NEZVJU #.4":ZMXO$<[*Y'W4/-;2[57"%=0&T3 MB^\)M3:@LAPY
FP=O59XA71AM$4H(5SQ.WG5["VA5@"%=,NS3@S>@Y!R<*GD M,XU6>(1T![/"?!AEWH/AZ%]O&H5T31)@F6I9_&X"E\7"/JE:5/DL#>.H3G4W
M^58@AG0!TEYDWO,K=Z[2S[NHMT(VI+N0U@+SO:T5=?%;H1O; M0N2L_G@#S58] 2'=BNP0CO<*@M?N+W>E NMIMH(NI&N0'<()]?6!ST6=&V'> M5FSV\F15V;II^ZK"R@W P*
<(MGS&R;L$;=EP\$C!NT^]4XN>PWXWDAUR_U" M[C?[DLWPYPG6$O0X"7<7%DMWSEN$X3M3\+*TP;VD*Z2\8;-5VFM1":B[]&0R M6>-+W(S+W4PX *RV3,
[=*9"/R>N^;.AC"OO'%/9N-UI--;E5U4-]J6\K:?3+ M332_A:PW&^H6(^P6C/=(P:[*Q'6L!*)+=Y,SB\7B+EK1&^ M)RA+ O",RO5THA#D";)1C2Q_-$]>3]C]('@VT?36Y-X-
IQTB\7^=/P9F6\AZ MZVKO!MMNP03A &?KLDTPK"A!)?(>>MH[^,(UPDB(&=X6ST4C5M?^(:DMUIV M_JIPO4#"\H2. -M,U5L;^R_&!QLSP>&ZB&?/PKOR!.N4O37N=['&VZ01Q!8
MG?W\D563P?T-6^CZZQ/O]A6V1Q&.OBJG.3",'!5E6+$=/#29T9(!V]F MPWDZ^.VGWNF(@[SP>OJ#DB8+\O(M:5=G[]W4 TD=;\5M.=/24E[>DV'KUGE1 M-HNENKGO;_^50*
[_!^*\17[C>_3%+^P?G-7JO_[C_P%02P$"% ,4 " "] MB&Q9GL&?VH0(""/P % @ $ <3,R,#(T97AH:6)I M=#,Q,2YH=&U02P$"% ,4 " "]B&Q9=+"_::8("O00 % M @ &V" <3,R,#
(T97AH:6)I=#,Q,BYH=&U02P$"% ,4 " "]B&Q9 M79FR(?4$!M&@ % @ &.$0 <3,R,#(T97AH:6)I=#,R M,2YH=&U02P$"% ,4 " "]B&Q9:@@!3-8$!R&0 % M@ &U%@ <3,R,#
(T97AH:6)I=#,R,BYH=&U02P$"% ,4 " "]B&Q9P%') MMB7+ 0"S-1X $0 @ &]&P @*C4! .,F"P 5 M " :97!@!R9&YT+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4 M" "]B&Q937#!F]JX
#AAP@ %0 @ $#C0< &UL4$L%!@ , P %@, /!%" $! end XML 70 rdnt-20240930_htm.xml IDEA: XBRL DOCUMENT 0000790526 2024-01-012024-09-30 0000790526 2024-11-08
0000790526 2024-09-30 0000790526 2023-12-31 0000790526 srt:AffiliatedEntityMember 2024-09-30 0000790526 srt:AffiliatedEntityMember 2023-12-31 0000790526 us-
gaap:HealthCarePatientServiceMember 2024-07-012024-09-30 0000790526 us-gaap:HealthCarePatientServiceMember 2023-07-012023-09-30 0000790526 us-
gaap:HealthCarePatientServiceMember 2024-01-012024-09-30 0000790526 us-gaap:HealthCarePatientServiceMember 2023-01-012023-09-30 0000790526
rdnt:CapitationArrangementsMember 2024-07-012024-09-30 0000790526 rdnt:CapitationArrangementsMember 2023-07-012023-09-30 0000790526
rdnt:CapitationArrangementsMember 2024-01-012024-09-30 0000790526 rdnt:CapitationArrangementsMember 2023-01-012023-09-30 0000790526 2024-07-012024-09-30
0000790526 2023-07-012023-09-30 0000790526 2023-01-012023-09-30 0000790526 us-gaap:CommonStockMember 2024-06-30 0000790526 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000790526 us-
gaap:RetainedEarningsMember 2024-06-30 0000790526 us-gaap:ParentMember 2024-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2024-06-30 0000790526
2024-06-30 0000790526 us-gaap:CommonStockMember 2024-07-012024-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000790526 us-
gaap:ParentMember 2024-07-012024-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0000790526 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000790526 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000790526 us-
gaap:CommonStockMember 2024-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000790526 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000790526 us-gaap:RetainedEarningsMember 2024-09-30 0000790526 us-gaap:ParentMember 2024-09-
30 0000790526 us-gaap:NoncontrollingInterestMember 2024-09-30 0000790526 us-gaap:CommonStockMember 2023-06-30 0000790526 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000790526 us-
gaap:RetainedEarningsMember 2023-06-30 0000790526 us-gaap:ParentMember 2023-06-30 0000790526 us-gaap:NoncontrollingInterestMember 2023-06-30 0000790526
2023-06-30 0000790526 us-gaap:CommonStockMember 2023-07-012023-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000790526 us-
gaap:ParentMember 2023-07-012023-09-30 0000790526 rdnt:DeepHealthInc.Memberus-gaap:CommonStockMember 2023-07-012023-09-30 0000790526 us-
gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000790526 us-
gaap:RetainedEarningsMember 2023-07-012023-09-30 0000790526 us-gaap:CommonStockMember 2023-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2023-
09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000790526 us-gaap:RetainedEarningsMember 2023-09-30 0000790526 us-
gaap:ParentMember 2023-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2023-09-30 0000790526 2023-09-30 0000790526 us-gaap:CommonStockMember 2023-
12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000790526 us-
gaap:RetainedEarningsMember 2023-12-31 0000790526 us-gaap:ParentMember 2023-12-31 0000790526 us-gaap:NoncontrollingInterestMember 2023-12-31 0000790526 us-
gaap:CommonStockMember 2024-01-012024-09-30 0000790526 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000790526 us-gaap:ParentMember 2024-
01-012024-09-30 0000790526 rdnt:DeepHealthInc.Memberus-gaap:CommonStockMember 2024-01-012024-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2024-
01-012024-09-30 0000790526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000790526 us-gaap:RetainedEarningsMember 2024-01-
012024-09-30 0000790526 us-gaap:CommonStockMember 2022-12-31 0000790526 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000790526 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000790526 us-gaap:RetainedEarningsMember 2022-12-31 0000790526 us-gaap:ParentMember 2022-12-
31 0000790526 us-gaap:NoncontrollingInterestMember 2022-12-31 0000790526 2022-12-31 0000790526 us-gaap:CommonStockMember 2023-01-012023-09-30 0000790526
us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000790526 us-gaap:ParentMember 2023-01-012023-09-30 0000790526 rdnt:DeepHealthInc.Memberus-
gaap:CommonStockMember 2023-01-012023-09-30 0000790526 us-gaap:NoncontrollingInterestMember 2023-01-012023-09-30 0000790526 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000790526 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0000790526 us-
gaap:CommercialPaperMember 2024-04-01 0000790526 rdnt:TriValleyImagingGroupLLCMemberrdnt:FixedAssetsMemberrdnt:TriValleyImagingGroupLLCMember 2024-03-29
0000790526 rdnt:TriValleyImagingGroupLLCMemberrdnt:TriValleyImagingGroupLLCMember 2024-03-29 0000790526
rdnt:HeartLungImagingLimitedMemberrdnt:StockHoldbackMember 2024-03-272024-03-27 0000790526 rdnt:HeartLungImagingLimitedMemberrdnt:StockHoldbackMember
2024-03-27 0000790526 us-gaap:CommercialPaperMember 2024-01-15 0000790526 us-gaap:CommonStockMemberrdnt:PublicOfferingMember 2024-03-012024-03-31
0000790526 us-gaap:CommonStockMemberrdnt:PublicOfferingMemberrdnt:SoldPursuantToExerciseMember 2024-03-012024-03-31 0000790526 us-
gaap:CommonStockMemberrdnt:PublicOfferingMember 2024-03-31 0000790526 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-09-30 0000790526 us-
gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-12-31 0000790526 rdnt:CommercialInsurance1Member 2024-07-012024-09-30 0000790526
rdnt:CommercialInsurance1Member 2023-07-012023-09-30 0000790526 rdnt:CommercialInsurance1Member 2024-01-012024-09-30 0000790526
rdnt:CommercialInsurance1Member 2023-01-012023-09-30 0000790526 rdnt:Medicare1Member 2024-07-012024-09-30 0000790526 rdnt:Medicare1Member 2023-07-
012023-09-30 0000790526 rdnt:Medicare1Member 2024-01-012024-09-30 0000790526 rdnt:Medicare1Member 2023-01-012023-09-30 0000790526 rdnt:Medicaid1Member
2024-07-012024-09-30 0000790526 rdnt:Medicaid1Member 2023-07-012023-09-30 0000790526 rdnt:Medicaid1Member 2024-01-012024-09-30 0000790526
rdnt:Medicaid1Member 2023-01-012023-09-30 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2024-07-012024-09-30 0000790526
rdnt:WorkersCompensationPersonalInjury1Member 2023-07-012023-09-30 0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2024-01-012024-09-30
0000790526 rdnt:WorkersCompensationPersonalInjury1Member 2023-01-012023-09-30 0000790526 rdnt:HealthCarePatientServiceOtherMember 2024-07-012024-09-30
0000790526 rdnt:HealthCarePatientServiceOtherMember 2023-07-012023-09-30 0000790526 rdnt:HealthCarePatientServiceOtherMember 2024-01-012024-09-30
0000790526 rdnt:HealthCarePatientServiceOtherMember 2023-01-012023-09-30 0000790526 rdnt:HealthCareManagementServiceMember 2024-07-012024-09-30
0000790526 rdnt:HealthCareManagementServiceMember 2023-07-012023-09-30 0000790526 rdnt:HealthCareManagementServiceMember 2024-01-012024-09-30
0000790526 rdnt:HealthCareManagementServiceMember 2023-01-012023-09-30 0000790526 rdnt:HeartAndLungMember 2024-07-012024-09-30 0000790526
rdnt:HeartAndLungMember 2023-07-012023-09-30 0000790526 rdnt:HeartAndLungMember 2024-01-012024-09-30 0000790526 rdnt:HeartAndLungMember 2023-01-012023-
09-30 0000790526 us-gaap:HealthCareOtherMember 2024-07-012024-09-30 0000790526 us-gaap:HealthCareOtherMember 2023-07-012023-09-30 0000790526 us-
gaap:HealthCareOtherMember 2024-01-012024-09-30 0000790526 us-gaap:HealthCareOtherMember 2023-01-012023-09-30 0000790526
rdnt:ImagingCenterSegmentRevenueMember 2024-07-012024-09-30 0000790526 rdnt:ImagingCenterSegmentRevenueMember 2023-07-012023-09-30 0000790526
rdnt:ImagingCenterSegmentRevenueMember 2024-01-012024-09-30 0000790526 rdnt:ImagingCenterSegmentRevenueMember 2023-01-012023-09-30 0000790526
rdnt:DigitalHealthMember 2024-07-012024-09-30 0000790526 rdnt:DigitalHealthMember 2023-07-012023-09-30 0000790526 rdnt:DigitalHealthMember 2024-01-012024-09-
30 0000790526 rdnt:DigitalHealthMember 2023-01-012023-09-30 0000790526 us-gaap:ServiceMember 2024-07-012024-09-30 0000790526 us-gaap:ServiceMember 2023-07-
012023-09-30 0000790526 us-gaap:ServiceMember 2024-01-012024-09-30 0000790526 us-gaap:ServiceMember 2023-01-012023-09-30 0000790526
srt:MinimumMemberrdnt:ProperyAndEquipmentNetMember 2024-09-30 0000790526 srt:MaximumMemberrdnt:ProperyAndEquipmentNetMember 2024-09-30 0000790526
srt:MinimumMemberus-gaap:LeaseholdImprovementsMember 2024-09-30 0000790526 srt:MaximumMemberus-gaap:LeaseholdImprovementsMember 2024-09-30
0000790526 2023-10-012023-10-01 0000790526 rdnt:ImagingCentersMember 2023-12-31 0000790526 rdnt:ArtificialIntelligenceMember 2023-12-31 0000790526
rdnt:ImagingCentersMember 2024-01-012024-09-30 0000790526 rdnt:ArtificialIntelligenceMember 2024-01-012024-09-30 0000790526 rdnt:ImagingCentersMember 2024-
09-30 0000790526 rdnt:ArtificialIntelligenceMember 2024-09-30 0000790526 rdnt:ManagementServiceContractsMember 2024-09-30 0000790526
rdnt:CovenantNotToCompeteMember 2024-09-30 0000790526 us-gaap:CustomerRelationshipsMember 2024-09-30 0000790526 rdnt:PatentAndTrademarksMember 2024-09-
30 0000790526 rdnt:DevelopedTechnologySoftwareMember 2024-09-30 0000790526 us-gaap:TradeNamesMember 2024-09-30 0000790526 us-gaap:TradeNamesMember
2024-09-30 0000790526 us-gaap:SoftwareDevelopmentMember 2024-09-30 0000790526 rdnt:ManagementServiceContractsMember 2023-12-31 0000790526
rdnt:CovenantNotToCompeteMember 2023-12-31 0000790526 us-gaap:CustomerRelationshipsMember 2023-12-31 0000790526 rdnt:PatentAndTrademarksMember 2023-12-
31 0000790526 rdnt:DevelopedTechnologySoftwareMember 2023-12-31 0000790526 us-gaap:TradeNamesMember 2023-12-31 0000790526 us-gaap:TradeNamesMember
2023-12-31 0000790526 us-gaap:SoftwareDevelopmentMember 2023-12-31 0000790526 rdnt:RestatedPlanMember 2023-06-07 0000790526 srt:MinimumMember 2024-01-
012024-09-30 0000790526 srt:MaximumMember 2024-01-012024-09-30 0000790526 rdnt:A2019SWAPSMember 2019-06-30 0000790526
rdnt:October2023Memberrdnt:A2019SWAPSMember 2019-06-30 0000790526 rdnt:October2025Memberrdnt:A2019SWAPSMember 2019-06-30 0000790526 us-
gaap:InterestRateSwapMemberrdnt:A2019SWAPSMember 2019-06-30 0000790526 us-gaap:InterestRateSwapMemberrdnt:A2019SWAPS1Member 2019-06-30 0000790526 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 0000790526 2020-07-012023-10-31 0000790526 srt:ScenarioForecastMember 2023-11-012025-10-
31 0000790526 us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-30 0000790526 us-
gaap:InterestRateSwapMember 2024-07-012024-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-
09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000790526 us-
gaap:InterestRateSwapMember 2024-01-012024-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember 2024-07-012024-09-30 0000790526
us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember 2024-01-012024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMember 2022-11-01 0000790526
rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember 2022-11-01 0000790526
rdnt:HeartAndLungImagingLimitedMemberrdnt:CashHoldbackMember 2022-11-01 0000790526 rdnt:HeartAndLungImagingLimitedMember 2022-11-012022-11-01
0000790526 rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember 2024-09-30 0000790526
rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember 2023-09-20 0000790526
rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember 2023-12-12 0000790526
rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember 2024-03-27 0000790526
rdnt:HeartAndLungImagingLimitedMemberrdnt:ContingentMilestoneConsiderationMember 2024-04-01 0000790526 rdnt:HeartAndLungImagingLimitedMember 2024-06-30
0000790526 rdnt:HeartAndLungImagingLimitedMember 2024-07-012024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMember 2024-09-30 0000790526
rdnt:HeartAndLungImagingLimitedMember 2023-06-30 0000790526 rdnt:HeartAndLungImagingLimitedMember 2023-07-012023-09-30 0000790526
rdnt:HeartAndLungImagingLimitedMember 2023-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMember 2023-12-31 0000790526
rdnt:HeartAndLungImagingLimitedMember 2024-01-012024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMember 2022-12-31 0000790526
rdnt:HeartAndLungImagingLimitedMember 2023-01-012023-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-
gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-

gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 rdnt:HeartAndLungImagingLimitedMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000790526 us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000790526 us-gaap:RestrictedStockMember 2024-07-012024-09-30 0000790526 us-gaap:RestrictedStockMember 2023-07-012023-09-30 0000790526 us-gaap:RestrictedStockMember 2024-01-012024-09-30 0000790526 us-gaap:RestrictedStockMember 2023-01-012023-09-30 0000790526 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000790526 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000790526 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000790526 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000790526 rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember 2024-07-012024-09-30 0000790526 rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember 2023-07-012023-09-30 0000790526 rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember 2024-01-012024-09-30 0000790526 rdnt:SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember 2023-01-012023-09-30 0000790526 us-gaap:CommonStockMember 2024-07-012024-09-30 0000790526 us-gaap:CommonStockMember 2023-07-012023-09-30 0000790526 us-gaap:CommonStockMember 2024-01-012024-09-30 0000790526 us-gaap:CommonStockMember 2023-01-012023-09-30 0000790526 rdnt:DignityHealthMembersrt:MinimumMemberrdnt:JointVentureMemberrdnt:GlendaleAdvancedImagingMember 2024-01-012024-09-30 0000790526 rdnt:DignityHealthMembersrt:MaximumMemberrdnt:JointVentureMemberrdnt:GlendaleAdvancedImagingMember 2024-01-012024-09-30 0000790526 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-09-30 0000790526 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-12-31 0000790526 rdnt:JointVentureInterestMember 2024-09-30 0000790526 rdnt:JointVentureInterestMember 2023-12-31 0000790526 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-012024-09-30 0000790526 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-01-012023-09-30 0000790526 rdnt:StanislausSurgicalHospitalLLCMember 2024-09-16 0000790526 rdnt:GlobalImagingLLPMember 2024-09-01 0000790526 rdnt:U.S.ImagingIncMember 2024-06-01 0000790526 rdnt:HoustonMedicalImagingLLCMember 2024-04-01 0000790526 rdnt:GrossmanImagingCenterOfCMHLLCMember 2024-03-31 0000790526 rdnt:ProvidenceHealthSystemSouthernCaliforniaMember 2024-03-31 0000790526 rdnt:AntelopeValleyOutpatientImagingMember 2024-02-01 0000790526 rdnt:BusinessAcquisitionsMember 2024-09-30 0000790526 rdnt:TriValleyImagingGroupLLCMember 2024-02-23 0000790526 rdnt:TriValleyImagingGroupLLCMember 2024-03-29 0000790526 rdnt:ProvidenceHealthSystemMember 2024-03-29 0000790526 rdnt:TriValleyImagingGroupLLCMemberrdnt:ProvidenceHealthSystemMember 2024-03-29 0000790526 rdnt:TriValleyImagingGroupLLCMemberus-gaap:AdditionalPaidInCapitalMember 2024-03-292024-03-29 0000790526 rdnt:TriValleyImagingGroupLLCMember 2024-03-292024-03-29 0000790526 rdnt:TriValleyImagingGroupLLCMemberrdnt:ProvidenceHealthSystemMember 2024-03-29 0000790526 rdnt:TriValleyImagingGroupLLCMemberrdnt:ProvidenceHealthSystemMember 2024-03-292024-03-29 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember 2024-07-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember 2024-07-012024-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember 2024-07-012024-09-30 0000790526 rdnt:ThirdPartyMember 2024-07-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember 2024-07-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember 2024-07-012024-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember 2024-07-012024-09-30 0000790526 rdnt:IntersegmentMember 2024-07-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember 2024-07-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember 2024-07-012024-09-30 0000790526 us-gaap:IntersegmentEliminationMember 2024-07-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember 2023-07-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember 2023-07-012023-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember 2023-07-012023-09-30 0000790526 rdnt:ThirdPartyMember 2023-07-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember 2023-07-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember 2023-07-012023-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember 2023-07-012023-09-30 0000790526 rdnt:IntersegmentMember 2023-07-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember 2023-07-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember 2023-07-012023-09-30 0000790526 us-gaap:IntersegmentEliminationMember 2023-07-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember 2024-01-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember 2024-01-012024-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember 2024-01-012024-09-30 0000790526 rdnt:ThirdPartyMember 2024-01-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember 2024-01-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember 2024-01-012024-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember 2024-01-012024-09-30 0000790526 rdnt:IntersegmentMember 2024-01-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember 2024-01-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember 2024-01-012024-09-30 0000790526 us-gaap:IntersegmentEliminationMember 2024-01-012024-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:ThirdPartyMember 2023-01-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:ThirdPartyMember 2023-01-012023-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:ThirdPartyMember 2023-01-012023-09-30 0000790526 rdnt:ThirdPartyMember 2023-01-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMemberrdnt:IntersegmentMember 2023-01-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMemberrdnt:IntersegmentMember 2023-01-012023-09-30 0000790526 us-gaap:IntersegmentEliminationMemberrdnt:IntersegmentMember 2023-01-012023-09-30 0000790526 rdnt:IntersegmentMember 2023-01-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:ImagingCentersMember 2023-01-012023-09-30 0000790526 us-gaap:OperatingSegmentsMemberrdnt:DigitalHealthMember 2023-01-012023-09-30 0000790526 us-gaap:IntersegmentEliminationMember 2023-01-012023-09-30 0000790526 rdnt:ImagingCentersMember 2024-07-012024-09-30 0000790526 rdnt:ImagingCentersMember 2023-07-012023-09-30 0000790526 rdnt:ImagingCentersMember 2023-01-012023-09-30 0000790526 rdnt:DigitalHealthMember 2024-07-012024-09-30 0000790526 rdnt:DigitalHealthMember 2023-07-012023-09-30 0000790526 rdnt:DigitalHealthMember 2024-01-012024-09-30 0000790526 rdnt:DigitalHealthMember 2023-01-012023-09-30 0000790526 rdnt:TermLoanMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMemberus-gaap:SecuredDebtMember 2024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember 2024-04-18 0000790526 rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember 2024-04-18 0000790526 rdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember 2024-04-182024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2023-01-012023-03-31 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember 2023-01-012023-03-31 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:LineOfCreditMemberus-gaap:EurodollarMember 2023-03-31 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementSixthAmendmentMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember 2023-03-31 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-04-012024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMember 2024-04-012024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienTermLoanMember 2024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienTermLoanMemberrdnt:OneMonthSecuredOvernightFinancingRateSOFRMember 2024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienTermLoanMemberus-gaap:BaseRateMember 2024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-04-192024-06-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:PrimeRateMember 2024-04-192024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienTermLoanMember 2024-04-19 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienTermLoanMemberrdnt:OneMonthSecuredOvernightFinancingRateSOFRMember 2024-04-19 0000790526 rdnt:TermLoanMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMemberus-gaap:SecuredDebtMember 2024-04-192024-09-30 0000790526 rdnt:TermLoanMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMemberus-gaap:SecuredDebtMember 2024-01-012024-04-18 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMemberus-gaap:LineOfCreditMember 2024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-012024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMemberus-gaap:PrimeRateMember 2024-01-012024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember 2024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:BarclaysCreditAgreementMemberrdnt:BarclaysMember 2024-01-012024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementMemberrdnt:BarclaysMemberus-gaap:LineOfCreditMember 2024-09-30 0000790526 rdnt:TermLoanMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TruistMember 2022-10-07 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TruistMember 2022-10-07 0000790526 rdnt:TermLoanMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TruistMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-012024-09-30 0000790526 rdnt:TermLoanMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TruistMember 2024-01-012024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TruistMember 2024-09-30 0000790526 us-gaap:RevolvingCreditFacilityMemberrdnt:FirstLienCreditAgreementEighthAmendmentMemberrdnt:TruistMember 2024-01-012024-09-30 0000790526 us-gaap:CommercialPaperMember 2023-02-01 0000790526 rdnt:FirstLienTermLoanMemberrdnt:TermLoanMember 2024-09-30 0000790526 rdnt:FirstLienTermLoanMemberrdnt:TermLoanMember 2023-12-31 0000790526 rdnt:RestatedAgreementMemberrdnt:TermLoanMember 2024-09-30 0000790526 rdnt:RestatedAgreementMemberrdnt:TermLoanMember 2023-12-31 0000790526 srt:MinimumMemberrdnt:EquipmentNotesPayableMember 2024-09-30 0000790526 srt:MaximumMemberrdnt:EquipmentNotesPayableMember 2024-09-30 0000790526 rdnt:EquipmentNotesPayableMember 2024-09-30 0000790526 rdnt:EquipmentNotesPayableMember 2023-12-31 0000790526 2023-06-07 0000790526 us-gaap:EmployeeStockOptionMember 2024-09-30 0000790526 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000790526 us-gaap:EmployeeStockOptionMemberrdnt:DeepHealthIncMember 2020-04-012020-06-30

0000790526 rdnt:DeepHealthIncMember 2020-04-012020-06-30 0000790526 rdnt:DeepHealthInc.Member 2023-12-31 0000790526 rdnt:DeepHealthInc.Member 2024-01-012024-09-30 0000790526 rdnt:DeepHealthInc.Member 2024-09-30 0000790526 rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember 2023-12-31 0000790526 rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember 2024-01-012024-09-30 0000790526 rdnt:RestrictedStockAwardsAndRestrictedStockUnitsMember 2024-09-30 0000790526 rdnt:PerformanceBasedStockUnitsMember 2023-01-012023-01-31 0000790526 srt:MinimumMemberrdnt:PerformanceBasedStockUnitsMember 2023-01-012023-01-31 0000790526 srt:MaximumMemberrdnt:PerformanceBasedStockUnitsMember 2023-01-012023-01-31 0000790526 srt:DirectorMemberrdnt:PerformanceBasedStockUnitsMember 2024-03-31 0000790526 rdnt:PerformanceBasedStockOptionsMember 2023-01-012023-01-31 0000790526 srt:MinimumMemberrdnt:PerformanceBasedStockOptionsMember 2023-01-012023-01-31 0000790526 srt:MaximumMemberrdnt:PerformanceBasedStockOptionsMember 2023-01-012023-01-31 0000790526 rdnt:PerformanceBasedStockOptionsMember 2024-03-31 0000790526 srt:DirectorMemberrdnt:PerformanceBasedStockOptionsMember 2024-03-31 0000790526 rdnt:PinkPerceptionLLCMemberus-gaap:SubsequentEventMember 2024-10-012024-10-01 0000790526 rdnt:PinkPerceptionLLCMemberus-gaap:SubsequentEventMember 2024-10-01 0000790526 rdnt:KheironMedicalTechnologiesLimitedMemberus-gaap:SubsequentEventMember 2024-10-222024-10-22 shares iso4217:USD shares rdnt:center pure rdnt:incentivePlan rdnt:agreement rdnt:security rdnt:jointVenture rdnt:location rdnt:tranche0000790526false--12-31Q32024http://fasb.org/us-gaap/2024#InterestExpenseDebthttp://fasb.org/us-gaap/2024#InterestExpenseDebt10-Qtrue2024-09-30false001-33307RadNet, Inc.DE13-3326724151O Cotner AvenueLos Angeles,CA90025310478-7808Common StockRDNTNASDAQYesYesLarge Accelerated FilerfalsefalsefalseFalse74026737748916000342570000199076000163707000302100002534200038051000476570001016253000579276000663867000604401000646750000596031843000-12484000-82130000-795780008953130006306950002243210001826640001119634000813359000327534200026904730004275790003619270001247513000107826500033563000400410001050600148000-527000-735000-11830003040001153000797000315700042723100035871700012724670001121884000339110004325100080096000743630001942700016115000617760004787600035950001167550000-1015000-7429000-9490001470000890900005414000408100016248000260900017320000-11965000-50558000-42281000165910003128600029538000320820004335000722000049270007741000122560002406600024611000243410009047000652600027163000194370003209000175400025520004904000.040.26-0.040.080.040.25-0.040.087349470967793404725873216211370775165435688098187258732163221251122560002406600024611000243410005228000-40350002399000-385000-986000-921000-8242000-2765000184700002095200035252000267210009047000652600027163000194370009423000144260008089000728400073968042700097435500080570008533900088096600021187400010928400090754727000472700047270008334000400040002010002010002010003400000340000052280005228000522800052280005228000-986000-986000-9860003209000320900090470001225600073976284700097927900018430000-821300008953130002243210001119634000676695647000703593000-15183000-952580005931590001678450007610040003424210002100021000344718714326000432600043260000-370000-370000-3700001699351230005123000512300028850002885000221700022170002217000-4035000-4035000-4035000-921000-921000-92100010001000-1000017540000175400006526000240660006784820970007149100000-18297000-77719000618901000177257000796158000679563187000722750000-12484000-795780006306950001826640008133590000606053670003670003670006669629377214060002140600021406000523250021838500021838500021838500095019460700046070008242000-8242000-8242000-2552000-2552000271630002461100073976284700097927900018430000-821300008953130002243210001119634000577231256000436288000-20677000-826220003329950001584570004914520008424720007200072000106932421956213810002138100021381000221700022170002217000871125010002458310002458320002458320002458320

*contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. As it relates to the Consolidated Medical Group, this service fee revenue includes payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans. Our total service revenues during the three and nine months ended September 30, 2024 and 2023 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial insurance</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">255,375 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">218,923 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">752,514 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">652,597 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,852 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89,981 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">298,001 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">262,719 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,894 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,519 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,804 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,279 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Workers' compensation/personal injury</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,088 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,785 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Other patient revenue</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,607 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,443 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,524 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,191 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Management fee revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,242 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,922 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-*

align:bottom">18,255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,203 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart and lung</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,696 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,441 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,553 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,377 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,314 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,768 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,918 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,248 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue under capitation arrangements</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,563 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,041 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105,050 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,982 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Imaging Center Segment Revenue</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">444,775 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,783 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,305,707 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,161,381 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> Digital Health Segment Revenue </td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,367 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,185 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,856 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,866 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total service revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience.
 We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion. Amounts remaining to be collected on these agreements were $5.9 million and $14.3 million at September 30, 2024 and December 31, 2023, respectively. We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis. DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities. Deferred financing costs, net of accumulated amortization, were $2.4 million and $1.6 million, as of September 30, 2024 and December 31, 2023, respectively. See Note 6, Credit Facilities and Notes Payable for more information. PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred. BUSINESS COMBINATIONS - When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations. <span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GOODWILL - Goodwill at September 30, 2024 totaled $711.8 million. Goodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2023 noting no impairment, and we have not identified any indicators of impairment through September 30, 2024.</div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"> Activity in goodwill for the nine months ended September 30, 2024 is provided below (in thousands):</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:31.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center segment</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:36pt">Digital Health segment</div></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">606,557 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">72,906 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">679,463 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Goodwill from acquisitions</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,729 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,729 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Currency translation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">426 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,649 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Segment reorganization</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,300)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,300 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">626,209 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85,632 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">711,841 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> INTANGIBLE ASSETS - Intangible assets are primarily related to our business combinations and software development. They include the estimated fair values of such items as service agreements, customer lists, covenants not to compete, acquired technologies, and trade names. The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at September 30, 2024 and December 31, 2023 are as follows (in thousands): As of September 30, 2024:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024*</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2025</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2027</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Thereafter</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average amortization period remaining in years</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Management service contracts</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">572 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,669 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,389 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.2</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Covenant not to compete and other contracts</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">261 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">897 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">315 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">225 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,376 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3.1</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer lists</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,141 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,019 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">844 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">803 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,108 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,233 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">17.4</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Patent and trademarks </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">197 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,519 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.2</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,913 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,651 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,611 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,077 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,856 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,185 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.8</td></tr><tr><td colspan="3"

style="padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names amortized</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">340 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">4.5</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names indefinite life </td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,899 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,899 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total annual amortization</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,161 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,364 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,915 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,911 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,766 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,324 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">84,441 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table> *Excluding the nine months ended September 30, 2024 As of December 31, 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2025</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2027</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Thereafter</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average amortization period remaining in years</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Management service contracts</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,671 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,106 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.9</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Covenant not to compete and other contracts</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">946 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">714 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">427 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,270 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3.4</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer lists</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,234 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,104 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">981 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">797 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">764 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,564 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">17.7</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Patent and trademarks</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">316 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">316 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">316 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">315 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,727 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.8</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,785 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,785 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,745 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,210 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,046 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,117 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,688 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">5.7</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names amortized</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-

height:100%">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">398 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.3</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names indefinite life</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,100 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total annual amortization</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,645 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,283 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,833 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,818 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,505 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,531 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">90,615 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table> Total intangible asset amortization expense was $3.1 million and $9.4 million for the three and nine months ended September 30, 2024, respectively. Total amortization expense was $3.0 million and $8.9 million for the three and nine months ended September 30, 2023, respectively. Intangible assets are amortized using the straight-line method over their useful life determined at acquisition. Management service contracts are amortized over 25 years using the straight line method. Developed technology is capitalized and amortized over the useful life of the software when placed into service. In process research and development (" IPR&D") and Trade names are reviewed annually for impairment. INCOME TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized. In 2021, the Organization for Economic Co-operation and Development ("OECD") announced an inclusive framework on base erosion and profit shifting including Pillar Two Model Rules defining the global minimum tax, which calls for taxation of large multinational corporations at a minimum rate of 15%. Subsequently, multiple sets of administrative guidance have been issued. Many non-US tax jurisdictions have either recently enacted legislation to support certain components of Pillar Two Model Rules beginning 2024 (including the European Union Member States) with the adoption of additional components in later years or announced their plans to enact legislation in future years. The model rules provide a framework for applying the minimum tax, countries may enact Pillar Two Model Rules slightly differently than the model rules and on different timelines and may adjust domestic tax incentives in response to Pillar Two Model Rules. On a long-term basis, we will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in all countries applicable to us. For 2024, we expect that we will meet one or more transactional safe harbor rules, and as such, we do not believe Pillar Two model will have an impact on our annual effective tax rate for the year ending December 31, 2024. We recorded an income tax expense of $4.3 million, or an effective tax rate of 26.1%, for the three months ended September 30, 2024 and $7.2 million, or an effective tax rate of 23.1% for the three months ended September 30, 2023. We recorded income tax expense of $4.9 million, or an effective tax rate of 16.7%, for the nine months ended September 30, 2024 and $7.7 million, or an effective tax rate of 24.1% for the nine months ended September 30, 2023. The income tax rates for the three and nine months ended September 30, 2024 diverge from the federal statutory rate due to (i) effects of state income taxes ; (ii) officer's compensation limitations; (iii) partial valuation allowance on losses in foreign jurisdictions, partially offset by (iv) excess tax benefits attributable to share based compensation; and (v) noncontrolling interests from controlled partnerships. <span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets, current operating lease liabilities, and long term operating lease liability in our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of September 30, 2024. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order. EQUITY BASED COMPENSATION – We have one long-term incentive plan that we adopted in 2006 and which we have amended and restated at various points in time: April 20, 2015, March 9, 2017, April 15, 2021 April 27, 2023, and most recently by our stockholders at our annual stockholders meeting on June 7, 2023 (the "Restated Plan"). We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three years to five years and expire five years to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes model. This model requires that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards' service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 7, Stock-Based Compensation, for more information. COMPREHENSIVE INCOME (LOSS) - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the three and nine months ended September 30, 2024 and September 30, 2023 are included in the consolidated statements of comprehensive income. INTEREST INCOME - We recognized interest income of approximately $9.6 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively, and $22.7 million and $6.3 million for the nine months ended September 30, 2024 and 2023, respectively. Interest income is recorded within Other non-operating income in our Condensed Consolidated Statements of Operations. COMMITMENTS AND CONTINGENCIES – We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. If one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected. DERIVATIVE INSTRUMENTS - In the second quarter of 2019, we entered into four forward interest rate agreements ("2019 Swaps"). The 2019 Swaps have total notional amounts of $500.0 million, consisting of two agreements of $50.0 million each and two agreements of $200.0 million each. The 2019 Swaps secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the smaller notional and will mature in October 2025 for the larger notional. We arranged the 2019 Swaps with locked in 1 month Term SOFR rates at 1.89% for the $100.0 million notional and at 1.98% for the $400.0 million notional. As of the effective date, we are liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates are above the arranged rates. At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive gain or loss in the consolidated statement of equity. The remaining gain or loss, if any, is recognized currently in earnings. The cash flows for both our $400.0 million notional interest rate swap contract locked in at 1.98% due October 2025 and our $100.0 million notional interest rate swap contract locked in at 1.89% did not match the cash flows for our term loans under our Barclays Credit Facility, so we determined that they are not effective as cash flow hedges. Accordingly, all changes in their fair value after April 1, 2020 for the $400.0 million notional and after July 1, 2020 for the $100.0 million notional are being recognized in earnings. As of July 1, 2020, the total change in fair value relating to swaps included in other comprehensive income was approximately $24.4 million, net of taxes. This amount was amortized to interest expense through October 2023 at approximately $0.4 million per month and continuing at approximately $0.3 million per month through October 2025. The effect for the release of the taxes from other comprehensive income is based on the current tax rate.</div><div style="margin-top:10pt;text-align:justify;text-indent:36pt">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):</div><div style="margin-top:10pt;text-align:justify;text-indent:36pt">
</div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:36.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.217%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Account</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of comprehensive loss recognized on derivative net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024 Balance </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Loss, net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(4,369)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$—</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$986</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(3,383)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Equity</td></tr></table> *Net of taxes of $0.4 million for the three months ended September 30, 2024. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:36.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.217%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Account</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of comprehensive loss recognized on derivative net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-

height:100%">September 30, 2024 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Loss, net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(11,625)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$—</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$8,242</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(3,383)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Equity</td></tr></table> *Net of taxes of $2.8 million for the nine months ended September 30, 2024.</div><div style="margin-top:5pt;text-align:justify">A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):</div><div style="margin-top:5pt;text-align:justify">
</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:23.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Ineffective interest rate swap</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount recognized (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location recognized in profit and loss (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount reclassified from accumulated OCI (prior period effective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location reclassified from accumulated OCI into profit and loss (prior period effective portion)</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,755 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Other income (expense)</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">986 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest Expense</td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:23.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the nine months ended September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Ineffective interest rate swap</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount recognized (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location recognized in profit and loss (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount reclassified from accumulated OCI (prior period effective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location reclassified from accumulated OCI into profit and loss (prior period effective portion)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,429 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Other income (expense)</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,242 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest Expense</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
 See Fair Value Measurements below for the fair value of the 2019 Swaps at September 30, 2024. CONTINGENT CONSIDERATION - The HLH Imaging Group Limited fka Heart and Lung Imaging Limited On November 1, 2022, we completed our acquisition of 75% of the equity interests of Heart and Lung Imaging Limited. The purchase included up to $10.2 million in contingent milestone consideration and cash holdback of $0.6 million to be issued 24 months after acquisition subject to adjustment for any indemnification claims, which will be adjusted to fair value in subsequent periods. The holdback had a value of approximately $0.6 million as of September 30, 2024. The contingent consideration is determined by the achievement of a specific number of physician reads. On September 20, 2023, we settled a milestone contingent liability by issuing 56,600 shares of our common stock at an ascribed value of $1.6 million and cash of $1.8 million. On December 12, 2023, we settled a milestone contingent liability by issuing 64,569 shares of our common stock at an ascribed value of $2.3 million and cash of $2.1 million. On March 27, 2024, we partially settled a milestone contingent liability by issuing 95,019 shares of our common stock at an ascribed value of $4.6 million. On April 1, 2024, we settled the remaining milestone contingent liability in cash of $3.6 million. A tabular roll forward of contingent consideration is as follows (amounts in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Entity</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Account</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Settlement of contingent consideration</td><td colspan="3" style="padding:0 1pt"></td><td

colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Change in valuation of contingent consideration</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Currency translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024 Balance</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart and Lung</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">632 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">632 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:bottom">Currency translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024 Balance</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart and Lung</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued expenses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,879 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(8,221)</td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,060 </td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">914 </td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">632 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

decoration:underline">Derivatives: The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Long term assets</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2019 Swaps - Interest Rate Contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,689 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,689 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Current and long term assets</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2019 Swaps - Interest Rate Contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The estimated fair value of these contracts was determined using Level 2 inputs. More specifically, the fair value was determined by calculating the value of the difference between the fixed interest rate of the interest rate swaps and the counterparty's forward SOFR curve. The forward SOFR curve is readily available in the public markets or can be derived from information available in the public markets. Contingent Consideration: The table below summarizes the estimated fair values of holdback relating to our Heart and Lung Imaging Limited acquisition on November 1, 2022 that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid

#000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:justify;vertical-align:bottom">Accrued expenses</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart & Lung Imaging Limited</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">632 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">632 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:justify;vertical-align:bottom">Accrued expenses</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart & Lung Imaging Limited</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,879 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The estimated fair value of these liabilities was determined using Level 3 inputs. For Heart & Lung Imaging Limited the contingent consideration is determined by the achievement of a specific number of physician reads. The fair value is measured based upon the probability adjusted amount expected to be paid. As significant inputs for the contingent consideration of Heart & Lung Imaging Limited are not observable and cannot be corroborated by observable market data they are classified as Level 3. Long Term Debt: The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Face Value</td></tr><tr><td colspan="3"

style="padding:2px 1pt;text-align:left;vertical-align:bottom">Barclays Term Loan and Truist Term Loan</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,010,778 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,010,778 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,009,687 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Face Value</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Barclays Term Loan and Truist Term Loan</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">824,759 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">824,759 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">823,063 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

 The estimated fair value of our long-term debt, which is discussed in Note 6, Credit Facilities and Notes Payable, was determined using Level 2 inputs primarily related to comparable market prices. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets, current liabilities and other notes payables to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization or payment. EARNINGS PER SHARE - Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.317%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,209 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">17,540 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,552)</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,904 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of common shares outstanding during the period</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,494,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,793,404 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,587,321 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,113,707 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.04 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.26 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.08 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of common shares outstanding during the period</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,494,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,793,404 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,587,321 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,113,707 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Add non-vested restricted stock subject only to service vesting</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">233,235 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">217,238 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">202,082 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Add additional shares issuable upon exercise of stock options and contingently issuable shares</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,437,491 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">799,176 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">905,462 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of common shares used in calculating diluted net income per share</td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,165,435 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,809,818 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,587,321 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,221,251 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.04 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">0.08 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-vested restricted stock subject to service vesting</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">680,318 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares issuable upon the exercise of stock options</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,600 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">820,932 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">761,708 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares issuable subject to satisfaction of certain contingencies</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">193,207 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average shares for which the exercise price exceeds average market price of common stock</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,346 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Equity contributions in existing joint ventures</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,496 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024</td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">104,514 </td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> We charged management service fees from the centers underlying these joint ventures of approximately $5.9 million and $3.9 million for the three months ended September 30, 2024 and 2023 and $17.8 million and $12.2 million for the nine months ended September 30, 2024 and 2023, respectively. We eliminate any unrealized portion of our management service fees with our equity in earnings of joint ventures. As we have the ability to exercise significant influence over our joint venture entities, we consider them related parties. Amounts transacted between ourselves and the entities are in the ordinary course of business and are disclosed on our balance sheet in the due from/to affiliate accounts.</div><div style="margin-top:10pt;text-align:justify;text-indent:36pt">The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2024 and December 31, 2023 and income statement data for the nine months ended September 30, 2024 and 2023 (in thousands):</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Data:</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Current assets</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64,175 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39,819 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219,478 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">224,936 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Current liabilities</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41,550) </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46,587)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(70,607)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(70,834)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total net assets</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">171,496 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">147,334 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Income statement data for the nine months ended September 30,</div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Net revenue</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195,905 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,020 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23,949 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,906 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> REVENUES - Our revenues generally relate to net patient fees received from various payors and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period when our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payor (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the fees for the services provided are dependent upon the terms provided by Medicare and Medicaid, or negotiated with managed care health plans and commercial insurance companies. The payment arrangements with third-party payors for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. As it relates to the Consolidated Medical Group, this service fee revenue includes

payments for both the professional medical interpretation revenue recognized by the Consolidated Medical Group as well as the payment for all other aspects related to our providing the imaging services, for which we earn management fees. As it relates to others centers, this service fee revenue is earned through providing the use of our diagnostic imaging equipment and the provision of technical services as well as providing administration services such as clerical and administrative personnel, bookkeeping and accounting services, billing and collection, provision of medical and office supplies, secretarial, reception and transcription services, maintenance of medical records, and advertising, marketing and promotional activities. Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payors. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Under capitation arrangements with various health plans, we earn a per-enrollee amount each month for making available diagnostic imaging services to all plan enrollees under the capitation arrangement. Revenue under capitation arrangements is recognized in the period in which we are obligated to provide services to plan enrollees under contracts with various health plans. Our total service revenues during the three and nine months ended September 30, 2024 and 2023 are presented in the table below based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30,</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial insurance</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">255,375 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">218,923 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">752,514 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">652,597 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicare</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,852 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89,981 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">298,001 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">262,719 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Medicaid</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,894 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,519 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,804 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,279 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Workers' compensation/personal injury</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,745 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,088 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,785 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Other patient revenue</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,607 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,443 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,524 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,191 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Management fee revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,242 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,922 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,203 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart and lung</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">4,696 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,441 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,553 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,377 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,314 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,768 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,918 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,248 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue under capitation arrangements</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,563 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,041 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105,050 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,982 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Imaging Center Segment Revenue</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">444,775 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,783 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,305,707 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,161,381 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> Digital Health Segment Revenue </td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,367 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,185 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,856 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,866 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total service revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
2553750002189230007525140006525970001028520008998100029800100026271900010894000105190003280400030279000102320009745000330880003478500010660
style="text-indent:36pt">ACCOUNTS RECEIVABLE - Substantially all of our accounts receivable are due under fee-for-service contracts from third party payors, such as insurance companies and government-sponsored healthcare programs, or directly from patients. Services are generally provided pursuant to one-year contracts with healthcare providers. We continuously monitor collections from our payors and maintain an allowance for bad debts based upon specific payor collection issues that we have identified and our historical experience. We have entered into factoring agreements with various institutions and sold certain accounts receivable under non-recourse agreements in exchange for notes receivables from the buyers. These transactions are accounted for as a reduction in accounts receivable as the agreements transfer effective control over and risk related to the receivables to the buyers. Proceeds on notes receivables are reflected as operating activities on our statement of cash flows and on our balance sheet as prepaid expenses and other current assets for the current portion and deposits and other for the long term portion.We do not utilize factoring arrangements as an integral part of our financing for working capital and assess the party's ability to pay upfront at the inception of the notes receivable and subsequently by reviewing their financial statements annually and reassessing any insolvency risk on a periodic basis.5900000143000000DEFERRED FINANCING COSTS - Costs of financing are deferred and amortized using the effective interest rate method and are related to our revolving credit facilities.240000001600000 PROPERTY AND EQUIPMENT - Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation of property and equipment is performed using the straight-line method over the estimated useful lives of the assets acquired, which range from 3 to 15 years. Leasehold improvements are amortized at the lesser of lease term or their estimated useful lives, which range from 3 to 15 years. Maintenance and repairs are charged to expense as incurred. P3YP15YP3YP15Y BUSINESS COMBINATIONS - When the qualifications for business combination accounting treatment are met, it requires us to recognize, separately from goodwill, the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations. GOODWILLGoodwill is recorded as a result of business combinations. If we determine the carrying value of a reporting unit exceeds its fair value an impairment charge would be recognized and should not exceed the total amount of goodwill allocated to that reporting unit. We tested goodwill and indefinite lived intangibles for impairment on October 1, 2023 noting no impairment, and we have not identified any indicators of impairment through September 30, 2024.7118000000Activity in goodwill for the nine months ended September 30, 2024 is provided below (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:31.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center segment</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px

1pt;text-align:left;vertical-align:bottom"> Digital Health segment </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">606,557 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">72,906 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">679,463 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Goodwill from acquisitions</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,729 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,729 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Currency translation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">426 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,649 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Segment reorganization</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,300)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,300 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">626,209 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85,632 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">711,841 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>6065570007290600067946300030729000030729000-1223000-426000-1649000-123000001230000006262090008563200071184100OThe components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at September 30, 2024 and December 31, 2023 are as follows (in thousands):<div style="margin-top:10pt;text-align:justify">As of September 30, 2024:</div><div style="margin-top:5pt;text-align:justify">
</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024*</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2025</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2027</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Thereafter</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average amortization period remaining in years</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Management service contracts</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">572 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,669 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,389 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.2</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Covenant not to compete and other contracts</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">261 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">897 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">610 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">315 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">225 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,376 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3.1</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer lists</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,141 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,019 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">844 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">803 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,108 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,233 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">17.4</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Patent and trademarks </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">197 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,519 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.2</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,913 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,651 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,611 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,077 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,077 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,856 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,185 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.8</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names amortized</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-

height:100%">340 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">4.5</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names indefinite life </td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,500 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,500 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,899 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,899 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total annual amortization</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,161 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,364 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,915 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,911 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,766 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,324 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">84,441 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:justify">*Excluding the nine months ended September 30, 2024</div><div style="margin-top:5pt">As of December 31, 2023;</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.332%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2025</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2026</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2027</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2028</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Thereafter</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted average amortization period remaining in years</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Management service contracts</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-

color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,287 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,671 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,106 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.9</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Covenant not to compete and other contracts</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">946 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">714 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">427 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,270 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3.4</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer lists</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,234 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,104 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">981 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">797 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">764 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,564 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,444 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">17.7</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Patent and trademarks</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">316 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">316 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">316 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">315 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,727 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.8</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,785 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,785 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,745 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,210 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,046 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,117 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,688 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">5.7</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Trade names amortized</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">398 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5.3</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names indefinite life</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,100 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,100 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,882 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total annual amortization</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,645 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,283 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,833 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,818 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,505 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,531 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">90,615 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table>
5720002287000228700022870002287000066690001638900OP7Y2M12D261000897000610000315000225000680002376000P3Y1M6D31800011410001019000844000803(
TAXES - Income tax expense is computed using an asset and liability method and using expected annual effective tax rates. Under this method, deferred income tax assets and liabilities result from temporary differences in the financial reporting bases and the income tax reporting bases of assets and liabilities. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. When it appears more likely than not that deferred taxes will not be realized, a valuation allowance is recorded to reduce the deferred tax asset to its estimated realizable value. For net deferred tax assets we consider estimates of future taxable income in determining whether our net deferred tax assets are more likely than not to be realized.43000000.26172000000.23149000000.167777000000.241 LEASES - We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets, current operating lease liabilities, and long term operating lease liability in our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. We include options to extend a lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For a contract in which we are a lessee that contains fixed payments for both lease and non-lease components, we have elected to account for the components as a single lease component. ROU assets are tested for impairment if circumstances suggest that the carrying amount may not be recoverable. Our ROU assets consist of facility and equipment assets on operating leases. No events have occurred such as fire, flood, or other acts which have impaired the integrity of our ROU assets as of September 30, 2024. Our facility leases require us to maintain insurance policies which would cover major damage to our facilities. We maintain business interruption insurance to cover loss of business due to a facility becoming non-operational under certain circumstances. Our equipment leases are covered by warranty and service contracts which cover repairs and provide regular maintenance to keep the equipment in functioning order. EQUITY BASED COMPENSATION - We have one long-term incentive plan that we adopted in 2006 and which we have amended and restated at various points in time: April 20, 2015, March 9, 2017, April 15, 2021 April 27, 2023, and most recently by our stockholders at our annual stockholders meeting on June 7, 2023 (the "Restated Plan"). We have reserved 20,100,000 shares of common stock for issuance under the Restated Plan which can be issued in the form of incentive and/or nonstatutory stock options, restricted and/or unrestricted stock, stock units, and stock appreciation rights. Terms and conditions of awards can be direct grants or based on achieving a performance metric. We also consider probability of achievement of performance conditions when determining expense recognition. For the awards where vesting is probable, equity-based compensation is recognized over the related vesting period. Stock options generally vest over three years to five years and expire five years to ten years from date of grant. We determine the compensation expense for each stock option award using the Black Scholes model. This model requires that our management make certain estimates concerning risk free interest rates and volatility in the trading price of our common stock. The compensation expense recognized for all equity-based awards is recognized over the awards' service periods. Equity-based compensation is classified in operating expenses within the same line item as the majority of the cash compensation paid to employees. In connection with our acquisition of DeepHealth Inc. on June 1, 2020, we assumed the DeepHealth, Inc. 2017 Equity Incentive Plan, including outstanding options awards that can be exercised for our common stock. No additional awards will be granted under the DeepHealth, Inc. 2017 Equity Incentive Plan. See Note 7, Stock-Based Compensation, for more information.
120100000P3YP5YP5YP10Y COMPREHENSIVE INCOME (LOSS) - Accounting guidance establishes rules for reporting and displaying other comprehensive income (loss) and its components. Our foreign currency translation adjustments and the amortization of balances associated with derivatives previously classified as cash flow hedges are included in other comprehensive income (loss). The components of other comprehensive income (loss) for the three and nine months ended September 30, 2024 and September 30, 2023 are included in the consolidated statements of comprehensive income. INTEREST INCOME - We recognized interest income of approximately $9.6 million and $3.6 million for the three months ended September 30, 2024 and 2023, respectively, and $22.7 million and $6.3 million for the nine months ended September 30, 2024 and 2023, respectively. Interest income is recorded within Other non-operating income in our Condensed <span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations. 960000036000002270000006300000 COMMITMENTS AND CONTINGENCIES - We are party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, we evaluate the developments on a regular basis and accrue a liability when we believe a loss is probable and the amount can be reasonably estimated. Based on current information, we do not believe that reasonably possible or probable losses associated with pending legal proceedings would either individually or in the aggregate, have a material adverse effect on our business and consolidated financial statements. However, the outcome of these matters is inherently uncertain. If one or more of these matters were resolved against us for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected. DERIVATIVE INSTRUMENTSThe 2019 Swaps secure a constant interest rate associated with portions of our variable rate bank debt and have an effective date of October 13, 2020. They matured in October 2023 for the smaller notional and will mature in October 2025 for the larger notional.As of the effective date, we are liable for premium payments if interest rates decline below arranged rates, but will receive interest payments if rates are above the arranged rates.At inception, we designated our 2019 Swaps as cash flow hedges of floating-rate borrowings. In accordance with accounting guidance, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e. change in fair value) is reported as a component of comprehensive gain or loss in the consolidated statement of equity.4500000000.0250000000.02200000000.00.0189100000000.00.0198400000000.0400000000.00.0198100000000.00.0189400000000.0100000000.0244000004000003000(

style="margin-top:10pt;text-align:justify;text-indent:36pt">A tabular presentation of the effect of derivative instruments on our consolidated statement of comprehensive income of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:36.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Account</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of comprehensive loss recognized on derivative net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024 Balance </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Loss, net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(4,369)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$—</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$986</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(3,383)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Equity</td></tr></table> *Net of taxes of $0.4 million for the three months ended September 30, 2024.</div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:36.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Account</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of comprehensive loss recognized on derivative net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024 Balance</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Other Comprehensive Loss, net of taxes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(11,625)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$—</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$8,242</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">$(3,383)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Equity</td></tr></table> *Net of taxes of $2.8 million for the nine months ended September 30, 2024.</div><div style="margin-top:5pt;text-align:justify">A tabular presentation of the effect of derivative instruments on our statement of operations of the 2019 Swaps which remain ineffective is as follows (amounts in thousands):</div><div style="margin-top:5pt;text-align:justify">
</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:23.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the three months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Ineffective interest rate swap</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount recognized (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location recognized in profit and loss (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount reclassified from accumulated OCI (prior period effective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location reclassified from accumulated OCI into profit and loss (prior period effective portion)</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,755 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Other income (expense)</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">986 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3"

style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest Expense</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:23.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">For the nine months ended September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Ineffective interest rate swap</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount recognized (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location recognized in profit and loss (current period ineffective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amount reclassified from accumulated OCI (prior period effective portion)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Location reclassified from accumulated OCI into profit and loss (prior period effective portion)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate contracts</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,429 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">Other income (expense)</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,242 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest Expense</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -43690000-986000-3383000400000-116250000-8242000-33830002800000-6755000-986000-7429000-82420000.751020000060000P24M600000056600160000180000064569230000021000009501946000003600000 A tabular roll forward of contingent consideration is as follows (amounts in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%">

family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency translation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023 Balance</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart and Lung</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued Expenses & Other Long Term Liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,358 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,402)</td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">915 </td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(772)</td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,099 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

weight:700;line-height:100%">September 30, 2023 Balance</td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart and Lung</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued Expenses & Other Long Term Liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,656 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,402)</td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,906 </td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(61)</td><td style="border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,099 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Current and long term assets</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2019 Swaps - Interest Rate Contracts</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The table below summarizes the estimated fair values of holdback relating to our Heart and Lung Imaging Limited acquisition on November 1, 2022 that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:justify;vertical-align:bottom">Accrued expenses</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart & Lung Imaging Limited</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">632 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">632 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:justify;vertical-align:bottom">Accrued expenses</td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-

color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"> </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Heart & Lung Imaging Limited</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,879 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,879 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Face Value</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Barclays Term Loan and Truist Term Loan</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,010,778 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,010,778 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Fair Value</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total Face Value</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Barclays Term Loan and Truist Term Loan</td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">824,759 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">824,759 </td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none

<table>
<tr><td colspan="3" rowspan="2" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="9" style="background-color:#eeeeee;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr>
<tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr>
<tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,209 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">17,540 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,552)</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,904 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr>
<tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of common shares outstanding during the period</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,494,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,793,404 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,587,321 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,113,707 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.04 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.26 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.08 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr>
<tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of common shares outstanding during the period</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,494,709 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,793,404 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,587,321 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62,113,707 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Add non-vested restricted stock subject only to service vesting</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">233,235 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">217,238 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">202,082 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Add additional shares issuable upon exercise of stock options and contingently issuable shares</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,437,491 </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">799,176 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">905,462 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted average number of common shares used in calculating diluted net income per share</td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,165,435 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,809,818 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72,587,321 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63,221,251 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.04 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(0.04)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.08 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 320900017540000-255200049040007349470967793404725873216211370 70.040.26-0.040.087349470967793404725873216211370723323521723802020821437491799176090546275165435688098187258732163221251 0.040.25-0.040.08006803180088600820932761708000193207000943461NVESTMENTS IN EQUITY SECURITIES-Accounting guidance requires entities to measure equity investments at fair value, with any changes in fair value recognized in net income. If there is no readily determinable fair value, the guidance allows entities the ability to measure investments at cost, adjusted for observable price changes and impairments, with changes recognized in net income.48000000.01200000 INVESTMENT IN JOINT VENTURES – We have 13 unconsolidated joint ventures with ownership interests ranging from 33% to 55%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method, since RadNet does not have a controlling interest in such ventures. We evaluate our investment in joint ventures, including cost in excess of book value (equity method goodwill) for impairment whenever indicators of impairment exist. No indicators of impairment existed as of September 30, 2024. 130,330.55 The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2024 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of December 31, 2023</td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">92,710 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Equity in earnings in these joint ventures</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,308 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Distribution of earnings</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,000)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Equity contributions in existing joint ventures</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,496 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024</td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">104,514 </td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 92710000113080001000000149600010451400059000003900000178000001220000 The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2024 and December 31, 2023 and income statement data for the nine months ended September 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Data:</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Current assets</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">64,175 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39,819 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219,478 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">224,936 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Current liabilities</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41,550)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46,587)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Noncurrent liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(70,607)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(70,834)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total net assets</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">171,496 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">147,334 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Income statement data for the nine months ended September 30, </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Net revenue</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">195,905 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-

align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">129,020 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23,949 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,906 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
64175000398190002194780002249360004155000046587000706070007083400017149600014733400019590500012902000023949000079060000RECENT ACCOUNTING AND REPORTING STANDARDS Recently Issued Accounting Pronouncements
 In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. Recently Issued Accounting Pronouncements
 In November 2023, the FASB issued Accounting Standards Updates (ASUs) 2023-07 ("ASU 2023-07"), Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in ASU 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. This ASU will likely result in us including the additional required disclosures when adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. BUSINESS COMBINATIONS AND RELATED ACTIVITY Imaging Center Segment
 Acquisitions During the nine months ended September 30, 2024, we completed the acquisition of certain assets of the following entities, which either engage directly in the practice of radiology or associated businesses. The primary reason for these acquisitions was to strengthen our presence in the California and Texas market. These acquisitions are reported as part of our Imaging Center segment. As of September 30, 2024, we made a preliminary fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands). The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2024, and the fair value determination is preliminary and may be subject to change:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Entity </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Date Acquired</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Consideration</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Property & Equipment</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Right of Use Assets</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Goodwill</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other Assets</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Right of Use Liabilities</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Notes payable</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:bottom">Stanislaus Surgical Hospital, LLC</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">9/16/2024</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">3,000</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">504</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1,468</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">2,382</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">100</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">15</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">(1,468)</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Global Imaging LLP</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9/1/2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,900 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. Imaging, Inc.</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">6/1/2024</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">4,200</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">4,025</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">5,597</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-

align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">175</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">(5,597)</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Houston Medical Imaging, LLC</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4/1/2024</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">22,703</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">15,826</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">7,929</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">11,584</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,660</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">90</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(8,089)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(6,297)</td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Grossman Imaging Center of CMH, LLC</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">3/31/2024</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">10,344</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1,717</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">6,304</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">8,501</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">280</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">56</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">(6,514)</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Providence Health System - Southern California</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3/31/2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,369 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,378 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,441 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,991 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,441) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:bottom">Antelope Valley Outpatient Imaging</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">2/1/2024</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">3,530 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,794 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">563 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">687 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(563)</td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">54,046</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">27,509</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">25,302</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">30,729</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2,315</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">160</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">(25,672)</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">(6,297)</td></tr></table> During the three months ended September 30, 2024, the Company revised the fair value of certain assets acquired and liabilities assumed of Houston Medical Imaging, LLC's, Grossman Imaging Center of CMH, LLC, and Providence Health System - Southern California, resulting in an increase of $4.4 million in the net fair value of these assets and liabilities and a corresponding decrease in goodwill. These adjustments did not have an impact on the Company's condensed consolidated statement of operations for the nine months ended September 30, 2024.
 Formation of majority owned subsidiary and sale of economic interest On February 23, 2024, we formed Tri Valley Imaging Group, LLC ("TVIG"), a partnership with Providence Health System - Southern California ("PHS"). The operation offers multi-modality services out of seven locations in Southern California. On March 29, 2024, we contributed the operations of four centers to the enterprise and PHS contributed a business comprising three centers including $1.4 million of fixed assets and $6.0 million in goodwill. Simultaneously, PHS purchased from us an additional economic interest in TVIG for cash payment of $9.6 million. As a result of the transaction, we recognized a gain of $7.9 million to additional paid-in capital and retained a 52% controlling economic interest in TVIG and PHS retains a $7.8 million or 48% noncontrolling

economic interest in TVIG. In determining the fair value of the imaging centers contributed to TVIG, we used an income approach which is considered a level 3 valuation technique. See Fair Value Measurements above for further detail on the valuation hierarchy. Key assumptions used in measuring the fair value are financial forecasts and a discount rate. We also utilized the cash paid for an additional interest in the joint venture to substantiate the fair value of the contributed assets. As of September 30, 2024, we made a preliminary fair value determination of the acquired assets and assumed liabilities and the following were recorded (in thousands). The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2024, and the fair value determination is preliminary and may be subject to change: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Entity </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Date Acquired</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Consideration</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Property & Equipment</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Right of Use Assets</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Goodwill</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intangible Assets</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other Assets</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">Right of Use Liabilities</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Notes payable</td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:bottom">Stanislaus Surgical Hospital, LLC</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">9/16/2024</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">3,000</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">504</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1,468</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">2,382</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">100</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">15</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">(1,468)</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Global Imaging LLP</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9/1/2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,900 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. Imaging, Inc.</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">6/1/2024</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">4,200</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">4,025</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">5,597</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">175</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">(5,597)</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Houston Medical Imaging, LLC</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">4/1/2024</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">22,703</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">15,826</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">7,929</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">11,584</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,660</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">90</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(8,089)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">(6,297)</td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Grossman Imaging Center of CMH, LLC</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">3/31/2024</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">10,344</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1,717</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">6,304</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">8,501</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">280</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">56</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">(6,514)</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">—</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">

Providence Health System - Southern California</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3/31/2024</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7,369 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,378 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,441 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,991 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,441) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:justify;vertical-align:bottom">Antelope Valley Outpatient Imaging</td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">2/1/2024</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">3,530 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,794 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">563 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">687 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">(563)</td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">54,046</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">27,509</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">25,302</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">30,729</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2,315</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">160</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">(25,672)</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">(6,297)</td></tr></table>
3000000504000146800023820001000001500014680000290000012660000158400050000000420000040250005597000017500005597000022703000158260000792900014400000743140000060000009600000790000000.5278000000.48SEGMENT REPORTING In the first quarter of 2024, we revised our reportable segments to combine our eRad business, which was included in the Imaging Center segment, with our AI segment to form a new Digital Health reportable segment. Prior period amounts were adjusted retrospectively to reflect the change in reportable segment. Accordingly, our reportable segments currently include our Imaging Center segment and our Digital Health segment. Our Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The vast majority of our centers offer multi-modality imaging services, a strategy that diversifies revenue streams, reduces exposure to reimbursement changes and provides patients and referring physicians one location to serve the needs of multiple procedures. Our Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. Included in the segment is our eRad subsidiary, which designs the underlying critical scheduling, data storage and retrieval systems necessary for imaging center operation. Our chief operating decision maker ("CODM"), who is also our CEO, evaluates the financial performance of our segments based upon their respective revenue and segmented internal profit and loss statements prepared on a basis not consistent with GAAP. We do not report balance sheet information by segment since it is not reviewed by our CODM. In the normal course of business, our Imaging Center and Digital Health segments enter into transactions with each other. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Digital Health </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">452,368 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">8,774 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:114%">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,593 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,593)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">452,368 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,367 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(7,593)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:36pt">
</div><div style="text-align:justify;text-indent:36pt">
</div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Digital Health</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">395,613 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">6,355 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,830 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,830)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">395,613 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,185 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5,830)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td

style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Digital Health </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,325,825 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">26,738 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,118 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20,118)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,325,825 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1325825000</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">46,856 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(20,118)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Digital Health</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,178,873 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">17,374 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,492 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,492)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-

align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,178,873 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1178873</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34,866 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(17,492)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The table below presents segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Revenue:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">444,775 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,783 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,305,707 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,161,381 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,367 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,185 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,856 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,866 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Cost of Operations</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">374,789 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">334,580 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,120,542 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,008,814 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,011 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,055 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,571 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,833 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total cost of operations</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">391,800 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">341,635 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,169,113 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,038,647 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Depreciation and Amortization:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">32,032 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">30,221 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">94,095 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">89,743 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,947 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,989 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,727 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,962 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total depreciation and amortization</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34,979 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,210 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">101,822 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">95,705 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Gain on contribution of imaging centers into joint venture:</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(16,808)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(16,808)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total (gain) loss on contribution of imaging centers into joint venture</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(16,808)</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(16,808)</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Loss (gain) on Disposal of Equipment:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">153 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">524 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">739 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,185 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total loss on disposal of equipment</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">148 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">527 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">735 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,183 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Severance</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">271 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,141 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">

</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">720 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,417 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,740 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total severance</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">304 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,153 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:0;text-align:right;vertical-align:bottom">797 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,157 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"> Income (Loss) from Operations</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">37,530 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">40,125 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">89,611 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">77,030 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,619)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,126 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,515)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,667)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total income from operations</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33,911 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">43,251 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">80,096 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">74,363 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Digital Health </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">452,368 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">8,774 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,593 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,593)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">452,368 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,367 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(7,593)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Digital Health</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">395,613 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">6,355 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,830 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,830)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">395,613 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12,185 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;

color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5,830)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center">Digital Health</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,325,825 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">26,738 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,118 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20,118)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,325,825 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1325825000</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">46,856 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(20,118)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:36pt">
</div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Imaging Center</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Digital Health</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Intersegment Elimination</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Consolidated Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue:</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Third Party</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,178,873 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">17,374 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Intersegment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,492 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,492)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,178,873 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom">1178873</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34,866 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(17,492)</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt">The table below presents segment information reconciled to our financial results, with segment operating income or loss including revenue less cost of operations, depreciation and amortization, and other operating expenses to the extent specifically identified by segment (in thousands):</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Revenue:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">444,775 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">389,783 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,305,707 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,161,381 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,367 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,185 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,856 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,866 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total revenue</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461,142 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">401,968 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,352,563 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,196,247 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td>

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Cost of Operations</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">374,789 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">334,580 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,120,542 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,008,814 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,011 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,055 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">48,571 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29,833 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total cost of operations</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">391,800 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">341,635 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,169,113 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,038,647 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Depreciation and Amortization:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">32,032 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">30,221 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">94,095 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">89,743 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,947 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,989 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,727 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,962 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total depreciation and amortization</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">34,979 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,210 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">101,822 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">95,705 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td>

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Gain on contribution of imaging centers into joint venture:</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(16,808)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total (gain) loss on contribution of imaging centers into joint venture</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(16,808)</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">153 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">524 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">739 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">1,185 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total loss on disposal of equipment</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">148 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">527 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">735 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,183 </td><td style="background-color:#dbdbdb;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3"

style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Severance</td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">271 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,141 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">720 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,417 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,740 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total severance</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">304 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,153 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">797 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,157 </td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"> Income (Loss) from Operations</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Imaging Center</td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">37,530 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">40,125 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">89,611 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom">77,030 </td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.57pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Digital Health</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,619)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,126 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,515)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,667)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom">Total income from operations</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33,911 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">43,251 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">80,096 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">74,363 </td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 4523680008774000046114200007593000-75930000452368000163670007593000461142000395613000635500004019680000583000-583000003956130001218500058300000395613000121850005830000401968000132582500026738000013525630000201180000132582500046856000-20118000132563000117887300017374000011962470000174920000117887300034866000-174920001196247000444775000389783000130570700011613810001636700012185000468560003486600046114200040196800013525630001196247000374789000033458000168080000-168080000000-168080000-16808000-153000-524000-739000-11850005000-300040002000-148000-527000-735000-118300027100011410007200001417000330001200770001740000304000115300079700031570003753000040125000896110007703000036190003126000-9515000-266700033911000432510008009600074363000CREDIT FACILITIES AND NOTES PAYABLE At September 30, 2024 we had two principal secured credit facilities consisting of our Barclays credit facility and our Truist credit facility. Each facility includes a term loan component and a revolving credit facility. At September 30, 2024, we were in compliance with all covenants under our credit facilities.
 Barclays Credit Facility On April 18, 2024, we entered into a Third Amended and Restated First Lien Credit and Guaranty Agreement (the "Barclays Credit Agreement"), with Barclays Bank Plc and the lenders and financial institutions named therein, which provides for $875.0 million of senior secured term loans (the "Barclays Term Loan") and a $282.0 million senior secured revolving credit facility (the "Barclays Revolving Credit Facility"). Our borrowing under the Barclays Revolving Credit Facility is secured by a lien on all of our assets.
 The proceeds from the April 18, 2024 restatement of the Barclays Credit Agreement were used to refinance the $678.7 million of term loans outstanding under the prior credit facility, to pay accrued interest through the date of closing, and to pay fees and expenses associated with the refinancing transaction. Total costs incurred in connection with the restatement amounted to approximately $19.9 million segregated as follows: $11.1 million recognized as discount and deferred finance cost, $2.1 million charged to loss on early extinguishment of debt and $6.7 million to related expenses. Amounts capitalized will be amortized over the remaining terms of the respective credit facilities under the Barclays Credit Agreement.
 Barclays Term Loan:
 The Barclays Term Loan provides for interest payments based on a base rate, plus an applicable margin. During the periods covered by this report, the base rates, margins and effective interest rates (without giving effect to our 2019 Swaps) were as follows for the periods indicated:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:22.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Period</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Base Rate plus Margin</td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Effective Rate</td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Through March 31, 2023</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Eurodollar plus 2.50% Alternative Base Rate plus 2.00% </td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> 4.63% 8.00% </td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">April 1, 2023 to April 18, 2024</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> SOFR plus 3.00% Alternative Base Rate plus 2.00% </td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> 8.33% (credit spread adjustment of 0.11%) 10.5% </td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">After April 18, 2024</td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> SOFR plus 2.5% Prime Rate plus 1.5% </td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> 7.70% (credit spread adjustment of 0.00%) 9.5% </td></tr></table>
 With the recent restatement, we are required to make quarterly principal payments of $2.2 million (up from $1.8 million under the prior credit agreement). The Barclays Term Loan will mature on April 18, 2031 unless otherwise accelerated under the terms of the Barclays Credit Agreement.
 Barclays Revolving Credit Facility:
 The Barclays Revolving Credit Facility is a $282.0 million senior secured revolving credit facility. Associated with the Barclays Revolving Credit Facility is deferred financing costs, net of accumulated amortization, of $2.0 million at September 30, 2024.
 Amounts borrowed under the Barclays Revolving Credit Facility bear interest at either SOFR plus 3.00% or the Prime Rate plus 2% (with step-downs based on attainment of certain first lien net leverage ratio benchmarks). As of September 30, 2024, the effective interest rate payable on revolving loans under the Barclays Revolving Credit Facility was 10.50%. In addition, a commitment fee of 0.50% per annum accrues on the unused revolver commitments under the Barclays Revolving Credit Facility.
 We had no outstanding balance under our $282.0 million Barclays Revolving Credit Facility at September 30, 2024. After reserves of $8.3 million for certain letters of credit, $273.7 million was available to draw upon as of September 30, 2024.
 The Barclays Revolving Credit Facility terminates on April 18, 2029, unless otherwise accelerated under the terms of the Barclays Credit Agreement. Truist Credit Facility On October 7, 2022 our subsidiary New Jersey Imaging Network, Inc.("NJIN") entered into Second Amended and Restated Revolving Credit and Term Loan Agreement (the "Truist Credit Agreement"), with Truist Bank and the lenders and financial institutions named therein, which provides for a $150.0 million term loan (the "Truist Term Loan") and a $50.0 million revolving credit facility (the "Truist Revolving Credit Facility"). The Truist Credit agreement is secured by the assets of NJIN. Truist Term Loan:
 The Truist Term Loan currently bears interest at SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. At September 30, 2024 the applicable margin for SOFR was 1.5%.
 We are required to make quarterly principal payments of $1.9 million, which increases by $0.9 million at scheduled intervals, with the remaining balance to be paid at maturity. The Truist Term Loan will mature on October 10, 2027 unless otherwise accelerated under the terms of the Truist Credit Agreement.
 Truist Revolving Credit Facility:
 The Truist Revolving Credit Facility is a $50.0 million secured revolving credit facility. Associated with the Truist Revolving Credit Facility are deferred financing costs, net of accumulated amortization, of $0.4 million at September 30, 2024.
 Amounts borrowed under the Truist Revolving Credit Facility bear interest at either SOFR or a Base Rate plus an applicable margin and fees which step down based on a leverage ratio. In addition, a commitment fee of 0.30% per annum accrues on the unused revolver commitments under the Truist Revolving Credit Facility.
 We had no balance under our $50.0 million Truist Revolving Credit Facility at September 30, 2024. With no letters of credit reserved against the facility, the full $50.0 million was available to draw upon as of September 30, 2024.
 The Truist Revolving Credit Facility terminates on October 7, 2027, unless otherwise accelerated under the terms of the Truist Credit Agreement.
 Notes Payable
 We have issued certain notes payable in connection with the purchase of equipment previously leased under operating leases. On April 1, 2024, January 15, 2024, and February 1, 2023 we issued promissory notes in the amount of $6.3 million, $6.9 million and $19.8 million, respectively, to purchase previously leased equipment.
 Debt Obligations As of September 30, 2024 and December 31, 2023 our term loan debt and other obligations are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:74.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.841%"></td><td

style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Barclays Term Loans collateralized by RadNet's tangible and intangible assets</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">872,812 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">678,687 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Discount on Barclays Term Loans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,234)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,041)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Truist Term Loan Agreement collateralized by NJIN's tangible and intangible assets</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136,875 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">144,375 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Discount on Truist Term Loan Agreement</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(792)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(990)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"> Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment </td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,989 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,011 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total debt obligations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,019,650 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">830,042 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current portion</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23,378)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,974)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long term portion of debt obligations</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">996,272 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">812,068 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
875000000282000000678700000199000011100000-21000006700000During the periods covered by this report, the base rates, margins and effective interest rates (without giving effect to our 2019 Swaps) were as follows for the periods indicated: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:22.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Period</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Base Rate plus Margin</td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Effective Rate</td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Through March 31, 2023</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> Eurodollar plus 2.50% Alternative Base Rate plus 2.00% </td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> 4.63% 8.00% </td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">April 1, 2023 to April 18, 2024</td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> SOFR plus 3.00% Alternative Base Rate plus 2.00% </td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> 8.33% (credit spread adjustment of 0.11%) 10.5% </td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">After April 18, 2024</td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> SOFR plus 2.5% Prime Rate plus 1.5% </td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> 7.78% (credit spread adjustment of 0.00%) 9.5% </td></tr></table> As of September 30, 2024 and December 31, 2023 our term loan debt and other obligations are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:74.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.841%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Barclays Term Loans collateralized by RadNet's tangible and intangible assets</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">872,812 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">678,687 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Discount on Barclays Term Loans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,234)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,041)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Truist Term Loan Agreement collateralized by NJIN's tangible and intangible assets</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136,875 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">144,375 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Discount on Truist Term Loan Agreement</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(792) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(990)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment</div></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,989 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,011 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total debt obligations</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,019,650 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">830,042 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: current portion</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23,378)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,974)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term portion of debt obligations</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">996,272 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">812,068 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
0.02500.02000.04630.08000.03000.02000.08330.00110.1050.0250.0150.07780.00000.0952200000180000028200000020000000.03000.020.10500.00500282000000830000
BASED COMPENSATION Stock Incentive Plans We have one long-term equity incentive plan, the RadNet, Inc. Equity Incentive Plan, which has been amended and restated on April 20, 2015, March 9, 2017, April 15, 2021, April 27, 2023, and most recently following approved by our stockholders at our annual stockholders meeting on June 7, 2023 (the "Restated Plan"). We have reserved for issuance under the Restated Plan 20,100,000 shares of common stock. We can issue options (incentive and nonstatutory), performance based options, stock awards (restricted or unrestricted), stock units, performance based stock units, and stock appreciation rights under the Restated Plan. Options Certain options granted under the Restated Plan to employees are intended to qualify as incentive stock options under existing tax regulations. Stock options generally vest over 3 to 5 years and expire 5 to 10 years from the date of grant. The following summarizes all of our option transactions for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Outstanding Options
Under the 2006 Plan</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Exercise price
Per Common Share</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Remaining
Contractual Life
(in years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value
(in thousands)</td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">911,411 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.60 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60,306)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.15 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt">

</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">851,105 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5.69</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">44,301 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at September 30, 2024</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">729,806 </td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.62 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">5.31</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,515 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2024 and the exercise price, multiplied by the number of in-the-money options as applicable) that would have been received by the holder had all holders exercised their options on September 30, 2024. As of September 30, 2024, total unrecognized stock-based compensation expense related to non-vested employee awards was $0.5 million, which is expected to be recognized over a weighted average period of approximately 0.39 years. DeepHealth Options During the second quarter of fiscal 2020, in connection with the completion of the DeepHealth acquisition, we granted options to acquire 412,434 shares at a grant date fair value of $16.93 per share unit to DeepHealth employees in replacement of their stock options that were outstanding as of the closing date. As of September 30, 2024, total unrecognized stock based compensation expense related to non-vested DeepHealth options was insignificant.</div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Outstanding Options
Under the Deep Health Plan</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Exercise price
Per Common Share</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Remaining
Contractual Life
(in years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value
(in thousands)</td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,073 </td><td style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,377)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,696 </td><td style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">5.0</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">4,836 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,696 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5.0</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,836 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Options issued in replacement of original DeepHealth options as a result of our acquisition are not included in the share count under the Restated Plan. Restricted Stock Awards ("RSAs") and Restricted Stock Units ("RSUs") The Restated Plan permits the award of RSAs and RSUs. The following summarizes all unvested RSA's and RSU's activities during the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">RSAs and RSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3"

style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average
Remaining
Contractual
Term (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average
Fair Value per Share</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">RSAs and RSUs unvested at December 31, 2023</td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">762,083 </td><td style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22.13 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Changes during the period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">797,309 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">37.40 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(875,185)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27.78 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Forfeited or Canceled</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,460)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">27.74 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSAs and RSUs unvested at September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">670,747 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">1.74</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">32.33 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> We determine the fair value of all RSAs and RSUs based on the closing price of our common stock on the award date. Performance based stock units ("PSUs") In January 2023, we granted certain employees PSUs with a target award of 60,685 shares of our common stock. The PSUs will vest in two equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 200% of the target award) depending upon the extent to which we achieve a performance condition as determined by the board of directors over the period from January 1, 2023 through December 31, 2023. In March of 2024, based on the performance condition being achieved, the board of directors issued 121,370 units with a fair value of $18.64 per unit. Performance based stock options ("PSOs") In January 2023, we granted certain employees PSOs with a potential to option a maximum of 235,227 shares of our common stock. The PSOs will vest in three equal parts, starting three years from the grant date based on continuous service, with the number of shares earned (0% to 100% of the target award) depending upon the extent to which we achieve a performance condition as determined the board of directors over the period from January 1, 2023 through December 31, 2023. In March 2024, based on the performance condition being achieved, the board of directors issued 235,227 options with a strike price of $18.64 per share.</div><div style="margin-top:10pt;text-align:justify">Shares available</div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:36pt">Of the 20,100,000 shares of common stock reserved for issuance under the Restated Plan, at September 30, 2024, there remain approximately 3,285,500 shares available under the Restated Plan for future issuance.</div>120100000P3YP5YP5YP10Y<div style="margin-top:10pt;text-align:justify;text-indent:36pt">The following summarizes all of our option transactions for the nine months ended September 30, 2024:</div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Outstanding Options
Under the 2006 Plan</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Exercise price
Per Common Share</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Remaining
Contractual Life
(in years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value
(in thousands)</td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">911,411 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16.60 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(60,306)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2"

style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.15 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">851,105 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17.34 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5.69</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">44,301 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at September 30, 2024</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">729,806 </td><td style="background-color:#eeeeee;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16.62 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">5.31</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,515 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:48.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Outstanding Options
Under the Deep Health Plan</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Exercise price
Per Common Share</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average
Remaining
Contractual Life
(in years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate
Intrinsic
Value
(in thousands)</td></tr><tr><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, December 31, 2023</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">79,073 </td><td style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercised</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,377)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,696 </td><td style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:right;vertical-align:bottom">5.0</td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">4,836 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Exercisable at September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,696 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">5.0</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,836 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
91141116.6000603066.1585110517.34P5Y8M8D44301000729806616.62P5Y3M21D38515000500000P0Y4M20D41243416.937907309377069696960P5Y4836000696960P5Y4
style="margin-top:10pt;text-align:justify;text-indent:36pt">The Restated Plan permits the award of RSAs and RSUs. The following summarizes all unvested RSA's and RSU's activities during the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">RSAs and RSUs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average
Remaining
Contractual
Term (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-Average
Fair Value per Share</td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt;text-align:left;vertical-align:bottom">RSAs and RSUs unvested at December 31, 2023</td><td colspan="2" style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">762,083 </td><td style="background-color:#eeeeee;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0

*1pt"></td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22.13 </td><td style="background-color:#eeeeee;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Changes during the period</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">797,309 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">37.40 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Vested</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(875,185)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27.78 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#eeeeee;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Forfeited or Canceled</td><td colspan="2" style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,460)</td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td colspan="3" style="background-color:#eeeeee;padding:0 1pt"></td><td style="background-color:#eeeeee;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#eeeeee;padding:2px 0;text-align:right;vertical-align:bottom">27.74 </td><td style="background-color:#eeeeee;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSAs and RSUs unvested at September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">670,747 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">1.74</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">32.33 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
76208322.1379730937.4087518527.7813460227.74670747P1Y8M26D32.33606852P3Y0212137018.642352273P3Y012352271 8.642010000032855000SUBSEQUENT EVENTS Pink Perception LLC
 On October 1, 2024, we entered into an agreement to acquire Pink Perception LLC for a purchase consideration of approximately $4.0 million. Pink Perception LLC consists of two multi-modality imaging centers located in New York. The acquisition closed in the fourth quarter of 2024.
 Kheiron Medical Technologies Limited On October 22, 2024, we acquired Kheiron Medical Technologies Limited for a purchase consideration of approximately $1.0 million. Kheiron Medical Technologies Limited is a UK-based AI cancer diagnostic company focused on developing deep learning solutions to support radiologists improve breast cancer detection. 40000002100000005falsefalsefalsefalse*

*I[N_KA[-M^M_5ILVVJG(92Y2+;!#X]/BLL/AP(Y))9#=4?TC5Q@.8$XVQL:[!P.Z8QE5N-M1!U.A[5/U08P)2WZQA.7S'3D.4"0>_<)F!0@,EAR?SH7=]!$+=/LC\[M)@Z=MWDF[9]#W0(8$P.[=:=IC;S.]#IXS'V"'\^S25K.#6?L^U.F?Z#T.[0T'JF,X M,[(8+]R433L'J1)&()*>HQ'K'RBP]8']6;? &S@T>(#GV%0: 0."V]A$\[:0 MS"!<>"S*N8#:56RF&S8N3-LO+A%/8I'W2IYA7]_JDD>Q8&P(<%#?)$BZ3P+$,U/2TYG)"I/4*;0"'AB*\+3? M(ACA,.4P4V WZ]\XQQHZAW$V%WFQP7QK2\R$JV+R*.MMQ5!JR2XTVY914_*DW):UU177:NEY/1J?1UC2]EB?I,5VM!P^LMBS5=7BR9.TI7?60 MR8GK=44V 80.^A4JY&:>QKX^89O?ZT2TG-WN6'DF^GAH&^,%L:CGLLEO 8YK M!N3\;WL\^2!@#=-DP9 YEXU^QY[1D?D=%-7KU7VT3G6/OR;SF<[N8W=>A//C M4>TZTZ-[H+9?'9L[9BK)!]3W90/V(:=ZB/<^!DHG[A1U_:)RA*58EZROJ{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{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€\%Q@.(R,"%I4/A<)W7D)B(-V*(.MS1Q>H*/- D))!L//SD:9XR'0]*3P0@':I$)9>[(/).1C40'C^@%8$") K]U M0V#B<"<-.^[*X]B1VQT!2P32#V8">=TL2(=T3/C&5)/.{6"I+ %G@B$)Z!W/X M3BF'-/RF.PC{SAYEX,C!W:$N.L'L*G4^@T<\H*7T1!0"+@#R!KBVE E7%2L MY\[/$\/GW%,-KKR,=SH"HT'L;-M[8,H$*;'D5!1&5)5'!Y'#5I$K83#S(1@C[JIX@FS!!QD5*G0G?$.&MMD-U!L M -!3]T7@#QTF&4$=#.>;!9. 6(&]MM%K@L3:^];*@6IJSX3HQ&=8^NOU]3>P M7< 8&/CT B:GX0Z7KC8<$8(,RR70>A-9W@(.@S2"D5(=N^+0U!AI7 -A0G MZAP0(U$!/82!"R!$1HWG.-?B"O06/)5BGA0R?SJ>kV!%2=\[MR(U_A,1. ,:? QL6*[RY>8)O]*LR %A^5Y@1S&GX@MW>"P15&>*>+5|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`S[?K%(*S_@BH^\6AYYI?.15\U8 MR\%"7JV9;.6N1!C#UC0"%K4EJ7)1HZJT9=6HHRI.,\MZM0*[\L]58W5]'5_4 M/A;5T?96U&@UOB015ZA#K9PG8#Q$&+.B1I(O:MRU5.M4X,*FUK-*W58E'T65 M^]=7 -!T9UN9&M6*Y*6BU@X$#.!>@XGC*\;2!.*Y4/U\I<\9L*P7.V\QA?V70 M2X[G@RR60E7*;,N48H<.V'>$J2WO9\O[C"+Jf,"6-;:>E'B?&-HJ=B?OV%C MBE7ID9L6O)QV,$.5]U5!:%JMKJ9IHF&1'V.<63SS4>K.TK(&S)M%6?I(N&U)3",TX*G!16R(1]U:!:"LV-Z YF')# M2*%.B_5$]>P-6Y_Q,B15WM49 M\]>6 +\W5=9 P0)FGE:Q_48=!W0"'N5="'>[$T6YOBK):")HM6I.)'WA-&_ M\W;.VP!Y=<:RIC9UAE-9WWI5=D&.@.!GQ)BGW>YB5^QTSJ9C?7_/|/"2Y)D5P9Q_P":MF15L\ M'\UK;<;C0UJLC#PPO/8&MTG--*6--1F>- ME*$ 9:B;)L2IPQ.&4VGC+4IGC52ADHM>$42!=VC0PV.&T>S1MK C"51-MDDS1E'>>2]7 %((3M:1J2*]E)*9-9'S&DE%/IT@);DIR=*\^.J@6.:$U8E*G MU05$TGD5WWDBTN$T6\SN,47=X"SI/#%I3=IHC9ADMKJ*)9IJ4^I#+ZAWQ:H\ MTGR/R*K:^ 4G1&P!@?-A'@=4C*U65[5DT93J\CPV) U!^<+!H+I;J#&1$R MMG309+&CUE5LQJF.4UUSMEYCBFV-1">SFGE+E.6=-65.=ISL3IOL#N;HD&FO*

M"DDUQ<{N2;B'H;M:DG#K|R!:9R(17|VIK>Z"O"K%2;B?EN=K7&?F;^S4)_38 MZ=C\?MZSLZ;$7-XTI,05L{4)N5DV"#^[!'\ !2W+#:LK:6JKJRJ@I=55:MZ M.!2GD?.ED36IN?
NA$0UH1!(5Y8PBMIQ&SI5&UB;I[H=&|%;7TD3).J/A&$XC MYTHC:Y-U!T,CG587^WEKYYBO<:+6%N_<6E?2[GY(QFAU%=&JS7_<@,.,QZG- MTW?W@U-TOKAU3L6H"^\=RSO?*
*%9'HN]^&(L ^TY;QLZ;#^\|R.GOM.GO&(.'HM!8 MFR+OG'+/Z8_3WVG3WS'(#UN*2+))H*I?35IW3'Z>_;;*]T. 6]MKX1#'NF*$ MIY -7%,FW%FUE>6KVWYU%^2%*(&/XH!LERK*
*M#"Y>,*F,;'X$-+&JW:*=LA>/6^2&3H^C ^"6 M*G'<.F_<.IZ6K,HIS+7%ZY/38 MG*W7D+-\"*E8>|R|652XX6HXD5XFD583FCFOS+&$9HWA_N,D.AN\{3%?74..? M*D$^H>
(TZ"_H!DI<0L 2/SGAQ]M%SU!MW_'SF2,Z^:]D<_H?AY4Y[V1*VVQ MV5K=C@G/2UI=6KB&BAVRQ@?O$12RA^&W *?P1=-OKNU%,!98J'*\9H*_I36G- MQ]M7Y!G(P6UU=V7F\/"
<';3@Y'R%>NGQRPP9M;5^,<3@Z<']9W'A' MMEMCBLF]]HS;:]#-%D4*F.GYS/>X/N.<6X=N5# MP\9AYU,.=>;84Y'=K.G$LP/6]*UNWG[CI,;4$69-+^(=$$9K=?.MT4ZZ>*$A*
*MH9U5Z;YIGN\@$]DAZ"Q/L.\$MVJ;SU*R$M%3FH':RE< M/ZEUT">_<*NB!C:/JFK;)T:-9Z%&#)]F#)EE7 M.@-'CV:AQYHTU9TU+VRO(QI.7;.TFU1DU(/ R:JLU. L7%(A+G5I*01,0.!\
*M&$4=2J@!2]BTSN@MR;13G M@#)6<>?U_3$1WF >^UMA&/ACX6$"S FY2<@[K9[1_3R*RCNM5MKB^>ACI=FA MM&U^PN^\9|8+D1/>_NRI,4+B.W$=;OP,D()?
JNMI,NAIAJBK3?'G\Q9[G$JJ M)Y7NFTJ45E>31%EI2FL]3B6<2JHGF^Z,2M16U[3$CKQS2C:G$DXE1\M1W3>5 M:)A\(TJ-T;AX31YOT[I+\FK1G\]DH^.CN6.G&\))SCLL-
*@ZU:LE[W5="=6BD M0NDTD2 8U7-#&NCP81[U"^CU;5$?>8=J,\/M7*YM@=&+:/55<1.)QIDY(FLV3ZLC9W3;P-I1QQ(N=$?F^^9ZW)#\:74T5%9T3.2=3N3'277>-
*XW+K;XIB9*ULS>$ MTSBG<4[CVR5A[YOE5;7T$2U4W/[WJ,1^1KG TYR<>TLI24\X1+O(H"[EUD MPUG!OP/GI4LQ K'4\6+]O"CZ!"ZDR.38LFW.G1[\,4QMV|_T-+,_4"5%'4BZ*
MKIO6O]'YF3P8;TJ6,;:#9\=CZ"#1%/L"2DUP8R_9Q8H$E'K_\'0K=(3__H>I MR/(('(2'<^W@,C^OGI?%B?<0GTHL^.6'?]<,X(${]PY4:?[__($)G]!V@1@;7 M4?HA/HD*
*24[@65$0DU;WYOOMI[LGX?/US=V7NZ>]VT?A^OZ3@(M[%+Y=_^_U MQR^W*9DF;^O.Z',9L!F2^2L.(V"7"R!XI(T:LO3 +'ZSL3 M6CW?
AU,$DH&_G$@8VGW=2(%@1@")T0V3#.@?+C0/AH!WV@H7#IXJE@>P-Z MP5,0PQW+7[<%X=;NC^:7P[N!F<,K;"$BP5AP?8 3?(<%
*MWYY[7/D>1=SD*PD(O(,^T76PDD=X=,:*18+LN?/9"/-N+0!!.P)?]JG-;AP4+ M%1"Mf.B+,(_^=6"2IW@Q.IL;MMO/"307EU?(\%;N9JEN2%/:!DBY#Q,_=/ ! M[P/BPI->R(=79Q"-8+7(?*
*[(W])3'EM!BIT!&QE'V+9DCZ--D)>=.H"#GC!+^_L;M%) MKA 32K&84$\%3#QXPC4(:9>QJG,L$!*42 1'"_R@0_C9Q@(%R";OY0'GS M=Q)&=@=2_?'8"X/9?\.*E7 6__C6V ^"P4^'Z,2*
$AVP(;Z(1H=J&(GU89D2S MJ^CW\H>W(N/6L^L^VMX/X9O;IP_'\[FXE""DOP|=X.9}A\:,? ,:13*-.5&.A M%P?$|>"!(P?DSR3P7QP4.V T"/]5++QI+9@K^K).] 4 _#!D.THYZU?[IS:.
*MQQ_](//?08[=V!/X)IIN9K1T,OJ4UN]:AMXNRYH#]'!Q!X#1(?$*C(:^RFX<$L+X*DY(5Z(OX2A#_P4V3ME MP_B$%'ZXI AX>\AVT!98Y+^/=?*HU,,C\^>^$'7L0.QY[*
M\0.S@._<:%)@6H@6^U\=J4PYRK&_7\|4-C9 M$=?U?\/W5+=>LK%[S!=@/(N<_5,:X&'Y. 4_7?NT-T:\)&X!5O =OER.U\E&]V MA0"TIV:F6 [CA] M'H;H8BC<'PZ!6+6]_L@.GAE>I<.,B1T
*7I&-R Y#. .==-_U"M]=0IF*WC*#* M=F)*P!96,07*MER*.REM O>_IH0#!K@]P;QM>HZO<(?0(TA4B#CP"=BX04)S M8P S)5M@,&'*-F%|$R3/%U)@\A=(KF7NVJFA(XC6(3,?
^F2#K^,5?937@U[M?X[2/,_-14U\)K1 ("%VA4+/1L&-"A#]40#0$5&8N#'**A08KM.G-ASSIJ)6 M5,F#^:=@?D4&,0P&1/,_ < AB^N8"9Z99Y! TY;PS\U,<4$)#80V+|,.]M8":;2
*3Q<)B0Y@PN|"KA#4I24 Z5Y9XQ"I\.H M'RJ2; F/K_8D?,MTG[F HD#.+@O0 N `G.7]8;VK#&I%9.#P6.12!P?UQ\|!0S1T M KC[PK|(^_2'#ZDOW_$HQM&;/B2>[<2=I-=.S)-D>V-
>):\62VHI${U=)!"5Y M<<)X:4O_7(R#LL\5,#:,3N%74ELN_+SL46JG;2IZ/8\RVH9EK7S4ND15!FX, MN;Z7Z4F MB!=CD"MOA2PT@/B[_UP4I?X.*08R/^2-\|$/ H_@$?>)[6N7=WTE+6-1
*MWK6_H%945GR:RTTS6#+G9[1+A1>YS!<9+C@CJ1>2LI>EE-:BLF/&P,"!!F-0 MZ$P3T\F6K5]>=)0MMJX39IWY*)+FGH^,CJYH*V]69Y[N15DJR7VI$F_;4M%N M+K[]>9!
*(M[9+5+B(?. ME%^P(%YK#;CO75^5U77ZZ@9Q\](P^5IHH'C8+4I>%9;,ALD+H$93!;65S+74
*MZ[DGE#\K>EH165+^6"OCZGO5:.N/6ZX+Z.\>M\P$MV0=L;1@(O7.8P#Y\ND6\SE8\"PQ_.C#EVS1#M-^6//>RGXK4Z_B MM@(")6G22@&#M;![:CXO9>ZQJK0T:TWR4?
G2@H&A79]S?NGEI*)*S>EU0^V M 9GV2%Y3&R)F.LRZ29?J%*/S2#Q#\$/YCH_/^/-|A(<>;&AI2O:Z_IE+8X@: M%;!:G36^2]&A&/^)|+-?I?P(M>EY7'36M)E*9,&?
*@Y"Z5C)-3]!0;@6(!E>' M;XO*60[<:]1H6[!:M=>HH;450ZVE0:@LM4VM^*NR1Y5_KFOU-$"EBUK]\]0__MPU*:E:Q35,[651[4^&(/;@GT?
*)A\;KZ:8ELQRGCEB?.\9D9&-2:@VS%51%)R+I(BF7%9__MO;4@T.A2RB>;3RIE9YM.@H^=V;S=1)0 5Z=@#]_145-1\X?ILQ MZ11CZ=XDT-+K"@T!CDWK,>|>I
*E[#XF2EF\&>7!DN@2#*9??-R^&R-M-F%M> MV6K:B)X*(!=6A5>ICM'2E6'D[RVE93(>QH\K9POI^&^0J*FT UBE(M#XY\H?IJJU7E55^MC&V)"QI^B<(@)K.QX*SG1MZ$&1.
<#.K.4S+6M++F:]>] M&WM4.U4E@SH!,^=B,6Z?'B0559QB]DBAI M.R)Y%.!M6Z-/0;5=RUCET@[5W4WYZ!P9BPU/^&>F.& 3O/=4@E MF?
*4J@'[@Q^@:6CO6ZJSSVVJ&3K,9RYZDTKWO|;=E+2:ZL#NB8M2LO.UZDD>R M)O:W.T[(50%T/K1<04?8A98M,,1D190Z956,QSO,K56-=2/FBEM@(T@V:!B, MK7[7]-JI(`S?V<9
{6'=;J3I..>6P@8D^P MS3I+[J"-YY%GCWR7=6R/Z&?8$LUV%[:.$TG.D,#]_A5[0)&F@HRYTI]YXUG,?- MSEMYIW@RZP2%,8^Q>4!FFI18%@/.V##?^1U75.YG7&?AM>QJ'(<@*S"?M8C/%-
*{M?&.R71.#&HE0P<$Y@.Z.IL_SQ&)M4X@E0 /8!(K1KB^!/6#>$-W,< MQ/.&!R'TXL@/IF]%&Q%X<03EK[I.?MS]E#'[QW!4Q#M0"&AB!< D.>_OTTO M1=A4M#/X]0:=M"=
MW"3]BE$>@9"6&QZM4B0D2^0\<3UI]@^$GMQ8#-*RKf@F[^!8<#>\L#_`"\9 M.J3/9\\E/YV0.1+(_@DNVCKUNK=75<^N>TN;Y M2-,DY\0)R';0[ZW?16]Y%[?X/GHQV\,F6]"+MK
*MZ ^U:*Q8D4H 3Z>)(Q4. ML*,KR 1^G^V"H8%XT"@7& M(TL:(Y6W(<[*^F$<[AN1E9;[\A5NOQ8GS@E*I8'NPS*10A>;EXTG&|&W) M4<-%)TU7. _^S8@]_LE+|2A)16^?M6BQ95RLK!H?.3#*
*[^0P)_=K12YF2U5M?S M\Z4*VJ[EGNW2FI%Y5?WI*%&*M&$-X0:.9X4B (R1^M&!;9#@A6QAXVKK#(M:!"\(4S@!S,^'">WJ@.G0$-H:L&!^>2HG7+0$*CKH(JH6$*W=8P$B?
*$_+7&I M!8P6&VI!9<[BGE' V"^VXU)Q%?G"(+!?A7B" G25^#O3"LX-* /M=+=#%(\;] M%X))EKA7H[^XBT]=[3PNN@&&P1M@-&,M!V^_H1XF(%3S2 MMAP/_<@'L2$8E#4]5)
*<*XU[H#!PIF-(7_0LD+)#D*Z<#4>Q*]^L$/4R(?OM-_MZ_Y?=_>MMXMM//\X!9[R2+AXYEHW?SIVUQ5T\%D^@<K(='

*KW]-.36G0SY?^.,;G,RG0ZG!VX-"]>SI2[M-Y M1KO &CR35ZT-MB=Y,EMF:AH=S=]!0D$!S$]F;P[Z*1!6TV|"G5#G4Y=3Z>K MF=UG.ITVA#D_R4Y:U$DC:X-%0Z.B"/M?5L=GM=,.UAJ.M,'PP/B0.MCZ'JRA62#=!WMG!*JC/8&C-?IPO(<6 M@]>KA0)FN'5B>5'41M.6$GM:U9?I1W7]?1,S=B[\$"=SE-IU7UMV%-)$S4] M';NK#?*

*O/=#IML+X_5T8D""K6"HVF+!\) M5<^D_#\(NH?30NUNTNY\HZ/H)!?DHZAC0X-YQV|2^]>U((;U#W9-A3;/""0 MJFZ*NBEMNRG&"&O%'N9?:,,;4IE(7DSF\MQ_O+A_"-ZH^V+ L,"_$X..="]WX M$AUOGE,YIY61%=#1Y[M+Y,_7$;,@B)>:;>S==XD-[;E(;OXN"U+1/>6#;<37ND M^<'F3IM]UN'%=YQ:*OF<1DT#ONR"$ERZUB9,,VVL[V<]JZ3+!*

*3/CP*4V=CBN;SF=L[S13K^9T?!DDW_G MG/W']GV^8!_2)&O;(;/Q+QDS\G'*8M8-HO@-@ ,(#3S[U48TU!?LCV)H-DY% MSZ(&BQCN++L.4\R +\/WDEE+\,=+"& GB(&?HC",816VE'2! U?? ZRQ7WYY M\Y}U[P"\!,'^,<3AYP$3#5+|#'P),!NM@UC^1F.?^5<[/D6H?].O]0+4]#1 M =9^,V&]3NS BWT]C=EU"GP83_GG,,;D7/_E6E[V/G0Y *U5[C16CYX@]#_YMX;@@;Z#JC^MAODY0/(C] E**HI;kH:*SY_,H_ XK!P5HP0;ZO;3*Q+B)M\'55RTX!QRV+ @EJ["TN!H=*[X&G AIC^-Z5$0@7@0;B?@]*

*MC!*ARH+MB:M1=U+X8$9KE\=UTV]VA_.C_10T:%#!HYG<@Z1009\1SNX6^C?N M#/Z9SN CW]/'GD^ZN%,6J7'8]AKRUA_A#M\S>%T><]?4!SAM&JX>;>5EA+CU M;GDQ9/],%Y4?2H. 4_5$'H-MGR;;?U+;M&"CS\1FK&X5'>7_3J-L-W.PF2[& M$;>_7-@3V.Q+V[^5%S%Z'RA,-E\#<".9D\&I""&M:/JOU?NS9[8=.(M3_[QXF_W^VI,$\0#S55'_1K>*"]*#[-?*

*KCG*OBU;,:\|\ 0Q!=[#\ 6!KQG*DU M0*Q?)H5#1_@&"]^.-?P&3[0LR3-=^HX#&L"R1J!:CT&,_T$8NA48B@47)6G" MIL(&Q2%'(,C)-(U*

C0P.W!BWO/K#2G&96,3LIJE4<(E_R^5B8=+,[2@)<$?G M)!EB8(OD=P&.CS\((!-0;W.\YO%W"#]]^OV? M[<[\?!TN!H=*[X&G AIC^-Z5$0@7@0;B?@]

*FMI.$93F3=S/F M[Y4Q%MYR=!MDRT^8CY$!N+AH6Y/30J@M&0Z$EB9B%O'4FTLND$&"?%FH.(X=-MDX_>C\.<==@HX2+W OT_"X%[=I[-TM98-B%4D[S %>XGZ3N:.XL6)P5"!!@-M<4LO +Y+)R DRY);)WX3(C^@5!_@3C<4)\@6+7Z?^5'B;T4X"_T5\$V,*3T8 M@8D(H9DRFF-88M^5NMBFGL@1#K]>0RMQZ_$R&X\KV08D:02^@0 M;&&>TI4[F*(Y^NTY[%FH*

*/",:[_%TIR\D0%![H&~)D'BE\F L27M8.IP!+-DI M&FLYT4XB:.F5?ETAH_*.!74*P8KWA7AC]@!\?I%19&[5@K7(("2;Y;DS98^*

MAHG^=\!]{DD^9^9ORCI7ELOS$W",!.:\WDFAXZ.8'696>W;"F4&F!5_B6X# HQ]!,<<=\?7!#BSI.G&#X..2:6 M3?I;G-]@:F&V231NYH[R4M!OXZS&#-WI@%ALI"3!.:**%]DN.!(O*

*M3F0R9OYPG +0*3C _4X,L!1?OB6Q'4T9%"QSPILCM%5 M+A\ *O:Y(R+GE8UG!$!F 2K4P)'3^=5WA-_709) '5@C96>>^ZA(CCF1-Z_ M@5(622D0"DRQO%*

*_)$NQ74H5CRE+2Z1M9)N$OZW17#->YB*78/!O;I= M08"2[FDN8+2_R?.C0LR.:58PROQ-3.+QESD# OB"|\$?@"4/++)>/]>>"W MZ_F2E/"OY:/XA9C[$^+#LBY)8D<&9?*

&]K98=\;1.$ZF,;6A(+J9!Y99B:7N794:^_%PGSV]$A,E=R3=<1*\I]?2-5! M\FK O;Q.Q^AW2<2IDETH+*N0E'E3/1(O))Y7CBNR8P3@?O"*A!^!!OUWW'52R;< M<< .A?^U)-@\8*

M<1FWN9(?EJ0!M7HR(P]?79**A2B\E\(4T-FLTA+2M08 MF<0V=4BE(*"]3R!N\fOPN@+>^,#=)MD M.8GL+28 Y16[=E'4(.5LR>KL UX,&V\^$%>,% XW@_, E=S&PF!?*

*M4Q5LYTY8+9/:,HR>F?5"U(O?RM!O7LH@'5&5.+"L:1":H!=57HANQ%*E!'K3 M@@4E*94J)?) JF7#Y.^9\$@F#O"OY(K.TX7RS*%M[\N?V1T0#34>O.).IE#< MA*%[Y_D^;*

*>,.8H4S;]/9,ZNR1 'Yl*8RXP52!$G4JCR;_-53=YEL4=FN\@OA!XA_=N[-MHB#W\|"F!R .0K,TIA,X/=5]O@MBY*A/89YX 5IKT*%,A_3)/SU54,%V2YO M%'2T003Q??*

*R6|&CD;!,OBJF8;5%,>"MCHA*V[2G"?I(<3B1S%,B"=7/V M"[D+KT!Y"6[00=>$/*\"UHTU&D Y@#F_ &Q@&/HP2Y,'3K4%-W#]8YF;M&E9 MRA@[,SNZ64G%)]?O:J51<*

MO<5>#71+SU],:3Z=4L@#7P?) M?5<4$7)ILT<1:0DY?!F_D1421:I3"I@FZ MDO-5?PG:4YR+!HK7B%H-^_&R/,PASGTC1!{XY3SRA)026IL1S$$6N+5V19KF4)RKRS9 DQ=*

M9$E>M WTL@#'>C.KGX.]SEU>N3C9&E3+"6G%?*JQY 1_T3HZ.)BN-#KK3M MJHW4QE7PF>KKWHOZNG<;ZQA'T DE$E"M\Y>57U@-NTS,=Z'5]3,>5,;)1Y2DA

*M2%V+"R=E1RPF*4?;*/"TC>R'/*V03H6%S:I/0PDA%<6$G9GK.ZI2(G]9\I M&.E2=-XK^[!>3#"YHCXARPK>O)&RM0AD 8*>*FJ2.W0/!?5^E5U0SB[HJ^R"-M>NSER;*

(+GD44["LIR2[+PK@'"K<> 42M4HN;2JU9,.9BSV/^,OO'^"9<[}> MO/0"V@S]Z%5U>:3GI,:L=)KBZX+4]8X@=SG[0;Y9?JW#5]^O?M[KZX-1=^U7*

M'=U8^_FFI49ZU^PW>]7AUI7NF;M1S_$:*[= #+<,0/D+4UC"W3P3VC!W@4T(MF5!!=Y]>6X'X)$]UZPCPC0=:ZQ^~J9'TMB$Q-3QI5+O:!:[5(G@/L#DHULBW

*MB:2_86\H_6$?)M6(R8FDF>URT)N /3T^V#!?00Y45K@ 7,@9Q H7@(M>5QN- M3(6"%Z^-+NCD#^.0)S@4[QJ];<*K>1 !W]R#8_ZK&N:VG!HM AB:VAH?:/3*

M(HB[AF;Y6W3$1D!$&'CR+1#BRQ2@CG3H096UXL25)%HBDK#HWE=79F'-6VD/^ M9IV@=?AGEO(ANB:'I9>K&8DK&T^8_O/O_\fGQ&I4HZ^)2R;IB#>XUD M6K=HE';I_P7T-

\;XLE0S%B>I2STW .IGV4"4PJGT==[WVA(MGV?=S]"4)KS?"ZF X,SJCO3!02M8@A%,0]P&HU15NN14_P<.&V<MPE/0Q%LN52 M6]WD.%Q!B&B-

*^^7)K9N27UJ[<^4?!IX\$C4Q];_7W#P8.NWAVM M_VK?@"E(SH&Q_B>;EMK\>6)X.-ZFS.;%<3W,>)XI8A+@_N;CS6K-:YD*YM+ .6-425'GF@0U"U{1I<&E;RB$:@ M<1(Z7RY$0BH:/:*

R5"NI[QO.?5_H9)ERFC;$?6_XZSVCW>Q.6]??WW-"^]Y(M.&0 ^X'7ML5Q%!&WA(B-CF89W1H2<2OBL#N*E!Q^YW3:H QD_=ZS?MPM4P+,OM;O#Y464-/3 M,31S^$PZVE.K

<\QH)20_(>J2R2SUR+Z:MWL'OEDIIVZG\|$'8]0[TI2A5 MY E.QS*?25%L@RKR9B5N_&\EY&&^POI1GS7H:II/AZ#!A6 O'IY'TE,8R=K-75 M>1-J39RG.%(C)=+!)-9+N6[0,.*"],\?*

=MX,AO^3SBCF?G YGL&68I_M5&=[%E M:AW+5)9B34^GHYFFT0Y++\3GP^Q/V604FD"<>RU3EY,Y47I"$U49<+?,FRP(# M9S!4.8YOFLN1!H:I#4,/4CI#

*M/8^FM[9X'P",28I3@[SY)RNF#$'^^JB2@-X*H:L&=UG.IPV* &; M:L,.=&S)DB(+L.V&*18H92"T-A?T^ BJ]X7M=@::V3TP"GP\+#V3#[;NB;HG M.[K NB.MWSO)>[*]*

\-2Z:I\V062)M6N5HI9+YZD+GI]Y;= _>I_OWN:3(KU MQ=I7HB _9F.I>,XKC,+)! >?9FE?&@[4L+WR8$Z.8SBX5@P\U8IY1HG]58Y1

M%#,)Y'M&Q_$?OD,Q'=&ZCE!I:09[."#ZP67YJO MM:ED_-[^X<\"->.XU?*BCT5FDJ[HQZ":H3=M@=4.O0R:.H9>VU\/=H5+X8YGW M_9'"+'NG?G[_EXE\KP;D&P]_N=NELEY-*

N>C/IL UG2KW!! M#4>]LESA OLHF[J@I_JE4Q!=[ZM^Z:UH+7UF6H;6L49M@KC3UI[=%K4/!XFG M]:UA>P V#'W4WG[H#]+R3NN@SPQ3ZYB#%@%L:2-#-4QO%\#:IA^3P/D5HX=*

M'E31H<8.-W?L<"T;?--D 0 B]F$@]UYR93BC5/X'MO4+_7LCUD08N]X>QS> M4AP8B=2>3# :Y^/@]UB.*7<11M%D'H/.893(QO03/_V*F)O#"2#F6,SY%_QY M9+L>*

'RSJ++.:_YU3HWFL1/&"E-IPAVQB.V(M$>[S L9G[@!U>^9M7 .J\2M%*25%L@=CMUZG-U_L5]U0--64]D!*C7@@)$[UGN:-?[=E>CS M%[.YO<"> ,%R"@+E?T03QI&"EGYKL"R" ,J,-

>V83 KH,NG_(^V#ZH8U=,6/ M _93<+U8M-N#Q[PX3]DM'ST_3I] F (S19O,PM#"YH/4'!,Q$F/7S]O00O\7: M; =PY24,E!0 J0F';U=G +2%)5M M;7^^P(\>W%W&&ZHGM>+Z7+#1V-

_4UK:8SZNI7WJL36K,70\/P@B7BS M"><K9LK)5)9],N)-DS5#7_AH!6-?E4TQ:7^JVNM?]LT=5YM-.,2(W^[9+5=; M1C5@'TYL'-YR<791A%Y5WXK6XF6N@9C]$9,+KLL/$$Z]?*

(7$ZW+N%TNA M0(U9K5{[8%B_^&A5:.1OB,$-C!@GCXA6D#\(N?RB?@BC2L>^4?0RQW"D+P1Q^IT2MPFE66D,,HB4L'?5'(@)'! M!U=_7,QB?_;T#3,5XR]^*=

(NL1+!%CX)'S@9W^_A5?X80S(99?C$-#R7K2F M_>3%7UZP,0=.(*D+GG!Y8GL^C71$"(HP $N 0&.;L+2EV?(C7OW"N^FTXDO M%YSL#DF[I-V:?[@HD4[P[H4\D*E@0/(0;N-1/(?*

*(5P/=@MP ^XW*V;M'&LP M4F,-ZK$?-=:@H,H?]VI7CGR66+.0P"%(B[_@27X(<\AD"1@Z:2Z_BS;F^*HS M0S>*+NCP& ^RF#^S!?Z N7VBQ^%M3[Q62%N2H9>C[;_1J=W.4I-*

A2O^AMOJ1# M8G_^R ,YBJO,)>>N09!8V-2-,A%=C6S;U#<_2%%ZCO$R!N$H4%6JF_ ^ M"1/=HU"S2.0\@T:,OY>ZBF'#B!J8._@PBC6#CN1TCP$H0'K#)#B(=CAVU*

*MGLCC8&6Z^,HH1"6L^A+<0*D-/ZUW&7E_P2H@F>Y;'0ZSV&?;-<#*K]92,O4 M-E-6QF 9N(->/.6Y2CZ!=R33)16HL_M !.D4NL @_%V_^Z[HQ9/" M2.Q$T"?Q)*!-]!8@S89*

*^*2$";S'[+1'0Q#8EQN'AFA$8A5*CM-Q[!+F>'=&0 MANR.6=T>$*FX?D+XTP0'05]CH="O466^FP(&%Q?A78 W$UA/,DU1\TQ(KF,\(\SJR:'<\%+E2R9OK!?0#EHRXLL[*R-*

!;#KC>1(M_#EB($AA=EV"[@&6CCKEP3,7LJQ4F82!&-1PHUS,!,;K-N;)'>?!WEMX GAQO&GZL@^<'3#+TM52_MT MZJD>@(U<{217]-Z+I_Q%F;]7K4-]^HJ!8!W>?+Z_H?T

MPFH"9Y0FM7I.8/.@R86-.@:1A\P.C04-F@J3U>SS+!"Q8O7AJEWVU?P>XU^_M">$3;D\/?V "JMG51MW#"/]4838Z \WL;*Z,.";#,QD ;6"V'V.CL_0TJP9A("H%^)\& MC%AQ)7.A'.*A'>-*

A7 $*W45OATG(O\;$Q?IVWX)%9AXQ.)2=G^>'X$Q M;Q'6%-%FW&AY$UDU4!F0C^!^__RFC(M2119\&B<89W-PKZ)>(TX)+?# I'\7 M$-

^,8[YSZI:+FP*!.J('94%W7\$6_*;]fV*K$NX[4,>V7^W//BYNM53K^(J M!12+#(9L '2>?1'@+;.PO$3FCQM7Z,LO0!T7,,*P)=[\!.5Q-($\TBHU^D%._W*

*M2DIMA242PVZIS&B/)2S!$2:A[X=WE&=+1EYZ2_8$+AG>[$ (4%4^EO"A*2#P* MWO($[G-*I)4QK6]?+I56]W]-%Z^[G2HZ5+U&*^U>IDB^9P3#$>F/K3Z^R8O M#(*

*QC=9_M6]X'Y2[@;'^)YN6VOQY;S@XWJ;.YB4=;+(7UG6[R(;]6R#![WF M#I'9.D<<'B??H SQH4,E3Q)K5NL\G->V+RI=4$$%A7[":;N4*LEMA(+< 9K, M]L; XR1TOER(]%*

(L0P=FF/2&HS7T7:..$S MG4X;--$?4L\G!9."_],O3F5$$;P'!MO62?OX4@;'CH[J 9:4]-/9ZCU1OLV M13W2Z,1!'<@JRN-T/O<]OKGRIYF"9M#3C+W;S2LUX,DL!6#-HW:H 8\9G]^*.MY*

*_8*W9=S#7#^/X!],BF6U0Q4Q.UT@>$/I(G4]'D,.CBREC#P6@M^L9(4\.MRDB0G?R%]2_ .%'

*<;_PP==F';T9?LH}$!V(<\G%YU3(_MZ59W0.G?"\N? MX?V>)1]3J-"K;/?DD*MH]Y\MP-% A<_4[9XB>A7M-*
I5V5;CO+S,$KTEGF!36W4524SCY;_AJJ2KK'DDX]%;QX)-1V5:E71JVK9(_'4@1^^G/$]^O \UL5.#G_R?:";VD&(T[QCFU?3.#"_M:%((?V$K=/G /<"I?'OKED"K&[4NM04>OQD6KV
*M^_J@?;4 -+3C9/0K;U?79^;HHH"]DG@)2;01K2PMZ5>;#GFL->[<#9/&"KF?;] M]1R5'"WPG!C*X?=8/BG5D>RQ;';0VUL&-*
*L7=U_S3W3MK1]V;W0,A0>S?;4,=AY/+H(@GG(-_&M/]N:7UC?W'5NT&^[&5+T5U#:,$Y2S/,4 *5*%175'\$?MO7 M!MT!ZKF>@NKV23AX 76\#!,HZ?O4;[TN(=1!Z57\: V*"1UC-*
*JQH,4U36> MZDRMW]^CA%%1G:*ZH^A;PVYM1'S+]2VSU]=/R47=?'WOJ;-27>_V>4Y>3%23 M":DY"F@[AQ2:-^M:;]/:*7EB]C]#)X@1-8H8>]..(@5%"H(O6 /%%Q0QB#:<*
M'5,_P9S5!NMN;;;&GM8U3C K2[&FQXDD#HR>(@9%#(HNC\Z)1^#(H;'5%IZ M2F>)E<[RU$EUS^9OHLRZ,9^$$6>)_;54 [V_SZF)KN#SOM8;UBP&V=K#,+6>*
M=4J&OB&Q\T.,$Q#WN M.HS'/(RAUNONWU9*'<;C^& S2?:4 E>Z1BS-EYIMZ#YV%3CA;-G:/JK+I6F)?OL! M7V!Z/[?V'X_Q/+FEBN2(6Q):E=K3O8?*
RB"HCI%=0^):6A=2T4[58!+.NM&>TFX M4!T47<4"6\ "SZU]3"E1TE=A7'-8'F>MK0W-)AJ(Z175'R7,Q)9: ^K M[Q&8;,ZRUX867=?\AH9?!SRA.=DJ&%K*
*(%*5O34YC('6Z9Q2UJTBAD=-4["T M?D\%8^MR&B.-+WV/(=/.#H>VFA]!64UDK=3F-7F__$7/]*|[K8G3VU5^O=>#@)\6=N^\F4 MQ=*$]P(GXG;,76;'S&81CU,_8>$$KGG$&8!P!P][*
0O3B/%/MLL^7KVY9N,T MAC?&L49+1Z'OARFNQ&O\?&WG,^GXFT?KC5F!\@[@L2#;,GY;^2S[X(I MCIQWV0^XFX2]P;]PB80[V $#[\P6.=?8;] M9##1OE<&/[({@'0>>3,[
K0#0/Q=Z>NN?)5T>+!$%$R!TO(0A@<4TX4@(4 M(GDUNX|@<]RCE+^\:GD'G!;]V.CE%;PX=%,GB0D=4S@P@#((M@PO'GN/QP I$_C/"0?KAG &ZK
%?"8_-80NX<)G8IB5U='H.#7$ M0L2=\";@W=FT7_@@C2+$ZXWM$;;G]UD0,D^ D[IVQTXTQLZA8GM1>S6|E.N-M2 NIX 8A@G_&GBO;O&OPY23F"1V7C>L")834)&GE& &
(2_RE>!,"PR<3Q :L MGTQM^%^X$0G<*+$_1$)QDGLC7),8%NZN_$YEEP@IBB")$_HS(PB@,GAR 6OK M'=.J^%YT?;P@JR_DG> P_RFX.G*T^/Y!H "0F#*](X &!\%/Z$E?!5< G8
M$3C9)|:]XX=F&;}3[8_B_P; {+=QQ=^BX%A"+V^GU>L1/?PVC]V+-Z^:. MW7B!$$6=]KR7VWEZL6*B6/D5*.*GR\N/|$ M5GQ)!.OL ,Z2HO!P>?
8$8HLV#K1)N@N1EF^L'P)_O1"DBWB7_K&(ZGMS5A"P0_[N- M?8#36CY8"A -'-NY#^?\;_'0.A.0)W1#) MPYZ%8%K]);4?U,"S58%E^.GX*&DTG\B%09^(<@-*
*]>+YV&,L\TGC/^9>J2Q M:)(V/%%W +_.!7VM";8$?NGR.6@U[4JD73\5/QD#1]"3-4]"!4& ^F]Y1_=(', M#=]-N5K[1PC0;_ Q$I21FM0"22^&FS1.L ^= S;ZA:\,1&<@W ,+E'V>WC*X<*
*MPI(L4)E&W8M>]W2=6$Y0(D8BK/?Y < >TF#8L_PBO)GQK?%Z3B);:+#P0YO MY#>(R6PV"9M">$!6P5AR,Z3UH<50/_TP(C((!*OX+A7/(<(_IUKHVB69]!]*
M)/87T!%]&VZV6_"#^R1%?2_'/=:/MLU]4$/U@/B)7'\DBPP,$U>W7EN,I5V M?OF'PN'PLE/AQ!Z3/;CY)R4D"U5TE/\[C;+=S.T;?C$&X^3+A3V! MS;ZT_3M[$:/#K2QA0;PNX7 9_(U
3B:/!]2@/A<,1''!7]9 B!$^\7NR:[,7 M!K;NY\|O_G;_[6:+UY_1I<2\H,W\$:\L?_[O?UZW5&>Q,5APQ+^'@"R^*%L@],91:*
*M<>X]*BLR^@HGCZ=AZJ,02$!XYEX!\C;DFOYD@U9$9TP;O>#,Z\-7-P#/B)E M6D00^W#.] F)'0@3P1,I2C=@X"==B&W$'PH6,=I R-FA!/$9NXV8]844$K?E9 M++%P1$Z)W*3R40!$DA/B=/8 MX?/$0Y('F&_M.(:"""3B*>B7Y+&Q?2?U"[TEF<("0FU&@&C3, MR);+"MS%'M"W'?E (E]BPR[EYDNAIA'Z68#>O 88&^B/G*\OXXT'.%C!;) MCV6N3*
*D_CHVZ11EIZV^G5B%*0.PR763>*>'=(IT*%=;U;CXALZ6OKTM/"Z>? M\"[\"1? 7.QU$CW!,OOA"<%/D 7#MV .8O\S^\0IU5]]>O/0"PAC|Z)5<2TH[M%&|+@0MV|EMK\>7>XWTH;-*
*V7]W2^+W_T3=4Z4[*I_OJOL]7N2>@\|$-J?'#"'C1 M+D)=;6,<'Q.C>"[V;C6,L1(#U5/L(+C+@>Y3QBAS:"IB%#B]O$):4 OR:VZ,.&8GPO>;F7R?*
M;!>^UMA5X.B4'8&)'$GH?)F&/ASZ\<;Z+|-*W-/O5N"O2Q+7>L M MS>R,CIS,MH9=/"B[<8]K6N9PBH3;0<+&0.MU.XJ&%0V?+@V?FUJO=\2R"T6^ MBGR?$//"N-NIT:\B!V]['7"+4N
*IE$=I;5.ZP%Q5,OQZ77K;7 FWDX \TT M#]7*U.$'\<.V!^JPZGDX VW0-9[G<-K@)KN2N8/_O[TG_TX;2?I?TVT/AU*8=R4T==.U%7":"9Q. M3QF;#06-#72S)^*
<@Z%YN2S'\,BL3MO1>YT- PV4YOSLT+%TR]SP"EU!Y]G5 MFY:I=RU+@:>9X.FY>]>U)Y?-,9B=GXIT]-$XC*>KH M'4N9/8T%CFVIN^F& LBSG> ^O6$SF!,O$O,$Z,2D+
*M16YR;1D;`>H:RP8 ,8C6=KM*XFPD:5]U?-Q4TG;#4]A1H=G=+TEW77%!FZOIF MZ]):NWG-,HT*R ZY?[=92-'A*G9MO>,JFZBAP#'UUMJ!+IPHX.PL)=2QEKS84 M.#UG3Z*
*Y!F/U,Q4BRZN `YD->N+]CKE^N LM'XW:5V6NU"8Q/'8,9 ^C.>?W>)$=F^6]&R9\-2S0HXSTUMMVY=D\UQ^ <.??^G 2B9W7A_BC:@@=!N*5NJZ*ON'H M,3DRIXBRO!L-*
'EOON;J<=D.!HVBGT>#9(^T40[_C\F0U(]NR(VZG73,@=SGWM MP_NKV\MS[52[C3.P\2_B$:QF6J R+'T+/3^?)NT]JF!U![2]GJ^SFV/ZO? M=*
M;A3=K+%KLJW675O1S;PMG@7ZM%!M8V_1@KO^%_9I0U\>,.)!B#E,/G>T=7]M#F9UQO_D.,](N SNL&*1)NL3W?"[C;/N#O=DS=:.MM0M]EO/G=UZ6]HG75.! M8[;TEJE:-#04.K;>*
*[NZ)=)IDXJGW&_9^4ZYTK)YAN0VZU=&N9 6F"ZK I.YU-MCM-CT&GICFTKAX&RM"FR6>=>Q!7;CO*S*;)19+.6?IKG*&CZ;1S=KW.I;> M=53X34,-*
*_L7>_]W;PVIIS[TT0L2W&8,G?:"'!8W3#4. M9^##6^.,C_H\$1S);NF:U;(<*G,)/]@Z+"@=D\P=-J/_#R5 M/X<%+QVS.W[;3SC[>LH&L-@S%CZP:8K(7L520-%'9_AX^PLW.1@\VR8%N?B*
MDR{^0RHFR?X=%)-68MB&B#VX=7?PF8R;]LW8=_.UUGX/E]^OY-N^QWW)= MM]OCV4!]6U 65=P(R 0.F//JG/=:!++*]HYHOLQAK3L>&@ M1N5T6SM^RIYY4;=F?*
*R]S>*D'H]#I^.]'I&"(P<_L.+?$P3N?J2FSLO&NZZ{C^ M.+;G.FZL]WAA:5[7;.U=9'0=\C^H:P^%O@>%OAV]U=HP[%.A<*,@>;0H?&(Z MNMNU%*
*M6^N0^.NZ#4/>8R@2=Y/%WEVHU/ZX&N$B:?HR_3OA(F%?">]CEU+$4Y#06_J_?:EJI-_ES'^SD:\D23 M_3VBN]JKHQ>NI9VX]WL]E.]*Y-3V33-!,R)HZBE>4!9PV&K#,PUA>.)2&QX*
*MDS>]TH]/&&RWE7K<3."XO3TIQPHT3ULNC]EZ.3<4.+;>V1=PCL&LO.&PS4A9Y M_AL27M=0=5[U]X\L.O*20697;E?55^KAD+&U#M.,SLK[!!5%.?.@:[_$I4*
*M&LC8MZ/K0'UBM]>.S5/6Q/,[176GLW[0I +,\Y.+H^BE@6!Q]:[5VSE@CL'R M_A1'IQ=LC*5WX"U?NZ;_J$OLR,#Y6!;CN0CCB:]]OI%14[_PB.Y_[[EV?G5L M%KMN.R[LJ'*
*42VI&PV>GMY3QGM3@=/D1MOOP@I%2>NQ=*AY0Q;=<:QLY\%+ ML'S,PXDK[WI7VW='-G]G,HL8!1M%-H\&S}[HY'JOUW/MS M$H@"]QK59 7+*%>11E(O8(,1 Q@98TY)1]=B-*
FPDJA4[H\]-D2.BY>[HL4)1 MM'/0X-DCI;B6<1OU|U=XXZ}PDDL28=29I13TE1S8%0#7685E2C[$91S3KI MM(CV4!][&U 65=P(R 0.F//JG/=:!++]HYHOLQAK3L>&@ M1N5T6SM^RIYY4;=F?*
*X/[UZNCN4.79? M+6_^A*2Z>_Y#[<9^#?Z0C'4.MS M+9T,!C"!;,,27PC&Q(^)W*G/D_?@B.#TM>^#A?=&5#Z?/J#<@+)IS:C(VF&23 MA!O(/WJLE0Y8TXX9O3X#^,9)$*"BA!6L*
*GI,.'KM &X)+\#]WL>QF/]%AS/-M ,H/FA^PNRB&37E:,&)WA%,4UP-0$E]AE>LY>*7 X,7O%9CRZ-4%L^%::46& MU@P\V@L<(XW)$*O'D?]!0$ X &XQST+)\ 4M'N6!/$DU;*
*($YF&>H%>@9 !^ MPED*!#X$4 C$%D!OL0)$#P:8C*NX!R3%&9.4V0[DS"#">#E<()BJ@HL^!R0 MGP.4D+H%/\;!X S]P F_,C02KX&2Q@_X&GH(?S(R%Z E2"HX,.%$VE*PM*
*MC!]P\X00<\!M2T1YB/K7[4HQ&#\)IGF$HS#MM>T:G7(64BJ!'M'K)&A+\!]8347(]P>R[//X%-R0.)#\&$R@95B"9QH758!YDF'WHE$$(4 M*1QP%:CO0A*]&,,(&1"#;--*
*P(0[!MJ!9V1)NZ)& MU:)%/(YK6#.Kf%+&$XLXYD(TY"AAAR M7 2KF]75+=O2W59+5.Y*ZU8^XPP#;RAK8<%(|>[,*V"Q^EAM"2M942DN@"!= M STD 1%-#(*.A6&D#\=W#BL*
MR^/+CY_[2X\>2TR%S"NHDBBK^:)]GL&AO.YVW((>8=$C+8P93*N=TQ9 . BH M#&B0O/81/CLWIX+&-Q&+DD"Y%' .XN"8_B>%\:I#; ^6FRH6]5*G$OEQ,IW
*MVH#+Z^O\Y.A@0,-!G!H#&+X!BZ2*6*_=+L>0&FW)=L1UMP3Q3$$6W'9Q>'C M IH3\2!+OUT(E/A8E'Y[2$/?P"G8|C\#,"XN,0=X7=!&N]9!%7[\NL%X00I M=9M,*
*L!*_,)84BKS((|%M$2E1,$GS*Z^_J_05V<61FN>74BY\-KJ6I6O$WX? MA_>DJ3P2"GNJ9TGGM+=ZEC3[!2)VAY4)SF8"J:94)%:R6T+X,V> ^\)CE@PR M$!H?C@ \$**WX!*
[HE)N+-1AGU=[,2Z3-RS\!H]>^V8I84U)GO; MJS&YI5BMQBYJ^5 '&:M5Y_2=BV446"YLJ47]10X^,-GL%:H[&TMU'YO@UJ5D MNL>Z?Y%3?,&2!/T/Y,2;OX==]RG=QYU/H?3?*
HKS^%2UBDH[SH">,I;?2NZ;5 MP(>%96FD'CU>|;=LW5+5&%2ZXI7C]A4740U%FNCY^M[O(\H:$GS:;FY$I6S"S3;. MI#.$JGF7TBVV=D -ITCTY>OM[O=5*-K".35;R5:4BN-*
)"MM(CMKA>B),\ M)&Y1F$^ 6UE6'AVND[N90!RM4]IR#,17CO(W\:PEDI .[&BUU;'KL0EE UL M<#ZD/ /DCWZ0;#;YIM M"(H5?
*_X+P]6#C"!AT<'#!V'^.]X)AW$]6D_W@>HPKAY[^UX'Z=>G0F\D]Z:E M[3.0>>F)? 2\@%5H%\3ZQIMf'[!)I"?(LM$&_3M'G #.$#1Y3]AEN5Q M*B(-!Q(&/#_Z!(Y>1*
#XN6=S66E[]D@? UV$X^ &60YV7/M"VH/VDU&!;CN M=.W#)(F!R[^(^0%L]Q+CN!(:Y1^3Z(XE^"&&@08!M[__@>0:,EL#C<"1W]]H M'L"3_2^QCE^CP*<\9\P@1^/=([}>F\ Z5T%_&*
*3$F*ZBC(-$N..4O5#V5!Q2'C'&@=H-T^4.A;BZ GG(0%[" M'E*0MO K^.5U5"Z!9:JE5+,R&29YZM/1C5&= _26Y.RVXH)=+HH(= G/)&N9E MI/F,@/KN.)9>;#C *0UMF3;.M.%T' .O(<-*
&,W\ EN+A:G)&-#^?2 'H\^R! M<\GNC!L#["W!.. ^ 25%V%"[_&W^!7Z()Z$O-E3D_&'],/X7@591)EIBMM9L MSE2XU-?QG3)%NL@+?
*F0V'@;H%ZAA>;+%-0+R!O874'[E=)_JQM.QU(>I;V!P M.\6;(]8F$S(5=&DK(((M-U+K$EPJ%MU<4E,?1'>93,,R[1X5#.1D1%42B[$O M:H*SA_#*3/J-1/=B'A@NHK6ASL0&*
U"&1%NH%52!M(A6GD473^;QK-"FMG! MP50D7=Q6&"$>TV"'"Z>+;((P%\U\M8QJZ9SXW /\3%]2MJC(R,1:9D`]>[>6!C MF*!'P(DI^%K=L-Y_7B-3,XUN[P=ZX#4H!-4,"&#U\!/P*
*MP'N,*27PED:O\)VECTL5#J$?Q@4[HIQPD?!9%3F\E1WD<(N- KFY:6.0YXUO\H\..WI^_5KG(>8RF13PS|V&XXJW^>")/U!\Y64)6NJGD*Q(#9"E _J#:E81"FK:S*W48=AYV;^T+D*
*M'DS+05P^P5$2[1RIJ"02W1CWJ#I=SW V446 \C7%J:0SOM$24>;#NM&S^K07 M]W6W8U7R *N#IY/^?Z5M#LNF!=/:I7=MHUE)Y!$"X89IS!G^H(W#28JZ8PB, M 7FAD%E4^;-*
*C=++H_S..2=/%ALK#@N*1]D>CLJ5(5KB?]P+RVTKDABWC2LM9 MRO-R%H7,F# QZ K\$C:H!9GA91_3,,+CPX6"G92RO^< -!JC5C&O]Q?;MU3\ MBW-(YY?VMWG-*
1S!6H=A+M;Z[S[]V]fUH*+RUR@V#(1&@JZ=6)P,6"3%RF3_MG3Y'>TC+V#=>P[.(} 5'>@[2/T3O>NY;FVQF(?5'@4ZT)-Z%IOL%*
*MBP;Y>*OS(MP['U!#E;=Z@\J=E;;NHO+V'!O>$LZ&>-=1"IW*TRAB-W1'6C5 MKX'?7 P#/M ^?_,-B'CA\Y\$@!+BX_!#??2PN4N5WLEP676=@:2.0)C/'BVLH MF&O$TS3_T.%68C*
*N82.YY/0GA9]-FIZ9[PM\;GU MY6IR)BHU)&Z*B!N2C3Y&'U$-4CH9_A\H=;TGFKCQ?+'N-RJD")? MBIH9)6=8?C]WCKA1>1U-NMY*QT!65"[\E]X>16=Q6P7\'O16JJJ8P@RBV LI*
ME95+[P2KY\GZ'GV>KZ=4-2^P_D@6"N_,4SD&2+$ (0/J[.CM43!CA,X M 4[Q\'B#GG@,,Q_%LDTQ1^+-E&^]"[@%%R41Y+B-0.JD<7X4@WO_H)!4%[M
MW7RXT!)"$5DE9B1^.@E@2N9Y$[#=62;'QYIGDPCD>"8VO)Q4RO(HO !U7 %U M^7T9>Q#G),-2(;WA(7+-@TH3DE\%=H.E,6$;5'L-MGS'R/%7@}}$BKVHKGOB
MV1>E^Y\X6AR279-A?(!'5-:((((V0W:53V;?N*.8F/Y8M,_S[APL*\2U-C3 MO08|-%!%65LK.%QSOPZOB1FT%28X?9470A^:]3:F5S!,9&^P8[4A8+[D9 M?4H@&$XU:D6!E^1E/$&*
[O'S>NTRTX7K7$SG1WD|WUM\/;^.:=)Y!2[U M7^2E_NX1M5YD?3F_OM6NKK2__[5KF>8[[?/M/SY<:U>?/GZ^_NW\|NKSIU7X
M_LP.%@GK%5'>;CT1:+AOTiN<,7[_!=TG%&881Q7H)50&_4CW8:BSXI45_OT@ MP|NB.X8772%M>EQN6L@=:TO+EQ)=!6,4EP=R1/B'4#T)VF !A9%ID#[1SLJFIE? MK\@P-*
*O)OD@%'EU9HEIR$>!64\YV.]AN-QW;SV?0'>-`:,:@YBQ_WB#!,3$>--MJ&)*BG!@*M()&Y6=?<'H3#*&D6QS4EI*TZMIW9 YZ_CTY2/"CT(GA)T!"(MQB*\@:8A!}@+?E6A*UL:.>^(*
*D<:<%1X$B2)F&HKU'\0)5/)V10$RT_\,H# M/N/W"MLMQM.F=8,8?X> M@14>I"+\XX:%H@CZ!$#'LVG5MR1[=^.74FB]!#K^%&=UCH9500=UK.*AGDQLN*
M^8"1A/I]#)A_PR.L75N">#UP'CKL"%OAL'-F8/<;QJC>L $'][SDH1P>S++!*MG>-W0,]M./3<&>A]QNP&[:I4&%,%VYZV@!_4=%]I%1O!GKGGG^%9XU&;YTER[LO-($L0 [? MLK-!\(W[
*MF>>IJ#+2&L9P9%HV(\FXQ'H_8#[MN=(^EOVEZ$])Y4XAS(!V(*RO0>P-B,?=X!3F@ MF(A"V27-KD+.)X;G _G> 7+/ZU2?2.I7L.HXAV1\;HN@'I5AMVM8]A P]XI M*
*P/ZDSWZ.=8MZ=[M&;ZS?%&,US=L8'EK2<+D@P.V#=+^ M6 MJ7Y(;,#RCE%9J>SIB;::DL_I^..O4"%GO)\YX,+VI%%S%K*7[2YWT8]V*
MAD)P$/NJB0\82>TL[2T3XN)>NZ0!1>2LZ(-"XXS[N]+U#>5 ZS;)R>O7W[M\/(@P#J-N_C^[3DHHZ"FI&^Y?]>2MS[++V-M.K^5;[;>P7+/=M>%_ "^9KVW;W
M+6B$<_^P[_!A*8QS >'T;C,!892..=W"9!BDVA\|]>-DK)U0#!&\RQNV(0"W8A,QI E58LG4-D9)BM&2S M.?)D=T__J9'?]YC?$O. ,6KN73?D@0?&-_9: LX9-,QIXW4(U=EFY+V M+*
*[BH^E&O/XC?F"\K_UB.;]Y F,IUL[2/HMX>QKY M6G\BG>42KU6I9BEKW1:V6HM870ZW6 FK%DE8:D.=-%H>8AZO{(\"4<=M2$O7E MT^CU'1+5[%*9F0=NC(%K3=E3B-*
*E^X\6LIN]=JKT#9VM\5;>^#MI7\?3FTO8G\M543]THC:.#5#7CW_]IW;R-9NZIP%>-KV7X85E M8I:V*XON)NR.O\EK\9GE 4H<@KSQM(7U<;2IV5CZ1Mf+*V\+%+XES]^4=7Z! M?*
*C\7X<;TYC]OXB5SPH>XFWN.AXCATR>_QFGZ!L>Z7V>H,HD-F)?W=1B'/L9^ MB%A"&&VMP;|@ST< OZR]='(/N_]4%SQ>,DR9*5<,.:!PE5]MOJY26LW_&MH^- M7U">VQ<@?*
*Y"*R43]\B7+&. F.(R3D^W*ZR%9&F2V5O!<\IW=GFF^^]G-L-% M\BYL"2 ?/Y5H4>S74_%AIWL,$M!7$O^NRs@*,?,BAE)%5L7G\A#N8#-(T+=I^K,/PY+*
MW&OVW,W5+Y_;W^_G#3F$C0>F+X4L%6@1F4]%_(Z94J4.!#UP5*49JQ/P$: M\=B$BIY7J$,@+-,.$(4HL+9"GP]9.,BK,I!A)1Z@D1,^022F =DD&|944F&E M2-5]! WU>D;7M=>-*
&7+.1L^RMQ+]XQJV8VUE),1G8 /=ST8OK%F M'\(NWT /MK^C_3EXWJ9O%[CKM\8U+PE.,)HJI.WF2E91 MI.?)DH6M3SK)9!8?N7 MVCBR_SY_A2]?*
*=O:FRA>;2Y2P.+Z63GTQVA!"#$6(OD=Y\KIZV!) MML'@AVP>B>[";,@T6%6JT[H4*I5+XK>_O\T=XQ4S3JC[4+FZJ%4.[%K4)N[T MH?(R:E<_5/!^Z9=?'ON?:O5?*
C\.NT:26/\>N9S081AZVC>_$FQG>#'!M]?M& M7!$Q<) WH6Q>K7Z29 VZ6#(RG7G&=>WZ-FH6/64?IVYN:S?VS:2*+?RA>OOA M'E7O\;MQ=7S_:ZVTM6LW[]Y_^-*
*OT8^WVW;L:QM=5?/L>FMD?]"IZ?W5=`8_O M)W>WN#9!-]>2Z1O_R*T9GB,#5'/YQS?^4)EYWN+CY>7W[|\OOM]<4#:]O*[5 MKB[_]=PU9=-*V-8A[K>-UF[CYD3M;R[%XS'B.&K,;-*
*?:,,Z0[6+OP]+S2Z%L M[?ZF%K45G$@.;^)R#[G6BK?ML:JW7&!^E4X$SR_%<[%1K5J[JEY?)4C5E-?5 MVDWUYBHNI+U6*2[AW67PL&(@SV-D[!NX#2@W\03Y#I#XI[\"X"*
<(OXF,I&>>)*L8@0UT MJ04\:=JB)8IT2K2_Q(I'Q:>]^'3OQNW*9?%>?5Z=(K0HU7<>N@]_*,,\'EF ME"9&*HGX5(WHJN*K*LRKFZN=95A/DW(R1'1[RI Z.I) 45"SWO2,5,3K+08*
*M(64I,=*G;4$L(@(!PEV9#CFV+]:T]=+<&LA$V&XN_BAC^AM,L&67Z3-J+OY(MZ1.Y+O4DO?@F_&ZQ(.Z$!E_ 5\)6/T8&.\23R(&F5!!PO;FZO[^_E$_]UTIB MQ"Q&'9S?^'+!Z (SCV*
*>7WTD@QG#DX>*6(.JD:?\]X+A"Y D:I+H8'/6B \5#C@X.!@BG?6W\;2L_D!"7/)?H;V#QF6U!Q+L_+]7 MW9).6<6!O/*=7:Q>D(_@N4'LATJ#0O \0%,03WS_,NQD13.RUW7SB&?$=6V&*
MGVKRORNCNHZVJX:D- 3l;Y?;!%NL?(]MOOM)_K!TNT/BL$D.X=;X%;G$ZI M9.&7T3CGC2_UVSUS%83_C#[W4ZS/FHU'^O=>]_1_1.I:K9%9<-C5?'+PN+^_MN[ZZ$WB8,) X B3B:*
<29&B%7(V!QBHIVQ@/$0+T9]@@(?"C@-IDJ4;S>!47C MUXU>_GK[]HC^/>YU1N9_79_T!K61QUXN@>B&0R5:-X40W/-WNBWC74'9QS7 MP]IH/P^&K2=HT_G2ZO3@8^M
*@*9Q5B)[NPNR&ST905=GC-=(F*-^XQ]/_6ZS M-31,_WSIC'X_$,0IC)4(W^V"<+RCOQA!5V>$8W.M;CZUN_VOAW+&:WY*/-_M M-&.!OR$[.*.8,NJ'BI@*%,?B^WX_?*
$\XANK51R_#5K_]<&>)V>BW3K/<@A#4] M@ 6L5B8,E8Q&BL%,D)<2S0IB=TFXY5#N,PP? L8"LXBU ;P-R5Q\&V=_0MB9 MG<^]3KO3[(JC4, I3?]H#-P-
H;G59!)YO/0HG4_392,7[&F]$1<3PA<(:M\M1BL^]&"PP|:@/Q1_@Q_]->O#9D&0BK%C2@?6N\M@U6P#>,DYA5%];&BO<)P18Y M& C/'SN]8"FLQ[LK5!!Z8]3Y4C@T+!L1)Q-"SFQ]*
*M%DO{RGP+.L!M*B4:UPF?%[!83YP3&O3&L-7LC-KU1]?;&8&#!QOL]4)62(8524G(\[JF'!X>109"/ 5K2]B$U(0@6T]Y=C?)<9^Q<((>)S2H.=% MN /]$(M@?H!@>><4]'Yl;V_>)\Y5P1-*
*/N-.1\2AO3W,$>H,%S$-1"1DK,DHN^ M"K. \RDA5BS<+0-=*8Y%#!-100$P^A3AWZ,2\VY=%HE1,FH83NV/D4D%%/Q*
*M&6'"L5+BE(@P"@3O1<:B;E<5#B]*YH%'Z*X!1+5S>QAXA3$*X"#\)7P MO=\G$6[\&O9S2ICF!GOB(7M.YA.3,Q>B87;& _Q*W9]7 KE?3M1XIYX :** M-*
*J%%V*U!)T;8L0$|&V'79V/8QJF'& /Y7O'5X,!^E1"7?8-BG "42_&U1G6 M[.GWF5+[.W&<8TSM;=XJF#\DWKV4F|%1?V>\LS&INZZ/G/[<,H_\1XK<>EM@ MEQ_%MRL[4U1$Z2S0ID4$*
AAQ"8QO4+.19/KEZR/X^NO"D)=.[5J_749UNSI MV)L.L.7121,S\BK]^-RC\5"9RZ#3]9C!Y)!/ &#(Y!. +66SX@):(:7V1#1"&0T2A52_O5L@IE>X.8(GN6FL%DD\V8E/,O- M&=;L^?
SH<^)BSNO6GS[ALG,^7L8^-;CK$7< P%_<6)C)4A[AF_95Q:E&25? M');R+I%\1EQ 8[R,?_Z;L1;2V)#R;(79R+<185^0XXO(DW/L<>3:78+&Q"'B M':*
*(QC*U@ETJ,2]8@2]F4$,.03$(XBY,-OX #-SAMA1 M-D-9?2AMQ'?+!G-A/T:T+$A>5Y;0F8P<7N$ .6V,-([9#37 !44',%^$KR5H%(Z)8RC76 (E5MT,HB5B"'7S!\D"LQ,$0U$6*
MMMNL\M4"5XBRUFDZNS4YYD"A76$]HS8E+@BS1.\)9 O*#P,RGM#Y)7<3QR\ M5Z5O[%22N!D.AK+(97DEC1&)8TAYSC;4A^8(LWF7(@C@QUY_[)"I%/Q(J]/H*
M3&DQB8L1(AA"!D,(8<2D.$D[22]6W6WU,A+B7(RQYA5 GO]*T7ZB*_G 4G6W\A+;LNW'+QE@=- 4J;E;B6XRKYB-,GSBAOT948=GP%- &-9%U-)3/S1?S*<W@\%<"G]PC%@->]"D7>-*
'KB<,_=;"T'+89Q K@[FK)E-WVX=3_=C!^N]R\LSGX MO\OL[C5,,RG7D(E;I3]R"X=W8Y<)#,G+;,^],E"_.EAK^-:CB]^&&$H?LV M3EXX#D)-%0.-N<>0Y3U4)L>15]6^ZH?*
CMR+>6_'3 1^! M$Z'V2%Y,&]S6]D6/QL@1=[<_5&P\)N*J;Q_D(9XO5/W,J+IXJ 0-B8?G%2.X MW#;X9D[!Y!!;=N")X+V^!3LQ-@VT(,'PU6$)=Z?R,7_&\S%F\2$(A Y&O)&
MK:CM\4X+!?5;_VC^1V0,7+J-5?R.(=OJ6=O+66XA,$K]6R00WI7C=;\]B^[D-VPA]X+@T73Q@YW@<C^(T6^8TMOJX5#ZU'7$K.-.H[0.TRM M@)@.
{X[C$['-Z#R]=:8U'X.YMO,]7SVADHD2$;J;-MU1W@#^.3AX]HZXV(1M-""^V!>]%W-,&56V2!G"%>A"KWW1[U, ?5NF(R<1@.M(7I.4%Z'!3$8XRZ9*

T<{7Q<%D0YZF1ZUOCU1QQXCZUN^_JE-M8@B5[F}(F\HXS MD+8S7S#Z&FSF,|U)'0[:^ME8J 9QB;PC,:G\.\)OWJ,#Z.7$,@5HCVBO7M1+ M 3W32P?KZ:6#\AH3M?Y(\3SF'"@5, -_#(CU)Q,I-I'YDSF|K0X>"5:SZ51* MU7H5&$##0E[/P)9L>0 ?,^VB3N3CQ2*7$. ^[1M\1KRA$HJ$O46 =$3/"! YIQ M'IF>B,(QLPC'BL4BET8'K7J^D*4_ :6#A^[*7AD2[BGOHX>_ \&_(O (<-= MN1HW:,Y&/M%.WY4K"(^"$3;Q5#P-+ZK)M[("A%H$* TZGXL9O81#MW!F%XI M7D;D4&BATC,8A(682H[$,XV$)W8AX6/-M!!>_ "HY,")Q+A^6*-G; #Y35]C* M'SY,*K0[3]^o'ND'FN@$V-(^NK%XG57?FV&FW^'I2S4$"VC U& 1;5.5, M0ET49"*>%KOA IOFK98ZQ M-,B4>QX+>K+(_C1M=*6[9O1F!7AL5A8O$9M&26\)4\}!> <.ROEG8D(0QI28B -MBTB+>968|3)G#JHHTFQJ.BW4*V9M7>)*V\C<*)9F\[-?[Z[0&&(+DUQE%>@JE\BBT4 G''PR#=-V+(QN JOBFL+H= "X6:L EV8/&R1]B: MN=2ATZ5)))YW$2l, MM--,?,7&/*6A%@KT(7(:;YKUS?Y"J0TU$R!NZ(*W&FE0%2+B.UXUB96IORX M7#<)ZVOJX+/M*'DMYG1VBOM0[']V9OP9PMZ9LXQ[Z?ZDB2>8,6P_87N*19%O M|C@4IM>U? B2>.RE=J)!+[\4TE0%\5^$P<6*U@8#:N#%1%H<6H]5 5\5FQLHRT MEEJH$%W_"#YE3%S96\;%E-&=)\N!E#!S?N!\4@:^HBHQ'#$+K\.;D97M1>< M^]CN;_%_(6K=MF4KY$1N5CKA;/=UP!Z.X\FYY'X? MG10J+G_\ ),)/<[1E#|=@+.V+Y=WTZTQ$W]VW(8/:[!K+6&?]W(G_SS5$7K2 M-= (_$3D1TQ__?LCT?4!%'X!$9&1DX-S#Q8*E9C("LBJ]1?=G[)*E*7+, MWK+@BZ)D4RT6[WA!7+X.;2VU4.&S@UT;B57N501Y& ^CFA],H'(M3%R|M#K0$5SB2"WY+;3= *I 7'B?]D,/^2KE46BAD@F>D4"8Z\/48E-B(>>):C?%IWH(H\TEOKH,G+A7D12M9QK7P|TMOJH,43]476+ZCJ7(^TPMQ4 M5#IH!KPXGR-WHQ@"=DK/3TKU"I'JH,. T5?80,,*$FR7S"4'(A-"TQEF;@,Y M9$*92Y#BQ7U)+CIH7A>5('2!@T.>?=|,!-6LA38T!#EUT#,E?S+$%H4M\G]@-M(P;@=(8%+V3Y_&C>HGKO.5-1?W5345E48TI_&6P-|E_PY/_ZLOU[U0W=QPO YU'>+TE767U5CS M-4D*S4EP7F9U"+@CKOY#SKJJ6!ZE7CC8PW7[#$_(+ZPR9@50+V-;/TPD7=[\'M1!G(+K7"LHWP8+/O>,29VLB1.4V9^5(?]2S(Y6=G $7=,,)EHH'OUT@F(=V6JEA>C1C"DVK[02?<1\HGHW-ML=E&"[%);'KWX@/"'NR(%98%"QOA\0+:Z.+(W#MG=V&GK>./SE$4](R9S;4 M.\N;F>1M;X^8SD,OM;,]Xl;1H8SV6FC3=[$L;92U&=CON+FBM4HO-P*8BHP M0+/)"BI.1Y1EHX7RZZ;L31*0Q'}A)K8[_]DD?QF.1&|U ^$=1_<=}KB(19C+0;IX=E]'SE=.1%9I8_&>?(<2GOL-Y/867HB.2& MRXDETXV9[RNSFO]L>3O(A!Q"ECZ%&E=H@)LZ_L"3G@73CKL__?$_0;^U<+2 MG2HK"S*;ZZ#+/V:8L%55Q^]PN[P%I_"!N<+I-D.N@:^<"--/9F=E&9$L^E_6&) M_*C^=ULHQ]J>CJ&I(L5VM" MEAR6JNKV$P-+0N9MBO0E*2_WUT^"6JS5HD@C%Y\QNEL.!G_]I+_PEZ^P'&.Y.'X^+>7?QR|!??R/_[QM[_]_7\|_.?K M#WLOWD25Z20F.YR^VIQCFF%\&|VJ-RD\;Z_WA-M*U'&,$0!]"0I]++L,P7(:,?]B%;(2I%A\Z6@X_O>O]4<,_WO!POO[%]>_EQ M/O_TZZM77[Y\^>5KG(Y^F4R/7PG&Y*N+3{\\__C76Y__(A>?Y%[[5XO?7GYT-M-KSK@_2U-_5_OML{3[_O),:P/)N'<:H/F U_G2W>W)ND,%(_4%<+^[!1'T% M%Q^#^A:03"3_Y>LLO_S'WUZ\.!/'=#+"#UA>U#__^+:|[!9'3D,V=PW_N[!P=TB@6WSK_]@E_M>SD;GGP:X<5[*Z=8?GLY$>,Y5'4S+UG%\K^7^-97W_&F,$]GHX5X]NCU^7=7 M>$VAXJ2>KBV:-)NO:A4=739'KQ+T^JO)IA:/Y ML:*=A407TKS^Y#/)K8[_]DD?QF.1@-O0S Z;Q!'TQRS48"3PH&D]Q3G(;*H M&H_@XMG7QW!%_UO3|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

*MV4_$;0:H(XK%I9_/&1?A:!E*PX@,V9,@:2X7QE&KDD5;O5?5U=.?/;^/%&2#`M(VDY.7:U576}->5!!F<|;CPT"B(CE)Q2+TE(GH4@E,$5U;96=@7Y[!6D+2T-`M2H!O !XP"LD)R*08<25YT!/O'2.@0Z)"*ZM,[6C+#0#'Q?].XKS+K=V7VW6? MDP\P/?OBI_#"SX9QX).F202TT%.I.6>>$QMQ"^/:>PM2.`;[*7]OCC<"">?9< MJR_>NYR[VJR_&HXNYI!PF_'X\%0:*H,CDD.90!8L29:E+'BF+M9N4;H"RM'Q M_A@1;PBU[%>'LP)U0Q=/QFF%[=(]!V^M0AR(,A0=:6H]L:,DB0=F(2>5 G3+ MD^QVO&?+=2N9;N:!][QC;/V#X^4L:5}W/L/[BR*AT[S /#N!F_.F?EQ2@9?I2 MDPXB*$'1,-'6HI8IE$H(7:+P&IA4>3}YZ?[!=`/;G.LTXGO3%S. [1:P*WG< MP3QP3[`WZR.QV93 )H]P3$;D+.F? FH79^]HX0?OJ%JL+1UN!NGZUCSCZ=`MOOQ_?SM]]^KUQ[/7_]_?WG[ZWS?A56HAL^$Q[5O)/+2V=BUEJ-5!:0[R9 M_7:B;4#<;5>XFM1[4PDN/?5**Y)=N9\Q3A#'2M<& [1FZZ$!0]%TQU*,]:&E/ M9WS]^2U? MA52@Y';XZ['R;-"TXM]DB!4@[GBPZ-(081B>;6 =NCDE3XAR)W5 GTK4?K/O M@.B? Y<=SLGWTQB,$YM_LC14XJA(8E0I2D8'&F(L66&,...8DUT6F,)G*]X+ MZ!DS7T_0AYF_L19!9@Y2I(2[,MZ!Y1)W4)QBR:RRUN+_E5/O\|PSN.6M'$P)Z MF*^Q0L5$AD@!B,\Z$^EM0OT-C(*SUE,FG)&U8]J;D3QC';@@VB:#W3=E5*P/`MK\@517.61&OQ(*)HT08N,^%,XOHEFY!A#<8>Z$]E#903WVYZ&GS>(F4(;^3=!!$2IB*)E;F01D MEE $KZF1EE9/DC]0HCQP8W08/=E%_+6;V+T"^+!LN(O&[9|7!UL,V>)|YHG)`MP1$12H&+TD)XGAB M%]!^.16S^]?]N@,@.3FN)K<%=TMSSU[H"5CVC5O)E, M__#3-(@^!FV+-FNTE*3UJN3DHN4<HIA=*UNWY%Q"X0GT1BU3X!R);4M+UM MO)M?015P5IKP,%-Z+.004;M+L4>*4@9+T1.j'82^#T__NM&4S.W7E/LQT<"N MJ#453'@)/ IB/3?%K6;$ B2B)*B Z\B"UKI;?*[CW?K4O .PV\!96J$B[6QV M >G5HA3_TR'DU76V,*7IU\7=8ZOOZ(./.9Q!&!0!-5!PXA&>B70BD@! [EHV) M-F 2'7Q:.W=\=Y0_@>ZU8ZW!;>P6Q(N&'YL!.Z^"SN#P32CEL5 &*&2T+1)# MM#%X3G.3J9:[@/PIM:P29ZWF)6I]+5;YMY&#*)2GZN\MNQHY;_+^(OHBBEDC-M'+$++1U8(G5+RE/O:%;"/@/E3*EHUWAK44)^D_[I8=1?X2E MDPVK@3'+M7Z$./F\Y'3Q?@TRY3K)%(AW9;_F M NH!YW;NUCC@)"]2ZVK==T MW$K\I#2BU;#]2_I>_AC\:O9 !A+5*M2Q+T;M5)++)H;+890JR?5MX% MV7%K7P-V&I2"WV=+17(,T?@L5*M]+A=%9L$GSW4&N7?!*]=`I"N$[^24H/V MX*9!#?NJ:G[M^GHVL-DYZGPD0CF-FFXHL9)R$B!R[GC2DO?JI5X'|U,JTIX<-M-2B.OT_C;^#4S*H0F""@=*SQ"CQY#;,D9T&ET"RQZE6-7;'E*]T'T,UB^WW M\&!0/AF&I5-+!.60'H$7U*Q'&3B@Z4DZFAUC,$I5CLE;1^\/Z7*U6>R1>W_MO3.F*U!*5!40;VDZ5,H]=,C,>Y%D#CUI81>X/Z425N=Q@P!N'5'X M?3B>3!?1D&6&8RV07P4@!V.5E]MBTD)MM2H@=I%662(_5(!0H0T%<)V+LT M54"4-6:H">JA?VXM?,@#&]0U?UZ?&^&M!C)1EH95U;RE=`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|=V$7*#;@KOO_H"=$ MT:<8:+ZD.V-0/KW2&N0P*$*=3\15RQ2GBW2[E^7>W2&NPN_MQNC2?!E^7>W2&NPN

*<5)\QH+7&[%#[4;H95!7C_M.MI4/>K>*SV"VZWF55\QLO=^.EVD*,A6,;&{3V@; WM@17O&O!XU25'2TG0' M54 *B]NC+T4M4AL2E' \9Z^==-*
Y,UMT>O)^EWNE9R\M%)1T!6]_8+G(WRIF,8O?@8GGZ>P3%,Y!7'MFG0 N4M4XP&MZ RLWY!&'0XG M?1%P,&U11D>>E20J6(`N1K'V)+Z#:&NIH"5C FKL'0?6DBWAB
,JR2YRKWUQ M^*HLF_,?OX&?S;^LKB"HE38GJ\JTRU(+:CEQW*_ %(42.7$LJTYFQX8/[_3 M:IMH"1DM)F$9M9RH8VPHL,;O'{@ MT1[CQ-IQ1O92Q@KMGT=8-0\U:\>W?
^Y_4GXAW9^G5/HZOP,^7*X:0.2A1/B3EVYY?/TB*E+604A696:0H1W0W#*]7R5"22 M#Y;CSA,BRT9:0V0/8]E2U'-TGX8T7X-DZ!9B++\;)++H(WH[H+?1^*2F:0F-W
M..Y@U\/8#E=#R8V+VA*-AK%E ;@*+TN[&:&< MM:^._F."6OXKC><_V'=9XD9[ZR&)DJ>AL1"/"P&$29]$\,[$;J.1'W_V_F@Q
M&EME4D^2^%;WFF$87{J)G=WF"KL#\]^PW!BQ/)1JO!L)!1%"G 1>^ <)>|T3DH M\]1(F%D*__@1^?9/ ,B,;0. _^+%;K'G@4;I$NRJV(I-6$>5&BM4E: *2+&G%SAEI1+\B0\8=!031 66T
MN.]PHCB*E8AMEM=JX^>9CAGMC=5#]HHK>*A^=*LI-_7^/Z?M2[_>=H_F5R/?^8 M7!Q=?O\US=/T"MT*/&=9=N>2#>7Q>I+)=9W.9\N:/9-LVO!$2_*%>/!.AD@N,0M M]>@/Z-
#)\E7$&7B8^6!E0L/;JD4[T&(1?R04/9Z.OZ79?,$4>V&9MC%&#TI8 M"2(+'Y9F]%*L=IY()O6O712[090CA$]-Y3>X*%@OU]+.*]],7-_Z4KKY.fJBC
MTZNO".SRNPNNM.6,^<);;T%86MBT=$90&Z^--5G$V@.3^DOYZI!4S605\(+_MU=SL@Y/\Y$A@ (R:B!@?Q[N/!.O"1VX==128B(4&BX=R-T* &2:%4)R*V*V[MK,/#CA 93?3;TQL,
[^^]QFLZ^C+Y^P @<)76?TX4EVN@D M(^Z%HK!^!@*>)W37DRE\U"D8UJDVI<<>TUFX(P106P-5O)%8:.0/-T81RL9V MGJ;?1B']EA#;1BE%7)* FQTN7M $UA@'45*2$-
DAFV<;*C9_]$;O9(N'UM7 M|HMN[NYF]^-D=,-X2]WC-5H2<7BJK8]%U6X@Q%5+>[KBJQV/W@-JK@(O] M.9/=1:O'1+?A23=7RH02$ZWFP#W\ MC=>4(:XE=:
Y!LsRN:Q#.X:YIR0;BCFN$5XV<\-5,\>^>X*>#B **^T=Q_'F M%^FF-"^IZ*+2%)(M/"8*CP(?> 8:&%%>;D7), ""?$T+NGY^M'E Z17RU##:8 MK<(&@5FF4!?A*F@3"1@[&$@64
M>,M(I$[%ZO.,#P5XS]2\'#[N~AAOWW@[FR[HQ,_RZ@K38XA M<8CX!0AB))BH CK3N&8D6?I,TH3Y(R B*2EZII"9QHXK-6T.3: M@Q7W/TYQ4,MOJ>P&@?-J*-
HHW<)1XM9#2]^OCB6&J:B%YA:%$(C+@)N2]>Z&AJ/.<4C24R37#O7MU:0 MUP"$+=?>@EUX[8K??X\39_=/+V=$?]ME;6'<'+0ZVAQ4MLD%:N!?@Q?
^);&UVEV$12S/@&W"!*TC,-R+A \V*5[[M0W]*GGHU7FN>,OOE^YWO;O(&F65M$'>XR=(RX@%=9*KP9&.92:KS5+6]P0ZTBY$M2"BK.Z:NPC8F*]HHW#[Y27:R90=X+&[M'?
8"&)>2]@[?$LMR:352&HRQ&#)0ZBCA.?G=1<)?_FLR^CN:N\MV[MRN.;^D2\;H.!#)EM&HL7)!* M@%8FJIA+%$DIF;K#PP;NSJIEE4E#E=;G'YEX=[EDSWCW[L-JIF6RR3/T@PCN
M62@2$*#1!8*D8F*\(! ?^H\,B4?6??X1&+,*XFJW9/_YC_,+ 4Z'8>E0#(] MQXGT$+W"\|\@G M8F#V5@XW22J[!".PX\Y*JY@N60CTK\QG%/ZG&R\:R
M6|P";+59,)=)U"B04]&67F\!AB@%@1JI?(K>IFZSH9Y^SA%8MJ(B:[T?__HA7XX"|@L>&,U*&(I#9[K^# ?MFD+ M?OYA1V#MVBJMF.I8R/=A.ODVBFDV Q7Z?O9}?
RKFX\0N/?)S"@E@N1R_VF9 I&3 8,%&01#-4Y:*VZL:AT M>MP1{8^^6A\;7C>@Y_?))/[WZ/+RS;I\SOLTOR 1 M"2]Y!:X# Q$MXIDJ"B0PJ;VFF4G3Z(*F\E(.
(N*ODXLX!&,W^/<%BJHSZ//[YEE[Q=K$E<)\(P_A$,D:N!!:ÝJRD#U*!8J746=-2!2L"MA$ \BU+A!M MR&XOZQ%_^!"M6OO"K^,RSM=C=H4B\EURLW3GIQ>,FXR>!@5%
M5*G>3@YL0.U+++37)1MM]."XW2CN3^BVLFWMJ\F:*WP_F.?9[_?]ILR.8A#'M'8,L@P>A @>#;R+PF#1/*46;X^" O2OA3XQ6M.#&B]/!NPC>NVEYS,ZEY@T"
MCYXT4.W_TRLP]],27[O4P[]:'BRM1(MX(L"TJI MB%*10.O!XX=GS-K!$.O,N8.6&QLV*&F41I Z*^4
ME3T$@S[!:M?&GGV4SDVZNBDC6!8/+"@GGV4S0E>[Q212>L,B1&TD@&<8#!EL>#\/?L3MHS[$Y3^ MGXUONT,6#83W/9#3\'5R'Q-4\%_X_?4T721+?7
&@T,KHR\B,A@:,.3!+A.14 M%/Z@3F=__VO6 M#[5KI_D>T\ D#1H"S]%EFKIQ2(L3DUYX+HUT++,D E>,GA(X]+#!QA14BHP8 M7C_4OR?"$4)A%R57;/%;[&VW+M*"RB 5A)
[\'2ZO(_[H8[H/+KZ:?? MWKP]??'ZZ?2D#%)]?`,!Y/S#F_]Z\|N[DQIS8OL^8N=.@1W65*G#X-?DYZ?C MV7QZ76#W V)<>)6%PP- &(Q1F$/[>U?&!?,8@N*1R?]N_U11=H|T[G|L389$
M&A=U=N@<6:3)WPN5S<;2MC%A.((|]-3FO$*H/H(-'WZ)$YZZf(?)<5==MB>[R2':0U!S^<9-,^TDM[FJS)R&PH*'|$3F7C&&;K"/K!0WE4M;SO$UHD%9 M+[)0KNTIL2?
RSJ%QT$?/M1..O^'!'7;KOL[?3%$?S-Y^G*=TID?$BY%R2:#H5 M\JN2[+&"9[ )CTT9HD[<=XHXGGS,\%%&'5-,FNBQ=EKRM]%TADY/&]\7+5L7
MB:0!@BN!#']E7),.:#8Y<;|)$]UN*9]^SC'8N*(FZX\26B ;R>CSE_F7-_AE MO".IQHTJ"\K!!H7>;U3HT%A)"]D=CT)H#) Y3C9?^]ACAL#N>FY0L'\CXV\N M+%@3%N>7=
]A6[Q4D2669C23!!\U ^ARX8HY&7]NW?RS%L?CV. ^JWN<678.\B M4R._?IT\^_'I=[75DZ;?0=$-_/FULC%J-"66@2\Y,.%+91P/ C01*%!(5*7: M]<3#&?\9/WX(V_?
1,_76C32]<=OJWY!G/(B98A0&7^G>6%Q9;B#IEL-A'-MM2=M=D"EL-A'=+K?_]SAC^_=3%YIHZ4&%4D?TI?)Y;>2O[ZWRX%6\0*PP23T3P(c%[7% M@%-D8*DL"G3RM2.O)\4Z
7;OK[*&VS9Y4[Z+*_9ITCRSL52RNI*,CI8"HZ, MPK=FDU1>&)=]-UMODN58O+8]NFY0,.).KG<;/OQZ>I8 ML@.|=C,#0%O&?
3DQA=VTAV+>Y,CDYJP!>X"M'F&$A&^K3PWDZ+Q0FSWA_>T)) M# ^VWNM.]O9R6*T=&.T84**93M:S%+K=]MS_W.%]@KI*7W=[NX7&M:E_7?
H>CV:W+:I>N&@B'.^4#ABF^G',N$E")D!R%,,&;;f[\G24\)\)L-MK:T6 M. .)D_F.049QG.J.\\4FHX3C(5(/,611K@ -%[B^..@F$L*1%8]UVD*MUX!-8)7]UT)F[AU8K4O-
MD\43Q6D&0=%4IE4GSSK191XH")YSP0;"0!\M-^G1#M=XQA6AEB<258RC(ZG-MS\[*-,&XVD&728P)[&82IW(§7L5;S\08@_'?07K/"K8WD6U#>[O[KHT*XED
MQGB"%_<##SJA_UCZ0X"FOOJ-P6.97)U15Z/,.R&0/= MGU5^ERAMRLVQD]G@%F8#F#(,@_ELB:/,T%B[>72M($=A]-U5W""A^I>;CHK3 M^M*-;TZM%!R+U$6PLA!^>2;
9(^PI*;4$FLJ2>T=_:,$,Q^++!Z3;!H.V!LJS M(N#K(%$'C_ZQ-/OQWW>$TA,FWT"%#3;X-9*5$!U.M_%+.0%1$!76XJN"?JO2 MRN:89>V4^5!&?\9?;VWS/HMYZ>??4O3<;G;.^FTT=N-
06L!0Q/-)7IT].06! M00A=]H<0:< 0)T Zl2FGVK+IVGCOSXDV_(&_JQ77^_-53=# R_\PQ7>FB+04 M1TIAX)01"">EQ%-8, ;=$XI2,L:52+EV^=P#$5Z\Y7=1Z4!IM# 85K@AFH
^KHW9"6+0'^65S=]'OGT7 MV+ZKTEG7S"*;P$NM),B.5EJ4@2&*MP2\#1'X#E%8I,.)K>LU3@^Z_?2:)/& M])RF*,G-X73#%?#[=#*;74@5?6*:@BO8$Q1=(:^")Y$"#*4Q==V#3<*\|3
MY|HV08&SG$+#@W#]%-I-]+LT(=!T;IZKY!LG@U>G3)@[<0B6D\YH(AP*4K MA"],F@^7X,8P\\?XR/Z3I:!)Y&/OOAV.I)= M(*N!O'#)HAP$O1MJ<=5)$C"))FF!IQF"HMOO83;+C
$8#*VSD_:GK(;:412<0[/PKTNX,_&82D*RT"]GF4)V9E:5Y8>E?"GUW@V.W M8%K$]IZ#@L6Z+<S-AYBG1'A'.I.YE\NDXH&<_2Q_[A,93BUX!EYUO9^V+C?I>6AR,UDHG2"
<@-2:@(3\%0]3'$8TP%QH2T M;0.F'[*\;'14U?0:",BA&;=7@RDG^0\W_3P:S]"IN@WOL9\LW:4W/UE:,W9 MO:-6&I-Z>R_+7#@-C/((C,&)D4&#"Y5]"2ULG]'QH"DWE23;'=)[&)4I9*J
M3%0R$G2D%"%%)"> UIY,.D-2[CXV!D'KWT>H!DWH]6/0D0,G$KWT3#-80P-X M;7C$A;!'PXB.G-2(EUV?)_7NH|\A.9R8/5:2;U!V:PKF?,V"A\2$(2H1)D M&)\+";+P(Z!['+
<#+2)GG/%M6OW3ML$F]F^"@CYYK$\|/\1"<+?:SXD*$X2A<- M*5,XA2:E/:^TU2D#T6ECB*>>F6YL.\095OU3RKKKC8GS-/DXL8Y1:QE MD$/IA-;9@T_9
J+\111FIO8R:HOA.1];]O6T^-0_-WGH|\?TH|AOZM*I.O MI'%0IAF"XXF6F00I.<6D8**3P?L\]1CLWTS+%>N.[POZ@+14)"5CPJU'LF! M>)? 2.8@:BX99P&1VI.X?
=|DUKWLE470NYM%#T4&7M4&%DH MBLYZMA:$H01,U@)PFOD]NYELU[&W@*.TCU:FDA^UBL(RWD%NH>CA8R M:B:B9PH4E[CL5ZJ@*4"@V@W7N1,JK=U'#PM9'T.]-
%R8XJ)U=U"4C:GT]%[M+0:W&'R"]YE#ML9F)5)PHIGJUZ^%2!?;RS_-4@7V4V^"\?T2>Q(PGC)L 2A=R M:\|)+H\(D"Q9ZX6VR=1N[#MDRKA=SOF==-N@FW<--
TX7B5X;95PO*SU/|:- MBH>AC+,:N M#WZQ-F^NY089F]XLE.4<,UJ7P8 E%^E5X2%S&*)F*;5@T7I;VX-_242@NVP1 M+4S0X#+O(6NE\AA@$MS*@E6Y3 \M,
[Y#@D"B|R0[R63MU.TA$H'N8OE=5-H@ ME.M,^$"2--S1!%(7-B%1XM/^)_5&O2K\2I9HX"[VHWF(7#,: MJ0-
>ADV+0A;BB"Q%IM*D8%PBC;LS7@SU\CWLU+!)QKMN*>+TI0[TBJN;>H M% M*9 HBH$XP%LH@.8\.99HX\ZEIZ0[=NCL9(V-;NL^6A57)7%EK6?^KC&QCPX:JR/*8*F6V4$(1-
P.HO=<9\B.H()=5CS7+@49L!]1 M!\H<$P:H*BZ[50:L;RD E_+]MV*8'IH^/A]AZZ2/5:2V!Z M6;Q;^<,VZAX0#(H4E@3H_*EZZ;PQ:A8R!\4X88RY:H/5#OT$I@6&.BAY=I7
M[P_Z,#QETB:+47LL$_VD)8!NN085=8XY^JAHMYOU?;>NU%#UI(Z>FM]N+' 9 MD\O2)PY$>(?1%4+2EZ'MB$UA20H1OVGJT!W3>,VC?AMD0S:V8G61ZJ5R"/2R M6=?
>|6T4/B2'0"G:BL$$T,Q9O+W!W V""R+K4FYCROP]>4ZHT8R9D$*,4#@)7V]VE^;-Y(;:V9PW=U7X_3_Y]/?JZ M6.!DGF8?W/?BD2SE!\A2*T^^2EN"98S"(0)RD3G7E%1[&UL:<(-
WV\!^/116V6Y_H*:NKJ^6 M@A#MK,"G 16\G!!6X&)X *>D#=Y+SERGFIUG+'?OH<,=D#NI?5)#9Q6=U84@ M-^-^5|0MA$FNF.,"!X$93:!DSF"'-9*}J@EO-
,8|N>,=_>A+|!X6^MLOY4M M+ ?K;&'DX:Y,#E >C/04< &,4*]D\FWY"%|&94N]-'(U:S2_=/YS|&[(XM/M M<-<+XUWTR>'"?0H@/"VT4%JB5\))M-
)9%|N6T:T1ZAA1LJON&R40/RWS+1?:.M*D6\"\"E3;C!9,@&ZX3HK-(R>]-(>%3=Y_'"_;6J_L-@]W97E[/9V6&2*9 M&:M]*>>++@*0'GW08%S)!V6K:?:Q^O2%-6(.
F)T[%\L36;J)=+\GQ&7Y+++6]LMZA8PHX^Z>SM__KE MS?G)KV-/_OAP\O[\S:?3L_?OW73J2M7V#B6J'3]YYPK4;590J<#T_(N;IM)M M&=].KLK@:W>#TVD)+!9=%-
]__,ER&L^;_W;3^ -BPCH3A97@HT8\" SZ2Q$* M..&D- M*$YSZ4-A&$[75E\MX8/XTA"]E+_A&GL;S34I) G! M"N=+LV,I,(RL,*N$!)2[R'P,46"T]H-1_<$>)V^T.ZV;$'\LK4B?BQC'#]V?
0;/O,/F;) MC*B=X=DHS/#7_2'NW14-&QBJ&EVZ_B%-\V1ZY<;A1A$+Z?Y$X\Q6DIN4]$0' M6VA&T2]AEH(SY7Z0&B="5E:Z9I,&G9[TBB%2WQ*U*^+7"G<=#XI5XW@C-,"20 M-
='+VX00'" (1#+1)2O8]D"YIZR?4*EJC09!P"_7L]$XS69OPK^O1[,XRRN MG)3@BT%Q.L,2>*OP] [<@9..14$3Q8BV\IFT0937'3'6L$*=#JH5U8I4OI^F6
MG[R#@(T"P6>%VT]45\64'>"QNQT:>+_/"Z]B)'Q###R($*PC/LK\Z!Q(Q1* M)\VZ53@?/E">":/V@Y,^Z]_MM/R:TM=_)7++>DLOXG%957.5_P;3OO9^;I.(Z^C>*UNUQ@5Q)C
MI5(H4'2TD$P6'@]E=4BB05!GHI*=9Q8D=$=8_*7Z4#4L45%CN&U OWG:/[E M8[]81_\,OKZ:?(RGO^8A]A%U#(UK]^!P#1P|54\E]14Y:BH3G M-20[+*2
5'+7R01%5HVW](#S1'G!?G'3QPB5\?(KGK !?WU+)V5L MR)&!4X&6(6L4G.?#T5 MO+'<*E.C\NO^4X?-7S3:+5|5%_%] MD'P8.-A'JOW)2_6_TFP^&G_^D*,C2:07F7&58N&,-
Z49.RL,3IW(0%&C7'(G MHE,'NDU\O1$\U#&,U?SY)!?BW^XEI,_OXZFBS^^6? M)G-W>??W;R>S0O,U7VG^,87)YW$Y8>YF)B|2D50KY.%PM^%I8SCX%%+IC12<
MIA:S]8GL@RSLU>'^\.!2\4*Q^2)O7OG?)M/EC\K?T0N,ORZR+WY\LO7_7?\P_GL='D@_CZ=S&87 MBO(D;/3 3!EG3Q.&)\9XT"&D:+54(1Y,E+IY&;|. ^/N&PF-T]\-"]W^F,HX5
MW_EO:>H^]\4O?W7S)L];3?]RE]?I@MHH.3,9B-*%E(+(@<@E:0Q(G3\>!\UQ[M',# 2_SY5AP0A!Z_,?IO;TPA#IY__'\4,CN;?TG33U_<>*TB+D@V0Q)1P&=C M\-
S3:!U))'#AC)DZ,.AERCY]I^OB.')K'+X?9;UYI>??U"?^\"45.ED\ M'$FP8&AVJ/$<2TN, !4(&GL|EUBAE!4.++6X#R.FP7CB5QH517)-F'+ADR<9,M"#F M4"*:9],R.N&Z;U"L0?O.*<)?
4TI3Z<9EE7+ \6!^$=7D_$BF_,QS=+T6RK7 MU;]=SZ^GJ;S*I7/QQ[2B29/PZ,\"A//X)EO"('OFG+.%2%]7AGGU1;PZ?.\7 M!FN /11,[JKM8I*7-PIOPAR7.?]>G3WWV2VD-
|R+@3RZ!WJ.LW2.^C1WV QC&A3*E!TFR (0E.;# M,J"HE\'G';>@ZX3HK-(R>]-(>%3=Y_'"_;6J_L-@]W97E[/9V6&2*9 M&:M]*>>++@*0'GW08%S)!V6K:?:Q^O2%-6(.
F)T[%\L36;J)=+\GQ&7Y+++6]LMZA8PHX^Z>SM__KE MS?G)KV-/_OAP\O[\S:?3L_?OW73J2M7V#B6J'3]YYPK4;590J<#T_(N;IM)M M&=].KLK@:W>#TVD)+!9=%-
]__,ER&L^;_W;3^ -BPCH3A97@HT8\" SZ2Q$* M..&D- M*$YSZ4-A&$[75E\MX8/XTA"]E+_A&GL;S34I) G! M"N=+LV,I,(RL,*N$!)2[R'P,46"T]H-1_<$>)V^T.ZV;$'\LK4B?BQC'#]V?
0;/O,/F;) MC*B=X=DHS/#7_2'NW14-&QBJ&EVZ_B%-\V1ZY<;A1A$+Z?Y$X\Q6DIN4]$0' M6VA&T2]AEH(SY7Z0&B="5E:Z9I,&G9[TBB%2WQ*U*^+7"G<=#XI5XW@C-,"20 M-
=

*2<2A;.S7HI@>'NR]< 8\GYL+-O46;_U1 KW@GWA!2?F$!* M>-=?;GR?+5]XWT9_V-C_(IELWN460/>-W5RGDOY$GX %(=?^!4 M,@8]\V?]&PJR9,H]DU]XH'U.5!]TG"I#"V O" <5*Q_YHY MXYI7;<$L'F&-&MY=VO/^X)8Z!3UDF#XG;\DO)'0ZB/MZ,WL\8L^JQ8<"W}_> M)4D%+ZW_I\!=CJ+'@V_CGZ++Y3JSQ%G]2C=NE;>VW-@{JSIP?,QX"V\I$<*X M%4D!).4PA^0,JEK*KP640G#+OYB*>FK8BEY>2 MI5?@IWI)P%CM5Y)Y%1=W(TZ{S*E9KP M%^,HM!@3M%*YBMZ;E"'..1O347(O('Q8_LKFTW4IVE^EL21Y4@V2'I[9FQS M;T$LS')T#-X>@-D'*A/GO6(LTO/$6=AN.Y(!%F?=5D8,;!!'6MD(2D,?N:'4s>_0!&MZAI=<)%YXQ29U:1+WFX[O\O. QU(7&_O//O6(QAC!MV[7GA,'W-SZ++TSL\7DG0AB;? _+9W3 MU"[,,SU$:F--7RW.5^_5^'T4KVDTS?>)]P 8K,.=I8[4D-$HW"<$!)]V3H"?S&:F$"F MH4I6P4H2WPL:3/=_&SN12(S;@D$<7'/3:LKMV;,GCN2G,#L[K;|='<_?U26: MB;>M:UAI+.V>V* IS3OE^#=`)[*UH:JZPIA>\|}SD_R73OL>Y}|J5_]"09 MU#(!2C$FC,FN!^;X#X,LPI*QW4*[/IX MUZES1$$/1_[0=,/]>=>VYXVV;0=$S9.*X?ZFS^H7A\53,8S8V M0_[E R6;/@N(;PA<=2857M*FF!CX)$1/E MT.!$HH(F!U+2:3S4+O2#NWI"=_24RJ-?L)*[JIYI/0%K_%>^ O?_^P194746 MQIBJI.6;* I3A5T?,<=(OH?W=4!%>U3ZP"N? Y'&;6Q#K3Z4]=T+Z,;NOJSF MV[651[34.9MHR3MFSF<_UMY#6F#*,!G >{O+<)WN-]A=LB!2 ^?4]-&R]\ M#UDV/?P'Z/RK-#SMWTL4]_G?2%%Y]&[^D(L"3*OC3X2Q2+T-TZ+%A=]NXK'GTY:VB8A(KD\10ZF]!5;QY&D(MZ#Y^=)>L2E:::LYC +-!OFOPD)V:@.LGM'G!P6V!"B89*2>V*+9(,M=@1BW%) M^]YKPRX9,.K&8A^"*.!20!<_+D? DLNWYA,_&);0.$WM4FN@36E^XYV7ZY;_Z MP7[3A<6,0#MD54QU'!]D+7_N)WJ1(SP^5T[NJJMJ@YF'K7&M-;6=Y^8-'!H)N MXZCS'@<(,O-"A_FE0_EB-P7R7QD ;Q"7^S1KX=[-R(TMPV%3?/D=,.[MJ-!5QD.@>$3D7F6O%ZF^D4B.?3<S1A.1NE5R_YW+O)!S2Z144'M:EMO$F[4CSP:7CP59K(50 BZQ-3&OSW79/9$1U-G3N7-0"/K0Q'@Q. [$HX|&9DJ7V>@@7Z;;7OfL HM1CVH#L3SK00?BK4B"HM%\?\=|F(-M 9E&#RIE]W-L35]YG4M5I>[OH2UXG=1RN0Y$2IA/'1 #I>)!"C!EN;,(S(;^ MF[+39L32/T"]< S3V,5+9!*3YJY0@(_X&.EB>?P:=#>DUQM"E!9C-C/O8BC M /\%L .PBEO$D1-VYK :-BUDLVL\;+W*MG^PC46/\&7!7UY).+*0IYT0R,K MPYXL8CO]) -E..P51?XQZ^-5'K(I3-^*TI%FB?EOO@[2HK@/Y7Z+-0[] 5/%G M"B)Q0$Y[<2E'&#<.M|HQU.WS)9@NHS/8"J,6*CA9$[K,/?79B&5D8,0=2&4 M&P[V*P6P]5MRF*1N$<6)@QP]+?9"}V|AWQ'C*WL0=;SPE3] !U^W\M&?)!8 M;Q3F.N](EWP,,3&627Z]#+/ CI"-O;M !#'Y_ =M*%U#"M7EPH*,V%'8M KW4A M&!R@E>;,BYO1 L['@2_@TUY1+687Q"!?(0W. +NQN.F@1](B@S 5(=[EWAXE2 M9D#&0.KD[/5\!2'U*/TK2V(2IE> ^9#42Y(@6%" 2C.WM()_-@$B;\IX;)]9% M$I10XL\H0!,3HI3E>(G,$HT9W+8QBX0A/'@<)K^E!'1]"%#Y>5;RQ^47,F/C M86#- S2V(,+D++DSE,@?0Y=-Z9E4%EY_-\>""" M68M!N!,"N(*C4)@ZN#K4N'XVNJ/UA^-K7R?"9IZ \D@D_8 0K5&_ISVRQF M7C52&S3=22@"A:+FL<$'ORI13 >8BQ3?F A Y* #9> =% 1R_I[+3;:P^ M<_'|=\T9?Y+^!?8G_8_VM\TM%6/_=N?+_]J^XO>QP#[IW_>VE+WZIS_T\/N= MP+]*TP:H0J,<\?42!6@H(D].M'$?4N> VX/L'DC]!N.^(8\'$\C7I$3]M$G/ M)TYUP<]BZ7SOXCF^/#*YT7RX?/L\/?9PY$"&UG>X3)3 M@O#TGOK6,7@[>Q'4Z1HU8E@;?_=A M9IVH ^W>%8+XE071']%$U!.?9C#SQ#2UM-N4XZ(0]@":FTD4]L/^_U:/ "? MN1C=.1O8!0>MOCXJ.NSY=2#C>_LYQ6(Q4'QUA$)%CPYCQ FT07Q/@P"1Y0WYJ_JK/87K^7U0@"2T@WVF# M#TXS^-!6#]=K*.8B;OGV5@<78]+G4^=#G@*V %M2U5^ATQ)XX(PN|NO%F99 MNW/9L?2I#X>N6O;?7-G>N2]YGC]@);G,K>]B\8D6#,V1 :0LK_H2G O>J3(U M=GBLT5NX(=#IM>^:CNXE]*TL;3J2/DJ>1]6H1.3C!<#/1- @;GJ[>YU)/_O38\5/!\X2,F2>._M=WQ1'641APT \5=E$=@)-@%GLR;ZXK\7XKWO-#Q02D\]TN^.WPYRBC_A=.M'E2CGZ G#9:L-`MU> [=*&W)"6T^O87*[*;WV0MQ^G%,]79,>4]4VISZPR16)9-MB_E(]45IER'3 MMKCJC]7#[_$<F.DW-<.R3CPV[!:?,_-=.X+WL5UADH\6JYP5\AKL*?2!E&] MOQN\K_F 2B"LLK{S7+]EA 3^/N;0'FLW)S-[)/-N/=;321(67K./$%%KZM&O*G:6Z:=1*WS?^X^,CI^'F/!%XAPB M3UF2A70=SW?9.X,>NMW@$?/2SF:;;O^.X)4[@)1PV G4Y>)\]G'4Y"X.C#%H M0XD8H<'LT'+S<>^I+\9ZWGY*)YOYDS.ZI-3H#=;,X=!!:5.OAVBI0M#?G)OE2 MZU MC7.&^?;-MJ]+[I]%"T7:'+LM/MB$2B'8EU#*Z K%%[T6N54'88[X0@.A8*=HQE N$5V\!,276 M%MS:%7>J:[fGQ#PNULO3;>*&E"79$&'IF-J4%J8(4CAX\R5=@"446.UIYNOPVTW0%-IQ@N5?#;" MVQJNB1-V,<.&T2X*^GS@B8>D4]9X;ZJ@:,F:MXS=[.V5]U'1_ MW37Y4OO^3<,=*=#IJ!OPV[$(U?73P$c*:U;\?9E=#$D376PJV[_+Q!WH M05C(0W,]<6BY'@H@@(^.1AM#*62U2G7SGD'0*:=.D\T80B8.S5XNURY(<75>0 M8S"^W]K? $P0FISK=I>SK0JZC)@?UT[OIQ?W%.=II%6LE[O59*F!\G! >R@G; MS2]7ZQOB>\4?]9=<X*<+%@#*KX6N+:QV7.(203! M;(TW8W6WG\$9>L0@5[*\V"<>]KZ1.EWA$*(QX7$\- *ZC9Z0R#Q>7,& ^"-(#T MUML .U0,>@GBJ&TF#')!S^^MAK3R#(\ILRJ_R+"U_'5"_<(6Z+%&L NSL"D< M2F] 2=]?!$UY=..F'OFT>_IB'%XZVM&E6ELL+|WV]X+F*IOAW,1+&-6"--O M-4[4K93X5@=#EK(1FYA+/E(f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`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{)MWVC>"49+67QHJ.[A?\N0Q("2/R'FU MPUX2!QWS]@J\YNU?:3>C_^WR>^5P.AGP@L5'"A VL.I2!5,VL<%A)#,N20:% MLR_.="T=5(Z;3>FAK2)1SJA)-#B:S)OC-+[S"&0Z(D/\.M*3ZFP<>%Y=]/KC M%7Z_MK8KQ.I\A$J%5AU9T $]::IF#VD3F Y]LU^8;=APU;?GFI\39XB3@<NC^.M7B2T=XL1HW)H1BJ W0G\,$V<8^2\RR/=.RV<)2&F99!1#>)HV^3ND.(8/G-.'\/WBL|I3N)OGI@+ {A]6Y=5/;Z"ZE1J1?B_KR"F-(\HSH M<1(?0.ON&BK.7)P8O",[-E"]?3!C)F.B6>&<;J#FZNAKI-6GS UP'_]#7U._M5 DTA,#G3(47CV#BY\H1!%YBC9@BQT&-N5.2G&8[Q+AFUB5W!" (:4X#[&GDD M@;'CD,48,=)'E&-2E>FF=K-*KJ>X*UCAH>6/"ULAWL[ZX*U^R$OPZ=_[.%5) MSW80^Q[_V%EZPRPV;U); W/ M+M/|&!, .:!-+/ ^-.17G$%0]_NKQ_4]U,RY>P;XZ1Z#/|H\%1*R#=@O^#9:$V@2%:^;EA5%N\B:U./,9HIC(EZ>W0V3AB=3D^XM\7A>SNY" >O:D2OC=6LS. M27TI+E';V_?%!P#RKY>CQ[$/B8WY[&. {",1>XA%XZ_88*OTKW'9=U6+2(\N_MZ\?>_<9$@T&3-T_!{^'"%,$$*\"PIS<"E!,K//:>AH%O(?XW4UX>#=:-R,G8 M6Y>U7X4/!+@*2AHB>[++(M^]E\.I&11;]?&S\.CKA=]G43+ (^5,WCNNWC1;> M,'G6[?KY21<32NN&S1^G8 M3H#;?F9@'84R2D#]\TKR+80H3UWSJ&8_OE2GN$]RYD:K_6*=MC3^?_17*-M&?2?[Y/WP#1DQF)VJ3X Y,3:IFV,P*74D<#K8_6"/BP>T865G+O>8+N37 M#RHZ/:T1:?W?LO OV\O7Y2ZOHE:V[@1=/)[\9)<<TBG %&OI^9RS#P\^9>DRV MQ_HTW%<{#5]%<(&RX]RQRO/A@SKZ? O2\AA 40F<>S^/&3_2!3\]YI4Z#@#G]@<-]]P)+DI*#J^/@X2OG MS\(XIQ)@A_P]#V.6)X O0[]O17LSS/ZLG_*J#Y+8SSC,9. O7TF)^\QFY7$) MW77:+R+>)Y5F'5$MMSU600S$5SDM4A/V1/N4? 6UWRR_!['#E0/K3'_DT_6*/-M-LDLME2&Y;,RZ3UI,Q*_P2^MQ;T;F?=_^GBN_=O',_#Q1>3I?Y)&^>SU5&V4CMB3(_Y%]5LF1SKQ$%^T M]"D=/XME.A.N>:TXG)T$ZX.8_SX)219UG^)-U+1=}B.#-^TJZO/!3#4X=!D M./D.GI*^Y+,>/=Q4F0C!F.9Q$77P]$!H9F>NZ'99Q7YZNVY6%2>9!&5#GY)T7 M(;3UEXR!@.M/M-*- $>'D%(4VZ5;N!I2],KW'6$OY:HBE4PQM3[>\38^^Z0R MS\A!PBI* 2D*U3<#\)M=VOP9*W(NWP^8MP30RA<_O2QTGJ'YF=/8^_!XFLR< M@-4C<*(96A<\2]H\RZ=)G[Y.8W'/=6? R@VM<8BA Q=4P]4K\>?9.1:I$8TY* M4F;23!-1\K!\X2D=;^SS>K]W1Q\QO[VGNLV)E4?*P1Y@K6)YKN(RK3R%F\]?*;E2LT:E8\M"+<\LLRV? A*4\!6R)Y1'=ORGR^)"7&Z%>\DY!YV_%^*I M_Z)"G[OX M]X/-R@% _.>L(V)RC(@"G&+&FI%C(?%@3"AU4GLO)M9B M"]#L,4^:$Q2ML/,QM?8[" 19WPZM&[+X =&PS]!T^8s]#20!:P#W^%02'1V' M%)S1G./!GB_*KXE6D$V@"BH0[H5P^9 _0V.P%.T(=3;FO-'U,1]$^BVPY&.9 M#Y\EW<+<3?PF)O*ES$OLQ\4J1QI&H3S/572K_% {@=GV:)R2WA*7KI,+-)Y1W3 M.8VOVHL+KQ28KCP1C0W<=#B@ZHK.J[!;U-HI@\"L6XT@EF"[V4J;/^X=D#;Q*V?L9H/KNW"8OIYXHW6E^_L]B MHB(&#Y<>_.-H_*DD%GRG'4; /{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}6>+?0EA2[ZCWD9BS$M3U;O^R[!S MW!X"I-;2V9.V"5MH2KR#0R2JV"31/2U*4U#O5 3R2T"+Z969]BCU/. M 5UOD'A7785.E7J9$J5O.XR9CRZQ@;_"|"_BWA;Q+#:[-Q<8@9ABYN.5RSG:M7W_V? %3IG"C;6T;/".0N^[=5V-X:DU,NOX]F !;-N>3CQ8%]>WO#86/17&-% M>?&TC8?E7,#M\YLORR X{4!QFD%H,Q&({[%],\K:Q0Y-%9*9%4]"7 M&LSIHP?/URDCGU!.XI+\SYF1Z.!* (\.M>W$SBX-FJCO&?)<5>=AT3?L:]H0 M\.A\&R;U1UO J1_'50*P)-$^@#H^_=.F.74H+[^!M,.8;3:0LIBE@I; MJG[W73ZA<*9UW5T+*I:5@;9O88.%E1_QHL\C16__X)N33P_=C.RNS:M5L-[M)K:^Q:>"3__P4,5E[?JLE95T^FX^YG]Z$M86Z!RNNY9LJ.4A$@M,8,WB#@:% M'NZ6X].MJ$M=TCS!'Z%ATLROA[H+> MY/(J1GR!K98MK]C>714W,:Z}>-=AVK!:U_[;*)ACNF=L:=?/HJ>-A#C=H@% M?FJZ8R6[$6?>UV9VBXB-;>K@WF2P;PL6O?Q+4+ N2M<K('ZI@B'82I5*$N-V M1:ML[=HSSHYJ?/7=[.X'<0(_S4+/UC.57AB$IJ/WBI\7P[+;L.C/?&A3)>TS M:.UF[5V4MDG]FE.8(-1#+Q%URS?45X:^G1_U*LSI"3FQC*Y:? QO&TEBX<3C% M4.19_#,S4R#@S4.T]:5REP9M-$EWW4$R1>HXP?S*;]6AH]P&/?/ MNFD56(HN[>E,VNB$MP?!$N90/3+\1>YY\/I3SG[{B6NO MV0^_V6H?? 0TRX.+QMAS;K=V^&D(RQ2U9(''JC?I*I8UE$C8&NE+AM3>I.#&^ M< 5'51.M\2N+)@R*YVQ)Y5XI*S&Q-0%8D,)5OM#A]]N,A 'I+1#^(F_7;M6Z M-B_FU(>&#)Q>F4/L:] %A>2(#? Z!Z$Y^RE=@;]D\I7&=E W3]]CD1?*F=:DV M19:,Z,I8.=)Z/>TW5-/_AA;:]QD.7M+6ACFUXG>Q>G>P_BOU/SB6Q2W'KYI= MMNV(Y;X5P&!F*4F;H42S]N3WN<80(!B-2M &W9VU@;1UV_0\]7@RO1IMVI!*M%]"C>KH0|@/PVNSV?6%.NYIE'%.88>7NDA*GF6CTNYJ7+"D+%FDN@;9UHWN MQ9XY&]6>6+F[CTNY]7+"D+%FDN@;9UHWN MQ9XY&]6>6+F(=Q9TXJ<.\T)*;]G%VS#5EOM+NQRPJZ-B**O*<{"'1$!1-MNM!49/_YU??QF9,&7P?>Z!Z,%_'J|(*WI@<4*M?A"W48(}X;]XQV-DBH:.@L-MM/5-ROGY446ESM3J3=_@+;L$+G.Z_54X!.?\KY'!P>0:X(6O[LT5QZ[LS4'3 M'$9K-]_QW?47+'I=O&_?M1#"'TD%-2]]J_?87Z2Y{)IF8E#<$S+8-L!Y_C=SL M&4&SM=1]5GG;%S"Z7&G 'Y!KT=:(EEF]CTRS:T/KY>G7#=-M(]/CZ;G793',,TRB[_UZ+D[$(_B\]#"8ZV#.43=$H]? TF69]L,21@:<;O6Q M-

W_E@X$)584^'Q_%5^)9EC{!7,W7V$,(;8 M_\+>>T>.<H7#>5;=!Y\FQW^4]G1&_`)-M3MS8HGD->>1QR.:8EA5F>HK9%M[?DDfP?1,[*)-3F'F@16(E>T&2T1Z,\A:?

*M4U;)PW'E602XY9BA@1<@ML.&?E9"_WV"U.AG$-,B#&)-G8F^_N.W;3Z@5W1 MMQM[-7-'(?ZQSQ,BQ9^ZO5R&#(S& 9OH^6(F[$$W(:17$!P-&9I3W$U3U6GF M(,^WAUA & U\R0=K7KBI%?H,M.BX.!)#7."X$BK0T_,V[&/;G9A,CQNC[< M(QU]^03(K__ADPR FC&#)/=E)=/DZE$O_Q<7\WA'#_X3.-C\WZVH"OE1C`0 M/RPR@*]FCN5V$)1G3 JV/FM.0_8^NK_"G3|FURA4+6_327Z#P_A_G^V4!8& M-E. 60,H#'YK0Z5+C\7DA2+F^H_ *FE@%TFV&K0+TPUQD2$N]UM+H]^\=, MW6?+)EVH|GH[,)3)V\+CV""7TV))(!D P8#*_A56XI$X6@<#B XAVS* JZ-= MS!D]Q60<"T^1/?I4!29^\)QG3C#?% ,@M@+4R^_0<#0VARZ,'%$G(.E'O9'D M&1 !@SP&6BB6UAWVG%S=B8KBV82E,21?PKZ3T'_*>@_!?VG MH{A4})^'"_E/0_\2"=[# .,"0R@,$P9J<-VV8&*WB^I\TFO_R]I\'HNC"9.7. M@^<9LR<)T9%Y,!/^9YM//Z@>|Q13-1!4B.,X,?53Q)6H"/#[1Z/,_^8)A/[9*

M_O[M'_]2B25O05G$,^<0H;H"I^:CF"Rl;3=_R>WRZ&B=D^(C|23#+SQ2G,P0.M;8/L2#3M%Y84&]W4T(?<1B/E)BC7QXO.UDJE1$,?]N#?NLS[24'-$[.+5\?

*M>H4!O'=&KIC"4M//G-_5&4",/\I?:?57&-$3_X2I&_2*WMVK?R;_-TL4{1(B@ M9#T+Q1?GB!CMSI$8]VO;Q@V8U:=0S_>WO382$WG(L\P9B-(G'Z<8!Y]2HIN^_MNQ)I'_*

*GGGEG'S4F99;\Q9HF'_V0UE\MVX.6Q=-U$?T=YXFG6[EO!/I:U(^?_MNIPLAU>$!0[1A+X@C*I//&%$CZ4OJ/N&HN^_PE7UV!SJ$$*(U%!.U\)C*TC;F%:VE/C7U/9I[>]4VA)G;E[<@4_%+*

(S2OZ"YYXEZ M=G+KM9C2:W?3,8\7Y3),0$'>56^/?NS7WF(DSE\'RN[[SX-MOF?ISYLCA1N\X#O7H]Z$G7AI7JP3'O8!)DWW_C&X,>_'6"74;;P>5!2+-1BL5

M\3Y^IW+&%U63E:Y;B&66M2ZJP.%&> 3H$[<0(OF9'2E!V,%0793GH\KM_K[@-M|Q^C&E,YK%RE%I;D=M=A,G_"))D9900G>\L MFPSF7,1.1C@^-=C%[1JS%9VG.QO6_U.MD-5@6$8;*

fYBL%[$UEMR$\[M&O:;_8-M>W-O8X>KA351%FVA'P*.0J&UH|)5H?!29)>QGBG.GI),OD07-MMTH"UE_SD6"C21YOH0G"_I*_OIH/I3-MVVW]+#^^NSIH*JAS,>*

*(1^&L>KQYYDCC7C09"M;PJR>5>*8?'.QLCCFF'3Kj$ M%24=N=0)+*;J!IQN 45"&K5Z4$E.Y^"\'B(BI-:NV.*XZ=N-_*+CAO;WN#I? M7NR2FA?0$2."R')PZ@LP^Q_GA+F#<]!/(-*

C&IAYX[,U"5H_8V$';+Y1/W\[_:N;[J_#-M:"LWMUO-9>$!Y-KD5AX-<'P\Z/RH=|"(JF/C@0N\O]VRZ+@"13IZQKPCAQQM?EA=Q^UCXl;'-\FOU;,,1P!96=H5,ERLG M,-*

*Z!FIP\^\)=WLGUJ_O^G17:.07*_&8\-7\IO+2)\0TND$K >G^_MP;>[$2P<;9]J?WTJJ,3RLS2PXIS%LU^G8M?V;^;0;4($[U0L#++9%^OHO^ML M.FQYO;$C^QZ;%-*

*,0_C@G\U)UX&3FZM\S(_PG(C3N*8[-[.\ ""><4G4?KLTXD M3(A8NC\X=_#DYB@9.HE09:*;Z$L"RCR^27;P(O,GDY)KKB#C\;WV1M"SVK MP[Z?^#B)3W=,ZBGR1]3Q8-\KE?*

*T__"6/]*W#$T^8J!&LW922HU%/;OF_%M]M[S8*) M9"-RR5_VWWAW@%8SN K.W,]QDT(<8L[+.11 2V4 'K0 4O0HU52S!?NU*72QK*OC11 M0-*

*O1$JL'KFG\!4APYKI05:6;BLG2A1YN0^))LZ$#*ZD0)!U1Y3 MT8GJ!R.IYW:/09\5PDZ?:C$(_XH!+=VLSK)MU(F17(.Q4,V)6EA4W(G)22\Q MZX+"&0-*

IOI390H&CCN8%;_.D4:]CWJ."F3>]@_P(P<%H?J/HM&%3)OCBHKUN M2!9<%X;P44$%/]?VGA@V9GY(SV5)=ZY'K,V?7LI:VA=G#2\-=DG,)9^%A[>;_MS,^(##3IT"-+5U)@YBZ-

*N=:7Z LWH0)M2]MJ:L%W#PR!VO MF>O=O_;IO.RG=,:U:C-TZ5?MT\GY%3+?,]S:Q2RU %@3H7^?]H*W]$OPREP. MGF#QK^TMWCNF~N: NVUWUX3!DXJM0)IP5=2(0N>H-OP?*

*+B8FN&\VYD^TT5AU MY9OT^4E85XO.\]0#8R8^FE,:-Z5SN&.S-<IAXN1G>4EF#@Y=+]J4(X@&[ULX M0X[<5TMJ8R\!*MA $V]1_(@^?Z>C1(VH7TD':8WYWNI:%N]6W3+-*

*KPLVIO(8 M6D4'$W],?)QE8P!1RQ0^\I:]4SWA^51U;K#PQ<':S+7N]7M@AYHAR0LJC^=?M/OKA^N4"RT$D')M]>L*I=4)J5/'4=Y]\&UETTF;1<2;5J*=@T ."VH80I;- MI6;?;&$*

=X>Y;""A,%V+/42>90(9 ;BP5+>6P'G1[WW_O.154KUFS/WL_ M>Z76S7#?P'5P0(KW\GSN>V1/KG"@.8ES MZ0S.4E96ZNE>3E37-<2_^<;> MTI+\U+YP T'H?*

I3@NE9NDV%5F=W[<*RU& YH6;$1C/N' M^A5>==M*=G(_J/M_5I0#.KICT4^8B;RT@-UZ5>M#/-<1?)/Q745NJGSY[/J6XO>_)F=\ MMJ7AEB]Y;N)N7J*.3R'_Q""B*

LWIG4SD=/U,.8B'+D:]PP"B,82!6#TOK.EZ M"-[@MMGM[1!3+2\,X:MN4XZ7K:8N% K+\$?X9JXS,53A'&^H)6XNSDFH]2M5 MHV+=NL=HFVLJ+&N]!7FY<890>H/5^T]0192"ZT?*

1>%U'W]=O(,X]P4>R=R!D<^[M1_HQ)'.8UT+5I8TH\K&&L[;N8[BG7Q/J-P5/LK#HN? MP>F#<4/X3'&;V=QO7B:2:6KZ>.'R91'ZRMM_K6L M\;2&5°> MKL56K?SD-4?

ZSD_YZ=G4MMP^M7"#(&(H^QR2!8DEU6'-NQ\""*BU3 M&?YA[KJ?/;%'V\1CV_:?%SDHR_!<[E\Z&Z[& #PE=!>,\&;+X,%*_I>=2I4&F/$TYY<&LQCHR6& MLN9YSM5N1>$M;S:V1-*

K5>U5=GOSZD$$5 MU-$7N1ZYT>]6BUK[WOC51W&I_^7\AFJ3P4[%]K!0_6AY7<<)UN!13UR6#\T M-_]<+V$^N,<$R*-NMK?Q9]KM_/@+2D=%+)XK$#?,76!7LRRT!KT(,IQ.XG7

*M24_30X9HVM+$Y>_SV?.;4/:99F'!QO#*!+X MG\&CUQOBVY#/(=SU'R>CTL9[$"!(C'IX])R=D,8 Y);1_]\VIM"..=Z1 IFC M^I-%/A6M&E?@O&4'VVNBW;=[*Z4G913,.6U-*

^I&Q4!FN3. ,+9:J7!SH2_(D M>+Z/D FI,HGR6;(2+TZ;B54(>7FA?8>3,4$!Q3'0RX2 VL@E=\V,H_KU=C$1P@G A(:1LI)O=#!$H_%CU/]MXT5G,?50XK3 M!3[;E)_X%'O\L8(,;9-')1GQ?

*67)AO7X4N+H?*_ "UP@%;;%.(IF MC^$WI-K0$<>>M:JH7GJV F78OWU)SYV]X4)Y!K9)0DX+5CE^\DR,PT@#MYCG M;H\,K35A%*MQQU6#)S% RDM#HT=> Y"[#" &K$*

8P&M4SWE)GOBN7G%F=,M9 M2ZM1H$=X03W0\7.>.R_R\^UL9D$D>D3A:,7 MQ/9B? 1F30=ONN1P"+[.:)BI33VOWQWQY(G7&B<@=VXS/I-$X.)MHP3LN(U MR=>D\=]B^%L$+1QJ

"GIJ;.5TWZC0YP<(OFV^N14L^MOGX1:GR,R^X7=1]^? MB%J<7]8@#N#%>?(D:0;R9>(FF]PI+'YEA9-XMQD-TE+>#1*J?FOX7S4PPMP-MI.HE4)4Z=']B.!0SVPY?=Z9)Z=*

KAT>GI6MUGZ1"(,5ZU)}3 M@"#+P9L[#?I>YB/.26;&]*DN&>\?$Y8^|[*^"DN?|?"G)= U'<@9)&>P#+&Z M*@6[7ZWHLVO??R;S1)J#;LW2;_DHC&6]G\Q$?*CZ5S_EZ:.%I8%DJHF7*

*H0K M5*TKI?BU+FSP!|\0OP0'/-W$?$_PIN$%ECV:X%_U__\0-I<Z<08L#"1 28W;/& M,;#-+]GZ^A $LS'XZN.IS^'N!S41V0=M)EO7,-D(R[@0TIPM CF'T#CR:*

M0ZRU^%YGNUAPL('<+%/6+TE4"4[&#M[RKA>M;!]DP2PEIWM"":6X/$$WZ[@ MM+YG$\L32M[3+KD_2%5Z03NV//P=Y;T6[%]WH+FA)\G$^:UDL6N_\K$25TQ[*

*M;U/NMT8'2HJ>#FILE^3;G S/M-71_<>.MVLK*U"UD#6X/LNM;!95(;EMV@;WYN+KE!.TLV8^SWLW0&.!#R ME7WTJ,51E)YM0>]R#RGSUL R^[4IJZG-*

Z,WQ/>GYET8U;'R7%_DNH\Z1WU!<.M0^7(ECC;4$CE^K99Q:4N"^\=BGLSY>*,_ZWZ"YMYZ1)!0(B?I"'H/CD9BXGK M,-%$9(]$L\=D#MO8<8G=ZM?:.F259HK.2U<6VKG=

*(MR$@.H9{)}|VQE\S:B MVJR#PP.!$-BG-$WUU%\6]^QMF.'18'4X/>LZBQK=ZRX6:WILU!W:#?L'&V. M#05N'JY:8)N16!-W8.8ZM&6EF430_|=LM-'LP/W2"_(<,+ ;6 =WMD+HT_*

*M7+|D5}?D\H9EQ99/32EX6|>"_ =V(0PP3)\5W<)$KO!7H L2SN=4*VJH#WLI; MSNSY'E]$C<;"#Z"P2X>%WA7W>?Q%Y>-N|9?M;6[PMY"*LH*FQF=BMFYI M$>],)|2IZ &*

*K#J+AE!7J#QY=1Z5:%K>%.GG/[XP*F.SZ4*1(;Q+GVGB/GWN-M(1[R].WCMR[N'_]Q1=S_>Q9_!Z7#ZO%=3-:?QS_M<.I"7Z5'(U:\]00^ELKA MO# ^Q@AR@W&DG'R<*BX#D*

*P,L)-0B29X7D*RP7 .PAZ8_@/_B/5/E1>ED^Q4@6I/;"^(_S3KGJ*7RV?D%,\%Y$@F MVF =AR:?\?6TS?%2!8E&\9G\VZ.#fO<,=U@;Q9*)=F"!8;(KL MWB,61TZ&AJQ4I^)T/?*

D5A0R.Z&8;?>[$=V*8B%"596>..:2T+J5K$@(U53^P< MFP,X?WYRHV341V\N=;$\[BKNWK-8CI>OIG^)(OR@PYG(C4CB^A]W.:HY8:$[

MYRP!/_",>EE7;P)Z@_A9.U6+$PQ3N2:U=VV9J>CU:-TCD2L/O0:V10GX70@ M6K7A%V9B-^CJP"&@W5U?L79,H&4W8>(>Y0%B9)1ZEO !_9RJL 5);C?6B]?& M]^|[OW-*

^_PE8#@&EL>_5(F/86)<8 %\@8MDAPX#V\@Q:8P /1NK+/%M'$@!?}S> M1HZS7&+N]]X>S>MT.{Y;IW2-!3P|SP"F0^9CNCX(W0AQ$==##7RQ,V<0GS2\ M3$|\%@

'I<0;5_=]^25[=^/UZ1=@Z\(8!(NN2(>)$IO8#*E8#C:QG\B9L% MGV2F\R6NE(4N5 @$.TMJ$.IZ?(H+.*K-$ MI8&)\TI'0=UAW BC@SK$X.EZNF6K+>>60R.?H7DRYGZI8=_JD*

(8]IA?WGY M2(/7LCE9EI.XF[R!Q(;[X-Z?!L_#0?<5]M@=U<_]J=1C=".XI_?75]B^R-I M6\%Z=,=Y_?5(LX3;X!"""?$'"@6\@(L094=!TM3+Q%#.Z2)1<,[_J/VDPX*

*MV9VSOVES+9\$#I63/O:%G6<,;~\8P"N_%B9*Q&/#\=%.U-QEB%Z<@B,W9)E+ M+5!L_U!U"5=#SA?,"..H_(0+8T)UQB-2DZ1LYW65+5HS93+MD5VZW6::,NW99 M8JYXJ9&\:>E@@4*

H%AZ[F_SBPJI82R"(I]Z/'IZ ,VY@SENMM6+6TFY0 MZ?ER3;BKZED33)6/V+]8XP8(B3\[R=LV%0X>(SL3D%%T@SM-CN5UV"F)7=>H.M)R!N3$![.R]*2HTO[U~ X]7, ^]+.?*

EL^3}I^^9OOV M?6-STE?N]Z#6$[H^K&56&@=:ER2MB&VDQX0F/$L8]HV>]52MK<<<3\].3=L-+ M9P9>_%+LS2S+"6W7EZN"AVD^"(P$ Z$%50K#JFP"[0M_?QC %/3N-O,.6]*

M#0=_VNLM%M7UHB"G>(1O(<8<^"7$9HR<1$ MN4(N7&GG[X$NNP^@?\!QI#Y\W(Z!WY9[_3LTWH\^/C/WVE6$@^\N:IJ3@<'I

*M*7&IX(27+%MS!-.Q<2@6$B>V:*R>/C[P8V_9AP&<#YUIP>_I! P'#5"/,X"; M7]M-4:$/,OJ_DS*8OY)V""P]YVICN\D]+?!S(2"CF<))4OXA2TI-OJ%CE*BB M >\\#R2+L!2_5+9O]*

*[;IBYL4Z|\GDQU4Q&MZ1# G)RR)RB1>,HRHW}?1(=/B M;'^UX\/+XOD"^[6+..+[S?5-9%B7M\BR\&1%YN#(,GDLG/IG M RI:?;7]+'?"9I;+LQ'V*_C7@CR+5=Z(83KK=XB7(/Q*

*M3_34T@E;T?,G\'D261\V$C4>N@IRE4]E/@\]"PV7-"*L_1_;]E_2*G=+ND4Z@<67:!|CG1EFIC8U*.M8X!CUYG[,.(2A_^)6[@G'ZD#1S)XVH9:X9 G3D'(CKO.FB(4/7M+_;*

*M4XWG-V73!J13?3-IW.2:^1.(\Z$:1-#SY=?39ZM!%>N33W:$;.JOQG27?Z<[EG#A&C+B."T+X]ZLZR MYA*CXV4WG"GW;&1C4#Z0FGLY4]BKWUR7:K(.V;A(EYYXQ 'JKOJ.MI$G9I 2*

MX+$=Y\@UIQF 0-7MT;[@Q,I#3&]3&/I.=..^6>G-T>P!+E/?8<2P!;LN\7AG M.T OALT++#R>@]/7M6KR\BQL>%1;GK-F+,5W22]"/S&TCP'PH/_$[5QF ">0 M\ZY,[24-

G=C%PAJ1_1"R92ZK1DB%"37;%\H 8IVRZ[%IBY8=E^FX(Q?H#D[M@#H]0A?PZ-"AE>030, ^4X-54O:FFR?L=[2EGT]HPOX+V3K]+ZS8>ZESP6(>9

*M(V;N!E:0RLD?L1+W,LVY'#0RLEG!8^ P8IQSSL!0XI&0.[F$&Y@G3F:Y+\#2 M,,95?BG,MPDLB>WWC'I]53:TFQBY>K#?LR= MFJZGUE*U]CFB3_*2GO-W+4;P,*/ZE#E704?_E.C-*

Y<)3^>_!WUT.;E3T=2_1 M/QVK-^D:,<'W2(V/[=EZ3G$;M]E A/1;@X".DRTMXPWGK?S:2NV78L%[M+S_KR*$PIR3"G9X,..#[<@^MP&J:D2??G!3'P:>]!N/27F9'O#VV- =\!EI<

*MW=R\7W1!??E3 8GK\^1C]FVTY*H=N&X/;@&4A.,$_ZE1-59DEMA>B]/^25M0 MJ'5YOY"V2(U\QX3>1C!MS+'2I?T|! <@3ZU?N_ K?[%WIH=/B0YPE7U$^&MCP5Y9_0[. @?*

0+ZG#.KWN?GE16=N;(MK^G\P\F_WN>;,;\IEYA;NODN I),-Z^@(V.AF(U=OZ,1UWN=;KXG4IY;_SI MY2/C+2;E B8$@"",>>KA.N7RSL#8O(>\@DJO$RN)S5/,B>B9CV3N\5M:.'?]0

*M&-68X?HX.ZU>T_^E5))XO(,X(3G.7:.$]W>UT7 Z@MZ5%FH1H@Q3TZ)"BR M+XX-R=WP*0K%!5WF&117L?KH)]'-]3ANM_45BIG!U)K.A>?.N_?.3#@SC@84KA M2/T3N=8+:.]*

MXFWVB8:X;9$F [%CT&MLQW,"SE=_B@.VX60W%!<20ZIB ,AW#&#!+P4W-]EW M=214K6Q-6"3SKPS_QBT=A=K^.WC1BRPL[S!>YS1V^/*EJ1,G1Y'B&Q59O2 M+X.R^)Y%#;*

$RGY'FZ_D\|,!48$08#>CGS.$ MMZ,$V%BWM%7ZK^RQU+P*1SPD(RF!@>O8B6X*+:%K(8'RXQ6)48EY:M]K.TN MD'N&;Q3X' F$=H862%V\L6^]CS=VU!<[M7QDO%:2U,1-

*1^046,+1Q1'ZK_!SK+_34Z*TCS?";B!& \E.]M:IAG6/=AWG MKY)Y;23E.F6[L%^P[QL-,\L-0_]-"<$@;AC55OO>(*DUPYSG9&WZ!S[%(W 2*QD;A49U=?H;CK>\"+U*

M^X397!PZ1X6:U$PPGQP,J!\NW0S2%F8 WEO)8D6Y/Q"\9&[7-B{MK''EP1# MP^&RARX@HQ9%!R%^K,<3(L MI8@!Y^HP0A(/4N]V7OX0''P5_97" RZKB.#

MH(75HI[^VCI<#NO%5#Q025#_7>NM:^[X@F=<,E+?!/6BXQCU^AC2>1T4VW&/(MB'SN]V8W^TY0L+.=?71N:LQ08C8'[A"R097'KRWY(3)9WI;ZJ0-1-9S[J8BK>H-XLYO'79DL_I

*M0=^[!,IE8K2M9Z&.% ?$-WFBSNO&'>^P4_1T.]9 8 M@X9GHH(LR[!:YGK7MU^_=$%XR74.]1&CENUJA14/$E(@&6K]=98"ETX9^7[Q MFD=.5^*

*4]_JWIDYCNL3XOC"'%Q'JJ0.4A1WDMI=Ui_;2*9/ADRLZ6=G=^1Z M"354\D_;7YUSCA8\^J(@#WATV"*YNU7&+F7,TNBIF4'0*[S7@PC'@0IX_Y.G M09A@X"/9DG*

*PA(7YV/(&WNSQC+Q>;P5[)K(+)RMH76_2\E3-.MI=;'!L0 ML0LIOKYW>GK&%,U(S(6&" S EE9*5W:B^A%W;!04"^FPF\U!#A6?*

*MQ*3AEK442?)^H4((GR_ZH6$6%HZ/(LSA#%P1W0AJWI;I7=7NC7CH+\MD/7\ MD5%;K^(HF.O?'CY5U)PS'WV(WZ$<<^'O\Q(2Z!.\KB-7'BX8PF)85OACW1.N M7CHY/3=ELC??*

&NN2V%'>&?D)! 0B'1MH11 X7K8/P6F[%:]2WR.8(59PB7C M!Q>(@XM%/#L"N"1SZ'&XUXY7/6?Q+QR/73ES>Y4'N?? M? P1Y7_/H\U_]TF:$M;I,KDG].'%8>/-IW>A:P&/F68:?7VW?*

*-L129=!UA^) M>@]V:=!5.Y9KS=()*O1;Q_/OAFR=5%%B>M$"\M@,[$&B^$^CP*_G$S43_EC M0-8:<]\7B&'8]NDYY(_KYC0AH>#A_Q$;]26AA3P:?*

*ZR=&3ME>=!PUXG^=8Y[9_=SQX51FZ>TH3?(^< K-MQR:3CUR<,2RATCU1K"$+V*NOFOWWR,UDN]Y_#!#V#.1XXV!G37]PDJR,.E M<,6Q?>O,F4\!TE2_&@,(,Y9/M\WAU/V>/.=:;?*

*=%)^'16Q@S\\P%GW#Z"0MK\ MZCSP@ZI#.D-+3 90@[MW M=#+)NUAV-^, JHM3.#39M*T#Y?[%&UCT&[SRKN-P"ZT.+(W9DQWUWL=L;G11 MP?>!5.%3T[B$-],X$SC,GCH%*

*=$>ODO.8&N\C3Q#=QO!AOK.](7.]8/RZZ'+-M7'/U$[VK]+UX)2-DZ@GHOE1E6W(2 ^#;K$/WVW7OT69&9>F1<7U$L'CA&3+R M37N@I1"IW(C(I*D[G^^HW:\69)-=^D.]*

<"S)FVN^RML/(LSC);72:NDJ1-;< M-]ZW?9GVXCMR_1HHGT3?\;273:Q;A7VF77V'5K3'0>,7[P_CJKRSQM,4CC:

M_#N"UO'/_9E]0;7J6S"BV09P)4R!F!WG@%@2O880*069:W]QFQG'BU#M/P7R"U\5 M-]E-1.7.5,%-E:UK4^T-SN]^@B9=^LH MMRD2U?ZQ'QPHHGW>UR=$2&BAQZ+5*4.-*

*ERQ:PGV3\+3M+7+;D &(Y58K]2'= M3?>38>_;GS^8&/I&8MH:.^87C[XWL'2B6UGI;5KDT0/%\0DZC..@/^;@SM!"" MHE7PD'B8LR"]B>==S[L;!AY%5=6@V*KE!8ZT1OVM UY"C7ND !*

*<_^I+'RKEOM AEN&$=:,C3BHAEY[&]?^#D.I-MJIX*==2V E36N#,#_$K((^OU\P*GY=53= MOD2BT-\4A73>NQ* 807@;Z4EF2I%ZQ[\4A1+WW$_L"H2YM2"PP>VJA#Q TF*

M]G=0/OOLE,Z4;^%W/3AYJ\Y^QSX1J^U+5]',GMYMOO1-W-TUF;UY/I MZZRWK5XR]^NA?W@ZN_\]?^@7;D-6OA$HAH6,S"T=8BLK[/8V&1ODV_BK;?]*

*MGNZ1LB|S\%&0)2GMLQ>D$887)T3CC]$DR"$S^IJV;/<:N.5, W\NZ-YV\6Y[MST%7RC['NO,@{C>,":H6BN,IET,A,;VM5\W=Y8R]40_/WL5X:P-I'RF?# Z) M)T1^/?E,D)1,>1**

(#_#\CT^YNEW6K),O"QD>4]8@%]DFB1GQAUPVAF(I+) ETA4 TL,UZ^ MCM.I5;AR?.9\H/28TC?AE,O >ZY@E]WJXHO"-N,CD05<%>_,2NT}[=<219/Q

*MMI0@^Q5CQ'B>YUY%RRTAG5825S^'> ",:)V,GG,-5? MLCH\VHEW7,\,=RS?O7!U1-3ME:CS%R'! +?[@CR+<53]P=E$5H MZSGTC>W,0F/=>YVHR823/G^]M#*2?A>NEM@?*

#C$YAXI$\,G8)47:)}CQ,7 MN0IK,:RQOK)QO[5U-+/_]>>)TZU\;$,*;@"&(D')0E@7?!W,7BL1D,-P:SS M6]7F,I]QZS&=(#E\?05]5#U/'',VT!ZHH:TC[.FY>DBQ_FU'W1Y-Z]9=]D56*

M3.//D=[JFF@4AU9^^T%)71HMA/5D4+M$*?$P^W^^:))!5;?> MQ^I$!3K5]MX?"H.(03'/^%!/]\Y#=NY8K6LLSM5!J2^:YD@"3!1W9I3';.?I>-W M=?=_SG)5VR1

*LAY8DT^.H*L$2G>O#=PFWLQ@/=\5ZV-M MEZ/H1(6[;,PV<1 MMDS<[$W\%%VC'SW$:U8C:O^BL52+-6\H@G!W3'\%C'3>7V< /'_E#M++=VV[! M9-*

*9A32^G5@L#C7*OP;2[_73%8JN#'[BKAUSW+P-*#A@,'2D>63"R7ZZ+K52=3E4ZA_.HJ MQ A,0./?V86^]>< 7\2Y##]A!!\<<#(M0#X)'M\8TQ-M^T7<_XT\QQS<6I5HB*

*M>!O64SA784K%6.=R?$?VE6>\@U.31Q6]<,L1{3HH6CZNZO3,1*3(^\A ^A@-M43R \EHT"]>IPOY/3OY..G88IAVM[X%2*CF.4?X-_C$-\4)O=S9X'1ZH"+RU@5*YP4$71:4\R2_#+(:*

*<7;A+' MVKEIZQ6-J\)8W+]*7#M[3H\H;^O+A>IG& 0'[,*IF#P_YE06P@8FL MJ(;JQ+L?V-,>;O,,*2RZ$ZHM;]^P+(^XJRHMV2.7C[1V!@MC6DM1MIM9\I'*

*M!*5KEO19PT)@*^2L&\IVC9(^!3?/?.E6FN*9$C<3NWWV9X]V21!/;&\SG"[C? M4A%?MKFHK/?M!BW N"]Y_=8M:]4RG=R36;K8FX+THT4K3(7MYO%OOM,LP*+W*

*M3]2C#P[B&8"!4+8=6)P!L,2;_BE&@MY1@?+&\D.B"EGCN0>A4Z8PE5:T?.Z[>JNSC6Y*B>?A M@GXUH5>;'8(;4R#5W^7[&O[*+]+OR:I?[C OTADU*-ZZWC^6WXJ@3J\&SF)*

*MO$GU+>+9P*45;HU15#DV[9]<-O9W9:61VD)G0NSY,N4HZS&QC2C_18L$;-M7_&*9^N+)1,)\NH/14VL)8YJ:P3/.8UY(\=G#/(G/S\%MCM.I5;]2^:YD@"3!1W9I3';.?I>-W M=?=_SG)5VR1*

*LAY8DT^.H*L$2G>O#=PFWLQ@/=\5ZV-M MEZ/H1(6[;,PV<1 MMDS<[$W\%%VC'SW$:U8C:O^BL52+-6\H@G!W3'\%C'3>7V< /'_E#M++=VV[! M9-*

*9A32^G5@L#C7*OP;2[_73%8JN#'[BKAUSW+P-*#A@,'2D>63"R7ZZ+K52=3E4ZA_.HJ MQ A,0./?V86^]>< 7\2Y##]A!!\<<#(M0#X)'M\8TQ-M^T7<_XT\QQS<6I5HB*

*M>!O64SA784K%6.=R?$?VE6>\@U.31Q6]<,L1{3HH6CZNZO3,1*3(^\A ^A@-M43R \EHT"]>IPOY/3OY..G88IAVM[X%2*CF.4?X-_C$-\4)O=S9X'1ZH"+RU@5*YP4$71:4\R2_#+(:*

*<7;A+' MVKEIZQ6-J\)8W+]*7#M[3H\H;^O+A>IG& 0'[,*IF#P_YE06P@8FL MJ(;JQ+L?V-,>;O,,*2RZ$ZHM;]^P+(^XJRHMV2.7C[1V!@MC6DM1MIM9\I'*

*M!*5KEO19PT)@*^2L&\IVC9(^!3?/?.E6FN*9$C<3NWWV9X]V21!/;&\SG"[C? M4A%?MKFHK/?M!BW N"]Y_=8M:]4RG=R36;K8FX+THT4K3(7MYO%OOM,LP*+W*

*M3]2C#P[B&8"!4+8=6)P!L,2;_BE&@MY1@?+&\D.B"EGCN0>A4Z8PE5:T?.Z[>JNSC6Y*B>?A M@GXUH5>;'8(;4R#5W^7[&O[*+]+OR:I?[C OTADU*-ZZWC^6WXJ@3J\&SF)*

*MO$GU+>+9P*45;HU15#DV[9]<-O9W9:61VD)G0NSY,N4HZS&QC2C_18L$;-M7_&*9^N+)1,)\NH/14VL)8YJ:P3/.8UY(\=G#/(G/S\%MCM.I5;]2^:YD@"3!1W9I3';.?I>-W M=?=_SG)5VR1*

*JJ_53J+WFH(*9;_POOBE9+>NCH2IOB) >A|KQ RV_0=8K7U+OLY MXM .XE.0P1F7O#B8YZ>NWYSN$W\KNED6/+M1LGQ|@K)&_`?S^?^/;'^30ZRBX5^D&*

*.Y'S!QB3{KOTPB|@OQ-UG&-M_K4^_K0UU7\GDO3;4\8O27VLWM_=.3SOFH^)\{'M4*1*NG.!T!)H;/&<;2M^-MT/JKE$2W,;&\L*3:4-)&A? M,AY\.S=H02*L_@*EHY\;_[\J;*

*(88D0L*1P|KD_@,'D;V7!3&_5N/86PUPTZ%&AT)!GR;_MQ|{S(|035HE^Y19?9-M/AWM8AEA 2(N_VI=_ZCO:5G(I5,]l)I69?]+-M38P;^^-LACD!Z@6%-"\OQ<*

*M7+OEA]N_OG=RGCP;$9/0^2@C8GS0A'?G V<') "+R0V^H_"\;8FF%;U^Q7U-A M8CG^B2,=^EUG+9/OV &1= XD8;P8*4PU^& 8)!&=X]fP-A5AZ^Z#Q+_ 4+1H[-MJ"@-*

VENP;/S)!OU//#8C>>+A4{MTMRO BY<;$Y27@OC=EP")OJ;D3M:N:VEOMGKHLRVL<UFG")-WU!* M"IN<'?CCY:HUI,L80H|+$W^>QOTFMQ05$-I7C96%'I<== +|KUW.+L+Y{DD'E6 MY"E@Y;3&]HQ'1VA95!0XB/Y|LWY,+[G!KL=W\7K=M65#T-#+IWX?L3'W+Y;] M76, I^DE#,"IE@&L'"D-?#4P>Y(01+/.5*$JL_,VB^+FZZ|8M MG4:,9R\OZ(XS

*'{D1S23=4Y4H@|8\GB'>?}E&N_1 VKG_R"(0WR[SY9XL((M>]*GP>+(C"B]O?+UD#-,N/#N8$"&PWJ8@>[(\{3(9L,0KLOVP,I3= MYEC>(C4-*

8_BNXSY1%C^,I=PHCI+B#6[7$[=OMIX@R3%O9A<+?^IW83B0:,8 MS&8^&MW1QK!455$'V1=,WT4R4,F?!W"@P9.U6=E1;U>G]&{J4FYG6\]%G&GPSCS6(0",=JP#J=H>BNA

*M<>NL5X8*Z]HQ7:-Y^4P49Y.@?NDWRMP^^O,!|[9)A11$U;! *3?03'H!MDH M\ FRT^:,V\I^;8-*4X'#A0B' |=>|8U%:UYHT%45$J4WJ,"HB @39 6&UU MFG0B(M($1+= !*67" @H+=($1$3!/=*,!"8=$CH$$F])-QXYKWOS)DI_,?. MS)EYRX?]XT-"UMI[K_7\R_/L9PMH7(\N3S5VRR/H..0A V>,ZREW4VL[;$A:.%]RPUK54 M-#*7T.P6TI0869_1RWP*

!B4(.2A$4FFJ>9_P?-=Z>P2D@L/ABB)+U\5(=;\|-M[0@N9!41,7)C%@4_E%:F7LIDZZWSAJ4+ ZM^2,I=I/KP0@<4,T,E>0 MYS/C>QN|*

*<+16SZ07;T<+*A5>@S26=?;)AH1/^4M^3B|CEJZ< L+MBX2@5E'[YC0O%%TQ M)KR -_*V=P^,H8X"4T*>9NU/LU;]M1OZ1V.Y;K>C:MCE*$B/Y"BX6ILR6O7?H*

MH]>JHM<6Y,1Z5Q%;T!1^_NL&-?\?T1)F8 ZN;(!8@<+,C1#B7-#^7%S "N-IZ8!) M6T-!9Q{GG&%@@#8J5>R/_GDN,H,-@7LBQMQ49#%M'PC^'LP6!TM/;"BG|F(G M??G^VL#X:@*

*S%4[G'7@^G2R'ZX^6$K%TB6 =>I0W|\!CC;,_)I'_V56;'_'G-M K|_'D,3:SX%_(8;$V G6C*M:T0M:^^\F$=/&\|PN8&=LKB_<4-9KG6?9+=4Y M4=K_,_@9HV5@" PC? IPL9?*

F(R@$-3E@R6&45^3WWAX/1\;7&3&O6 M@KS1"?=%5IU!=&99GGE9%EA-NAYJ<5SQV52)A1:VZ!#_$7O5T'BJL%'1 MV4 _,E?@>52X@D6)3^CJM.IPIU:!S&')BKWX)!4#*

PWU4.G-K!U#3WHD++=M M'7L[;9)0)^72Q@?_O?'Y5 9RHFO)I\"(+]PU1=EA:HML!UQ>]C^/ALY5&@! M?UT05[:GWT',N:-)IFP%H9_%P!:N6&>3V$D4L? ,RJR8J !Z;'4*" *$IG"R*

M%OY_GVAOB!54KANSF7#A-0A8XP]!M!<("KX\DI.%%,Q4-R@|U1=$"!IKF)P M80 [_'1,U+1=Z4<+1VNI=PN\J ^G8

*M;U!1.&)$6CCI\=J6Z++]Sl_X(/-6QHYMWO1/!]DZU\a_2:+$6/KGA(*M\M5]BJVVQOOO7SZ[_!=!:'ZB"'3P< 5%'Z M46R!#<%>-?*

*G#H99,^Z1H01#+GMT*X<81<#@#%>(42D=%C?$8GB_]Y'Z MQ&V]AGL98HNHCBP^_0%/P:=]$-YN&6Z25 0^C^#442X6\.6VU50/$W-?I*

*M^!.LL5X^%\FIO$;KNCQO3Y:$WH+\@NE:X-H&$69^&3[ZV8FE.KH4P#S;_, Q!>UVP&Z*U+#992=_NGOMFC^>#TM.L^RB6I%3 M/0O@%BV_%954W<9O)-*

.\XTVM2/7GZV_>&'3^^J:V79IV_%UGFQ?B'.P>3D6$ MFN4310HZ/6D-@4JI 5="%RZGT=#&<{@W"6E+2$9'Q_7+9382PXNAE2)PR4VF M\,AZ9:FD8V5X\G]^&>0Z*

,GV^R"VY10"F\1&'1/N--]'/2&!AG.H_=VJXRP+R'2'(Y-67ND7{^>%U2M!\?> '-N<F4)72[Z,GX>"5$1P_0E ?*\GA&^$X3+,I(D+ZI)TR&/U-MR;#&-,+ ^- DR1F;&Q2!SQ$]8;*

*(H+EFK!#"%Y]?C&GXIVUN.F*Z=TJT_4/"1$0;EF2IN5J8I8 M^4-)EP*&%+RS^(.U$!P2ZCE|ALJ@7;!*7AD\A,|+2&8G,YYG(.5:LU_0 LE5EA^(%BFJD:|%%Q@EDP?&Z%WGC9%|*

*M.$VNSB4&N;=NJ-{D'>33$ENT92H).<_C]9N^]\ H3K7PZBS8D)F]*F>N!"#7 MQ#)ONB;D!ON>#]>[R5"U0##(4A.C,UFXL/VNOC/9T,D-ZZ80(Z PB#A>*

*M5=/I@@\U7LB2[GE"BXO.78MJ=*GZ&$@_;:>2DD$!E3H)^%#@@8UWRB(+*\ M3P0O|",:<<6R&Q$%,(s\|#(6 !0AA=*.*6OT0GAV3:D6C$P?]M@&L4S^ER|< M*

*/Z@MV1"IX=;"N!_S3HW%,^NA]V!TG]+\"F2KV1(/.<^8M2#%B<4&>&_W:WS M.*E4*]-/7G@#;_]:L#Y\^[4?1/I:^[_]EBN6OI:OM/|.WABWHQSH+M]MVI>#% MV\FD-*

K)AD!GYG_CK@55FA'CP34K8NZ043@'!UM7_=!K84&^3Y<$K00!55S&] MX(/:,7[2T.9]4(;MPK.\1OS=SPMJD_0"%/:]V\Z)Q^GJ!"0.LY:|CTVO3(O M;?]61#4<=LA5FT]U!4]B7E>E;:*

[9/HI/^@;SO2$/0UAFU0;?3"HX MH+_G8WQ]_OLIP.[P^:|EO9KI{Y>K*.]Z>DCC!WDC7BIQ_0 6D^*CSCUP),2-[M$RFB75B/,K=&ME)F-

KKV5S>#T6Q&R_9J_,6#F!=YNRRC|C"FBBAND:;8 M8_"Q0[5+4]C^^11.86.#='#0[^;B2X:)WY0EQ\N1D:9:!Z.UC.9JKH?MB_TC-ML?"A66-*

52/7&=T>%I5"9CG+7O{|&^.9CU1'(\KA]7/(E9C(A&_C#)U[]0, M..S$F GFB=AKS$?L&,)@CB%M])8=M.Y+|S' P M/"#:[__V#?I?|W6V 3X^UR[:G"#_+++]J7<*:%*$O3H%*

*MT!!5<++|P!2LTEG,.8A7H,27OV)|R.U@%$M==5=\U>++DWU6&Z@XI(H8.4;F/S M'!3$&WLTRT:*Q42I=H&LNzU+T;MOG_6SU9/CE>BPQ0+-N\=QGXV*

^E30.L=F#6]$F#)\83L*>KVGE^*CJH)L M-S.L.YVPUSY(B9?)L[!H7;K&?PI@NC+,LG](9';|@(A7YRX^QX5$3TF[,-^+ MU6K0ZY.@VMR9]9Y

*QF'$P2!S6*$AX&7IWT|#^A3$)$"NWRWE6S*HQ.C_9VM M^4Z",SY2K8#+;X7""#?#6O+K'U+;H>6OO*X"K\=:6]#\HWWGBB6?QK+||>>-.M3P'-C-$F9AX&KZRT1S?{J=:6=5:A*

MRR]IV-T#&>"+ZVDW>&3QF]WZ- 1'ATX\'TD-V'O4O0UVC8*8R9<_-"D_]3. M\1Z#PL?75%P;JL_O?/E!{@.0:A3WR38@534]E$+%<(G3'XB*.,1L8&W1\U/*

*M.KWJO^P[E|",JA9(35P,&%Z T*X%7L0MIW]9K8RPSK7'B30TU =<8;,&"Q8(MQJL+)D"HUTRK(L&4Q<+DXSXOV)P.(*H#6E_CF6U BRC+%%3|3+3:74#?S.8J M??*

22:3KWCYL8OL@ ;^)X)6&OT,Q+PR7*#QPXI(NR?WZM2TN25QTZ ZU\&/O MT.:X2"OJ)#9_Q_01V6@>GF5R\#ZO,B6>#[=G7#Z]%T,GU59"ZFSRZ;+|Z+8@/4Y"Q.?C1*%F,+O/*

M,_3DG3 .5B(WQ+?31NAGRQ\9WE#W]YS 4?XOHC*HLSBB_U-MS>TTSQ_IV0Z<,X?1C1M21@\$$HQ:4R>=1$0$*:/;G/P9/8?TH,2,S *5]!:0 M(*,V,<72O1\C|\S]Z);<"2)_H4#6Z,-*

*PHM!#G[KFA!;&-&DL7/P4()%S"O@9 MXL7+0A=@#,YF6D|8TY'+85T[2"4WLI *"1H[%^[OHW(#RO^.0¥J^H5*3Y@ MES]^24V))K8U&<.JXQXFVC;#>?U-*

RJTF'H@C9'\.!VB&EF&@-(Z?!GKX.II MO"Z$856(.7XS_XQ6KKCF0[>XG1.|G'.&8XF89Y;,B">GQV.IGK.P$0^J^+(M65$P %9:\W8=982?1Q2$M+RW^=]BW_|O0V2*>2B\9?*

3WIY^QYY96$M[KSJ7DLOV# M-7##MH-+;3T\=R;V3'|7C:IDU=(!IZ1=B]0>FH|ETH:)V=,W'$I4TYLR("-A-(Y M$_<#-V%L9,CG.K08U\R&|

(&C)RNG'^[H_8/\8+IP:E8D.FU)=_;)OOU0 M"/M.DPGEFIFD_%LWALUCQN$4H!HPYNTVM1O ;>]6<6P8OF1.E5!Q_A-$>|H1%RO2/W2VRR, ^_&6;8A*

*$\4(R%AOO^I)YA=!>\3 MO|FVLIZQ\;K7Z_2B3L#DKSKC:#I&'Y95Y4AG9?0&*D{:9>WG ('L{V-LA73/XREX&4 M95?:U,L<"|^N?.OR#Y\K9(H.,?+_)UC"W&S,?*

[>X4$'(MIK'[,,W2|%?|H).N@6U"F:C&DNJ3 M'>&MXW]?!O "W06^]_LL'3Y1"Z 0]'1-WA"FDH)[#8BM5*5];B:* A"Z2=V) M6GCF4]4,!H938\66^!';N>$!)Q">UV4>'S>?9RQ ?*

OPT&_:/$ M:N% .%O*5C^_?/WM/3$@!!D.%5&96U+(K%]%_%Y\+&EX9<)XGGQTW.X>'-S+Y MF+76I:QH1%Z<(IM-!J[MKGOA=$8X%V$+!H1*RHCOZPUO:105B8S.[K0?>&)T"*

*M>$"F@/U)89_D]7_I/TNZ^(6A,?+\)2EQG{C\K?,1[4U!9WL?LZ7G"LCMLMDU\AJGT43:Z-'<8O0;KW%3Y2R M+;?^E! .1KE[E30A*APK)JL0O/YZ86)O':8BIH:[BVB,>7|6I&M>'6W(?=MW*

M0YW?R^J|(CYA,9-&D.1\S+O+'T'GQ'|=P!G\Z|<;.(^Z-!QO&>4(HR8(U5] MKW9A7-?%7 1ONWW]>I0Z@="WU.5'\?%L&.\HLF#OU3%IDW-1=XUT*F_(>RYB M%D$^T?*

*NOS*7[S&XCQ-*U[EK)]4[VG@.2CZ9-Z-M]'=Y-$C?;_ D%!2|;CY&OD MD0PY_*|6&0?0;SGK8)3XU2'<,=1S@GVPON5APB-'=87O|3O*<9K";#@*WZP MN#*N%*

L+@=4T$E33N%FF[+OGZ3XROW_SD:7_SLDTO-4N7]O@VF3V7E=TEG M9Q,"5XP%1BXX)2=G:#,S$/8+I(%L]F2NF.)R*;/4>A;_M?.NV-5M8O6V]5M.*

*MS===-5'%T35INFY8%V;*HC)1@O=#C63?^JB7A8VGT$F(#?@HP0CDL$94QFKVN M2GUO3>S7[U3^\/BI\(0BVUL6NI WNS.ZTQ_&3EH;.UB/S"N$:46.[%%A_ M(/O]4^@^2*

IU;A5ET1QYLT2__M_SG+FPOBI>)>|+WM:C"^23NJS3N4<4%HW_M[V[;%6WMOD)?\ZH$;C@0&1JR1*E%[7IQLPTJ,2V-"Q85%(L4R_#<7D*KLWM|HPKQ2SV1) M#P2OA-*

*89#@882:7!S[-@*M2N*%_QFXBK^+Y}&'<*N-[&K&N6]!];#8%0\C0"U"A 4,6T(Q;$: BQ&RIECK36 M/!6?E"7ZA:NG?ZEH!^I&SUOG(6=L'}PCY2EHXXH'OB'X%/)]F/R)<;I?< MB.#*

[G$5?:CQGOR'4R\!'<92[> X0\%G9RF>[G14")+*5^"3KRI8.%2W5?[0] M%WS+*7OZ ^#P.DI@OW*A/$]V/ 16OCGV:0=7K&30^AO@TGW@7[;@IZ&LSA_)3S-

*[9NI4[.F+PG6[FO*_4^O_E_0K^ZDCLHF"@3@A1JZ:D/#\SO687-M"_,XVI?W 8=+*C^O>YWTQGB:\9%UC]BZ2>>#:#HU["=/\% M8N-M7#G<^2]0Y$*]!*

(@2!D20\;O>%0:8%Q0851FL5GB_@<<>> FZ+@3TF|KKF M$9G2O_]QJR;,K)+J]EY+U\O3]>_D%+_.0XO@'&;,4'WAP-:>852KD9 MU%F*6@8O&B*

(%XX';$IT+2EJB5;^G1=X!#5=)9XYL^BCQP2 Z6(|3%+|`EK9'3<+H M*SRIQ2X5;6 K@L"$K?4Q@G-HRUJ8S,1B5I,4X6T\FY;*+_KE2S ;SP4JD5"*

*M*ER;A\|=5G4A:'@:8IS2WII=PVQK!0,A_3#9R/G&X4;&PBIN6329!>M1JZKL,KK^C8^4QS5##$P7B?5RTB.)P)'|KB]%AGN,"A'}E. 7;C]'^?V\|2F$/P6C'0%[\^V?O*

*MCHY\.!Y/*HBJMT9H7'''*$*R6LA* MG'4,QU\DK'3]Y"O$P]=G*^.))DE=]Y=F/7AUC3@&CVP;!0 7"QO%W)%]+4@VI[+4MZ/M4EE]?WF^.+-]L'O\WR05>9Y?Q_*

MY^=^5CYCNJN&Z"NKCI_57@+2K,N!VK\-:MU-'\AE$;!@I:%/JK?9Y4XP%+-]MG%$:O-Q-%IL"]0_5;?CGNUPS^9)X(Z)QHITIB@,73/E5+!,K663'#U8N5TA[IFXUSO/1'R'[% .(<-*

*,;M=I*B[R&?)02]&AC?=/78-F#C(-MV?LER_<8[48Q-AY6B3;WSO]IL^R5^_X->1[:.^UK1?*&09A"487UT_YY<"9V MD]1B[OU]TX!YN4H$K=#5:L@N!2!?>*M?+Q(89L!-*

*BXB1M'TG/LHPJW#%AVLROF">P?KX*N ZXN_+4ICH1$U*DH] MUS$;(.@ {6-,}2$@D"@ZI,!A(\MF>,UZ=^L,]RD@J_G1\U- PS4X36,|.OD? M6@[B"LB7B5<&E\.Z1IRE-*

F8>JZ[B[|F!?Z?TO4(9PS(NC?K3@Q)@\@&/8: M8"2A?O6RBO(TF5_TZ5DN->2=.\|UBH(;LLF7:DX!?#0MJ./|!@H!7/@"+.12

*MQ>N$PVP4^;1P5[ZD&$6*UDM;\R0NQK.W/K&*A1#EV0SP MYU+G",EHZ'@@WV=-=<'?&0LRF+?Z5;7#HTS[FQ"_JUI,Q\/Z M$XK,[4UMWK,IRP1\ZG*N2:")#M&/QE?'*

C6.MN=!FRC;$Q6B>"_A D^+]OK^.MN*RI2I+S:&/?#UY3WQNWY0_GP,]IZV\0<1!&&MIP F.Q3K?G^H7V//WOG&HH1V.<#QGW.K(/*46]"BB^CWQ03HD'M MQ>0QU$[@7=@^*?

*L4L'IGX#P,2W5RG:A&\)[7QVNV!0I%F8Y!"0@]Y135C-&< MYU?>YRQ\W_SF-4]'D2UCX\VG@ M0.U*U I^+50&AY03 G,]/5+O(S0(TF)7<#ZMX#:.?*

*ISU,T*E&);BA2F/UQG;$Z5Y\IEKU9GG^ MAF'LZGY)'?F2(=I)LP7%"65QM?*5.C^GKOD^Y]6-%GKY43P5; .4Z,ZW0LRI M!)]P4&+99GNFS,"(+%UGC\/TI8/,L>"_+%-*

!+R#RY233%[7PZ6"_,?M^]WO ME6$& ;QN[6I.KO4A?(O1WZ"SMS\ )32|'?C,%$8'][L0A!O6P9M76EX9A4 W4<]EUK=7)D9[\@OF6=O:@-:7BX8 %K83[KF=V1-

OJAY"I!6 M)2_ 3GSO\PI^>8 |_2X[R!B86AWM:.N:O(9T3[;)-&;:2MZ\]V@ H_A@LJM) M\GQC/0F%LBN&S^\\T_"'2_6M<"MG$'GC=!EAU4H4W-2%3 M3P$NE.U(ST9N*-*

\F<0Z.PIKTRIFJB2;S3HXO8ZQ%/AIXX[QN1UR%^C.'%/8 M^\P#PXNX=W:0.%'?!*C!'|OBROCQ3"P_U;FOB0:ON('+X5%^SO9\9V'E=M3IO/^;EIG\5QUN MC=<)D 4XTY.CS*

*V6/RY,]4Y.?X%P-/E>R;?4?W $\B-I)<5_ CPIHB&^JHD$ M:RYZB8%EHADTUSO.UF&[YW3(>$)(T!\E"F.?] *OX5P<;P8L1B[/MKD6QE[MY@N_N"#UMZ"T-#U"W4'\D(>BKI-*

4X=VQ."XF}XO0%AZ<7)?40+ M(MPT^CAF^0?2SC0'N]OEHS0!>B+VI)&&OD]G=4[^S"KMQR\69WH'//]@-11 M],B>0?F96\R3UP*<@1K;6S,!OZ(Z0!6]$9[H6L"P\(&B:R\,31A-*

*7NV)55\& MS_VZ)S_P4\8S2-$QV& 9^UJ=R49G8L')LW=U.]Y=BG]Y('335(/?.M&]]I"-M%72R"#%&09=T%]=ES*$Q'^2\7? E8 A!_T^YZI81G\|5Q3) M:-[;H,?!;6?XVR16ZBM*E5 V4O|*

*#V[C|"M&MX5J5A0%XV M%@VHI[0]QV*EC@'M2&7.'G_]"YQK?C94*[GON|&U:$G1[[>%X*?:1]D=@(> MC-0F%MY2K1KY66.DGW$16GEOTU$;$]%T";]OW08&%L7;@\<@=GI<)I*

(AKJL MW@8MO[@.W><;X)+>N 3;.!VYXI-V^)'QD..?6F$!FO,4CLL|PXL!B3OFF) M;9]I/D"TO=!UQ7BFR)N=2<(1K;6S,!OZ{Z0!6]$9[H6L"P\(&B:R\,31A-*

*7NV)55\& MS_VZ)S_P4\8S2-$QV& 9^UJ=R49G8L')LW=U.]Y=BG]Y('335(/?.M&]]I"-M%72R"#%&09=T%]=ES*$Q'^2\7? E8 A!_T^YZI81G\|5Q3) M:-[;H,?!;6?XVR16ZBM*E5 V4O|*

*#V[C|"M&MX5J5A0%XV M%@VHI[0]QV*EC@'M2&7.'G_]"YQK?C94*[GON|&U:$G1[[>%X*?:1]D=@(> MC-0F%MY2K1KY66.DGW$16GEOTU$;$]%T";]OW08&%L7;@\<@=GI<)I*

(AKJL MW@8MO[@.W><;X)+>N 3;.!VYXI-V^)'QD..?6F$!FO,4CLL|PXL!B3OFF) M;9]I/D"TO=!UQ7BFR)N=2<(1K;6S,!OZ(Z0!6]$9[H6L"P\(&B:R\,31A-*

*7NV)55\& MS_VZ)S_P4\8S2-$QV& 9^UJ=R49G8L')LW=U.]Y=BG]Y('335(/?.M&]]I"-M%72R"#%&09=T%]=ES*$Q'^2\7? E8 A!_T^YZI81G\|5Q3) M:-[;H,?!;6?XVR16ZBM*E5 V4O|*

*#V[C|"M&MX5J5A0%XV M%@VHI[0]QV*EC@'M2&7.'G_]"YQK?C94*[GON|&U:$G1[[>%X*?:1]D=@(> MC-0F%MY2K1KY66.DGW$16GEOTU$;$]%T";]OW08&%L7;@\<@=GI<)I*

(AKJL MW@8MO[@.W><;X)+>N 3;.!VYXI-V^)'QD..?6F$!FO,4CLL|PXL!B3OFF) M;9]I/D"TO=!UQ7BFR)N=2<(1K;6S,!OZ{Z0!6]$9[H6L"P\(&B:R\,31A-*

*7NV)55\& MS_VZ)S_P4\8S2-$QV& 9^UJ=R49G8L')LW=U.]Y=BG]Y('335(/?.M&]]I"-M%72R"#%&09=T%]=ES*$Q'^2\7? E8 A!_T^YZI81G\|5Q3) M:-[;H,?!;6?XVR16ZBM*E5 V4O|*

*#V[C|"M&MX5J5A0%XV M%@VHI[0]QV*EC@'M2&7.'G_]"YQK?C94*[GON|&U:$G1[[>%X*?:1]D=@(> MC-0F%MY2K1KY66.DGW$16GEOTU$;$]%T";]OW08&%L7;@\<@=GI<)I*

(AKJL MW@8MO[@.W><;X)+>N 3;.!VYXI-V^)'QD..?6F$!FO,4CLL|PXL!B3OFF) M;9]I/D"TO=!UQ7BFR)N=2<(1K;6S,!OZ(

M(6_H$05ZCC^50AV&Z]4[HA7HLS9^_5*OK7!D[)KGIEFBOI@P=3Q2;P%O$9Y-MK,8=1M:KX[;U8GY-8U@:SK_WH6OKD@9T=0=!"J9#.P<*HH(\[Z!5,V)Y;U4LUD9RI;XP.M++80#-V6TE1$X=X134;K[W075FGA^1\: ^:?,YU4_.3W4%2\5VRHP.HW[T#6 MJR)KR@ (VE\'ATE#1NAUBO!LE>'C"939J/0 9;LM7B=*

M%@0=4;7T5<$OMZ@X[%#O^A3!N3WHH;,%$F:.SXQI8MG;TG7;>I- M;GAI$P%D;UIXN!$CLQ3-_6VI-*\/'$%#>6W'"%W$;/22C=A\R*:.,N=H]:C MX\@#)_T#*

*{ISM!.=@C$L=KUVVF0:L.S@,9<,VI\H#I2#,_VO@\UT2(@U73(M-1]:@3F2:GG:]HRHXY{UA_@7!IZ[*$F0!'\'8*QIZ;3)M.*'6-/592E?9=+!QDC30SZ*

*M1W/R"WZ<&)9*KBEVW_^'4H2|OZT406]R4BM HN6LT^V8P6<54@BZW@"VR1)S MD]_Y/3HWSJM6PM*-1NO=G7)_'ECRPGOT[AP6*7D=4Q/[D0],W?)+'&)[*|T M]*

*I$-32V<9:H13NM\XGSA-;;;!'L$8>F;~_]O9E3P/C^JB,+PWR.'^\2:FU;?"!M8Y9\E?LBKQLC03[TH+2P4 =OS%D>I%+WK!S=DUE M7%;*0*(-\CG...8]95-P'$RM7[H'5P#7G@)"_*

*FO30NW^E6@H?*B2:##C_OP-M14_*&O(3#/|C3;K#&!7X\.'U5&@Q>N5\|80;O5:2'QIC9.IY7[#,5;FM<*S% M(70AJ9!*U4W4 F2B9V$[.$$E?D-W3*QD11.KA\4-.\5<,(R&YG])".I:29(^*

*M3H#0P9H,P(M/<4 2S *V6OX%"""/%P!9_-X(H=R8*MCI>=<=MC^%"[[F6;#VQESS^\N0Z57M\HS<6XY!?_U/R)?5U9%CL^HK<5:AT](/ M:O<-*

*GTJH"WXY\U;IW"D@./P!;GL&&3UY59+/[X,WDPQ?G0("S;V18_)FQ[^= MK*JJ(JR"F;]T<%M?BCP/H/A^Y]U B=\'?EB^N\ETE1*A IUFT*7(^CRQVGJK-U=[&,MIH&H*?>|.,- MV-*

%=ADS%<6S!R0M^.QLGAJV]Q^FJ<;E-\3HG HDFJ+EDGHW]V+$Q+BY(C)RS: M^'G(6=<.]N:LH+> 34)(88@4!")#CQ9. 0PAM&=#SXK0UR*I7W"S*

*M7@7T_6ZGO@DXA/^&'W@WX+03O?%[84"Q8$5,=B[2;1,X_12VKMQ\2E/T M]ZAV-/RG3:4JM0LJ?LOC[?U\2@;QURVG\0U.GJMA*Y<&-#>;,3'R"Z-)*

MS>>6BV_^NNOP&W/2YR^V#L0)AH3?CA22/G?O/,*:?89Y 77;RB;\?P_Z. M5V&AQ4;*^_'QX8;>D=Z:Q0^+*4>OIV2,S0:_;(-[R!FN-5(RO'*

{]^0Y5(JYO6AP.#'0'#;QX8!.UR.%=VLT#/F7!+WZ1Q^9XG_TV7VP=^,D,]N5| 6WW65SOTU5L80_W")]\0/_@8LA%26FO1^:*]N MDM[W&5_8-*

@E5>ER+,$@L8+>3OI#'I:C,=5TWV?.7"[2/?ZA\6#CW'WHK3Z[*3<MEW/BG5\(CXYB%S9M&/0 F&.=#;1^>P5KT?<4)MWIP8TOO_>%^?%QGO+B?V.7 M"?ZX_E:%-4NA$05%2?

*I9E>+7-QZ,+|%5=SCGD*41OB]<M[^S'(\VX]^F#,H" E&4A-5&!BD2;4-5(Y1,D%PO?JK*-V#=#L@"7;UL%01[Y MTR%6-!E76+7$GTLH,2*4IH^]PX#"O"VA22F-*

*0:*RU='J#*IE2!HDTF_-XQ0P MR=869Q9E85@$5;>NNS%G5*ZN^L:77?$B]W+%GDNTY9W!.S\U@MV@9X(QVU-M8S9W"J"ZMR&4")O]/EBPPHH\U!@[4FLMQ>>U.%GNW-*

*N&BN03P$]!8E2;#W,U.WOOW>RUZB^2X8N5T.N0*IF)$0+2CF<2 MS-)G F&:+Y4+6MC7/F6Z]+L0U$KRS1ZU%W%GD!(##9>)?H.1-EAH!9:KM2OZ MR&O|^<@HV5R%T.>AM,+\)GFU@M"68>,@>RG%X&//D99%P(X.+EX. MP@R5"(.@K$0KS8,YUA7KP=>K&:Z1G-/26WA_D:GHJ*LDI,GCJ99Z5K<>#/D MRFM_.;2!?2!?2-'R,U SA!N1Y54(FP*

*SDEF7,&'F@YGFP0-L=T\!;6F)W2"T M BE@0P4\2;TWFFV18)*Y.BM2.?4C!IN5\[OKI"1[22'#Z[!H*;I9:P==4 V6 M)?]8@D%-GC997^,%"AC*G@*\(#DUR3-2OL@HL"TDW!*

{8DUN<2]=R;=HQVBW M=9]K5Y>7. #(?1#NRZM&K-M9OE>{]U6]0KRAWM-]18C-MN!5*IG.SU!#.1 MY:LQAWZ>XY-%|=K:UF_<)-1_ZLZ-LTP MG*<==6 GJ&&?1! YIA=6-*

*C(]JX@[_>/ 2EF 6"HSZYN7YRY*5]L ['E 9\0 = M-#(I\%R<38#J0SRDI3"H*?&%7&Q:V/@OK0[0.PAN0?048)-NK?=^FK)U3-FB*

*M%U:N3%@4Z0=US*K*Z@=+T+]F+!8DO;B*9>E=0Y'/8,5^,N:E+'RMR3DRRI@C M,-;#F%I72]ZU@8!$S?F:NQLI/ >?&"IXAW,\71FL!?TM_ZB$_Y#Q%/7!YZ!R3WYT"5$1>/D-*

1_BXZ#8(WCH$D]HI< M<'$25T^EBWZ@3++<*>##+FQZL"?:MC.|:5|\XY]>NVVA6-%1(Q(DR1 4&J M*%5*+!L0$"|$Q40(2 = H1$40%I$1 +T'$[ ]>07]3WGMH(:1'\3W?

M./> ^YSOE/=_=^]W[WOO'(.,C$%^>9XUUYS/6L]*]Y&?C)Q!!PB:)S6C+Q8| MST> N4=F6EE]ZA=1[BD8P^[>BD0AOW0''PB?42D:O/%58"8^]RQK/Z\^J#SQ M6EHI]86P$[\&7

*RE-W.2D;B=7QK/II M?;)O5)YG:SS_1#^.J_-Y9IKJN.*7,(/XD$.-M(8IO?<#L&=6G<"K;@JU*P^Q MW;NB4$EYN9$AI)I: 'Y?*ZBS#C?Z!?4YR.O_ E!+ P04 " "]B&Q90;9B M@&8# !L"P*

*& 'AL+W=O)- M_!#/?SR_Q.,9K(1\5Q&BAI])G*JA%6F=7=NV"B),F+H4&:;T9BYDPC0-Y<)6 MF406%D9);+<=Q[.3QE-K-'CF9G(T$+F.>8HS"2I/$B9_W6(L5D.K9:TGOO)% MI,V$/1ID;*

*($^ZF_93-+(KE5"GF"]N$A!XGQHW;2N)WVSOECP-|>5VNB#B>1- MB'-B'EF,VA#$&VB@P:I8XQC@V0K2-'Y6F5;LTAIO]M?I=$3O%\L84CD7\ MG8O-/!?]7F:/K_Z\'(*XQO_*

*M'NX>7!ff!<#9G

7PT5T|)!@[ZU=2=%U\-MB'U>&-"YO4$M<\[^9]D7SYQ=@?-%0K-VH=)8?-X& M'_TA/(!(;_]JW&A T76L'#^*VA#8'^ADD7OTNM'6+!&3]!,0lLEJY.=XU5;?U MIU&3IBK"C,;IO):Z\?2';_# ^\S3Z$)P# 1;'+Q\?TI5\2A?O:M8(:1-;I#, MXKEX-X3]5MT&-EK2PN^;!M15Z%,08\9+%WQ((OCQ9@8LA'$1|)K1(XH+$^0P M]9ILA%2YW*]BKYK*TY=&),Z,7/;)2KL7N#Z,]76O/3I#(,-QNXE;RN/^&P)-MZIP3W>4SG2O@V%FOMVFF>;VVR4(3>[;7?R4Q.GQK13MO,O8,/T8NIFEOVY&P M#0\8,Y.5/B!2.36#A2^FIH0TI?-#VR'%77T:ZJ!-WQ!K.4P_/9=]E=U2VUY-/H&_/2YN8G-/1Q=7-S2MP2KT#GFS0%[7 M-(G!52LD4H@CN\0,>)GS:^CC MV 3/;.^TB$!9"2H_T,C9#Y*;@-G#L>OZX,!7U[OP\M#@;DZ;K8'#3L<%U/C* MP&MQ>G%\;D_NO+98/[LF\I ;93TCG7,_DO!"X7!JXR"U$TQN:IMQY94C]X_MG]]B9\H--J<7M%A8Y-+.FE,-H2*:D/%,2I,6O3O<1&*VZ4 S@PKI-$\4K, M)SEB)L-\)P; $&N.12 11UIFFGBE$P$>_P42C^8I=*&K@ '<8!97FE&|)P9 MT.W(>()]5 O4#^4?!H*1M+]Z+Z73B 8US<^!GOYC M<3/%0'9$V-3PUE*? L@=I*BA%P^BU?>2#XG;;)*BBW4^(I#Q(W6)'M@X M:SNIQ/A+B$#'PC$ZR#_76[3&Y$2V^^Q"(1M+8V08^]27G*_%9@'8V:B6M-QQFJ43,-Z M3Z#7''IT@$^KFX=H71R(TG)7F)RX_C^U)|(AF"2I-]NNX*EP(2,N(-$E0^9/MQ7?][4WD1U/'+E|8Z>]?><.;(*(BL)W,_(LB4%K]]SE,6ZC+8P%CE*2-DKB ML.EW:A-7]S%6C[&>"NV%Z'+JJ:4AL.F5HQZ>P>18'M@V@HVG/2"P2*&)2A? M2$]N/=AW;<'8V'?/L>?)N0$691Y&:)D)V(_2"A'KZ OK&ZN/EX,+Z5486LT M=AFEP["&{1],=/-XY-W<; JRY);6F]5Y4VZD4Y9P0D$Y,L#-6<;7RXKN+;5]J MKF<B:7;/RJ4^$H#M9518K&L\D)/H M!LG$PV^388C1T20C-7 ,A&3B^^S,8.PW9^.9^^MWK>]@9I.2&G'%%1XT$;-] M@D? Hf8#"TJLH\KO?D*,Y^"6ZU@1D(A2\U6%'E,M_;-]*C+AM);U5'<@H?E M 5 &,Y=DA7[$\9A&8KB"G%\MVU+&M3/VJ64GZ?`]X&VI49^V,$G#+;!%MNL.CM MA!OQ/*6L-^76N*!XA[2(!40 TNG^ 8SO(*1F]KW&Q.C=C':2\8 M'QEW'G.3%LB.V9WSK=V"<"X*D@)HN9$(KSX(XAEOEN.4B= MGJLSMLWUE"F7]68J_2HK67%8CU#-JXUAWO9:CHH*K> M]5N;/K[(#Y;8# >|[%7357=BJU;KL)/ K:=1/:3X=.<-81YR\1&P>+=/?[@Z M/6>KTX0S@*^SW!C-.WKE59W*_]JT1+.8"W,JV8D_'Q',.6UU%Z0*:JLX/.H% MW<'XE3HTS0:'X]$ +G>#]]C|RL34_GKI/X3F9WMOX?\3.^.B]<_KSY%]W.V$ M^']W-G+, P&G;Z_Z2,ZUNSI|>RXUNP7Q8'^*.%2DR>>1 .H/EB+GZ;Y38\@"_M$;KQB.S(GF%DO.%=V4@_--4- AL\:RX'@2%;ZENL$^Q21U[!Z8BPB M.AUPGYK@O(9 O]5M$ S[YBP_PU.BL%]AMQ)()/OP1!3YBZ3(_^WC_\@^#H-> M9[Q_'UD8[>PD)F@^HMWX&]F-GUU72B&^K7TA@K,N=P5#8Q=URX6",_'KS?G9 MY)IK)XI) OMT\+\! G8U]@<25B['ODG?UX@6<_FAO-+5>INL0S?!S1"YV M>SQ6ZT0;_W@K,S? L_\E*1O:'KAH2KC\`19Q(7^5@IH(/10'IWA4%*VH+ M(>$:.DK9Q E-@+E+%^?@WM.BI8#7%%+/"K-Y= H(I12Z(9A)F[W]#'|OWDDO M+@'%4H^7D*O4G? (J0FT2^F))/OX03;>O>V:4_\0$YN?1618N.^BN;3X-.58 M_!7MKX7BE)1%6AU5<>%[?Z8!JE['$+F#$].*!L?BAKM-$<_BB$L(N:C?S=ZQ M;8@/U%1"QUM'|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f=[K!NT*<'NI,_"-_M AS2)':N^9IQ*W0MPAXM]HO*.\VIYV6'Y?(_.85V M.Y<7";CF^FJ,8*MX9:QMH LH+@NZ\=&Q f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sQ-,7J3!8M6S+@I1(KHIU++1OSLH^)/F \;!D.THG1]7W6((75/E*S5 M3]:)2D(?=Q&W@5.5+%74=]+6XB"08!MO+=- UX!D++EJ(9Y,C.@I+9)D#@C'-MH6\?_#W@KWIE^01F]K+T>;ITS46QZIX8(9%BL5X9"O?05$[-M*,1A**+_/A11GGBS(,(*IB;)4RC\P,OAQTHB^+?#:UEY>AV(H/0B_(2/YX M9"O_$Z7Q_STI B*85I(-H8S+XVR)V#@-<*:S*++#<(2^%P09F[KKRX!LM018 MX.K[OLT*+TMFA,XH8%?C#P#T/T@5Y&V:>5EJHYEZT5[AX'4^\|(X/0P03L1Y MR*;N^AI HY8 "Z!S^L>8N9-=]_1%2%:(*5 MG4@MU6 ;XD!3PX^1\2V^8(B,8TP-&W;WMPO3"[&ZROT#S"?L4/TH-#(,8D M*)9,L/12/$_P8 =T^\'8FT]VR#3%37X&'XKOMDM2+,41B[*?&"4>T4A9[O:! MJ1UN5&\@UAR]_6.F^;'ZLSFV76UR9"_MXC@&I28LRG(OS2*7OG[BI7[J@@;Z MB[)@/ST'HAQ(8JB&(>S/Z'5@T)$^=BME-R\NAT#<;.*Q;RPR*X6Y64XK:$LR MWTE $2;00&O?1S8&\3.#4|\/ C0$'Z099UZ2!BS,P6S18,_S-+/!T&'B9+?@H M#KQ9E R8Y^AY9[P?9=X,QK_?SYB+G8QYACKDA3A*%B-@81A@D<>>GY,"BD0< M[3L0>CG4 $%XGWIF(+1\UDX6/]PKQ*K=/, '/^W\N?SKP&CXYZ<-MG2VAZI$KZO_(*_#P+.^O0B$AQ+.^?!K_X8 /T'WK94L5?,#_(*"T2$*BW#3* M7=[@4QU\G29'#/-)?(0^5$,0LI3R+ (W]P2"S$4S9&CM)UK\T)R,BW%$3L60[M)<".V$*K^@*V4LBVTG1/\,A[6>!M0|%BE?[4$5XG1^1MG#&IKF7! G!YLUF MZ0C=0/A6^=,ZCKS5^X+]W; [>Y[^4>NX;]!QUG@J'^<)A.FW3=H=],IUG[WG:NN4[5= MK@3';U?;@/<++I;KQAA1L_A%P_B]02P,$% @ O8AL62F&O[1R"@ JA\ M !D !X;"]W;W)K&ULM5EM4^,X$OXK]BSL097/ MQ$[("P-4P0!3#% 7=35U?W0:&51#>VY9%D,MROO^Z6[=AY 9;=^P*Q)?5[-M/TM'R^4_FI[+OEVC,TTR<]*96YL'1R8:"Y2;GR5BPQ6IDJGW,*CGAV87 L> MTZ$T.0B]W<%!RF76.3VF=_?Z]%@5-I&9N-?,%&G*]PU/!S656*8B,U)E3(OI2>;OBOH5Z0ZZ3+@1 MGU7R3<9V?M(9=5@LIKQ(|(- ;_$V4^APBO4@EAOZRA=O;&W185!BKTO(P2)#* MS/WG/TL[- Z,NEL.A.6!D.1VC$C*"V[YZ,%6"Z9Q-U##'Z0]G0;A9(9,>,0; M5B6?*RXOKI_8U=GGZYOKI^O+1W9V>|%N[Y[=U_W9_;RZ/#RPPPNT'M44GTW!$-M9=LZ]LW/#+K-8Q.WS!R!@+65827D>ODKP4>0^ZW4]%G;#_BOT M>K76/:+7VT+O0DPLNY F2!0IM&#_.IL8JR%"_KU)64>KOYD69LV1R7DD3CJ0 M%D:H9I$Y_?678-#]|(JD_5K2_FO4/^]?5XEN%OD=G-B99>_**]*)T+4_V$*P M.8^972B6:YE%,N<),R("R\8L@C_2LBF/9"*M%(9%"E+,6)G-F)HR56AV5G64 M\|>SLOF%\2RF#4^Z@!,KRSZ[Y-%\N1M8)T4,'#BS0[M] MYSS[SNZ3B(@CH01%T8;>IQ(,$$GPNLS L;9 P#4LXZF@S5K(# C.)7@KU^I9 MHI.@H+"=T?#0[P*N)0E"-(2#$9F$A2IZ:C^:S>(_X?H-K%=REU[>"4=A@_*MU:TQL)G)0[U]Q7<54Y_=@=,G2D- RXS87"$C];11,FE]N"40\2|"36*\@MLK\ MX,8(*+T0!0+M%PD1@_VT2HE'.W1 .0H,1(08=V M!L.1/VSZIN$,*,_)8O;VH(@:C7X7SPDG7-0+8ITX4):H)!P1*MB-J>C,8B, M//!"1@:CGXLP=G KAXDS\A%[$X(,Q"N(-PY_'"%'E4TJ-(@.69X53WP6K*(0UG9&S2(+(W'4U5DUIF&YV#WGQ*Z)&\L)U@[(;P07FG)$P M',,Z@4;'',&FP_]35I$:I:)_]I- ,90>)$Y:00\A2*,*^BBJ!R'<.|[-N9XY M4D-X)LNC8-=\MD7(L%4T04VRP4U5QO ?D,JK 9A QOK=#ZB6%]_MWX;/.I(@2I"2H08MINRAGTR#QA[+DP(#"+V8R(A/$@$ME)Y)"(Z+0I- "&+T"MPC.5),K(G$Y+$]0RT2ZVAZ%%V<)FDK+:?,41W M8&*"W6#,'A<\-LN%9=AE+0HM M/95)\]N M8N#$M3L<^H?=77:6@< 9I],KU-%.04/^_1VV8A^_ME[A3$@2- 5H#H\>[JP9WMN?UO$1_Y/2"^5P:1&S(8C_\#77-5W%T_":,W6=#U M#X'@% ANYQKBGGI-(T2#4X OA_YP]"8CE&B?C7'_MR4\1+C>0 DJUESCTH[M:I>B*?\NV ^HP" ? Y.BR*:KC%#A ?H=U>NX5N0/TG< ?U6^W("NO,F??WY8F ME,6 5MC=WB#@!M%]""[0$IVWEF,E9JQ&?;CK@(@9*_*_QFJ1.-'26H#U*O CH?$1 M#(%M)34C:()$ "C"E(ZP)A7(DT5S ,#O9A_-C@@30RKY!B.[7HJ74I##^'2&F$.(!50.RO2LB>A>HKL MBHQZ(2R;FXDRU6[5)CRA"K<%%9B_1WZ;HLO L-RFG, WA: M+$)Q4KDV$=9BZX[>)N+8, O[C6X!;8+5N08+5N<[:\WQ1%5 M(,FLLWH+OGPU-Y>"X8>:ZBZQ"^8?$.21GF&)B9"RY?F&W8L&^@)'$"[M. M^0P5N146;Y@\B++(W^ORW! [5'Z/*R+7/:FD5P=8G8F^>TMOS;IK1R M%\UH?^Λ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|2M^2.W%=4)13FJ\O>@Q\"S# MIEK5:B'L[W]-9[71@,F_#SGO=/56O>",:>JB- 6N@[T3O_]9=X&+U^ MOO)^9WG_.>W?E:0?T\NCNG7[2@.V7LIL",TUFPF!ND3P 1C& MJQO57AMN\(!ZG;ZT+)(]RG\\"- A[KB$VL8^CP'^F#X!'W#XG(_NX,A%75/'.6$*9(786]!_@M&SN_P:5&E#.RS!/J*W;5& 2M MRFF/-M*W#F6?;3.#W!3.H#<_?C%=+! 2,ON"%Y3V@+U!H;DM8E\7DS@.^G', M7K!X& XC]D^?-RJ+.'G=_7]!+WOT"34OAU&01L,C-@5CP5;U8_/9>|"C-@8L M'H5!GPW"X03,}/N0CEM]?%@(*N<#T]-D$HSM@:70:LW0<#++#GUC& 1DM, M'QF[XT5#SS:XQJF=*5O- ENTK@~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{;.H&/5'+"9)6)"$:4H#<2[HG$+1)(OW M^8SRLK^)'X&K/>KQ/=@!=7?B;A+!S)GAHI0.F5P&/[61*);56=`RC^06M MQP[\^.]RJ]$N'\RE.UVABQ(Z$P0:U=2,CC)V^NA:U';H|+9!7T5YCOY&C)M$ M^.}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|<R>1Y#1[;I*A%HPO7Z!5Q""N"]F M3,[,6B5.8P_E:916RKB_GBG_D/"+F-YP!S&-/N=QB(9&-\,%,,2KS,Q M1]MKJ.+I*+V(9EQ_T,;$=B\-%*VYH'E%EB?(4U+ ^\5.5ASV"U&DFV!7!?DEP

*MWR X%<%YKX-,$=SW.G0]@@[=+&/7B?.QP%Z?T2UB"BW5U$!G7[-EOE*BWDDH MF-Q-)4]X,_R,-AS-@.DW1R) ?LJCC/(U W2!]D,?G9Z#V+O"1?50PA**% M'.L05-EUW*N($C M&!BR>'%@&S"\KU`.:7>M[4Z8_4\S_3+'@D\0.IL2M[\0]IN[=!0MT>3@)T M>CL-PS,T7"SF-Z/[Q7!T&Z#%%,V'O@2=*U0+2>.!D>H?"Q73\\WIZZP?SL.GB M2L^N]E0]9.,YMG75-S?[%_(.U+|LN-8ARG^-NK ['?L0%,Q&N5>66X/*U)A[ M!2P'MM*=@Z.(KHDH7W&]6C>GH.(}+)9'[=ZXW,#NRV96]IY`\F4GG&"V2@E'-M&2REE=6ZE/65E=VEG A;Z/+Y0(4LQGJ8R(8,3'D_D2L9LH@K%>W\14&L# M!!0 (+V(;%D >H^&OF(@ (H& 9 >&PO=V!R-W-H965T%1IV- MD:WD(,2SG6O{[56"!MS>)VV\7Q\IHGlUM9M:#EC! M@V" -*-%%['WP$($,UTSO1/,-NGIFEI<*IMP5-6WLY*.'TEIH47;)OQ"DO+WC ME^XJRC1SE]J7LM31/J!=>%0E\X ?)O MOF_,>KWPI+<.!X%[J$9H$MRA, BG {O)7^{$\297>)?*O$.'5[3AA!XJ]3&[M5'4+G5Z&VN]EF2]<0NR9#T.!/(*7O'\WG@>?!I2GO?)TB)IL;@9H''QF]^-S M,;0BHM+_'W*K.PS,,%,P(#;KQ6;#G.^''W]\@-PQ]2V[>R\UO.K4GD.8KPE?<.MAIEONJ2UZM\7-!S?L-\RZN>?!8<29.ZGH$*IJ+EN6T6_VC?:5=M?_H:W72'H1 MRYQRA14ND)C48+ N_*-ZOGSR9684"-R_]T&V11&VYGEP*/Z]*IZF:6UN;IT5>5+!<.*MS>~/SYU4ZMXNDZI=+6]l OT](MDIH^NMGS:NEL,N%!B_SY^>GIR^>+)"N. M7O_,W]VZUS^739UGA;UUIFH6B\2MW]B\7/UR=';DO(C+9O,:7SQ_,3.R+F1 MK1^6MXX^/0^S3+*%+.JL+(RSTU^,+L]^?'/._B)CYE=5=':?!D<9E^4G?!A. M?CDZQ8YL;M,;4R3T5Z.!LGF.F6@?_]9)C*:&!C_[6=_QX>GPXR3REZ5^>_9 MD[_KD]<^N7!F'IVDV_,%'Y=&TN:P 5T:U MHU\S&E>_`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|\X)'S'2"7&=%Hl;G$;Z6SQW+NZ4E%BSQV&K*1ROQ M1)7!N. P)"E6Y.8G_8\X2W2,WFRDL,Z.VMR;UV\>#G[!X;W((+'JA,+0+P' MD2JRY>3D(=EL_T#]+V7I+"OEJ[1|O7-)HB'AMI,J6+9JN026C3B$<&<>,)\SQ0>+^5@X"1&%52B[-5APA6\921>ENIZDL,"IV&0FSWR2) M1!84.5:1.&,0VE4;=-YP51]K?0-I+;'A9$**DP%+.?"PU5#AZ8GTYR,/Z;! M*O'0*C^RTJK(H;-XS +2?K%WRE'BRQ2PM-<+=9GOL""!$JY.UU-'Y% P^1;0;1 MJF:YS-EX5S:%L#BR>I<9%'1BRANL*;"V$W#W#<#G1O.JV,'2-[+%4[JH4W'8NSUNIM@_A M=4GLBYATX(*LZ)C_SA9FSHICB5!,#'5-P>O&3D/V%7P3?2+7V!'MQ[D-U!/S MKR-6\|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{JUEDCG9@@2X M+'+0QZ*R8@33!@)]2.R^#V+V_4'Q>/,P&EX/1B-2H@IO2*/NAS?7.[7R&Z8A MC?L=Z2G0[M^$DV":HKS2&"R'9)$1'Y/&.C8[A &ULTD=9)+DH"=Q$!.6'&G M..RG ?7)9Q #O&&?E>5D10%$;Y=DA!@HSY*QJBV>.1:!WYF3IZN,=X9(DG2< MOGU,\@:(_E=== #SQ\K@O-&XDDS:&Z;.A5F#%QL/+D%:$$5 :\| {(%|Q/TJTS M]'C=:$d'(TSA,+&=UFA(*9PZ0 *RS?A/Q;;.DHU73$?Q=**IC%Z<6JS9W-8PWNFQ)CJK%FJ%WNCPOX M@[O_.9[#C_V.Y+L F3: $)F+-'-ILT"65.ICLQGB*SY.!R;JET)4$KR"U":8 MU2@<14NRB1.QUX535@1"BRW[S)VC4)R2,?D:E1ID)*" E6POJD(.\|+*6E M0(NAG-]D[DC]D.]IO8NOL;B"/'S!B6(.2 ELN(,N^+QUP><' M/2GRC?=_F#'D3]\B-70[N!YQ:FBG5_[&N0R\V-G93V"Q"#79'5_$_9_\,N% M5)1B?%6+YF0D1-OC$Y/BA4>|_>%ID@5Z<2:.E&MSHQ%5K.P*:0$C|&I_-)=+ ME^4T&23\I$?/2 $@'#1#X33WKX) M#G%V>MH[/3TE]Y\X7S=>+%!DP*)B[2J40U(;U=TZ"W@1I;_&5DH0H9H&A\J1 M7> .$> YP"F9-YJBH=!6KN1@^LQ%URFP0|_W131=_QT3P?8XR^LP^-#D!-/$6V(_7@,*[Q'5M\KSOJ=NC'=^PI9-/,((S\C MLDJ7SLF\0_7K]8F< HZ-)DNT3M3QY]YM^]*\'GTT23WTSBODJE3>;X?]QU"%Z\NQ! EE MHDK#FSRA'T)SF[JEZ=Z2L_M-;NK#@M31VT9) M39TR*O3I62S=/M^3 3#==>GY\H:8*QBWN"RV;FGL2^6]5]J6XG@%XWC M\RGX=&$V#0'_^_&8UV-^[_\VP4MD?M[[.& MHEGNQR4&C?,,@EE2@<8G+MN4%#<1915!!{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{GNB3#;XX6M@2O+ M.> *%W6(LS/D[FHD=AB>:KLI@'-HAFBA]7]56G1)-.Z3=BO4I#;*QWS8]GPA M9(K!6<;]IZ1'6^OY MG'0NA^+6..L*\Q(C9BA H,P>\B-BZ"R BCYR7[&A/A%N^>D3EX<'KV9 MA7=\#C9EH\E,'EO.6X3=@"2"+;>WHIKH:E6(}NXI@6!)VJUMDQ"$"I/ M+2R!^3"X'#W<#?;,@6^,^1+37W>7]{N<AO M);K5>\9ICY$4=G%!@HC5HKPD'CW/R)Z[=*YW0W?]@O|)3U7;2:A9<6=;[,#) MQ"5%XBBF|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lV1_4Z<;!Y1I- MJM1RVYKG8$_1HJTY3VB+84_21,T2]_3@$0.6D!=';WE 070CE22^YIU^Y!9 M,2-T)W*(>Q.^OTZ;U;S94A1\$#>UMQS.#M]/&%S>70^O?QV9V\&=&?UV>;<[ME?>UDY@3,TBXV'.O$.!B*<1NXLBE^B \2@-TZ+AA-F1)HH]55_]39\$4E" M7&_H^1L"G8?GL.!0)?6/!EN:'0MOHFC5HJ=A4+&.W!00J4WWZBC8HQED)$UJKLIR:^G.SJf.0A"=-ML.E$N-=N&9&@8M]HP^QOfE@M<_<-1QX.EUKGH568_!2<'0P53I0?VO>X\UZ5(-M;=:ICO<_-?-\K>?*2/%)CLE{XOGF]H]V&D;,+I+;B .Y/!H$-$HU M3FN8IEP5UN%*2%$#BO?_8(=%%F]C&F=[+R#%KI+2]+5/+)86' FQ\I*M$PR18P QF!)/TC[BAD9*_]2-(@"M:;J8.K7DHDQ@AV@!%64B5'8]!XC-AZ23 M?#KE191 J/-A=IGI.)KE.?1D^%[AKO,.PCC\$FY&;HIN8[M)O.#+?-9@:^INNXNZ;F&4'+=HG13O.#FVX.7EOHI-ND"M,+V*]PD+P0/V"2 M4[AU(:=_,,.K/)/<_59!2NAJ6B8+-,]VF&5NN\5R]8\WV&7D&.1BK&&!G5P M=8]NMFU14|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| M5U@RJ>);LLDH+PA\%#04;/DC//THLBU7,45N7GH;)PCV(%2@/ MUJCSM;R=HJM#%Y XK,/S M 0M']AT_WCBD",9)J9(>!R/(0/GL;[]FNH0Y8CQ #HAHZO',0Y?/(,;'%M")380>#Q9@_5D7,0^ SC(5_M(R#G3]'5 ?>G\,DI5DCHQ;-)EJ?Y'>(GHI#%,UU#+H;=-41L=2U!O"^\/?. M 51$X[$LG"+'J!4!>AB NL@_^!7HT]U9A\|"^T74#SFK0=X[NYK#OR%NC;O MAE27WX23V4^G6U.!OPB"^M]4RCK,Z!=1&D$15(_.;%5)(5)0!(8P'A]$> M/)<9 $3:9BI?&"5#[?PC+0*Z#.J)2.=)K/?:BR=3R_9JT]6$B<>P+^K(1EC MMJ6Y2$,=C-UO+ZVQS.TEH/;6-[$7#T+1Z^M7V0MR2G7=QEY@)Z[MJ ?3MY3! M^);EL.0W?/?@Z-0&E;YC$58"9,.0_H8P[K5AW-LZC)^-QSPJE3T5R7U(M10V MS+!8KE0B##0ZOT$%4GE#)1GX),/(]=IZ+_O+!YL$'M#"LTK!H5HR+2\&6G7C. M3K+(3EY6Q!8V\=RU2A0}DD^D4+S":2V8;Z2=%B]!#.:'N8)-&DMG"T4N/* M'F(A5D-U%8Vf%+/?U=FL6C$_Z[!418+]7,&[M6^;=&X@AUCE/86 929RETE3 MP-0[0LFX[%*&C\#_G$33J5X)4[=*?A%&436%W$E@ER=#RJ7R1CQ[6$AC0K7; MF\MB1K#-M3UZ?U<$5?

RA1]W@LW(-Z/-MR=I)PB%E2WW]J-LT0H3_(=$0G+!9JZ=!M5MF^@B5+'_%\L#DGI'=CN=,;VQ_M :H#G|3_B/#?(/B35=(!;/Q%]5=2@P/T?Y>ERN;P0?L9[$-CYC;DIN&N0\;M9,J>O?UX0/!_$@UPCPQ:ZSJS9CNJ1*?*-D69@TX=='!N1R-P()Q"911/V?"4 M^6V1;5/NLR9BZ3X?9 /C)+5QED9!2TAO@&VT1A()V9?FED2(D;U$7+!M6X<-MR%S)^AN)3,/0W;2X/WD;](@ES_)"D6-IW58CE?&"U\83TZPHY#RV';R -EFKR@4E!'%Z-"/^G#G-54+M7!O1GMAK!OC'U;,MVT3Y=Z(?&+ER;[.)-'CIN>X23VNA M[:LSZ4TW< JV#S61W\!4$L#!!0 (+V(;%D%>1FR&PO=V|R:W-H965T6'>)9XYIG'GA>[?Q#RD|HC M:OB2I;FZK^VU+G]MEMKL,6.]*0K;:64K?R;?3RAC/-M:X.^EK?BKFD M6>N,DO ,<|5%#A*W][6AUQN%1M\J_,QH"[&8':R%N*3F4R3^YIK"&&*&VT0 M&/U>|\ '3U 1C<[*S-K9I3&\')_0'^W>:2]KIO!!I'_P1,_O:U$-$MRR,M4+M&Z"LM225CG9Z<'#8C*>KN!Q^=#"=35?3 MR1*&SV-X_KBBT7SXYW TFT!]Q=8I]D:_IQS+ETU,%V^!]C>I#H7S!VN#"!R.^ ,_IN&9;7@+ M?;"D#KM,>EY/D.]!ZA0,E% MHF C7I"IF#X%G,Rf 22E%0fZ8K(S!-I9MN]@\%*Y'-FK;!]YLN*83-3G 'D1T/"\E3. '2CHZ"J$I:6'\\7%2V0:7_ M/?"H&!\X?5-%NNJlP))_J#F8BN)N$<)N>2 -$VVV"7!+@.[!8W.7%)GO2#DM&6&WV8V^Z/@P:D!L'2DCHI+4F*W)Y:DN;>C'N#E*3T=A(DO,,D@%RZES4N49 M14'1E"#6*=|QTZ@I<]Y&O$!1,\FB2%LU>MX?.-G1-%,V:N"E?$S(S\F;RF< M9>}E_-|?14;]DP+-\AVGUF9Y4(:>ITJA5O !HJ[O1)Y/HTXW@_R6G&^[JW=@WO&*W-9//)2^L-!>F'@OVRJP'35G9N3-IVVWZ=PXD)=+A M5[5"48R=*ZPS-"68 IV!_;831S%X7G3K26E 3'LQ%W?=#VB;5GO+A+9SL3IC>9+9YT*__A_|\XKCC^%T3 M/@JBXW8BN-:(6Q>W9X9R9]\()F_H2*N+|"P|/T.&U>W[5;UZPSP=>U^*6S)U MFUVZ]67U+J@F6A3V+EX+33>[']>ZIRE ;!5K?"@K'<6(&PO=V|R:W-H965T\"AZKLI838ZM4R*%;4Q';E="S$=\YTJBQH7 N2NJIAX MFF')IQ/#-8X#=)5FJ_2 /1TW;(-+5)^;A;">W;/D186U\'@-M<3(W4O9Z&M;P.^%+B7S]|@5I+B_)ON?,PGA[,%88F9T@R,_AYPCF6IB4C&/P=.HT^]@<_,M1_;?VK736E9.XIR77XM<;2=&8D":.[8KU1W?_X&']:0",U[*IA?V76S@&Y#M ML+5 4P*JJ+N_MGC81^> 1+G%8!W 'BM[BY1]_***38="[X'H:.)33?:I;9H M$E?4^E"62M!L03@U7=[?SO^\F*7+ZRN8W]XLKC\MT_N/MY_@()ZM2I3G8UM1 M&AUL9P;*64? IO4(Y@AM>]ZV$ZSX'_"7>)GF|1N^H<>8-$BZQLDEI+>2:O(s$Q2F!E]=/8NO)I@;:HU]RK)-!WP=0A*TI M"51= : N_*#C4UBM4/1G> FW.R45]W.<X]B0]E@D?>G2V-1+CT 05]%WX>2#<; M@1NF$&:L9'6&)EQA=DCAMBE\&+FN&;@N_)N9$4_ $YB-A_Z_^M' M%%FA2^$L8.H4 M.O9&9N)$K2Z/T+X+?F*&E//_WY5X9@]Q3VI(+']D^G%\WL\,;4 T.J-1U(>& MEJ,WP$S\JZ WK/P'NH ,&"7N#A&\VR-TRI;JM",B+ MYN+ '*NH'7L;WDN@D3Q13Y)E.HJO)\RS7A_E6?I')?B*1-*7C>FR\>Q602[18_ MM@('OG3L9TDH_*7-=AJ>-Q M8\9!#*Y&D@+/ZO4)-6<_NTXK%)OVT2 AX[M:=3=K/]4 1+N.OX>WCUJ:6<8 M%.3B$M<$=:R82DUT#X6NHWC37LXKKNBJ;YM;>ENAT $TO^9<'3LZ0?I:F_X' M4$L#!!0 (+V(;%G^:[B;6@8 -PN 9 >&PO=V|R:W-H965T;-E98L":.A9@<8,XZ3 ,>\'(M="Q4$EV2=E*@'W[40R3+HCF[N+Z))8;W.XK_DW0\\?*%LB]\38A KVF2\;O> M6HC-1;-/HS5),?](-R23_UE1EF(A3|ESGV\8P2WRAO{DA):5&Q0)/L?DA>|=H_Q2GBC]DI_<-+*]Z1CXBDH!(MY @L?W;DFB1)3I+C^%!+]7/W'#_^(I>%!]5'V-'HJV7-"T,I8C2..L _,6OU43L&3C'#*S* MP#HPL,9'#.S*P#XTL(&8.)6!)ED;?>W?L+?_XP?;CY-$?O/2)PG/#?I#O41WR-&>$HSM!C%@O^03;*.MXXG*MM\F=65K@+68?D6U^>9A>.AQX;'WIUIS5_ZHKE0/7I"-!!L' MX(AD@C %S3N=9K_15-,`J@ 9E"A'N.1J);@"*8EK5W?-W,!M8]P9ULN6SA'.MT^CK-N9Q\5S]Y7_9AFX$2?F_JO OD8X.F;IT+O@&1^2J)]\JG+ =Z4U^_<4< M&K^K(@02YD'"?$A8 D+(@6"MB"JB'%T].E\FSX1ANBJNB4X^G(\YIAI6>>& M2@D;%+ |-IE-[/'XLK_;CP!(A_X)#@-(AR$0K"7LH!9VH!5V=G\;(OG&0_:_ M4Q,|&-B&<;"MHI?9Z>5W>YE#:W#8+5!T M&YB=;]91;n#(IX>T;D5:,Q7*V-%GNN-L/.3:#21M%+H4VW MEU(;13>5-D"7V=+&K;5QM=K1B1J<'4]3I%@=:,$NJ42W5Z-S;`M"$<1W68B?\))%)-[AIX2HY-%RSY5GU'V96.[ =JP#?2"=^B*^*X>X^9@X%KC Y$A'3JG^@T@'0:=IV:.M(|TSXA6O%A(H<2)H'2O-!:0$H+82B MM2/";B+'^DGI@!Y\=OA8W2>L.3(Z^]JH5_]$KP&HUU#A=>R8>TL6C,5*U:,`MZOC1E$///5M(6Y%1=Q0]#]2I?YK3 -1J'!J#MVC,C8E)5-?4[JF:2H?WPM! MHR_H.[K;/B5QA#ZM5H3)I.Y20=#"$BC- Z7YH+0 E!9"T=IATQ2LS,%/R %"M"U>@-_^4YH/2 E!;"$5K1TY36#/UE;6FB/WVI8_S+5GF'_X$PQG'Y0?F[_*|MJ/";?"P=_DB(DE31+,9(HA8ZB(BCP\FN^ARA#I%LH!TGQ06@1'Z%%I0!HZI*F MOC!9Y;NTRE>UGV8[5"N%SM=?AY$ 6EKF_|% MC&Q9T&0IFQG? XDSDWXG\5*BF"N7]7IGYZ;]H#0/E..#T@)06@A%;X=44^BT M?D*ATP(M=(+2/%":#TH+0&DA%*T=.4VAT|(7.H$7.5;WAC<<*=8X^E&='2V@ MU4]06@!*"Z%H9,3T]_;2HI0|%]ND.2[JH^7VP+]UWHH]+38@'[1?FQ>>]6CW MS8N@W&C=X,M]W[>8/<<91PE9252?&1U>&#"NW4I$ MY1WD_U>4BK>3W$&|H7WR'U!+ P04_" "]B&Q9Y#^_M@+4#]2#@ &0 'AL+W=OZ%_*;2@G1X$?&N)IV=;[4]\7<4HRK$[$CG#S9B-DAK49 MR]VO=I+@I C*F{^"\@VS3>2"%-9O>:)<D-R(KK MX_H9U KE+<*"=7$[@\R[#\N2!,|&<>|!X> M7--M]NT#?$I=X2U9$WV(N9)FY-]6Z M!{:4.R&^V<$]F7F!S8@P$FL+@6,/)&2#)R3Y(=XWQ=05H8>*%L@)N":[$S (_@ H0$-PNSX'KU^^<> .ZI4:%+B# M'MRZ]K^OA?DU9V%9?*UJ^(2:-@-9'5VJG8X)C//"$D1>4^|^:L7, S>.=(<.MUFD.7>CS!=E2SBG?FL/*.(I)5X(E1%A 6-W>S\-H.@P'4_ ^^@WI44X^\F1 TI>D8%5V!'2A@V1@N=!GFTB"N8WU2.4(^)P<9 MH=M!C]=Q!=1.X"U$@Z\'S; Q4NAVTL?U# _M.T0A"OH6OS%0Z';0<[JE&C/P MD6"F4X>DW4U/54KGCMC!Z-DT[C?NIF3;F#-WN?)RF.QP;38*P9S\;AX9NB_Z/-MDIX<'|>$&O-%3LL6LX53)M[B'KJ1XVA(K>A']JF=.BJ#C&CQE21VU0?%W,% MT/X>&X_ ?H7L]_ZS,^(W!,-C *QR+DNO_CKIW7#=%:V"8|QLA],/ $M1MY/P74$L# M!!0 (+V(;%DDJ4RW' H (1+ 9 >&PO=V|R:W-H965TC M=5EN7X_'Q6(M-E'Q*MN*5/YEE>6.;)0?]_MQL MU+ ^[R:<7V4.9Q*FXR4'QL-E$^;?21)(}78[@Z/D7'^/[=5G|8CR|V$;WXE:4 MG[8WN? PTWFM9QAN1%G&6@ERL+D=7/\5L$E0-;HD_8_%4'/P,*E<^9]F7ZL-| M>3D**HM$(A9EI2*2_SV*F4B22I.TXY]&Z6C?9]7P\.=G[6]JYZ4SGZ-"S++D MKWA9KB]'?268A4|).7'[.D_IG5P/P5/C6PP HN'HLPV36-IP29. M=_]'7\N:I.&B]*4!:AJ@4QO@I#&N'=U95KMU'9T0*.*M5G6$9C-K_LK4BK=J M^5Y8@Y^$.2CG[M=;6[SY^UL1)Q.55.O[9AXE',YWA^UO]-=[_O _6\,,V^N MGODT*4K&6#$C#>/MS^CFQM MF8%F9I-(]9F;]AS)._W_]Z#Y3]MR=%IMW]\|[EBK'JQ=F\)Z%R[2.W$;WR?Q M73R)DD)<3B;I0[F%)??B)IW'DUCEXM_EVV%+-0B_T_7Y\ZZHV%W1]60Y$.^_MC",JO%>..7*5/;K>Q3_^9AP-_ME57"1FDYA#8BZ)>23FDY@DL8#$0@AKU=YP M4WMM&G7YQ_,#XHK*]I);EQW@N_GSQ<_U]#8Y68#5*?IPPSOJ/SPM'Y^6AA?-B M=P[9G4MB'HGY)"9)+""Q$,);U3#.5,-HSVI8[W1%]%#.TBS^0TW%FSBIWWU;_M5LG.G?*5MH=#=T$D9I.80V(NB7DDYI.8'&U|E)5C]D'UU?Y$"\A>0PAK%=31 MI]"M 4EDT*5;E'M5=*%Z]J7-7#T;*6<'G6LD_'V=%;7=/;V=*9YW#&ALSWA MD=4QG:M=PD,W3A+S24R26$!B(82U-N#CS09\K-V +Q?5,4BU1YBG>2XR-4G+ M(Y1]?U#N\M8;M4@3,559_+@^,_)F\|E\Y0A*+,OWTFHZ=7>G5F<+Q3+,H.`MG:=,CK-#=PI[=^N0W,IDIH0&0[U"RH^%H]/1U@]19+R7NHSCI M'#[IJ4/'3R1FDYA#8BZ)>2=;!3#LV"WZ9)^2Q (2"R&L54]GFU(ZU9:2FY;[MFR@ONLI$V_+0.B$QF\0<$G->S",QG\0DB04D%D)8]FB,07-Y;_!:YYGKG]#R M0S4;U1Q4?523]!:@6DAI;(RF[(R|;JOFH)E$M0+60TMHE MV_09C%=+,AAHE '5;%1S4,U%-0_5?%23]!:@6DAI[3IL0@V&/M7P>F?M]3-R M<)FBR0E4X]R:M18QYVRJ%|B$BV;G'P5 MK=T1F]!+D4P C%'-1C4'U5Q4\U=+1S6):@&]A;7V/-LXW Q(V_75!$D;?9+D M.JT.NZ)Y=:&@W+%UGZY$XR*H9]..@VHNJGFHYJ..1!+4 U4)C.VLS&M1?.Z]G MR8X8^O!(B4THJW.UEQJG29%%DQWEA<9,4,U&-0?57%3S M4,U'-8EJ .]%E-;^'[U-WL1\M;R)B>9-4,U&-0?57%3S4,U'-8EJ .]%E-.N MPR9O8NKS)ON,(_7$P06&9DI0S4$U%|4\5/-13:):@&JAN9WL,?3C2+,)E9CZ M6,E5E,>Y6-^DHHHAAE_V\=BG29%6YPZK&WQTUA"._D U&]4<5'-1 MS4,U'|4DJ@6H%E):N]*:](@6HVJCFHYJ*:AVH^JDE4"U MI+1V'381$'?NVD0U\?TG1UYW?0 >]&:CFH-J+JIYJ.:CFD2U -5"< L>+2/;!8TFO&'JPQNI#L=& MG56$9C-0S48U!]5<5/-0S4QR.64WOQHK<$Q/"%HUJ&:CFH-J+JIYJ..CFD2U -7"6FO!YS/]96:K M"6E8^!I&:CFHYI$M0#5PEK[,,!X>K*CCIKXAJ6/;WR,DWCQL.BL+@6HV MJCFHYJ*:AVH^JDE4"U MI+1V736O@#>O5;M]AH>D.5+-1S4$U%|4\5/-13:); M@&HAI;7KL$F 6/H$R&WU"*]WU3.8IV(9?:LN=(FHNB[VT_J;>%3YJAS7MX3K MK#\I7%X)]|@M+;XEO*LJZ#8T==#Y<5/-0S4E#WE\ MC+[N/&A#$QNH9J.:@VHNJGFHYJ..1!+4 U4)*:S\EN0EW#%_M7AY#- ."C:J M..CFHIJ:CZJ250+4"VDM'8=-C&1H3XF ARTZ7LXN/I0B.@+2J92Z+SX.*: MAVH^JDE4"U MI+1VK35QD*^SA]_I:-SQ!<;&@&Y(5%-P:,:2D,#'ZB#O+*.U:=.4W@8Z@/?'PN=UJKYS;=S*.DLY30M >JV:CFH)!+:AZJ^:@F M42U M9#2VM75!$*%PU<[=D.C([AFIHYJ#:BZ]>:CFHYI$M0#50DIKUV$3*\GN M>S^0O!I9YB)Z*&9IMGHNTYLXJ=!]*_ZL? ^HL0#1Y@FHVJCFHYJ*:AVH^JLEA MQYTV!D;'$Y(''M-^0TM;%U<]G2A5V5$079PN5W:NQFL|SL=IC57NZ9^^*3-U5 MMP/_<&GV^EOO7QD?QD;'^[;QP5F!WV_XB]-E=*\^1ME]G.1BKN[*K@<0C\% MR^+]V>9%D2[/>^6AZ9>T*-+%ZL>9BJ8]JR8H?W^7IL7W%U4'3VGV^VQ1+0X' M4&L#!!0 (+V(;%G>XP-%]4 !L@ 9 >&PO=V|R:W-H965TID>RCVP%BT M+502/9**O6$_?]2D2-8EBKVR6%X2B>+Y#L]W#LXES&1'Z#>VP9B#?1PE[&IP MX7QII]6ELN<$Q8N_(%B?BRXK0&"Q2M<:VU*,@DPHCC1#UQTM1FRFZRM5LZ MG9"41V&",RE@:1PC^M)-*U&"_M,,8)"TD"*%Y=#6;PTC=T*9#M^"W$.W.P#*0I#X1\DR_SX&J@RQ/A""^YA$#B MURV<11))'&./,PO00:E3"AX^/Z& SXP7OCP@AET2_1X&?'.U>@+EB_N%F_G]NSFINP.QU/],W;UO/H#&,SQ_G[MO?@ NP$+9!$& M9 7\U4HX6#YYF(;/2#H9S!/&:2[^AS,@7.^26(3L1L92|G%)8@S./A+&WH(S M#W,41N+1 MPO/'#VYBUX\(S$W&U(RE 2L(G&A57R;-JRL. ZM\!XQ@(3?"()-MWS#@)P$...N2]? OEQC[PFV"PI-9XHO39Z 1=X^PZ8^CDP=,/],(]O+C99<[W M.:??_L_8:&6897V:&9SZ#-_OLSF401&D0)FMP2VB6'V:A!!!8GX(-(M.$DX)5$DM\T3CBEF_!S?/TBO@*1'G:(!G!T4I^%*Of'#+E7K(M M6N*K@0A0ANDC'DQ__@DZ^B]=7E0\YJD$\Q6!U?0ZI^ZT^M"GUW@=)HGTT0.*M4++$77](9P.0EJORG4Q\,(TB?:XR^%[7U#'!^JZ5=_FM;>-H&G:X_HVO[W- M&D/+-LIM-8/MTF"[U^!93-*$BYJXC!!CX2K$ 5A1$HL2MTSC-$)<+,@@/]O2 MD%"P%8F1! !GF5)FP&T>\F^[B,I5VP=''H^PS88*B]9V181IH.?]B9C MZ-C=[#@E.TXO.R)GOA +3CL6(!P|9L/);GO?<.Q >]2P]$@X_T6XFKG#TMQA MK[E5U3L"T075M2U<[#@(@YD"93)]JAY(A@Z;^%?^_EBDO]?B(*)T4R0#HS M6O]QGM(DP'O1.+(N_MU>A%/3V'=3Q".0591:J;-V7+T M IU:252">2K!?5<@6^,2V+,7TIG;%;I3Y$@GDHP7Q%8S9]0KT8}_9A2*9RR MK.8J.1(64#).@G_%M52>#FHQH|$=_>NM5-!L(_K/=:I'7E;HJU)8 M)_I@9H/_7T]2Z.YO2OH/>#+C;94=_8LJG772C8ITHY=T%[$-6$5"3,S#:]$ MB(@%*/-$)XU&RR9+,P5NK|J3:6RK-$9-G;XJG74:JWD0]HXG!|'IE |.EBFE MLG4JPE0(!>H9LM<9VC;38J5SG$=.H>6T9Q$5.FL4UR.:+|_'1GNFSP'_E-43 M^,IV:-?]X*762]5HGE(T7Q5:W4W58 GMU], P=X#IV2OJD3SE*+YJM#]7]T& M8M@_$?_8VNP<4YM|#WBR<|HJNVJS(IUUTJNQ'!XY>,8RWNR0=,/!S9E@*J=H5RFJO3-5X56=V0UH4C1?%5K=]]6D#WL'S^/^ M:%Q@"":,"MTQLWLIG3ZI[E(*H6/8S?SV(R9KHVJLC?]) ^N4_LQKMH?7"-$=F M@U[^;>R=YQ27Y72G#SMX+(SQG2=W3SD?1%V.GGAJ)05?'YM_@E1$<@,1'@E5.GOAJ)N:'X3G;]PLLVN6A\(YR3.'C<3 M+++$77|+[BA#^]"(5EA/,/T74$L#!!0 (+V(;%E"^T*11 4 'XQ 9 M >&PO=V|R:W-H965T|SCBV] M.8H0DR>62^4;0@3ZGB89O|8V0FS?Z3[/-R3%_(IM22;OK%F>8B%/\P>=;W." M5X4H373+,&P|Q333H/BVET^G;"=2&A&{G+$=VF*\Q_O2<*>KC53>[{PB3YL MA+J@3R=;_$"61'S9WN7R3*\H*YJ2C%.6H9RLKJ4;\UUD]H2@:/$')4_\X!BI M1[EG|*LZ";5;7F]$R(@F)A4)@^>N1$&B2>5K,XUL\U;I82$&QWBX>7#W,/ M.9FQY^{Z}IMX;2A%5GC72(^L2>2*E \T4+R8);SXB9[*MH.&XAT7+"W%,H.4 M9OO?^'OY(@X$9O^,P"H%5E=!KQ3TN@KZI:#?53 H!8.N KL4V%T%PU(P[*H8 ME8)15\&X%(R[*DSCN>>,SI*JLSOWMOGT*Y:B]Y MZJ 8VH5>#D:,*1NOL8!;-@ MOD2_H5NH9Y1R/L-

*M%;NM$N9 P#Q+F0\("2%@("5M PB(@6,W(OWZ(MR6.2"3E150Y_9(6C;2;(3$"4;7.R:K+S M/IR:+LAX:I\.#6NAH.)_GCHT]:D+O4I)&P."7,A81XDS(>$!9"P$!*V@(1% M0+";3_N53_NM/OU`$VD|)BMIS(H"*^VI#CE=$36!95F3&5N9E];6/0,+FD# 7$N9!PGQ(6)"R%A"TA8! 2K6=6NK&IWM>I+Z9G]6fUI95Y: M;R!A#B1L#@ES(6$>),R'A 60L! 2MH"$14"PFF>'E6>'_]>BS!#2R) P!Q(V MAX2YD# /$N9#P@)(6 @)6T#"(B!8S6TE7W< MQFG-[E*/0<)<2)@'"?-/WZO5.WZQ 63$L*& 3[HR 1DQ H+5/#&N/#%N|<3- M:E4L3N($9;OTGN2]S-EI$0Y7'O'5N@US!IR8)!;"3)D! 2K64D[,/:.QD1;D.K_DDK#$OSORF99X4 M884_,: T'Y06@-)"4-H"E!9F!T?:;^U |V5ZMO)GS ^0/-.$K(6N+5UBT-Y?O- _OL3 MP;,%ANM|@1+B\,-P=*3]H&|OV9,/)^H/=S55RZF_P!02P,$% @ O8AL M66!,TL/| P SQ !D !X,"]W;W)K&ULQ5A1 M*/$QRS MW="*

QM/$+5FMI9XP1X,-6N$YEO>;&ZY&9LD2D01301@%'"^'QAA>3F$&R"S^ M(G@G]HZ!EK)@{(<>S**A8>D5X1B'4E,@L;/%/HYCS:36\;,@-4J?&KC__,3^ M*1.OQ"R0P#Z+_R:17 ^-O@BO1!+&_9(@LN!'4U7\ABD?T%N\+6,D"8"TM2_M JQ6D!",_Z"(A!,53#[+@%T%=$X G +@O-9#IP!T7NNAG6P RZ6:N/0M< M@"0:#3C; ;ZM%9M^R"?H56\"-4,92ZY>DL43H|FL_7LT\S?WQ]!\;^_^W^ M^FYV_1G3\3DG^,H-X|-D02AJWB!GX(]@!8F) M? 3?;UD< W48[!"/_JG;%[GG3KUG?B@T\=!0)ZC ?(N-T9]_0-?Z6)>4 M-LF"-LFF+9$=I*]3I]_3Q#[RUTBE25?H%L5!7L3]& B?\O?NYZ\N2XT.W]E M-LF"G,S-R/3W=#N"7D_5S'8_^L=&YQT(I=+](*S=,)S=QK!^P8A+H,X|<)72 M55W4&O%OC5[;9$&;9-.6RZ2X)9)/1+X?U&X>KN+F.88I)QC&CX"R1$5\4FA!4V3TAJ3\UZOFN\;*P]6/Y1U5"X\H76O.X&_M5>68UEWU)P5;5Y5]2NXIB]RY;K-O08MP7R5=<9"[=64ROPR7 %`!&-+0 &0 'AL+W=Q_FW;!'OI4C.5\=M:N31M!X_\##9W.5??#QO6=L3%3WQ?70KIY)G=G*{GQC++AW^7IS^QE.#U!^)E'+&(3E4%0_>^!#5@494C:CW*T$;9 M9V;X^?R(?I$/7@_FCDHV2*,_^53-3QJ=!|JR>[J,U$VZ^L** 34SO$D:R?PO M6A5M_0:,:+*5*X\)8>Q#S9/V?_B[(V# (PF<,<&& =S4@A4'.G+?V+|_6.56T MWQ/I"HFLM4,+'G)N75\.+X>#TZA:=#@;?OE_= M#]\NT?6WT7 P_#Q&[!%81\YT&3&4WJ,+R@7Z0:-E_G8J)5,2T62*1IS>|8@K MSB1Z<\X4Y9%]JXV_C_1A=OT2O$=W0[3Y9=2MY8]3VG7,P>2>'FV=I-_)R; M,/$!$?]=PCX.*\P'L/DYFVCS(-_H7G2= M&=M*8#2:C%.]9U1,(OI;HELF M8C1*;9+'RZU8]W6YUVSWO8'-YVNPXF?HN4S2S'-MP]+Q$'3\LU1/&^%-ETPY K.8 M:I5,M0X5X6O@IA7A@=]N=YY$^.'[#@[;S6YUA+=+Q|LOC'#T+_K"[%##H-8T7-MG]!HFVPD6 !KL#K!ON>2#WM0>X8=H=E\&>47A$?.!Z A3. L FMK,;I3M8O]5(!5+IMMO:W"&*<|A(M0TR.'.=.A:$K>)LM(PPQ7!-\P190((!#C6O/3;B#,/BK$ZP[[GNPQ[4GN%# ME/*PT8>X=>1| <"H@7.'9;!D!B>$*X[|K?N'LD|5HV?K/MB(. R+,.P'731> MT85$[!$#44S3HM:-EB$#0!)TK]/-BO^ _M&M"#U'/PT8QXNZ1,\G7G2% M9>AJR&,U(K'KB*-6+1.HV)H?BE:>9_E. {=UN=;1/3[,.(>6(D7{$EG*#I1#9 M-&;[6K3+H)R6]LBVW@N:0=*I3GMB-!^!-9^SM(>KPK 7MU";B$+*.&%E'CEP7}$[K@J!0;+:,[*2PI-PI\[?K>E5;_R$4'S&* MC\ UPMK)[U3 D>V#7F#K#XTR'V%EYGX|]*P*P5[4OOES"!$8&A$8'OE .'2J M&EVAV6P9<1G"XG*?!;" : %;/]S+OJ,P&PO M=V]R:W-H965TV=L_N(^?5D(^ZC(\O MUL$3F1/QL+YC<-((+Q!:,; MQ"0:V.1%H7YA#7K%F724N6#P-@8I.9I/?KJ9_3B;3FX6:#*=WC[<.+&8W/Z&[MV^O9=.,/T7LT!]^.\H0@NDI^P+(X>^+!CC T7P6,H#<>$&<+<.?9AfZ,YW M;I&WJ(^X?,M1G*&'+;\'3R$Z\6*YCS((G[1%!]IV8=^N.OIU;.G^$A/+?21 M9F+%VD9]%)%+8>]WVIHP[[/JA62H?WTEWA3LQY69\ARWB'(%M17^F+S>W5,/Y M=ZW[JCUFAA6Z4=6P6<=X9N$(S]X?%Y.K:1XM;=#_Q /1.HLX0 #_>W]#YXG;Z M\X?;.\^_GZLF;MOFH&A3[D//8PL;HXO^\^&M&FZ|A&'>6U4>^QX^ ZRF^C MJ)%AEZ":-$XIC=/IK\3>7 6R*V4=+=?=H_F%R[VN1RM'I5X)(/)UDOB:RYD0. MRHD<=/KXKT4J0*(4/!,&J0W*\O01=B?8K4*:H"+/{'8PTQ

{^U5U7+S=?'\MB7C8|0/__OJZ[+S_Z#O;O|+O^_M/U!+_P04_" "]B&Q9+/AP09T1 V(@$ &0 'AL+W=OK\>^?%M#$ZOR/+^(J.?-_V^?>|\^*V\$Z)2 M?
E^OLO+CT5U5W7\X/BZ7=V*=E,_S>Y'5O{G)BW52U3\6M\?E?2&2Z^V@]>I8 MFTP6Q^LDS8XNSK?WQ<7%>;ZI5FDFXD(I-^MU4OSX)%;Y]X\'ZM'3'9_3V[NJ MN>/XXOP^N15?
1/7K75S4/QT_*]?I6F1EFF=*(6X^'EVJ''+^%(!FPW>(?]?A>_MOKBM-_E6Y[_UOS@7'\\FC1I)%9B635$4O_G05R)U;J1ZOWX9XL>/<_9#'QY M^TDWMP^^?C#?DE},E^5V_]7
MOK?;3HZ4Y:.L\G4[N-Z#=9H]_C?YO3T0+P:HLST#M'_]GK ?,:^ ;3M@>NB M63M@=NB > 3M@?NAC6+0#%H<..&D'G!RZ2Z?M@--#!YRU\X.':.GIZYR:&/
M0GU^L@]^MM6GIUO=>;[W#GEZPM6=9WSOD*>G7-UYSO<.>7K2U9UG?>\1>WK: MU>WS?OSX(MF^PO2D2BI.B_R[4C3;UUY$8_LRW8ZO7UAIUB3*EZJH?YO6XZJ+ MJ\^&
[GQ5S,LKQW>^.L87Y3+4E3#Z6M^*+__[\I-Q*/^IA$E1),U+7_E%%U62 MKL]_U??^^D5?7OG+W\Z/JWI'&NYXV4YZ]3BIMF=250GRK+HK%2.[%M<#XW?Y
M>.VM\89_/2W\i,9_.RM\8Y_/RM\;Y_)ED_"]\;_#\5Z]_15\!TJ3@Y7VQ M7E%/WRG:1)L-/9_-UR7#WVH_&W6^=W@H'ZZ+I?2) MB^3#3?'M>>>'AL?RX=&RJH>?;(=KDE?
P]#G'IUMONO?1?*L4)RNK8E.?[U7*_M__CU!HI3B777YOP-[|^E1FPUK56GLA_(^68J/1_5Y:BF*!W%T1=?_4!>3OP^E M XGD)&:0F$EB%HG9)..0F$MB'HGY)!:06AB8G%$-9+N-
ESPLUD^H6?EZ52 MKT"%[U6:W6[2\FX;=/E-O8#\5@UEG-0;FW$DH.806(FB5DD9I.80V+N(|;8 M8LT5G(<+!,7(ZJ?W?OSP,KYVMWNUA4_N5D!B(8E%)!9#6"^3YL^9-)=FDI-5
MHE:K.I3N15:*H122"F-3B,1T$C/F.W_DD9BQV_]V=37;_S37)22T2LTG,.?!PN =NYY$[YY-80&+A[N%0 M%P.'(R(GC2&L%S4GSU%$(HV:N,C7:5GFQ0\ES*O!\Q4I,#9 2$PG,8/$3!*S
M2,PE,8?$7!+S2,R2&IQ#$0A*+2"R&L%ZHG3Z'YBEZ[?N43#@2TTG,(#&3Q*P2 MLTG,(3&7Q#P2\TL(+&0Q"(2BR&LE W>ISPEWBB2%9;0/
MX*36V'PC,9W$#!(S2XFC3IXCIRF^DV3.IZ18KI(?I7)5B.NT4BYO"R&VZ>QY>EW M0^DC9\?&#ZKJ&:@FHEJ%K9J:.@FHMJ'IKYJ!:@6HA[$.K%E-:/OAU-'5"5(M0+:.T?
N1I7>1ITK.] MKWF5K)3EXZE>O;Q,5VF5BE+)-U59)=EUFMT:)I^V>P9]G'YHLKJJ<3\51HH]5F1[K M054'LTFZ-Z.7?*1FH)]):A;JV:CFH)J++:AZJ^:@6H%[(:A&JQ936S[BN=EV5
M%Z^,/:ZA1=VN5M>$\0^C4WMT6PU>KT-)W5#-0S40U"!5L5'-0S44U#]5\5'-0S44U#!5\5 M0+42U M-5B2NLG6%>E%_4-[^(Y;9I'+=WG;*AY?RHHJ.: M@6HFJEFH9J..@VHNJGFHYJ-
:@6HAJD6H%E-:/Q6[ZGZ5+>]7T?I^5--1S4 U M$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LIK1]Y7;F_*[_W#Y+?I_5FK7S+BWKL
MMB$\J:=+JQ^#@7>VLZ@]/9E/!J>UN\7'>S;5Y;LXJK0:GU4LU#-/OS9<-") M753S4,U"M0#50E2+4"VFM/ZG@G8!)]\!R 619I?ITOE/OG1G'N]4^Z+-%NF M]\EJ*
(CDVM@S+U3343#9T I_5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LIK9^1 M6I>1&GH932.KB;1034U -5:?TN1U M/02:O(?@4U*FI?+X54M-
I=M#4J3)MY50BF3XL_DWNC,>]2:9M;G)='D_63Z MZD);N]E93?RMMWM_,0/?-1#7KL(=@HY,ZJ:.BFH=J/JH%J!:B6H1J,:7UXZ=K M{JAQ_K^L2N,B700E\[!0DN[%Z- B-
1W5#%0S4N"!;ZB\0SL?4,U -1/5+%2S M4TW78$[50;I%PX?%-=OHNCHPKM M?$ U"]7LPP^Q@T[LHIJ':CZJ!:@6HE]$:C&E|7)HVG4N3.6="\;-C5A6Z8-0
MTJ>/!=EW84TNC3WK0C4=0U8Q6ZU\@4B>O+A"9Z*06]MFHYAQV0-S#-O/0?>1 M+4"U$-4B5(LIK1\\72O"5-Z"\&NV*<7U\UG/.Y69K]=!2BU34(0IIZ)8UK>3
MV^$L0OL,4$U'-0/53%2S4,U&-0?5W%9[!9;|;K*A#02H%J!:B&H1JL64UD\V MK4LV^5<$^**JSZ3*IC*M_9Z -[X<0.Z-#C.T@P#5C.GN!^^?#GWAF(E..Z&: MC6K.H8?
$/71##]T_'14"5 M1+4*UF-+Z(=25]$_E)?W;*^A= K7?5%*29A5B MG;19<\'IL$MAGE&AQ.IZ:AF3'<_EE\[F0Y[ZJ6)3FRAFHU]SN$'Q6TW7;R] MJ8?NHXJ]
:]%J!:A6DQI_8G2]RQIKFW!,82D#5T^\^C0(C4=U0Q4,U'-0C4;MU1Q4&'UOVCFH%] M)!9J&:CFH-J++JIY]:.C6H![(:I%]!936B_,9EWSP$S>/_"L<9_] M5!XW&@I
MLU#-1C4'U5Q4\U#-1[4 U4)4BU MIK1^Y'5U_U-YW?_X-2Y9;7R%:CJ]&:AF MHIJ%:C:].:CFMMKK:.[V>HV+-@^@6H!J(:I%]!936B_,9EWSP$S>/_"L<9_] M5!XW&@I
^3Z,#4!4TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BRFMGY-= MK\-,1=>Y,[2[=5T5#-0S40U"!5L5'-0S44U#!5\5 M0+42U"-5B2NM'GM9% MGKP)0AK.I5[[62K/.B2O^5
M5&F>#>8AVB"!:CJ]&:W6*[<=:BPWT6DM5++1S3GTD+BSW0:)P0T]=/]\5 M0 M+42U"-5B2NL'5-<@,9,W2)AI45;U\E-D?^[]%6V?0#4=U0Q4,U'-0C4;U1Q4
ML,C3Q2TU'-0#43U2Q4LU'-0347 MU3Q4\U$M0+40U2)4BRFM'WE==\\5,6NE[\3GODM6KWME4E&\[U\LO5TK@5B)F^+ MD*U^C?3VKKI3+NL?KMMEZE=1K!4_3[+F=K%)R^$U*-
HF@6HZ[AFH9J*:A6HV MJCFHVJ*:AVH^]@6H%J):A&HQI?5SL>NFF)VP:U"T.0+5=%0S4,U$-0O5;%1S M4,U%-0_5?%0+4"U$M0C58DKK1U]7'#&>35B*/_(1P.38Z|-
#6'"%0S4,U$-0O5 M;%1S4,U%-0_5?%0+4"U$M0C5XE9[^0:Z.I^\>@N]GV9=W\,WO>P/8%+GT_@ MWC6?[YOFU^E2N4]^-/<,AAK:^X!J.JH9J&:BFH5J-JHYJ..VVLNK=.K98 4)
MVOV :@&JA:@6H5I,.:UCFW?=#W-Y1T^%*L%Z96QUUBT+D92#/5UR>&RNH9J. M,@;JE.AFH9J.:@ZJN:WV4A_VP5A#9_51+4"U$-4B5(LIK1]K7;"/7(%##_] M:%H3DQFY0S4
U$]4L5+-1S4$UM]5>?3N7^OK;N=!)?50+4"U$ MM0C58DKKAUG7S5#?!)>WLD:P_15W\GT8'8"DIJ.:@6HFJEFH9J.:@VHNJGFH MYJ-.@&HAJD6H%E-:/R>[%H@Y^_T3<[3W
=5T5#-0S40U"]5L5'-0S44U#]5\ M5 M0+42U"-5B2NM'7M=\,9+I>@KF\ MEP#]-#,Y7*/C'&TU0#6CU5Z^O&:#ISUH$P&]V:CF"A$W/EN*?G0=AZZ=SZJ
M!:@6H5[$:G&]-IZPV8RWL#?LTV99T]3XNM=W4VK==IM;WL=-*$TRJPK&\G MM\-O-I)- JBFHYJ!:B.]6:AFHYJ#:NY\|L27G\(#GCVH]HSFWHB%>3&F] M8%MT'0(++>8?-]I)Y?
7;57_'5 5>(=9)FS6G88=>:Y/.,S3A4TU'-6.R6JN^Y MUH3.:Z&:C6K.P[\^FXO!.BTI,JN3A?B^)6 M7(G5]JS/IC99U:S1]^\++>.H%NZOQ2/UQJ1<[JQOJ'TL=N-I5/WC;^X[_N+|
MOCXO"Y+B-LU*925NZ]DF[T_]%4+15%,'_5#E]_6_F4=UWE55OM[>O!/)M2B:.M#>K?W^1Y]?1#,\'WO/AM^W N_@]02P,$% @-O8AL66I:V?[*!0 .C0 M-!D
!X,"]W:W)K&ULK9Ol;^(V';,_%8M)TR;=_M2A+>;Q2)$EMCZMU5I=LT3?LA)0:BRPNS#>U)\]\?/"2$A67#A]O2'DH"?CO,_MSC?A$1Z_}.*SW'''NR&L4QO*VM5%]^[!=ELL-
CSQYDVQXY8&#9)2+RE-X5Z[;<_M"N[YF2@*VXYE]=N1%\2MR3A[!T%,QLE.A4','P21NRCRQ)<{'B8OMRVf=7SC M,5AO5/I&>S+>>>FN^X.JW]8/0>^V"X@<1CV60Q$3PU6UK:K]GSB
59"U^_B+ M/-DFZ;D\)\GG=&?NWJ:L}(AXR)Y+,D_"/PU>.V-6P1GZ^\7:@>DY=?>'Y"O92W3$*9_25NK198[MJ9(H%^LCB(+X\,]IY@-Q(M"
<9H&3"YQ+!9U^/*]*2_*#V R47A/)+7]D^R3U<89]$M_.,.0*G6W%#[.$IXEA.MVQ:Y9K]>"EMN9O-.T M&E;Y@F^-Q;-
+SGW4)*^,9:>X%#H9KWN&=^>+)9>A]D<=I.ET+SG415>0KN==M MT\F??_25W.EJELWUIDEL[">]5[R76V_);UOZ9B"YV//6Y/OO[+!U>]A?/=C-XYX[S+GY6N8%*)7>;W7YG=
<\4C^7>3OUVDOTB8BX11 M)(R:8!5 _>X6_O3>N;!E(UUB(2Y2!A%PA@(M5C%]4)@^?@-;9 =)?),Q%PB@2QD"PBK_#PM\AMLX.&XM>IU9G#ZU&MU89,]8Y_KF[3G4C\)
P]T>BVL?.KW4;2 M7"B-0FD,1:M.BC)FLCO8X@V-DZ T%T]C4!I#T:HVEYF2;8PT)F4V'ARS\;-E M&QHH06EN3]L5VFZ_]I!.H;TR%*WJ79D7V>; Z/_6;6,Z;.[[:K>A*1241]$T
MAJ)5YT096-E];-F&IE-0F@NE42B-H6A5I^U0Q4,U'-0C4;MU1N:/;%H5>O*],DVQT\G5?N)BXC<)UIEL&3KPZ[XMUB8&PO=V]R:W-1M695T&?&(:GVQW?&.'Z
L4+D M;?,A^''0\)3G7]XZ.I]>C[*O?$B+ 4QA$O*IMA8BO=)TOMR3O-C$LDI:\[" M+.0IV^@\)9@2OTJ0PT)%AV']{.4@;]>)K]VS0HXD(_(C<,\"3,,3L^9H$=-?7 MIU/9RX<'?;(6ZH
]Z,=Z0&1%?XGLFS_0<9>6'),(^C0 CZ[XVA%WS)0+7^F2BP?OZ#? MIN*EF 7F9$2#/_R5V/8U5P,KLI9)(![HI[E>2">H]O"4-><H?[+)80P/+A L: M9LF20>A'^U_\E!6BE
"M$PDH2T^G9RAIC@0<]1G> J6B)[@[2 MYJ394HT?]=]66>&(P>;L:3.;@=CB;3R7QR,P/#NS&X^SR71.?#/X?7 MTQMP"6:R>U9)0
!=@6A(9A2'($Q60CP>1'X&ZQ>"0/<1O -^!.9;FG K2^S A>[PFB$P1G)>X T[@ R$!63?]H.7U. MEC(=INEF-5V7I+V:%8] MFIK1*Q(C)>E6<@@Y88]$& S\$[2-
7^]DM@16$6[FPLTF],&<"AS(9'R:?'* MZR3O<>P41ZTBCP-H0,_N&CW]L.SF.,XU#<-">5B%IY7SM!IY3@GG5W)R&%.O M)Z9,\:RCN8?IEAY_B4S3<0]8UH1!QW.L>I,=G&6WF26--
D"H2!Y%T"N4P8&6@3^_T-68/$.0K+RE[*ER MHG=Q& M/N>.3TM@E=(Y>>F<5M<-ITWA+8%5A+NY<+>E=<.]6@1U}Y€SH;.@:$ MJ8WMY22[_[&QP7?PR8_\.
GK9#WR(]P4+"P4-!L=SX:+=G9XEM"JXHO?!EL-F9O MF@^K;CXED<=;=1;.#C9;N^+/Z#NX]9D4//5)5'PVU>HA#$[1;>$ M5BU
81*AW6Z7MVKRVD*KBB]L'FPT4X.QSYS66K9X5S"+C*MPP9VCK\Y M/,,ZX7%@X<1@6U8,'KLLUT'R$ ^*0Z7&<[;BVZYR@6O@QV&S(RD-T]]ODKK3K M,-
PP0DY]+S3#GMU+A).H<).H7;M%&K53K6%5A5?V"G4;*>.:!BE+K0R(XOTV M9UV4YQGUK8E*&T#,;NCU4Y0!579'3#D&ULQ9UO4^.X <.:.BB.]Z>S.L,1__VPA,X"D'KVR,)>C?=']
M"Y.(Q+.QG;_= C?]!)4<$T?!46+NVS$1HB0O MR30M+C]3LIQ]f7:+X40D47&(L);EXNNA+^KM.APSG19DE=6&Y M!$F<+G]&+_6&6"O@G6TIX-4%O(T"OK>E@%\7\#<*!/Z6 D%=
(-BWAK N$&ZN M@[NE0*\NT*NV_7)C55N:1F74/\^S!.1R)Y^H**-X6GPF/Y$N M*291+@H2I^OAC#=8;T(5\M%\+8L@DMNL[2< M%(2E(S%]*'}M+^_O*D_MY<\LY;MRV3;!*_?
47L?/>(+(GDS*/M4CD>U)NM:?5T.*YE0T9SV K4!]!P$;&. DD_?981#D6]TKZ?1NEV M-K.S;Z-\M>K!?@O+!UA[YZ3>EDT4(R)_U>S]"NMOVP8*$4-22-RG25RG"ZB
M.J2[E&T^'0LY=I;D)96L?^\^>]T^OEQ$^8C\YY\226Y*D13_;6KSR_]#YOK5 M?/&UF$5#<=&1$T(A\F?1Z?_U+V[/^5M3"T"'*!+&D# .@ADM(EBUB,!&[W^; M)X\B)}D3F?
=Y/3=D=1P$,W(+ M5[F%>^96CS31O)OD>?R'!+&?%K>1[':3?E9PY_R0.(}$,22.A^];EN>XCOJW M.F!&C+U5C#UKC#=%.9?SI%!!#K.DD4.QW/<9?B?SF7PI7D0^C(O]MIE.#=3%
MKG"MU:4-%PFCO7>;T-GHG,CJ_AFI'JR2O7$FNJ@I+/IP*(@^%R-.|MG.>"O'7B1V^)'I&%VN-,U2YEW9=EW)'FO*N.?C>:.1@ZFXT"62D'P8Q&<;I]%*?6D%&F/TLHFDY M(3?
I\+@1+2N@;5I(&$7"&!+&03 CTK-5I&<'WIT^0[8(0)PB80P)XR"8T2)<_M1XL%Q]K-[^IY>JR&!'IG;)1-IU%>D)D%[.GSOP.-|O0"HAH&D42B-06D<13,;AM9IKM7-]!_2 M7
RS<5H==E>]OTY_N-Y*Q(MZ+=28WY@\U)E!:,2FN>[Z8=MQN+&/#]V3HVAF MIE]{N78C9F3Z%MVB.E4C/XB>11Z-A9K*XZS)NE_9\:WCA JR':L>D&1Y2L!S MR"AZ;13AT
7B*)J9M99HKMVBM9_592?>XT#.7FWK-@"5;% :@]{XBF8V!RWC MW-ZAYWFBXQ/2*)3&H#2.HID-0_L\UR[TX)K67E_K=O!>I@6N%_C!YO$=LE8& MI7$4S4Q8RSG7;N?
N15Y=KZ)"OJHZJ[*N#K73SYU[@<>YMVY4'D!5$HC4%I'$4S+V1+1 L^S"[SUP$=UX-7)EJ/E#_(L MBC).QY9#@!TU^.151'GS-3%(9T:A- :E<13-3%G[/_N_Z^IFTIO=,_^-
I>6>O8H"8.2N.HFAF,-G&>5>BL7?;PU@O+'/!LA#HNJZ\X:XS1 M>W_^?C-"]#.#TAB4QE$T.T+MS#R[.]MO3TOF>96IT59&3>-<#,NL<<2\LM?6 M=I:%TBB4QJ TCJ*9K4!;-
B)X\.Z7!_5P4!]%TAB4QE$TLV%H)>?MK>3VF)ZA MG@U*HU :|]Y?>9ZKG^R<;D,1]5JJ<-FF>_GLU;,W6^^Z-
GP>VUM]8#/>'^'!/.W!/+L'VS9WOUWTH&;ONRV>Q(YNG2?T8C0HC4%I M'$4S{J=BS#LJ]$0-%6A0&H72&)3&432S86B!YED]#,23V&NP>1*H#8/2&)3& M433S?B%MPWRIJX*?
^:CK.PI%_=#S3C:.Q^W+U?KF'Z@)@[XBF8FK$V8;S=A M'U0[_GLSYF]&"+5B4!J#TCB*9D:HK9B_KQ4K-N\\D)YQNA)U9[>$7H &I5$H MC?D-+K!A
.*H6LU,U^[4_)@FV]S5WEN4V>MKG3#VWDSLS9G8NS-_A"CSM2CS M#RW*:*@H@]HE,.@-(ZBF0U#BS*_C2C[TZK%7EOK5@!5:5 ;JVF[5 NJ4C->
M;=)\NTF[C=,XF2>-44&M&)1&H30&I7$4S4Q4RS/_Y- C.52Q06D42F-0&D?1-MS(:A%9MOO_8.8%+L-,1.'NK0=]S]=LO#H,O!430S9>W+,__[,O$RB_/E6&") M&'HY&91&=ZQZ:
(D8*LM0-/-/J6A9%MAE63UGRWVMGU]..]^B;FW1 O? DWL O7<42]-0&H/2.(IF-@SMV@*[F[LT9O! MJ'V#TAB4QE$T,_RUOXYV:/L60.T;E$:A- :E<13-;!C:O@5V^_:A83W<8UB'
MBC,HC4%I'$4S]1^+=CAUZ*?;?[-7K)UEX3Z-2B-06D<13,3U7XM.+1?"Z! ^ M#4]C4!]#TCB*9C8,[=>"'^[7[#6T3A[FUW:LO46^0)>#HVAFRMJO!3_6K]GQ
MK2.&^K4=]^XZEHRA@@U%,__FK19LX0!=MRNT_Y1@IU^1!$4S+V+1 L^S"[SUP$=UX-7)EJ/E#_(L MBC).QY9#@!TU^.151'GS-3%(9T:A- :E<13-3%G[/_N_Z^IFTIO=,_^-
I>6>O8H"8.2N.HFAF,-G&>5>BL7?;PU@O+'/!LA#HNJZ\X:XS1 M>W_^?C-"]#.#TAB4QE$T,

LONHZSV"9B/FPK\NGY$B=Z-/-YF5%NLE4=EZ3>,M*Y+XA"7:6[HOWS MR2'N,.VN_.K\KLRYP#ASYHSU\<0<71YW.))V]<#&0N1">?X3CXFQ]-7?1^UI MYY3_,CMN[X=QR^X\/.MNU^_QUS,^UK^P#P'2AP3I0X'T<0/2QPBDCUN0/NY M^K@'Z8,/41U$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D%2BR"A19 M!8JL D56@2*K0)%5H,@J4&25*+)*%%DEBJP215;)(JM$D56BR"I19)4HLDH4 M616*K I%5H4BJT*15;'(JE!D52BR*A19U7_*^F[,\J__P+7WM-9E<\AGW6_.MZ2=02P$"%,4_" "]B&O9!T%-8H$ "Q $ @ $ M 9&|C4')O<',O87!P+GAM;%!+ 0(4 Q0 (+V(;%F+&RD!(@ "L" M 1 "_:\ !D;V-0&UL4$L! A0#% @ O8AL6;871Q"V!0 K1X !@ M ("!#0@ 'AL+W=O%@ >&PO=V]R:W-H965T&UL4$L! M A0#% @ O8AL6338M/JS" 6BL !@ ("!#!D 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL68AF M]U&!"0 $RD !@ ("!53@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ O8AL6= I=)T>*@ $88 !D M ("!Q%, 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ O8AL6;ZJ/J1S"0 %!@ !D ("!;(H M 'AL+W=O&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% @ MO8AL6<(P"+HI P *0< !D ("!Oj<-'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL60(8WE+-!0 N \ !D M ("!YN$ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ O8AL6?X'N)M:!@ W"X !D ("!I? 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL M6>0_C8"U P 4@X !D ("!4@4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL6=[C T6H!0 &R M !D ("!#1\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL6:(+^'7@!0 1BT !D M ("!^RX! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ O8AL65I/AM:? P U T !D ("!-T$' 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL6>VQ M'N>/" G5D !D ("!\5@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ O8AL66I:V?[*!0 .C0 !D M ("!AGT' 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ O8AL6503@=TT!0 H1D !D ("!_M>)(('AL+W=O&PO=V]R:W-H965T; 0!X;"]W;W)K&UL4$L! A0#% M @ O8AL60-4]XXW P [A, T (!LIX! 'AL+W-T>6QE M&PO=V]R:V)O:VLN>&UL4$L! A0#% @ MO8AL69(LH);X 0 YQP !H (!(* XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html3813271false1120false11 falsefalseR1.htm0000001 - Document - Cover PageSheethttp://www.radnet.com/role/CoverPageCover PageCover1 falsefalseR2.htm9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSCONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSStatements4 falsefalseR5.htm9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMESheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMECONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEStatements5 falsefalseR6.htm9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYSheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYStatements6 falsefalseR7.htm9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements7 falsefalseR8.htm9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)Sheethttp://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)Statements8 falsefalseR9.htm9952158 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATIONSheethttp://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONNATURE OF BUSINESS AND BASIS OF PRESENTATIONNotes9 falsefalseR10.htm9952159 - Disclosure - SIGNIFICANT ACCOUNTING POLICIESSheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESSIGNIFICANT ACCOUNTING POLICIESNotes10 falsefalseR11.htm9952160 - Disclosure - RECENT ACCOUNTING AND REPORTING STANDARDSSheethttp://www.radnet.com/role/RECENTACCOUNTINGANDREPORTINGSTANDARDSRECENT ACCOUNTING AND REPORTING STANDARDSNotes11 falsefalseR12.htm9952161 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITYSheethttp://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYBUSINESS COMBINATIONS AND RELATED ACTIVITYNotes12 falsefalseR13.htm9952162 - Disclosure - SEGMENT REPORTINGSheethttp://www.radnet.com/role/SEGMENTREPORTINGSEGMENT REPORTINGNotes13 falsefalseR14.htm9952163 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLENoteshttp://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLECREDIT FACILITIES AND NOTES PAYABLENotes14 falsefalseR15.htm9952164 - Disclosure - STOCK-BASED COMPENSATIONSheethttp://www.radnet.com/role/STOCKBASEDCOMPENSATIONSTOCK-BASED COMPENSATIONNotes15 falsefalseR16.htm9952165 - Disclosure - SUBSEQUENT EVENTSSheethttp://www.radnet.com/role/SUBSEQUENTEVENTSSUBSEQUENT EVENTSNotes16 falsefalseR17.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes17 falsefalseR18.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes18 falsefalseR19.htm9954471 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPoliciesSIGNIFICANT ACCOUNTING POLICIES (Policies)Policies19 falsefalseR20.htm9954472 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTablesSIGNIFICANT ACCOUNTING POLICIES (Tables)Tableshttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES20 falsefalseR21.htm9954473 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables)Sheethttp://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYTablesBUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables)Tableshttp://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITY21 falsefalseR22.htm9954474 - Disclosure - SEGMENT REPORTING (Tables)Sheethttp://www.radnet.com/role/SEGMENTREPORTINGTablesSEGMENT REPORTING (Tables)Tableshttp://www.radnet.com/role/SEGMENTREPORTING22 falsefalseR23.htm9954475 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE (Tables)Noteshttp://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLETablesCREDIT FACILITIES AND NOTES PAYABLE (Tables)Tableshttp://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLE23 falsefalseR24.htm9954476 - Disclosure - STOCK-BASED COMPENSATION (Tables)Sheethttp://www.radnet.com/role/STOCKBASEDCOMPENSATIONTablesSTOCK-BASED COMPENSATION (Tables)Tableshttp://www.radnet.com/role/STOCKBASEDCOMPENSATION24 falsefalseR25.htm9954477 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)Sheethttp://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetailsNATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)Detailshttp://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION25 falsefalseR26.htm9954478 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Service Fee Revenue (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Service Fee Revenue (Details)Details26 falsefalseR27.htm9954479 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 1 (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1DetailsSIGNIFICANT ACCOUNTING POLICIES - Narrative 1 (Details)Details27 falsefalseR28.htm9954480 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Goodwill (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Goodwill (Details)Details28 falsefalseR29.htm9954481 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Annual Amortization Expense (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Annual Amortization Expense (Details)Details29 falsefalseR30.htm9954482 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 2 (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2DetailsSIGNIFICANT ACCOUNTING POLICIES - Narrative 2 (Details)Details30 falsefalseR31.htm9954483 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Effect of Derivative Instruments on Comprehensive Income (Loss) (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Effect of Derivative Instruments on Comprehensive Income (Loss) (Details)Details31 falsefalseR32.htm9954484 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 3 (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3DetailsSIGNIFICANT ACCOUNTING POLICIES - Narrative 3 (Details)Details32 falsefalseR33.htm9954485 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Business Acquisitions by Acquisition, Contingent Consideration (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Business Acquisitions by Acquisition, Contingent Consideration (Details)Details33 falsefalseR34.htm9954486 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value of Assets and Liabilities (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value of Assets and Liabilities (Details)Details34 falsefalseR35.htm9954487 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details)Details35 falsefalseR36.htm9954488 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 4 (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4DetailsSIGNIFICANT ACCOUNTING POLICIES - Narrative 4 (Details)Details36 falsefalseR37.htm9954489 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Investment in Joint Ventures (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Investment in Joint Ventures (Details)Details37 falsefalseR38.htm9954490 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Joint Venture Investment and Financial Information (Details)Sheethttp://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetailsSIGNIFICANT ACCOUNTING POLICIES - Schedule of Joint Venture Investment and Financial Information (Details)Details38 falsefalseR39.htm9954491 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY - Valuation of Assets Acquired and Liabilities Assumed (Details)Sheethttp://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetailsBUSINESS COMBINATIONS AND RELATED ACTIVITY - Valuation of Assets Acquired and Liabilities Assumed (Details)Details39 falsefalseR40.htm9954492 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY - Narrative (Details)Sheethttp://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetailsBUSINESS COMBINATIONS AND RELATED ACTIVITY - Narrative (Details)Details40 falsefalseR41.htm9954493 - Disclosure - SEGMENT REPORTING (Details)Sheethttp://www.radnet.com/role/SEGMENTREPORTINGDetailsSEGMENT REPORTING (Details)Detailshttp://www.radnet.com/role/SEGMENTREPORTINGTables41 falsefalseR42.htm9954494 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Narrative

(Details)Noteshttp://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetailsCREDIT FACILITIES AND NOTES PAYABLE - Narrative (Details)Details42 falsefalseR43.htm9954495 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Margins and Effective Interest Rates (Details)Noteshttp://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetailsCREDIT FACILITIES AND NOTES PAYABLE - Schedule of Margins and Effective Interest Rates (Details)Details43 falsefalseR44.htm9954496 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Term Loan Debt Obligations (Details)Noteshttp://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetailsCREDIT FACILITIES AND NOTES PAYABLE - Schedule of Term Loan Debt Obligations (Details)Details44 falsefalseR45.htm9954497 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)Sheethttp://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetailsSTOCK-BASED COMPENSATION - Narrative (Details)Details45 falsefalseR46.htm9954498 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Options Activity (Details)Sheethttp://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetailsSTOCK-BASED COMPENSATION - Schedule of Options Activity (Details)Details46 falsefalseR47.htm9954499 - Disclosure - STOCK-BASED COMPENSATION - Schedule of RSAs and RSUS Activity (Details)Sheethttp://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetailsSTOCK-BASED COMPENSATION - Schedule of RSAs and RSUS Activity (Details)Details47 falsefalseR48.htm9954500 - Disclosure - SUBSEQUENT EVENTS (Details)Sheethttp://www.radnet.com/role/SUBSEQUENTEVENTSDetailsSUBSEQUENT EVENTS (Details)Detailshttp://www.radnet.com/role/SUBSEQUENTEVENTS48 falsefalseAll ReportsBookAll Reports rdnt-20240930.htmrdnt-20240930.xsdrdnt-20240930_cal.xmlrdnt-20240930_def.xmlrdnt-20240930_lab.xmlrdnt-20240930_pre.xml rdnt-20240930_g1.jpgrdnt-20240930_g2.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rdnt-20240930.htm": { "nsprefix": "rdnt", "nsuri": "http://www.radnet.com/20240930", "dts": { "inline": { "local": ["rdnt-20240930.htm"] }, "schema": { "local": ["rdnt-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["rdnt-20240930_cal.xml"] }, "definitionLink": { "local": ["rdnt-20240930_def.xml"] }, "labelLink": { "local": ["rdnt-20240930_lab.xml"] }, "presentationLink": { "local": ["rdnt-20240930_pre.xml"] } }, "keyStandard": 289, "keyCustom": 38, "axisStandard": 37, "axisCustom": 1, "memberStandard": 40, "memberCustom": 65, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 381, "entityCount": 1, "segmentCount": 112, "elementCount": 686, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1134, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.radnet.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "rdnt:OperatingExpensesExcludingDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R5": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R6": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-71", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R8": { "role": "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "rdnt:EquipmentAcquiredAndLeaseholdImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "rdnt:EquipmentAcquiredAndLeaseholdImprovements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "longName": "9952158 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952159 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.radnet.com/role/RECENTACCOUNTINGANDREPORTINGSTANDARDS", "longName": "9952160 - Disclosure - RECENT ACCOUNTING AND REPORTING STANDARDS", "shortName": "RECENT ACCOUNTING AND REPORTING STANDARDS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITY", "longName": "9952161 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY", "shortName": "BUSINESS COMBINATIONS AND RELATED ACTIVITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.radnet.com/role/SEGMENTREPORTING", "longName": "9952162 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLE", "longName": "9952163 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE", "shortName": "CREDIT FACILITIES AND NOTES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATION", "longName": "9952164 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":

null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.radnet.com/role/SUBSEQUENTEVENTS", "longName": "9952165 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-15", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYTables", "longName": "9954473 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables)", "shortName": "BUSINESS COMBINATIONS AND RELATED ACTIVITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.radnet.com/role/SEGMENTREPORTINGTables", "longName": "9954474 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLETables", "longName": "9954475 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE (Tables)", "shortName": "CREDIT FACILITIES AND NOTES PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954476 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "longName": "9954477 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-3", "name": "rdnt:NumberOfCenters", "unitRef": "center", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityRevenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R26": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails", "longName": "9954478 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Service Fee Revenue (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Service Fee Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-128", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R27": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "longName": "9954479 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 1 (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative 1 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-3", "name": "rdnt:ContractsReceivableFactoringReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "rdnt:ContractsReceivableFactoringReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R28": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails", "longName": "9954480 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Goodwill (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R29": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails", "longName": "9954481 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Annual Amortization Expense (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Annual Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "longName": "9954482 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 2 (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative 2 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "rdnt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "unitRef": "incentiveplan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:InterestIncomeExpenseNonoperatingNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "rdnt:InterestIncomePolicyPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R31": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails", "longName": "9954483 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Effect of Derivative Instruments on Comprehensive Income (Loss) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Effect of Derivative Instruments on Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-24", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R32": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "longName": "9954484 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 3 (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative 3 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-185", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-185", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails", "longName": "9954485 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Business Acquisitions by Acquisition, Contingent Consideration (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Business Acquisitions by Acquisition, Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-195", "name": "rdnt:BusinessCombinationContingentConsiderationArrangementsSettlements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals":

```
"-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } },
"R34": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails", "longName": "9954486 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value of Assets and Liabilities (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails", "longName": "9954487 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R36": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details", "longName": "9954488 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative 4 (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative 4 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "rdnt:EquitySecuritiesWithoutReadilyDeterminableFairValueNumberOfSecurities", "unitRef": "security", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R37": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetails", "longName": "9954489 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Investment in Joint Ventures (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Investment in Joint Ventures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentDividendsOrDistributions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R38": { "role": "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails", "longName": "9954490 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Joint Venture Investment and Financial Information (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Joint Venture Investment and Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-249", "name": "us-gaap:EquityMethodInvestmentAggregateCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "rdnt:JointVentureInvestmentAndFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R39": { "role": "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954491 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY - Valuation of Assets Acquired and Liabilities Assumed (Details)", "shortName": "BUSINESS COMBINATIONS AND RELATED ACTIVITY - Valuation of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-259", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R40": { "role": "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "longName": "9954492 - Disclosure - BUSINESS COMBINATIONS AND RELATED ACTIVITY - Narrative (Details)", "shortName": "BUSINESS COMBINATIONS AND RELATED ACTIVITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "rdnt:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFairValueAssetsAcquiredAndLiabilitiesAssumed", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "rdnt:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFairValueAssetsAcquiredAndLiabilitiesAssumed", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.radnet.com/role/SEGMENTREPORTINGDetails", "longName": "9954493 - Disclosure - SEGMENT REPORTING (Details)", "shortName": "SEGMENT REPORTING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R42": { "role": "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "longName": "9954494 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Narrative (Details)", "shortName": "CREDIT FACILITIES AND NOTES PAYABLE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R43": { "role": "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "longName": "9954495 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Margins and Effective Interest Rates (Details)", "shortName": "CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Margins and Effective Interest Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-328", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-328", "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails", "longName": "9954496 - Disclosure - CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Term Loan Debt Obligations (Details)", "shortName": "CREDIT FACILITIES AND NOTES PAYABLE - Schedule of Term Loan Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954497 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "rdnt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "unitRef": "incentiveplan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "unique": true } }, "R46": { "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails", "longName": "9954498 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Options Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails", "longName": "9954499 - Disclosure - STOCK-BASED COMPENSATION - Schedule of RSAs and RSUS Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of RSAs and RSUS Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-367", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-367", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails", "longName": "9954500 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-379", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-379", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "rdnt-20240930.htm", "first": true, "unique": true } }, "tag": { "rdnt_A2019SWAPS1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "A2019SWAPS1Member", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "2019 SWAPS-1", "label": "2019 SWAPS1 [Member]", "documentation": "2019 SWAPS1 [Member]" } } }, "auth_ref": [] }, "rdnt_A2019SWAPSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "A2019SWAPSMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "2019 SWAPS", "label": "2019 SWAPS [Member]", "documentation": "2019 SWAPS [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable, accrued expenses and other", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r83", "r84" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r908" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss, net of taxes", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r182", "r190", "r191", "r470", "r713", "r886" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r101", "r175", "r560", "r605", "r608" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r14", "r23", "r474", "r477", "r517", "r601", "r602", "r886", "r887", "r888", "r896", "r897", "r898", "r900" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r825" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r94", "r757", "r1052" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r619", "r896", "r897", "r898", "r900", "r986", "r1053" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r838" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r838" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r838" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r838" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r44", "r45", "r402" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliates", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r657", "r701", "r779", "r949", "r1005", "r1006", "r1008" ] }, "rdnt_AggregateIntrinsicValue": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "AggregateIntrinsicValue", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value (in thousands)", "label": "Aggregate Intrinsic Value", "documentation": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r871" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r797", "r807", "r817", "r849" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r800", "r810", "r820", "r852" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r872" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r838" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r845" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r801", "r811", "r821", "r845", "r853", "r857", "r865" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r863" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDeferredHedgeGains": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDeferredHedgeGains", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of cash flow hedge, net of taxes", "label": "Amortization of Deferred Hedge Gains", "documentation": "The amount of expense charged against earnings by an Entity to record deferred gains and losses on hedge instruments. Examples include gain on economic hedges, amortization of gain on designated fair value hedge and so forth." } } }, "auth_ref": [ "r892" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs and loan discount", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r106", "r375", "r892", "r1003" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs and discounts", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r375", "r733", "r734", "r892", "r1003" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r311", "r318", "r729" ] }, "rdnt_AntelopeValleyOutpatientImagingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "AntelopeValleyOutpatientImagingMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antelope Valley Outpatient Imaging", "label": "Antelope Valley Outpatient Imaging [Member]", "documentation": "Antelope Valley Outpatient Imaging" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares for which the exercise price exceeds average market price of common stock (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r241"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r30"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r30"] }, "rdnt_ArtificialIntelligenceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ArtificialIntelligenceMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Digital Health segment", "label": "Artificial Intelligence [Member]", "documentation": "Artificial Intelligence" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "BRMG and NY Groups accounts receivable", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r145", "r156", "r172", "r206", "r244", "r250", "r268", "r272", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r466", "r471", "r498", "r556", "r650", "r722", "r723", "r757", "r788", "r941", "r942", "r1009"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails": { "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": 1.0, "order": 3.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "terseLabel": "Current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r167", "r176", "r206", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r466", "r471", "r498", "r757", "r941", "r942", "r1009"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails": { "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r206", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r466", "r471", "r498", "r941", "r942", "r1009"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r860"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r861"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r856"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r856"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r856"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r856"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r856"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r856"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r859"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r858"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r857"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r857"] }, "rdnt_BarclaysCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BarclaysCreditAgreementMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Barclays Credit Agreement", "label": "Barclays Credit Agreement [Member]", "documentation": "Barclays Credit Agreement" } } }, "auth_ref": [] }, "rdnt_BarclaysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BarclaysMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Barclays", "label": "Barclays [Member]", "documentation": "Barclays [Member]" } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails", "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r312", "r313", "r314", "r315", "r316", "r459", "r740", "r741"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails", "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r46", "r49", "r312", "r313", "r314", "r315", "r316", "r459", "r740", "r741"] }, "rdnt_BusinessAcquisitionEquityInterestIssuedOrIssuableAdditionalNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableAdditionalNumberOfShares", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details"], "lang": { "en-us": { "role": { "terseLabel": "Additional number of shares issued (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Additional Number of Shares", "documentation": "Business Acquisition, Equity Interest Issued or

Issuable, Additional Number of Shares" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Equity interest issued, value assigned", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity." } } }, "auth_ref": ["r138"] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": ["r138"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r459"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, percentage of voting interests acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r47"] }, "rdnt_BusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessAcquisitionsMember", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions", "label": "Business Acquisitions [Member]", "documentation": "Business Acquisitions" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r1", "r2", "r13"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration", "verboseLabel": "Change in valuation of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r462", "r891"] }, "rdnt_BusinessCombinationContingentConsiderationArrangementsChangeInCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInCurrencyTranslation", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Currency translation", "label": "Business Combination Contingent Consideration Arrangements Change In Currency Translation", "documentation": "Business Combination Contingent Consideration Arrangements Change In Currency Translation" } } }, "auth_ref": [] }, "rdnt_BusinessCombinationContingentConsiderationArrangementsSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationContingentConsiderationArrangementsSettlements", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Settlement of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Settlements", "documentation": "Business Combination, Contingent Consideration Arrangements, Settlements" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationAsset", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration settlement", "label": "Business Combination, Contingent Consideration, Asset", "documentation": "Amount of asset recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r55", "r137", "r461"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone contingent consideration", "periodStartLabel": "Accrued expenses at the beginning", "periodEndLabel": "Accrued expenses at the end", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r54", "r137", "r461", "r487", "r488", "r489"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r54", "r137"] }, "rdnt_BusinessCombinationContingentConsiderationLiabilityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationContingentConsiderationLiabilityPeriod", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, liability, period", "label": "Business Combination, Contingent Consideration, Liability, Period", "documentation": "Business Combination, Contingent Consideration, Liability, Period" } } }, "auth_ref": [] }, "rdnt_BusinessCombinationContingentConsiderationLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationContingentConsiderationLiabilityRollForward", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability [Roll Forward]", "label": "Business Combination, Contingent Consideration, Liability [Roll Forward]", "documentation": "Business Combination, Contingent Consideration, Liability" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITY"], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS COMBINATIONS AND RELATED ACTIVITY", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r132", "r460"] }, "rdnt_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFairValueAssetsAcquiredAndLiabilitiesAssumed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFairValueAssetsAcquiredAndLiabilitiesAssumed", "crdr": "debit", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in fair value assets acquired and liabilities assumed", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Fair Value Assets Acquired and Liabilities Assumed", "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Fair Value Assets Acquired and Liabilities Assumed" } } }, "auth_ref": [] }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsLiabilitiesOther", "crdr": "debit", "calculation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (Liabilities), Other", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets (Liabilities), Other" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r51"] }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNotesPayable", "crdr": "credit", "calculation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Notes payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Notes Payable", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Notes Payable" } } }, "auth_ref": [] }, "rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Right of Use Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities", "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-

gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 6.0 }], "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Property & Equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
"documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r50", "r51"] },
"rdnt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.radnet.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset", "crdr": "debit",
"calculation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Right of Use Assets", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right Of Use Asset", "documentation":
"Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Right Of Use Asset" } } }, "auth_ref": [] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": {
"totalLabel": "Total Consideration", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation":
"Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r51"] }, "us-
gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationSeparatelyRecognizedTransactionsAxis", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"],
"lang": { "en-us": { "role": { "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]", "label": "Business Combination, Separately Recognized
Transactions [Axis]", "documentation": "Information by type of transaction recognized separately from acquisition of asset and assumption of liability in business
combination." } } }, "auth_ref": ["r48"] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Separately
Recognized Transactions [Domain]", "label": "Business Combination, Separately Recognized Transactions [Domain]", "documentation": "Type of transaction that is recognized
separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction." } } }, "auth_ref": ["r48"] }, "us-
gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS COMBINATIONS", "label": "Business
Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or
combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting
(including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values
of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction
generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that
accounting policy." } } }, "auth_ref": ["r133", "r134", "r135", "r136"] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION"], "lang": { "en-us": { "role": { "terseLabel": "NATURE OF BUSINESS AND BASIS OF
PRESENTATION", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of
presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to
holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the
reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles,
Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r80", "r114", "r115"] }, "rdnt_CapitationArrangementsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.radnet.com/20240930", "localname": "CapitationArrangementsMember", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Revenue under
capitation arrangements", "terseLabel": "Revenue under capitation arrangements", "label": "Capitation Arrangements [Member]", "documentation": "Capitation Arrangements
[Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": {
"role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand
deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid
investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes
in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r27", "r169", "r709"] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "CASH AND CASH EQUIVALENTS,
beginning of period", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and
discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general
characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts
of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r111", "r203"] },
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE IN CASH AND CASH
EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange
rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of
demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r111"] },
"rdnt_CashHoldbackMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "CashHoldbackMember", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details"], "lang": { "en-us": { "role": { "terseLabel": "Cash Holdback", "label": "Cash Holdback
[Member]", "documentation": "Cash Holdback" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
"terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r836"] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards
Vested in Covered Year [Member]" } } }, "auth_ref": ["r833"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are
Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } },
"auth_ref": ["r831"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } },
"auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation":
["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount"
} } }, "auth_ref": ["r837"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name",
"label": "Company Selected Measure Name" } } }, "auth_ref": ["r837"] }, "rdnt_CommercialInsurance1Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.radnet.com/20240930", "localname": "CommercialInsurance1Member", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial insurance",
"label": "Commercial Insurance1 [Member]", "documentation": "Commercial Insurance1 [Member]" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Promissory Note", "label": "Commercial
Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r119", "r341",
"r780", "r781", "r782", "r785"] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-
us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": ["r37",
"r700"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock",
"verboseLabel": "Weighted average shares for which the exercise price exceeds average market price of common stock", "label": "Common Stock [Member]", "documentation":
"Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r776", "r777", "r778", "r780", "r781", "r782", "r785", "r896", "r897", "r900", "r986", "r1049",
"r1053"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": {
"role": { "terseLabel": "Common stock - par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated
value per share of common stock." } } }, "auth_ref": ["r93"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"],
"lang": { "en-us": { "role": { "terseLabel": "Common stock - shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum
number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r93", "r638"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype":

```
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock - shares issued (in
shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes
common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or
only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r93" ] }, "us-
gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding",
"presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock - shares
outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r93", "r638",
"r656", "r1053", "r1054" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue",
"crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock -
$0.0001 par value, 200,000,000 shares authorized; 73,976,284 and 67,956,318 shares issued and outstanding at September\u00a030, 2024 and December\u00a031, 2023,
respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable
solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and
other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r93", "r559", "r757" ] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation
Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r842" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually
Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r841" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid
vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r843" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } },
"auth_ref": [ "r840" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "EQUITY BASED COMPENSATION", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for
salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for
measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r124", "r129" ] }, "us-
gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr":
"credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order":
null, "root": true } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": {
"totalLabel": "COMPREHENSIVE INCOME ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to
Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive
income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r24", "r185", "r187",
"r195", "r551", "r573", "r575" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight":
-1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": {
"terseLabel": "Less comprehensive income attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling
Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other
comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } },
"auth_ref": [ "r8", "r58", "r63", "r185", "r187", "r194", "r550", "r573", "r574" ] }, "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight":
1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": {
"totalLabel": "COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation":
"Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes
in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r63", "r139", "r185", "r187", "r193", "r549", "r573" ] }, "us-
gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for
comprehensive income." } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ConsolidatedEntitiesAxis", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r210", "r466", "r467", "r471", "r472", "r523", "r701", "r940", "r943",
"r944" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]",
"label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r210", "r466", "r467", "r471", "r472", "r523", "r701", "r940", "r943", "r944" ] }, "srt_ConsolidationItemsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [
"http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } }
}, "auth_ref": [ "r154", "r210", "r244", "r252", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350",
"r351", "r722", "r723", "r941", "r942" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ConsolidationItemsDomain", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items
[Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r154", "r210", "r244", "r252", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r342",
"r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r722", "r723", "r941", "r942" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]",
"label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-
gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain",
"presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]",
"label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] },
"rdnt_ContingentMilestoneConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname":
"ContingentMilestoneConsiderationMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details" ], "lang": { "en-us": {
"role": { "terseLabel": "Contingent Milestone Consideration", "label": "Contingent Milestone Consideration [Member]", "documentation": "Contingent Milestone
Consideration" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ],
"lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good
or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r385", "r386", "r389" ] },
"rdnt_ContractsReceivableFactoringReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname":
"ContractsReceivableFactoringReceivable", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": {
"en-us": { "role": { "terseLabel": "Contracts receivable, factoring receivable", "label": "Contracts Receivable, Factoring Receivable", "documentation": "Contracts Receivable,
Factoring Receivable" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"CounterpartyNameAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details" ], "lang": { "en-us": { "role": { "terseLabel":
"Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r207", "r208", "r357", "r383", "r522", "r532", "r555", "r710", "r712" ] },
"rdnt_CovenantNotToCompeteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "CovenantNotToCompeteMember",
"presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Covenant not to compete and other contracts", "label": "Covenant Not To Compete [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover
[Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditDerivativesByContractTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CreditDerivativesByContractTypeAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ],
"lang": { "en-us": { "role": { "terseLabel": "Credit Derivatives Contract Type [Axis]", "label": "Credit Derivatives Contract Type [Axis]", "documentation": "Information by major
type of contract of credit derivatives." } } }, "auth_ref": [ "r73" ] }, "us-gaap_CreditDerivativesContractTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CreditDerivativesContractTypeDomain", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Derivatives Contract Type [Domain]",
"label": "Credit Derivatives Contract Type [Domain]", "documentation": "Represents major types of credit derivative contracts." } } }, "auth_ref": [ "r73" ] }, "us-
gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails",
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit
Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to
structure a loan for each borrowing." } } }, "auth_ref": [ "r341", "r938" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails",
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit
Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a
loan for each borrowing." } } }, "auth_ref": [ "r341", "r938", "r939" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel":
"Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
```

gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer lists", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r53", "r918", "r919", "r920", "r921", "r923", "r924", "r927", "r928"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLE"], "lang": { "en-us": { "role": { "terseLabel": "CREDIT FACILITIES AND NOTES PAYABLE", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r118", "r205", "r327", "r328", "r329", "r330", "r331", "r340", "r341", "r353", "r359", "r360", "r361", "r362", "r363", "r364", "r369", "r376", "r377", "r379", "r507"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r21", "r83", "r84", "r146", "r147", "r210", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r730", "r731", "r732", "r733", "r734", "r756", "r893", "r932", "r933", "r934", "r1002", "r1004"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument face value", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r354", "r507", "r508", "r731", "r732", "r756"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Barclays Term Loan and Truist Term Loan", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r367", "r497", "r731", "r732", "r987", "r988", "r989", "r990", "r997"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r86", "r381", "r507", "r508", "r756"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate, stated percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r86", "r355"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r210", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r730", "r731", "r732", "r733", "r734", "r756", "r893", "r1002", "r1004"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r21", "r210", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r730", "r731", "r732", "r733", "r734", "r756", "r893", "r932", "r933", "r934", "r1002", "r1004"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, periodic payment", "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r21", "r79"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Periodic payment, principal", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r21"] }, "rdnt_DebtInstrumentPeriodicPaymentTermsAmortizationIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DebtInstrumentPeriodicPaymentTermsAmortizationIncrease", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Periodic payment amortization increase", "label": "Debt Instrument, Periodic Payment Terms, Amortization Increase", "documentation": "Debt Instrument, Periodic Payment Terms, Amortization Increase" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r21", "r41", "r42", "r78", "r120", "r121", "r210", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r730", "r731", "r732", "r733", "r734", "r756", "r893", "r1002", "r1004"] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r946", "r1001", "r1002", "r1004"] }, "rdnt_DebtRestructuringAndExtinguishmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DebtRestructuringAndExtinguishmentExpenses", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Debt restructuring and extinguishment expenses", "label": "Debt Restructuring and Extinguishment Expenses", "documentation": "Debt Restructuring and Extinguishment Expenses" } } }, "auth_ref": [] }, "rdnt_DeepHealthInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DeepHealthInc.Member", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "DeepHealth, Inc.", "label": "DeepHealth, Inc. [Member]", "documentation": "DeepHealth, Inc. [Member]" } } }, "auth_ref": [] }, "rdnt_DeepHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DeepHealthIncMember", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "DeepHealth Inc.", "label": "Deep Health Inc [Member]", "documentation": "Deep Health, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredChargesPolicyTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "DEFERRED FINANCING COSTS", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": ["r171"] }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares available for future issuance, options, warrants, shares of restricted stock and other bonus awards (in shares)", "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance", "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1002", "r1004"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details"], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs, net of accumulated amortization", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r946", "r1001", "r1002", "r1004"] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Noncurrent, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1001", "r1002", "r1004"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability, net", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with

jurisdictional netting." } } }, "auth_ref": ["r438", "r439", "r557"] }, "us-gaap_DepositsAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssets", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Deposits and other", "label": "Deposits Assets", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future." } } }, "auth_ref": ["r883"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SEGMENTREPORTINGDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "netLabel": "Total depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r11", "r244", "r255", "r272", "r722", "r723"] }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotionalAmount", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "Notional amounts", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": ["r686", "r688", "r691", "r694", "r981", "r982", "r983"] }, "us-gaap_DerivativeAssetNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNumberOfInstrumentsHeld", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "Number of forward interest rate cap agreements", "label": "Derivative Asset, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular derivative asset or group of derivative assets held by the entity." } } }, "auth_ref": ["r66", "r67"] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current and long term assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r177", "r178", "r485", "r486", "r493", "r497", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r644", "r645", "r686", "r689", "r692", "r693", "r695", "r696", "r712", "r749", "r752", "r778", "r988", "r989", "r990", "r1050"] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long term assets", "label": "Derivative Asset, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r177"] }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeBasisSpreadOnVariableRate", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Derivative, Basis Spread on Variable Rate", "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r628", "r630", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r664", "r665", "r666", "r667", "r670", "r671", "r672", "r673", "r686", "r687", "r692", "r695", "r776", "r778", "r991", "r992", "r993", "r994", "r995", "r996", "r998", "r999"] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Amount recognized (current period ineffective portion)", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r984"] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": ["r984"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r69", "r70", "r72", "r142", "r628", "r630", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r664", "r665", "r666", "r667", "r670", "r671", "r672", "r673", "r686", "r687", "r692", "r695", "r712", "r776", "r778", "r991", "r992", "r993", "r994", "r995", "r996", "r998", "r999"] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": ["r16", "r64", "r65", "r68", "r74", "r209", "r228"] }, "rdnt_DevelopedTechnologySoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DevelopedTechnologySoftwareMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Developed Technology & Software [Member]", "documentation": "Developed technology [Member]" } } }, "auth_ref": [] }, "rdnt_DigitalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DigitalHealthMember", "presentation": ["http://www.radnet.com/role/SEGMENTREPORTINGDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Digital Health", "label": "Digital Health [Member]", "documentation": "Digital Health" } } }, "auth_ref": [] }, "rdnt_DignityHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "DignityHealthMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Dignity Health", "label": "Dignity Health [Member]" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors", "label": "Director [Member]" } } }, "auth_ref": ["r907", "r1051"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATION"], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r400", "r404", "r431", "r432", "r434", "r743"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r792"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r824"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r835"] }, "rdnt_EarningPerShareBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "EarningPerShareBasicAndDilutedAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "WEIGHTED AVERAGE SHARES OUTSTANDING", "label": "Earning Per Share, Basic and Diluted [Abstract]", "documentation": "Earning Per Share, Basic and Diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS, Basic (in dollars per share)", "terseLabel": "Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r196", "r220", "r221", "r222", "r223", "r224", "r225", "r231", "r233", "r238", "r239", "r240", "r243", "r457", "r464", "r482", "r483", "r552", "r576", "r715"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "BASIC NET INCOME

{(LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS, Diluted (in dollars per share)", "verboseLabel": "Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r196", "r220", "r221", "r222", "r223", "r224", "r225", "r233", "r238", "r239", "r240", "r243", "r457", "r464", "r482", "r483", "r552", "r576", "r715"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive.", "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r30", "r31", "r242"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r499"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details"], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r441", "r746"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized expense weighted average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r433"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r976"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable upon the exercise of stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r790"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Current", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r790"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r790"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r874"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r790"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r790"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r790"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r790"] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External

Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r829"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r870"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r870"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r870"] }, "rdnt_EquipmentAcquiredAndLeaseholdImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "EquipmentAcquiredAndLeaseholdImprovements", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Equipment acquired and leasehold improvements", "label": "Equipment Acquired and Leasehold Improvements" } } }, "auth_ref": [] }, "rdnt_EquipmentNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "EquipmentNotesPayableMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equipment notes payable at 3.6% to 7.2%, due through 2029, collateralized by medical equipment", "label": "Equipment Notes Payable [Member]", "documentation": "Equipment Notes Payable" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r15", "r162", "r189", "r190", "r191", "r211", "r212", "r213", "r217", "r224", "r226", "r228", "r245", "r291", "r294", "r324", "r384", "r448", "r449", "r452", "r453", "r454", "r458", "r463", "r464", "r473", "r474", "r475", "r476", "r477", "r479", "r481", "r500", "r501", "r502", "r503", "r504", "r505", "r509", "r511", "r517", "r572", "r601", "r602", "r603", "r619", "r676"] }, "rdnt_EquityContributionsInJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "EquityContributionsInJointVentures", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity contributions in existing joint ventures", "label": "Equity Contributions In Joint Ventures", "documentation": "Equity Contributions In Joint Ventures" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r287", "r288", "r289", "r451", "r876", "r877", "r878", "r977", "r978", "r979", "r980"] }, "us-gaap_EquityMethodInvestmentAggregateCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentAggregateCost", "crdr": "debit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total net assets", "label": "Equity Method Investment, Aggregate Cost", "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting." } } }, "auth_ref": ["r81"] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distribution of earnings", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": ["r9", "r11", "r103", "r567"] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": ["r166", "r206", "r290", "r498", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769"] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": ["r166", "r206", "r290", "r498", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769"] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity." } } }, "auth_ref": ["r881", "r894", "r912", "r1000"] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss on investment", "label": "Equity Method Investment, Other-than-Temporary Impairment", "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting." } } }, "auth_ref": ["r910"] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Book value of RadNet joint venture interests", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r244", "r260", "r272", "r285", "r882", "r911"] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENTS IN EQUITY SECURITIES", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": ["r9", "r77", "r288"] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Investment in Joint Ventures", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": ["r286"] }, "rdnt_EquitySecuritiesWithoutReadilyDeterminableFairValueNumberOfSecurities": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueNumberOfSecurities", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Number of securities without readily determinable fair value", "label": "Equity Securities Without Readily Determinable Fair Value, Number Of Securities", "documentation": "Equity Securities Without Readily Determinable Fair Value, Number Of Securities" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r839"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r797", "r807", "r817", "r849"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r794", "r804", "r814", "r846"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r367", "r497", "r731", "r732"] }, "us-gaap_EurodollarMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EurodollarMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Eurodollar", "label": "Eurodollar [Member]", "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r845"] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r75", "r76" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Assets and Liabilities", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r75" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r367", "r391", "r392", "r393", "r394", "r395", "r396", "r484", "r486", "r487", "r488", "r489", "r492", "r493", "r495", "r527", "r528", "r529", "r731", "r732", "r737", "r738", "r739", "r749", "r752" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r367", "r731", "r732" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueDisclosureItemAmountsDomain", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r367", "r731", "r732" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r367", "r391", "r396", "r486", "r493", "r527", "r737", "r738", "r739", "r749" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r367", "r391", "r396", "r486", "r487", "r493", "r528", "r731", "r732", "r737", "r738", "r739", "r749" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r367", "r391", "r392", "r393", "r394", "r395", "r396", "r486", "r487", "r488", "r489", "r493", "r529", "r731", "r732", "r737", "r738", "r739", "r749", "r752" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r367", "r391", "r392", "r393", "r394", "r395", "r396", "r484", "r486", "r487", "r488", "r489", "r492", "r493", "r495", "r527", "r528", "r529", "r731", "r732", "r737", "r738", "r739", "r749", "r752" ] }, "rdnt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r925", "r1055" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year one", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r319", "r704", "r729" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of fiscal year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year five", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r319", "r704", "r729" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year four", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [
"r319", "r704", "r729" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year three", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [
"r319", "r704", "r729" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected amortization, year two", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [
"r319", "r704", "r729" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r310", "r312", "r313", "r314", "r316", "r317", "r321", "r322", "r535", "r539", "r704" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r310", "r317", "r321",
"r322", "r323", "r535", "r704", "r729" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details",
```

```
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r310", "r312", "r313", "r314", "r316", "r317", "r321", "r322", "r704" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortization total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r535", "r924" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average amortization period remaining in years", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r535" ] }, "rdnt_FirstLienCreditAgreementEighthAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "FirstLienCreditAgreementEighthAmendmentMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Credit Agreement Eighth Amendment [Member]", "label": "First Lien Credit Agreement Eighth Amendment [Member]", "documentation": "First Lien Credit Agreement Eighth Amendment" } } }, "auth_ref": [] }, "rdnt_FirstLienCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "FirstLienCreditAgreementMember", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Credit Agreement", "label": "First Lien Credit Agreement [Member]" } } }, "auth_ref": [] }, "rdnt_FirstLienCreditAgreementSixthAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "FirstLienCreditAgreementSixthAmendmentMember", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Credit Agreement, Sixth Amendment", "label": "First Lien Credit Agreement Sixth Amendment [Member]", "documentation": "First Lien Credit Agreement Sixth Amendment [Member]" } } }, "auth_ref": [] }, "rdnt_FirstLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "FirstLienTermLoanMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "label": "First Lien Term Loan [Member]" } } }, "auth_ref": [] }, "rdnt_FixedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "FixedAssetsMember", "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Assets", "label": "Fixed Assets [Member]", "documentation": "Fixed Assets" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r801", "r811", "r821", "r853" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r801", "r811", "r821", "r853" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r801", "r811", "r821", "r853" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r801", "r811", "r821", "r853" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r801", "r811", "r821", "r853" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r834" ] }, "rdnt_GainLossOnContributionIntoJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "GainLossOnContributionIntoJointVenture", "crdr": "credit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 3.0 },
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on contribution of imaging centers into joint venture", "label": "Gain (Loss) On Contribution Into Joint Venture", "documentation": "Gain (Loss) On Contribution Into Joint Venture" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 4.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on sale and disposal of equipment and other", "negatedTerseLabel": "Loss on sale and disposal of equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r892", "r930", "r931" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on disposition of property plant equipment", "negatedNetLabel": "Total loss on disposal of equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r11" ] }, "rdnt_GainOnContributionOfImagingCentersIntoJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "GainOnContributionOfImagingCentersIntoJointVenture", "crdr": "credit", "presentation": [
"http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on contribution of imaging centers into joint venture:", "label": "Gain On Contribution Of Imaging Centers Into Joint Venture", "documentation": "Gain On Contribution Of Imaging Centers Into Joint Venture" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r11", "r39", "r40" ] }, "rdnt_GlendaleAdvancedImagingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "GlendaleAdvancedImagingMember", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details" ], "lang": { "en-us": { "role": { "terseLabel": "Glendale Advanced Imaging", "label": "Glendale Advanced Imaging [Member]" } } }, "auth_ref": [] }, "rdnt_GlobalImagingLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "GlobalImagingLLPMember", "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Global Imaging LLP", "label": "Global Imaging LLP [Member]", "documentation": "Global Imaging LLP" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 },
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails",
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r170", "r297", "r548", "r723", "r728", "r750", "r757", "r914", "r916" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill from acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r301", "r728" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r296", "r309", "r728" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r305" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r11", "r298", "r304", "r309", "r728", "r750" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r728" ] }, "us-gaap_GoodwillOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillOtherIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reorganization", "label": "Goodwill, Other Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other." } } }, "auth_ref": [ "r306" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation adjustment", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r915" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "rdnt_GrossmanImagingCenterOfCMHLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "GrossmanImagingCenterOfCMHLLCMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grossman Imaging Center of CMH, LLC", "label": "Grossman Imaging Center of CMH, LLC [Member]", "documentation": "Grossman Imaging Center of CMH, LLC" } } }, "auth_ref": [] }, "rdnt_HealthCareManagementServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "HealthCareManagementServiceMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fee revenue", "label": "Health Care, Management Service [Member]", "documentation": "Health Care, Management Service [Member]" } } }, "auth_ref": [] }, "us-gaap_HealthCareOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOtherMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Health Care, Other [Member]", "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other." } } }, "auth_ref": [ "r948" ] }, "us-gaap_HealthCarePatientServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCarePatientServiceMember", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "verboseLabel": "Service fee revenue", "label": "Health Care, Patient Service [Member]", "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility." } } }, "auth_ref": [ "r948" ] }, "rdnt_HealthCarePatientServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "HealthCarePatientServiceOtherMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other patient revenue", "label": "Health Care, Patient Service Other [Member]", "documentation": "Health Care, Patient Service Other [Member]" } } }, "auth_ref": [] }, "rdnt_HeartAndLungImagingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "HeartAndLungImagingLimitedMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heart and Lung", "verboseLabel": "Heart & Lung Imaging Limited", "label": "Heart and Lung Imaging Limited [Member]", "documentation": "Heart and Lung Imaging Limited" } } }, "auth_ref": [] }, "rdnt_HeartAndLungMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "HeartAndLungMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heart and lung", "label": "Heart and Lung [Member]", "documentation": "Heart and Lung" } } }, "auth_ref": [] }, "rdnt_HeartLungImagingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "HeartLungImagingLimitedMember", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Heart & Lung Imaging Limited", "label": "Heart & Lung Imaging Limited [Member]", "documentation": "Heart & Lung Imaging Limited" } } }, "auth_ref": [] }, "rdnt_HoustonMedicalImagingLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "HoustonMedicalImagingLLCMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston Medical Imaging, LLC", "label": "Houston Medical Imaging, LLC [Member]", "documentation": "Houston Medical Imaging, LLC" } } }, "auth_ref": [] }, "rdnt_ImagingCenterSegmentRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ImagingCenterSegmentRevenueMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Imaging Center Segment Revenue", "label": "Imaging Center Segment Revenue [Member]", "documentation": "Imaging Center Segment Revenue" } } }, "auth_ref": [] }, "rdnt_ImagingCentersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ImagingCentersMember", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Imaging Center segment", "terseLabel": "Imaging Center", "label": "Imaging Centers [Member]", "documentation": "Imaging Centers" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on impairment", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r311", "r892", "r929" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r102", "r151", "r155", "r553", "r568", "r717", "r722", "r902", "r903", "r904", "r905", "r906" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Equity in earnings of joint ventures", "terseLabel": "Equity in earnings in these joint ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r11", "r103", "r150", "r244", "r257", "r272", "r285", "r567" ] }, "rdnt_IncomeLossFromEquityMethodInvestmentsNetOfDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDistributions", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Equity in earnings of joint ventures, net of dividends", "label": "Income (Loss) from Equity Method Investments, Net Of Distributions", "documentation": "Income (Loss) from Equity Method Investments, Net Of Distributions" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r325", "r332", "r333", "r490", "r491", "r494", "r598", "r600", "r661", "r704", "r751", "r1020" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r332", "r333", "r490", "r491", "r494", "r598", "r600", "r661", "r704", "r751", "r1020" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for income taxes", "terseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r157", "r160", "r227", "r228", "r244", "r258", "r272", "r440", "r441", "r450", "r578", "r746" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r188", "r436", "r437", "r442", "r443", "r444", "r447", "r614" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r28", "r202", "r445", "r446" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable, accrued expenses and other", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts
```

payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": { "r10" } }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Deferred taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r705"] }, "us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash change in fair value of interest rate hedge", "label": "Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge", "documentation": "Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective." } } }, "auth_ref": ["r69", "r71"] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r880", "r891"] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r891"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r891"] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Add additional shares issuable upon exercise of stock options and contingently issuable shares (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": ["r234", "r235", "r236", "r240"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r310", "r315", "r320", "r729"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r310", "r320", "r323", "r729"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r295", "r320", "r729"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r310", "r315", "r320", "r729"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r801", "r811", "r821", "r845", "r853", "r857", "r865"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r863"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r793", "r869"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r793", "r869"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r793", "r869"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "totalLabel": "Other intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r310", "r924", "r926"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r106", "r373", "r382", "r733", "r734"] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": ["r20"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r722", "r889", "r903"] }, "rdnt_InterestIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "InterestIncomePolicyPolicyTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "INTEREST INCOME", "label": "Interest Income Policy [Policy Text Block]", "documentation": "Interest Income Policy" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the period for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest,

```
classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r197", "r200", "r201" } }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "2019 Swaps - Interest Rate Contracts", "verboseLabel": "Interest rate contracts", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": { "r707", "r783", "r784" } }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": { "http://www.radnet.com/role/SEGMENTREPORTINGDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Intersegment Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": { "r154", "r244", "r252", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r722" } }, "rdnt_IntersegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "IntersegmentMember", "presentation": { "http://www.radnet.com/role/SEGMENTREPORTINGDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Intersegment", "label": "Intersegment [Member]", "documentation": "Intersegment" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "INVESTMENTS IN JOINT VENTURES", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": { "r577", "r610", "r611", "r612", "r613", "r681", "r682" } }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment in joint ventures", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": { "r884" } }, "rdnt_InvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVenturesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "InvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVenturesRollForward", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofInvestmentinJointVenturesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward]", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Roll Forward]", "documentation": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures" } } }, "auth_ref": [] }, "rdnt_JointVentureInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "JointVentureInterestMember", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Joint Venture Interest", "label": "Joint Venture Interest [Member]", "documentation": "Joint Venture Interest" } } }, "auth_ref": [] }, "rdnt_JointVentureInvestmentAndFinancialInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "JointVentureInvestmentAndFinancialInformationTableTextBlock", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Joint Venture Investment and Financial Information", "label": "Joint Venture Investment And Financial Information [Table Text Block]", "documentation": "Joint Venture Investment And Financial Information" } } }, "auth_ref": [] }, "rdnt_JointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "JointVentureMember", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details" }, "lang": { "en-us": { "role": { "terseLabel": "Joint Venture", "label": "Joint Venture [Member]" } } }, "auth_ref": [] }, "rdnt_KheironMedicalTechnologiesLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "KheironMedicalTechnologiesLimitedMember", "presentation": { "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Kheiron Medical Technologies Limited", "label": "Kheiron Medical Technologies Limited [Member]", "documentation": "Kheiron Medical Technologies Limited" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" }, "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": { "r117", "r515" } }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details" }, "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r514" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "BRMG and NY Groups accounts payable", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r21", "r83", "r84", "r85", "r88", "r89", "r90", "r91", "r206", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r467", "r471", "r472", "r498", "r637", "r716", "r788", "r941", "r1009", "r1010" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r98", "r149", "r563", "r757", "r894", "r912", "r1000" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails": { "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": -1.0, "order": 2.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "negatedLabel": "Current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r85", "r168", "r206", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r467", "r471", "r472", "r498", "r757", "r941", "r1009", "r1010" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails": { "parentTag": "us-gaap_EquityMethodInvestmentAggregateCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r21", "r88", "r89", "r90", "r91", "r206", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r467", "r471", "r472", "r498", "r941", "r1009", "r1010" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM LIABILITIES", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest", "documentation": "Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minority partner ownership percent", "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest", "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_LimitedPartnersContributedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LimitedPartnersContributedCapital", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited partners' contributed capital", "label": "Limited Partners' Contributed Capital", "documentation": "The amount of capital contributed by the limited partners." } } }, "auth_ref": [ "r123" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total credit facilities outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r21", "r147", "r1018" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender
```

Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r82", "r87", "r893", "r938", "r939"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r82", "r87", "r893", "r938"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r82", "r87"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r82", "r87", "r341"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unused capacity, commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofMarginsandEffectiveInterestRatesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.radnet.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total debt obligations", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r21", "r147", "r366", "r380", "r731", "r732", "r756", "r1018"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r173"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long term portion of debt obligations", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r174"] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Notes payable, net of current portion", "label": "Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r21"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r21", "r932", "r933", "r934"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofMarginsandEffectiveInterestRatesDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r21", "r38", "r932", "r933", "r934"] }, "rdnt_ManagementServiceContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ManagementServiceContractsMember", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Management service contracts", "label": "Management Service Contracts [Member]" } } }, "auth_ref": [] }, "rdnt_ManagementServiceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ManagementServiceFees", "crdr": "credit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Management service fees", "label": "Management Service Fees", "documentation": "Management service fees." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r336", "r337", "r338", "r339", "r398", "r435", "r489", "r533", "r597", "r599", "r609", "r629", "r630", "r680", "r683", "r684", "r685", "r697", "r702", "r703", "r727", "r735", "r742", "r752", "r753", "r754", "r755", "r771", "r945", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure.", "label": "Measure [Axis]" } } }, "auth_ref": ["r837"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r837"] }, "rdnt_Medicaid1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "Medicaid1Member", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Medicaid", "label": "Medicaid1 [Member]", "documentation": "Medicaid1 [Member]" } } }, "auth_ref": [] }, "rdnt_Medicare1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "Medicare1Member", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Medicare", "label": "Medicare1 [Member]", "documentation": "Medicare1 [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r336", "r337", "r338", "r339", "r398", "r435", "r489", "r533", "r597", "r599", "r609", "r629", "r630", "r680", "r683", "r684", "r685", "r697", "r702", "r703", "r727", "r735", "r742", "r752", "r753", "r754", "r771", "r945", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r97", "r148", "r206", "r290", "r342", "r345", "r346", "r347", "r351", "r352", "r498", "r562", "r640"] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions paid to noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": ["r122"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r856"] }, "rdnt_MonthlyAmortizationOfDeferredHedgeGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "MonthlyAmortizationOfDeferredHedgeGains", "crdr": "debit", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "Monthly amortization of deferred hedge gains", "label": "Monthly Amortization Of Deferred Hedge Gains", "documentation": "Monthly Amortization Of Deferred Hedge Gains" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r864"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r838"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {

{"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r199"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r199"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r111", "r112", "r113"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS", "terseLabel": "NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r104", "r113", "r152", "r166", "r184", "r186", "r191", "r206", "r216", "r220", "r221", "r222", "r223", "r224", "r227", "r228", "r237", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r457", "r464", "r483", "r498", "r571", "r658", "r674", "r675", "r786", "r941"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r62", "r140", "r184", "r186", "r224", "r227", "r228", "r570", "r888"] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": ["http://www.radnet.com/role/RECENTACCOUNTINGANDREPORTINGSTANDARDS"], "lang": { "en-us": { "role": { "terseLabel": "RECENT ACCOUNTING AND REPORTING STANDARDS", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": ["r161", "r164", "r214", "r215", "r218", "r219", "r229", "r230", "r279", "r292", "r293", "r455", "r456", "r458", "r464", "r478", "r480", "r516", "r518", "r519", "r536", "r537", "r538", "r604", "r605", "r606", "r607", "r608"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r837"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r801", "r811", "r821", "r845", "r853"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r828"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r827"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r845"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r864"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r864"] }, "rdnt_NoncontrollingInterestIncreaseContributionFromNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "NoncontrollingInterestIncreaseContributionFromNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Contributions from noncontrolling interests", "label": "Noncontrolling Interest, Increase Contribution From Noncontrolling Interest", "documentation": "Noncontrolling Interest, Increase Contribution From Noncontrolling Interest" } } }, "auth_ref": [] }, "rdnt_NoncontrollingInterestIncreaseFromSaleOfParentEconomicInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEconomicInterest", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Sale of economic interests in majority owned subsidiary, net of taxes", "label": "Noncontrolling Interest, Increase from Sale of Parent Economic Interest", "documentation": "Noncontrolling Interest, Increase from Sale of Parent Economic Interest" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r56", "r384", "r896", "r897", "r898", "r900", "r1053"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expenses", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r105"] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current portion of notes payable", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": ["r83", "r84"] }, "rdnt_NumberOfCenters": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "NumberOfCenters", "presentation": ["http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of centers", "label": "Number Of Centers", "documentation": "Number Of Centers" } } }, "auth_ref": [] }, "rdnt_NumberOfLocationOfferingMultiModalityServices": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "NumberOfLocationOfferingMultiModalityServices", "presentation": ["http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of location offering multi-modality services", "label": "Number Of Location Offering Multi-Modality Services", "documentation": "Number Of Location Offering Multi-Modality Services" } } }, "auth_ref": [] }, "rdnt_NumberOfMultiModalityImagingCenters": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "NumberOfMultiModalityImagingCenters", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of multi-modality imaging centers", "label": "Number Of Multi Modality Imaging Centers", "documentation": "Number Of Multi Modality Imaging Centers" } } }, "auth_ref": [] }, "rdnt_NumberofUnconsolidatedJointVentures": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "NumberofUnconsolidatedJointVentures", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Number of unconsolidated joint ventures", "label": "Number of Unconsolidated Joint Ventures", "documentation": "Number of Unconsolidated Joint Ventures" } } }, "auth_ref": [] }, "rdnt_October2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "October2023Member", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "October 2023", "label": "October 2023 [Member]", "documentation": "October 2023 [Member]" } } }, "auth_ref": [] }, "rdnt_October2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "October2025Member", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "terseLabel": "October 2025", "label": "October 2025 [Member]", "documentation": "October 2025 [Member]" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsLineItems", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Offsetting Assets [Line Items]", "label": "Offsetting Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_OffsettingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OffsettingAssetsTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Offsetting Assets [Table]", "label": "Offsetting Assets [Table]", "documentation": "Disclosure of information about derivative and financial assets that are
subject to offsetting, including enforceable master netting arrangements." } } }, "auth_ref": [ "r99", "r100" ] },
"rdnt_OneMonthSecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname":
"OneMonthSecuredOvernightFinancingRateSOFRMember", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One
Month SOFR", "label": "One Month Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "One Month Secured Overnight Financing Rate (SOFR)" } } },
"auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "verboseLabel":
"Cost of Operations", "label": "Operating Costs and Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these
expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } },
"presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating
expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can
be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-
gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING EXPENSES", "label":
"Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "rdnt_OperatingExpensesExcludingDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.radnet.com/20240930", "localname": "OperatingExpensesExcludingDepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of operations,
excluding depreciation and amortization", "label": "Operating Expenses, Excluding Depreciation And Amortization", "documentation": "Operating Expenses, Excluding
Depreciation And Amortization" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME FROM OPERATIONS", "label":
"Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r155", "r717",
"r902", "r903", "r904", "r905", "r906" ] }, "rdnt_OperatingIncomeLossExcludingReliefFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930",
"localname": "OperatingIncomeLossExcludingReliefFunding", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Income (Loss) from Operations", "label": "Operating Income (Loss) Excluding Relief Funding", "documentation": "Operating Income (Loss)
Excluding Relief Funding" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag":
"us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us":
{ "role": { "terseLabel": "Current operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for
lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r513" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liability", "label":
"Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
} } }, "auth_ref": [ "r513" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag":
"rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label":
"Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r512" ] }, "us-
gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 16.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Noncash operating lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of
carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r892" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business
activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r266", "r267", "r268",
"r269", "r270", "r273", "r722", "r723" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
} } }, "auth_ref": [] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract",
"presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER ASSETS", "label": "Other
Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr":
"credit", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ],
"lang": { "en-us": { "role": { "netLabel": "Amount of comprehensive loss recognized on derivative net of taxes", "label": "Other Comprehensive Income (Loss), Cash Flow
Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated
and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r179", "r180" ] }, "us-
gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role":
{ "negatedLabel": "Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes", "negatedTerseLabel": "Change in fair value of cash flow
hedge from prior periods reclassified to earnings, net of taxes", "negatedNetLabel": "Amount reclassified from accumulated OCI (prior period effective portion)", "label":
"Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from
accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } },
"auth_ref": [ "r180", "r183" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "crdr": "credit", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Cash flow hedge, tax amount", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "documentation": "Amount
of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash
flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r181" ] }, "us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Change in cumulative
foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
"documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated
and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } },
"auth_ref": [ "r5", "r101", "r572" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency
translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount
after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic
hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r572" ] },
"us-gaap_OtherExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpensesAbstract", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER INCOME AND EXPENSES",
"label": "Other Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": {
"role": { "terseLabel": "Due to affiliates", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal
operating cycle, if longer." } } }, "auth_ref": [ "r84", "r757" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": {
"en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after
one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r89" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": {
```

```
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other income", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r107" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r837" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Due from affiliates", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r799", "r809", "r819", "r851" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r802", "r812", "r822", "r854" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r802", "r812", "r822", "r854" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total RadNet, Inc.'s Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "rdnt_PatentAndTrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PatentAndTrademarksMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patent and trademarks", "label": "Patent and Trademarks [Member]", "documentation": "Patent and Trademarks" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r826" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsToAcquireBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBuildings", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of imaging facilities and other acquisitions", "label": "Payments to Acquire Buildings", "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of property and equipment and other", "label": "Payments to Acquire Other Property, Plant, and Equipment", "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions paid to noncontrolling interests", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r26" ] }, "rdnt_PaymentstoAcquireInterestinJointVentureAndContributionsToExistingJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PaymentstoAcquireInterestinJointVentureAndContributionsToExistingJointVenture", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Equity contributions in existing and purchase of interest in joint ventures", "label": "Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture", "documentation": "Payments to Acquire Interest in Joint Venture And Contributions To Existing Joint Venture" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r836" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r836" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r828" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r845" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r838" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r827" ] }, "rdnt_PerformanceBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PerformanceBasedStockOptionsMember", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Based Stock Options (\"PSOs\")", "label": "Performance Based Stock Options [Member]", "documentation": "Performance Based Stock Options" } } }, "auth_ref": [] }, "rdnt_PerformanceBasedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PerformanceBasedStockUnitsMember", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Based Stock Units (\"PSUs\")", "label": "Performance Based Stock Units [Member]", "documentation": "Performance Based Stock Units" } } }, "auth_ref": [] }, "rdnt_PinkPerceptionLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PinkPerceptionLLCMember", "presentation": [ "http://www.radnet.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pink Perception LLC", "label": "Pink Perception LLC [Member]", "documentation": "Pink Perception LLC" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r829" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r873" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r828" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r496" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r885" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "rdnt_PrincipalRepaymentsOnNotesAndLeasesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PrincipalRepaymentsOnNotesAndLeasesPayable", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on notes and leases payable", "label": "Principal Repayments On Notes And Leases Payable", "documentation": "Principal Repayments On Notes And Leases Payable" } } }, "auth_ref": [] },
```

```
"us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt refinancing, net of issuing costs", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r890" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock upon exercise of options", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r6", "r19" ] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution from noncontrolling partners", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": [ "r25" ] }, "rdnt_ProceedsFromSaleOfEconomicInterestInAMajorityOwnedSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ProceedsFromSaleOfEconomicInterestInAMajorityOwnedSubsidiary", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of economic interests in majority owned subsidiary, net of taxes", "label": "Proceeds From Sale Of Economic Interest In A Majority Owned Subsidiary", "documentation": "Proceeds From Sale Of Economic Interest In A Majority Owned Subsidiary" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r108" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r275", "r534", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r708", "r736", "r770", "r771", "r772", "r774", "r775", "r936", "r937", "r947", "r1019", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r275", "r534", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r708", "r736", "r770", "r771", "r772", "r774", "r775", "r936", "r937", "r947", "r1019", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "verboseLabel": "NET INCOME", "terseLabel": "Net (loss) income", "netLabel": "Net Income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r166", "r184", "r186", "r198", "r206", "r216", "r224", "r227", "r228", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r457", "r464", "r465", "r468", "r469", "r483", "r498", "r553", "r569", "r618", "r658", "r674", "r675", "r747", "r748", "r787", "r888", "r941" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12", "r515" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r515", "r554", "r566", "r757" ] }, "us-gaap_PropertyPlantAndEquipmentNetIncludingAndExcludingCapitalLeasedAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetIncludingAndExcludingCapitalLeasedAssetAbstract", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS", "label": "Property, Plant and Equipment, Net, Including and Excluding Capital Leased Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r158", "r159", "r565" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r117", "r515" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "PPE estimated useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "rdnt_PropertyPlantandEquipmentNetIncludingRightofUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PropertyPlantandEquipmentNetIncludingRightofUseAssets", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total property, equipment and right-of-use assets", "label": "Property Plant and Equipment Net Including Right of Use Assets", "documentation": "Property Plant and Equipment Net Including Right of Use Assets" } } }, "auth_ref": [] }, "rdnt_ProperyAndEquipmentNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ProperyAndEquipmentNetMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts Returned to Property and Equipment", "label": "Propery and Equipment, Net [Member]" } } }, "auth_ref": [] }, "rdnt_ProvidenceHealthSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ProvidenceHealthSystemMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Providence Health System", "label": "Providence Health System [Member]", "documentation": "Providence Health System" } } }, "auth_ref": [] }, "rdnt_ProvidenceHealthSystemSouthernCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ProvidenceHealthSystemSouthernCaliforniaMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Providence Health System - Southern California", "label": "Providence Health System - Southern California [Member]", "documentation": "Providence Health System - Southern California" } } }, "auth_ref": [] }, "rdnt_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "PublicOfferingMember", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Offering", "label": "Public Offering [Member]", "documentation": "Public Offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r826" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r826" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r390", "r398", "r427", "r428", "r429", "r435", "r489", "r530", "r531", "r533", "r597", "r599", "r609", "r629", "r630", "r680", "r683", "r684", "r685", "r697", "r702", "r703", "r727", "r735", "r742", "r752", "r753", "r754", "r755", "r771", "r778", "r935", "r945", "r989", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r390", "r398", "r427", "r428", "r429", "r435", "r489", "r530", "r531", "r533", "r597", "r599", "r609", "r629", "r630", "r680", "r683", "r684", "r685", "r697", "r702", "r703", "r727", "r735", "r742", "r752", "r753", "r754", "r755", "r771", "r778", "r935", "r945", "r989", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS RECEIVABLE", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r909" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r794", "r804", "r814", "r846" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r280", "r397", "r520", "r521", "r558", "r564", "r632", "r633", "r634", "r635", "r636", "r655", "r657", "r679", "r1008" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r280", "r397", "r520", "r521", "r558", "r564", "r632", "r633", "r634", "r635", "r636", "r655", "r657", "r679", "r1008" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Payments on Term Loan Debt", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r110" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r207", "r208", "r357", "r383", "r522", "r532", "r555", "r711", "r712" ] }, "rdnt_RestatedAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "RestatedAgreementMember", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofMarginsandEffectiveInterestRatesDetails",
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofTermLoanDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restated Agreement", "verboseLabel": "NJIN Term Loan Agreement", "label": "Restated Agreement [Member]", "documentation": "Restated Agreement [Member]" } } }, "auth_ref": [] }, "rdnt_RestatedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "RestatedPlanMember", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Restated Plan", "label": "Restated Plan [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r795", "r805", "r815", "r847" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r803", "r813", "r823", "r855" ] }, "rdnt_RestrictedStockAwardsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember", "presentation": [
"http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSAs and RSUs", "label": "Restricted Stock Awards and Restricted Stock Units [Member]", "documentation": "Restricted Stock Awards and Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-vested restricted stock subject to service vesting", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r30" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r95", "r122", "r561", "r604", "r608", "r616", "r639", "r757" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r162", "r211", "r212", "r213", "r217", "r224", "r226", "r228", "r291", "r294", "r324", "r448", "r449", "r452", "r453", "r454", "r458", "r463", "r464", "r473", "r475", "r476", "r479", "r481", "r509", "r511", "r601", "r603", "r619", "r1053" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total service revenue", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r153", "r154", "r244", "r251", "r252", "r266", "r272", "r275", "r277", "r278", "r387", "r388", "r534" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUES", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r659", "r706", "r714" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
"http://www.radnet.com/role/SEGMENTREPORTINGDetails",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Net revenue", "netLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r153", "r154", "r192", "r206", "r244", "r251", "r252", "r266", "r272", "r275", "r277", "r278", "r290", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r498", "r553", "r722", "r941" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails",
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLESScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r864" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r864" ] }, "rdnt_SaleOfStockCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "SaleOfStockCost", "crdr": "credit", "presentation": [
```

```
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public offering expenses", "label": "Sale Of Stock, Cost", "documentation": "Sale Of Stock, Cost" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScenarioForecastMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": {
"terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r399", "r899" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"
], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r229", "r399", "r875", "r899" ] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r30" ]
}, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails",
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofBusinessAcquisitionsbyAcquisitionContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r46", "r49", "r459" ] }, "us-
gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYTables" ], "lang":
{ "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation":
"Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r46", "r49" ] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Derivative Instruments on Comprehensive Income( Loss)", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation":
"Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [
"http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of First Lien Credit Agreement", "label":
"Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r21", "r41", "r42", "r78", "r120", "r121", "r731", "r733",
"r895", "r1002" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation":
"Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r901" ] }, "us-
gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": [ "r36" ]
}, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails",
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r287", "r288", "r289", "r451", "r876", "r877", "r878", "r977", "r978", "r979",
"r980" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
} } }, "auth_ref": [ "r206", "r287", "r288", "r289", "r290", "r498" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofJointVentureInvestmentandFinancialInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": [ "r166", "r206", "r287", "r288", "r289", "r290", "r498" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r310", "r317", "r321", "r322", "r323", "r535", "r704", "r729" ] }, "us-gaap_ScheduleOfGoodwillTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r728" ] }, "us-
gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r310", "r320", "r323", "r729" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [
"http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } },
"auth_ref": [ "r913", "r917" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [
"http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSAs and RSUS Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } },
"auth_ref": [ "r128" ] }, "us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfPrincipalTransactionsRevenueTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role":
{ "terseLabel": "Schedule of Service Fee Revenue", "label": "Schedule of Principal Transactions Revenue [Table Text Block]", "documentation": "Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers." } } },
"auth_ref": [ "r1017" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]",
"documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r33", "r34", "r35" ] }, "us-
gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
"documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r33", "r34", "r35" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
```

```
"http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r401", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Options Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r125" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Annual Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r729", "r925" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r985" ] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Financing Transaction [Axis]", "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth_ref": [ "r144" ] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Financing Transaction [Domain]", "label": "Securities Financing Transaction [Domain]", "documentation": "Measurement of financing transaction securities held." } } }, "auth_ref": [ "r144" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r789" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r791" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r153", "r154", "r155", "r156", "r244", "r247", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r278", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r323", "r334", "r335", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r719", "r722", "r723", "r728", "r773", "r1019", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r156", "r244", "r246", "r247", "r248", "r249", "r250", "r262", "r264", "r265", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r718", "r720", "r721", "r722", "r724", "r725", "r726" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r736" ] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance costs", "verboseLabel": "Severance", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award, award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r743" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited or Canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited or Canceled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r416", "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Fair Value per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested,
```

Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r130"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r420"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r420"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r401", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r126", "r127"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "RSAs and RSUs", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "rdnt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of plans", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r745"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available in grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r43"] }, "rdnt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingTranches", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of vesting traches", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Vesting Tranches", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Vesting Tranches" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable Shares at the end (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r410"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price Per Common Share, Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r410"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options (in shares)", "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r412"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r422"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate value outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r43"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r408", "r409"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (in dollars per share)", "periodEndLabel": "Ending Balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r408", "r409"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise price Per Common Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",

```
"http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofRSAsandRSUSActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting rights, percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r950" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award, expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r744" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate value exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r130" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at the end", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r131" ] }, "rdnt_SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "SharesIssuableSubjectToSatisfactionOfCertainContingenciesMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable subject to satisfaction of certain contingencies", "label": "Shares Issuable Subject to Satisfaction of Certain Contingencies [Member]", "documentation": "Shares Issuable Subject to Satisfaction of Certain Contingencies" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r15" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued per share (in dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r114", "r204" ] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "rdnt_SoldPursuantToExerciseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "SoldPursuantToExerciseMember", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sold Pursuant to Exercise", "label": "Sold Pursuant to Exercise [Member]", "documentation": "Sold Pursuant to Exercise" } } }, "auth_ref": [] }, "rdnt_StanislausSurgicalHospitalLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "StanislausSurgicalHospitalLLCMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stanislaus Surgical Hospital, LLC", "label": "Stanislaus Surgical Hospital, LLC [Member]", "documentation": "Stanislaus Surgical Hospital, LLC" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r153", "r154", "r155", "r156", "r165", "r244", "r247", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r278", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r323", "r326", "r334", "r335", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r719", "r722", "r723", "r728", "r773", "r1019", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r93", "r96", "r97", "r162", "r189", "r190", "r191", "r211", "r212", "r213", "r217", "r224", "r226", "r228", "r245", "r291", "r294", "r324", "r384", "r448", "r449", "r452", "r453", "r454", "r458", "r463", "r464", "r473", "r474", "r475", "r476", "r477", "r479", "r481", "r500", "r501", "r502", "r503", "r504", "r505", "r509", "r511", "r517", "r572", "r601", "r602", "r603", "r619", "r676" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r211", "r212", "r213", "r245", "r511", "r534", "r610", "r620", "r631", "r632", "r633", "r634", "r635", "r636", "r638", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r655", "r657", "r659", "r660", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r779" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r229", "r399", "r875", "r879", "r899" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r211", "r212", "r213", "r245", "r280", "r511", "r534", "r610", "r620", "r631", "r632", "r633", "r634", "r635", "r636", "r638", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r651", "r652", "r653", "r654", "r655", "r657", "r659", "r660", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r779" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r798", "r808", "r818", "r850" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock
```

Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "rdnt_StockHoldbackMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "StockHoldbackMember", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Stock Holdback", "label": "Stock Holdback [Member]", "documentation": "Stock Holdback" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with acquisitions (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r92", "r93", "r122"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r15", "r92", "r93", "r122", "r615", "r676", "r698"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under the equity compensation plan (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r15", "r92", "r93", "r122"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeiture of restricted stock and share cancellation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r15", "r92", "r93", "r122", "r413"] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with acquisitions", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r15", "r93", "r96", "r97", "r122"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r15", "r92", "r93", "r122", "r619", "r676", "r698", "r787"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeiture of restricted stock and share cancellation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited", "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r125"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r15", "r93", "r96", "r97", "r122"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details"], "lang": { "en-us": { "role": { "totalLabel": "Total RadNet, Inc.'s Stockholders' equity:", "terseLabel": "Amount of loss recognized in income on derivative (current period ineffective portion)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r93", "r96", "r97", "r116", "r640", "r656", "r677", "r678", "r757", "r788", "r894", "r912", "r1000", "r1053"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEffectofDerivativeInstrumentsonComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r56", "r57", "r61", "r162", "r163", "r190", "r211", "r212", "r213", "r217", "r224", "r226", "r291", "r294", "r324", "r384", "r448", "r449", "r452", "r453", "r454", "r458", "r463", "r464", "r473", "r474", "r475", "r476", "r477", "r479", "r481", "r500", "r501", "r505", "r510", "r517", "r602", "r603", "r617", "r640", "r656", "r677", "r678", "r699", "r787", "r894", "r912", "r1000", "r1053"] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": ["http://www.radnet.com/role/SEGMENTREPORTINGDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": ["http://www.radnet.com/role/SEGMENTREPORTINGDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r506", "r525"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r506", "r525"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r506", "r525"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r506", "r525"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r506", "r525"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.radnet.com/role/SUBSEQUENTEVENTS"], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r524", "r526"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "rdnt_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies [Line Items]", "label": "Summary of Significant Accounting Policies [Line Items]", "documentation": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "rdnt_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative1Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative2Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative3Details", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies [Table]", "label": "Summary of Significant Accounting Policies [Table]", "documentation": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [

```
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r844" ] }, "rdnt_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "TermLoanMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofTermLoanDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]" } } }, "auth_ref": [] }, "rdnt_ThirdPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "ThirdPartyMember", "presentation": [ "http://www.radnet.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party", "label": "Third Party [Member]", "documentation": "Third Party" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r907", "r1007" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.radnet.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r836" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r843" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAnnualAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade names amortized", "verboseLabel": "Trade names indefinite life", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r52", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r926", "r927", "r928" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r863" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r865" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.radnet.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r866" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r867" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r867" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r865" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r865" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r868" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r866" ] }, "rdnt_TriValleyImagingGroupLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "TriValleyImagingGroupLLCMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYNarrativeDetails", "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Tri Valley Imaging Group, LLC", "label": "Tri Valley Imaging Group, LLC [Member]", "documentation": "Tri Valley Imaging Group, LLC" } } }, "auth_ref": [] }, "rdnt_TriggeringEventAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "TriggeringEventAxis", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triggering Event [Axis]", "label": "Triggering Event [Axis]", "documentation": "Triggering Event" } } }, "auth_ref": [] }, "rdnt_TriggeringEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "TriggeringEventDomain", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Triggering Event [Domain]", "label": "Triggering Event [Domain]", "documentation": "Triggering Event" } } }, "auth_ref": [] }, "rdnt_TruistMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "TruistMember", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Truist", "label": "Truist [Member]", "documentation": "Truist" } } }, "auth_ref": [] }, "rdnt_U.S.ImagingIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "U.S.ImagingIncMember", "presentation": [ "http://www.radnet.com/role/BUSINESSCOMBINATIONSANDRELATEDACTIVITYValuationofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Imaging, Inc.", "label": "U.S. Imaging, Inc [Member]", "documentation": "U.S. Imaging, Inc" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r862" ] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash change in fair value of interest rate hedge", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": [ "r11", "r670", "r671", "r672", "r673", "r690" ] }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityActivityBetweenVIEAndEntityExpense", "crdr": "debit", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BRMG and NY Groups operating expenses", "label": "Variable Interest Entity, Measure of Activity, Expense", "documentation": "The amount of expense between the reporting entity and the Variable Interest Entity (VIE)." } } }, "auth_ref": [ "r141" ] }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management services provided to BRMG and NY Groups", "label": "Variable Interest Entity, Measure of Activity, Income or Loss before Tax", "documentation": "Description of the amount of pre-tax income (loss) derived by the reporting entity from the Variable Interest Entity (VIE)." } } }, "auth_ref": [ "r141" ] }, "us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityActivityBetweenVIEAndEntityRevenues", "crdr": "credit", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BRMG and NY Groups revenues", "label": "Variable Interest Entity, Measure of Activity, Revenues", "documentation": "The amount of income between the reporting entity and the Variable Interest Entity (VIE)." } } }, "auth_ref": [ "r141" ] }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": [ "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrative4Details" ], "lang": { "en-us": { "role": { "terseLabel": "Variable interest entity, ownership percentage", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)." } } }, "auth_ref": [ "r60" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.radnet.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r59", "r466", "r467", "r471", "r472" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLENarrativeDetails", "http://www.radnet.com/role/CREDITFACILITIESANDNOTESPAYABLEScheduleofMarginsandEffectiveInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r832" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average number of common shares used in calculating diluted net income per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r232", "r240" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.radnet.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)",
```

{"verboseLabel": "Weighted average number of common shares outstanding during the period basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r231", "r240"] }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesRestrictedStock", "calculation": { "http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Add non-vested restricted stock subject only to service vesting (in shares)", "label": "Weighted Average Number of Shares, Restricted Stock", "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends." } } }, "auth_ref": ["r29"] }, "rdnt_WeightedAverageRemainingContractualLife": { "xbrltype": "stringItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "WeightedAverageRemainingContractualLife", "presentation": ["http://www.radnet.com/role/STOCKBASEDCOMPENSATIONScheduleofOptionsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in years)", "label": "Weighted Average Remaining Contractual Life", "documentation": "Weighted Average Remaining Contractual Life abstract" } } }, "auth_ref": [] }, "rdnt_WorkersCompensationPersonalInjury1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.radnet.com/20240930", "localname": "WorkersCompensationPersonalInjury1Member", "presentation": ["http://www.radnet.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofServiceFeeRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Workers' compensation/personal injury", "label": "Workers' Compensation/Personal Injury1 [Member]", "documentation": "Workers' Compensation/Personal Injury1 [Member]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PypDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r830"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-7" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
```

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",

"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-
30-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r324": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-
50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r328": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r330": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-
50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r335": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r336": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-
50-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r343": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r344": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r345": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r346": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r349": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r350": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r351": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r352": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r357": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r361": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1C" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r365": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1D" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r369": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1E" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r373": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1F" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r377": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1I" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r381": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
```

"Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r510": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef": {"Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r576": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r577": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r578": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r579": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r580": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r581": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r582": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r583": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r584": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r585": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r586": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r587": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r588": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r589": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r590": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r591": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r592": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r593": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r594": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r595": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r596": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-
50-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r601": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-
40-65-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r608": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r609": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r610": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r611": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r612": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r613": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r614": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r615": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r616": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" },
"r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r619": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r623": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r624": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r625": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r689": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
```

```
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "f", "Paragraph": "a" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
```

```
"Subparagraph": "vi" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r875": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r876": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r971": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479048/940-320-50-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 69 0001628280-24-047285-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-047285-xbrl.zip M4$L#!!0 (+V(;%F>P9_;A`@`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|=:MG"F J"0="@XUCBI5^Q2\8->-O M98]!;2&#- @>TK;/E6G:@G"M(D$C70MI(Z5MCG($F$:K8"29T1$(O&W9>[0) 6AD8>$O'](^3^^ G2(6W>0* M;]0:O%QKOH_1"QT5;?6TV5IM5);LZS9;*PE^2U=V\U*M=5Z5K/!?A["'7.!LVXRG'_<; M>X]8>Z>>/;#:F+'/!'L69EQG?5RP^;05GS#X\9A?- APBWX!'$TSGE0;TZ$%; M:U'"%K!FH<0FP]_BL&>H3[N($!'GB.?V^2+$8GO)CT%7JQS@PT@WQA(ZUD, MUH+4MT.Q)3_S'(H XI[_U$0XZD/*!7\B@HEJAL/R2DRI.4H$HC\; MG^"W'E!%9%,H#V*>/4T>^'T/H-L&S]^"PWKEL%?'GBN-YH_%CSW=O"\C?#\ M;'Z]@-+/9^;//!FL$^(§4A,'(WY3\(&#F1HQ!$F%;\IY4THTH#EW6 M+;D,CZ<>*@/;SU6=29[X2.>A&%"6FPRAVQJX.8H0$[T"/HUR!RF&PPH1&TL@`M(U=_5?+4!51&ER$S##:>P.77)^X[W-_A_O> DVB'^]N!^S#@*Q?X%$0&;0- R<.>SMW]OI\3)_!);;#,:(QT)IOU MQCE7![.*,4!]/#[/97E6<^?-LM=#F-[P5+LP'(]P+) HT54H_W (K'L2Y;F MV5] C2DOH;,H-X1=,TF):TFVC]\3XU M"\4CA$;_E4F[G&D^T>M#T*K/[21C0G37@S8('P?X^2@X^H@I>0^]V-=\5+_T M7T_1RX#Z]7GU*RO3K 1UGO.YWB:1/[

"